Sequential	O
involvement	O
of	O
NFAT	B-Gene
and	O
Egr	B-Gene
transcription	I-Gene
factors	I-Gene
in	O
FasL	B-Gene
regulation	O
.	O

The	O
critical	O
function	O
of	O
NFAT	B-Gene
proteins	I-Gene
in	O
maintaining	O
lymphoid	O
homeostasis	O
was	O
revealed	O
in	O
mice	O
lacking	O
both	O
NFATp	B-Gene
and	O
NFAT4	B-Gene
(	O
DKO	O
)	O
.	O

DKO	O
mice	O
exhibit	O
increased	O
lymphoproliferation	O
,	O
decreased	O
activation	O
-induced	O
cell	O
death	O
,	O
and	O
impaired	O
induction	O
of	O
FasL	B-Gene
.	O

The	O
transcription	B-Gene
factors	I-Gene
Egr2	I-Gene
and	O
Egr3	B-Gene
are	O
potent	O
activators	O
of	O
FasL	B-Gene
expression	O
.	O

Here	O
we	O
find	O
that	O
Egr2	B-Gene
and	O
Egr3	B-Gene
are	O
NFAT	B-Gene
target	O
genes	O
.	O

Activation	O
of	O
FasL	B-Gene
occurs	O
via	O
the	O
NFAT	B-Gene
-dependent	O
induction	O
of	O
Egr3	B-Gene
,	O
as	O
demonstrated	O
by	O
the	O
ability	O
of	O
exogenously	O
provided	O
NFATp	B-Gene
to	O
restore	O
Egr	B-Gene
-dependent	O
FasL	B-Gene
promoter	I-Gene
activity	O
in	O
DKO	O
lymph	O
node	O
cells	O
.	O

Further	O
,	O
Egr3	B-Gene
expression	O
is	O
enriched	O
in	O
Th1	O
cells	O
,	O
suggesting	O
a	O
molecular	O
basis	O
for	O
the	O
known	O
preferential	O
expression	O
of	O
FasL	B-Gene
in	O
the	O
Th1	O
versus	O
Th2	O
subset	O
.	O

LIGHT	B-Gene
,	O
a	O
TNF	B-Gene
-like	O
molecule	O
,	O
costimulates	O
T	O
cell	O
proliferation	O
and	O
is	O
required	O
for	O
dendritic	O
cell	O
-mediated	O
allogeneic	O
T	O
cell	O
response	O
.	O

LIGHT	B-Gene
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
TNF	B-Gene
superfamily	O
and	O
its	O
receptors	O
,	O
herpesvirus	O
entry	O
mediator	O
and	O
lymphotoxin	B-Gene
beta	I-Gene
receptor	I-Gene
,	O
are	O
found	O
in	O
T	O
cells	O
and	O
stromal	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
LIGHT	B-Gene
is	O
selectively	O
expressed	O
on	O
immature	O
dendritic	O
cells	O
(	O
DCs	O
)	O
generated	O
from	O
human	O
PBMCs	O
.	O

In	O
contrast	O
,	O
LIGHT	B-Gene
is	O
not	O
detectable	O
in	O
DCs	O
either	O
freshly	O
isolated	O
from	O
PBMCs	O
or	O
rendered	O
mature	O
in	O
vitro	O
by	O
LPS	B-Chemical
treatment	O
.	O

Blockade	O
of	O
LIGHT	B-Gene
by	O
its	O
soluble	O
receptors	O
,	O
lymphotoxin	B-Gene
beta	I-Gene
receptor-Ig	I-Gene
or	O
HVEM-Ig	B-Gene
,	O
inhibits	O
the	O
induction	O
of	O
DC	O
-mediated	O
primary	O
allogeneic	O
T	O
cell	O
response	O
.	O

Furthermore	O
,	O
engagement	O
of	O
LIGHT	B-Gene
costimulates	O
human	O
T	O
cell	O
proliferation	O
,	O
amplifies	O
the	O
NF-kappaB	B-Gene
signaling	O
pathway	O
,	O
and	O
preferentially	O
induces	O
the	O
production	O
of	O
IFN-gamma	B-Gene
,	O
but	O
not	O
IL-4	B-Gene
,	O
in	O
the	O
presence	O
of	O
an	O
antigenic	O
signal	O
.	O

Our	O
results	O
suggest	O
that	O
LIGHT	B-Gene
is	O
a	O
costimulatory	O
molecule	O
involved	O
in	O
DC	O
-mediated	O
cellular	O
immune	O
responses	O
.	O

Tumor	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
-induced	O
proliferation	O
requires	O
synthesis	O
of	O
granulocyte-macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
.	O

OBJECTIVE	O
:	O
Tumor	B-Gene
necrosis	I-Gene
factor-	I-Gene
alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
induces	O
a	O
variety	O
of	O
cellular	O
responses	O
,	O
some	O
of	O
them	O
being	O
at	O
least	O
seemingly	O
contradictory	O
.	O

Thus	O
,	O
we	O
set	O
out	O
to	O
find	O
differences	O
in	O
the	O
modes	O
of	O
proliferative	O
and	O
apoptotic	O
responses	O
to	O
TNF-	B-Gene
alpha	I-Gene
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
a	O
panel	O
of	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
-derived	O
cell	O
lines	O
for	O
TNF-	B-Gene
alpha	I-Gene
-responsiveness	O
.	O

In	O
two	O
lines	O
(	O
OCI-AML-1	O
,	O
OCI-AML-11	O
)	O
,	O
TNF-	B-Gene
alpha	I-Gene
acted	O
as	O
an	O
apoptotic	O
agent	O
;	O
in	O
others	O
(	O
HU-3	O
,	O
M-07e	O
,	O
TF-1	O
)	O
,	O
it	O
had	O
the	O
opposite	O
effect	O
,	O
preventing	O
apoptosis	O
and	O
inducing	O
proliferation	O
.	O

Direct	O
and	O
indirect	O
signaling	O
mechanisms	O
,	O
including	O
NF-kappaB	B-Gene
activation	O
and	O
cytokine	O
synthesis	O
,	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
All	O
cell	O
lines	O
tested	O
expressed	O
TNF-	B-Gene
alpha	I-Gene
receptors	I-Gene
I	I-Gene
and	O
II	B-Partial_Gene
and	O
responded	O
to	O
TNF-	B-Gene
alpha	I-Gene
by	O
upregulation	O
of	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
.	O

In	O
contrast	O
to	O
granulocyte-macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
GM-CSF	B-Gene
)	O
,	O
TNF-	B-Gene
alpha	I-Gene
did	O
not	O
activate	O
the	O
MAP	B-Gene
kinase	I-Gene
and	O
p70S6	B-Gene
kinase	I-Gene
pathways	O
.	O

Nevertheless	O
,	O
inhibitors	O
of	O
these	O
pathways	O
clearly	O
reduced	O
the	O
TNF-alpha	B-Gene
-induced	O
cell	O
growth	O
,	O
indicating	O
that	O
TNF-	B-Gene
alpha	I-Gene
-proliferative	O
cells	O
produced	O
a	O
growth	O
factor	O
that	O
induced	O
proliferation	O
upon	O
stimulation	O
of	O
the	O
above	O
pathways	O
.	O

Anti-GM-CSF	B-Gene
antibodies	I-Gene
inhibited	O
the	O
TNF-alpha	B-Gene
-induced	O
growth	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
autocrine	O
loop	O
for	O
cell	O
proliferation	O
mediated	O
by	O
GM-CSF	B-Gene
.	O

Supporting	O
this	O
notion	O
,	O
TNF-alpha	B-Gene
-induced	O
upregulation	O
of	O
GM-CSF	B-Gene
mRNA	I-Gene
levels	O
and	O
protein	O
secretion	O
in	O
the	O
TNF-alpha	B-Gene
-proliferative	O
,	O
but	O
not	O
in	O
the	O
TNF-alpha-apoptotic	B-Gene
cell	O
lines	O
.	O

CONCLUSION	O
:	O
These	O
data	O
identify	O
GM-CSF	B-Gene
synthesis	O
as	O
an	O
early	O
and	O
essential	O
step	O
in	O
TNF-	B-Gene
alpha	I-Gene
-induced	O
proliferation	O
.	O

We	O
show	O
for	O
the	O
first	O
time	O
that	O
TNF-alpha	B-Gene
-treated	O
cell	O
lines	O
producing	O
no	O
or	O
only	O
minimal	O
amounts	O
of	O
GM-CSF	B-Gene
demonstrate	O
an	O
apoptotic	O
phenotype	O
,	O
while	O
cell	O
lines	O
with	O
high	O
GM-CSF	B-Gene
expression	O
rates	O
can	O
escape	O
from	O
growth	O
arrest	O
or	O
even	O
apoptosis	O
.	O

In	O
this	O
context	O
,	O
we	O
discuss	O
arguments	O
pointing	O
at	O
NF-kappaB	B-Gene
as	O
regulator	O
of	O
GM-CSF	B-Gene
synthesis	O
and	O
thus	O
indirectly	O
as	O
regulator	O
for	O
the	O
escape	O
of	O
TNF-alpha	B-Gene
-induced	O
apoptosis	O

Transcriptional	O
activation	O
of	O
heme	B-Gene
oxygenase-1	I-Gene
and	O
its	O
functional	O
significance	O
in	O
acetaminophen	B-Chemical
-induced	O
hepatitis	B-Disease
and	O
hepatocellular	O
injury	O
in	O
the	O
rat	O
.	O

BACKGROUND	O
/	O
AIM	O
:	O
Glutathione	B-Chemical
depletion	O
contributes	O
to	O
acetaminophen	B-Chemical
hepatotoxicity	O
and	O
is	O
known	O
to	O
induce	O
the	O
oxidative	O
stress	O
reactant	O
heme	B-Gene
oxygenase-1	I-Gene
.	O

The	O
metabolites	O
of	O
the	O
heme	B-Gene
oxygenase	I-Gene
pathway	O
,	O
biliverdin	B-Chemical
,	O
carbon	B-Chemical
monoxide	I-Chemical
,	O
and	O
iron	B-Chemical
may	O
modulate	O
acetaminophen	B-Chemical
toxicity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
cell-type	O
specific	O
expression	O
of	O
heme	B-Gene
oxygenase-1	I-Gene
and	O
its	O
impact	O
on	O
liver	B-Disease
injury	I-Disease
and	O
microcirculatory	O
disturbances	O
in	O
a	O
model	O
of	O
acetaminophen	B-Chemical
-induced	O
hepatitis	B-Disease
.	O

METHODS	O
:	O
Gene	O
expression	O
of	O
heme	B-Gene
oxygenase-1	I-Gene
was	O
studied	O
by	O
Northern-	O
and	O
Western	O
analysis	O
as	O
well	O
as	O
immunohistochemistry	O
.	O

The	O
time	O
course	O
of	O
heme	B-Gene
oxygenase-1	I-Gene
and	O
-2	B-Partial_Gene
,	O
cytokine	B-Gene
-induced	I-Gene
neutrophil	I-Gene
chemoattractant-1	I-Gene
,	O
and	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
was	O
studied	O
by	O
Northern	O
analysis	O
.	O

DNA	O
-binding	O
activity	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
was	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Sinusoidal	O
perfusion	O
and	O
leukocyte-endothelial	O
interactions	O
were	O
assessed	O
by	O
intravital	O
microscopy	O
.	O

RESULTS	O
:	O
Acetaminophen	B-Chemical
caused	O
a	O
moderate	O
sinusoidal	O
perfusion	O
failure	O
(	O
-15	O
%	O
)	O
and	O
infiltration	O
of	O
neutrophils	O
along	O
with	O
activation	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
and	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
and	O
cytokine	B-Gene
-induced	I-Gene
neutrophil	I-Gene
chemoattractant-1	I-Gene
mRNAs	I-Gene
.	O

Induction	O
of	O
heme	B-Gene
oxygenase-1	I-Gene
mRNA	I-Gene
and	O
protein	O
(	O
approximately	O
30-fold	O
)	O
in	O
hepatocytes	O
and	O
non-parenchymal	O
cells	O
paralleled	O
the	O
inflammatory	O
response	O
.	O

Blockade	O
of	O
heme	B-Gene
oxygenase	I-Gene
activity	O
with	O
tin-protoporphyrin-IX	B-Chemical
abrogated	O
acetaminophen	B-Chemical
-induced	O
hepatic	O
neutrophil	O
accumulation	O
and	O
nuclear	B-Gene
factor-kappaB	I-Gene
activation	O
,	O
but	O
failed	O
to	O
affect	O
sinusoidal	O
perfusion	O
and	O
liver	B-Disease
injury	I-Disease
.	O

CONCLUSIONS	O
:	O
The	O
inflammatory	O
response	O
associated	O
with	O
acetaminophen	B-Chemical
hepatotoxicity	O
is	O
modulated	O
by	O
the	O
parallel	O
induction	O
of	O
the	O
heme	B-Gene
oxygenase-1	I-Gene
gene	I-Gene
.	O

However	O
,	O
heme	B-Gene
oxygenase-1	I-Gene
has	O
no	O
permissive	O
effect	O
on	O
sinusoidal	O
perfusion	O
and	O
does	O
not	O
affect	O
liver	B-Disease
injury	I-Disease
in	O
this	O
model	O
.	O

These	O
data	O
argue	O
against	O
a	O
central	O
role	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
activation	O
and	O
neutrophil	O
infiltration	O
as	O
perpetuating	O
factors	O
of	O
liver	B-Disease
injury	I-Disease
in	O
acetaminophen	B-Chemical
toxicity	O
.	O

Functional	O
characterization	O
of	O
the	O
two	O
alternative	O
promoters	O
of	O
human	B-Gene
p45	I-Gene
NF-E2	I-Gene
gene	I-Gene
.	O

OBJECTIVE	O
:	O
The	O
transcription	B-Gene
factor	I-Gene
NF-E2	I-Gene
,	O
a	O
heterodimeric	O
protein	O
complex	O
composed	O
of	O
p45	B-Gene
and	O
small	B-Gene
Maf	I-Gene
family	I-Gene
proteins	I-Gene
,	O
is	O
considered	O
crucial	O
for	O
the	O
proper	O
differentiation	O
of	O
erythrocytes	O
and	O
megakaryocytes	O
in	O
vivo	O
.	O

We	O
report	O
the	O
results	O
of	O
studies	O
aimed	O
at	O
understanding	O
the	O
regulatory	O
mechanisms	O
controlling	O
p45	B-Gene
gene	I-Gene
expression	O
in	O
erythroid	O
cells	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	B-Gene
p45	I-Gene
mRNAs	I-Gene
have	O
two	O
alternative	O
isoforms	O
,	O
aNF-E2	B-Gene
and	O
fNF-E2	B-Gene
,	O
and	O
these	O
isoforms	O
are	O
transcribed	O
from	O
the	O
alternative	O
promoters	O
.	O

We	O
investigated	O
lineage-specific	O
expression	O
of	O
both	O
isomers	O
in	O
human	O
erythroid	O
and	O
megakaryocytic	O
cells	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
or	O
Northern	O
blot	O
analysis	O
.	O

For	O
functional	O
characterization	O
of	O
both	O
promoters	O
,	O
plasmids	O
in	O
which	O
reporter	O
genes	O
were	O
placed	O
under	O
the	O
control	O
of	O
a	O
series	O
of	O
truncated	O
or	O
mutated	O
promoter	O
fragments	O
were	O
transfected	O
to	O
human	O
hematopoietic	O
cell	O
lines	O
.	O

RESULTS	O
:	O
When	O
CD34	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
isolated	O
from	O
human	O
cord	O
blood	O
were	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
in	O
liquid	O
suspension	O
culture	O
,	O
both	O
transcripts	O
,	O
although	O
barely	O
detected	O
at	O
day	O
0	O
,	O
were	O
induced	O
in	O
both	O
erythroid	O
and	O
megakaryocytic	O
cultures	O
.	O

fNF-E2	B-Gene
mRNA	I-Gene
was	O
found	O
to	O
be	O
more	O
abundant	O
in	O
erythroid	O
cells	O
than	O
megakaryocytic	O
cells	O
at	O
day	O
7	O
of	O
culture	O
.	O

Although	O
both	O
isomers	O
were	O
expressed	O
in	O
human	O
erythroid-megakaryocytic	O
cell	O
lines	O
,	O
megakaryocytic	O
maturation	O
with	O
loss	O
of	O
erythroid	O
phenotype	O
induced	O
by	O
phorbol	B-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
(	O
PMA	B-Chemical
)	O
resulted	O
in	O
exclusive	O
downregulation	O
of	O
fNF-E2	B-Gene
,	O
suggesting	O
that	O
fNF-E2	B-Gene
promoter	I-Gene
is	O
more	O
erythroid	O
specific	O
.	O

Functional	O
analysis	O
of	O
fNF-E2	B-Gene
promoter	I-Gene
showed	O
that	O
the	O
promoter	O
is	O
active	O
only	O
in	O
erythroid-megakaryocytic	O
cells	O
and	O
that	O
the	O
double	O
GATA	B-Gene
sit	O
e	O
in	O
the	O
proximal	O
region	O
is	O
necessary	O
for	O
its	O
efficient	O
activity	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
GATA	B-Gene
proteins	I-Gene
,	O
which	O
govern	O
the	O
differentiation	O
of	O
erythroid	O
lineage	O
cells	O
,	O
are	O
required	O
for	O
full	O
promoter	O
activity	O
of	O
the	O
p45	B-Gene
gene	I-Gene
.	O

Activation	O
of	O
the	O
Lck	B-Gene
tyrosine	I-Gene
protein	I-Gene
kinase	I-Gene
by	O
the	O
Herpesvirus	B-Gene
saimiri	I-Gene
tip	I-Gene
protein	I-Gene
involves	O
two	O
binding	O
interactions	O
.	O

The	O
Tip	B-Gene
protein	I-Gene
of	O
Herpesvirus	O
saimiri	O
strain	O
484C	O
binds	O
to	O
and	O
activates	O
the	O
Lck	B-Gene
tyrosine	I-Gene
protein	I-Gene
kinase	I-Gene
.	O

Two	O
sequences	O
in	O
the	O
Tip	B-Gene
protein	I-Gene
were	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
to	O
Lck	B-Gene
.	O

A	O
proline-rich	B-Chemical
region	O
,	O
residues	O
132-141	O
,	O
binds	O
to	O
the	O
SH3	O
domain	O
of	O
the	O
Lck	B-Gene
protein	I-Gene
.	O

We	O
show	O
here	O
that	O
the	O
other	O
Lck	B-Gene
-binding	O
domain	O
,	O
residues	O
104-113	O
,	O
binds	O
to	O
the	O
carboxyl-terminal	B-Chemical
half	O
of	O
Lck	B-Gene
and	O
that	O
this	O
binding	O
does	O
not	O
require	O
the	O
Lck	B-Gene
SH3	O
domain	O
.	O

Mutated	B-Gene
Tip	I-Gene
containing	O
only	O
one	O
functional	O
Lck	B-Gene
-binding	O
domain	O
can	O
bind	O
stably	O
to	O
Lck	B-Gene
,	O
although	O
not	O
as	O
strongly	O
as	O
wild-type	O
Tip	B-Gene
.	O

Interaction	O
of	O
Tip	B-Gene
with	O
Lck	B-Gene
through	O
either	O
Lck	B-Gene
-binding	O
domain	O
increases	O
the	O
activity	O
of	O
Lck	B-Gene
in	O
vivo	O
.	O

Simultaneous	O
binding	O
of	O
both	O
domains	O
is	O
required	O
for	O
maximal	O
activation	O
of	O
Lck	B-Gene
.	O

The	O
transient	O
expression	O
of	O
Tip	B-Gene
in	O
T	O
cells	O
was	O
found	O
to	O
stimulate	O
both	O
Stat3	B-Gene
-dependent	O
and	O
NF-AT	B-Gene
-dependent	O
transcription	O
.	O

Mutant	O
forms	O
of	O
Tip	B-Gene
lacking	O
one	O
or	O
the	O
other	O
of	O
the	O
two	O
Lck	B-Gene
-binding	O
domains	O
retained	O
the	O
ability	O
to	O
stimulate	O
Stat3	B-Gene
-dependent	O
transcription	O
.	O

Tip	B-Gene
lacking	O
the	O
proline-rich	B-Chemical
Lck	B-Gene
-binding	O
domain	O
exhibited	O
almost	O
wild-type	O
activity	O
in	O
this	O
assay	O
.	O

In	O
contrast	O
,	O
ablation	O
of	O
either	O
Lck	B-Gene
-binding	O
domain	O
abolished	O
the	O
ability	O
of	O
Tip	B-Gene
to	O
stimulate	O
NF-AT	B-Gene
-dependent	O
transcription	O
.	O

Full	O
biological	O
activity	O
of	O
Tip	B-Gene
,	O
therefore	O
,	O
appears	O
to	O
require	O
both	O
Lck	B-Gene
-binding	O
domains	O
.	O

The	O
Epstein-Barr	O
virus	O
promoter	O
initiating	O
B-cell	O
transformation	O
is	O
activated	O
by	O
RFX	B-Gene
proteins	I-Gene
and	O
the	O
B-cell-specific	B-Gene
activator	I-Gene
protein	I-Gene
BSAP	I-Gene
/	I-Gene
Pax5	I-Gene
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
B-cell	O
growth	O
transformation	O
,	O
a	O
central	O
feature	O
of	O
the	O
virus	O
'strategy	O
for	O
colonizing	O
the	O
human	O
B-cell	O
system	O
,	O
requires	O
full	O
virus	O
latent	O
gene	O
expression	O
and	O
is	O
initiated	O
by	O
transcription	O
from	O
the	O
viral	O
promoter	O
Wp	B-Gene
.	O

Interestingly	O
,	O
when	O
EBV	O
accesses	O
other	O
cell	O
types	O
,	O
this	O
growth	O
-transforming	O
program	O
is	O
not	O
activated	O
.	O

The	O
present	O
work	O
focuses	O
on	O
a	O
region	O
of	O
Wp	B-Gene
which	O
in	O
reporter	O
assays	O
confers	O
B-cell	O
-specific	O
activity	O
.	O

Bandshift	O
studies	O
indicate	O
that	O
this	O
region	O
contains	O
three	O
factor	O
binding	O
sites	O
,	O
termed	O
sites	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
in	O
addition	O
to	O
a	O
previously	O
characterized	O
CREB	B-Gene
site	O
.	O

Here	O
we	O
show	O
that	O
site	O
C	O
binds	O
members	O
of	O
the	O
ubiquitously	O
expressed	O
RFX	B-Gene
family	I-Gene
of	O
proteins	O
,	O
notably	O
RFX1	B-Gene
,	O
RFX3	B-Gene
,	O
and	O
the	O
associated	O
factor	O
MIBP1	B-Gene
,	O
whereas	O
sites	O
B	O
and	O
D	O
both	O
bind	O
the	O
B-cell-specific	B-Gene
activator	I-Gene
protein	I-Gene
BSAP	I-Gene
/	I-Gene
Pax5	I-Gene
.	O

In	O
reporter	O
assays	O
with	O
mutant	O
Wp	B-Gene
constructs	O
,	O
the	O
loss	O
of	O
factor	O
binding	O
to	O
any	O
one	O
of	O
these	O
sites	O
severely	O
impaired	O
promoter	O
activity	O
in	O
B	O
cells	O
,	O
while	O
the	O
wild-type	O
promoter	O
could	O
be	O
activated	O
in	O
non-B	O
cells	O
by	O
ectopic	O
BSAP	B-Gene
expression	O
.	O

We	O
suggest	O
that	O
Wp	B-Gene
regulation	O
by	O
BSAP	B-Gene
helps	O
to	O
ensure	O
the	O
B-cell	O
specificity	O
of	O
EBV	O
's	O
growth	O
-transforming	O
function	O
.	O

Functional	O
uncoupling	O
of	O
the	O
Janus	B-Gene
kinase	I-Gene
3-Stat5	I-Gene
pathway	O
in	O
malignant	O
growth	O
of	O
human	O
T	B-Disease
cell	I-Disease
leukemia	I-Disease
virus	O
type	O
1	O
-transformed	O
human	O
T	O
cells	O
.	O

Human	O
T	B-Disease
cell	I-Disease
leukemia	I-Disease
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transforms	O
cytokine	O
-dependent	O
T	O
lymphocytes	O
and	O
causes	O
adult	B-Disease
T	I-Disease
cell	I-Disease
leukemia	I-Disease
.	O

Janus	B-Gene
tyrosine	I-Gene
kinase	I-Gene
(	I-Gene
Jak	I-Gene
)	I-Gene
3	I-Gene
and	O
transcription	B-Gene
factors	I-Gene
Stat5a	I-Gene
and	O
Stat5b	B-Gene
are	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	O
T	O
cells	O
and	O
are	O
constitutively	O
hyperactivated	O
in	O
both	O
HTLV-1	O
-transformed	O
human	O
T	O
cell	O
lines	O
and	O
lymphocytes	O
isolated	O
from	O
HTLV-1	O
-infected	O
patients	O
;	O
therefore	O
,	O
a	O
critical	O
role	O
for	O
the	O
Jak3-Stat5	B-Gene
pathway	O
in	O
the	O
progression	O
of	O
this	O
disease	O
has	O
been	O
postulated	O
.	O

We	O
recently	O
reported	O
that	O
tyrphostin	B-Chemical
AG-490	I-Chemical
selectively	O
blocked	O
IL-2	B-Gene
activation	O
of	O
Jak3	B-Gene
/	I-Gene
Stat5	I-Gene
and	O
growth	O
of	O
murine	O
T	O
cell	O
lines	O
.	O

Here	O
we	O
demonstrate	O
that	O
disruption	O
of	O
Jak3	B-Gene
/	I-Gene
Stat5a	I-Gene
/	I-Gene
b	I-Gene
signaling	O
with	O
AG-490	B-Chemical
(	O
50	O
&	O
mgr	O
;	O
M	O
)	O
blocked	O
the	O
proliferation	O
of	O
primary	O
human	O
T	O
lymphocytes	O
,	O
but	O
paradoxically	O
failed	O
to	O
inhibit	O
the	O
proliferation	O
of	O
HTLV-1	O
-transformed	O
human	O
T	O
cell	O
lines	O
,	O
HuT-102	O
and	O
MT-2	O
.	O

Structural	O
homologues	O
of	O
AG-490	B-Chemical
also	O
inhibited	O
the	O
proliferation	O
of	O
primary	O
human	O
T	O
cells	O
,	O
but	O
not	O
HTLV-1	O
-infected	O
cells	O
.	O

Disruption	O
of	O
constitutive	O
Jak3	B-Gene
/	I-Gene
Stat5	I-Gene
activation	O
by	O
AG-490	B-Chemical
was	O
demonstrated	O
by	O
inhibition	O
of	O
1	O
)	O
tyrosine	B-Chemical
phosphorylation	O
of	O
Jak3	B-Gene
,	O
Stat5a	B-Gene
(	O
Tyr	B-Chemical
(	O
694	O
)	O
)	O
,	O
and	O
Stat5b	B-Gene
(	O
Tyr	B-Chemical
(	O
699	O
)	O
)	O
;	O
2	O
)	O
serine	B-Chemical
phosphorylation	O
of	O
Stat5a	B-Gene
(	O
Ser	B-Chemical
(	O
726	O
)	O
)	O
as	O
determined	O
by	O
a	O
novel	O
phosphospecific	O
Ab	O
;	O
and	O
3	O
)	O
Stat5a	B-Gene
/	I-Gene
b	I-Gene
DNA	I-Gene
binding	O
to	O
the	O
Stat5	B-Gene
-responsive	O
beta-casein	B-Gene
promoter	I-Gene
.	O

In	O
contrast	O
,	O
AG-490	B-Chemical
had	O
no	O
effect	O
on	O
DNA	O
binding	O
by	O
p50	B-Gene
/	I-Gene
p65	I-Gene
components	I-Gene
of	O
NF-kappaB	B-Gene
,	O
a	O
transcription	O
factor	O
activated	O
by	O
the	O
HTLV-1	O
-encoded	O
phosphoprotein	O
,	O
Tax	B-Gene
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
Jak3-Stat5	B-Gene
pathway	O
in	O
HTLV-1	O
-transformed	O
T	O
cells	O
has	O
become	O
functionally	O
redundant	O
for	O
proliferation	O
.	O

Reversal	O
of	O
this	O
functional	O
uncoupling	O
may	O
be	O
required	O
before	O
Jak3	B-Gene
/	I-Gene
Stat5	I-Gene
inhibitors	O
will	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
this	O
malignancy	B-Disease
.	O

Characterization	O
of	O
IL-4	B-Gene
and	O
IL-13	B-Gene
signals	O
dependent	O
on	O
the	O
human	B-Gene
IL-13	I-Gene
receptor	I-Gene
alpha	I-Gene
chain	I-Gene
1	I-Gene
:	O
redundancy	O
of	O
requirement	O
of	O
tyrosine	B-Chemical
residue	I-Chemical
for	O
STAT3	B-Gene
activation	O
.	O

IL-4	B-Gene
and	O
IL-13	B-Gene
are	O
pleiotropic	O
cytokines	O
whose	O
biological	O
activities	O
overlap	O
with	O
each	O
other	O
.	O

IL-13	B-Gene
receptor	I-Gene
alpha	I-Gene
chain	I-Gene
1	I-Gene
(	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
)	O
is	O
necessary	O
for	O
binding	O
to	O
IL-13	B-Gene
,	O
and	O
the	O
heterodimer	O
composed	O
of	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
and	O
IL-4R	B-Gene
alpha	I-Gene
chain	I-Gene
transduces	O
IL-13	B-Gene
and	O
IL-4	B-Gene
signals	O
;	O
however	O
,	O
the	O
functional	O
mapping	O
of	O
the	O
intracellular	O
domain	O
of	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
is	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
wild	O
and	O
mutated	O
types	O
of	O
human	B-Gene
IL-13R	I-Gene
alpha	I-Gene
1	I-Gene
,	O
and	O
analyzed	O
IL-4	B-Gene
and	O
IL-13	B-Gene
signals	O
using	O
an	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
-transfected	O
human	O
B	O
cell	O
line	O
.	O

Expression	O
of	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
evoked	O
STAT3	B-Gene
activation	O
by	O
IL-4	B-Gene
and	O
IL-13	B-Gene
,	O
and	O
in	O
stimulated	O
human	O
B	O
cells	O
,	O
on	O
which	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
was	O
highly	O
expressed	O
,	O
IL-4	B-Gene
and	O
IL-13	B-Gene
induced	O
STAT3	B-Gene
activation	O
.	O

Replacement	O
of	O
the	O
two	O
tyrosine	B-Chemical
residues	I-Chemical
completely	O
abolished	O
STAT3	B-Gene
activation	O
,	O
although	O
replacing	O
either	O
tyrosine	B-Chemical
residue	I-Chemical
alone	O
retained	O
it	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
Box1	O
region	O
and	O
the	O
C-terminal	O
tail	O
of	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
were	O
critical	O
for	O
binding	O
to	O
Tyk2	B-Gene
,	O
and	O
activation	O
of	O
Jak1	B-Gene
,	O
Tyk2	B-Gene
,	O
the	O
insulin	B-Gene
receptor	I-Gene
substrate-1	I-Gene
and	O
STAT6	B-Gene
respectively	O
.	O

These	O
results	O
suggest	O
that	O
STAT3	B-Gene
activation	O
is	O
involved	O
with	O
IL-4	B-Gene
and	O
IL-13	B-Gene
signals	O
in	O
human	O
B	O
cells	O
along	O
with	O
the	O
activation	O
of	O
STAT6	B-Gene
,	O
and	O
that	O
there	O
is	O
a	O
unique	O
sequence	O
in	O
IL-13R	B-Gene
alpha	I-Gene
1	I-Gene
to	O
activate	O
STAT3	B-Gene
.	O

Effects	O
of	O
deregulated	O
Raf	B-Gene
activation	O
on	O
integrin	B-Gene
,	O
cytokine-receptor	B-Gene
expression	O
and	O
the	O
induction	O
of	O
apoptosis	O
in	O
hematopoietic	O
cells	O
.	O

The	O
effects	O
of	O
deregulated	O
Raf	B-Gene
activation	O
on	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
were	O
investigated	O
.	O

The	O
cytokine	O
-dependent	O
murine	O
myeloid	O
FDC-P1	O
and	O
human	O
erythroleukemic	O
TF-1	O
cell	O
lines	O
were	O
transformed	O
to	O
grow	O
in	O
response	O
to	O
deregulated	O
Raf	B-Gene
expression	O
in	O
the	O
absence	O
of	O
exogenous	O
cytokines	O
.	O

The	O
conditionally	O
active	O
Raf	B-Gene
proteins	I-Gene
were	O
regulated	O
by	O
beta-estradiol	B-Chemical
as	O
cDNAs	O
containing	O
the	O
Raf	B-Gene
catalytic	O
,	O
but	O
lacking	O
negative-regulatory	O
domains	O
,	O
were	O
ligated	O
to	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B-Gene
receptor	I-Gene
(	O
deltaRaf	B-Gene
:	O
ER	B-Gene
)	O
.	O

Continuous	O
deltaRaf	B-Gene
expression	O
prevented	O
apoptosis	O
in	O
the	O
absence	O
of	O
exogenous	O
cytokines	O
and	O
altered	O
the	O
morphology	O
of	O
the	O
FD	O
/	O
deltaRaf	B-Gene
:	O
ER	B-Gene
cells	O
as	O
they	O
grew	O
in	O
large	O
aggregated	O
masses	O
(	O
>	O
100	O
cells	O
)	O
whereas	O
the	O
parental	O
cytokine	O
-dependent	O
FDC-P1	O
cells	O
grew	O
in	O
smaller	O
grape	O
-like	O
clusters	O
(	O
<	O
10	O
cells	O
)	O
.	O

FD	O
/	O
deltaRaf-1	B-Gene
:	O
ER	B-Gene
cells	O
growing	O
in	O
response	O
to	O
Raf	B-Gene
activation	O
displayed	O
decreased	O
levels	O
of	O
the	O
Mac-2	B-Gene
and	O
Mac-3	B-Gene
molecules	O
on	O
their	O
cell	O
surface	O
.	O

In	O
contrast	O
,	O
when	O
these	O
cells	O
were	O
cultured	O
in	O
IL-3	B-Gene
,	O
higher	O
levels	O
of	O
these	O
adhesion	O
molecules	O
were	O
detected	O
.	O

Expression	O
of	O
activated	B-Gene
Raf	I-Gene
oncoproteins	I-Gene
also	O
abrogated	O
cytokine	O
dependency	O
and	O
prevented	O
apoptosis	O
of	O
TF-1	O
cells	O
.	O

Moreover	O
,	O
the	O
differentiation	O
status	O
of	O
these	O
Raf	B-Gene
-responsive	O
cells	O
was	O
more	O
immature	O
upon	O
Raf	B-Gene
activation	O
as	O
culture	O
with	O
the	O
differentiation	O
-inducing	O
agent	O
phorbol	B-Chemical
12	I-Chemical
myristate	I-Chemical
13-acetate	I-Chemical
(	O
PMA	B-Chemical
)	O
and	O
beta-estradiol	B-Chemical
resulted	O
in	O
decreased	O
levels	O
of	O
the	O
CD11b	B-Gene
and	O
CD18	B-Gene
integrin	I-Gene
molecules	O
on	O
the	O
cell	O
surface	O
.	O

In	O
contrast	O
when	O
the	O
Raf	B-Gene
-responsive	O
cells	O
were	O
induced	O
to	O
differentiate	O
with	O
PMA	B-Chemical
and	O
GM-CSF	B-Gene
,	O
in	O
the	O
absence	O
of	O
deltaRaf	B-Gene
:	O
ER	B-Gene
activation	O
,	O
increased	O
levels	O
of	O
the	O
CD11b	B-Gene
and	O
CD18	B-Gene
molecules	O
were	O
detected	O
.	O

Retinoic	B-Chemical
acid	I-Chemical
(	O
RA	B-Chemical
)	O
inhibited	O
3H-thymidine	B-Chemical
incorporation	O
in	O
response	O
to	O
GM-CSF	B-Gene
.	O

Interestingly	O
,	O
Raf	B-Gene
activation	O
counterbalanced	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
caused	O
by	O
RA	B-Chemical
but	O
not	O
PMA	B-Chemical
.	O

Thus	O
deregulated	O
Raf	B-Gene
expression	O
can	O
alter	O
cytokine	O
dependency	O
,	O
integrin	B-Gene
expression	O
and	O
the	O
stage	O
of	O
differentiation	O
.	O

These	O
Raf	B-Gene
-responsive	O
cell	O
lines	O
will	O
be	O
useful	O
in	O
elucidating	O
the	O
roles	O
of	O
the	O
MAP	B-Gene
kinase	I-Gene
cascade	O
on	O
hematopoietic	O
cell	O
differentiation	O
and	O
malignant	O
transformation	O

Cyclic	B-Chemical
AMP	I-Chemical
activates	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
in	O
Th2	O
cells	O
:	O
phosphorylation	O
of	O
GATA-3	B-Gene
and	O
stimulation	O
of	O
Th2	O
cytokine	O
gene	O
expression	O
.	O

cAMP	B-Chemical
is	O
an	O
important	O
second	O
messenger	O
with	O
immunomodulatory	O
properties	O
.	O

Elevation	O
of	O
intracellular	O
cAMP	B-Chemical
in	O
T	O
cells	O
,	O
induced	O
by	O
agents	O
such	O
as	O
IL-1alpha	B-Gene
or	O
PGs	B-Chemical
,	O
inhibits	O
T	O
cell	O
activation	O
.	O

In	O
effector	O
T	O
cells	O
,	O
an	O
increase	O
in	O
the	O
level	O
of	O
intracellular	O
cAMP	B-Chemical
inhibits	O
cytokine	O
production	O
in	O
Th1	O
cells	O
but	O
stimulates	O
cytokine	O
production	O
in	O
Th2	O
cells	O
.	O

Here	O
we	O
report	O
that	O
cAMP	B-Chemical
-induced	O
effects	O
in	O
Th2	O
cells	O
occur	O
independently	O
of	O
the	O
protein	B-Gene
kinase	I-Gene
A	I-Gene
pathway	O
,	O
which	O
is	O
the	O
major	O
mediator	O
of	O
cAMP	B-Chemical
-induced	O
signaling	O
events	O
in	O
most	O
cell	O
types	O
.	O

Instead	O
,	O
cAMP	B-Chemical
stimulates	O
activation	O
of	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
in	O
Th2	O
cells	O
.	O

This	O
appears	O
to	O
be	O
a	O
Th2	O
-selective	O
event	O
because	O
cAMP	B-Chemical
barely	O
increased	O
p38	B-Gene
phosphorylation	O
in	O
Th1	O
cells	O
.	O

We	O
show	O
that	O
in	O
Th2	O
cells	O
,	O
cAMP	B-Chemical
promotes	O
the	O
production	O
of	O
both	O
IL-5	B-Gene
and	O
IL-13	B-Gene
,	O
which	O
play	O
distinct	O
but	O
critical	O
roles	O
in	O
asthma	B-Disease
pathogenesis	O
.	O

Our	O
data	O
also	O
show	O
that	O
cAMP	B-Chemical
causes	O
increased	O
phosphorylation	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
GATA-3	I-Gene
,	O
which	O
we	O
have	O
shown	O
is	O
a	O
critical	O
regulator	O
of	O
Th2	O
cytokine	O
gene	O
expression	O
and	O
,	O
in	O
turn	O
,	O
of	O
airway	B-Disease
inflammation	I-Disease
in	O
mice	O
.	O

Thus	O
,	O
Th2	O
-specific	O
GATA-3	B-Gene
expression	O
and	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
activation	O
together	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
differential	O
effects	O
of	O
cAMP	B-Chemical
in	O
the	O
two	O
T	O
helper	O
cell	O
subsets	O
.	O

2	B-Chemical
,	I-Chemical
2',	I-Chemical
4	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
6'-pentachlorobiphenyl	I-Chemical
induces	O
apoptosis	O
in	O
human	O
monocytic	O
cells	O
.	O

Polychlorinatedbiphenyls	B-Chemical
(	O
PCBs	B-Chemical
)	O
are	O
a	O
group	O
of	O
persistent	O
and	O
widely	O
dispersed	O
environmental	O
pollutants	O
,	O
some	O
of	O
which	O
may	O
be	O
immunotoxic	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
PCBs	B-Chemical
on	O
immune	O
system	O
by	O
assessing	O
apoptotic	O
cell	O
death	O
in	O
human	O
monocytic	O
U937	O
cells	O
.	O

Among	O
the	O
various	O
congeners	O
tested	O
,	O
2	B-Chemical
,	I-Chemical
2',	I-Chemical
4	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
6'-pentachlorobiphenyl	I-Chemical
(	O
PeCB	B-Chemical
)	O
,	O
a	O
highly	O
ortho	O
-substituted	O
congener	O
,	O
specifically	O
induced	O
DNA	O
fragmentation	O
,	O
a	O
hallmark	O
of	O
apoptosis	O
,	O
while	O
the	O
other	O
examined	O
di-	O
,	O
tri-	O
,	O
tetra-	O
,	O
and	O
pentachlorobiphenyls	B-Chemical
did	O
not	O
.	O

To	O
further	O
study	O
the	O
2	B-Chemical
,	I-Chemical
2',	I-Chemical
4	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
6'-PeCB	I-Chemical
-induced	O
cell	O
death	O
,	O
various	O
features	O
of	O
apoptosis	O
were	O
examined	O
.	O

2	B-Chemical
,	I-Chemical
2',	I-Chemical
4	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
6'-PeCB	I-Chemical
caused	O
a	O
decrease	O
in	O
cell	O
viability	O
and	O
induced	O
cellular	O
morphologic	O
features	O
characteristic	O
of	O
apoptosis	O
such	O
as	O
chromatin	O
aggregation	O
and	O
apoptotic	O
bodies	O
.	O

In	O
addition	O
,	O
caspase-3	B-Gene
,	O
an	O
executioner	O
of	O
apoptosis	O
,	O
was	O
activated	O
and	O
its	O
substrate	O
,	O
poly	B-Gene
(	I-Gene
ADP-ribose	I-Gene
)	I-Gene
polymerase	I-Gene
(	O
PARP	B-Gene
)	O
,	O
was	O
cleaved	O
during	O
2	B-Chemical
,	I-Chemical
2',	I-Chemical
4	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
6'-PeCB	I-Chemical
-induced	O
apoptosis	O
.	O

In	O
contrast	O
,	O
3	B-Chemical
,	I-Chemical
3',	I-Chemical
4	I-Chemical
,	I-Chemical
4',	I-Chemical
5-PeCB	I-Chemical
,	O
a	O
congener	O
of	O
coplanar	O
structure	O
,	O
as	O
well	O
as	O
2	B-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
7	I-Chemical
,	I-Chemical
8-TCDD	I-Chemical
did	O
not	O
induce	O
apoptosis	O
in	O
these	O
human	O
monocytic	O
cells	O
,	O
although	O
they	O
potently	O
induced	O
CYP	B-Gene
1A1	I-Gene
in	O
human	O
hepatoma	B-Disease
Hep	O
G2	O
cells	O
.	O

Taken	O
together	O
,	O
the	O
data	O
indicate	O
that	O
2	B-Chemical
,	I-Chemical
2',	I-Chemical
4	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
6'-PeCB	I-Chemical
induces	O
apoptosis	O
in	O
human	O
monocytic	O
cells	O
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
the	O
arylhydrocarbon	B-Gene
receptor	I-Gene
.	O

This	O
suggests	O
a	O
possibly	O
separate	O
mechanism	O
by	O
which	O
PCBs	B-Chemical
cause	O
immunosuppression	O
.	O

Activation	O
of	O
oncogenic	B-Gene
transcription	I-Gene
factor	I-Gene
AP-1	I-Gene
in	O
T	O
cells	O
infected	O
with	O
human	O
T	B-Disease
cell	I-Disease
leukemia	I-Disease
virus	O
type	O
1	O
.	O

Human	B-Gene
T	I-Gene
cell	I-Gene
leukemia	I-Gene
virus	I-Gene
type	I-Gene
1	I-Gene
(	I-Gene
HTLV-1	I-Gene
)	I-Gene
Tax	I-Gene
protein	I-Gene
transforms	O
primary	O
human	O
T	O
cells	O
in	O
vitro	O
.	O

We	O
previously	O
showed	O
that	O
Tax	B-Gene
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
AP-1	I-Gene
such	O
as	O
c-Jun	B-Gene
,	O
JunD	B-Gene
,	O
c-Fos	B-Gene
,	O
and	O
Fra-1	B-Gene
at	O
the	O
mRNA	O
level	O
in	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
Tax	B-Gene
to	O
activate	O
transcription	O
through	O
the	O
AP-1	B-Gene
-binding	O
site	O
(	O
AP-1	B-Gene
site	O
)	O
.	O

A	O
transient	O
transfection	O
study	O
showed	O
that	O
Tax	B-Gene
can	O
activate	O
transcription	O
through	O
the	O
AP-1	B-Gene
-binding	O
site	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
whereas	O
any	O
combination	O
of	O
AP-1	B-Gene
proteins	I-Gene
did	O
so	O
much	O
less	O
than	O
Tax	B-Gene
,	O
indicating	O
that	O
the	O
activation	O
of	O
the	O
AP-1	B-Gene
site	O
by	O
Tax	B-Gene
may	O
require	O
a	O
mechanism	O
other	O
than	O
the	O
induction	O
of	O
AP-1	B-Gene
mRNA	I-Gene
.	O

Fresh	O
peripheral	O
blood	O
leukemia	B-Disease
cells	O
of	O
all	O
surveyed	O
ATL	B-Disease
patients	O
displayed	O
constitutive	O
AP-1	B-Gene
DNA	I-Gene
-binding	O
activity	O
,	O
whereas	O
no	O
normal	O
individuals	O
did	O
.	O

However	O
,	O
the	O
HTLV-1	O
genes	O
,	O
including	O
tax	B-Gene
,	O
are	O
not	O
significantly	O
expressed	O
in	O
fresh	O
leukemia	B-Disease
cells	O
from	O
ATL	B-Disease
patients	O
.	O

Our	O
present	O
results	O
suggest	O
that	O
activation	O
of	O
AP-1	B-Gene
occurs	O
through	O
Tax	B-Gene
-dependent	O
and	O
-independent	O
mechanisms	O
in	O
HTLV-1	O
-infected	O
T	O
cells	O
,	O
which	O
may	O
play	O
some	O
roles	O
in	O
dysregulated	O
phenotypes	O
of	O
HTLV-1	O
-infected	O
cells	O
.	O

Cutting	O
edge	O
:	O
STAT6	B-Gene
-deficient	O
mice	O
have	O
enhanced	O
tumor	B-Disease
immunity	O
to	O
primary	O
and	O
metastatic	O
mammary	B-Disease
carcinoma	I-Disease
.	O

STAT4	B-Gene
and	O
STAT6	B-Gene
are	O
essential	O
for	O
the	O
development	O
of	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
Th1	O
and	O
Th2	O
development	O
,	O
respectively	O
.	O

Tumor	B-Disease
immunologists	O
have	O
hypothesized	O
that	O
Th1	O
cells	O
are	O
critical	O
in	O
tumor	B-Disease
immunity	O
because	O
they	O
facilitate	O
differentiation	O
of	O
CD8	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
,	O
which	O
are	O
potent	O
anti-tumor	B-Disease
effectors	O
.	O

We	O
have	O
used	O
STAT4	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
and	O
STAT6	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
to	O
test	O
this	O
hypothesis	O
.	O

BALB	O
/	O
c	O
and	O
knockout	O
mice	O
were	O
challenged	O
in	O
the	O
mammary	O
gland	O
with	O
the	O
highly	O
malignant	O
and	O
spontaneously	O
metastatic	O
BALB	O
/	O
c	O
-derived	O
4T1	O
mammary	B-Disease
carcinoma	I-Disease
.	O

Primary	O
tumor	B-Disease
growth	O
and	O
metastatic	O
disease	O
are	O
reduced	O
in	O
STAT6	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
relative	O
to	O
BALB	O
/	O
c	O
and	O
STAT4	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
.	O

Ab	O
depletions	O
demonstrate	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
CD8	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
,	O
and	O
immunized	O
STAT6	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
have	O
higher	O
levels	O
of	O
4T1-specific	O
CTL	O
than	O
BALB	O
/	O
c	O
or	O
STAT4	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
.	O

Surprisingly	O
,	O
Th1	O
or	O
Th2	O
cells	O
are	O
not	O
involved	O
,	O
because	O
CD4	B-Gene
depletion	O
does	O
not	O
diminish	O
the	O
anti-tumor	B-Disease
effect	O
.	O

Therefore	O
,	O
deletion	O
of	O
the	O
STAT6	B-Gene
gene	I-Gene
facilitates	O
development	O
of	O
potent	O
anti-tumor	B-Disease
immunity	O
via	O
a	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-independent	O
pathway	O
.	O

hsp70	B-Gene
interacting	I-Gene
protein	I-Gene
Hip	I-Gene
does	O
not	O
affect	O
glucocorticoid	B-Gene
receptor	I-Gene
folding	O
by	O
the	O
hsp90	B-Gene
-based	I-Gene
chaperone	I-Gene
machinery	O
except	O
to	O
oppose	O
the	O
effect	O
of	O
BAG-1	B-Gene
.	O

Reticulocyte	O
lysate	O
contains	O
a	O
chaperone	O
system	O
that	O
assembles	O
glucocorticoid	B-Gene
receptor	I-Gene
(	I-Gene
GR	I-Gene
)	I-Gene
.hsp90	I-Gene
heterocomplexes	I-Gene
.	O

Using	O
purified	O
proteins	O
,	O
we	O
have	O
prepared	O
a	O
five-protein	O
heterocomplex	O
assembly	O
system	O
consisting	O
of	O
two	O
proteins	O
essential	O
for	O
heterocomplex	O
assembly-	O
hsp90	B-Gene
and	O
hsp70	B-Gene
-and	O
three	O
proteins	O
that	O
act	O
as	O
co-chaperones	O
to	O
enhance	O
assembly-	O
Hop	B-Gene
,	O
hsp40	B-Gene
,	O
p23	B-Gene
[	O
Morishima	O
,	O
Y.	O
,	O
Kanelakis	O
,	O
K.	O
C.	O
,	O
Silverstein	O
,	O
A.	O
M.	O
,	O
Dittmar	O
,	O
K.	O
D.	O
,	O
Estrada	O
,	O
L.	O
,	O
and	O
Pratt	O
,	O
W.	O
B.	O
(	O
2000	O
)	O
J.	O
Biol.	O
Chem.	O
275	O
,	O
6894-6900	O
]	O
.	O

The	O
hsp70	B-Gene
co-chaperone	I-Gene
Hip	I-Gene
has	O
been	O
recovered	O
in	O
receptor.hsp90	B-Gene
heterocomplexes	I-Gene
at	O
an	O
intermediate	O
stage	O
of	O
assembly	O
in	O
reticulocyte	O
lysate	O
,	O
and	O
Hip	B-Gene
is	O
also	O
thought	O
to	O
be	O
an	O
intrinsic	O
component	O
of	O
the	O
assembly	O
machinery	O
.	O

Here	O
we	O
show	O
that	O
immunodepletion	O
of	O
Hip	B-Gene
from	O
reticulocyte	O
lysate	O
or	O
addition	O
of	O
high	O
levels	O
of	O
Hip	B-Gene
to	O
the	O
purified	O
five-protein	O
system	O
does	O
not	O
affect	O
GR.hsp90	B-Gene
heterocomplex	I-Gene
assembly	O
or	O
the	O
activation	O
of	O
steroid	B-Chemical
binding	O
activity	O
that	O
occurs	O
with	O
assembly	O
.	O

Despite	O
the	O
fact	O
that	O
Hip	B-Gene
does	O
not	O
affect	O
assembly	O
,	O
it	O
is	O
recovered	O
in	O
GR.hsp90	B-Gene
heterocomplexes	I-Gene
assembled	O
by	O
both	O
systems	O
.	O

In	O
the	O
five-protein	O
system	O
,	O
Hip	B-Gene
prevents	O
inhibition	O
of	O
assembly	O
by	O
the	O
hsp70	B-Gene
co-chaperone	I-Gene
BAG-1	I-Gene
,	O
and	O
cotransfection	O
of	O
Hip	B-Gene
with	O
BAG-1	B-Gene
opposes	O
BAG-1	B-Gene
reduction	O
of	O
steroid	B-Chemical
binding	O
activity	O
in	O
COS	O
cells	O
.	O

We	O
conclude	O
that	O
Hip	B-Gene
is	O
not	O
a	O
component	O
of	O
the	O
assembly	O
machinery	O
but	O
that	O
it	O
could	O
play	O
a	O
regulatory	O
role	O
in	O
opposition	O
to	O
BAG-1	B-Gene
.	O

Identification	O
and	O
characterization	O
of	O
SKAT-2	B-Gene
,	O
a	O
novel	O
Th2-specific	O
zinc	O
finger	O
gene	O
.	O

We	O
have	O
identified	O
a	O
novel	O
Kruppel-type	O
zinc	O
finger	O
(	O
ZF	O
)	O
gene	O
,	O
SKAT-2	B-Gene
,	O
which	O
is	O
selectively	O
expressed	O
by	O
murine	O
Th2	O
cells	O
.	O

The	O
protein	O
encoded	O
by	O
this	O
gene	O
has	O
14	O
C2H2-type	O
ZF	O
tandemly	O
arrayed	O
at	O
its	O
C	O
terminus	O
and	O
N-terminal	O
SCAN	O
box	O
and	O
KRAB	O
domains	O
.	O

SKAT-2	B-Gene
is	O
tissue	O
restricted	O
in	O
expression	O
at	O
the	O
RNA	O
level	O
,	O
detectable	O
only	O
in	O
brain	O
and	O
at	O
low	O
levels	O
in	O
kidney	O
and	O
spleen	O
and	O
few	O
hematopoietic	O
cell	O
lines	O
.	O

By	O
in	O
situ	O
hybridization	O
,	O
SKAT-2	B-Gene
expression	O
was	O
found	O
to	O
peak	O
in	O
antigen	O
-stimulated	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
after	O
2-3	O
days	O
of	O
culture	O
under	O
Th2	O
but	O
not	O
Th1	O
biasing	O
conditions	O
.	O

This	O
pattern	O
of	O
expression	O
closely	O
mirrored	O
that	O
of	O
GATA-3	B-Gene
in	O
the	O
same	O
cells	O
.	O

In	O
transient	O
transfection	O
experiments	O
in	O
phorbol	B-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
/	O
ionomycin	B-Chemical
-stimulated	O
EL4	O
cells	O
,	O
SKAT-2	B-Gene
was	O
found	O
to	O
up-regulate	O
the	O
activity	O
of	O
the	O
IL-4	B-Gene
but	O
not	O
the	O
IL-5	B-Gene
promoter	I-Gene
,	O
contrasting	O
with	O
the	O
ability	O
of	O
GATA-3	B-Gene
to	O
activate	O
both	O
promoters	O
.	O

This	O
result	O
was	O
confirmed	O
using	O
clones	O
of	O
EL4	O
cells	O
stably	O
expressing	O
an	O
inducible	O
form	O
of	O
SKAT-2	B-Gene
,	O
thus	O
SKAT-2	B-Gene
is	O
a	O
novel	O
Th2-specific	O
gene	O
that	O
may	O
play	O
a	O
role	O
in	O
selective	O
regulation	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Adhesion	O
of	O
immature	O
and	O
mature	O
T	O
cells	O
induces	O
in	O
human	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
activation	O
of	O
IL-6	B-Gene
gene	I-Gene
trascription	I-Gene
factors	I-Gene
(	O
NF-kappaB	B-Gene
and	O
NF-IL6	B-Gene
)	O
and	O
IL-6	B-Gene
gene	I-Gene
expression	O
:	O
role	O
of	O
alpha3beta1	B-Partial_Gene
and	O
alpha6beta4	B-Gene
integrins	I-Gene
.	O

T	O
cell	O
precursors	O
homed	O
to	O
thymus	O
develop	O
in	O
close	O
contact	O
with	O
stromal	O
cells	O
.	O

Among	O
them	O
,	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
are	O
known	O
to	O
exert	O
dominant	O
roles	O
in	O
their	O
survival	O
and	O
functional	O
shaping	O
.	O

Key	O
molecules	O
mediating	O
TEC	O
/	O
thymocytes	O
interactions	O
include	O
cytokines	O
and	O
growth	O
factors	O
secreted	O
by	O
the	O
two	O
cell	O
types	O
and	O
adhesion	O
receptors	O
mediating	O
cell	O
contact	O
.	O

Signaling	O
events	O
triggered	O
in	O
thymocytes	O
by	O
adhesion	O
to	O
epithelial	O
cells	O
have	O
been	O
extensively	O
investigated	O
,	O
whereas	O
little	O
is	O
known	O
on	O
the	O
opposite	O
phenomenon	O
.	O

We	O
have	O
previously	O
investigated	O
this	O
issue	O
in	O
a	O
co-culture	O
system	O
composed	O
of	O
TEC	O
cultures	O
derived	O
from	O
human	O
normal	O
thymus	O
and	O
heterologous	O
thymocytes	O
.	O

We	O
demonstrated	O
that	O
thymocytes	O
adhere	O
to	O
TEC	O
involving	O
beta1	B-Partial_Gene
and	O
beta4	B-Gene
integrins	I-Gene
and	O
induce	O
the	O
clustering	O
of	O
alpha3beta1	B-Partial_Gene
and	O
alpha6beta4	B-Partial_Gene
heterodimers	O
at	O
the	O
TEC	O
surface	O
.	O

In	O
addition	O
thymocyte	O
adhesion	O
was	O
followed	O
by	O
activation	O
of	O
NF-kappaB	B-Gene
and	O
NF-IL6	B-Gene
gene	I-Gene
transcription	I-Gene
factors	I-Gene
and	O
enhanced	O
IL-6	B-Gene
production	O
.	O

The	O
two	O
latter	O
phenomena	O
were	O
reproduced	O
by	O
the	O
cross	O
-linking	O
of	O
the	O
alpha3	B-Partial_Gene
,	O
alpha6	B-Partial_Gene
,	O
beta1	B-Partial_Gene
and	O
beta4	B-Gene
integrins	I-Gene
,	O
thus	O
implying	O
that	O
the	O
alpha3beta1	B-Partial_Gene
and	O
alpha6beta4	B-Partial_Gene
heterodimers	O
can	O
signal	O
during	O
thymocyte	O
adhesion	O
.	O

We	O
have	O
extended	O
our	O
previous	O
work	O
investigating	O
in	O
the	O
same	O
experimental	O
setting	O
the	O
inducing	O
activity	O
of	O
non	O
stimulated	O
or	O
activated	O
policlonal	O
or	O
clonal	O
mature	O
T	O
cells	O
as	O
representative	O
of	O
the	O
more	O
mature	O
thymocyte	O
subset	O
.	O

We	O
found	O
that	O
adhesion	O
of	O
unstimulated	O
T	O
cell	O
i	O
)	O
involved	O
beta1	B-Partial_Gene
,	O
but	O
not	O
beta4	B-Gene
integrin	I-Gene
functions	O
at	O
the	O
surface	O
ii	O
)	O
induced	O
the	O
clustering	O
of	O
alpha3beta1	B-Partial_Gene
,	O
but	O
not	O
alpha2beta1	B-Partial_Gene
heterodimers	O
at	O
the	O
TEC	O
surface	O
and	O
iii	O
)	O
up	O
-regulated	O
the	O
nuclear	O
binding	O
activity	O
of	O
NF-kappaB	B-Gene
transcription	I-Gene
factor	I-Gene
and	O
the	O
IL-6	B-Gene
secretion	O
.	O

We	O
propose	O
that	O
alpha3beta1	B-Partial_Gene
and	O
alpha6beta4	B-Partial_Gene
heterodimers	O
are	O
induced	O
to	O
cluster	O
at	O
the	O
TEC	O
surface	O
recognizing	O
yet	O
unknown	O
cellular	O
ligands	O
differentially	O
expressed	O
during	O
T	O
cell	O
development	O
.	O

Stromal	B-Gene
-derived	I-Gene
factor	I-Gene
1	I-Gene
and	O
thrombopoietin	B-Gene
regulate	O
distinct	O
aspects	O
of	O
human	O
megakaryopoiesis	O
.	O

The	O
role	O
of	O
the	O
chemokine	O
binding	O
stromal	B-Gene
-derived	I-Gene
factor	I-Gene
1	I-Gene
(	O
SDF-1	B-Gene
)	O
in	O
normal	O
human	O
megakaryopoiesis	O
at	O
the	O
cellular	O
and	O
molecular	O
levels	O
and	O
its	O
comparison	O
with	O
that	O
of	O
thrombopoietin	B-Gene
(	O
TPO	B-Gene
)	O
have	O
not	O
been	O
determined	O
.	O

In	O
this	O
study	O
it	O
was	O
found	O
that	O
SDF-1	B-Gene
,	O
unlike	O
TPO	B-Gene
,	O
does	O
not	O
stimulate	O
alpha	O
(	O
IIb	O
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cell	O
proliferation	O
or	O
differentiation	O
or	O
have	O
an	O
antiapoptotic	O
effect	O
.	O

However	O
,	O
it	O
does	O
induce	O
chemotaxis	O
,	O
trans-Matrigel	O
migration	O
,	O
and	O
secretion	O
of	O
matrix	B-Gene
metalloproteinase	I-Gene
9	I-Gene
(	O
MMP-9	B-Gene
)	O
and	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
(	O
VEGF	B-Gene
)	O
by	O
these	O
cells	O
,	O
and	O
both	O
SDF-1	B-Gene
and	O
TPO	B-Gene
increase	O
the	O
adhesion	O
of	O
alpha	O
(	O
IIb	O
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cells	O
to	O
fibrinogen	B-Gene
and	O
vitronectin	B-Gene
.	O

Investigating	O
the	O
intracellular	O
signaling	O
pathways	O
induced	O
by	O
SDF-1	B-Gene
and	O
TPO	B-Gene
revealed	O
some	O
overlapping	O
patterns	O
of	O
protein	O
phosphorylation	O
/	O
activation	O
(	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
[	O
MAPK	B-Gene
]	O
p42	B-Gene
/	I-Gene
44	I-Gene
,	O
MAPK	B-Gene
p38	I-Gene
,	O
and	O
AKT	B-Gene
[	O
protein	B-Gene
kinase	I-Gene
B	I-Gene
]	O
)	O
and	O
some	O
that	O
were	O
distinct	O
for	O
TPO	B-Gene
(	O
eg	O
,	O
JAK-STAT	B-Gene
)	O
and	O
for	O
SDF-1	B-Gene
(	O
eg	O
,	O
NF-kappa	B-Gene
B	I-Gene
)	O
.	O

It	O
was	O
also	O
found	O
that	O
though	O
inhibition	O
of	O
phosphatidyl-inositol	B-Gene
3-kinase	I-Gene
(	O
PI-3K	B-Gene
)	O
by	O
LY294002	B-Chemical
in	O
alpha	O
(	O
IIb	O
)	O
beta	O
(	O
3	O
)	O
(	O
+	O
)	O
cells	O
induced	O
apoptosis	O
and	O
inhibited	O
chemotaxis	O
adhesion	O
and	O
the	O
secretion	O
of	O
MMP-9	B-Gene
and	O
VEGF	B-Gene
,	O
the	O
inhibition	O
of	O
MAPK	B-Gene
p42	I-Gene
/	I-Gene
44	I-Gene
(	O
by	O
the	O
MEK	B-Gene
inhibitor	O
U0126	B-Chemical
)	O
had	O
no	O
effect	O
on	O
the	O
survival	O
,	O
proliferation	O
,	O
and	O
migration	O
of	O
these	O
cells	O
.	O

Hence	O
,	O
it	O
is	O
suggested	O
that	O
the	O
proliferative	O
effect	O
of	O
TPO	B-Gene
is	O
more	O
related	O
to	O
activation	O
of	O
the	O
JAK-STAT	B-Gene
pathway	O
(	O
unique	O
to	O
TPO	B-Gene
)	O
,	O
and	O
the	O
PI-3K-AKT	B-Gene
axis	O
is	O
differentially	O
involved	O
in	O
TPO-	B-Gene
and	O
SDF-1	B-Gene
-dependent	O
signaling	O
.	O

Accordingly	O
,	O
PI-3K	B-Gene
is	O
involved	O
in	O
TPO	B-Gene
-mediated	O
inhibition	O
of	O
apoptosis	O
,	O
TPO-	B-Gene
and	O
SDF-1	B-Gene
-regulated	O
adhesion	O
to	O
fibrinogen	B-Gene
and	O
vitronectin	B-Gene
,	O
and	O
SDF-1	B-Gene
-mediated	O
migration	O
.	O

This	O
study	O
expands	O
the	O
understanding	O
of	O
the	O
role	O
of	O
SDF-1	B-Gene
and	O
TPO	B-Gene
in	O
normal	O
human	O
megakaryopoiesis	O
and	O
indicates	O
the	O
molecular	O
basis	O
of	O
the	O
observed	O
differences	O
in	O
cellular	O
responses	O
.	O

(	O
Blood.	O
2000	O
;	O
96	O
:	O
4142-4151	B-Chemical
)	O

The	O
physical	O
association	O
of	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
theta	I-Gene
with	O
a	O
lipid	B-Chemical
raft	O
-associated	O
inhibitor	B-Gene
of	I-Gene
kappa	I-Gene
B	I-Gene
factor	I-Gene
kinase	I-Gene
(	I-Gene
IKK	I-Gene
)	I-Gene
complex	I-Gene
plays	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	B-Gene
B	I-Gene
cascade	O
by	O
TCR	B-Gene
and	O
CD28	B-Gene
.	O

We	O
investigated	O
the	O
role	O
of	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
theta	I-Gene
(	O
PKCtheta	B-Gene
)	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-Gene
cascade	O
in	O
primary	O
human	B-Gene
CD4	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
lymphocytes	O
.	O

Among	O
six	O
or	O
so	O
PKC	B-Gene
isoforms	I-Gene
expressed	O
in	O
T	O
cells	O
,	O
only	O
PKCtheta	B-Gene
participates	O
in	O
the	O
assembly	O
of	O
the	O
supramolecular	O
activation	O
clusters	O
at	O
the	O
contact	O
site	O
of	O
the	O
TCR	B-Gene
with	O
Ag	O
.	O

Signaling	O
via	O
both	O
the	O
TCR	B-Gene
and	O
CD28	B-Gene
is	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
multisubunit	O
IkappaB	B-Gene
kinase	I-Gene
(	I-Gene
IKK	I-Gene
)	I-Gene
complex	I-Gene
in	O
primary	O
human	O
T	O
lymphocytes	O
;	O
this	O
activation	O
could	O
be	O
inhibited	O
by	O
a	O
Ca	O
(	O
2+	O
)	O
-independent	O
PKC	B-Gene
isoform	I-Gene
inhibitor	O
,	O
rottlerin	B-Chemical
.	O

Moreover	O
,	O
endogenous	B-Gene
PKCtheta	I-Gene
physically	O
associates	O
with	O
activated	B-Gene
IKK	I-Gene
complexes	I-Gene
in	O
CD3	B-Gene
/	I-Gene
CD28	I-Gene
-costimulated	O
primary	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
.	O

The	O
same	O
set	O
of	O
stimuli	O
also	O
induced	O
relocation	O
of	O
endogenous	B-Gene
PKCtheta	I-Gene
and	O
IKKs	B-Gene
to	O
a	O
GM1	B-Chemical
ganglioside	I-Chemical
-enriched	O
,	O
detergent-insoluble	O
membrane	O
compartment	O
in	O
primary	O
T	O
cells	O
.	O

IKKs	B-Gene
recruited	O
to	O
these	O
lipid	B-Chemical
rafts	O
were	O
capable	O
of	O
phosphorylating	O
a	O
recombinant	B-Gene
IkappaBalpha	I-Gene
sustrate	O
.	O

Confocal	O
microscopy	O
further	O
demonstrated	O
that	O
exogenously	O
expressed	O
PKCtheta	B-Gene
and	O
IKKss	B-Gene
colocalize	O
in	O
the	O
membrane	O
of	O
CD3	B-Gene
/	I-Gene
CD28	I-Gene
-costimulated	O
Jurkat	O
T	O
cells	O
.	O

Constitutively	O
active	O
but	O
not	O
kinase	O
-inactive	O
PKCtheta	B-Gene
activated	O
IKKbeta	B-Gene
in	O
Jurkat	O
T	O
cells	O
.	O

Expression	O
of	O
dominant	O
-active	O
PKCtheta	B-Gene
also	O
had	O
stimulatory	O
effects	O
on	O
the	O
CD28	B-Gene
response	I-Gene
element	I-Gene
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
activation	O
of	O
PKCtheta	B-Gene
by	O
the	O
TCR	B-Gene
and	O
CD28	B-Gene
plays	O
an	O
important	O
role	O
in	O
the	O
assembly	O
and	O
activation	O
of	O
IKK	B-Gene
complexes	I-Gene
in	O
the	O
T	O
cell	O
membrane	O

Peroxisome	B-Gene
proliferator	I-Gene
activator	I-Gene
receptor-gamma	I-Gene
agonists	I-Gene
and	O
15-deoxy-Delta	B-Chemical
(	I-Chemical
12	I-Chemical
,	I-Chemical
14	I-Chemical
)	I-Chemical
(	I-Chemical
12	I-Chemical
,	I-Chemical
14	I-Chemical
)	I-Chemical
-PGJ	I-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
induce	O
apoptosis	O
in	O
normal	O
and	O
malignant	O
B-lineage	O
cells	O
.	O

The	O
research	O
described	O
herein	O
evaluates	O
the	O
expression	O
and	O
functional	O
significance	O
of	O
peroxisome	B-Gene
proliferator	I-Gene
activator	I-Gene
receptor-gamma	I-Gene
(	O
PPAR-gamma	B-Gene
)	O
on	O
B-lineage	O
cells	O
.	O

Normal	O
mouse	O
B	O
cells	O
and	O
a	O
variety	O
of	O
B	B-Disease
lymphoma	I-Disease
cells	O
reflective	O
of	O
stages	O
of	O
B	O
cell	O
differentiation	O
(	O
e.g.	O
,	O
70Z	O
/	O
3	O
,	O
CH31	O
,	O
WEHI-231	O
,	O
CH12	O
,	O
and	O
J558	O
)	O
express	O
PPAR-gamma	B-Gene
mRNA	I-Gene
and	O
,	O
by	O
Western	O
blot	O
analysis	O
,	O
the	O
67-kDa	B-Gene
PPAR-gamma	I-Gene
protein	I-Gene
.	O

15-Deoxy-Delta	B-Chemical
(	I-Chemical
12	I-Chemical
,	I-Chemical
14	I-Chemical
)	I-Chemical
-PGJ	I-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
(	O
15d-PGJ	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
,	O
a	O
PPAR-gamma	B-Gene
agonist	O
,	O
has	O
a	O
dose	O
-dependent	O
antiproliferative	O
and	O
cytotoxic	O
effect	O
on	O
normal	O
and	O
malignant	O
B	O
cells	O
as	O
shown	O
by	O
[	O
(	O
3	O
)	O
H	O
]	O
thymidine	O
and	O
3-	O
[	O
4	O
,	O
5-dimethylthiazol-2-yl	O
]	O
-2	O
,	O
5-diphenyltetrazolium	O
bromide	O
assays	O
.	O

Only	O
PPAR-gamma	B-Gene
agonists	O
(	O
thiazolidinediones	B-Chemical
)	O
,	O
and	O
not	O
PPAR-alpha	B-Gene
agonists	I-Gene
,	O
mimicked	O
the	O
effect	O
of	O
15d-PGJ	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
on	O
B-lineage	O
cells	O
,	O
indicating	O
that	O
the	O
mechanism	O
by	O
which	O
15d-PGJ	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
negatively	O
affects	O
B-lineage	O
cells	O
involves	O
in	O
part	O
PPAR-gamma	B-Gene
.	O

The	O
mechanism	O
by	O
which	O
PPAR-gamma	B-Gene
agonists	I-Gene
induce	O
cytotoxicity	O
is	O
via	O
apoptosis	O
,	O
as	O
shown	O
by	O
annexin	O
V	O
staining	O
and	O
as	O
confirmed	O
by	O
DNA	O
fragmentation	O
detected	O
using	O
the	O
TUNEL	O
assay	O
.	O

Interestingly	O
,	O
addition	O
of	O
PGF	B-Chemical
(	I-Chemical
2alpha	I-Chemical
)	I-Chemical
,	O
which	O
was	O
not	O
known	O
to	O
affect	O
lymphocytes	O
,	O
dramatically	O
attenuated	O
the	O
deleterious	O
effects	O
of	O
PPAR-gamma	B-Gene
agonists	I-Gene
on	O
B	B-Disease
lymphomas	I-Disease
.	O

Surprisingly	O
,	O
15d-PGJ	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
induced	O
a	O
massive	O
increase	O
in	O
nuclear	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
activation	O
,	O
and	O
pretreatment	O
with	O
PGF	B-Chemical
(	I-Chemical
2alpha	I-Chemical
)	I-Chemical
blunted	O
the	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
activation	O
.	O

This	O
is	O
the	O
first	O
study	O
evaluating	O
PPAR-gamma	B-Gene
expression	O
and	O
its	O
significance	O
on	O
B	O
lymphocytes	O
.	O

PPAR-gamma	B-Gene
agonists	I-Gene
may	O
serve	O
as	O
a	O
counterbalance	O
to	O
the	O
stimulating	O
effects	O
of	O
other	O
PGs	B-Chemical
,	O
namely	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
,	O
which	O
promotes	O
B	O
cell	O
differentiation	O
.	O

Finally	O
,	O
the	O
use	O
of	O
PGs	B-Chemical
,	O
such	O
as	O
15d-PGJ	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
,	O
and	O
synthetic	O
PPAR-gamma	B-Gene
agonists	I-Gene
to	O
induce	O
apoptosis	O
in	O
B-lineage	O
cells	O
may	O
lead	O
to	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
fatal	O
B	B-Disease
lymphomas	I-Disease

The	O
murine	B-Gene
IL-2	I-Gene
promoter	I-Gene
contains	O
distal	O
regulatory	O
elements	O
responsive	O
to	O
the	O
Ah	B-Gene
receptor	I-Gene
,	O
a	O
member	O
of	O
the	O
evolutionarily	O
conserved	O
bHLH-PAS	B-Gene
transcription	I-Gene
factor	I-Gene
family	I-Gene
.	O

Signaling	O
through	O
the	O
TCR	B-Gene
and	O
costimulatory	O
signals	O
primarily	O
control	O
transcription	O
of	O
the	O
IL-2	B-Gene
gene	I-Gene
in	O
naive	O
T	O
cells	O
.	O

The	O
minimal	O
promoter	O
necessary	O
for	O
this	O
expression	O
lies	O
proximal	O
,	O
between	O
-300	O
and	O
the	O
transcription	O
start	O
site	O
.	O

We	O
had	O
previously	O
shown	O
that	O
activation	O
of	O
the	O
arylhydrocarbon	B-Gene
receptor	I-Gene
(	O
AHR	B-Gene
)	O
,	O
a	O
member	O
of	O
the	O
bHLH-PAS	B-Gene
family	I-Gene
of	O
transcription	O
factors	O
,	O
leads	O
to	O
increased	O
mRNA	O
expression	O
of	O
IL-2	B-Gene
in	O
murine	O
fetal	O
thymocytes	O
.	O

The	O
AHR	B-Gene
is	O
abundant	O
in	O
the	O
thymus	O
and	O
may	O
play	O
a	O
role	O
for	O
the	O
development	O
of	O
the	O
immune	O
system	O
.	O

Moreover	O
,	O
its	O
overactivation	O
by	O
chemicals	O
such	O
as	O
dioxins	B-Chemical
leads	O
to	O
immunosuppression	O
and	O
thymic	O
involution	O
.	O

Binding	O
motifs	O
for	O
the	O
liganded	B-Gene
AHR	I-Gene
can	O
be	O
identified	O
in	O
the	O
distal	O
region	O
-1300	O
to	O
-800	O
of	O
the	O
mouse	B-Gene
IL-2	I-Gene
promoter	I-Gene
.	O

We	O
show	O
here	O
that	O
these	O
DNA	O
motifs	O
,	O
the	O
so	O
-called	O
dioxin	B-Chemical
response	O
elements	O
,	O
after	O
binding	O
to	O
the	O
liganded	B-Gene
AHR	I-Gene
are	O
sufficient	O
to	O
transactivate	O
luciferase	O
expression	O
in	O
a	O
reporter	O
gene	O
system	O
.	O

The	O
IL-2	B-Gene
gene	I-Gene
can	O
be	O
induced	O
by	O
the	O
AHR	B-Gene
also	O
in	O
thymocytes	O
in	O
vivo	O
after	O
injection	O
of	O
2	B-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
7	I-Chemical
,	I-Chemical
8-tetrachlorodibenzo-p-dioxin	I-Chemical
,	O
a	O
potent	O
ligand	O
of	O
the	O
AHR	B-Gene
.	O

The	O
AHR	B-Gene
mediates	O
the	O
IL-2	B-Gene
induction	O
as	O
shown	O
with	O
AHR	B-Gene
-deficient	O
mice	O
.	O

However	O
,	O
in	O
spleen	O
cells	O
in	O
vitro	O
costimulation	O
via	O
the	O
TCR	B-Gene
is	O
necessary	O
for	O
optimal	O
IL-2	B-Gene
gene	I-Gene
induction	O
.	O

Thus	O
,	O
the	O
IL-2	B-Gene
promoter	I-Gene
region	O
contains	O
novel	O
distal	O
regulatory	O
elements	O
that	O
can	O
be	O
addressed	O
by	O
the	O
AHR	B-Gene
to	O
induce	O
IL-2	B-Gene
and	O
can	O
cooperate	O
with	O
the	O
proximal	O
promoter	O

Multiple	O
signals	O
required	O
for	O
cyclic	B-Gene
AMP	I-Gene
-responsive	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
(	I-Gene
CREB	I-Gene
)	I-Gene
binding	I-Gene
protein	I-Gene
interaction	O
induced	O
by	O
CD3	B-Gene
/	I-Gene
CD28	I-Gene
costimulation	O
.	O

The	O
optimal	O
activation	O
of	O
cAMP	B-Gene
-responsive	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
(	O
CREB	B-Gene
)	O
,	O
similar	O
to	O
the	O
full	O
activation	O
of	O
T	O
lymphocytes	O
,	O
requires	O
the	O
stimulation	O
of	O
both	O
CD3	B-Gene
and	O
CD28	B-Gene
.	O

Using	O
a	O
reporter	O
system	O
to	O
detect	O
interaction	O
of	O
CREB	B-Gene
and	O
CREB	B-Gene
-binding	I-Gene
protein	I-Gene
(	O
CBP	B-Gene
)	O
,	O
in	O
this	O
study	O
we	O
found	O
that	O
CREB	B-Gene
binds	O
to	O
CBP	B-Gene
only	O
by	O
engagement	O
of	O
both	O
CD3	B-Gene
and	O
CD28	B-Gene
.	O

CD3	B-Gene
/	I-Gene
CD28	I-Gene
-promoted	O
CREB	B-Gene
-	I-Gene
CBP	I-Gene
interaction	O
was	O
dependent	O
on	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
MAPK	B-Gene
)	O
and	O
calcium	B-Gene
/	I-Gene
calmodulin	I-Gene
-dependent	I-Gene
protein	I-Gene
kinase	I-Gene
(	I-Gene
CaMK	I-Gene
)	I-Gene
IV	I-Gene
in	O
addition	O
to	O
the	O
previously	O
identified	O
extracellular	B-Gene
signal	I-Gene
-regulated	I-Gene
kinase	I-Gene
pathway	O
.	O

Extracellular	B-Gene
signal	I-Gene
-regulated	I-Gene
kinase	I-Gene
,	O
CaMKIV	B-Gene
,	O
and	O
p38	B-Gene
MAPK	I-Gene
were	O
also	O
the	O
kinases	O
involved	O
in	O
CREB	B-Gene
Ser	B-Chemical
(	O
133	O
)	O
phosphorylation	O
induced	O
by	O
CD3	B-Gene
/	I-Gene
CD28	I-Gene
.	O

A	O
reconstitution	O
experiment	O
illustrated	O
that	O
optimum	O
CREB	B-Gene
-	I-Gene
CBP	I-Gene
interaction	O
and	O
CREB	B-Gene
trans-activation	O
were	O
attained	O
when	O
these	O
three	O
kinase	O
pathways	O
were	O
simultaneously	O
activated	O
in	O
T	O
cells	O
.	O

Our	O
results	O
demonstrate	O
that	O
coordinated	O
activation	O
of	O
different	O
kinases	O
leads	O
to	O
full	O
activation	O
of	O
CREB	B-Gene
.	O

Notably	O
,	O
CD28	B-Gene
ligation	O
activated	O
p38	B-Gene
MAPK	I-Gene
and	O
CaMKIV	B-Gene
,	O
the	O
kinases	O
stimulated	O
by	O
CD3	B-Gene
engagement	O
,	O
suggesting	O
that	O
CD28	B-Gene
acts	O
by	O
increasing	O
the	O
activation	O
extent	O
of	O
p38	B-Gene
MAPK	I-Gene
and	O
CaMKIV	B-Gene
.	O

These	O
results	O
support	O
the	O
model	O
of	O
a	O
minimum	O
activation	O
threshold	O
for	O
CREB	B-Gene
-	I-Gene
CBP	I-Gene
interaction	O
that	O
can	O
be	O
reached	O
only	O
when	O
both	O
CD3	B-Gene
and	O
CD28	B-Gene
are	O
stimulated	O
.	O

Activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
in	O
healthy	O
lymphomonocytes	O
exposed	O
to	O
bystander	O
HIV-1	O
-infected	O
cells	O
.	O

Persistent	O
activation	O
of	O
the	O
immune	O
system	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
HIV-1	O
infection	O
.	O

In	O
this	O
study	O
we	O
analysed	O
the	O
induction	O
of	O
factors	O
involved	O
in	O
cytokine	O
signal	O
transduction	O
,	O
such	O
as	O
STAT	B-Gene
1	I-Gene
proteins	I-Gene
and	O
IRF-1	B-Gene
mRNA	I-Gene
,	O
in	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
exposed	O
to	O
HIV	O
-infected	O
cells	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
.	O

Western	O
blot	O
analyses	O
and	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
results	O
indicate	O
that	O
both	O
cells	O
infected	O
with	O
a	O
X4	O
strain	O
and	O
cells	O
infected	O
with	O
a	O
R5	O
strain	O
are	O
able	O
to	O
increase	O
intracellular	O
levels	O
of	O
STAT	B-Gene
1alpha	I-Gene
and	O
beta	B-Partial_Gene
proteins	I-Partial_Gene
as	O
well	O
as	O
IRF-1	B-Gene
mRNA	I-Gene
.	O

This	O
effect	O
was	O
prevented	O
by	O
neutralizing	O
antibodies	O
against	O
interferon-alpha	B-Gene
(	O
IFN-alpha	B-Gene
)	O
.	O

HIV-1	O
-infected	O
cells	O
dose	O
-dependently	O
induced	O
apoptotic	O
commitment	O
in	O
normal	O
PBMC	O
,	O
as	O
revealed	O
by	O
DNA	O
fragmentation	O
analysis	O
,	O
but	O
this	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
of	O
caspase-3	B-Gene
activity	O
,	O
even	O
if	O
a	O
slight	O
up-regulation	O
of	O
IL-1beta	B-Gene
-converting	I-Gene
enzyme	I-Gene
mRNA	I-Gene
was	O
detected	O
.	O

Apoptosis	O
induction	O
could	O
be	O
abrogated	O
mainly	O
by	O
antibodies	O
against	O
tumour	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
antibodies	O
against	O
IFN-gamma	B-Gene
.	O

All	O
these	O
findings	O
suggest	O
that	O
uninfected	O
PBMC	O
can	O
undergo	O
activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
after	O
exposure	O
to	O
bystander	O
HIV	O
-infected	O
cells	O
,	O
subsequent	O
to	O
the	O
induction	O
of	O
cytokines	O
such	O
as	O
IFNs	B-Gene
and	O
TNF-alpha	B-Gene
.	O

The	O
proteasome	O
regulates	O
receptor	O
-mediated	O
endocytosis	O
of	O
interleukin-2	B-Gene
.	O

Recent	O
studies	O
have	O
increasingly	O
implicated	O
the	O
proteasome	O
in	O
the	O
regulation	O
of	O
cell	O
surface	O
receptors	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
proteasome	O
for	O
ligand	O
-dependent	O
endocytosis	O
and	O
degradation	O
of	O
the	O
interleukin-2	B-Gene
(	I-Gene
IL-2	I-Gene
)	I-Gene
-interleukin-2	I-Gene
receptor	I-Gene
(	I-Gene
IL-2R	I-Gene
)	I-Gene
complex	I-Gene
.	O

Proteasome	O
inhibitors	O
impaired	O
internalization	O
of	O
IL-2.IL-2R	B-Gene
and	O
prevented	O
the	O
lysosomal	O
degradation	O
of	O
this	O
cytokine	O
.	O

Based	O
on	O
time-course	O
studies	O
,	O
proteasome	O
activity	O
is	O
primarily	O
required	O
after	O
initial	O
endocytosis	O
of	O
the	O
IL-2.IL-2R	B-Gene
.	O

Proteasome	O
function	O
was	O
also	O
necessary	O
for	O
the	O
lysosomal	O
degradation	O
of	O
IL-2	B-Gene
internalized	O
by	O
IL-2R	B-Gene
that	O
were	O
comprised	O
of	O
cytoplasmic	O
tailless	O
beta-	B-Partial_Gene
or	O
gamma	B-Gene
c-subunits	I-Gene
,	O
suggesting	O
that	O
the	O
target	O
protein	O
for	O
the	O
proteasome	O
is	O
independent	O
of	O
either	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
IL-2R	B-Gene
beta-	I-Gene
or	O
gamma	B-Gene
c-subunits	I-Gene
and	O
their	O
associated	O
signaling	O
components	O
.	O

Therefore	O
,	O
a	O
functional	O
proteasome	O
is	O
required	O
for	O
optimal	O
endocytosis	O
of	O
the	O
IL-2R	B-Gene
/	I-Gene
ligand	I-Gene
complex	I-Gene
and	O
is	O
essential	O
for	O
the	O
subsequent	O
lysosomal	O
degradation	O
of	O
IL-2	B-Gene
,	O
possibly	O
by	O
regulating	O
trafficking	O
to	O
the	O
lysosome	O
.	O

Design	O
and	O
use	O
of	O
an	O
inducibly	O
activated	B-Gene
human	I-Gene
immunodeficiency	I-Gene
virus	I-Gene
type	I-Gene
1	I-Gene
Nef	I-Gene
to	O
study	O
immune	O
modulation	O
.	O

The	O
Nef	B-Gene
protein	I-Gene
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
infectivity	O
of	O
virus	O
particles	O
,	O
downmodulate	O
cell	O
surface	O
proteins	O
,	O
and	O
associate	O
with	O
many	O
intracellular	O
proteins	O
that	O
are	O
thought	O
to	O
facilitate	O
HIV	O
infection	O
.	O

One	O
of	O
the	O
challenges	O
in	O
defining	O
the	O
molecular	O
events	O
regulated	O
by	O
Nef	B-Gene
has	O
been	O
obtaining	O
good	O
expression	O
of	O
Nef	B-Gene
protein	I-Gene
in	O
T	O
cells	O
.	O

This	O
has	O
been	O
attributed	O
to	O
effects	O
of	O
Nef	B-Gene
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

We	O
have	O
designed	O
a	O
Nef	B-Gene
protein	I-Gene
that	O
is	O
readily	O
expressed	O
in	O
T-cell	O
lines	O
and	O
whose	O
function	O
is	O
inducibly	O
activated	O
.	O

It	O
is	O
composed	O
of	O
a	O
fusion	O
between	O
full-length	O
Nef	B-Gene
and	O
the	O
estrogen	B-Gene
receptor	I-Gene
hormone	O
-binding	O
domain	O
(	O
Nef-ER	B-Gene
)	O
.	O

The	O
Nef-ER	B-Gene
is	O
kept	O
in	O
an	O
inactive	O
state	O
due	O
to	O
steric	O
hindrance	O
,	O
and	O
addition	O
of	O
the	O
membrane-permeable	O
drug	O
4-hydroxytamoxifen	B-Chemical
(	O
4-HT	B-Chemical
)	O
,	O
which	O
binds	O
to	O
the	O
ER	B-Gene
domain	O
,	O
leads	O
to	O
inducible	O
activation	O
of	O
Nef-ER	B-Gene
within	O
cells	O
.	O

We	O
demonstrate	O
that	O
Nef-ER	B-Gene
inducibly	O
associates	O
with	O
the	O
62-kDa	B-Gene
Ser	I-Gene
/	I-Gene
Thr	I-Gene
kinase	I-Gene
and	O
is	O
localized	O
to	O
specific	O
membrane	O
microdomains	O
(	O
lipid	B-Chemical
rafts	O
)	O
only	O
after	O
activation	O
.	O

Using	O
this	O
inducible	O
Nef	B-Gene
,	O
we	O
also	O
compared	O
the	O
specific	O
requirements	O
for	O
CD4	B-Gene
and	O
HLA-A2	B-Gene
downmodulation	O
in	O
a	O
SupT1	O
T-cell	O
line	O
.	O

Half-maximal	O
downmodulation	O
of	O
cell	B-Gene
surface	I-Gene
CD4	I-Gene
required	O
very	O
little	O
active	O
Nef-ER	B-Gene
and	O
occurred	O
as	O
early	O
as	O
4	O
h	O
after	O
addition	O
of	O
4-HT	B-Chemical
.	O

In	O
contrast	O
,	O
50	O
%	O
downmodulation	O
of	O
HLA-A2	B-Gene
by	O
Nef	B-Gene
required	O
16	O
to	O
24	O
h	O
and	O
about	O
50-	O
to	O
100-fold-greater	O
concentrations	O
of	O
4-HT	B-Chemical
.	O

These	O
data	O
suggest	O
that	O
HLA-A2	B-Gene
downmodulation	O
may	O
require	O
certain	O
threshold	O
levels	O
of	O
active	O
Nef	B-Gene
.	O

The	O
differential	O
timing	O
of	O
CD4	B-Gene
and	O
HLA-A2	B-Gene
downmodulation	O
may	O
have	O
implications	O
for	O
HIV	O
pathogenesis	O
and	O
immune	O
evasion	O
.	O

Strict	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
genetic	O
switch	O
:	O
Tet	O
for	O
Tat	B-Gene
.	O

Live	O
-attenuated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
variants	O
have	O
shown	O
great	O
promise	O
as	O
AIDS	B-Disease
vaccines	O
,	O
but	O
continued	O
replication	O
can	O
lead	O
to	O
the	O
selection	O
of	O
faster	O
-replicating	O
variants	O
that	O
are	O
pathogenic	O
.	O

We	O
therefore	O
designed	O
HIV-1	O
genomes	O
that	O
replicate	O
exclusively	O
upon	O
addition	O
of	O
the	O
nontoxic	O
effector	O
doxycycline	B-Chemical
(	O
dox	B-Chemical
)	O
.	O

This	O
was	O
achieved	O
by	O
replacement	O
of	O
the	O
viral	O
TAR-Tat	B-Gene
system	O
for	O
transcriptional	O
activation	O
by	O
the	O
Escherichia	O
coli	O
-derived	O
Tet	O
system	O
for	O
inducible	O
gene	O
expression	O
.	O

These	O
designer	O
``	O
HIV-rtTA	O
''viruses	O
replicate	O
in	O
a	O
strictly	O
dox	B-Chemical
-dependent	O
manner	O
both	O
in	O
a	O
T-cell	O
line	O
and	O
in	O
primary	O
blood	O
cells	O
,	O
and	O
the	O
rate	O
of	O
replication	O
can	O
be	O
fine	O
-tuned	O
by	O
simple	O
variation	O
of	O
the	O
dox	B-Chemical
concentration	O
.	O

These	O
HIV-rtTA	O
viruses	O
provide	O
a	O
tool	O
to	O
perform	O
genetics	O
,	O
e.g.	O
,	O
selection	O
and	O
optimization	O
experiments	O
,	O
with	O
the	O
E.	O
coli	O
-derived	O
Tet	O
reagents	O
in	O
a	O
eukaryotic	O
background	O
.	O

Furthermore	O
,	O
such	O
viruses	O
may	O
represent	O
improved	O
vaccine	O
candidates	O
because	O
their	O
replication	O
can	O
be	O
turned	O
on	O
and	O
off	O
at	O
will	O
.	O

Human	O
renal	O
mesangial	O
cells	O
are	O
a	O
target	O
for	O
the	O
anti-inflammatory	O
action	O
of	O
9-cis	B-Chemical
retinoic	I-Chemical
acid	I-Chemical
.	O

Mesangial	O
cells	O
play	O
an	O
active	O
role	O
in	O
the	O
inflammatory	O
response	O
to	O
glomerular	O
injury	O
.	O

We	O
have	O
studied	O
in	O
cultured	O
human	O
mesangial	O
cells	O
(	O
CHMC	O
)	O
several	O
effects	O
of	O
9-cis	B-Chemical
retinoic	I-Chemical
acid	I-Chemical
(	O
9-cRA	B-Chemical
)	O
,	O
an	O
activator	O
of	O
both	O
retinoic	B-Gene
acid	I-Gene
receptors	I-Gene
(	O
RARs	B-Gene
)	O
and	O
retinoid	B-Gene
X	I-Gene
receptors	I-Gene
(	O
RXRs	B-Gene
)	O
.	O

9-cRA	B-Chemical
inhibited	O
foetal	O
calf	O
serum	O
-induced	O
CHMC	O
proliferation	O
.	O

It	O
also	O
prevented	O
CHMC	O
death	O
induced	O
by	O
the	O
inflammatory	O
mediator	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O

This	O
preventive	O
effect	O
was	O
not	O
due	O
to	O
any	O
increase	O
in	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
catabolism	O
and	O
it	O
persisted	O
even	O
when	O
both	O
catalase	B-Gene
and	O
glutathione	B-Chemical
synthesis	O
were	O
inhibited	O
.	O

Finally	O
,	O
9-cRA	B-Chemical
diminished	O
monocyte	O
adhesion	O
to	O
FCS	O
-stimulated	O
CHMC	O
.	O

Interestingly	O
,	O
the	O
retinoid	B-Chemical
also	O
inhibited	O
in	O
FCS	O
-stimulated	O
cells	O
the	O
protein	O
expression	O
of	O
two	O
mesangial	O
adhesion	O
molecules	O
,	O
fibronectin	B-Gene
and	O
osteopontin	B-Gene
,	O
but	O
it	O
did	O
not	O
modify	O
the	O
protein	O
expression	O
of	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
and	O
vascular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
.	O

All	O
major	O
RARs	B-Gene
and	O
RXRs	B-Gene
isotypes	O
were	O
expressed	O
in	O
CHMC	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
9-cRA	B-Chemical
.	O

Transcripts	O
to	O
RAR-alpha	B-Gene
,	O
RAR-beta	B-Gene
and	O
RXR-alpha	B-Gene
increased	O
after	O
incubation	O
with	O
9-cRA	B-Chemical
whereas	O
RXR-gamma	B-Gene
was	O
inhibited	O
,	O
suggesting	O
a	O
major	O
role	O
for	O
RARs	B-Gene
and	O
RXRs	B-Gene
in	O
9-cRA-anti-inflammatory	B-Chemical
effects	O
.	O

9-cRA	B-Chemical
was	O
toxic	O
only	O
at	O
50	O
microM	O
(	O
a	O
concentration	O
50	O
-	O
5000	O
times	O
higher	O
than	O
required	O
for	O
the	O
effects	O
above	O
)	O
.	O

Cell	O
death	O
occurred	O
by	O
apoptosis	O
,	O
whose	O
onset	O
was	O
associated	O
with	O
a	O
pronounced	O
increase	O
in	O
catalase	B-Gene
activity	O
and	O
reduced	O
glutathione	B-Chemical
content	O
,	O
being	O
more	O
effectively	O
induced	O
by	O
all-trans	B-Chemical
retinoic	I-Chemical
acid	I-Chemical
.	O

Modulation	O
of	O
the	O
oxidant	O
/	O
antioxidant	O
balance	O
failed	O
to	O
inhibit	O
apoptosis	O
.	O

We	O
conclude	O
that	O
mesangial	O
cells	O
might	O
be	O
a	O
target	O
for	O
the	O
treatment	O
of	O
inflammatory	O
glomerulopathies	B-Disease
with	O
9-cRA	B-Chemical
.	O

Combined	O
corticosteroid	B-Chemical
/	O
granulocyte	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
G-CSF	B-Gene
)	O
therapy	O
in	O
the	O
treatment	O
of	O
severe	B-Disease
congenital	I-Disease
neutropenia	I-Disease
unresponsive	O
to	O
G-CSF	B-Gene
:	O
Activated	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
synergize	O
with	O
G-CSF	B-Gene
signals	O
.	O

More	O
than	O
90	O
%	O
of	O
patients	O
with	O
severe	B-Disease
congenital	I-Disease
neutropenia	I-Disease
(	O
SCN	B-Disease
)	O
respond	O
to	O
granulocyte	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
G-CSF	B-Gene
)	O
therapy	O
.	O

The	O
basis	O
for	O
the	O
refractory	O
state	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
studied	O
a	O
child	O
with	O
SCN	B-Disease
who	O
was	O
totally	O
unresponsive	O
to	O
G-CSF	B-Gene
and	O
had	O
a	O
novel	O
point	O
mutation	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
G-CSF	B-Gene
receptor	I-Gene
(	O
GCSF-R	B-Gene
)	O
.	O

Marrow	O
stromal	O
support	O
of	O
granulopoiesis	O
was	O
evaluated	O
by	O
plating	O
CD34	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
on	O
preformed	O
stromal	O
layers	O
.	O

Nonadherent	O
cells	O
were	O
harvested	O
and	O
assayed	O
in	O
clonogenic	O
assays	O
for	O
granulocytic	O
colony	O
production	O
.	O

The	O
in	O
vitro	O
effect	O
of	O
G-CSF	B-Gene
and	O
corticosteroids	B-Chemical
on	O
granulopoiesis	O
was	O
evaluated	O
in	O
clonogenic	O
assays	O
of	O
marrow	O
mononuclear	O
cells	O
,	O
by	O
proliferation	O
studies	O
of	O
the	O
murine	O
myeloid	O
cell	O
line	O
32D	O
expressing	O
the	O
patient	O
's	O
mutated	B-Gene
G-CSFR	I-Gene
,	O
and	O
by	O
measuring	O
STAT5	B-Gene
activation	O
in	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
.	O

Patient	O
's	O
stroma	O
supported	O
granulopoiesis	O
derived	O
from	O
control	O
marrow	B-Gene
CD34	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
in	O
a	O
normal	O
manner	O
.	O

Normal	O
stroma	O
,	O
however	O
,	O
failed	O
to	O
induce	O
granulopoiesis	O
from	O
patient	O
's	O
CD34	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
.	O

Clonogenic	O
assays	O
of	O
the	O
patient	O
's	O
marrow	O
mononuclear	O
cells	O
incorporating	O
either	O
G-CSF	B-Gene
or	O
hydrocortisone	B-Chemical
produced	O
little	O
neutrophil	O
growth	O
.	O

In	O
contrast	O
,	O
inclusion	O
of	O
both	O
G-CSF	B-Gene
and	O
hydrocortisone	B-Chemical
in	O
the	O
cytokine	O
``	O
cocktail	O
''markedly	O
increased	O
the	O
neutrophil	O
numbers	O
.	O

Proliferation	O
of	O
32D	O
cells	O
expressing	O
the	O
mutated	O
receptor	O
and	O
STAT5	B-Gene
activation	O
were	O
improved	O
by	O
a	O
combination	O
of	O
G-CSF	B-Gene
and	O
dexamethasone	B-Chemical
.	O

When	O
small	O
daily	O
doses	O
of	O
oral	O
prednisone	B-Chemical
were	O
then	O
administered	O
to	O
the	O
patient	O
with	O
conventional	O
doses	O
of	O
subcutaneous	O
G-CSF	B-Gene
,	O
the	O
patient	O
responded	O
with	O
increased	O
neutrophil	O
numbers	O
and	O
with	O
a	O
complete	O
reversal	O
of	O
the	O
infectious	O
problems	O
.	O

These	O
data	O
provide	O
insight	O
into	O
SCN	B-Disease
unresponsive	O
to	O
standard	O
G-CSF	B-Gene
treatment	O
and	O
to	O
the	O
potential	O
corrective	O
action	O
of	O
combined	O
treatment	O
with	O
G-CSF	B-Gene
and	O
corticosteroids	B-Chemical
through	O
synergistic	O
activation	O
of	O
STAT5	B-Gene
.	O

Human	O
eosinophils	O
constitutively	O
express	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T	I-Gene
cells	I-Gene
p	I-Gene
and	O
c	B-Partial_Gene
.	O

BACKGROUND	O
:	O
Eosinophils	O
are	O
now	O
known	O
to	O
produce	O
a	O
variety	O
of	O
proinflammatory	O
cytokines	O
,	O
although	O
the	O
molecular	O
factors	O
that	O
regulate	O
their	O
production	O
are	O
poorly	O
understood	O
.	O

The	O
expression	O
of	O
almost	O
all	O
of	O
the	O
cytokines	O
produced	O
by	O
eosinophils	O
,	O
including	O
the	O
proallergic	B-Gene
cytokine	I-Gene
IL-4	I-Gene
,	O
is	O
now	O
known	O
to	O
be	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
members	O
of	O
the	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T	I-Gene
cells	I-Gene
(	I-Gene
NFAT	I-Gene
)	I-Gene
family	I-Gene
of	O
transcription	O
factors	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
characterize	O
the	O
expression	O
of	O
different	O
NFAT	B-Gene
proteins	I-Gene
in	O
resting	O
and	O
activated	O
eosinophils	O
.	O

METHODS	O
:	O
Nuclear	O
and	O
whole	O
cell	O
extracts	O
were	O
obtained	O
from	O
both	O
peripheral	O
blood	O
eosinophils	O
and	O
those	O
obtained	O
from	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
asthmatic	O
subjects	O
after	O
endobronchial	O
allergen	O
challenge	O
.	O

NFAT	B-Gene
expression	O
was	O
determined	O
by	O
using	O
immunoprecipitation	O
and	O
Western	O
blot	O
analysis	O
,	O
DNA	O
-binding	O
assays	O
,	O
and	O
RT-PCR	O
analysis	O
of	O
eosinophil	O
mRNA	O
.	O

RESULTS	O
:	O
Both	O
peripheral	O
blood	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
eosinophils	O
expressed	O
NFATp	B-Gene
and	O
NFATc	B-Gene
protein	I-Gene
.	O

Unlike	O
activated	O
T	O
cells	O
,	O
which	O
express	O
multiple	O
NFATc	B-Gene
isoforms	I-Gene
,	O
eosinophils	O
preferentially	O
express	O
the	O
approximately	O
85-kd	O
isoform	O
.	O

In	O
addition	O
,	O
eosinophils	O
were	O
found	O
to	O
constitutively	O
express	O
NFATc	B-Gene
mRNA	I-Gene
.	O

A	O
brief	O
incubation	O
with	O
the	O
T	O
(	O
H	O
)	O
2	O
cytokines	B-Gene
IL-4	I-Gene
and	O
IL-5	B-Gene
was	O
sufficient	O
to	O
induce	O
the	O
nuclear	O
translocation	O
of	O
NFATc	B-Gene
.	O

Eosinophil	O
nuclear	O
extracts	O
contain	O
multiple	O
factors	O
that	O
can	O
specifically	O
recognize	O
the	O
IL-4	B-Gene
promoter	I-Gene
P1	I-Gene
NFAT	I-Gene
site	O
in	O
DNA	O
-binding	O
assays	O
,	O
including	O
NFATp	B-Gene
.	O

CONCLUSION	O
:	O
NFATp	B-Gene
and	O
NFATc	B-Gene
can	O
regulate	O
the	O
expression	O
of	O
cytokines	O
and	O
other	O
genes	O
in	O
eosinophils	O
but	O
appear	O
to	O
be	O
regulated	O
by	O
a	O
novel	O
signal	O
transduction	O
mechanism	O
in	O
these	O
cells	O
.	O

Constitutive	O
expression	O
of	O
NF-kappa	B-Gene
B	I-Gene
is	O
a	O
characteristic	O
feature	O
of	O
mycosis	B-Disease
fungoides	I-Disease
:	O
implications	O
for	O
apoptosis	O
resistance	O
and	O
pathogenesis	O
.	O

The	O
NF-kappa	B-Gene
B	I-Gene
family	I-Gene
of	O
transcription	O
factors	O
is	O
an	O
important	O
regulator	O
of	O
genes	O
expressed	O
during	O
inflammatory	O
responses	O
,	O
immunoglobulin	B-Gene
(	O
Ig	B-Gene
)	O
class	O
switching	O
,	O
cellular	O
differentiation	O
,	O
and	O
apoptosis	O
.	O

Recently	O
,	O
members	O
of	O
the	O
NF-kappaB	B-Gene
family	I-Gene
,	O
including	O
p65	B-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
,	O
have	O
been	O
implicated	O
in	O
promoting	O
survival	O
of	O
various	O
hematopoeitic	B-Disease
neoplasms	I-Disease
,	O
including	O
T	O
cell	O
malignancies	O
such	O
as	O
adult	B-Disease
T	I-Disease
cell	I-Disease
leukemia-lymphoma	I-Disease
.	O

We	O
investigated	O
the	O
expression	O
of	O
active	O
NF-kappa	B-Gene
B	I-Gene
p65	I-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
in	O
cases	O
of	O
mycosis	B-Disease
fungoides	I-Disease
(	O
MF	B-Disease
)	O
and	O
the	O
effect	O
of	O
chemical	O
inhibitors	O
of	O
NF-kappa	B-Gene
B	I-Gene
on	O
apoptosis	O
in	O
cutaneous	B-Disease
T	I-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
CTCL	B-Disease
)	O
cell	O
lines	O
.	O

Paraffin	B-Chemical
-embedded	O
tissues	O
from	O
23	O
cutaneous	O
lesions	O
and	O
a	O
single	O
lymph	O
node	O
biopsy	O
from	O
patients	O
diagnosed	O
with	O
MF	B-Disease
were	O
evaluated	O
for	O
p65	B-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
expression	O
by	O
using	O
a	O
monoclonal	O
mouse	O
antibody	O
that	O
detects	O
the	O
activated	O
form	O
of	O
p65	B-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
.	O

Apoptosis	O
after	O
treatment	O
with	O
the	O
NF-kappa	B-Gene
B	I-Gene
inhibitors	I-Gene
gliotoxin	B-Chemical
,	O
MG132	B-Chemical
,	O
BAY	B-Chemical
11-7082	I-Chemical
,	O
and	O
BAY	B-Chemical
11-7085	I-Chemical
was	O
quantitatively	O
measured	O
in	O
the	O
CTCL	B-Disease
cell	O
lines	O
HuT-78	O
and	O
HH	O
by	O
propidium	B-Chemical
iodide	I-Chemical
(	O
PI	B-Chemical
)	O
/	O
cell	O
cycle	O
analysis	O
for	O
detection	O
of	O
a	O
hypodiploid	O
(	O
sub-G	O
(	O
0	O
)	O
)	O
population	O
and	O
by	O
determination	O
of	O
increased	O
Annexin	B-Gene
V	I-Gene
/	O
7-amino-actinomycin	B-Chemical
D	I-Chemical
(	O
7-AAD	B-Chemical
)	O
expression	O
.	O

Nuclear	O
extracts	O
from	O
CTCL	B-Disease
cells	O
before	O
and	O
after	O
chemical	O
inhibition	O
were	O
analyzed	O
for	O
NF-kappa	B-Gene
B	I-Gene
nuclear	I-Gene
DNA	I-Gene
-binding	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
quantitative	O
densitometry	O
.	O

Nuclear	O
expression	O
of	O
p65	B-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
before	O
and	O
after	O
treatment	O
with	O
the	O
various	O
inhibitory	O
compounds	O
was	O
measured	O
by	O
immunofluorescence	O
staining	O
in	O
each	O
CTCL	B-Disease
cell	O
line	O
.	O

Neoplastic	O
T	O
lymphocytes	O
from	O
22	O
of	O
24	O
cases	O
of	O
MF	B-Disease
showed	O
strong	O
nuclear	O
and	O
cytoplasmic	O
expression	O
of	O
active	O
p65	B-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
.	O

Compared	O
with	O
untreated	O
control	O
cells	O
,	O
a	O
marked	O
increase	O
in	O
apoptosis	O
,	O
a	O
significant	O
decrease	O
in	O
NF-kappa	B-Gene
B	I-Gene
DNA	I-Gene
-binding	O
activity	O
,	O
and	O
a	O
marked	O
decrease	O
in	O
nuclear	B-Gene
p65	I-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
expression	O
were	O
seen	O
in	O
cells	O
from	O
both	O
CTCL	B-Disease
cell	O
lines	O
after	O
chemical	O
NF-kappa	B-Gene
B	I-Gene
inhibition	O
.	O

These	O
data	O
show	O
that	O
the	O
active	O
form	O
of	O
NF-kappa	B-Gene
B	I-Gene
p65	I-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
is	O
commonly	O
expressed	O
in	O
neoplastic	O
T	O
lymphocytes	O
in	O
patients	O
with	O
MF	B-Disease
.	O

In	O
CTCL	B-Disease
cell	O
lines	O
,	O
the	O
significant	O
decrease	O
in	O
nuclear	B-Gene
NF-kappa	I-Gene
B	I-Gene
expression	O
and	O
the	O
marked	O
increase	O
in	O
spontaneous	O
apoptosis	O
caused	O
by	O
chemical	O
NF-kappa	B-Gene
B	I-Gene
inhibition	O
suggest	O
a	O
critical	O
role	O
for	O
NF-kappa	B-Gene
B	I-Gene
in	O
the	O
pathogenesis	O
and	O
tumor	B-Disease
cell	O
maintenance	O
of	O
CTCLs	B-Disease
.	O

HUM	O
PATHOL	O
31	O
:	O
1482-1490	O
.	O

Down-regulation	O
of	O
BOB.1	B-Gene
/	I-Gene
OBF.1	I-Gene
and	O
Oct2	B-Gene
in	O
classical	O
Hodgkin	B-Disease
disease	I-Disease
but	O
not	O
in	O
lymphocyte	O
predominant	O
Hodgkin	B-Disease
disease	I-Disease
correlates	O
with	O
immunoglobulin	B-Gene
transcription	O
.	O

In	O
contrast	O
to	O
the	O
tumor	B-Disease
cells	O
(	O
L	O
&	O
H	O
cells	O
)	O
of	O
lymphocyte	O
predominant	O
Hodgkin	B-Disease
disease	I-Disease
(	O
LPHD	B-Disease
)	O
,	O
Hodgkin	O
and	O
Reed-Sternberg	O
(	O
HRS	O
)	O
cells	O
of	O
classical	O
Hodgkin	B-Disease
disease	I-Disease
(	O
cHD	B-Disease
)	O
are	O
unable	O
to	O
transcribe	O
immunoglobulin	B-Gene
,	O
despite	O
the	O
presence	O
of	O
rearranged	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

Although	O
initial	O
studies	O
have	O
suggested	O
crippling	O
immunoglobulin	B-Gene
gene	I-Gene
mutations	O
to	O
be	O
the	O
cause	O
of	O
absent	O
immunoglobulin	B-Gene
expression	O
in	O
cHD	B-Disease
,	O
recent	O
work	O
of	O
our	O
group	O
has	O
demonstrated	O
an	O
impaired	O
activation	O
of	O
the	O
immunoglobulin	B-Gene
promoter	I-Gene
as	O
a	O
superior	O
mechanism	O
.	O

As	O
immunoglobulin	B-Gene
transcription	O
is	O
mainly	O
regulated	O
by	O
the	O
B-cell	B-Gene
transcription	I-Gene
factors	I-Gene
Oct2	I-Gene
and	O
BOB.1	B-Gene
/	I-Gene
OBF.1	I-Gene
,	O
we	O
analyzed	O
35	O
cases	O
of	O
LPHD	B-Disease
,	O
32	O
cases	O
of	O
cHD	B-Disease
,	O
and	O
2	O
Hodgkin	B-Disease
disease	I-Disease
cell	O
lines	O
for	O
the	O
expression	O
of	O
these	O
transcription	O
factors	O
and	O
also	O
in	O
parallel	O
for	O
immunoglobulin	B-Gene
expression	O
.	O

Our	O
results	O
demonstrate	O
an	O
absence	O
of	O
Oct2	B-Gene
and	O
/	O
or	O
BOB.1	B-Gene
/	I-Gene
OBF.1	I-Gene
in	O
cHD	B-Disease
and	O
a	O
striking	O
overexpression	O
of	O
Oct2	B-Gene
in	O
LPHD	B-Disease
.	O

Immunoglobulin	B-Gene
expression	O
was	O
lacking	O
in	O
cHD	B-Disease
but	O
present	O
in	O
LPHD	B-Disease
.	O

Furthermore	O
,	O
the	O
reintroduction	O
of	O
BOB.1	B-Gene
/	I-Gene
OBF.1	I-Gene
and	O
Oct2	B-Gene
into	O
cultured	O
HRS	O
cells	O
restored	O
the	O
activity	O
of	O
cotransduced	O
immunoglobulin	B-Gene
promoter	I-Gene
constructs	O
.	O

Our	O
findings	O
dismiss	O
the	O
concept	O
that	O
the	O
different	O
immunoglobulin	B-Gene
expression	O
in	O
cHD	B-Disease
and	O
LPHD	B-Disease
is	O
due	O
to	O
disrupting	O
mutations	O
of	O
immunoglobulin	B-Gene
V	I-Gene
genes	I-Gene
in	O
cHD	B-Disease
but	O
is	O
most	O
likely	O
due	O
to	O
a	O
down-regulation	O
of	O
Oct2	B-Gene
and	O
/	O
or	O
BOB.1	B-Gene
/	I-Gene
OBF.1	I-Gene
.	O

This	O
study	O
further	O
revealed	O
Oct2	B-Gene
as	O
a	O
new	O
and	O
valuable	O
marker	O
for	O
the	O
identification	O
of	O
L	O
&	O
H	O
cells	O
and	O
their	O
distinction	O
from	O
HRS	O
cells	O
.	O

The	O
impairment	O
of	O
immunoglobulin	B-Gene
transcription	O
with	O
a	O
down	O
-regulated	O
synthesis	O
of	O
Oct2	B-Gene
and	O
BOB.1	B-Gene
/	I-Gene
OBF.1	I-Gene
is	O
the	O
first	O
established	O
general	O
recurrent	O
defect	O
found	O
in	O
HRS	O
cells	O
.	O

Suppression	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
a	O
dominant	O
-negative	O
Ets-1	B-Gene
mutant	I-Gene
.	O

Activity	O
of	O
the	O
distal	O
region	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
which	O
contains	O
binding	O
sites	O
for	O
the	O
Ets-1	B-Gene
and	O
USF-1	B-Gene
proteins	I-Gene
,	O
is	O
integral	O
for	O
HIV-1	O
replication	O
.	O

The	O
Ets-1	B-Gene
and	O
USF-1	B-Gene
proteins	I-Gene
play	O
a	O
critical	O
role	O
in	O
the	O
activity	O
of	O
the	O
HIV-1	O
LTR	O
distal	O
enhancer	O
region	O
,	O
as	O
indicated	O
by	O
the	O
potent	O
dominant	O
negative	O
effect	O
of	O
a	O
mutant	B-Gene
Ets-1	I-Gene
lacking	O
trans-activation	O
domains	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
LTR	O
.	O

To	O
determine	O
the	O
biological	O
relevance	O
of	O
the	O
Ets-1	B-Gene
and	O
USF-1	B-Gene
proteins	I-Gene
in	O
HIV-1	O
replication	O
,	O
we	O
examined	O
the	O
effect	O
of	O
expression	O
of	O
the	O
dominant	O
-negative	O
mutant	O
of	O
Ets-1	B-Gene
(	O
dnEts-1	B-Gene
)	O
on	O
HIV-1	O
infection	O
of	O
T	O
cells	O
.	O

We	O
demonstrated	O
that	O
expression	O
of	O
dnEts	B-Gene
markedly	O
suppressed	O
HIV-1	O
infection	O
of	O
a	O
T	O
cell	O
line	O
.	O

This	O
finding	O
indicates	O
that	O
formation	O
of	O
a	O
transcriptionaly	O
active	O
USF-1	B-Gene
/	I-Gene
Ets-1	I-Gene
complex	I-Gene
is	O
important	O
in	O
the	O
productive	O
infection	O
of	O
cells	O
by	O
HIV-1	O
,	O
and	O
suggests	O
that	O
inhibition	O
of	O
the	O
interaction	O
between	O
USF-1	B-Gene
and	O
Ets-1	B-Gene
with	O
the	O
HIV-1	O
LTR	O
may	O
provide	O
a	O
new	O
target	O
for	O
anti-HIV-1	O
gene	O
therapy	O
.	O

T-cell	O
-mediated	O
regulation	O
of	O
osteoclastogenesis	O
by	O
signalling	O
cross-talk	O
between	O
RANKL	B-Gene
and	O
IFN-gamma	B-Gene
.	O

Bone	O
resorption	O
is	O
regulated	O
by	O
the	O
immune	O
system	O
,	O
where	O
T-cell	O
expression	O
of	O
RANKL	B-Gene
(	O
receptor	B-Gene
activator	I-Gene
of	I-Gene
nuclear	I-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
ligand	I-Gene
)	O
,	O
a	O
member	O
of	O
the	O
tumour-necrosis	B-Gene
factor	I-Gene
family	I-Gene
that	O
is	O
essential	O
for	O
osteoclastogenesis	O
,	O
may	O
contribute	O
to	O
pathological	O
conditions	O
,	O
such	O
as	O
autoimmune	B-Disease
arthritis	I-Disease
.	O

However	O
,	O
whether	O
activated	O
T	O
cells	O
maintain	O
bone	O
homeostasis	O
by	O
counterbalancing	O
the	O
action	O
of	O
RANKL	B-Gene
remains	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
T-cell	O
production	O
of	O
interferon	B-Gene
(	I-Gene
IFN	I-Gene
)	I-Gene
-gamma	I-Gene
strongly	O
suppresses	O
osteoclastogenesis	O
by	O
interfering	O
with	O
the	O
RANKL	B-Gene
-RANK	I-Gene
signalling	O
pathway	O
.	O

IFN-gamma	B-Gene
induces	O
rapid	O
degradation	O
of	O
the	O
RANK	B-Gene
adapter	I-Gene
protein	I-Gene
,	O
TRAF6	B-Gene
(	O
tumour	B-Gene
necrosis	I-Gene
factor	I-Gene
receptor	I-Gene
-associated	I-Gene
factor	I-Gene
6	I-Gene
)	O
,	O
which	O
results	O
in	O
strong	O
inhibition	O
of	O
the	O
RANKL	B-Gene
-induced	O
activation	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappaB	I-Gene
and	O
JNK	B-Gene
.	O

This	O
inhibition	O
of	O
osteoclastogenesis	O
is	O
rescued	O
by	O
overexpressing	O
TRAF6	B-Gene
in	O
precursor	O
cells	O
,	O
which	O
indicates	O
that	O
TRAF6	B-Gene
is	O
the	O
target	O
critical	O
for	O
the	O
IFN-gamma	B-Gene
action	O
.	O

Furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
accelerated	O
degradation	O
of	O
TRAF6	B-Gene
requires	O
both	O
its	O
ubiquitination	O
,	O
which	O
is	O
initiated	O
by	O
RANKL	B-Gene
,	O
and	O
IFN-gamma	B-Gene
-induced	O
activation	O
of	O
the	O
ubiquitin-proteasome	B-Gene
system	O
.	O

Our	O
study	O
shows	O
that	O
there	O
is	O
cross-talk	O
between	O
the	O
tumour	B-Gene
necrosis	I-Gene
factor	I-Gene
and	O
IFN	B-Gene
families	I-Gene
of	O
cytokines	O
,	O
through	O
which	O
IFN-gamma	B-Gene
provides	O
a	O
negative	O
link	O
between	O
T-cell	O
activation	O
and	O
bone	O
resorption	O
.	O

Our	O
results	O
may	O
offer	O
a	O
therapeutic	O
approach	O
to	O
treat	O
the	O
inflammation	O
-induced	O
tissue	O
breakdown	O
.	O

Synovial	O
fluid	O
induced	O
nuclear	B-Gene
factor-kappaB	I-Gene
DNA	I-Gene
binding	O
in	O
a	O
monocytic	O
cell	O
line	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
effects	O
of	O
synovial	O
fluids	O
(	O
SF	O
)	O
on	O
DNA	O
binding	O
activity	O
of	O
transcription	B-Gene
factor	I-Gene
nuclear	I-Gene
factor-kappaB	I-Gene
(	O
NF-kappaB	B-Gene
)	O
in	O
the	O
Mono	O
Mac	O
6	O
monocytic	O
/	O
macrophage	O
cell	O
line	O
as	O
a	O
model	O
for	O
the	O
interaction	O
between	O
SF	O
and	O
synovial	O
tissue	O
macrophages	O
in	O
arthritis	B-Disease
.	O

METHODS	O
:	O
Mono	O
Mac	O
6	O
cells	O
were	O
incubated	O
with	O
SF	O
from	O
the	O
knee	O
joints	O
of	O
human	O
subjects	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
,	O
undifferentiated	O
seronegative	O
oligoarthritis	B-Disease
,	O
and	O
osteoarthritis	B-Disease
(	O
OA	B-Disease
)	O
.	O

Nuclear	O
extracts	O
prepared	O
from	O
the	O
Mono	O
Mac	O
6	O
cells	O
and	O
RA	B-Disease
synovial	O
tissue	O
were	O
analyzed	O
by	O
electrophoretic	O
mobility	O
shift	O
analysis	O
(	O
EMSA	O
)	O
for	O
NF-kappaB	B-Gene
DNA	I-Gene
binding	I-Gene
proteins	I-Gene
.	O

RESULTS	O
:	O
Induction	O
of	O
NF-kappaB	B-Gene
DNA	I-Gene
binding	O
by	O
the	O
p65	B-Gene
(	I-Gene
RelA	I-Gene
)	I-Gene
/	I-Gene
p50	I-Gene
heterodimer	O
was	O
observed	O
in	O
response	O
to	O
incubation	O
of	O
Mono	O
Mac	O
6	O
cells	O
with	O
SF	O
(	O
20	O
%	O
in	O
culture	O
medium	O
)	O
from	O
5	O
of	O
8	O
subjects	O
with	O
RA	B-Disease
,	O
4	O
of	O
5	O
with	O
OA	B-Disease
,	O
and	O
none	O
of	O
3	O
with	O
undifferentiated	O
seronegative	O
oligoarthritis	B-Disease
.	O

Incubation	O
of	O
SF	O
with	O
neutralizing	O
antibodies	O
against	O
tumor	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
,	O
but	O
not	O
antibodies	O
against	O
interleukin	B-Gene
6	I-Gene
(	O
IL-6	B-Gene
)	O
,	O
significantly	O
reduced	O
the	O
induction	O
of	O
p65	B-Gene
/	I-Gene
p50	I-Gene
binding	O
activity	O
in	O
SF	O
from	O
subjects	O
with	O
RA	B-Disease
and	O
OA	B-Disease
.	O

Unexpectedly	O
,	O
a	O
slowly	O
migrating	O
SF	O
inducible	O
NF-kappaB	B-Gene
-binding	O
complex	O
was	O
observed	O
in	O
EMSA	O
of	O
Mono	O
Mac	O
6	O
cells	O
after	O
incubation	O
with	O
SF	O
from	O
5	O
of	O
8	O
RA	B-Disease
and	O
2	O
of	O
5	O
OA	B-Disease
subjects	O
.	O

The	O
induction	O
of	O
this	O
complex	O
by	O
SF	O
was	O
not	O
affected	O
by	O
neutralization	O
of	O
TNF-alpha	B-Gene
or	O
IL-6	B-Gene
in	O
SF	O
,	O
and	O
the	O
complex	O
was	O
not	O
inducible	O
by	O
TNF-alpha	B-Gene
,	O
IL-1beta	B-Gene
,	O
TNF-alpha	B-Gene
/	I-Gene
IL-1beta	I-Gene
,	O
IL-6	B-Gene
,	O
platelet	B-Gene
derived	I-Gene
growth	I-Gene
factor	I-Gene
,	O
lipopolysaccharide	B-Chemical
,	O
or	O
tetradecanoyl	B-Chemical
phorbol	I-Chemical
acetate	I-Chemical
.	O

The	O
slowly	O
migrating	O
complex	O
could	O
not	O
be	O
supershifted	O
with	O
antibodies	O
against	O
NF-kappaB	B-Gene
,	O
Jun	B-Gene
,	O
or	O
the	O
transcriptional	B-Gene
coactivators	I-Gene
p300	I-Gene
or	O
CBP	B-Gene
.	O

A	O
NF-kappaB	B-Gene
-binding	O
complex	O
with	O
similar	O
slow	O
mobility	O
was	O
observed	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
fresh	O
human	O
RA	B-Disease
synovial	O
tissue	O
.	O

CONCLUSION	O
:	O
Biological	O
activity	O
of	O
TNF-alpha	B-Gene
in	O
SF	O
from	O
RA	B-Disease
and	O
OA	B-Disease
subjects	O
is	O
capable	O
of	O
inducing	O
p65	B-Gene
/	I-Gene
p50	I-Gene
NF-kappaB	I-Gene
DNA	I-Gene
binding	O
activity	O
in	O
macrophages	O
.	O

A	O
property	O
of	O
SF	O
that	O
is	O
independent	O
of	O
TNF-alpha	B-Gene
and	O
other	O
cytokines	O
is	O
responsible	O
for	O
the	O
induction	O
of	O
a	O
novel	O
slowly	O
migrating	O
NF-kappaB	B-Gene
-binding	O
complex	O
.	O

Soluble	O
mediators	O
in	O
SF	O
of	O
subjects	O
with	O
RA	B-Disease
and	O
OA	B-Disease
can	O
therefore	O
modulate	O
binding	O
of	O
nuclear	O
proteins	O
to	O
the	O
NF-kappaB	B-Gene
binding	O
site	O
in	O
macrophages	O
and	O
may	O
play	O
a	O
role	O
in	O
inflammatory	O
gene	O
expression	O
in	O
arthritis	B-Disease
.	O

Expression	O
of	O
mammalian	B-Gene
defensin	I-Gene
genes	I-Gene
.	O

Antimicrobial	O
peptides	O
are	O
a	O
prevalent	O
mechanism	O
of	O
host	O
defense	O
found	O
throughout	O
nature	O
.	O

In	O
mammals	O
,	O
defensins	B-Gene
are	O
among	O
the	O
most	O
abundant	O
of	O
these	O
broad-spectrum	O
antibiotics	O
,	O
and	O
are	O
expressed	O
in	O
epithelial	O
and	O
hematopoietic	O
cells	O
.	O

The	O
defensin	B-Gene
peptides	O
are	O
especially	O
abundant	O
in	O
neutrophils	O
;	O
however	O
,	O
gene	O
expression	O
is	O
limited	O
to	O
the	O
promyelocyte	O
stage	O
.	O

In	O
epithelial	O
cells	O
,	O
defensin	B-Gene
genes	I-Gene
are	O
found	O
as	O
both	O
constitutively	O
expressed	O
and	O
inducible	O
.	O

Induction	O
has	O
been	O
observed	O
in	O
vitro	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	B-Chemical
as	O
well	O
as	O
inflammatory	O
mediators	O
.	O

In	O
vivo	O
,	O
up-regulation	O
of	O
several	O
defensin	B-Gene
genes	I-Gene
occurs	O
in	O
both	O
infectious	O
and	O
inflammatory	O
states	O
.	O

Gene	O
regulation	O
occurs	O
via	O
signal	O
transduction	O
pathways	O
common	O
to	O
other	O
innate	O
immune	O
responses	O
,	O
utilizing	O
transcription	O
factors	O
such	O
as	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
and	O
NF	B-Gene
interleukin-6	I-Gene
.	O

Together	O
,	O
the	O
data	O
suggest	O
a	O
broad	O
-based	O
innate	O
host	O
defense	O
whereby	O
potent	O
antimicrobial	O
peptides	O
are	O
present	O
to	O
prevent	O
initial	O
colonization	O
by	O
pathogenic	O
microorganisms	O
.	O

In	O
addition	O
,	O
the	O
recognition	O
of	O
bacteria	O
coupled	O
with	O
a	O
nascent	O
inflammatory	O
response	O
can	O
bolster	O
this	O
defense	O
by	O
a	O
coordinated	O
up-regulation	O
of	O
the	O
peptides	O
.	O

Regulation	O
of	O
chemokine	O
mRNA	O
expression	O
in	O
a	O
rat	O
model	O
of	O
vanadium	B-Chemical
-induced	O
pulmonary	B-Disease
inflammation	I-Disease
.	O

Environmental	O
and	O
occupational	O
exposure	O
to	O
vanadium	B-Chemical
dusts	O
results	O
in	O
toxic	O
effects	O
mainly	O
confined	O
to	O
the	O
respiratory	O
system	O
.	O

Using	O
a	O
rat	O
model	O
of	O
acute	B-Disease
lung	I-Disease
inflammation	I-Disease
induced	O
by	O
intratracheal	O
instillation	O
of	O
sodium	B-Chemical
metavanadate	I-Chemical
(	O
NaVO3	O
)	O
at	O
the	O
dose	O
of	O
200	O
microg	O
V	O
/	O
kg	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
cytologic	O
characterization	O
of	O
pulmonary	B-Disease
inflammation	I-Disease
and	O
the	O
expression	O
of	O
chemokine	O
mRNA	O
.	O

Significant	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
influx	O
(	O
P	O
<	O
0.01	O
)	O
into	O
the	O
lung	O
was	O
noted	O
4	O
h	O
after	O
NaVO3	O
instillation	O
,	O
whereas	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
appeared	O
to	O
decrease	O
significantly	O
.	O

In	O
contrast	O
,	O
neither	O
PMNs	O
nor	O
AMs	O
changed	O
substantially	O
1	O
h	O
after	O
NaVO3	O
instillation	O
.	O

By	O
Northern	O
analysis	O
,	O
macrophage	B-Gene
inflammatory	I-Gene
protein	I-Gene
(	I-Gene
MIP	I-Gene
)	I-Gene
-2	I-Gene
mRNA	I-Gene
in	O
BAL	O
cells	O
increased	O
markedly	O
1	O
h	O
after	O
NaVO3	O
instillation	O
and	O
reduced	O
a	O
little	O
bit	O
at	O
4	O
h	O
,	O
whereas	O
MIP-1alpha	B-Gene
mRNA	I-Gene
in	O
BAL	O
cells	O
was	O
expressed	O
relatively	O
high	O
1	O
h	O
after	O
NaVO3	O
instillation	O
,	O
although	O
a	O
basal	O
expression	O
was	O
detected	O
in	O
control	O
group	O
,	O
and	O
returned	O
rapidly	O
nearly	O
to	O
control	O
level	O
at	O
4	O
h	O
.	O

Since	O
MIP-2	B-Gene
is	O
a	O
potent	O
PMN	O
chemoattractant	O
and	O
MIP-1alpha	B-Gene
is	O
a	O
potent	O
macrophage	O
/	O
monocyte	O
chemoattractant	O
has	O
been	O
well	O
known	O
.	O

The	O
facts	O
that	O
PMN	O
influx	O
was	O
preceded	O
by	O
increased	O
MIP-2	B-Gene
mRNA	I-Gene
expression	O
,	O
suggesting	O
that	O
MIP-2	B-Gene
is	O
involved	O
in	O
the	O
development	O
of	O
NaVO3	O
-induced	O
pulmonary	B-Disease
inflammation	I-Disease
,	O
whereas	O
increased	O
MIP-1alpha	B-Gene
mRNA	I-Gene
expression	O
was	O
followed	O
by	O
decreased	O
AMs	O
in	O
BAL	O
cells	O
,	O
suggesting	O
AMs	O
might	O
be	O
activated	O
by	O
MIP-1alpha	B-Gene
,	O
adherent	O
to	O
the	O
lining	O
surface	O
of	O
the	O
airways	O
and	O
then	O
resistant	O
to	O
be	O
washed	O
out	O
.	O

To	O
delineate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
,	O
we	O
recently	O
cloned	O
the	O
5'-flanking	O
region	O
of	O
the	O
MIP-2	B-Gene
gene	I-Gene
.	O

The	O
promotor	O
region	O
contains	O
consensus	O
binding	O
sites	O
for	O
transcription	B-Gene
factor	I-Gene
nuclear	I-Gene
factor	I-Gene
kappaB	I-Gene
(	O
NF-kappaB	B-Gene
)	O
and	O
activator	B-Gene
protein-1	I-Gene
(	O
AP-1	B-Gene
)	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
increased	O
nuclear	B-Gene
NF-kappaB	I-Gene
,	O
not	O
AP-1	B-Gene
,	O
binding	O
activity	O
was	O
detected	O
1	O
h	O
after	O
NaVO3	O
instillation	O
,	O
which	O
correlated	O
with	O
the	O
induction	O
of	O
MIP-2	B-Gene
mRNA	I-Gene
.	O

p65	B-Gene
(	O
Rel	B-Gene
A	I-Gene
)	O
and	O
p50	B-Gene
protein	I-Gene
appears	O
to	O
be	O
involved	O
in	O
MIP-2	B-Gene
NF-kappaB	I-Gene
binding	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
MIP-2	B-Gene
is	O
an	O
important	O
mediator	O
of	O
NaVO3	O
-induced	O
pulmonary	B-Disease
inflammation	I-Disease
in	O
the	O
rat	O
model	O
.	O

In	O
addition	O
,	O
elevated	O
MIP-2	B-Gene
mRNA	I-Gene
levels	O
are	O
accompanied	O
by	O
increased	O
NF-kappaB	B-Gene
binding	O
activity	O
in	O
BAL	O
cells	O
,	O
suggesting	O
possible	O
MIP-2	B-Gene
transcriptional	O
regulation	O
through	O
NF-kappaB	B-Gene
.	O

High	O
glucose	B-Chemical
-induced	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
(	O
ICAM-1	B-Gene
)	O
expression	O
through	O
an	O
osmotic	O
effect	O
in	O
rat	O
mesangial	O
cells	O
is	O
PKC-NF-kappa	B-Gene
B	I-Gene
-dependent	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Infiltration	O
of	O
mononuclear	O
cells	O
and	O
glomerular	O
enlargement	O
accompanied	O
by	O
glomerular	O
cell	O
proliferation	O
are	O
very	O
early	O
characteristics	O
of	O
the	O
pathophysiology	O
of	O
diabetes	B-Disease
.	O

To	O
clarify	O
the	O
mechanism	O
of	O
early	O
diabetic	B-Disease
nephropathy	I-Disease
,	O
we	O
measured	O
[	O
3H	O
]	O
-thymidine	B-Chemical
incorporation	O
and	O
cell	O
numbers	O
to	O
show	O
the	O
influence	O
of	O
a	O
high	O
ambient	O
glucose	B-Chemical
concentration	O
and	O
the	O
osmotic	O
effect	O
on	O
rat	O
mesangial	O
cell	O
proliferation	O
.	O

We	O
also	O
measured	O
the	O
effect	O
of	O
high	O
glucose	B-Chemical
on	O
the	O
expression	O
of	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
and	O
vascular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
by	O
flow	O
cytometry	O
and	O
semiquantitative	O
RT-PCR	O
in	O
mesangial	O
cells	O
and	O
the	O
adhesion	O
of	O
leukocytes	O
to	O
mesangial	O
cells	O
.	O

METHODS	O
/	O
RESULTS	O
:	O
Cells	O
exposed	O
to	O
high	O
D-glucose	B-Chemical
(	O
30	O
mmol	O
/	O
l	O
)	O
caused	O
an	O
increase	O
in	O
[	O
3H	O
]	O
-thymidine	B-Chemical
incorporation	O
and	O
cell	O
numbers	O
at	O
24	O
and	O
48	O
h	O
and	O
normalized	O
at	O
72	O
h	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
these	O
changes	O
were	O
not	O
found	O
in	O
high	O
mannitol	B-Chemical
(	O
30	O
mmol	O
/	O
l	O
)	O
,	O
IL-1	B-Gene
beta	I-Gene
,	O
or	O
TNF	B-Gene
alpha	I-Gene
-stimulated	O
mesangial	O
cells	O
.	O

Cells	O
exposed	O
to	O
high-glucose	B-Chemical
(	O
15	O
,	O
30	O
,	O
or	O
60	O
mmol	O
/	O
l	O
)	O
or	O
osmotic	O
agents	O
(	O
L-glucose	B-Chemical
,	O
raffinose	B-Chemical
and	O
mannitol	B-Chemical
)	O
showed	O
that	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
expression	O
began	O
to	O
increase	O
after	O
24	O
h	O
,	O
reached	O
its	O
maximum	O
at	O
24	O
and	O
48	O
h	O
and	O
gradually	O
decreased	O
afterwards	O
.	O

The	O
stimulatory	O
effects	O
of	O
high	O
glucose	B-Chemical
and	O
high	O
mannitol	B-Chemical
on	O
mRNA	O
expression	O
were	O
observed	O
as	O
early	O
as	O
6	O
h	O
and	O
reached	O
its	O
maximum	O
at	O
12	O
h	O
.	O

Up-regulation	O
of	O
ICAM-1	B-Gene
protein	I-Gene
and	O
mRNA	O
was	O
also	O
found	O
in	O
IL-1-beta	B-Gene
and	O
TNF-alpha	B-Gene
-stimulated	O
mesangial	O
cells	O
.	O

Neither	O
vascular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
protein	I-Gene
nor	O
mRNA	O
expression	O
was	O
,	O
however	O
,	O
affected	O
by	O
high	O
glucose	B-Chemical
and	O
high	O
mannitol	B-Chemical
.	O

Notably	O
,	O
the	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
inhibitors	O
calphostin	B-Chemical
C	I-Chemical
and	O
staurosporine	B-Chemical
reduced	O
high	O
glucose-	B-Chemical
or	O
high	O
mannitol	B-Chemical
-induced	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
mRNA	I-Gene
expression	O
and	O
high	O
glucose	B-Chemical
-induced	O
proliferation	O
.	O

Furthermore	O
,	O
the	O
NF-kappa	B-Gene
B	I-Gene
inhibitor	I-Gene
N-tosyl-L-phenylalanine	B-Chemical
chloromethyl	I-Chemical
ketone	I-Chemical
reduced	O
high	O
glucose-	B-Chemical
or	O
high	O
mannitol	B-Chemical
-induced	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
mRNA	I-Gene
expression	O
and	O
high	O
glucose	B-Chemical
-induced	O
proliferation	O
.	O

Results	O
showed	O
that	O
high	O
glucose	B-Chemical
(	O
15	O
,	O
30	O
mmol	O
/	O
l	O
)	O
or	O
high	O
concentrations	O
of	O
osmotic	O
agents	O
remarkably	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
to	O
mesangial	O
cells	O
(	O
p	O
<	O
0.01	O
)	O
compared	O
with	O
control	O
cells	O
(	O
5	O
mmol	O
/	O
l	O
D-glucose	B-Chemical
)	O
.	O

Functional	O
blocking	O
of	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
on	O
mesangial	O
cells	O
with	O
rat	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
monoclonal	I-Gene
antibody	I-Gene
,	O
calphostin	B-Chemical
C	I-Chemical
,	O
staurosporine	B-Chemical
,	O
or	O
N-tosyl-L-phenylalanine	B-Chemical
chloromethyl	I-Chemical
ketone	I-Chemical
significantly	O
inhibited	O
high	O
glucose-	B-Chemical
or	O
high	O
mannitol	B-Chemical
-induced	O
increase	O
in	O
leukocyte	O
adhesion	O
(	O
p	O
<	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
/	O
INTERPRETATION	O
:	O
These	O
results	O
suggest	O
that	O
high	O
glucose	B-Chemical
can	O
upregulate	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
protein	I-Gene
and	O
mRNA	O
expression	O
but	O
not	O
vascular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
expression	O
in	O
mesangial	O
cells	O
and	O
promote	O
leukocyte	O
adhesion	O
through	O
up-regulation	O
of	O
intercellular	B-Gene
adhesion	I-Gene
molecule-1	I-Gene
through	O
osmotic	O
effect	O
,	O
possibly	O
depending	O
on	O
the	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
nuclear	I-Gene
factor-kappa	I-Gene
B	I-Gene
(	O
PKC	B-Gene
-	I-Gene
NF-kappa	I-Gene
B	I-Gene
)	O
pathway	O
.	O

High	O
glucose	B-Chemical
itself	O
can	O
also	O
promote	O
mesangial	O
cell	O
proliferation	O
through	O
the	O
PKC-NF-kappa	B-Gene
B	I-Gene
pathways	O
.	O

We	O
conclude	O
that	O
hyperglycaemia	B-Disease
in	O
itself	O
seems	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
early	O
diabetic	B-Disease
nephropathy	I-Disease
.	O

Mechanisms	O
and	O
clinical	O
relevance	O
of	O
nongenomic	O
glucocorticoid	B-Chemical
actions	O
.	O

Glucocorticoids	B-Chemical
have	O
profound	O
anti-inflammatory	O
and	O
immunosuppressive	O
actions	O
when	O
used	O
therapeutically	O
.	O

The	O
therapeutic	O
dose	O
is	O
quite	O
variable	O
and	O
depends	O
on	O
the	O
disease	O
,	O
but	O
ranges	O
from	O
very	O
low	O
to	O
extremely	O
high	O
.	O

The	O
rationale	O
for	O
the	O
use	O
of	O
various	O
dosage	O
regimens	O
for	O
specific	O
clinical	O
indications	O
is	O
the	O
existence	O
of	O
three	O
distinct	O
,	O
therapeutically	O
relevant	O
effects	O
:	O
genomic	O
,	O
specific	O
nongenomic	O
and	O
unspecific	O
nongenomic	O
.	O

Genomic	O
effects	O
are	O
mediated	O
by	O
cytosolic	O
receptors	O
that	O
alter	O
expression	O
of	O
specific	O
genes	O
.	O

Specific	O
nongenomic	O
effects	O
occur	O
within	O
a	O
few	O
minutes	O
and	O
are	O
mediated	O
by	O
steroid	B-Chemical
-selective	O
membrane	O
receptors	O
.	O

Unspecific	O
nongenomic	O
effects	O
occur	O
within	O
seconds	O
,	O
but	O
only	O
at	O
high	O
glucocorticoid	B-Chemical
dosages	O
,	O
and	O
seem	O
to	O
result	O
from	O
direct	O
interactions	O
with	O
biological	O
membranes	O
.	O

For	O
unspecific	O
nongenomic	O
effects	O
,	O
methylprednisolone	B-Chemical
and	O
other	O
glucocorticoids	B-Chemical
have	O
been	O
shown	O
to	O
inhibit	O
cation	O
cycling	O
across	O
the	O
plasma	O
membrane	O
,	O
but	O
to	O
have	O
little	O
effect	O
on	O
protein	O
synthesis	O
.	O

Thus	O
,	O
glucocorticoids	B-Chemical
could	O
diminish	O
or	O
prevent	O
the	O
acute	O
immune	O
response	O
by	O
interfering	O
with	O
processes	O
such	O
as	O
the	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
.	O

It	O
is	O
proposed	O
that	O
the	O
additional	O
therapeutic	O
benefit	O
of	O
higher	O
doses	O
is	O
obtained	O
via	O
these	O
nongenomic	O
effects	O
.	O

Inhibition	O
of	O
Th1	O
differentiation	O
by	O
IL-6	B-Gene
is	O
mediated	O
by	O
SOCS1	B-Gene
.	O

Interleukin	B-Gene
6	I-Gene
(	O
IL-6	B-Gene
)	O
is	O
a	O
cytokine	O
produced	O
by	O
immune	O
and	O
nonimmune	O
cells	O
and	O
exhibits	O
functional	O
pleiotropy	O
and	O
redundancy	O
.	O

IL-6	B-Gene
plays	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
function	O
of	O
IL-6	B-Gene
:	O
the	O
negative	O
regulation	O
of	O
CD4	B-Gene
+	I-Gene
Th1	O
cell	O
differentiation	O
.	O

While	O
IL-6	B-Gene
-directed	O
CD4	B-Gene
+	I-Gene
Th2	O
differentiation	O
is	O
mediated	O
by	O
IL-4	B-Gene
,	O
inhibition	O
of	O
Th1	O
differentiation	O
by	O
IL-6	B-Gene
is	O
independent	O
of	O
IL-4	B-Gene
.	O

IL-6	B-Gene
upregulates	O
suppressor	B-Gene
of	I-Gene
cytokine	I-Gene
signaling	I-Gene
1	I-Gene
(	O
SOCS1	B-Gene
)	O
expression	O
in	O
activated	B-Gene
CD4+	I-Gene
T	O
cells	O
,	O
thereby	O
interfering	O
with	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
1	I-Gene
(	O
STAT1	B-Gene
)	O
phosphorylation	O
induced	O
by	O
interferon	B-Gene
gamma	I-Gene
(	O
IFNgamma	B-Gene
)	O
.	O

Inhibition	O
of	O
IFNgamma	B-Gene
receptor	I-Gene
-mediated	O
signals	O
by	O
IL-6	B-Gene
prevents	O
autoregulation	O
of	O
IFNgamma	B-Gene
gene	I-Gene
expression	O
by	O
IFNgamma	B-Gene
during	O
CD4+	B-Gene
T	O
cell	O
activation	O
,	O
thereby	O
preventing	O
Th1	O
differentiation	O
.	O

Thus	O
,	O
IL-6	B-Gene
promotes	O
CD4	B-Gene
+	I-Gene
Th2	O
differentiation	O
and	O
inhibits	O
Th1	O
differentiation	O
by	O
two	O
independent	O
molecular	O
mechanisms	O
.	O

BLyS	B-Gene
BINDS	O
TO	O
B	O
CELLS	O
WITH	O
HIGH	O
AFFINITY	O
AND	O
INDUCES	O
ACTIVATION	O
OF	O
THE	O
TRANSCRIPTION	B-Gene
FACTORS	I-Gene
NF-kappaB	I-Gene
AND	O
ELF-1	B-Gene
.	O

B	B-Gene
lymphocyte	I-Gene
stimulator	I-Gene
(	O
BLyS	B-Gene
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
TNF	B-Gene
family	I-Gene
of	O
proteins	O
expressed	O
by	O
myeloid	O
cells	O
as	O
membrane-bound	O
and	O
soluble	O
forms	O
.	O

BLyS	B-Gene
was	O
shown	O
to	O
act	O
specifically	O
on	O
B	O
cells	O
,	O
inducing	O
proliferation	O
and	O
immunoglobulin	B-Gene
production	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
characterize	O
binding	O
of	O
radiolabeled	O
BLyS	B-Gene
to	O
its	O
cognate	O
receptor	O
on	O
human	O
B	O
lymphocytes	O
and	O
examine	O
intracellular	O
events	O
initiated	O
by	O
BLyS	B-Gene
binding	O
.	O

Similar	O
to	O
other	O
TNF	B-Gene
family	I-Gene
members	O
,	O
BLyS	B-Gene
is	O
present	O
in	O
solution	O
as	O
a	O
homotrimer	O
as	O
determined	O
by	O
gel	O
filtration	O
chromatography	O
and	O
light	O
scattering	O
analysis	O
.	O

BLyS	B-Gene
binding	O
to	O
B	O
cells	O
is	O
specific	O
as	O
other	O
TNF	B-Gene
family	I-Gene
members	O
tested	O
did	O
not	O
compete	O
for	O
(	O
125	O
)	O
I-	O
BLyS	B-Gene
binding	O
.	O

Analysis	O
of	O
equilibrium	O
binding	O
of	O
(	O
125	O
)	O
I	O
-labeled	O
BLyS	B-Gene
to	O
purified	O
human	O
tonsillar	O
B	O
cells	O
demonstrated	O
saturable	O
binding	O
.	O

Scatchard	O
analysis	O
of	O
the	O
binding	O
data	O
revealed	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
on	O
human	O
B	O
cells	O
with	O
approximately	O
2600	O
binding	O
sites	O
per	O
cell	O
and	O
an	O
apparent	O
dissociation	O
constant	O
(	O
K	O
(	O
D	O
)	O
)	O
of	O
about	O
0.1	O
nM	O
.	O

In	O
addition	O
we	O
report	O
that	O
BLyS	B-Gene
binding	O
to	O
B	O
cells	O
results	O
in	O
the	O
activation	O
of	O
NF-kappaB	B-Gene
and	O
the	O
Ets	B-Gene
family	I-Gene
transcription	I-Gene
factor	I-Gene
,	O
ELF-1	B-Gene
,	O
and	O
in	O
the	O
induction	O
of	O
mRNA	O
for	O
Polo	B-Gene
-like	I-Gene
kinase	I-Gene
(	O
PLK	B-Gene
)	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Human	B-Gene
T-cell	I-Gene
leukemia	I-Gene
virus	I-Gene
type	I-Gene
1	I-Gene
tax	I-Gene
protein	I-Gene
activates	O
transcription	O
through	O
AP-1	B-Gene
site	O
by	O
inducing	O
DNA	O
binding	O
activity	O
in	O
T	O
cells	O
.	O

Human	B-Gene
T-cell	I-Gene
leukemia	I-Gene
virus	I-Gene
type	I-Gene
1	I-Gene
(	I-Gene
HTLV-1	I-Gene
)	I-Gene
Tax	I-Gene
protein	I-Gene
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
AP-1	I-Gene
,	O
such	O
as	O
c-Jun	B-Gene
,	O
JunD	B-Gene
,	O
c-Fos	B-Gene
,	O
and	O
Fra-1	B-Gene
,	O
at	O
the	O
level	O
of	O
RNA	O
expression	O
in	O
T	O
cells	O
.	O

We	O
examined	O
the	O
activity	O
of	O
Tax	B-Gene
in	O
transcription	O
through	O
AP-1	B-Gene
-binding	O
sites	O
(	O
AP-1	B-Gene
site	O
)	O
in	O
T	O
cells	O
.	O

Transient	O
transfection	O
studies	O
showed	O
that	O
Tax	B-Gene
activated	O
the	O
expression	O
of	O
a	O
luciferase	O
gene	O
regulated	O
by	O
two	O
copies	O
of	O
an	O
AP-1	B-Gene
site	O
in	O
the	O
human	O
Jurkat	O
T-cell	O
line	O
.	O

Tax	B-Gene
activates	O
the	O
expression	O
of	O
viral	O
and	O
cellular	O
genes	O
through	O
two	O
different	O
enhancers	O
:	O
a	O
cAMP	B-Chemical
-responsive	O
(	O
CRE	O
)	O
-like	O
element	O
and	O
a	O
kappaB	O
element	O
.	O

Two	O
Tax	B-Gene
mutants	I-Gene
differentially	O
activated	O
expression	O
of	O
these	O
two	O
elements	O
.	O

Tax703	B-Gene
preferentially	O
activated	O
the	O
kappaB	O
element	O
but	O
not	O
the	O
CRE	O
-like	O
one	O
,	O
whereas	O
TaxM22	B-Gene
showed	O
the	O
reverse	O
.	O

In	O
addition	O
,	O
Tax703	B-Gene
and	O
Tax	B-Gene
,	O
but	O
not	O
TaxM22	B-Gene
,	O
converted	O
cell	O
growth	O
of	O
a	O
mouse	O
T-cell	O
line	O
from	O
being	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-2	I-Gene
-dependent	O
to	O
being	O
IL-2	B-Gene
-independent	O
.	O

Unlike	O
the	O
wild-type	B-Gene
Tax	I-Gene
,	O
Tax703	B-Gene
and	O
TaxM22	B-Gene
only	O
weakly	O
activated	O
the	O
AP-1	B-Gene
site	O
in	O
the	O
T-cell	O
line	O
.	O

Thus	O
,	O
Tax	B-Gene
seems	O
to	O
activate	O
the	O
AP-1	B-Gene
site	O
via	O
mechanisms	O
distinct	O
from	O
those	O
of	O
kappaB	O
or	O
CRE	O
-like	O
elements	O
,	O
and	O
the	O
activation	O
of	O
the	O
AP-1	B-Gene
site	O
is	O
dispensable	O
for	O
IL-2	B-Gene
-independent	O
growth	O
of	O
CTLL-2	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
Tax	B-Gene
induced	O
strong	O
binding	O
activity	O
to	O
an	O
AP-1	B-Gene
site	O
in	O
CTLL-2	O
,	O
whereas	O
Tax703	B-Gene
did	O
not	O
,	O
indicating	O
that	O
the	O
induction	O
of	O
binding	O
activity	O
to	O
the	O
AP-1	B-Gene
site	O
is	O
essential	O
for	O
the	O
transcriptional	O
activation	O
by	O
Tax	B-Gene
.	O

The	O
binding	O
complex	O
induced	O
by	O
Tax	B-Gene
in	O
CTLL-2	O
contained	O
JunD	B-Gene
and	O
Fra-2	B-Gene
.	O

Other	O
AP-1	B-Gene
proteins	I-Gene
were	O
undetectable	O
.	O

Activation	O
of	O
transcription	O
through	O
the	O
AP-1	B-Gene
site	O
in	O
Jurkat	O
cells	O
by	O
JunD	B-Gene
and	O
/	O
or	O
Fra-2	B-Gene
was	O
weak	O
.	O

c-Jun	B-Gene
,	O
JunB	B-Gene
,	O
and	O
c-Fos	B-Gene
activation	O
was	O
greater	O
,	O
although	O
the	O
level	O
was	O
still	O
less	O
than	O
that	O
with	O
Tax	B-Gene
.	O

Thus	O
,	O
the	O
induction	O
of	O
AP-1	B-Gene
mRNA	I-Gene
by	O
Tax	B-Gene
may	O
not	O
be	O
sufficient	O
for	O
a	O
complete	O
activation	O
of	O
AP-1	B-Gene
site	O
by	O
Tax	B-Gene
.	O

Our	O
results	O
suggest	O
that	O
Tax	B-Gene
activates	O
the	O
transcription	O
of	O
cellular	O
genes	O
with	O
AP-1	B-Gene
sites	O
by	O
inducing	O
the	O
DNA	O
-binding	O
activity	O
of	O
AP-1	B-Gene
proteins	I-Gene
in	O
T	O
cells	O
,	O
a	O
mechanism	O
distinct	O
from	O
those	O
of	O
CRE	O
-like	O
and	O
kappaB	O
elements	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Expression	O
and	O
function	O
of	O
a	O
stem	B-Gene
cell	I-Gene
promoter	I-Gene
for	O
the	O
murine	B-Gene
CBFalpha2	I-Gene
gene	I-Gene
:	O
distinct	O
roles	O
and	O
regulation	O
in	O
natural	O
killer	O
and	O
T	O
cell	O
development	O
.	O

The	O
Runt	B-Gene
family	I-Gene
transcription	I-Gene
factor	I-Gene
CBFalpha2	I-Gene
(	O
AML1	B-Gene
,	O
PEBP2alphaB	B-Gene
,	O
or	O
Runx1	B-Gene
)	O
is	O
required	O
by	O
hematopoietic	O
stem	O
cells	O
and	O
expressed	O
at	O
high	O
levels	O
in	O
T-lineage	O
cells	O
.	O

In	O
human	O
T	O
cells	O
CBFalpha2	B-Gene
is	O
usually	O
transcribed	O
from	O
a	O
different	O
promoter	O
(	O
distal	O
promoter	O
)	O
than	O
in	O
myeloid	O
cells	O
(	O
proximal	O
promoter	O
)	O
,	O
but	O
the	O
developmental	O
and	O
functional	O
significance	O
of	O
this	O
promoter	O
switch	O
has	O
not	O
been	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
both	O
coding	O
and	O
noncoding	O
sequences	O
of	O
the	O
distal	O
5	O
'end	O
are	O
highly	O
conserved	O
between	O
the	O
human	O
and	O
the	O
murine	O
genes	O
,	O
and	O
the	O
distal	O
promoter	O
is	O
responsible	O
for	O
the	O
overwhelming	O
majority	O
of	O
CBFalpha2	B-Gene
expression	O
in	O
murine	O
hematopoietic	O
stem	O
cells	O
as	O
well	O
as	O
in	O
T	O
cells	O
.	O

Distal	O
promoter	O
activity	O
is	O
maintained	O
throughout	O
T	O
cell	O
development	O
and	O
at	O
lower	O
levels	O
in	O
B	O
cell	O
development	O
,	O
but	O
downregulated	O
in	O
natural	O
killer	O
cell	O
development	O
.	O

The	O
distal	O
N-terminal	O
isoform	O
binds	O
to	O
functionally	O
important	O
regulatory	O
sites	O
from	O
known	O
target	O
genes	O
with	O
two-	O
to	O
threefold	O
higher	O
affinity	O
than	O
the	O
proximal	O
N-terminal	O
isoform	O
.	O

Neither	O
full-length	O
isoform	O
alters	O
growth	O
of	O
a	O
myeloid	O
cell	O
line	O
under	O
nondifferentiating	O
conditions	O
,	O
but	O
the	O
proximal	O
isoform	O
selectively	O
delays	O
mitotic	O
arrest	O
of	O
the	O
cell	O
line	O
under	O
differentiating	O
conditions	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
greater	O
numbers	O
of	O
neutrophils	O
.	O

Granulocytic	O
differentiation	O
of	O
human	O
NB4	O
promyelocytic	B-Disease
leukemia	I-Disease
cells	O
induced	O
by	O
all-trans	B-Chemical
retinoic	I-Chemical
acid	I-Chemical
metabolites	O
.	O

The	O
metabolism	O
of	O
all-trans	B-Chemical
retinoic	I-Chemical
acid	I-Chemical
(	O
ATRA	B-Chemical
)	O
has	O
been	O
reported	O
to	O
be	O
partly	O
responsible	O
for	O
the	O
in	O
vivo	O
resistance	O
to	O
ATRA	B-Chemical
seen	O
in	O
the	O
treatment	O
of	O
human	O
acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
(	O
APL	B-Disease
)	O
.	O

However	O
,	O
ATRA	B-Chemical
metabolism	O
appears	O
to	O
be	O
involved	O
in	O
the	O
growth	O
inhibition	O
of	O
several	O
cancer	B-Disease
cell	O
lines	O
in	O
vitro	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vitro	O
activity	O
of	O
the	O
principal	O
metabolites	O
of	O
ATRA	B-Chemical
[	O
4-hydroxy-retinoic	B-Chemical
acid	I-Chemical
(	O
4-OH-RA	B-Chemical
)	O
,	O
18-hydroxy-retinoic	B-Chemical
acid	I-Chemical
(	O
18-OH-RA	B-Chemical
)	O
,	O
4-oxo-retinoic	B-Chemical
acid	I-Chemical
(	O
4-oxo-RA	B-Chemical
)	O
,	O
and	O
5	B-Chemical
,	I-Chemical
6-epoxy-retinoic	I-Chemical
acid	I-Chemical
(	O
5	B-Chemical
,	I-Chemical
6-epoxy-RA	I-Chemical
)	O
]	O
in	O
NB4	O
,	O
a	O
human	O
promyelocytic	B-Disease
leukemia	I-Disease
cell	O
line	O
that	O
exhibits	O
the	O
APL	B-Disease
diagnostic	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
and	O
expresses	O
the	O
PML-RAR	B-Gene
alpha	I-Gene
fusion	I-Gene
protein	I-Gene
.	O

We	O
established	O
that	O
the	O
four	O
ATRA	B-Chemical
metabolites	O
were	O
indeed	O
formed	O
by	O
the	O
NB4	O
cells	O
in	O
vitro	O
.	O

NB4	O
cell	O
growth	O
was	O
inhibited	O
(	O
69-78	O
%	O
at	O
120	O
h	O
)	O
and	O
cell	O
cycle	O
progression	O
in	O
the	O
G1	O
phase	O
(	O
82-85	O
%	O
at	O
120	O
h	O
)	O
was	O
blocked	O
by	O
ATRA	B-Chemical
and	O
all	O
of	O
the	O
metabolites	O
at	O
1	O
microM	O
concentration	O
.	O

ATRA	B-Chemical
and	O
its	O
metabolites	O
could	O
induce	O
NB4	O
cells	O
differentiation	O
with	O
similar	O
activity	O
,	O
as	O
evaluated	O
by	O
cell	O
morphology	O
,	O
by	O
the	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
reduction	O
test	O
(	O
82-88	O
%	O
at	O
120	O
h	O
)	O
or	O
by	O
the	O
expression	O
of	O
the	O
maturation	B-Gene
specific	I-Gene
cell	I-Gene
surface	I-Gene
marker	I-Gene
CD11c	I-Gene
.	O

In	O
addition	O
,	O
nuclear	O
body	O
reorganization	O
to	O
macropunctated	O
structures	O
,	O
as	O
well	O
as	O
the	O
degradation	O
of	O
PML-RAR	B-Gene
alpha	I-Gene
,	O
was	O
found	O
to	O
be	O
similar	O
for	O
ATRA	B-Chemical
and	O
all	O
of	O
its	O
metabolites	O
.	O

Comparison	O
of	O
the	O
relative	O
potency	O
of	O
the	O
retinoids	O
using	O
the	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
reduction	O
test	O
showed	O
effective	O
concentrations	O
required	O
to	O
differentiate	O
50	O
%	O
of	O
cells	O
in	O
72	O
h	O
as	O
follows	O
:	O
ATRA	B-Chemical
,	O
15.8	O
+	O
/	O
-	O
1.7	O
nM	O
;	O
4-oxo-RA	B-Chemical
,	O
38.3	O
+	O
/	O
-	O
1.3	O
nM	O
;	O
18-OH-RA	B-Chemical
,	O
55.5	O
+	O
/	O
-	O
1.8	O
nM	O
;	O
4-OH-RA	B-Chemical
,	O
79.8	O
+	O
/	O
-	O
1.8	O
nM	O
;	O
and	O
5	B-Chemical
,	I-Chemical
6-epoxy-RA	I-Chemical
,	O
99.5	O
+	O
/	O
-	O
1.5	O
nM	O
.	O

The	O
ATRA	B-Chemical
metabolites	O
were	O
found	O
to	O
exert	O
their	O
differentiation	O
effects	O
via	O
the	O
RAR	B-Gene
alpha	I-Gene
nuclear	I-Gene
receptors	I-Gene
,	O
because	O
the	O
RAR	B-Gene
alpha-specific	I-Gene
antagonist	O
BMS614	O
blocked	O
metabolite	O
-induced	O
CD11c	B-Gene
expression	O
in	O
NB4	O
cells	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
principal	O
ATRA	B-Chemical
Phase	O
1	O
metabolites	O
can	O
elicit	O
leukemia	B-Disease
cell	O
growth	O
inhibition	O
and	O
differentiation	O
in	O
vitro	O
through	O
the	O
RAR	B-Gene
alpha	I-Gene
signaling	O
pathway	O
,	O
and	O
they	O
suggest	O
that	O
these	O
metabolites	O
may	O
play	O
a	O
role	O
in	O
ATRA	B-Chemical
antileukemic	O
activity	O
in	O
vivo	O
.	O

Homocysteine	B-Chemical
stimulates	O
the	O
expression	O
of	O
monocyte	B-Gene
chemoattractant	I-Gene
protein-1	I-Gene
in	O
endothelial	O
cells	O
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

Hyperhomocysteinemia	B-Disease
has	O
been	O
identified	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
atherosclerosis	B-Disease
.	O

The	O
infiltration	O
of	O
monocytes	O
into	O
the	O
arterial	O
wall	O
is	O
one	O
of	O
the	O
key	O
events	O
during	O
atherogenesis	O
.	O

Monocyte	B-Gene
chemoattractant	I-Gene
protein-1	I-Gene
(	O
MCP-1	B-Gene
)	O
is	O
a	O
potent	O
chemokine	O
that	O
stimulates	O
the	O
migration	O
of	O
monocytes	O
into	O
the	O
intima	O
of	O
the	O
arterial	O
wall	O
.	O

The	O
mechanism	O
by	O
which	O
increased	O
monocyte	O
infiltration	O
occurs	O
in	O
atherosclerotic	B-Disease
lesions	I-Disease
in	O
patients	O
with	O
hyperhomocysteinemia	B-Disease
has	O
not	O
been	O
delineated	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
homocysteine	B-Chemical
on	O
MCP-1	B-Gene
production	O
in	O
endothelial	O
cells	O
.	O

Cells	O
were	O
incubated	O
with	O
homocysteine	B-Chemical
.	O

The	O
secretion	O
of	O
MCP-1	B-Gene
protein	I-Gene
was	O
significantly	O
increased	O
(	O
195	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
cells	O
treated	O
with	O
pathological	O
concentrations	O
of	O
homocysteine	B-Chemical
.	O

Such	O
effect	O
was	O
accompanied	O
by	O
an	O
increased	O
expression	O
of	O
MCP-1	B-Gene
mRNA	I-Gene
(	O
176	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
endothelial	O
cells	O
which	O
resulted	O
in	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

The	O
p38	B-Gene
MAP	I-Gene
kinase	I-Gene
as	O
well	O
as	O
other	O
members	O
of	O
the	O
p38	B-Gene
MAP	I-Gene
kinase	I-Gene
pathway	O
,	O
including	O
MKK3	B-Gene
,	O
MKK6	B-Gene
,	O
ATF-2	B-Gene
and	O
Elk-1	B-Gene
,	O
were	O
activated	O
in	O
homocysteine	B-Chemical
-treated	O
cells	O
.	O

Homocysteine	B-Chemical
-induced	O
MCP-1	B-Gene
expression	O
and	O
subsequent	O
monocyte	O
chemotaxis	O
were	O
blocked	O
by	O
a	O
p38	B-Gene
MAP	I-Gene
kinase	I-Gene
inhibitor	O
(	O
SB203580	B-Chemical
)	O
suggesting	O
that	O
the	O
p38	B-Gene
MAP	I-Gene
kinase	I-Gene
pathway	O
might	O
be	O
involved	O
in	O
homocysteine	B-Chemical
-induced	O
MCP-1	B-Gene
expression	O
in	O
endothelial	O
cells	O
.	O

In	O
contrast	O
,	O
staurosporine	B-Chemical
,	O
a	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
inhibitor	I-Gene
,	O
had	O
no	O
effect	O
on	O
homocysteine	B-Chemical
-induced	O
MCP-1	B-Gene
expression	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
homocysteine	B-Chemical
stimulates	O
MCP-1	B-Gene
expression	O
in	O
endothelial	O
cells	O
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O

Transcription	B-Gene
factor	I-Gene
AP-4	I-Gene
is	O
a	O
ligand	O
for	O
immunoglobulin-kappa	B-Gene
promoter	I-Gene
E-box	O
elements	O
.	O

Immunoglobulin	B-Gene
(	I-Gene
Ig	I-Gene
)	I-Gene
-kappa	I-Gene
promoters	I-Gene
from	O
humans	O
and	O
mice	O
share	O
conserved	O
sequences	O
.	O

The	O
octamer	O
element	O
is	O
common	O
to	O
all	O
Ig	B-Gene
promoters	I-Gene
and	O
pivotal	O
for	O
their	O
function	O
.	O

However	O
,	O
other	O
conserved	O
sequence	O
motifs	O
,	O
that	O
differ	O
between	O
Ig	B-Gene
variable	I-Gene
gene	I-Gene
families	I-Gene
,	O
are	O
required	O
for	O
normal	O
promoter	O
function	O
.	O

These	O
conserved	O
motifs	O
do	O
not	O
stimulate	O
transcription	O
in	O
the	O
absence	O
of	O
an	O
octamer	O
.	O

One	O
example	O
is	O
an	O
E-box	O
of	O
the	O
E47	B-Gene
/	I-Gene
E12	I-Gene
type	O
(	O
5'-CAGCTG-3')	O
,	O
which	O
is	O
found	O
in	O
all	O
promoters	O
of	O
the	O
human	O
and	O
murine	B-Gene
Ig-kappa	I-Gene
gene	I-Gene
subgroups	O
/	O
families	O
,	O
with	O
the	O
exception	O
of	O
subgroups	O
II	O
and	O
VI	O
and	O
their	O
related	O
murine	O
families	O
.	O

In	O
the	O
present	O
study	O
we	O
show	O
that	O
the	O
ubiquitously	O
expressed	O
transcription	B-Gene
factor	I-Gene
AP-4	I-Gene
,	O
and	O
not	O
E47	B-Gene
,	O
interacts	O
specifically	O
with	O
the	O
kappa	O
promoter	O
E-boxes	O
when	O
tested	O
in	O
electrophoretic	O
mobility-shift	O
assays	O
using	O
nuclear	O
extracts	O
derived	O
from	O
human	O
and	O
murine	O
B-cell	O
lines	O
.	O

Furthermore	O
,	O
AP-4	B-Gene
,	O
unlike	O
E47	B-Gene
,	O
did	O
not	O
act	O
as	O
a	O
transactivator	O
,	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
studies	O
on	O
intact	O
kappa	O
promoters	O
,	O
showing	O
that	O
transcription	O
is	O
absent	O
when	O
the	O
octamer	O
element	O
has	O
been	O
mutated	O
.	O

Based	O
on	O
these	O
data	O
,	O
and	O
the	O
conservation	O
of	O
the	O
5'-CAGCTG-3	O
'motif	O
among	O
human	O
and	O
murine	O
kappa	O
promoters	O
,	O
we	O
propose	O
that	O
AP-4	B-Gene
is	O
the	O
major	O
ligand	O
for	O
Ig-kappa	B-Gene
promoter	I-Gene
E-boxes	O
.	O

NF	B-Gene
kappa	I-Gene
b	I-Gene
signaling	O
in	O
posthypoxic	O
endothelial	O
cells	O
:	O
relevance	O
to	O
E-selectin	B-Gene
expression	O
and	O
neutrophil	O
adhesion	O
.	O

Our	O
previous	O
studies	O
have	O
implicated	O
the	O
nuclear	B-Gene
transcription	I-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
)	O
in	O
the	O
regulation	O
of	O
adhesion	O
molecule	O
expression	O
in	O
endothelial	O
cells	O
exposed	O
to	O
anoxia-reoxygenation	O
(	O
A	O
/	O
R	O
)	O
or	O
a	O
redox	O
imbalance	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
(	O
1	O
)	O
to	O
define	O
the	O
kinetics	O
of	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
activation	O
by	O
examining	O
I	B-Gene
kappa	I-Gene
B	I-Gene
alpha	I-Gene
degradation	O
and	O
the	O
nuclear	O
translocation	O
of	O
p65	B-Gene
in	O
response	O
to	O
A	O
/	O
R	O
or	O
redox	O
imbalance	O
(	O
induced	O
by	O
treatment	O
of	O
cells	O
with	O
diamide	B-Chemical
and	O
buthionine	B-Chemical
sulfoximine	I-Chemical
)	O
and	O
(	O
2	O
)	O
to	O
determine	O
whether	O
the	O
signal	O
for	O
I	B-Gene
kappa	I-Gene
B	I-Gene
alpha	I-Gene
degradation	O
,	O
nuclear	O
translocation	O
of	O
p65	B-Gene
,	O
and	O
E-selectin	B-Gene
-mediated	O
neutrophil	O
adhesion	O
is	O
related	O
to	O
the	O
activity	O
of	O
protein	B-Gene
tyrosine	I-Gene
kinase	I-Gene
(	O
PTK	B-Gene
)	O
,	O
protein	B-Gene
tyrosine	I-Gene
phosphatase	I-Gene
(	O
PTPase	B-Gene
)	O
and	O
/	O
or	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
.	O

The	O
results	O
demonstrate	O
that	O
both	O
A	O
/	O
R	O
and	O
redox	O
imbalance	O
led	O
to	O
I	B-Gene
kappa	I-Gene
B	I-Gene
alpha	I-Gene
degradation	O
within	O
30	O
min	O
and	O
the	O
concomitant	O
appearance	O
of	O
p65	B-Gene
in	O
the	O
nucleus	O
,	O
consistent	O
with	O
rapid	O
cytosolic	O
activation	O
of	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
and	O
subsequent	O
nuclear	O
translocation	O
of	O
the	O
activated	O
p65	B-Gene
subunit	I-Gene
.	O

Inhibition	O
of	O
PKC	B-Gene
blocked	O
I	B-Gene
kappa	I-Gene
B	I-Gene
alpha	I-Gene
degradation	O
and	O
p65	B-Gene
translocation	O
in	O
A	O
/	O
R	O
-challenged	O
,	O
but	O
not	O
redox	O
-altered	O
,	O
endothelial	O
cells	O
.	O

However	O
,	O
both	O
A	O
/	O
R-	O
and	O
redox	O
-induced	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
activation	O
was	O
blocked	O
by	O
inhibition	O
of	O
PTK	B-Gene
.	O

Similarly	O
,	O
A	O
/	O
R	O
-induced	O
E-selectin	B-Gene
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
were	O
blocked	O
by	O
inhibition	O
of	O
PKC	B-Gene
or	O
PTK	B-Gene
,	O
while	O
only	O
PTK	B-Gene
inhibited	O
the	O
redox	O
-induced	O
adhesion	O
response	O
.	O

Pretreatment	O
of	O
cells	O
with	O
N-acetyl	B-Chemical
cysteine	I-Chemical
effectively	O
blocked	O
A	O
/	O
R-	O
or	O
redox	O
-induced	O
I	B-Gene
kappa	I-Gene
B	I-Gene
degradation	O
and	O
significantly	O
attenuated	O
the	O
respective	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A	O
/	O
R	O
-induced	O
E-selectin	B-Gene
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
are	O
mediated	O
by	O
both	O
PKC	B-Gene
and	O
PTK	B-Gene
,	O
which	O
signal	O
rapid	O
activation	O
of	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
.	O

This	O
A	O
/	O
R	O
-induced	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
signaling	O
response	O
appears	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
intracellular	O
redox	O
imbalance	O
.	O

Copyright	O
2001	O
S	O
.	O

Karger	O
AG	O
,	O
Basel	O

Renal	O
interstitial	O
fibrosis	O
is	O
reduced	O
in	O
angiotensin	B-Gene
II	I-Gene
type	I-Gene
1a	I-Gene
receptor	I-Gene
-deficient	O
mice	O
.	O

Unilateral	B-Disease
ureteral	I-Disease
obstruction	I-Disease
(	O
UUO	B-Disease
)	O
results	O
in	O
tubulointerstitial	O
fibrosis	O
of	O
the	O
affected	O
kidney	O
by	O
stimulating	O
the	O
renin-angiotensin	B-Gene
system	O
.	O

This	O
study	O
established	O
a	O
UUO	B-Disease
model	O
in	O
angiotensin	B-Gene
type	I-Gene
1a	I-Gene
receptor	I-Gene
(	O
AT1a	B-Gene
)	O
deficient	O
(	O
mutant	O
)	O
mice	O
to	O
elucidate	O
the	O
role	O
of	O
angiotensin	B-Gene
II	I-Gene
through	O
AT1a	B-Gene
on	O
the	O
fibrosis	O
of	O
the	O
obstructed	O
kidney	O
(	O
OBK	O
)	O
.	O

The	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	O
was	O
measured	O
by	O
an	O
image	O
analyzer	O
;	O
deposition	O
of	O
collagen	B-Gene
types	I-Gene
III	I-Gene
and	O
IV	B-Gene
and	O
monocyte	O
/	O
macrophage	O
infiltration	O
were	O
histologically	O
examined	O
using	O
specific	O
antibodies	O
.	O

Also	O
determined	O
were	O
the	O
mRNA	O
levels	O
of	O
transforming	B-Gene
growth	I-Gene
factor-beta	I-Gene
by	O
Northern	O
blot	O
analysis	O
.	O

Nuclear	B-Gene
factor-kappaB	I-Gene
activity	O
was	O
assessed	O
by	O
gel	O
shift	O
assay	O
.	O

UUO	B-Disease
in	O
wild	O
mice	O
resulted	O
in	O
a	O
marked	O
expansion	O
of	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	O
,	O
together	O
with	O
increased	O
deposition	O
of	O
collagen	B-Gene
types	I-Gene
III	I-Gene
and	O
IV	B-Gene
and	O
number	O
of	O
infiltrated	O
monocytes	O
/	O
macrophages	O
in	O
the	O
interstitium	O
,	O
relative	O
to	O
sham	O
-operated	O
mice	O
.	O

In	O
comparison	O
,	O
these	O
changes	O
were	O
significantly	O
lower	O
in	O
mutant	O
mice	O
with	O
UUO	B-Disease
.	O

The	O
mRNA	O
level	O
of	O
transforming	B-Gene
growth	I-Gene
factor-beta	I-Gene
was	O
significantly	O
higher	O
in	O
the	O
OBK	O
of	O
wild	O
mice	O
with	O
UUO	B-Disease
compared	O
with	O
sham	O
-operated	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
increase	O
in	O
mRNA	O
level	O
in	O
the	O
OBK	O
of	O
mutant	O
mice	O
was	O
significantly	O
less	O
than	O
in	O
wild	O
mice	O
.	O

Finally	O
,	O
UUO	B-Disease
resulted	O
in	O
activation	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
in	O
wild	O
mice	O
but	O
was	O
inhibited	O
in	O
the	O
OBK	O
of	O
mutant	O
mice	O
.	O

The	O
results	O
provide	O
direct	O
evidence	O
that	O
angiotensin	B-Gene
II	I-Gene
acting	O
via	O
the	O
AT1a	B-Gene
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
tubulointerstitial	O
fibrosis	O
in	O
UUO	B-Disease
.	O

Decreased	O
immediate	O
inflammatory	O
gene	O
induction	O
in	O
activating	B-Gene
transcription	I-Gene
factor-2	I-Gene
mutant	O
mice	O
.	O

Transcription	B-Gene
factor	I-Gene
activating	I-Gene
transcription	I-Gene
factor	I-Gene
(	I-Gene
ATF	I-Gene
)	I-Gene
-2	I-Gene
is	O
activated	O
by	O
inflammatory	O
signals	O
transduced	O
by	O
the	O
JNK	B-Gene
and	O
p38	B-Gene
MAP	I-Gene
kinase	I-Gene
pathways	O
.	O

To	O
better	O
define	O
the	O
role	O
of	O
ATF-2	B-Gene
in	O
inflammation	O
,	O
adult	O
mice	O
expressing	O
small	O
amounts	O
of	O
a	O
mutant	B-Gene
ATF-2	I-Gene
protein	I-Gene
were	O
challenged	O
with	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
,	O
anti-CD3	B-Gene
antibody	I-Gene
or	O
virus	O
.	O

Within	O
3	O
h	O
of	O
challenge	O
by	O
LPS	B-Chemical
,	O
ATF-2	B-Gene
mutant	I-Gene
mice	O
had	O
decreased	O
induction	O
of	O
the	O
adhesion	O
molecules	O
E-selectin	B-Gene
,	O
P-selectin	B-Gene
and	O
VCAM-1	B-Gene
as	O
well	O
as	O
the	O
cytokines	B-Gene
tumor	I-Gene
necrosis	I-Gene
factor-alpha	I-Gene
,	O
IL-1beta	B-Gene
and	O
IL-6	B-Gene
compared	O
with	O
control	O
mice	O
.	O

Stimulation	O
of	O
T	O
lymphocytes	O
by	O
anti-CD3	B-Gene
antibody	I-Gene
also	O
showed	O
less	O
induction	O
of	O
IL-1	B-Gene
and	O
IL-6	B-Gene
in	O
ATF-2	B-Gene
mutant	I-Gene
tissues	O
.	O

ATF-2	B-Gene
mutant	I-Gene
thymocytes	O
treated	O
with	O
anti-CD3	B-Gene
antibody	I-Gene
in	O
vitro	O
demonstrated	O
reduced	O
induction	O
of	O
c-Jun	B-Gene
,	O
JunB	B-Gene
,	O
JunD	B-Gene
and	O
Fra-2	B-Gene
.	O

However	O
,	O
similar	O
to	O
what	O
was	O
observed	O
after	O
p38	B-Gene
kinase	I-Gene
inhibition	O
in	O
normal	O
mice	O
,	O
relative	O
ATF-2	B-Gene
deficiency	O
did	O
not	O
prevent	O
the	O
development	O
of	O
a	O
mononuclear	O
cell	O
infiltrate	O
in	O
the	O
week	O
following	O
an	O
inflammatory	O
stimulus	O
.	O

ATF-2	B-Gene
mutant	I-Gene
mice	O
proved	O
more	O
susceptible	O
to	O
death	O
than	O
control	O
mice	O
from	O
LPS	B-Chemical
plus	O
D-galactosamine	B-Chemical
injection	O
or	O
Coxsackievirus	O
B3	O
infection	O
and	O
had	O
a	O
higher	O
incidence	O
of	O
mononuclear	O
pulmonary	O
infiltrates	O
after	O
exposure	O
to	O
Herpes	O
simplex	O
virus-1	O
.	O

ATF-2	B-Gene
is	O
essential	O
for	O
maximal	O
immediate	O
induction	O
of	O
adhesion	O
molecules	O
and	O
cytokine	O
genes	O
,	O
but	O
at	O
later	O
time	O
points	O
may	O
even	O
protect	O
against	O
overactive	O
immune	O
responses	O
.	O

Lymphokine	O
dependence	O
of	O
STAT3	B-Gene
activation	O
produced	O
by	O
surface	B-Gene
immunoglobulin	I-Gene
cross	O
-linking	O
and	O
by	O
phorbol	B-Chemical
ester	I-Chemical
plus	O
calcium	B-Chemical
ionophore	O
treatment	O
in	O
B	O
cells	O
.	O

Stimulation	O
of	O
B	O
cells	O
by	O
surface	B-Gene
immunoglobulin	I-Gene
(	O
sIg	B-Gene
)	O
triggering	O
,	O
or	O
through	O
the	O
mitogenic	O
combination	O
of	O
phorbol	B-Chemical
ester	I-Chemical
and	O
calcium	B-Chemical
ionophore	O
,	O
is	O
accompanied	O
by	O
activation	O
of	O
STAT	B-Gene
transcription	I-Gene
factors	I-Gene
.	O

The	O
mechanism	O
responsible	O
for	O
the	O
delayed	O
nuclear	O
accumulation	O
of	O
phosphorylated	B-Gene
STAT3	I-Gene
was	O
examined	O
in	O
detail	O
,	O
focusing	O
on	O
the	O
role	O
of	O
B	O
cell	O
-derived	O
lymphokines	O
.	O

sIg	B-Gene
-induced	O
activation	O
of	O
STAT3	B-Gene
was	O
partially	O
inhibited	O
in	O
B	O
cells	O
obtained	O
from	O
IL-6-	B-Gene
or	O
IL-10	B-Gene
-deficient	O
mice	O
,	O
and	O
was	O
partially	O
blocked	O
by	O
neutralizing	O
antibodies	O
directed	O
against	O
either	O
of	O
these	O
lymphokines	O
.	O

sIg	B-Gene
-induced	O
STAT3	B-Gene
activation	O
was	O
completely	O
inhibited	O
by	O
combining	O
IL-6-	B-Gene
and	O
IL-10-specific	B-Gene
neutralizing	I-Gene
antibodies	I-Gene
,	O
or	O
by	O
adding	O
individual	O
neutralizing	O
antibodies	O
to	O
B	O
cells	O
obtained	O
from	O
lymphokine	O
-deficient	O
animals	O
.	O

In	O
contrast	O
,	O
IL-10	B-Gene
alone	O
appeared	O
to	O
account	O
for	O
STAT3	B-Gene
activation	O
resulting	O
from	O
B	O
cell	O
stimulation	O
with	O
phorbol	B-Chemical
ester	I-Chemical
and	O
calcium	B-Chemical
ionophore	O
.	O

In	O
keeping	O
with	O
these	O
results	O
,	O
soluble	O
IL-6	B-Gene
and	O
IL-10	B-Gene
were	O
found	O
in	O
supernatant	O
fluid	O
obtained	O
from	O
stimulated	O
B	O
cells	O
.	O

This	O
work	O
indicates	O
that	O
a	O
lymphokine	O
pathway	O
is	O
responsible	O
for	O
STAT3	B-Gene
activation	O
that	O
occurs	O
late	O
after	O
B	O
cell	O
stimulation	O
,	O
and	O
points	O
out	O
differences	O
in	O
B	O
cell	O
activation	O
that	O
result	O
from	O
stimulation	O
through	O
the	O
antigen	O
receptor	O
and	O
through	O
pharmacological	O
mimicry	O
of	O
signaling	O
mediators	O
.	O

Bone	O
marrow	O
cells	O
promote	O
TH2	O
polarization	O
and	O
inhibit	O
virus-specific	O
CTL	O
generation	O
.	O

This	O
laboratory	O
recently	O
reported	O
that	O
human	O
bone	O
marrow	O
cells	O
(	O
BMC	O
)	O
inhibit	O
the	O
generation	O
of	O
virus-specific	O
CTL	O
in	O
culture	O
.	O

The	O
culture	O
supernatants	O
contained	O
increased	O
levels	O
of	O
prostaglandin	B-Chemical
E	I-Chemical
(	O
2	O
)	O
(	O
PGE	B-Chemical
(	O
2	O
)	O
)	O
(	O
shown	O
to	O
favor	O
TH2	O
cell	O
development	O
)	O
and	O
also	O
inhibited	O
EBV-CTL	O
effector	O
cell	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
PBL	O
from	O
Epstein-Barr	B-Gene
virus	I-Gene
(	I-Gene
EBV	I-Gene
)	I-Gene
IgG	I-Gene
antibody	I-Gene
positive	O
kidney	O
transplant	O
recipients	O
(	O
R	O
)	O
and	O
their	O
living	O
-related	O
donors	O
(	O
LRD	O
)	O
one	O
year	O
after	O
renal	O
transplantation	O
.	O

EBV-specific	O
CTL	O
were	O
then	O
generated	O
in	O
vitro	O
by	O
stimulating	O
PBL	O
with	O
autologous	O
EBV	O
-transformed	O
B	O
cells	O
(	O
EBV-B	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
autologous	O
BMC	O
.	O

The	O
addition	O
of	O
BMC	O
to	O
the	O
EBV-CTL	O
generation	O
cultures	O
increased	O
the	O
intracellular	O
expression	O
in	O
CD3+	B-Gene
cells	O
of	O
IL-4	B-Gene
,	O
-5	B-Partial_Gene
,	O
-6	B-Partial_Gene
,	O
-10	B-Partial_Gene
,	O
and	O
-13	B-Partial_Gene
.	O

These	O
CD3+	B-Gene
cells	O
also	O
expressed	O
increased	O
levels	O
of	O
the	O
TH2	O
associated	O
receptor	B-Gene
CCR3	I-Gene
.	O

Inhibition	O
was	O
even	O
observed	O
by	O
preparing	O
EBV-CTL	O
generating	O
cultures	O
in	O
trans-wells	O
that	O
separated	O
the	O
autologous	O
BMC	O
from	O
the	O
PBL	O
+	O
EBV-B	O
.	O

It	O
was	O
then	O
observed	O
that	O
CD3+	B-Gene
cells	O
obtained	O
after	O
7	O
days	O
of	O
culture	O
in	O
the	O
presence	O
of	O
autologous	O
BMC	O
could	O
be	O
used	O
as	O
inhibitors	O
of	O
EBV-CTL	O
generation	O
.	O

Protein	B-Gene
Kinase	I-Gene
A	I-Gene
(	O
PKA	B-Gene
)	O
,	O
a	O
cAMP	B-Gene
kinase	I-Gene
that	O
is	O
involved	O
in	O
the	O
upregulation	O
of	O
TH2	O
cytokine	O
activity	O
,	O
was	O
increased	O
in	O
EBV-CTL	O
cultures	O
by	O
the	O
presence	O
of	O
BMC	O
.	O

Additionally	O
,	O
IL-4	B-Gene
-mediated	O
signal	B-Gene
transduction	I-Gene
and	I-Gene
activation	I-Gene
of	I-Gene
transcription	I-Gene
(	O
STAT-6	B-Gene
)	O
phosphorylation	O
was	O
slightly	O
increased	O
.	O

These	O
results	O
show	O
that	O
the	O
BMC	O
inhibition	O
is	O
mediated	O
by	O
soluble	O
factors	O
(	O
cytokines	O
)	O
and	O
that	O
cell-cell	O
contact	O
in	O
this	O
autologous	O
system	O
is	O
not	O
required	O
,	O
so	O
that	O
BMC	O
(	O
at	O
least	O
partially	O
,	O
via	O
cytokine	O
production	O
)	O
promote	O
TH2	O
polarization	O
in	O
culture	O
.	O

Moreover	O
,	O
TH2	O
cells	O
induced	O
by	O
culturing	O
with	O
autologous	O
BMC	O
directly	O
inhibit	O
EBV-CTL	O
generation	O
,	O
and	O
TH2	O
associated	O
PKA	B-Gene
,	O
CCR3	B-Gene
,	O
and	O
STAT-6	B-Gene
phosphorylation	O
are	O
enhanced	O
by	O
BMC	O
.	O

Induction	O
of	O
apoptosis	O
in	O
human	O
lymphocytes	O
by	O
the	O
herbicide	B-Chemical
2	I-Chemical
,	I-Chemical
4-dichlorophenoxyacetic	I-Chemical
acid	I-Chemical
.	O

Dimethylammonium	O
salt	O
of	O
2	B-Chemical
,	I-Chemical
4-dichlorophenoxyacetic	I-Chemical
acid	I-Chemical
(	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
)	O
is	O
a	O
widely	O
used	O
herbicide	O
that	O
is	O
considered	O
moderately	O
toxic	O
.	O

In	O
the	O
present	O
study	O
we	O
found	O
that	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
is	O
able	O
to	O
cause	O
apoptosis	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
healthy	O
individuals	O
and	O
Jurkat	O
T	O
cells	O
.	O

Apoptosis	O
induced	O
by	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
was	O
dose	O
and	O
time	O
dependent	O
,	O
independent	O
of	O
Fas	B-Gene
,	O
TNF	B-Gene
receptor	I-Gene
1	I-Gene
or	O
the	O
aromatic	B-Gene
hydrocarbon	I-Gene
receptor	I-Gene
,	O
and	O
involved	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
activation	O
of	O
caspase-9	B-Gene
.	O

ZVAD-FMK	B-Chemical
,	O
a	O
broad-spectrum	O
inhibitor	O
of	O
caspases	B-Gene
,	O
blocked	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
-induced	O
apoptosis	O
completely	O
.	O

While	O
an	O
inhibitor	O
of	O
caspase-9	B-Gene
,	O
as	O
well	O
as	O
caspase-9	B-Gene
and	O
caspase-3	B-Gene
inhibitors	I-Gene
in	O
combination	O
,	O
strongly	O
blocked	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
-induced	O
apoptosis	O
,	O
an	O
inhibitor	O
of	O
caspase-3	B-Gene
had	O
a	O
moderate	O
inhibitory	O
effect	O
.	O

Unlike	O
Fas	B-Gene
-mediated	O
apoptosis	O
,	O
the	O
initiator	B-Gene
caspase	I-Gene
,	O
caspase-8	B-Gene
,	O
was	O
not	O
involved	O
in	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
-induced	O
apoptosis	O
.	O

Transfection	O
of	O
Jurkat	O
cells	O
with	O
Bcl-2	B-Gene
prevented	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
-induced	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
led	O
to	O
a	O
complete	O
blockage	O
of	O
apoptosis	O
.	O

Our	O
data	O
indicate	O
that	O
DMA-2	B-Chemical
,	I-Chemical
4-D	I-Chemical
kills	O
human	O
lymphocytes	O
by	O
initiating	O
apoptosis	O
via	O
a	O
direct	O
effect	O
on	O
mitochondria	O
.	O

The	O
activation	O
of	O
caspases	B-Gene
occurs	O
downstream	O
of	O
mitochondrial	O
damage	O
,	O
and	O
the	O
dysfunction	O
of	O
mitochondria	O
appears	O
to	O
be	O
sufficient	O
for	O
triggering	O
all	O
downstream	O
events	O
leading	O
to	O
apoptosis	O
.	O

Inhibition	O
of	O
STAT3	B-Gene
signaling	O
leads	O
to	O
apoptosis	O
of	O
leukemic	O
large	O
granular	O
lymphocytes	O
and	O
decreased	O
Mcl-1	B-Gene
expression	O
.	O

Large	B-Disease
granular	I-Disease
lymphocyte	I-Disease
(	I-Disease
LGL	I-Disease
)	I-Disease
leukemia	I-Disease
is	O
characterized	O
by	O
the	O
expansion	O
of	O
antigen	O
-activated	O
cytotoxic	O
T	O
lymphocytes	O
.	O

These	O
leukemic	O
cells	O
are	O
resistant	O
to	O
Fas	B-Gene
-mediated	O
apoptosis	O
despite	O
expressing	O
high	O
levels	O
of	O
Fas	B-Gene
.	O

We	O
found	O
that	O
leukemic	O
LGL	O
from	O
19	O
patients	O
displayed	O
high	O
levels	O
of	O
activated	B-Gene
STAT3	I-Gene
.	O

Treatment	O
of	O
leukemic	O
LGL	O
with	O
the	O
JAK	B-Gene
-selective	I-Gene
tyrosine	I-Gene
kinase	I-Gene
inhibitor	O
AG-490	B-Chemical
induced	O
apoptosis	O
with	O
a	O
corresponding	O
decrease	O
in	O
STAT	B-Gene
-DNA	I-Gene
binding	O
activity	O
.	O

Moreover	O
,	O
using	O
an	O
antisense	O
oligonucleotide	O
approach	O
to	O
diminish	O
STAT3	B-Gene
expression	O
,	O
we	O
found	O
that	O
Fas	B-Gene
sensitivity	O
was	O
restored	O
in	O
leukemic	O
LGL	O
.	O

AG-490	B-Chemical
-induced	O
apoptosis	O
in	O
leukemic	O
LGL	O
was	O
independent	O
of	O
Bcl-xL	B-Gene
or	O
Bcl-2	B-Gene
expression	O
.	O

However	O
,	O
we	O
found	O
that	O
the	O
Bcl-2-family	B-Gene
protein	I-Gene
Mcl-1	I-Gene
was	O
significantly	O
reduced	O
by	O
AG-490	B-Chemical
treatment	O
.	O

Activated	B-Gene
STAT3	I-Gene
was	O
shown	O
to	O
bind	O
an	O
SIE	O
-related	O
element	O
in	O
the	O
murine	B-Gene
mcl-1	I-Gene
promoter	I-Gene
.	O

Using	O
a	O
luciferase	O
reporter	O
assay	O
,	O
we	O
demonstrated	O
that	O
v-src	B-Gene
overexpression	O
in	O
NIH3T3	O
induced	O
STAT3	B-Gene
-dependent	O
transcriptional	O
activity	O
from	O
the	O
mcl-1	B-Gene
promoter	I-Gene
and	O
increased	O
endogenous	B-Gene
Mcl-1	I-Gene
protein	I-Gene
levels	O
.	O

We	O
conclude	O
that	O
STAT3	B-Gene
activation	O
contributed	O
to	O
accumulation	O
of	O
the	O
leukemic	O
LGL	O
clones	O
.	O

These	O
findings	O
suggest	O
that	O
investigation	O
should	O
focus	O
on	O
novel	O
strategies	O
targeting	O
STAT3	B-Gene
in	O
the	O
treatment	O
of	O
LGL	B-Disease
leukemia	I-Disease
.	O

Visualization	O
of	O
Syk-antigen	B-Gene
receptor	I-Gene
interactions	O
using	O
green	O
fluorescent	O
protein	O
:	O
differential	O
roles	O
for	O
Syk	B-Gene
and	O
Lyn	B-Gene
in	O
the	O
regulation	O
of	O
receptor	O
capping	O
and	O
internalization	O
.	O

The	O
cross	O
-linking	O
of	O
the	O
B	B-Gene
cell	I-Gene
Ag	I-Gene
receptor	I-Gene
(	O
BCR	B-Gene
)	O
is	O
coupled	O
to	O
the	O
stimulation	O
of	O
multiple	O
intracellular	O
signal	O
transduction	O
cascades	O
via	O
receptor	O
-associated	O
,	O
protein	B-Gene
tyrosine	I-Gene
kinases	I-Gene
of	O
both	O
the	O
Src	B-Gene
and	O
Syk	B-Gene
families	I-Gene
.	O

To	O
monitor	O
changes	O
in	O
the	O
subcellular	O
distribution	O
of	O
Syk	B-Gene
in	O
B	O
cells	O
responding	O
to	O
BCR	B-Gene
cross	O
-linking	O
,	O
we	O
expressed	O
in	O
Syk	B-Gene
-deficient	O
DT40	O
B	O
cells	O
a	O
fusion	O
protein	O
consisting	O
of	O
Syk	B-Gene
coupled	O
to	O
green	O
fluorescent	O
protein	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
anti-IgM	B-Gene
Abs	I-Gene
leads	O
to	O
the	O
recruitment	O
of	O
the	O
kinase	O
from	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
to	O
the	O
site	O
of	O
the	O
cross	O
-linked	O
receptor	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
Syk-receptor	B-Gene
complexes	I-Gene
aggregate	O
into	O
membrane	O
patches	O
that	O
redistribute	O
to	O
form	O
a	O
cap	O
at	O
one	O
pole	O
of	O
the	O
cell	O
.	O

Syk	B-Gene
is	O
not	O
demonstrably	O
associated	O
with	O
the	O
internalized	O
receptor	O
.	O

Catalytically	O
active	O
Syk	B-Gene
promotes	O
and	O
stabilizes	O
the	O
formation	O
of	O
tightly	O
capped	O
BCR	B-Gene
complexes	I-Gene
at	O
the	O
plasma	O
membrane	O
.	O

Lyn	B-Gene
is	O
not	O
required	O
for	O
the	O
recruitment	O
of	O
Syk	B-Gene
to	O
the	O
cross	O
-linked	O
receptor	O
,	O
but	O
is	O
required	O
for	O
the	O
internalization	O
of	O
the	O
clustered	O
BCR	B-Gene
complexes	I-Gene
.	O

In	O
the	O
absence	O
of	O
Lyn	B-Gene
,	O
receptor-Syk	B-Gene
complexes	I-Gene
at	O
the	O
plasma	O
membrane	O
are	O
long	O
lived	O
,	O
and	O
the	O
receptor	O
-mediated	O
activation	O
of	O
the	O
NF-AT	B-Gene
transcription	I-Gene
factor	I-Gene
is	O
enhanced	O
.	O

Thus	O
,	O
Lyn	B-Gene
appears	O
to	O
function	O
to	O
negatively	O
regulate	O
aspects	O
of	O
BCR	B-Gene
-dependent	O
signaling	O
by	O
stimulating	O
receptor	O
internalization	O
and	O
down-regulation	O
.	O

NF-kappa	B-Gene
B	I-Gene
/	I-Gene
Rel	I-Gene
participation	O
in	O
the	O
lymphokine	O
-dependent	O
proliferation	O
of	O
T	O
lymphoid	O
cells	O
.	O

Proliferative	O
responses	O
of	O
lymphoid	O
cells	O
to	O
IL-2	B-Gene
and	O
IL-4	B-Gene
depend	O
on	O
activation	O
of	O
the	O
cells	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
activation	O
enhances	O
cellular	O
competence	O
to	O
respond	O
to	O
cytokines	O
is	O
not	O
fully	O
understood	O
.	O

The	O
NF-kappaB	B-Gene
/	I-Gene
Rel	I-Gene
family	I-Gene
represents	O
one	O
signal	O
transduction	O
pathway	O
induced	O
during	O
such	O
activation	O
.	O

We	O
show	O
in	O
this	O
study	O
that	O
inhibition	O
of	O
NF-kappaB	B-Gene
through	O
the	O
expression	O
of	O
an	O
IkappaBalpha	B-Gene
(	O
inhibitory	O
protein	O
that	O
dissociates	O
from	O
NF-kappaB	B-Gene
)	O
mutant	O
refractory	O
to	O
signal	O
-induced	O
degradation	O
(	O
IkappaBalpha	B-Gene
(	O
DeltaN	O
)	O
)	O
interfered	O
with	O
the	O
acquisition	O
of	O
competence	O
to	O
proliferate	O
in	O
response	O
to	O
IL-4	B-Gene
as	O
well	O
as	O
IL-2	B-Gene
.	O

Thymocytes	O
and	O
T	O
cells	O
from	O
IkappaBalpha	B-Gene
(	O
DeltaN	O
)	O
transgenic	O
mice	O
expressed	O
normal	O
levels	O
of	O
IL-2R	B-Gene
subunits	O
.	O

However	O
,	O
transgenic	O
cells	O
exhibited	O
a	O
dramatic	O
defect	O
in	O
Stat5A	B-Gene
activation	O
treatment	O
with	O
IL-2	B-Gene
,	O
and	O
a	O
similar	O
defect	O
was	O
observed	O
for	O
IL-4	B-Gene
-induced	O
Stat5	B-Gene
.	O

In	O
contrast	O
,	O
T	O
lymphoid	O
cells	O
with	O
inhibition	O
of	O
NF-kappaB	B-Gene
showed	O
normal	O
insulin	B-Gene
receptor	I-Gene
substrate-2	I-Gene
phosphorylation	O
and	O
only	O
a	O
modest	O
decrease	O
in	O
Stat6	B-Gene
activation	O
and	O
insulin	B-Gene
receptor	I-Gene
substrate-1	I-Gene
phosphorylation	O
after	O
IL-4	B-Gene
stimulation	O
.	O

These	O
results	O
indicate	O
that	O
the	O
NF-kappaB	B-Gene
/	I-Gene
Rel	I-Gene
/	I-Gene
IkappaBalpha	I-Gene
system	O
can	O
regulate	O
cytokine	O
receptor	O
capacitation	O
through	O
effects	O
on	O
the	O
induction	O
of	O
downstream	O
signaling	O
by	O
the	O
Stat	B-Gene
transcription	I-Gene
factor	I-Gene
family	I-Gene
.	O

Reduction	O
in	O
DNA	O
binding	O
activity	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
Pax-5a	I-Gene
in	O
B	O
lymphocytes	O
of	O
aged	O
mice	O
.	O

Aging	O
has	O
been	O
associated	O
with	O
intrinsic	O
changes	O
of	O
the	O
humoral	O
immune	O
response	O
,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
occurrence	O
of	O
autoimmune	B-Disease
disorders	I-Disease
and	O
pathogenic	O
susceptibility	O
.	O

The	O
transcription	B-Gene
factor	I-Gene
Pax-5	I-Gene
is	O
a	O
key	O
regulator	O
of	O
B	O
cell	O
development	O
.	O

Pax-5a	B-Gene
/	I-Gene
B	I-Gene
cell-specific	I-Gene
activator	I-Gene
protein	I-Gene
and	O
an	O
alternatively	O
spliced	O
isoform	O
,	O
Pax-5d	B-Gene
,	O
may	O
have	O
opposing	O
functions	O
in	O
transcriptional	O
regulation	O
due	O
to	O
the	O
lack	O
of	O
a	O
transactivation	O
domain	O
in	O
Pax-5d	B-Gene
.	O

To	O
study	O
B	O
cell	O
-specific	O
changes	O
that	O
occur	O
during	O
the	O
aging	O
process	O
,	O
we	O
investigated	O
expression	O
patterns	O
of	O
Pax-5a	B-Gene
and	O
5d	B-Partial_Gene
in	O
mature	O
B	O
cells	O
of	O
young	O
and	O
aged	O
mice	O
.	O

RNase	O
protection	O
assays	O
showed	O
a	O
similar	O
transcriptional	O
pattern	O
for	O
both	O
age	O
groups	O
that	O
indicates	O
that	O
aging	O
has	O
no	O
affect	O
on	O
transcription	O
initiation	O
or	O
alternative	O
splicing	O
for	O
either	O
isoform	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
Pax-5a	B-Gene
but	O
not	O
Pax-5d	B-Gene
protein	I-Gene
was	O
observed	O
in	O
aged	O
B	O
cells	O
in	O
vitro	O
,	O
while	O
Western	O
blot	O
analyses	O
showed	O
that	O
similar	O
levels	O
of	O
Pax-5a	B-Gene
and	O
5d	B-Gene
proteins	I-Gene
were	O
present	O
in	O
both	O
age	O
groups	O
.	O

The	O
observed	O
decrease	O
in	O
Pax-5a	B-Gene
binding	O
activity	O
correlated	O
with	O
changes	O
in	O
expression	O
of	O
two	O
Pax-5	B-Gene
target	I-Gene
genes	I-Gene
in	O
aged	O
B	O
cells	O
.	O

Expression	O
of	O
the	O
Ig	B-Gene
J	I-Gene
chain	I-Gene
and	O
the	O
secreted	O
form	O
of	O
Ig	B-Gene
mu	I-Gene
,	O
which	O
are	O
both	O
known	O
to	O
be	O
suppressed	O
by	O
Pax-5a	B-Gene
in	O
mature	O
B	O
cells	O
,	O
were	O
increased	O
in	O
B	O
cells	O
of	O
aged	O
mice	O
.	O

Together	O
,	O
our	O
studies	O
suggest	O
that	O
changes	O
associated	O
with	O
the	O
aging	O
phenotype	O
cause	O
posttranslational	O
modification	O
(	O
s	O
)	O
of	O
Pax-5a	B-Gene
but	O
not	O
Pax-5d	B-Gene
,	O
which	O
may	O
lead	O
to	O
an	O
abnormal	O
B	O
cell	O
phenotype	O
in	O
aged	O
mice	O
,	O
associated	O
with	O
elevated	O
levels	O
of	O
J	B-Partial_Gene
chain	I-Partial_Gene
,	O
and	O
secretion	O
of	O
IgM	B-Gene

Interaction	O
between	O
CCAAT	B-Gene
/	I-Gene
enhancer	I-Gene
binding	I-Gene
protein	I-Gene
and	O
cyclic	B-Gene
AMP	I-Gene
response	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
1	I-Gene
regulates	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
cells	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

Recent	O
observations	O
have	O
shown	O
two	O
CCAAT	B-Gene
/	I-Gene
enhancer	I-Gene
binding	I-Gene
protein	I-Gene
(	O
C	B-Gene
/	I-Gene
EBP	I-Gene
)	O
binding	O
sites	O
to	O
be	O
critically	O
important	O
for	O
efficient	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
within	O
cells	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
a	O
cell	O
type	O
likely	O
involved	O
in	O
transport	O
of	O
the	O
virus	O
to	O
the	O
brain	O
.	O

Additionally	O
,	O
sequence	O
variation	O
at	O
C	B-Gene
/	I-Gene
EBP	I-Gene
site	O
I	O
,	O
which	O
lies	O
immediately	O
upstream	O
of	O
the	O
distal	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
site	O
and	O
immediately	O
downstream	O
of	O
a	O
binding	O
site	O
for	O
activating	B-Gene
transcription	I-Gene
factor	I-Gene
(	O
ATF	B-Gene
)	O
/	O
cyclic	B-Gene
AMP	I-Gene
response	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
(	O
CREB	B-Gene
)	O
,	O
has	O
been	O
shown	O
to	O
affect	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activity	O
.	O

Given	O
that	O
C	B-Gene
/	I-Gene
EBP	I-Gene
proteins	I-Gene
have	O
been	O
shown	O
to	O
interact	O
with	O
many	O
other	O
transcription	O
factors	O
including	O
members	O
of	O
the	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
family	I-Gene
,	O
we	O
proceeded	O
to	O
determine	O
whether	O
an	O
adjacent	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
binding	O
site	O
could	O
affect	O
C	B-Gene
/	I-Gene
EBP	I-Gene
protein	I-Gene
binding	O
to	O
C	B-Gene
/	I-Gene
EBP	I-Gene
site	O
I	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
indicated	O
that	O
selected	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
site	O
variants	O
assisted	O
in	O
the	O
recruitment	O
of	O
C	B-Gene
/	I-Gene
EBP	I-Gene
proteins	I-Gene
to	O
an	O
adjacent	O
,	O
naturally	O
occurring	O
,	O
low-affinity	O
C	B-Gene
/	I-Gene
EBP	I-Gene
site	O
.	O

This	O
biophysical	O
interaction	O
appears	O
to	O
occur	O
via	O
at	O
least	O
two	O
mechanisms	O
.	O

First	O
,	O
low	O
amounts	O
of	O
CREB-1	B-Gene
and	O
C	B-Gene
/	I-Gene
EBP	I-Gene
appear	O
to	O
heterodimerize	O
and	O
bind	O
to	O
a	O
site	O
consisting	O
of	O
a	O
half	O
site	O
from	O
both	O
the	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
and	O
C	B-Gene
/	I-Gene
EBP	I-Gene
binding	O
sites	O
.	O

In	O
addition	O
,	O
CREB-1	B-Gene
homodimers	O
bind	O
to	O
the	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
site	O
and	O
recruit	O
C	B-Gene
/	I-Gene
EBP	I-Gene
dimers	O
to	O
their	O
cognate	O
weak	O
binding	O
sites	O
.	O

This	O
interaction	O
is	O
reciprocal	O
,	O
since	O
C	B-Gene
/	I-Gene
EBP	I-Gene
dimer	O
binding	O
to	O
a	O
strong	O
C	B-Gene
/	I-Gene
EBP	I-Gene
site	O
leads	O
to	O
enhanced	O
CREB-1	B-Gene
recruitment	O
to	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
sites	O
that	O
are	O
weakly	O
bound	O
by	O
CREB	B-Gene
.	O

Sequence	O
variation	O
at	O
both	O
C	B-Gene
/	I-Gene
EBP	I-Gene
and	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
sites	O
affects	O
the	O
molecular	O
interactions	O
involved	O
in	O
mediating	O
both	O
of	O
these	O
mechanisms	O
.	O

Most	O
importantly	O
,	O
sequence	O
variation	O
at	O
the	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
binding	O
site	O
affected	O
basal	O
LTR	O
activity	O
as	O
well	O
as	O
LTR	O
function	O
following	O
interleukin-6	B-Gene
stimulation	O
,	O
a	O
treatment	O
that	O
leads	O
to	O
increases	O
in	O
C	B-Gene
/	I-Gene
EBP	I-Gene
activation	O
.	O

Thus	O
,	O
HIV-1	O
LTR	O
ATF	B-Gene
/	I-Gene
CREB	I-Gene
binding	O
site	O
sequence	O
variation	O
may	O
modulate	O
cellular	O
signaling	O
at	O
the	O
viral	O
promoter	O
through	O
the	O
C	B-Gene
/	I-Gene
EBP	I-Gene
pathway	O

Epstein-barr	B-Gene
virus	I-Gene
immediate-early	I-Gene
protein	I-Gene
BZLF1	I-Gene
is	O
SUMO-1	B-Gene
modified	O
and	O
disrupts	O
promyelocytic	B-Gene
leukemia	I-Gene
bodies	O
.	O

Although	O
the	O
immediate-early	B-Gene
proteins	I-Gene
of	O
both	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
are	O
known	O
to	O
modify	O
promyelocytic	B-Gene
leukemia	I-Gene
(	O
PML	B-Gene
)	O
(	O
ND10	O
)	O
bodies	O
in	O
the	O
nucleus	O
of	O
the	O
host	O
cell	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
lytic	O
infection	O
with	O
gamma	O
herpesviruses	O
induces	O
a	O
similar	O
effect	O
.	O

The	O
PML	B-Gene
protein	I-Gene
is	O
induced	O
by	O
interferon	O
,	O
involved	O
in	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
class	I-Gene
I	I-Gene
presentation	O
,	O
and	O
necessary	O
for	O
certain	O
types	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
PML	B-Gene
bodies	O
function	O
in	O
an	O
antiviral	O
capacity	O
.	O

SUMO-1	B-Gene
modification	O
of	O
PML	B-Gene
is	O
known	O
to	O
be	O
required	O
for	O
the	O
formation	O
of	O
PML	B-Gene
bodies	O
.	O

To	O
examine	O
whether	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
replication	O
interferes	O
with	O
PML	B-Gene
bodies	O
,	O
we	O
expressed	O
the	O
EBV	B-Gene
immediate-early	I-Gene
genes	I-Gene
BZLF1	I-Gene
(	O
Z	B-Gene
)	O
and	O
BRLF1	B-Gene
(	O
R	B-Gene
)	O
in	O
EBV	O
-positive	O
cell	O
lines	O
and	O
examined	O
PML	B-Gene
localization	O
.	O

Both	O
Z	B-Gene
and	O
R	B-Gene
expression	O
resulted	O
in	O
PML	B-Gene
dispersion	O
in	O
EBV	O
-positive	O
cells	O
.	O

Z	B-Gene
but	O
not	O
R	B-Gene
expression	O
is	O
sufficient	O
to	O
disrupt	O
PML	B-Gene
bodies	O
in	O
EBV	O
-negative	O
cell	O
lines	O
.	O

We	O
show	O
that	O
dispersion	O
of	O
PML	B-Gene
bodies	O
by	O
Z	B-Gene
requires	O
a	O
portion	O
of	O
the	O
transcriptional	O
activation	O
domain	O
of	O
Z	B-Gene
but	O
not	O
the	O
DNA	O
-binding	O
function	O
.	O

As	O
was	O
previously	O
reported	O
for	O
the	O
HSV-1	B-Gene
ICP0	I-Gene
and	O
CMV	B-Gene
IE1	I-Gene
proteins	I-Gene
,	O
Z	B-Gene
reduces	O
the	O
amount	O
of	O
SUMO-1	B-Gene
-modified	I-Gene
PML	I-Gene
.	O

We	O
also	O
found	O
that	O
Z	B-Gene
itself	O
is	O
SUMO-1	B-Gene
modified	O
(	O
through	O
amino	O
acid	O
12	O
)	O
and	O
that	O
Z	B-Gene
competes	O
with	O
PML	B-Gene
for	O
limiting	O
amounts	O
of	O
SUMO-1	B-Gene
.	O

These	O
results	O
suggest	O
that	O
disruption	O
of	O
PML	B-Gene
bodies	O
is	O
important	O
for	O
efficient	O
lytic	O
replication	O
of	O
EBV	O
.	O

Furthermore	O
,	O
Z	B-Gene
may	O
potentially	O
alter	O
the	O
function	O
of	O
a	O
variety	O
of	O
cellular	O
proteins	O
by	O
inhibiting	O
SUMO-1	B-Gene
modification	O

Expression	O
of	O
oestrogen	B-Chemical
and	O
progesterone	B-Gene
receptors	I-Gene
by	O
mast	O
cells	O
alone	O
,	O
but	O
not	O
lymphocytes	O
,	O
macrophages	O
or	O
other	O
immune	O
cells	O
in	O
human	O
upper	O
airways	O
.	O

BACKGROUND	O
:	O
Nasal	B-Disease
polyposis	I-Disease
often	O
coexists	O
with	O
asthma	B-Disease
in	O
airway	O
inflammatory	O
conditions	O
characterised	O
by	O
the	O
infiltration	O
of	O
a	O
range	O
of	O
immune	O
cells	O
.	O

A	O
potentially	O
important	O
role	O
for	O
ovarian	O
hormones	O
has	O
been	O
implicated	O
in	O
airway	B-Disease
inflammation	I-Disease
but	O
the	O
cellular	O
target	O
for	O
such	O
action	O
is	O
not	O
known	O
.	O

METHODS	O
:	O
Expression	O
of	O
oestrogen	B-Gene
receptors	I-Gene
(	O
ER	B-Gene
)	O
and	O
progesterone	B-Gene
receptors	I-Gene
(	O
PR	B-Gene
)	O
was	O
examined	O
using	O
immunohistochemistry	O
in	O
formalin	B-Chemical
fixed	O
nasal	B-Disease
polyp	I-Disease
tissues	O
from	O
47	O
subjects	O
.	O

The	O
cells	O
positive	O
for	O
ER	B-Gene
or	O
PR	B-Gene
were	O
confirmed	O
by	O
spatial	O
location	O
,	O
dual	O
immunolabelling	O
,	O
and	O
histochemical	O
staining	O
.	O

RESULTS	O
:	O
Consistent	O
with	O
the	O
known	O
features	O
of	O
nasal	B-Disease
polyps	I-Disease
,	O
CD4+	B-Gene
(	O
T	O
helper	O
/	O
inducer	O
)	O
,	O
CD8+	B-Gene
(	O
cytotoxic	O
/	O
suppressor	O
)	O
,	O
CD68+	B-Gene
(	O
macrophages	O
)	O
,	O
mast	O
cells	O
,	O
eosinophils	O
and	O
neutrophils	O
were	O
all	O
clearly	O
detected	O
by	O
their	O
relevant	O
monoclonal	O
antibodies	O
or	O
appropriate	O
histochemical	O
staining	O
,	O
but	O
only	O
mast	O
cells	O
tested	O
positive	O
for	O
ER	B-Gene
/	I-Gene
PR	I-Gene
labelling	O
with	O
their	O
polyclonal	O
and	O
monoclonal	O
antibodies	O
.	O

The	O
frequencies	O
for	O
expression	O
were	O
61.7	O
%	O
for	O
ER	B-Gene
positive	O
and	O
59.6	O
%	O
for	O
PR	B-Gene
positive	O
cells	O
.	O

The	O
expression	O
of	O
ER	B-Gene
/	I-Gene
PR	I-Gene
was	O
independent	O
of	O
patient	O
sex	O
and	O
age	O
but	O
was	O
highly	O
correlated	O
with	O
the	O
numbers	O
of	O
mast	O
cells	O
(	O
r	O
=	O
0.973	O
,	O
p	O
<	O
0.001	O
for	O
ER	B-Gene
;	O
r	O
=	O
0.955	O
,	O
p	O
<	O
0.001	O
for	O
PR	B-Gene
)	O
.	O

Fewer	O
than	O
5	O
%	O
of	O
mast	O
cells	O
were	O
found	O
to	O
be	O
negative	O
for	O
ER	B-Gene
/	I-Gene
PR	I-Gene
expression	O
.	O

CONCLUSIONS	O
:	O
Mast	O
cells	O
alone	O
,	O
but	O
not	O
lymphocytes	O
,	O
macrophages	O
,	O
or	O
other	O
immune	O
cells	O
,	O
express	O
ER	B-Gene
/	I-Gene
PR	I-Gene
in	O
human	O
upper	O
airways	O
.	O

Numerous	O
ER	B-Gene
/	I-Gene
PR	I-Gene
positive	O
mast	O
cells	O
exist	O
in	O
nasal	B-Disease
polyps	I-Disease
,	O
indicating	O
that	O
this	O
may	O
be	O
a	O
major	O
route	O
for	O
the	O
involvement	O
of	O
sex	O
hormones	O
in	O
airway	B-Disease
inflammation	I-Disease
when	O
exposed	O
to	O
the	O
higher	O
and	O
varying	O
concentration	O
of	O
oestrogen	B-Chemical
and	O
progesterone	B-Chemical
characteristic	O
of	O
females	O
.	O

A	O
16-mer	O
peptide	O
(	O
RQIKIWFQNRRMKWKK	O
)	O
from	O
antennapedia	B-Gene
preferentially	O
targets	O
the	O
Class	O
I	O
pathway	O
.	O

Translocation	O
of	O
antigenic	O
peptides	O
into	O
the	O
cytosol	O
of	O
antigen	O
presenting	O
cells	O
facilitates	O
proteosomal	O
processing	O
and	O
loading	O
into	O
Class	O
I	O
molecules	O
for	O
MHC	B-Gene
presentation	O
on	O
the	O
cell	O
surface	O
.	O

The	O
DNA	O
binding	O
domain	O
of	O
the	O
Drosophila	O
transcription	O
factor	O
(	O
Antennapedia	B-Gene
)	O
,	O
a	O
60	O
amino	O
acid	O
protein	O
,	O
is	O
rapidly	O
taken	O
up	O
by	O
cells	O
and	O
has	O
been	O
fused	O
to	O
selected	O
antigens	O
to	O
enhance	O
their	O
immunogenicity	O
.	O

We	O
now	O
demonstrate	O
that	O
a	O
16	O
amino	O
acid	O
peptide	O
from	O
antennapedia	B-Gene
can	O
facilitate	O
the	O
cytoplasmic	O
uptake	O
of	O
CTL	O
epitope	O
9-mer	O
peptides	O
.	O

Synthetic	O
peptides	O
were	O
made	O
containing	O
the	O
16-mer	O
antennapedia	B-Gene
peptide	O
linked	O
in	O
tandem	O
to	O
the	O
ovalbumin	B-Gene
SIINFEKL	O
CTL	O
peptide	O
.	O

The	O
peptide	O
complex	O
was	O
shown	O
to	O
rapidly	O
internalise	O
into	O
APCs	O
by	O
confocal	O
microscopy	O
.	O

This	O
peptide	O
induced	O
CTL	O
in	O
C57BL	O
/	O
6	O
mice	O
and	O
protected	O
them	O
against	O
growth	O
of	O
an	O
ovalbumin	B-Gene
expressing	O
tumour	B-Disease
cell	O
line	O
(	O
E.G7-OVA	O
)	O
.	O

The	O
ability	O
of	O
the	O
hybrid	O
peptide	O
to	O
be	O
processed	O
and	O
presented	O
by	O
APCs	O
was	O
similar	O
,	O
whether	O
the	O
SIINFEKL	O
sequence	O
was	O
appended	O
at	O
the	O
C-terminus	O
or	O
N-terminus	O
of	O
the	O
Antennapedia	B-Gene
peptide	O
.	O

The	O
production	O
of	O
synthetic	O
peptides	O
containing	O
other	O
CTL	O
peptide	O
epitopes	O
may	O
be	O
useful	O
for	O
priming	O
CTLs	O
in	O
vitro	O
and	O
in	O
vivo	O

NFATc1	B-Gene
and	O
NFATc2	B-Gene
together	O
control	O
both	O
T	O
and	O
B	O
cell	O
activation	O
and	O
differentiation	O
.	O

NFAT	B-Gene
transcription	I-Gene
factors	I-Gene
play	O
critical	O
roles	O
in	O
gene	O
transcription	O
during	O
immune	O
responses	O
.	O

To	O
investigate	O
further	O
the	O
two	O
most	O
prominent	O
NFAT	B-Gene
family	I-Gene
members	O
,	O
NFATc1	B-Gene
and	O
NFATc2	B-Gene
,	O
we	O
generated	O
mice	O
bearing	O
lymphoid	O
systems	O
devoid	O
of	O
both	O
.	O

Doubly	O
deficient	O
T	O
cells	O
displayed	O
cell	O
surface	O
markers	O
of	O
activation	O
yet	O
were	O
significantly	O
deficient	O
in	O
the	O
development	O
of	O
multiple	O
effector	O
functions	O
,	O
including	O
Th	O
cytokine	O
production	O
,	O
surface	O
effector	O
molecule	O
expression	O
,	O
and	O
cytolytic	O
activity	O
.	O

Nevertheless	O
,	O
doubly	O
deficient	O
B	O
cells	O
were	O
hyperactivated	O
,	O
as	O
evidenced	O
by	O
extremely	O
elevated	O
serum	B-Gene
IgG1	I-Gene
and	O
IgE	B-Gene
,	O
as	O
well	O
as	O
plasma	O
cell	O
expansion	O
and	O
infiltration	O
of	O
end	O
organs	O
.	O

Thus	O
,	O
in	O
T	O
cells	O
,	O
NFATc1	B-Gene
and	O
NFATc2	B-Gene
are	O
dispensable	O
for	O
inflammatory	O
reactivity	O
but	O
are	O
required	O
for	O
effector	O
differentiation	O
,	O
while	O
in	O
B	O
cells	O
,	O
NFATs	B-Gene
regulate	O
both	O
normal	O
homeostasis	O
and	O
differentiation	O
.	O

The	O
lack	O
of	O
NF-kappa	B-Gene
B	I-Gene
transactivation	O
and	O
PKC	B-Gene
epsilon	I-Gene
expression	O
in	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
CD8	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
thymocytes	O
correlates	O
with	O
negative	O
selection	O
.	O

Deletion	O
of	O
autoreactive	O
thymocytes	O
at	O
the	O
DP	O
stage	O
is	O
the	O
basis	O
for	O
tolerance	O
to	O
thymus	O
-expressed	O
self	O
antigens	O
.	O

In	O
this	O
study	O
we	O
investigated	O
whether	O
distinct	O
signalling	O
pathways	O
are	O
induced	O
in	O
DP	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
upon	O
stimulation	O
with	O
antigen	O
.	O

Using	O
triple	O
transgenic	O
mice	O
expressing	O
a	O
TCR	B-Gene
transgene	I-Gene
,	O
dominant	O
negative	O
ras	B-Gene
/	I-Gene
Mek	I-Gene
proteins	I-Gene
and	O
a	O
reporter	O
gene	O
construct	O
with	O
AP-1	B-Gene
or	O
NF-kappa	B-Gene
B	I-Gene
binding	O
sites	O
,	O
we	O
showed	O
a	O
complete	O
lack	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	B-Gene
B	I-Gene
but	O
not	O
AP-1	B-Gene
in	O
DP	O
thymocytes	O
,	O
whereas	O
both	O
were	O
transcriptionally	O
active	O
in	O
mature	O
T	O
cells	O
after	O
antigenic	O
stimulation	O
.	O

Lack	O
of	O
NF-kappa	B-Gene
B	I-Gene
induction	O
correlated	O
with	O
increased	O
death	O
in	O
response	O
to	O
antigen	O
.	O

AP-1	B-Gene
induction	O
was	O
dependent	O
on	O
the	O
integrity	O
of	O
the	O
ras	B-Gene
/	I-Gene
Mek	I-Gene
pathway	O
indicating	O
that	O
this	O
pathway	O
was	O
activated	O
in	O
the	O
DP	O
thymocytes	O
.	O

In	O
contrast	O
,	O
we	O
found	O
a	O
complete	O
lack	O
of	O
constitutive	O
expression	O
of	O
the	O
epsilon	B-Partial_Gene
isoform	O
of	O
Protein	B-Gene
Kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
in	O
DP	O
thymocytes	O
,	O
although	O
it	O
was	O
present	O
in	O
mature	O
thymocytes	O
and	O
peripheral	O
T	O
cells	O
.	O

Taken	O
together	O
the	O
results	O
suggest	O
that	O
the	O
lack	O
of	O
PKC	B-Gene
epsilon	I-Gene
in	O
DP	O
thymocytes	O
could	O
lead	O
to	O
the	O
absence	O
of	O
NF-kappa	B-Gene
B	I-Gene
activity	O
after	O
antigenic	O
stimulation	O
contributing	O
to	O
negative	O
selection	O
.	O

Cell	O
Death	O
and	O
Differentiation	O
(	O
2000	O
)	O
7	O
,	O
1253	O
-	O
1262	O
.	O

BMS-189453	B-Chemical
,	O
a	O
novel	O
retinoid	B-Gene
receptor	I-Gene
antagonist	O
,	O
is	O
a	O
potent	O
testicular	O
toxin	O
.	O

BMS-189453	B-Chemical
is	O
a	O
synthetic	O
retinoid	B-Chemical
that	O
acts	O
as	O
an	O
antagonist	O
at	O
retinoic	B-Gene
acid	I-Gene
receptors	I-Gene
alpha	I-Gene
,	O
beta	B-Partial_Gene
,	O
and	O
gamma	B-Partial_Gene
.	O

In	O
Sprague	O
Dawley	O
rats	O
at	O
daily	O
oral	O
doses	O
of	O
15	O
,	O
60	O
,	O
or	O
240	O
mg	O
/	O
kg	O
for	O
1	O
month	O
,	O
BMS-189453	B-Chemical
produced	O
increases	O
in	O
leukocyte	O
counts	O
,	O
alkaline	B-Gene
phosphatase	I-Gene
and	O
alanine	B-Gene
aminotransferase	I-Gene
levels	O
,	O
and	O
marked	O
testicular	O
degeneration	O
and	O
atrophy	O
at	O
all	O
doses	O
.	O

Significant	O
overt	O
signs	O
of	O
toxicity	O
and	O
deaths	O
occurred	O
at	O
240	O
mg	O
/	O
kg	O
,	O
whereas	O
body-weight	O
and	O
food-consumption	O
decreases	O
occurred	O
at	O
60	O
and	O
240	O
mg	O
/	O
kg	O
.	O

When	O
BMS-189453	B-Chemical
was	O
administered	O
to	O
male	O
rats	O
at	O
daily	O
doses	O
ranging	O
from	O
12.5	O
to	O
100	O
mg	O
/	O
kg	O
for	O
1	O
week	O
,	O
only	O
minimal	O
testicular	O
changes	O
occurred	O
at	O
all	O
doses	O
,	O
shortly	O
after	O
the	O
dosing	O
period	O
.	O

However	O
,	O
after	O
a	O
1-month	O
drug-free	O
observation	O
period	O
,	O
marked	O
testicular	O
atrophy	O
was	O
evident	O
at	O
all	O
doses	O
.	O

BMS-189453	B-Chemical
was	O
then	O
administered	O
at	O
doses	O
of	O
2	O
,	O
10	O
,	O
or	O
50	O
mg	O
/	O
kg	O
to	O
male	O
rats	O
for	O
1	O
,	O
3	O
,	O
or	O
7	O
consecutive	O
days	O
.	O

Dose-	O
and	O
duration	O
-dependent	O
testicular	O
toxicity	O
that	O
occurred	O
after	O
a	O
1-month	O
observation	O
period	O
did	O
not	O
recover	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
was	O
more	O
severe	O
4	O
months	O
after	O
the	O
last	O
dose	O
.	O

In	O
rabbits	O
administered	O
BMS-189453	B-Chemical
at	O
oral	O
doses	O
of	O
2	O
,	O
10	O
,	O
or	O
50	O
mg	O
/	O
kg	O
for	O
1	O
week	O
,	O
testicular	O
degeneration	O
and	O
atrophy	O
were	O
evident	O
in	O
the	O
high-dose	O
group	O
at	O
1	O
month	O
following	O
treatment	O
.	O

These	O
studies	O
indicate	O
that	O
retinoid	B-Chemical
antagonists	O
can	O
selectively	O
produce	O
progressive	O
and	O
prolonged	O
testicular	O
toxicity	O
after	O
single	O
or	O
repeated	O
oral	O
doses	O
that	O
are	O
otherwise	O
well	O
tolerated	O
.	O

Constitutive	O
PI3-K	B-Gene
activity	O
is	O
essential	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
,	O
of	O
Theileria	O
parva	O
-transformed	O
B	O
cells	O
.	O

Theileria	O
is	O
an	O
intracellular	O
parasite	O
that	O
causes	O
lymphoproliferative	B-Disease
disorders	I-Disease
in	O
cattle	O
,	O
and	O
infection	O
of	O
leucocytes	O
induces	O
a	O
transformed	O
phenotype	O
similar	O
to	O
tumour	B-Disease
cells	O
,	O
but	O
the	O
mechanisms	O
by	O
which	O
the	O
parasite	O
induces	O
this	O
phenotype	O
are	O
not	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
infected	O
B	O
lymphocytes	O
display	O
constitutive	O
phosphoinositide	B-Gene
3-kinase	I-Gene
(	O
PI3-K	B-Gene
)	O
activity	O
,	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
.	O

Importantly	O
,	O
we	O
demonstrate	O
that	O
one	O
mechanism	O
by	O
which	O
PI3-K	B-Gene
mediates	O
the	O
proliferation	O
of	O
infected	O
B	O
lymphocytes	O
is	O
through	O
the	O
induction	O
of	O
a	O
granulocyte-monocyte	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
GM-CSF	B-Gene
)	O
-dependent	O
autocrine	O
loop	O
.	O

PI3-K	B-Gene
induction	O
of	O
GM-CSF	B-Gene
appears	O
to	O
be	O
at	O
the	O
transcriptional	O
level	O
and	O
,	O
consistently	O
,	O
we	O
demonstrate	O
that	O
PI3-K	B-Gene
is	O
also	O
involved	O
in	O
the	O
constitutive	O
induction	O
of	O
AP-1	B-Gene
and	O
NF-kappaB	B-Gene
,	O
which	O
characterizes	O
Theileria	O
-infected	O
leucocytes	O
.	O

Taken	O
together	O
,	O
our	O
results	O
highlight	O
a	O
novel	O
strategy	O
exploited	O
by	O
the	O
intracellular	O
parasite	O
Theileria	O
to	O
induce	O
continued	O
proliferation	O
of	O
its	O
host	O
leucocyte	O
.	O

Mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitor	O
on	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
production	O
of	O
monocytes	O
.	O

If	O
the	O
inflammatory	O
response	O
becomes	O
excessive	O
or	O
uncontrolled	O
by	O
some	O
stimuli	O
,	O
inappropriate	O
inflammatory	O
responses	O
occur	O
.	O

Monocytes	O
are	O
extremely	O
important	O
cells	O
for	O
regulating	O
the	O
cytokine	O
network	O
and	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	O
TNFalpha	B-Gene
)	O
and	O
interleukin-	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
10	I-Gene
,	O
which	O
are	O
mainly	O
synthesized	O
by	O
monocytes	O
,	O
are	O
representative	O
cytokines	O
that	O
play	O
a	O
central	O
role	O
in	O
the	O
cytokine	O
network	O
.	O

Protease	O
inhibitors	O
such	O
as	O
gabexate	B-Chemical
mesilate	I-Chemical
(	O
GM	B-Chemical
)	O
and	O
ulinastatin	B-Chemical
(	O
UTI	B-Chemical
)	O
have	O
been	O
shown	O
to	O
have	O
various	O
beneficial	O
effects	O
by	O
inhibiting	O
the	O
activation	O
of	O
leukocytes	O
,	O
but	O
the	O
mechanism	O
for	O
this	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
proinflammatory	O
cytokine	O
production	O
of	O
lipopolysaccharide-	B-Chemical
(	O
LPS	B-Chemical
)	O
stimulated	O
monocytes	O
.	O

LPS	B-Chemical
-stimulated	O
monocytes	O
were	O
treated	O
with	O
GM	B-Chemical
or	O
UTI	B-Chemical
.	O

The	O
value	O
of	O
TNFalpha	B-Gene
and	O
IL-10	B-Gene
in	O
the	O
culture	O
medium	O
of	O
monocytes	O
was	O
measured	O
and	O
each	O
mRNA	O
expression	O
was	O
assayed	O
.	O

The	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
activity	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
such	O
as	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
and	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NFkappaB	B-Gene
)	O
were	O
also	O
evaluated	O
.	O

GM	B-Chemical
decreased	O
the	O
TNFalpha	B-Gene
production	O
of	O
LPS	B-Chemical
-stimulated	O
monocytes	O
as	O
shown	O
by	O
the	O
inhibition	O
of	O
mRNA	O
expression	O
and	O
increased	O
the	O
IL-10	B-Gene
production	O
of	O
LPS	B-Chemical
-stimulated	O
monocytes	O
.	O

GM	B-Chemical
also	O
suppressed	O
the	O
NFkappaB	B-Gene
activity	O
of	O
LPS	B-Chemical
-stimulated	O
monocytes	O
.	O

UTI	B-Chemical
decreased	O
the	O
TNFalpha	B-Gene
production	O
of	O
LPS	B-Chemical
-stimulated	O
monocytes	O
,	O
but	O
did	O
not	O
inhibit	O
the	O
TNFalpha	B-Gene
mRNA	I-Gene
expression	O
.	O

The	O
present	O
study	O
shows	O
that	O
the	O
inhibitory	O
effect	O
of	O
GM	B-Chemical
on	O
the	O
TNFalpha	B-Gene
production	O
of	O
activated	O
human	O
monocytes	O
is	O
mediated	O
by	O
the	O
suppression	O
of	O
NFkappaB	B-Gene
activation	O
,	O
while	O
the	O
mechanism	O
of	O
UTI	B-Chemical
inhibiting	O
TNFalpha	B-Gene
production	O
of	O
human	O
monocytes	O
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
either	O
the	O
translation	O
or	O
secretion	O
of	O
TNFalpha	B-Gene
.	O

Molecular	O
and	O
cellular	O
mediators	O
of	O
interleukin-1	B-Gene
-dependent	O
acute	O
inflammatory	O
arthritis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
in	O
a	O
model	O
of	O
acute	O
inflammatory	O
monarticular	O
arthritis	B-Disease
induced	O
by	O
methylated	B-Gene
bovine	I-Gene
serum	I-Gene
albumin	I-Gene
(	O
mBSA	B-Gene
)	O
and	O
interleukin-1	B-Gene
(	O
IL-1	B-Gene
)	O
.	O

METHODS	O
:	O
Mice	O
were	O
injected	O
intraarticularly	O
with	O
mBSA	B-Gene
on	O
day	O
0	O
and	O
subcutaneously	O
with	O
recombinant	O
human	B-Gene
IL-1beta	I-Gene
on	O
days	O
0-2	O
.	O

At	O
day	O
7	O
,	O
knee	O
joints	O
were	O
removed	O
and	O
assessed	O
histologically	O
.	O

Flow	O
cytometry	O
and	O
RNase	O
protection	O
were	O
used	O
to	O
analyze	O
IL-1	B-Gene
-dependent	O
events	O
.	O

RESULTS	O
:	O
C57BL	O
/	O
6	O
(	O
B6	O
)	O
,	O
129	O
/	O
Sv	O
,	O
and	O
(	O
B6	O
x	O
129	O
/	O
Sv	O
)	O
F1	O
hybrid	O
mice	O
,	O
all	O
H-2b	O
strains	O
,	O
were	O
susceptible	O
to	O
mBSA	B-Gene
/	I-Gene
IL-1	I-Gene
-induced	O
arthritis	B-Disease
,	O
whereas	O
C3H	O
/	O
HeJ	O
(	O
H-2k	O
)	O
mice	O
were	O
not	O
.	O

B6	O
mice	O
lacking	O
T	O
and	O
B	O
cells	O
(	O
RAG1-	B-Gene
/	I-Gene
-	I-Gene
)	O
or	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
(	I-Gene
MHC	I-Gene
)	I-Gene
class	I-Gene
II	I-Gene
antigens	I-Gene
(	O
MHCII-	B-Gene
/	I-Gene
-	I-Gene
)	O
,	O
and	O
B6	O
mice	O
treated	O
with	O
a	O
CD4+	B-Gene
T	O
cell	O
-depleting	O
monoclonal	O
antibody	O
,	O
were	O
resistant	O
to	O
disease	O
.	O

In	O
contrast	O
,	O
B	O
cell	O
-deficient	O
(	O
muMT	O
/	O
muMT	O
)	O
mice	O
developed	O
arthritis	B-Disease
at	O
an	O
incidence	O
and	O
severity	O
similar	O
to	O
that	O
of	O
controls	O
.	O

RelB	B-Gene
-deficient	O
(	O
RelB-	B-Gene
/	I-Gene
-	I-Gene
)	O
bone	O
marrow	O
chimeric	O
mice	O
had	O
arthritis	B-Disease
that	O
was	O
significantly	O
reduced	O
in	O
incidence	O
and	O
severity	O
.	O

In	O
B6	O
mice	O
,	O
flow	O
cytometry	O
demonstrated	O
an	O
IL-1	B-Gene
-dependent	O
leukocyte	O
infiltration	O
into	O
the	O
synovial	O
compartment	O
and	O
RNase	O
protection	O
assays	O
revealed	O
induction	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
for	O
the	O
chemokines	B-Gene
monocyte	I-Gene
chemoattractant	I-Gene
protein	I-Gene
1	I-Gene
,	O
macrophage	B-Gene
inhibitory	I-Gene
protein	I-Gene
2	I-Gene
(	O
MIP-2	B-Gene
)	O
,	O
RANTES	B-Gene
,	O
MIP-1alpha	B-Gene
,	O
and	O
MIP-1beta	B-Gene
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

CONCLUSION	O
:	O
Arthritis	B-Disease
induced	O
by	O
mBSA	B-Gene
/	I-Gene
IL-1	I-Gene
is	O
strain	O
specific	O
and	O
dependent	O
on	O
CD4+	B-Gene
T	O
lymphocytes	O
and	O
at	O
least	O
partially	O
on	O
RelB	B-Gene
,	O
but	O
not	O
on	O
B	O
lymphocytes	O
or	O
antibody	O
.	O

IL-1	B-Gene
contributes	O
to	O
leukocyte	O
recruitment	O
to	O
the	O
synovium	O
and	O
directly	O
induces	O
chemokine	O
mRNA	O
production	O
by	O
synovial	O
cells	O
.	O

This	O
model	O
of	O
acute	O
monarticular	O
arthritis	B-Disease
is	O
particularly	O
suitable	O
for	O
further	O
investigations	O
into	O
cell	O
-mediated	O
immunity	O
in	O
arthritis	B-Disease
and	O
the	O
role	O
of	O
IL-1	B-Gene
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulopoiesis	O
by	O
endogenous	B-Gene
RARalpha	I-Gene
.	O

Acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
(	O
APL	B-Disease
)	O
is	O
always	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
retinoic	B-Gene
acid	I-Gene
receptor	I-Gene
alpha	I-Gene
(	I-Gene
RARalpha	I-Gene
)	I-Gene
gene	I-Gene
.	O

Whether	O
these	O
translocations	O
relate	O
to	O
a	O
role	O
for	O
endogenous	B-Gene
RARalpha	I-Gene
in	O
normal	O
granulopoiesis	O
remains	O
uncertain	O
because	O
most	O
studies	O
addressing	O
this	O
question	O
have	O
used	O
non-physiological	O
overexpression	O
systems	O
.	O

Granulocyte	O
differentiation	O
in	O
cells	O
derived	O
from	O
RARalpha	B-Gene
-deficient	O
(	O
RARalpha	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
)	O
mice	O
was	O
studied	O
and	O
evaluated	O
in	O
the	O
context	O
of	O
agonist-bound	O
and	O
ligand-free	O
RARalpha	B-Gene
.	O

Our	O
results	O
demonstrate	O
that	O
RARalpha	B-Gene
is	O
dispensable	O
for	O
granulopoiesis	O
,	O
as	O
RARalpha	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
have	O
a	O
normal	O
granulocyte	O
population	O
despite	O
an	O
impaired	O
ability	O
to	O
respond	O
to	O
retinoids	B-Chemical
.	O

However	O
,	O
although	O
it	O
is	O
not	O
absolutely	O
required	O
,	O
RARalpha	B-Gene
can	O
bidirectionally	O
modulate	O
granulopoiesis	O
.	O

RARalpha	B-Gene
stimulates	O
differentiation	O
in	O
response	O
to	O
exogenous	O
retinoic	B-Chemical
acid	I-Chemical
.	O

Furthermore	O
,	O
endogenous	O
retinoids	B-Chemical
control	O
granulopoiesis	O
in	O
vivo	O
,	O
as	O
either	O
vitamin	B-Chemical
A	I-Chemical
-deficient	O
mice	O
or	O
animals	O
treated	O
with	O
an	O
RAR	B-Gene
antagonist	I-Gene
accumulate	O
more	O
immature	O
granulocytes	O
in	O
their	O
bone	O
marrow	O
.	O

Conversely	O
,	O
RARalpha	B-Gene
acts	O
to	O
limit	O
differentiation	O
in	O
the	O
absence	O
of	O
ligand	O
because	O
granulocyte	O
precursors	O
from	O
RARalpha	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
differentiate	O
earlier	O
in	O
culture	O
.	O

Thus	O
,	O
the	O
block	O
in	O
granulopoiesis	O
exerted	O
by	O
RARalpha	B-Gene
fusion	I-Gene
proteins	I-Gene
expressed	O
in	O
APL	B-Disease
cells	O
may	O
correspond	O
to	O
an	O
amplification	O
of	O
a	O
normal	O
function	O
of	O
unliganded	O
RARalpha	B-Gene
.	O

In	O
vitro	O
-activated	O
human	O
lupus	B-Disease
T	O
cells	O
express	O
normal	O
estrogen	B-Gene
receptor	I-Gene
proteins	I-Gene
which	O
bind	O
to	O
the	O
estrogen	B-Chemical
response	O
element	O
.	O

We	O
have	O
shown	O
that	O
estrogen	B-Gene
receptor	I-Gene
(	O
ERalpha	B-Gene
,	O
ERbeta	B-Gene
)	O
transcripts	O
are	O
expressed	O
in	O
SLE	B-Disease
and	O
normal	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
T	O
cell	O
nuclear	O
extracts	O
from	O
female	O
lupus	B-Disease
patients	O
and	O
normal	O
donors	O
were	O
tested	O
for	O
biologically	O
active	O
ER	B-Gene
proteins	I-Gene
capable	O
of	O
binding	O
to	O
the	O
human	O
estrogen	B-Chemical
response	O
element	O
(	O
hERE	O
)	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

When	O
peripheral	O
blood	O
T	O
cells	O
were	O
stimulated	O
with	O
17beta-estradiol	B-Chemical
(	O
E2	B-Chemical
)	O
,	O
PMA	B-Chemical
and	O
ionomycin	B-Chemical
,	O
two	O
major	O
retarded	O
bands	O
in	O
T	O
cell	O
nuclear	O
extracts	O
exhibited	O
a	O
migration	O
pattern	O
similar	O
to	O
slow	O
migrating	O
protein-ERE	B-Gene
complexes	I-Gene
in	O
human	O
breast	B-Disease
cancer	I-Disease
cell	O
extracts	O
.	O

T	O
cells	O
cultured	O
only	O
with	O
E2	B-Chemical
did	O
not	O
have	O
these	O
complexes	O
.	O

The	O
formation	O
of	O
the	O
complexes	O
was	O
inhibited	O
by	O
competition	O
with	O
the	O
hERE	O
cold	O
oligonucleotide	O
and	O
partially	O
with	O
anti-ERalpha	B-Gene
antibodies	I-Gene
.	O

There	O
was	O
no	O
notable	O
difference	O
in	O
the	O
migration	O
pattern	O
of	O
ERE	O
-binding	O
proteins	O
between	O
the	O
SLE	B-Disease
and	O
normal	O
T	O
cell	O
extracts	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
activated	O
human	O
T	O
cells	O
,	O
whether	O
lupus	B-Disease
-derived	O
or	O
normal	O
-derived	O
,	O
contain	O
biologically	O
active	O
ERalpha	B-Gene
proteins	I-Gene
.	O

Other	O
factors	O
may	O
be	O
responsible	O
for	O
differential	O
sensitivity	O
of	O
lupus	B-Disease
T	O
cells	O
to	O
estrogen	B-Chemical
.	O

Existence	O
of	O
retinoic	B-Gene
acid-receptor	I-Gene
-independent	O
retinoid	B-Gene
X-receptor	I-Gene
-dependent	O
pathway	O
in	O
myeloid	O
cell	O
function	O
.	O

We	O
previously	O
reported	O
that	O
ER-27191	B-Chemical
(	O
4-	B-Chemical
[	I-Chemical
4	I-Chemical
,	I-Chemical
5	I-Chemical
,	I-Chemical
7	I-Chemical
,	I-Chemical
8	I-Chemical
,	I-Chemical
9	I-Chemical
,	I-Chemical
10-hexahydro-7	I-Chemical
,	I-Chemical
7	I-Chemical
,	I-Chemical
10	I-Chemical
,	I-Chemical
10-tetramethyl-1-	I-Chemical
(	I-Chemical
3-pyridylmethyl	I-Chemical
)	I-Chemical
anthra	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
2-b	I-Chemical
]	I-Chemical
pyrrol-3-yl	I-Chemical
]	I-Chemical
benzoic	I-Chemical
acid	I-Chemical
)	O
is	O
a	O
potent	O
antagonist	O
of	O
retinoic	B-Gene
acid	I-Gene
receptor	I-Gene
(	O
RAR	B-Gene
)	O
,	O
and	O
ER-35795	B-Chemical
(	O
(	B-Chemical
2E	I-Chemical
,	I-Chemical
4E	I-Chemical
,	I-Chemical
6E	I-Chemical
)	I-Chemical
-7-	I-Chemical
[	I-Chemical
1-	I-Chemical
(	I-Chemical
1-methylethyl	I-Chemical
)	I-Chemical
-8-chloro-1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4-tetrahydroquinolin-6-yl	I-Chemical
]	I-Chemical
-6-fluoro-3-methyl-2	I-Chemical
,	I-Chemical
4	I-Chemical
,	I-Chemical
6-nonatrienoic	I-Chemical
acid	I-Chemical
)	O
is	O
a	O
novel	O
retinoid	B-Gene
X	I-Gene
receptor	I-Gene
(	O
RXR	B-Gene
)	O
-specific	O
agonist	O
.	O

By	O
using	O
these	O
compounds	O
,	O
we	O
investigated	O
whether	O
distinct	O
RAR	B-Gene
-dependent	O
and	O
RXR	B-Gene
-dependent	O
pathways	O
operate	O
to	O
mediate	O
the	O
diverse	O
activities	O
of	O
retinoids	B-Chemical
,	O
particularly	O
,	O
the	O
effects	O
of	O
the	O
RXR	B-Gene
pathway	O
on	O
cellular	O
function	O
.	O

ER-27191	B-Chemical
completely	O
antagonized	O
HL60	O
cell	O
differentiation	O
induced	O
by	O
all-trans-retinoic	B-Chemical
acid	I-Chemical
(	O
atRA	B-Chemical
)	O
.	O

However	O
,	O
the	O
differentiation	O
induced	O
by	O
the	O
ER-35795	B-Chemical
was	O
not	O
antagonized	O
at	O
all	O
by	O
the	O
RAR	B-Gene
antagonist	I-Gene
,	O
but	O
was	O
inhibited	O
by	O
an	O
RXR	B-Gene
homodimer	O
antagonist	O
(	O
LGD100754	B-Chemical
,	O
(	B-Chemical
2E	I-Chemical
,	I-Chemical
4E	I-Chemical
,	I-Chemical
6Z	I-Chemical
)	I-Chemical
-7-	I-Chemical
(	I-Chemical
3-n-propoxy-5	I-Chemical
,	I-Chemical
6	I-Chemical
,	I-Chemical
7	I-Chemical
,	I-Chemical
8-tetrahydro-5	I-Chemical
,	I-Chemical
5	I-Chemical
,	I-Chemical
8	I-Chemical
,	I-Chemical
8-tetramethylnaphthalen-2-yl	I-Chemical
)	I-Chemical
-3-methylocta-2	I-Chemical
,	I-Chemical
4	I-Chemical
,	I-Chemical
6-trienoic	I-Chemical
acid	I-Chemical
)	O
.	O

Its	O
agonistic	O
action	O
on	O
RXR	B-Gene
/	I-Gene
RAR	I-Gene
heterodimer	O
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
neutralized	O
by	O
the	O
RAR	B-Gene
antagonist	I-Gene
.	O

During	O
HL60	O
cell	O
differentiation	O
,	O
atRA	B-Chemical
induced	O
RARbeta	B-Gene
mRNA	I-Gene
,	O
while	O
the	O
RXR	B-Gene
had	O
no	O
effect	O
.	O

Interestingly	O
,	O
a	O
functional	O
RXR	B-Gene
-pathway	O
was	O
also	O
seen	O
in	O
lipopolysaccharide	B-Chemical
-induced	O
inhibition	O
of	O
mouse	O
splenocyte	O
proliferation	O
.	O

These	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
pharmacological	O
RXR	B-Gene
-dependent	O
pathway	O
that	O
is	O
activated	O
by	O
a	O
ligand	O
that	O
can	O
bind	O
to	O
RXR	B-Gene
.	O

Selective	O
inhibition	O
of	O
interleukin-4	B-Gene
gene	I-Gene
expression	O
in	O
human	O
T	O
cells	O
by	O
aspirin	B-Chemical
.	O

Previous	O
studies	O
indicated	O
that	O
aspirin	B-Chemical
(	O
acetylsalicylic	B-Chemical
acid	I-Chemical
[	O
ASA	B-Chemical
]	O
)	O
can	O
have	O
profound	O
immunomodulatory	O
effects	O
by	O
regulating	O
cytokine	O
gene	O
expression	O
in	O
several	O
types	O
of	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
in	O
which	O
concentrations	O
of	O
ASA	B-Chemical
in	O
the	O
therapeutic	O
range	O
were	O
found	O
to	O
significantly	O
reduce	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-4	I-Gene
secretion	O
and	O
RNA	O
expression	O
in	O
freshly	O
isolated	O
and	O
mitogen	O
-primed	O
human	B-Gene
CD4+	I-Gene
T	O
cells	O
.	O

In	O
contrast	O
,	O
ASA	B-Chemical
did	O
not	O
affect	O
IL-13	B-Gene
,	O
interferon-gamma	B-Gene
,	O
and	O
IL-2	B-Gene
expression	O
.	O

ASA	B-Chemical
inhibited	O
IL-4	B-Gene
,	O
but	O
not	O
IL-2	B-Gene
,	O
promoter-driven	O
chloramphenicol	B-Gene
acetyltransferase	I-Gene
expression	O
in	O
transiently	O
transfected	O
Jurkat	O
T	O
cells	O
.	O

The	O
structurally	O
unrelated	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
indomethacin	B-Chemical
and	O
flurbiprofen	B-Chemical
did	O
not	O
affect	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
,	O
whereas	O
the	O
weak	O
cyclo-oxygenase	B-Gene
inhibitor	I-Gene
salicylic	B-Chemical
acid	I-Chemical
was	O
at	O
least	O
as	O
effective	O
as	O
ASA	B-Chemical
in	O
inhibiting	O
IL-4	B-Gene
expression	O
and	O
promoter	O
activity	O
.	O

The	O
inhibitory	O
effect	O
of	O
ASA	B-Chemical
on	O
IL-4	B-Gene
transcription	O
was	O
not	O
mediated	O
by	O
decreased	O
nuclear	O
expression	O
of	O
the	O
known	O
salicylate	B-Chemical
target	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
and	O
was	O
accompanied	O
by	O
reduced	O
binding	O
of	O
an	O
inducible	O
factor	O
to	O
an	O
IL-4	B-Gene
promoter	I-Gene
region	O
upstream	O
of	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
NF	B-Gene
of	I-Gene
activated	I-Gene
T	I-Gene
cells-	I-Gene
and	O
NF-kappaB	B-Gene
-binding	I-Gene
P1	I-Gene
element	I-Gene
.	O

It	O
is	O
concluded	O
that	O
anti-inflammatory	O
salicylates	B-Chemical
,	O
by	O
means	O
of	O
a	O
previously	O
unrecognized	O
mechanism	O
of	O
action	O
,	O
can	O
influence	O
the	O
nature	O
of	O
adaptive	O
immune	O
responses	O
by	O
selectively	O
inhibiting	O
the	O
expression	O
of	O
IL-4	B-Gene
,	O
a	O
critical	O
effector	O
of	O
these	O
responses	O
,	O
in	O
CD4+	B-Gene
T	O
cells	O
.	O

Suppression	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
and	O
stimulation	O
of	O
inhibitor	B-Gene
kappaB	I-Gene
by	O
troglitazone	B-Chemical
:	O
evidence	O
for	O
an	O
anti-inflammatory	O
effect	O
and	O
a	O
potential	O
antiatherosclerotic	O
effect	O
in	O
the	O
obese	O
.	O

To	O
elucidate	O
whether	O
troglitazone	B-Chemical
exerts	O
an	O
antiinflammatory	O
effect	O
in	O
humans	O
,	O
in	O
vivo	O
,	O
we	O
investigated	O
the	O
suppression	O
of	O
nuclear	B-Gene
factor	I-Gene
kappaB	I-Gene
(	O
NFkappaB	B-Gene
)	O
in	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
by	O
this	O
drug	O
.	O

We	O
measured	O
intranuclear	B-Gene
NFkappaB	I-Gene
,	O
total	O
cellular	B-Gene
NFkappaB	I-Gene
,	O
inhibitor	B-Gene
kappaB	I-Gene
(	I-Gene
IkappaB	I-Gene
)	I-Gene
alpha	I-Gene
,	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
generation	O
,	O
and	O
p47	B-Gene
(	I-Gene
phox	I-Gene
)	I-Gene
subunit	O
(	O
a	O
key	O
component	O
protein	O
of	O
nicotinamide	B-Gene
adenine	I-Gene
dinucleotide	I-Gene
phosphate	I-Gene
oxidase	I-Gene
)	O
in	O
MNC	O
.	O

Plasma	B-Gene
tumor	I-Gene
necrosis	I-Gene
factor	I-Gene
(	I-Gene
TNF	I-Gene
)	I-Gene
-alpha	I-Gene
,	O
soluble	B-Gene
intercellular	I-Gene
adhesion	I-Gene
molecule-1	I-Gene
(	O
sICAM-1	B-Gene
)	O
,	O
monocyte	B-Gene
chemoattractant	I-Gene
protein-1	I-Gene
(	O
MCP-1	B-Gene
)	O
,	O
plasminogen	B-Gene
activator	I-Gene
inhibitor	I-Gene
type	I-Gene
1	I-Gene
(	O
PAI-1	B-Gene
)	O
,	O
C	B-Gene
-reactive	I-Gene
protein	I-Gene
(	O
CRP	B-Gene
)	O
,	O
and	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-10	I-Gene
(	O
antiinflammatory	O
cytokine	O
)	O
concentrations	O
were	O
also	O
measured	O
as	O
mediators	O
of	O
inflammatory	O
activity	O
that	O
are	O
regulated	O
by	O
the	O
proinflammatory	O
transcription	B-Gene
factor	I-Gene
NFkappaB	I-Gene
.	O

Seven	O
nondiabetic	O
obese	O
patients	O
were	O
given	O
400	O
mg	O
troglitazone	B-Chemical
daily	O
for	O
4	O
weeks	O
.	O

Blood	O
samples	O
were	O
collected	O
before	O
and	O
at	O
weekly	O
intervals	O
thereafter	O
.	O

MNC	O
were	O
separated	O
;	O
and	O
the	O
levels	O
of	O
intranuclear	B-Gene
NFkappaB	I-Gene
,	O
total	O
cellular	B-Gene
NFkappaB	I-Gene
,	O
IkappaBalpha	B-Gene
,	O
and	O
p47	B-Gene
(	I-Gene
phox	I-Gene
)	I-Gene
subunit	O
and	O
ROS	B-Chemical
generation	O
were	O
determined	O
.	O

Plasma	O
was	O
used	O
to	O
measure	O
insulin	B-Gene
glucose	B-Chemical
,	O
TNFalpha	B-Gene
,	O
sICAM	B-Gene
,	O
MCP-1	B-Gene
,	O
PAI-1	B-Gene
,	O
CRP	B-Gene
,	O
and	O
IL-10	B-Gene
.	O

Plasma	B-Gene
insulin	I-Gene
concentrations	O
fell	O
significantly	O
at	O
week	O
1	O
,	O
from	O
31.2	O
+	O
/	O
-	O
29.1	O
to	O
14.2	O
+	O
/	O
-	O
11.4	O
mU	O
/	O
L	O
(	O
P	O
<	O
0.01	O
)	O
and	O
remained	O
low	O
throughout	O
4	O
weeks	O
.	O

Plasma	O
glucose	B-Chemical
concentrations	O
did	O
not	O
alter	O
significantly	O
.	O

There	O
was	O
a	O
fall	O
in	O
intranuclear	B-Gene
NFkappaB	I-Gene
,	O
total	O
cellular	B-Gene
NFkappaB	I-Gene
,	O
and	O
p47	B-Gene
(	I-Gene
phox	I-Gene
)	I-Gene
subunit	O
,	O
with	O
an	O
increase	O
in	O
cellular	B-Gene
IkappaBalpha	I-Gene
at	O
week	O
2	O
,	O
which	O
persisted	O
until	O
week	O
4	O
.	O

There	O
was	O
a	O
parallel	O
fall	O
in	O
ROS	B-Chemical
generation	O
by	O
MNC	O
at	O
week	O
1	O
;	O
this	O
progressed	O
and	O
persisted	O
until	O
week	O
4	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Plasma	B-Gene
TNF-alpha	I-Gene
,	O
sICAM-1	B-Gene
,	O
MCP-1	B-Gene
,	O
and	O
PAI-1	B-Gene
concentrations	O
fell	O
significantly	O
at	O
week	O
4	O
.	O

Plasma	B-Gene
IL-10	I-Gene
concentration	O
increased	O
significantly	O
,	O
whereas	O
plasma	B-Gene
CRP	I-Gene
concentrations	O
decreased	O
.	O

We	O
conclude	O
that	O
troglitazone	B-Chemical
has	O
an	O
antiinflammatory	O
action	O
that	O
may	O
contribute	O
to	O
its	O
putative	O
antiatherosclerotic	O
effects	O
.	O

An	O
instructive	O
component	O
in	O
T	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
development	O
mediated	O
by	O
GATA-3	B-Gene
.	O

Although	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-12	I-Gene
and	O
IL-4	B-Gene
polarize	O
naive	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
toward	O
T	O
helper	O
cell	O
type	O
1	O
(	O
Th1	O
)	O
or	O
Th2	O
phenotypes	O
,	O
it	O
is	O
not	O
known	O
whether	O
cytokines	O
instruct	O
the	O
developmental	O
fate	O
in	O
uncommitted	O
progenitors	O
or	O
select	O
for	O
outgrowth	O
of	O
cells	O
that	O
have	O
stochastically	O
committed	O
to	O
a	O
particular	O
fate	O
.	O

To	O
distinguish	O
these	O
instructive	O
and	O
selective	O
models	O
,	O
we	O
used	O
surface	O
affinity	O
matrix	O
technology	O
to	O
isolate	O
committed	O
progenitors	O
based	O
on	O
cytokine	O
secretion	O
phenotype	O
and	O
developed	O
retroviral	O
-based	O
tagging	O
approaches	O
to	O
directly	O
monitor	O
individual	O
progenitor	O
fate	O
decisions	O
at	O
the	O
clonal	O
and	O
population	O
levels	O
.	O

We	O
observe	O
IL-4	B-Gene
-dependent	O
redirection	O
of	O
phenotype	O
in	O
cells	O
that	O
have	O
already	O
committed	O
to	O
a	O
non-IL-4	B-Gene
-producing	O
fate	O
,	O
inconsistent	O
with	O
predictions	O
of	O
the	O
selective	O
model	O
.	O

Further	O
,	O
retroviral	O
tagging	O
of	O
naive	O
progenitors	O
with	O
the	O
Th2-specific	B-Gene
transcription	I-Gene
factor	I-Gene
GATA-3	I-Gene
provided	O
direct	O
evidence	O
for	O
instructive	O
differentiation	O
,	O
and	O
no	O
evidence	O
for	O
the	O
selective	O
outgrowth	O
of	O
cells	O
committed	O
to	O
either	O
the	O
Th1	O
or	O
Th2	O
fate	O
.	O

These	O
data	O
would	O
seem	O
to	O
exclude	O
selection	O
as	O
an	O
exclusive	O
mechanism	O
in	O
Th1	O
/	O
Th2	O
differentiation	O
,	O
and	O
support	O
an	O
instructive	O
model	O
of	O
cytokine-driven	O
transcriptional	O
programming	O
of	O
cell	O
fate	O
decisions	O
.	O

Targeting	O
Src	B-Gene
homology	I-Gene
2	I-Gene
domain	I-Gene
-containing	I-Gene
tyrosine	I-Gene
phosphatase	I-Gene
(	O
SHP-1	B-Gene
)	O
into	O
lipid	B-Chemical
rafts	O
inhibits	O
CD3	B-Gene
-induced	O
T	O
cell	O
activation	O
.	O

To	O
study	O
the	O
mechanism	O
by	O
which	O
protein	B-Gene
tyrosine	I-Gene
phosphatases	I-Gene
(	O
PTPs	B-Gene
)	O
regulate	O
CD3	B-Gene
-induced	O
tyrosine	B-Chemical
phosphorylation	O
,	O
we	O
investigated	O
the	O
distribution	O
of	O
PTPs	B-Gene
in	O
subdomains	O
of	O
plasma	O
membrane	O
.	O

We	O
report	O
here	O
that	O
the	O
bulk	O
PTP	B-Gene
activity	O
associated	O
with	O
T	O
cell	O
membrane	O
is	O
present	O
outside	O
the	O
lipid	B-Chemical
rafts	O
,	O
as	O
determined	O
by	O
sucrose	O
density	O
gradient	O
sedimentation	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
approximately	O
5	O
--	O
10	O
%	O
of	O
Src	B-Gene
homology	I-Gene
2	I-Gene
domain	I-Gene
-containing	I-Gene
tyrosine	I-Gene
phosphatase	I-Gene
(	O
SHP-1	B-Gene
)	O
is	O
constitutively	O
associated	O
with	O
plasma	O
membrane	O
,	O
and	O
nearly	O
50	O
%	O
of	O
SHP-2	B-Gene
is	O
translocated	O
to	O
plasma	O
membrane	O
after	O
vanadate	B-Chemical
treatment	O
.	O

Similar	O
to	O
transmembrane	O
PTP	B-Gene
,	O
CD45	B-Gene
,	O
the	O
membrane	O
-associated	O
populations	O
of	O
SHP-1	B-Gene
and	O
SHP-2	B-Gene
are	O
essentially	O
excluded	O
from	O
lipid	B-Chemical
rafts	O
,	O
where	O
other	O
signaling	O
molecules	O
such	O
as	O
Lck	B-Gene
,	O
linker	B-Gene
for	I-Gene
activation	I-Gene
of	I-Gene
T	I-Gene
cells	I-Gene
,	O
and	O
CD3	B-Gene
zeta	I-Gene
are	O
enriched	O
.	O

We	O
further	O
demonstrated	O
that	O
CD3	B-Gene
-induced	O
tyrosine	B-Chemical
phosphorylation	O
of	O
these	O
substrates	O
is	O
largely	O
restricted	O
to	O
lipid	B-Chemical
rafts	O
,	O
unless	O
PTPs	B-Gene
are	O
inhibited	O
.	O

It	O
suggests	O
that	O
a	O
restricted	O
partition	O
of	O
PTPs	B-Gene
among	O
membrane	O
subdomains	O
may	O
regulate	O
protein	O
tyrosine	B-Chemical
phosphorylation	O
in	O
T	O
cell	O
membrane	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
targeted	O
SHP-1	B-Gene
into	O
lipid	B-Chemical
rafts	O
by	O
using	O
the	O
N-terminal	O
region	O
of	O
Lck	B-Gene
(	O
residues	O
1	O
--	O
14	O
)	O
.	O

The	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
Lck	B-Gene
/	I-Gene
SHP-1	I-Gene
chimera	I-Gene
inside	O
lipid	B-Chemical
rafts	O
profoundly	O
inhibits	O
CD3	B-Gene
-induced	O
tyrosine	B-Chemical
phosphorylation	O
of	O
CD3	B-Gene
zeta	I-Gene
/	I-Gene
epsilon	I-Gene
,	O
IL-2	B-Gene
generation	O
,	O
and	O
nuclear	O
mobilization	O
of	O
NF-AT	B-Gene
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
exclusion	O
of	O
PTPs	B-Gene
from	O
lipid	B-Chemical
rafts	O
may	O
be	O
a	O
mechanism	O
that	O
potentiates	O
TCR	B-Gene
/	I-Gene
CD3	I-Gene
activation	O

Stromal	B-Gene
cell	I-Gene
-derived	I-Gene
factor	I-Gene
1	I-Gene
alpha	I-Gene
-induced	O
chemotaxis	O
in	O
T	O
cells	O
is	O
mediated	O
by	O
nitric	B-Chemical
oxide	I-Chemical
signaling	O
pathways	O
.	O

Stromal	B-Gene
cell	I-Gene
-derived	I-Gene
factor	I-Gene
1	I-Gene
alpha	I-Gene
(	O
SDF1	B-Gene
alpha	I-Gene
)	O
and	O
its	O
cognate	O
chemokine	B-Gene
receptor	I-Gene
CXCR4	I-Gene
act	O
as	O
potent	O
chemoattractants	O
and	O
regulate	O
trafficking	O
and	O
homing	O
of	O
hematopoietic	O
progenitor	O
cells	O
and	O
lymphocytes	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
SDF1	B-Gene
alpha	I-Gene
-driven	O
cell	O
migration	O
are	O
not	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
roles	O
of	O
the	O
second	O
messenger	O
NO	O
and	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
in	O
SDF1	B-Gene
alpha	I-Gene
-induced	O
T	O
cell	O
migration	O
.	O

SDF1	B-Gene
alpha	I-Gene
treatment	O
of	O
Jurkat	O
T	O
cells	O
increased	O
the	O
activity	O
of	O
NO	B-Gene
synthase	I-Gene
,	O
which	O
catalyzes	O
the	O
generation	O
of	O
NO	O
.	O

We	O
observed	O
that	O
pretreatment	O
of	O
Jurkat	O
cells	O
or	O
activated	O
PBLs	O
with	O
several	O
NO	O
donors	O
significantly	O
enhanced	O
the	O
SDF1	B-Gene
alpha	I-Gene
-induced	O
migration	O
,	O
whereas	O
various	O
inhibitors	O
of	O
NO	B-Gene
synthase	I-Gene
markedly	O
abrogated	O
the	O
chemotactic	O
response	O
in	O
a	O
concentration	O
-dependent	O
manner	O
.	O

Furthermore	O
,	O
we	O
observed	O
that	O
inhibitors	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
,	O
which	O
is	O
linked	O
to	O
NO	O
signaling	O
pathways	O
,	O
also	O
significantly	O
blocked	O
the	O
SDF1	B-Gene
alpha	I-Gene
-induced	O
chemotactic	O
response	O
.	O

However	O
,	O
these	O
compounds	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
SDF1	B-Gene
alpha	I-Gene
-induced	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
activity	O
.	O

In	O
addition	O
,	O
the	O
MAP	B-Gene
/	I-Gene
Erk	I-Gene
kinase	I-Gene
kinase	I-Gene
inhibitor	O
PD98059	B-Chemical
did	O
not	O
abrogate	O
SDF1	B-Gene
alpha	I-Gene
-induced	O
chemotaxis	O
.	O

AKT	B-Gene
,	O
which	O
has	O
been	O
shown	O
to	O
mediate	O
NO	O
production	O
,	O
was	O
also	O
phosphorylated	O
upon	O
SDF1	B-Gene
alpha	I-Gene
stimulation	O
.	O

These	O
studies	O
suggest	O
that	O
NO	O
-related	O
signaling	O
pathways	O
may	O
mediate	O
SDF1	B-Gene
alpha	I-Gene
-induced	O
chemotaxis	O
,	O
but	O
not	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
activation	O
.	O

Transcriptional	O
regulation	O
in	O
lymphocytes	O
.	O

Lymphocytes	O
have	O
been	O
used	O
to	O
investigate	O
many	O
cellular	O
processes	O
,	O
including	O
lineage	O
commitment	O
,	O
differentiation	O
,	O
proliferation	O
and	O
apoptosis	O
.	O

The	O
transcription	O
factors	O
that	O
mediate	O
these	O
processes	O
are	O
often	O
expressed	O
broadly	O
in	O
many	O
cell	O
types	O
.	O

The	O
emerging	O
theme	O
is	O
one	O
of	O
cell-type-specific	O
regulation	O
,	O
affecting	O
not	O
only	O
the	O
functional	O
activation	O
of	O
transcription	O
factors	O
but	O
also	O
their	O
access	O
to	O
appropriate	O
regions	O
of	O
DNA	O
.	O

Tyrosine	B-Chemical
phosphorylation	O
-dependent	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
.	O

Requirement	O
for	O
p56	B-Gene
LCK	I-Gene
and	O
ZAP-70	B-Gene
protein	I-Gene
tyrosine	I-Gene
kinases	I-Gene
.	O

Phosphorylation	O
of	O
the	O
N-terminal	O
domain	O
of	O
I	B-Gene
kappa	I-Gene
B	I-Gene
inhibitory	O
subunits	O
induces	O
activation	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
.	O

Although	O
serine	B-Chemical
phosphorylation	O
has	O
been	O
shown	O
to	O
induce	O
ubiquitination	O
and	O
subsequent	O
proteasome	O
-mediated	O
degradation	O
of	O
I	B-Gene
kappa	I-Gene
B-alpha	I-Gene
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
lead	O
to	O
release	O
of	O
active	O
NF-kappa	B-Gene
B	I-Gene
in	O
T	O
cells	O
as	O
a	O
consequence	O
of	O
tyrosine	B-Chemical
phosphorylation	O
of	O
I	B-Gene
kappa	I-Gene
B-alpha	I-Gene
[	O
Imbert	O
,	O
V.	O
,	O
Rupec	O
,	O
R.A.	O
,	O
Livolsi	O
,	O
A.	O
,	O
Pahl	O
,	O
H.L.	O
,	O
Traenckner	O
,	O
B.M.	O
,	O
Mueller-Dieckmann	O
,	O
C.	O
,	O
Farahifar	O
,	O
D.	O
,	O
Rossi	O
,	O
B.	O
,	O
Auberger	O
,	O
P.	O
,	O
Baeuerle	O
,	O
P.	O
&	O
Peyron	O
,	O
J.F.	O
(	O
1996	O
)	O
Cell	O
86	O
,	O
787	O
--	O
798	O
]	O
.	O

The	O
involvement	O
of	O
the	O
tyrosine	B-Gene
kinases	I-Gene
p56	I-Gene
(	O
lck	B-Gene
)	O
and	O
ZAP-70	B-Gene
in	O
this	O
reaction	O
is	O
demonstrated	O
here	O
using	O
specific	O
pharmacological	O
inhibitors	O
and	O
Jurkat	O
mutants	O
unable	O
to	O
express	O
these	O
kinases	O
.	O

Although	O
the	O
inhibitors	O
prevented	O
both	O
pervanadate	B-Chemical
-induced	O
phosphorylation	O
of	O
I	B-Gene
kappa	I-Gene
B-alpha	I-Gene
on	O
Tyr42	B-Chemical
and	O
NF-kappa	B-Gene
B	I-Gene
activation	O
,	O
we	O
observed	O
that	O
,	O
in	O
p56	B-Gene
(	O
lck	B-Gene
)	O
-deficient	O
Jurkat	O
mutants	O
,	O
NF-kappa	B-Gene
B	I-Gene
could	O
still	O
associate	O
with	O
I	B-Gene
kappa	I-Gene
B-alpha	I-Gene
despite	O
phosphorylation	O
on	O
Tyr42	B-Chemical
.	O

Furthermore	O
,	O
the	O
SH2	O
domain	O
of	O
p56	B-Gene
(	O
lck	B-Gene
)	O
appeared	O
to	O
be	O
required	O
for	O
pervanadate	B-Chemical
-induced	O
NF-kappa	B-Gene
B	I-Gene
activation	O
but	O
not	O
for	O
Tyr42	B-Chemical
phosphorylation	O
.	O

These	O
results	O
show	O
that	O
p56	B-Gene
(	O
lck	B-Gene
)	O
and	O
ZAP-70	B-Gene
are	O
key	O
components	O
of	O
the	O
signaling	O
pathway	O
that	O
leads	O
to	O
phosphotyrosine	B-Chemical
-dependent	O
NF-kappa	B-Gene
B	I-Gene
activation	O
in	O
T	O
cells	O
and	O
confirm	O
that	O
tyrosine	B-Gene
kinases	I-Gene
must	O
control	O
at	O
least	O
two	O
different	O
steps	O
to	O
induce	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
.	O

Finally	O
,	O
we	O
show	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
which	O
stimulates	O
p56	B-Gene
(	O
lck	B-Gene
)	O
and	O
ZAP-70	B-Gene
in	O
T	O
cells	O
,	O
is	O
an	O
activator	O
of	O
NF-kappa	B-Gene
B	I-Gene
through	O
tyrosine	B-Chemical
phosphorylation	O
of	O
I	B-Gene
kappa	I-Gene
B-alpha	I-Gene
.	O

CD28	B-Gene
and	O
T	O
cell	O
co-stimulation	O
.	O

Over	O
the	O
last	O
decade	O
the	O
concept	O
of	O
T	O
cell	O
co-stimulation	O
has	O
emerged	O
to	O
take	O
a	O
central	O
role	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
.	O

However	O
,	O
the	O
exact	O
definition	O
of	O
co-stimulation	O
is	O
still	O
unclear	O
.	O

In	O
this	O
review	O
,	O
we	O
re-examine	O
the	O
concept	O
of	O
co-stimulation	O
.	O

We	O
suggest	O
that	O
while	O
co-stimulation	O
is	O
important	O
,	O
there	O
is	O
little	O
evidence	O
to	O
link	O
co-stimulation	O
with	O
T	O
cell	O
anergy	O
.	O

We	O
then	O
suggest	O
a	O
framework	O
for	O
studying	O
co-stimulation	O
.	O

Focusing	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
CD28	B-Gene
,	O
we	O
discuss	O
four	O
areas	O
of	O
T	O
cell	O
activation	O
where	O
co-stimulation	O
may	O
play	O
a	O
role	O
.	O

Retinoic	B-Chemical
acid	I-Chemical
up-regulates	O
myeloid	B-Gene
ICAM-3	I-Gene
expression	O
and	O
function	O
in	O
a	O
cell-specific	O
fashion	O
--	O
evidence	O
for	O
retinoid	O
signaling	O
pathways	O
in	O
the	O
mast	O
cell	O
lineage	O
.	O

Investigation	O
of	O
mast	O
cell	O
responsiveness	O
toward	O
retinoic	B-Chemical
acid	I-Chemical
(	O
RA	B-Chemical
)	O
revealed	O
selective	O
promotion	O
of	O
ICAM-3	B-Gene
expression	O
in	O
the	O
human	O
mast	O
cell	O
line	O
HMC-1	O
.	O

This	O
process	O
was	O
dose-	O
and	O
time	O
-dependent	O
and	O
detectable	O
by	O
flow	O
cytometry	O
,	O
Western	O
blot	O
analysis	O
,	O
ELISA	O
,	O
and	O
Northern	O
blot	O
analysis	O
.	O

ICAM-3	B-Gene
modulation	O
was	O
found	O
to	O
be	O
cell-type	O
dependent	O
,	O
detectable	O
also	O
for	O
HL-60	O
cells	O
and	O
monocytes	O
but	O
not	O
U-937	O
and	O
only	O
weakly	O
for	O
KU812	O
cells	O
.	O

Terminally	O
differentiated	O
skin	O
mast	O
cells	O
also	O
failed	O
to	O
up-modulate	O
their	O
ICAM-3	B-Gene
,	O
suggesting	O
the	O
requirement	O
for	O
some	O
degree	O
of	O
immaturity	O
for	O
the	O
process	O
.	O

RA	B-Chemical
-mediated	O
effects	O
on	O
ICAM-1	B-Gene
expression	O
,	O
studied	O
in	O
parallel	O
,	O
were	O
clearly	O
distinct	O
from	O
those	O
on	O
ICAM-3	B-Gene
.	O

Investigation	O
of	O
retinoid	B-Gene
receptor	I-Gene
expression	O
,	O
known	O
to	O
mediate	O
intracellular	O
RA	B-Chemical
signaling	O
,	O
revealed	O
presence	O
of	O
RAR	B-Gene
alpha	I-Gene
,	O
RAR	B-Gene
gamma	I-Gene
,	O
RXR	B-Gene
beta	I-Gene
,	O
and	O
RXR	B-Gene
gamma	I-Gene
transcripts	O
in	O
all	O
cell	O
lines	O
studied	O
,	O
and	O
HMC-1	O
cells	O
were	O
the	O
only	O
line	O
lacking	O
RXR	B-Gene
alpha	I-Gene
.	O

RAR	B-Gene
beta	I-Gene
,	O
not	O
expressed	O
at	O
baseline	O
,	O
was	O
induced	O
by	O
RA	B-Chemical
in	O
a	O
fashion	O
obviously	O
correlating	O
with	O
ICAM-3	B-Gene
up-regulation	O
.	O

Increased	O
ICAM-3	B-Gene
expression	O
was	O
of	O
functional	O
significance	O
,	O
such	O
that	O
processes	O
stimulated	O
or	O
co	O
-stimulated	O
via	O
ICAM-3	B-Gene
(	O
homotypic	O
aggregation	O
,	O
IL-8	B-Gene
secretion	O
)	O
were	O
clearly	O
enhanced	O
upon	O
RA	B-Chemical
pretreatment	O
,	O
suggesting	O
that	O
RA	B-Chemical
may	O
contribute	O
via	O
hitherto	O
unrecognized	O
pathways	O
to	O
immune	O
function	O
and	O
host	O
defense	O
.	O

Specific	O
missense	O
mutations	O
in	O
NEMO	B-Gene
result	O
in	O
hyper-IgM	B-Disease
syndrome	I-Disease
with	O
hypohydrotic	B-Disease
ectodermal	I-Disease
dysplasia	I-Disease
.	O

The	O
gene	O
that	O
encodes	O
nuclear	B-Gene
factor	I-Gene
kappaB	I-Gene
(	I-Gene
NF-kappaB	I-Gene
)	I-Gene
essential	I-Gene
modulator	I-Gene
(	O
or	O
NEMO	B-Gene
,	O
also	O
known	O
as	O
IKKgamma	B-Gene
)	O
is	O
required	O
for	O
activation	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappaB	I-Gene
.	O

We	O
describe	O
mutations	O
in	O
the	O
putative	O
zinc	O
-finger	O
domain	O
of	O
NEMO	B-Gene
that	O
result	O
in	O
an	O
X	B-Disease
-linked	I-Disease
primary	I-Disease
immunodeficiency	I-Disease
characterized	O
by	O
hyper-IgM	B-Disease
syndrome	I-Disease
and	O
hypohydrotic	B-Disease
ectodermal	I-Disease
dysplasia	I-Disease
(	O
XHM-ED	B-Disease
)	O
.	O

These	O
mutations	O
prevent	O
CD40	B-Gene
ligand	I-Gene
(	O
CD40L	B-Gene
)	O
-mediated	O
degradation	O
of	O
inhibitor	B-Gene
of	I-Gene
NF-kappaB	I-Gene
alpha	I-Gene
(	O
IkappaB-alpha	B-Gene
)	O
and	O
account	O
for	O
the	O
following	O
observations	O
:	O
B	O
cells	O
from	O
XHM-ED	B-Disease
patients	O
are	O
unable	O
to	O
undergo	O
immunoglobulin	B-Gene
class-switch	O
recombination	O
and	O
antigen	O
-presenting	O
cells	O
(	O
APCs	O
)	O
are	O
unable	O
to	O
synthesize	O
the	O
NF-kappaB	B-Gene
-regulated	O
cytokines	B-Gene
interleukin	I-Gene
12	I-Gene
(	O
IL-12	B-Gene
)	O
or	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
when	O
stimulated	O
with	O
CD40L	B-Gene
.	O

Nevertheless	O
,	O
innate	O
immunity	O
is	O
preserved	O
in	O
XHM-ED	B-Disease
patients	O
because	O
APCs	O
retain	O
the	O
capacity	O
to	O
respond	O
to	O
stimulation	O
by	O
lipopolysaccharide	B-Chemical
or	O
Staphylococcus	O
aureus	O
Cowan	O
's	O
antigen	O
(	O
SAC	O
)	O
.	O

Overall	O
,	O
the	O
phenotype	O
observed	O
in	O
XHM-ED	B-Disease
patients	O
shows	O
that	O
the	O
putative	O
zinc	O
-finger	O
domain	O
of	O
NEMO	B-Gene
has	O
a	O
regulatory	O
function	O
and	O
demonstrates	O
the	O
definite	O
requirement	O
of	O
CD40	B-Gene
-mediated	O
NF-kappaB	B-Gene
activation	O
for	O
B	B-Gene
cell	I-Gene
immunoglobulin	I-Gene
class	O
-switching	O
.	O

Regulation	O
of	O
the	O
helix-loop-helix	O
proteins	O
,	O
E2A	B-Gene
and	O
Id3	B-Gene
,	O
by	O
the	O
Ras	B-Gene
-	I-Gene
ERK	I-Gene
MAPK	I-Gene
cascade	O
.	O

Activation	O
of	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
MAPK	B-Gene
)	O
pathways	O
leads	O
to	O
cellular	O
differentiation	O
and	O
/	O
or	O
proliferation	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
including	O
developing	O
thymocytes	O
.	O

The	O
basic	B-Gene
helix-loop-helix	I-Gene
(	I-Gene
bHLH	I-Gene
)	I-Gene
proteins	I-Gene
E12	I-Gene
and	O
E47	B-Gene
and	O
an	O
inhibitor	O
HLH	O
protein	O
,	O
Id3	B-Gene
,	O
play	O
key	O
roles	O
in	O
thymocyte	O
differentiation	O
.	O

We	O
show	O
here	O
that	O
E2A	B-Gene
DNA	I-Gene
binding	O
is	O
lowered	O
in	O
primary	O
immature	O
thymocytes	O
consequent	O
to	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
(	O
TCR	B-Gene
)	O
-mediated	O
ligation	O
.	O

Whereas	O
expression	O
of	O
E2A	B-Gene
mRNA	I-Gene
and	O
protein	O
are	O
unaltered	O
,	O
Id3	B-Gene
transcripts	I-Gene
are	O
rapidly	O
induced	O
upon	O
signaling	O
from	O
the	O
TCR	B-Gene
.	O

Activation	O
of	O
Id3	B-Gene
transcription	O
is	O
regulated	O
in	O
a	O
dose	O
-dependent	O
manner	O
by	O
the	O
extracellular	B-Gene
signal	I-Gene
-regulated	I-Gene
kinase	I-Gene
(	I-Gene
ERK	I-Gene
)	I-Gene
MAPK	I-Gene
module	O
.	O

These	O
observations	O
directly	O
connect	O
the	O
ERK	B-Gene
MAPK	I-Gene
cascade	O
and	O
HLH	O
proteins	O
in	O
a	O
linear	O
pathway	O
.	O

Immunohistochemical	O
detection	O
of	O
interferon-gamma	B-Gene
-producing	O
cells	O
in	O
dermatophytosis	B-Disease
.	O

Skin	O
lesions	O
of	O
dermatophytosis	B-Disease
are	O
thought	O
to	O
be	O
a	O
result	O
of	O
a	O
T	O
cell	O
-dependent	O
inflammatory	O
response	O
that	O
is	O
mediated	O
by	O
various	O
cytokines	O
.	O

We	O
examined	O
whether	O
IFN-gamma	B-Gene
-positive	O
cells	O
(	O
as	O
expression	O
of	O
Th1	O
response	O
)	O
were	O
present	O
in	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	B-Disease
in	O
situ	O
by	O
immunohistochemical	O
techniques	O
.	O

Mixtures	O
of	O
CD4	B-Gene
-positive	O
T	O
cells	O
and	O
CD8	B-Gene
-positive	O
T	O
cells	O
were	O
found	O
to	O
be	O
present	O
in	O
the	O
dermal	O
infiltrates	O
of	O
the	O
lesions	O
.	O

Considerable	O
numbers	O
of	O
CD1a	B-Gene
-positive	O
cells	O
were	O
detected	O
in	O
the	O
upper	O
dermis	O
and	O
epidermis	O
.	O

A	O
marked	O
accumulation	O
of	O
CD68	B-Gene
-positive	O
cells	O
was	O
found	O
in	O
the	O
upper	O
dermis	O
.	O

IFN-gamma	B-Gene
-positive	O
cells	O
were	O
present	O
in	O
the	O
upper	O
dermis	O
of	O
the	O
lesions	O
.	O

The	O
pattern	O
of	O
IFN-gamma	B-Gene
staining	O
appeared	O
to	O
be	O
intracellular	O
in	O
mononuclear	O
lymphoid	O
cells	O
.	O

The	O
staining	O
was	O
considered	O
to	O
be	O
highly	O
specific	O
because	O
it	O
could	O
be	O
completely	O
blocked	O
by	O
preabsorption	O
with	O
recombinant	B-Gene
IFN-gamma	I-Gene
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	B-Disease
may	O
be	O
associated	O
with	O
a	O
Th1	O
response	O
.	O

Th1	O
response	O
,	O
which	O
is	O
characterized	O
by	O
IFN-gamma	B-Gene
release	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
host	O
defense	O
against	O
dermatophytes	O
and	O
to	O
reflect	O
cutaneous	O
reaction	O
in	O
dermatophytosis	B-Disease
.	O

Decreased	O
expression	O
of	O
c-myc	B-Gene
family	I-Gene
genes	I-Gene
in	O
thymuses	O
from	O
myasthenia	B-Disease
gravis	I-Disease
patients	O
.	O

The	O
thymus	O
is	O
a	O
critical	O
organ	O
for	O
the	O
elimination	O
of	O
autoreactive	O
T	O
cells	O
by	O
apoptosis	O
.	O

We	O
studied	O
the	O
expression	O
of	O
apoptosis	O
-associated	O
genes	O
,	O
bcl-xL	B-Gene
,	O
bad	B-Gene
,	O
caspase-3	B-Gene
,	O
and	O
c-myc	B-Gene
family	I-Gene
genes	I-Gene
in	O
myasthenia	B-Disease
gravis	I-Disease
(	O
MG	B-Disease
)	O
thymuses	O
.	O

We	O
observed	O
that	O
the	O
mRNA	O
levels	O
of	O
myc	B-Gene
family	I-Gene
genes	I-Gene
,	O
c-myc	B-Gene
and	O
max	B-Gene
,	O
were	O
markedly	O
reduced	O
in	O
MG	B-Disease
thymuses	O
.	O

These	O
results	O
indicate	O
that	O
c-myc	B-Gene
-mediated	O
signaling	O
is	O
abnormal	O
in	O
MG	B-Disease
thymuses	O
.	O

The	O
levels	O
of	O
molecules	O
whose	O
expressions	O
are	O
associated	O
with	O
myc	B-Gene
,	O
such	O
as	O
STAM	B-Gene
,	O
prothymosin-alpha	B-Gene
,	O
and	O
NFkappaB	B-Gene

Expression	O
of	O
SART3	B-Gene
antigen	I-Gene
and	O
induction	O
of	O
CTLs	O
by	O
SART3	B-Gene
-derived	O
peptides	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O

We	O
recently	O
reported	O
the	O
SART3	B-Gene
tumour-rejection	B-Disease
antigen	O
as	O
possessing	O
tumour	B-Disease
epitopes	O
capable	O
of	O
inducing	O
HLA-class	B-Gene
I	I-Gene
-restricted	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O

This	O
study	O
investigated	O
expression	O
of	O
the	O
SART3	B-Gene
antigen	I-Gene
in	O
breast	B-Disease
cancer	I-Disease
to	O
explore	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O

The	O
SART3	B-Gene
antigen	I-Gene
was	O
detected	O
in	O
all	O
of	O
the	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
tested	O
,	O
30	O
of	O
40	O
(	O
75	O
%	O
)	O
breast	B-Disease
cancer	I-Disease
tissue	O
samples	O
,	O
and	O
0	O
of	O
3	O
non-tumourous	O
breast	O
tissue	O
samples	O
.	O

SART3	B-Gene
derived	O
peptides	O
at	O
positions	O
109-118	O
and	O
315-323	O
induced	O
HLA-A24	B-Gene
restricted	O
CTLs	O
that	O
reacted	O
to	O
breast	B-Disease
cancer	I-Disease
cells	O
from	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O

Therefore	O
,	O
the	O
SART3	B-Gene
antigen	I-Gene
and	O
its	O
peptides	O
could	O
be	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
the	O
majority	O
of	O
HLA-A24	B-Gene
-positive	O
breast	B-Disease
cancer	I-Disease
patients	O

The	O
latency	O
pattern	O
of	O
Epstein-Barr	O
virus	O
infection	O
and	O
viral	B-Gene
IL-10	I-Gene
expression	O
in	O
cutaneous	O
natural	B-Disease
killer	I-Disease
/	I-Disease
T-cell	I-Disease
lymphomas	I-Disease
.	O

The	O
nasal	O
type	O
,	O
extranodal	O
natural	O
killer	O
or	O
T	B-Disease
(	I-Disease
NK	I-Disease
/	I-Disease
T	I-Disease
)	I-Disease
-cell	I-Disease
lymphoma	I-Disease
is	O
usually	O
associated	O
with	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
EBV	O
gene	O
expression	O
patterns	O
in	O
vivo	O
,	O
we	O
examined	O
eight	O
patients	O
with	O
cutaneous	O
EBV	O
-related	O
NK	B-Disease
/	I-Disease
T-cell	I-Disease
lymphomas	I-Disease
,	O
including	O
six	O
patients	O
with	O
a	O
NK-cell	O
phenotype	O
and	O
two	O
patients	O
with	O
a	O
T-cell	O
phenotype	O
.	O

The	O
implication	O
of	O
EBV	O
in	O
the	O
skin	O
lesions	O
was	O
determined	O
by	O
the	O
presence	O
of	O
EBV-DNA	O
,	O
EBV	B-Gene
-encoded	I-Gene
nuclear	I-Gene
RNA	I-Gene
(	O
EBER	B-Gene
)	O
and	O
a	O
clonality	O
of	O
EBV-DNA	O
fragments	O
containing	O
the	O
terminal	O
repeats	O
.	O

Transcripts	O
of	O
EBV	O
-encoded	O
genes	O
were	O
screened	O
by	O
reverse	O
transcription-	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
,	O
and	O
confirmed	O
by	O
Southern	O
blot	O
hybridization	O
.	O

The	O
expression	O
of	O
EBV	O
-related	O
antigens	O
was	O
examined	O
by	O
immunostaining	O
using	O
paraffin	B-Chemical
-embedded	O
tissue	O
sections	O
and	O
cell	O
pellets	O
of	O
EBV	O
-positive	O
cell	O
lines	O
.	O

Our	O
study	O
demonstrated	O
that	O
all	O
samples	O
from	O
the	O
patients	O
contained	O
EBV	B-Gene
nuclear	I-Gene
antigen	I-Gene
(	I-Gene
EBNA	I-Gene
)	I-Gene
-1	I-Gene
mRNA	I-Gene
which	O
was	O
transcribed	O
using	O
the	O
Q	O
promoter	O
,	O
whereas	O
both	O
the	O
Q	O
promoter	O
and	O
another	O
upstream	O
promoter	O
(	O
Cp	O
/	O
Wp	O
)	O
were	O
used	O
in	O
EBV	O
-positive	O
cell	O
lines	O
,	O
B95.8	O
,	O
Raji	O
and	O
Jiyoye	O
.	O

Latent	B-Gene
membrane	I-Gene
protein-1	I-Gene
(	I-Gene
LMP-1	I-Gene
)	I-Gene
mRNA	I-Gene
was	O
detected	O
in	O
seven	O
of	O
eight	O
patients	O
and	O
all	O
cell	O
lines	O
,	O
whereas	O
EBNA-2	B-Gene
transcripts	O
were	O
found	O
only	O
in	O
the	O
cell	O
lines	O
.	O

Immunostaining	O
showed	O
no	O
LMP-1	B-Gene
,	O
EBNA-2	B-Gene
or	O
ZEBRA	B-Gene
antigens	I-Gene
in	O
the	O
paraffin	B-Chemical
-embedded	O
tissue	O
sections	O
,	O
although	O
they	O
were	O
positive	O
in	O
the	O
cell	O
line	O
cells	O
.	O

Latent	O
BHRF1	B-Gene
transcripts	O
encoding	O
bcl-2	B-Gene
homologue	O
and	O
BCRF1	B-Gene
transcripts	O
encoding	O
viral	B-Gene
interleukin	I-Gene
(	I-Gene
vIL	I-Gene
)	I-Gene
-10	I-Gene
were	O
detected	O
in	O
one	O
and	O
two	O
of	O
eight	O
patients	O
,	O
respectively	O
.	O

A	O
patient	O
with	O
NK-cell	B-Disease
lymphoma	I-Disease
expressing	O
both	O
transcripts	O
died	O
of	O
rapid	O
progression	O
of	O
the	O
illness	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
restricted	O
expression	O
of	O
the	O
latency	O
-associated	O
EBV	O
genes	O
and	O
the	O
production	O
of	O
vIL-10	B-Gene
and	O
bcl-2	B-Gene
homologue	O
may	O
favour	O
tumour	B-Disease
growth	O
,	O
evading	O
the	O
host	O
immune	O
surveillance	O
.	O

Copyright	O
2001	O
Cancer	B-Disease
Research	O
Campaign	O
.	O

Core	B-Gene
-binding	I-Gene
factor	I-Gene
beta	I-Gene
(	O
CBFbeta	B-Gene
)	O
,	O
but	O
not	O
CBFbeta-smooth	B-Gene
muscle	I-Gene
myosin	I-Gene
heavy	I-Gene
chain	I-Gene
,	O
rescues	O
definitive	O
hematopoiesis	O
in	O
CBFbeta	B-Gene
-deficient	O
embryonic	O
stem	O
cells	O
.	O

Core	B-Gene
-binding	I-Gene
factor	I-Gene
beta	I-Gene
(	O
CBFbeta	B-Gene
)	O
is	O
the	O
non-DNA	O
-binding	O
subunit	O
of	O
the	O
heterodimeric	O
CBFs	B-Gene
.	O

Genes	O
encoding	O
CBFbeta	B-Gene
(	O
CBFB	B-Gene
)	O
,	O
and	O
one	O
of	O
the	O
DNA	O
-binding	O
CBFalpha	B-Gene
subunits	I-Gene
,	O
Runx1	B-Gene
(	O
also	O
known	O
as	O
CBFalpha2	B-Gene
,	O
AML1	B-Gene
,	O
and	O
PEBP2alphaB	B-Gene
)	O
,	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
and	O
are	O
also	O
frequent	O
targets	O
of	O
chromosomal	O
translocations	O
in	O
acute	B-Disease
leukemias	I-Disease
in	O
humans	O
.	O

Homozygous	O
disruption	O
of	O
either	O
the	O
Runx1	B-Gene
or	O
Cbfb	B-Gene
gene	I-Gene
in	O
mice	O
results	O
in	O
embryonic	O
lethality	O
at	O
midgestation	O
due	O
to	O
hemorrhaging	O
in	O
the	O
central	O
nervous	O
system	O
,	O
and	O
severely	O
impairs	O
fetal	O
liver	O
hematopoiesis	O
.	O

Results	O
of	O
this	O
study	O
show	O
that	O
Cbfb	B-Gene
-deficient	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
can	O
differentiate	O
into	O
primitive	O
erythroid	O
colonies	O
in	O
vitro	O
,	O
but	O
are	O
impaired	O
in	O
their	O
ability	O
to	O
produce	O
definitive	O
erythroid	O
and	O
myeloid	O
colonies	O
,	O
mimicking	O
the	O
in	O
vivo	O
defect	O
.	O

Definitive	O
hematopoiesis	O
is	O
restored	O
by	O
ectopic	O
expression	O
of	O
full-length	O
Cbfb	B-Gene
transgenes	I-Gene
,	O
as	O
well	O
as	O
by	O
a	O
transgene	O
encoding	O
only	O
the	O
heterodimerization	O
domain	O
of	O
CBFbeta	B-Gene
.	O

In	O
contrast	O
,	O
the	O
CBFbeta	B-Gene
-	I-Gene
smooth	I-Gene
muscle	I-Gene
myosin	I-Gene
heavy	I-Gene
chain	I-Gene
(	I-Gene
SMMHC	I-Gene
)	I-Gene
fusion	I-Gene
protein	I-Gene
generated	O
by	O
the	O
inv	O
(	O
16	O
)	O
associated	O
with	O
acute	B-Disease
myeloid	I-Disease
leukemias	I-Disease
(	O
M4Eo	O
)	O
can	O
not	O
rescue	O
definitive	O
hematopoiesis	O
by	O
Cbfb	B-Gene
-deficient	O
ES	O
cells	O
.	O

Sequences	O
responsible	O
for	O
the	O
inability	O
of	O
CBFbeta	B-Gene
-SMMHC	I-Gene
to	O
rescue	O
definitive	O
hematopoiesis	O
reside	O
in	O
the	O
SMMHC	B-Gene
portion	O
of	O
the	O
fusion	O
protein	O
.	O

Results	O
also	O
show	O
that	O
the	O
CBFbeta-SMMHC	B-Gene
fusion	I-Gene
protein	I-Gene
transdominantly	O
inhibits	O
definitive	O
hematopoiesis	O
,	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
homozygous	O
loss	O
of	O
Runx1	B-Gene
or	O
Cbfb	B-Gene
.	O

CBFbeta-SMMHC	B-Gene
preferentially	O
inhibits	O
the	O
differentiation	O
of	O
myeloid	O
lineage	O
cells	O
,	O
while	O
increasing	O
the	O
number	O
of	O
blastlike	O
cells	O
in	O
culture	O
.	O

Analysis	O
of	O
BCL-6	B-Gene
mutations	O
in	O
classic	O
Hodgkin	B-Disease
disease	I-Disease
of	O
the	O
B-	O
and	O
T-cell	O
type	O
.	O

BCL-6	B-Gene
is	O
essential	O
for	O
germinal	O
center	O
formation	O
and	O
thus	O
for	O
affinity	O
maturation	O
of	O
immunoglobulin	B-Gene
(	I-Gene
Ig	I-Gene
)	I-Gene
genes	I-Gene
by	O
somatic	O
mutations	O
.	O

The	O
5'-noncoding	O
region	O
of	O
the	O
BCL-6	B-Gene
gene	I-Gene
is	O
even	O
a	O
target	O
for	O
the	O
mutation	O
machinery	O
.	O

Translocations	O
of	O
the	O
BCL-6	B-Gene
gene	I-Gene
to	O
heterologous	O
promoters	O
and	O
mutations	O
of	O
its	O
5'-noncoding	O
regulatory	O
region	O
were	O
reported	O
to	O
be	O
potential	O
mechanisms	O
for	O
deregulating	O
BCL-6	B-Gene
expression	O
and	O
for	O
playing	O
a	O
role	O
in	O
the	O
genesis	O
of	O
non-Hodgkin	B-Disease
lymphoma	I-Disease
.	O

In	O
line	O
with	O
this	O
hypothesis	O
is	O
the	O
observation	O
that	O
B-cell	B-Disease
lymphoma	I-Disease
with	O
somatic	O
mutations	O
,	O
such	O
as	O
diffuse	B-Disease
large	I-Disease
B-cell	I-Disease
lymphoma	I-Disease
and	O
follicular	B-Disease
lymphoma	I-Disease
,	O
also	O
carry	O
BCL-6	B-Gene
mutations	O
,	O
some	O
of	O
which	O
are	O
recurrently	O
detectable	O
.	O

Classic	O
Hodgkin	B-Disease
disease	I-Disease
(	O
cHD	B-Disease
)	O
is	O
also	O
derived	O
from	O
B	O
cells	O
with	O
high	O
loads	O
of	O
somatic	O
mutations	O
and	O
thus	O
a	O
further	O
candidate	O
for	O
BCL-6	B-Gene
mutations	O
.	O

To	O
determine	O
the	O
presence	O
and	O
potential	O
role	O
of	O
BCL-6	B-Gene
mutations	O
in	O
cHD	B-Disease
,	O
the	O
5'-noncoding	O
BCL-6	B-Gene
proportion	O
of	O
single	O
Hodgkin	O
and	O
Reed-Sternberg	O
(	O
HRS	O
)	O
cells	O
from	O
6	O
cases	O
of	O
cHD	B-Disease
and	O
6	O
cases	O
of	O
HD	B-Disease
-derived	O
cell	O
lines	O
was	O
analyzed	O
.	O

All	O
B-cell	O
-derived	O
HD	B-Disease
cases	O
and	O
cell	O
lines	O
harbored	O
BCL-6	B-Gene
mutations	O
.	O

In	O
contrast	O
,	O
both	O
T-cell	O
-derived	O
HD	B-Disease
cases	O
and	O
cell	O
lines	O
were	O
devoid	O
of	O
BCL-6	B-Gene
mutations	O
.	O

With	O
only	O
one	O
exception	O
,	O
there	O
were	O
no	O
lymphoma-specific	B-Disease
recurrent	O
BCL-6	B-Gene
mutations	O
detected	O
,	O
and	O
BCL-6	B-Gene
protein	I-Gene
was	O
absent	O
from	O
the	O
HRS	O
cells	O
of	O
most	O
cases	O
.	O

In	O
conclusion	O
,	O
(	O
1	O
)	O
somatic	O
BCL-6	B-Gene
mutations	O
are	O
restricted	O
to	O
cHD	B-Disease
cases	O
of	O
B-cell	O
origin	O
,	O
and	O
(	O
2	O
)	O
the	O
BCL-6	B-Gene
mutations	O
represent	O
mostly	O
irrelevant	O
somatic	O
base	O
substitutions	O
without	O
consequences	O
for	O
BCL-6	B-Gene
protein	I-Gene
expression	O
and	O
the	O
pathogenesis	O
of	O
cHD	B-Disease
.	O

Notch1	B-Gene
regulates	O
maturation	O
of	O
CD4+	B-Gene
and	O
CD8+	B-Gene
thymocytes	O
by	O
modulating	O
TCR	B-Gene
signal	O
strength	O
.	O

Notch	B-Gene
signaling	O
regulates	O
cell	O
fate	O
decisions	O
in	O
multiple	O
lineages	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
retroviral	O
expression	O
of	O
activated	O
Notch1	B-Gene
in	O
mouse	O
thymocytes	O
abrogates	O
differentiation	O
of	O
immature	O
CD4	B-Gene
+	I-Gene
CD8+	I-Gene
thymocytes	O
into	O
both	O
CD4	B-Gene
and	O
CD8	B-Gene
mature	O
single	O
-positive	O
T	O
cells	O
.	O

The	O
ability	O
of	O
Notch1	B-Gene
to	O
inhibit	O
T	O
cell	O
development	O
was	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
both	O
normal	O
and	O
TCR	B-Gene
transgenic	O
thymocytes	O
.	O

Notch1	B-Gene
-mediated	O
developmental	O
arrest	O
was	O
dose	O
dependent	O
and	O
was	O
associated	O
with	O
impaired	O
thymocyte	O
responses	O
to	O
TCR	B-Gene
stimulation	O
.	O

Notch1	B-Gene
also	O
inhibited	O
TCR	B-Gene
-mediated	O
signaling	O
in	O
Jurkat	O
T	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
constitutively	O
active	O
Notch1	B-Gene
abrogates	O
CD4+	B-Gene
and	O
CD8+	B-Gene
maturation	O
by	O
interfering	O
with	O
TCR	B-Gene
signal	O
strength	O
and	O
provide	O
an	O
explanation	O
for	O
the	O
physiological	O
regulation	O
of	O
Notch	B-Gene
expression	O
during	O
thymocyte	O
development	O
.	O

Suppression	O
of	O
lung	B-Disease
inflammation	I-Disease
in	O
rats	O
by	O
prevention	O
of	O
NF-kappaB	B-Gene
activation	O
in	O
the	O
liver	O
.	O

Activation	O
of	O
NF-kappaB	B-Gene
and	O
production	O
of	O
NF-kappaB	B-Gene
-dependent	I-Gene
chemokines	I-Gene
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neutrophilic	O
lung	B-Disease
inflammation	I-Disease
.	O

Calpain-1	B-Gene
inhibitor	I-Gene
(	O
CI-1	B-Gene
)	O
blocks	O
activation	O
of	O
NF-kappaB	B-Gene
by	O
preventing	O
proteolysis	O
of	O
the	O
inhibitory	B-Gene
protein	I-Gene
IkappaB-alpha	I-Gene
by	O
the	O
ubiquitin	B-Gene
/	O
proteasome	O
pathway	O
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	O
proteasome	O
function	O
with	O
CI-1	B-Gene
would	O
block	O
NF-kappaB	B-Gene
activation	O
in	O
vivo	O
after	O
intraperitoneal	O
(	O
i.p.	O
)	O
treatment	O
with	O
bacterial	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
,	O
and	O
that	O
NF-kappaB	B-Gene
inhibition	O
would	O
be	O
associated	O
with	O
suppression	O
of	O
chemokine	O
gene	O
expression	O
and	O
attenuation	O
of	O
neutrophilic	O
alveolitis	B-Disease
.	O

We	O
treated	O
rats	O
with	O
a	O
single	O
i.p.	O
injection	O
of	O
CI-1	B-Gene
(	O
10	O
mg	O
/	O
kg	O
)	O
two	O
hours	O
prior	O
to	O
i.p	O
.	O

LPS	B-Chemical
(	O
7	O
mg	O
/	O
kg	O
)	O
.	O

Treatment	O
with	O
Cl-1	B-Gene
prevented	O
degradation	O
of	O
IkappaB-alpha	B-Gene
and	O
activation	O
of	O
NF-kappaB	B-Gene
in	O
the	O
liver	O
in	O
response	O
to	O
LPS	B-Chemical
;	O
however	O
,	O
Cl-1	B-Gene
treatment	O
had	O
no	O
detected	O
effect	O
on	O
NF-kappaB	B-Gene
activation	O
in	O
lung	O
tissue	O
.	O

CI-1	B-Gene
treatment	O
prior	O
to	O
LPS	B-Chemical
resulted	O
in	O
40	O
%	O
lower	O
MIP-2	B-Gene
concentration	O
in	O
lung	O
lavage	O
fluid	O
compared	O
to	O
rats	O
treated	O
with	O
vehicle	O
prior	O
to	O
LPS	B-Chemical
(	O
502	O
+	O
/	O
-	O
112	O
pg	O
/	O
ml	O
vs.	O
859	O
+	O
/	O
-144	O
pg	O
/	O
ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
CI-1	B-Gene
treatment	O
substantially	O
inhibited	O
LPS	B-Chemical
-induced	O
neutrophilic	O
alveolitis	B-Disease
(	O
2.7+	O
/	O
-	O
1.2	O
x	O
10	O
(	O
5	O
)	O
vs.	O
43.7	O
+	O
/	O
-	O
12.2	O
x	O
10	O
(	O
5	O
)	O
lung	O
lavage	O
neutrophils	O
,	O
P	O
<	O
0.01	O
)	O
.	O

These	O
data	O
indicate	O
that	O
NF-kappaB	B-Gene
inhibition	O
in	O
the	O
liver	O
can	O
alter	O
lung	B-Disease
inflammation	I-Disease
induced	O
by	O
systemic	O
LPS	B-Chemical
treatment	O
and	O
suggest	O
that	O
a	O
liver-lung	O
interaction	O
contributes	O
to	O
the	O
inflammatory	O
response	O
of	O
the	O
lung	O
.	O

In	O
vivo	O
detection	O
of	O
intracellular	O
signaling	O
pathways	O
in	O
developing	O
thymocytes	O
.	O

Information	O
regarding	O
the	O
intracellular	O
signaling	O
processes	O
that	O
occur	O
during	O
the	O
development	O
of	O
T	O
cells	O
has	O
largely	O
been	O
obtained	O
with	O
the	O
use	O
of	O
transgenic	O
mouse	O
models	O
,	O
which	O
although	O
providing	O
invaluable	O
information	O
are	O
time	O
consuming	O
and	O
costly	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
developed	O
a	O
novel	O
system	O
that	O
facilitates	O
the	O
in	O
vivo	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
during	O
T-lymphocyte	O
development	O
.	O

This	O
approach	O
uses	O
reporter-plasmids	O
for	O
the	O
detection	O
of	O
intracellular	O
signals	O
mediated	O
by	O
the	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
or	O
cyclic	B-Gene
AMP	I-Gene
-dependent	I-Gene
protein	I-Gene
kinase	I-Gene
.	O

Reporter-plasmids	O
are	O
transfected	O
into	O
thymocytes	O
in	O
fetal	O
thymic	O
organ	O
culture	O
by	O
accelerated	O
DNA	O
/	O
particle	O
bombardment	O
(	O
gene	O
gun	O
)	O
,	O
and	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
is	O
determined	O
in	O
the	O
form	O
of	O
a	O
standard	O
luciferase	O
assay	O
.	O

Importantly	O
,	O
this	O
powerful	O
technique	O
preserves	O
the	O
structural	O
integrity	O
of	O
the	O
thymus	O
,	O
and	O
will	O
provide	O
an	O
invaluable	O
tool	O
to	O
study	O
how	O
thymocytes	O
respond	O
to	O
normal	O
environmental	O
stimuli	O
encountered	O
during	O
differentiation	O
within	O
the	O
thymic	O
milieu	O
.	O

Thus	O
,	O
this	O
method	O
allows	O
for	O
the	O
monitoring	O
of	O
signals	O
that	O
occur	O
in	O
a	O
biological	O
time	O
frame	O
,	O
such	O
as	O
during	O
differentiation	O
,	O
and	O
within	O
the	O
natural	O
environment	O
of	O
differentiating	O
cells	O
.	O

The	O
nuclear	B-Gene
receptor	I-Gene
PPAR	I-Gene
gamma	I-Gene
is	O
expressed	O
by	O
mouse	O
T	O
lymphocytes	O
and	O
PPAR	B-Gene
gamma	I-Gene
agonists	O
induce	O
apoptosis	O
.	O

Peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor	I-Gene
(	I-Gene
PPAR	I-Gene
)	I-Gene
-gamma	I-Gene
is	O
a	O
nuclear	O
hormone	O
receptor	O
that	O
serves	O
as	O
a	O
trans	O
factor	O
to	O
regulate	O
lipid	B-Chemical
metabolism	O
.	O

Intense	O
interest	O
is	O
focused	O
on	O
PPAR-gamma	B-Gene
and	O
its	O
ligands	O
owing	O
to	O
its	O
putative	O
role	O
in	O
adipocyte	O
differentiation	O
.	O

Little	O
is	O
known	O
,	O
however	O
,	O
about	O
the	O
functions	O
of	O
PPAR-gamma	B-Gene
in	O
the	O
immune	O
system	O
,	O
especially	O
in	O
T	O
lymphocytes	O
.	O

We	O
demonstrate	O
that	O
both	O
naive	O
and	O
activated	O
ovalbumin-specific	B-Gene
T	O
cells	O
from	O
DO11.10-transgenic	O
mice	O
express	O
PPAR-gamma	B-Gene
mRNA	I-Gene
and	O
protein	O
.	O

In	O
order	O
to	O
determine	O
the	O
function	O
of	O
PPAR-gamma	B-Gene
,	O
T	O
cells	O
were	O
stimulated	O
with	O
phorbol	B-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
and	O
ionomycin	B-Chemical
or	O
antigen	O
and	O
antigen	O
-presenting	O
cells	O
.	O

Simultaneous	O
exposure	O
to	O
PPAR-gamma	B-Gene
ligands	O
(	O
e.g.	O
15-deoxy-Delta	B-Chemical
(	I-Chemical
12	I-Chemical
,	I-Chemical
14	I-Chemical
)	I-Chemical
-prostaglandin	I-Chemical
J	I-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
,	O
troglitazone	B-Chemical
)	O
showed	O
drastic	O
inhibition	O
of	O
proliferation	O
and	O
significant	O
decreases	O
in	O
cell	O
viability	O
.	O

The	O
decrease	O
in	O
cell	O
viability	O
was	O
due	O
to	O
apoptosis	O
of	O
the	O
T	O
lymphocytes	O
,	O
and	O
occurred	O
only	O
when	O
cells	O
were	O
treated	O
with	O
PPAR-gamma	B-Gene
,	O
and	O
not	O
PPAR-alpha	B-Gene
agonists	I-Gene
,	O
revealing	O
specificity	O
of	O
this	O
response	O
for	O
PPAR-gamma	B-Gene
.	O

These	O
observations	O
suggest	O
that	O
PPAR-gamma	B-Gene
agonists	I-Gene
play	O
an	O
important	O
role	O
in	O
regulating	O
T	O
cell	O
-mediated	O
immune	O
responses	O
by	O
inducing	O
apoptosis	O
.	O

T	O
cell	O
death	O
via	O
PPAR-gamma	B-Gene
ligation	O
may	O
act	O
as	O
a	O
potent	O
anti-inflammatory	O
signal	O
in	O
the	O
immune	O
system	O
,	O
and	O
ligands	O
could	O
possibly	O
be	O
used	O
to	O
control	O
disorders	O
in	O
which	O
excessive	O
inflammation	O
occurs	O
.	O

T-cell	B-Gene
factor-1	I-Gene
expression	O
during	O
human	O
natural	O
killer	O
cell	O
development	O
and	O
in	O
circulating	O
CD56	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
bright	I-Gene
natural	O
killer	O
cells	O
.	O

Transcription	O
factors	O
are	O
essential	O
to	O
govern	O
differentiation	O
along	O
the	O
lymphoid	O
lineage	O
from	O
uncommitted	O
hematopoietic	O
stem	O
cells	O
.	O

Although	O
many	O
of	O
these	O
transcription	O
factors	O
have	O
putative	O
roles	O
based	O
on	O
murine	O
knockout	O
experiments	O
,	O
their	O
function	O
in	O
human	O
lymphoid	O
development	O
is	O
less	O
known	O
and	O
was	O
studied	O
further	O
.	O

Transcription	O
factor	O
expression	O
in	O
fresh	O
and	O
cultured	O
adult	O
human	O
bone	O
marrow	O
and	O
umbilical	O
cord	O
blood	O
progenitors	O
was	O
evaluated	O
.	O

We	O
found	O
that	O
fresh	O
CD34	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
Lin	O
(	O
-	O
)	O
cells	O
that	O
are	O
human	B-Gene
leukocyte	I-Gene
antigen	I-Gene
(	I-Gene
HLA	I-Gene
)	I-Gene
-DR	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
or	O
CD38	B-Gene
(	I-Gene
-	I-Gene
)	I-Gene
constitutively	O
express	O
GATA-3	B-Gene
but	O
not	O
T-cell	B-Gene
factor-1	I-Gene
(	O
TCF-1	B-Gene
)	O
or	O
Id-3	B-Gene
.	O

Culture	O
with	O
the	O
murine	O
fetal	O
liver	O
cell	O
line	O
AFT024	O
and	O
defined	O
cytokines	O
was	O
capable	O
of	O
inducing	O
TCF-1	B-Gene
mRNA	I-Gene
.	O

However	O
,	O
no	O
T-cell	B-Gene
receptor	I-Gene
gene	I-Gene
rearrangement	O
was	O
identified	O
in	O
cultured	O
progeny	O
.	O

Id-3	B-Gene
,	O
a	O
basic	O
helix	O
loop	O
helix	O
factor	O
with	O
dominant	O
negative	O
function	O
for	O
T-cell	O
differentiation	O
transcription	O
factors	O
,	O
also	O
was	O
upregulated	O
and	O
may	O
explain	O
unsuccessful	O
T-cell	O
maturation	O
.	O

To	O
better	O
understand	O
the	O
developmental	O
link	O
between	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
derived	O
from	O
progenitors	O
,	O
we	O
studied	O
NK	O
cell	O
subsets	O
circulating	O
in	O
blood	O
.	O

CD56	B-Gene
(	I-Gene
+bright	I-Gene
)	I-Gene
,	O
but	O
not	O
CD56	B-Gene
(	I-Gene
+dim	I-Gene
)	I-Gene
,	O
NK	O
cells	O
constitutively	O
express	O
TCF-1	B-Gene
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
analysis	O
.	O

The	O
TCF-1	B-Gene
isoform	I-Gene
found	O
in	O
CD56	B-Gene
(	I-Gene
+bright	I-Gene
)	I-Gene
cells	O
,	O
which	O
express	O
lectin	B-Gene
but	O
not	O
immunoglobulin	B-Gene
class	I-Gene
I	I-Gene
recognizing	O
inhibitory	O
receptors	O
,	O
was	O
identical	O
to	O
that	O
induced	O
in	O
NK	O
cell	O
differentiation	O
culture	O
and	O
was	O
distinctly	O
different	O
from	O
isoforms	O
in	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
TCF-1	B-Gene
does	O
not	O
target	O
human	B-Gene
killer	I-Gene
immunoglobulin	I-Gene
receptor	I-Gene
genes	I-Gene
,	O
TCF-1	B-Gene
is	O
uniquely	O
expressed	O
in	O
circulating	O
CD56	B-Gene
(	I-Gene
+bright	I-Gene
)	I-Gene
NK	O
cells	O
,	O
and	O
specific	O
TCF-1	B-Gene
isoforms	I-Gene
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
NK	O
differentiation	O
from	O
a	O
common	O
NK	O
/	O
T-cell	O
progenitor	O
.	O

Benzene	B-Chemical
-extracted	O
components	O
are	O
important	O
for	O
the	O
major	O
activity	O
of	O
diesel	O
exhaust	O
particles	O
:	O
effect	O
on	O
interleukin-8	B-Gene
gene	I-Gene
expression	O
in	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Epidemiologic	O
and	O
experimental	O
studies	O
suggest	O
that	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
may	O
be	O
related	O
to	O
increasing	O
respiratory	O
mortality	O
and	O
morbidity	O
.	O

We	O
have	O
shown	O
that	O
DEPs	O
augmented	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
by	O
human	O
airway	O
epithelial	O
cells	O
in	O
vitro	O
.	O

To	O
better	O
understand	O
the	O
mechanisms	O
of	O
their	O
proinflammatory	O
activities	O
,	O
we	O
studied	O
the	O
effects	O
of	O
several	O
components	O
extracted	O
from	O
DEPs	O
on	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-8	I-Gene
expression	O
in	O
human	O
bronchial	O
epithelial	O
cell	O
line	O
BEAS-2B	O
and	O
normal	O
human	O
airway	O
epithelial	O
cells	O
obtained	O
from	O
very	O
peripheral	O
airways	O
by	O
an	O
ultrathin	O
bronchoscope	O
.	O

We	O
used	O
several	O
agents	O
active	O
on	O
signal	O
transduction	O
pathways	O
in	O
cytokine	O
expression	O
,	O
such	O
as	O
the	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
inhibitor	O
staurosporin	B-Chemical
,	O
antioxidant	O
agents	O
including	O
N-acetyl	B-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
and	O
pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
,	O
and	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
MAPK	B-Gene
)	O
inhibitor	O
SB203580	B-Chemical
.	O

Benzene	B-Chemical
-extracted	O
components	O
showed	O
effects	O
mimicking	O
DEPs	O
on	O
IL-8	B-Gene
gene	I-Gene
expression	O
,	O
release	O
of	O
several	O
cytokines	O
(	O
IL-8	B-Gene
;	O
granulocyte	B-Gene
macrophage	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
;	O
and	O
regulated	B-Gene
on	I-Gene
activation	I-Gene
,	I-Gene
normal	I-Gene
T	I-Gene
cells	I-Gene
expressed	I-Gene
and	I-Gene
secreted	I-Gene
)	O
and	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappa	I-Gene
B	I-Gene
activation	O
.	O

We	O
also	O
found	O
that	O
NAC	B-Chemical
,	O
PDTC	B-Chemical
,	O
and	O
SB203580	B-Chemical
suppressed	O
the	O
activities	O
of	O
DEPs	O
and	O
their	O
benzene	B-Chemical
extracts	O
,	O
suggesting	O
the	O
roles	O
of	O
oxidants	O
-mediated	O
NF-kappa	B-Gene
B	I-Gene
activation	O
and	O
p38MAPK	B-Gene
pathways	O
.	O

Finally	O
,	O
benzo	B-Chemical
[	I-Chemical
a	I-Chemical
]	I-Chemical
pyrene	I-Chemical
,	O
one	O
of	O
the	O
important	O
compounds	O
included	O
in	O
the	O
benzene	B-Chemical
component	O
,	O
replicated	O
the	O
activities	O
shown	O
by	O
DEPs	O
.	O

Regulation	O
of	O
cytokine	O
production	O
in	O
T-cell	O
responses	O
to	O
inhalant	O
allergen	O
:	O
GATA-3	B-Gene
expression	O
distinguishes	O
between	O
Th1-	O
and	O
Th2	O
-polarized	O
immunity	O
.	O

BACKGROUND	O
:	O
The	O
precise	O
nature	O
of	O
allergen-specific	O
cytokine	O
responses	O
in	O
atopics	O
versus	O
non-atopics	O
,	O
in	O
particular	O
the	O
'Th1	O
polarity	O
'of	O
responses	O
in	O
non-atopics	O
,	O
remains	O
controversial	O
.	O

This	O
is	O
due	O
in	O
part	O
to	O
the	O
relative	O
insensitivity	O
of	O
cytokine	O
detection	O
systems	O
,	O
and	O
associated	O
variations	O
in	O
kinetics	O
of	O
cytokine	O
production	O
and	O
catabolism	O
in	O
in	O
vitro	O
culture	O
systems	O
.	O

As	O
an	O
alternative	O
to	O
cytokine	O
measurement	O
,	O
this	O
study	O
focuses	O
on	O
expression	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
GATA-3	I-Gene
for	O
analysis	O
of	O
allergen-specific	O
Th	O
cell	O
responses	O
.	O

METHODS	O
:	O
Cord	O
blood	O
mononuclear	O
cells	O
were	O
Th1-	O
or	O
Th2	O
-polarized	O
by	O
culture	O
in	O
IL-12-	B-Gene
or	O
IL-4	B-Gene
-employing	O
established	O
methods	O
;	O
PBMC	O
from	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
-sensitive	O
atopics	O
and	O
controls	O
were	O
stimulated	O
overnight	O
with	O
HDM	O
;	O
cytokine	O
production	O
was	O
measured	O
by	O
ELISA	O
and	O
GATA-3	B-Gene
mRNA	I-Gene
expression	O
by	O
PCR	O
.	O

RESULTS	O
:	O
Cytokine	O
-driven	O
Th2	O
polarization	O
of	O
naive	O
T	O
cells	O
is	O
associated	O
with	O
marked	O
upregulation	O
of	O
GATA-3	B-Gene
expression	O
,	O
whereas	O
a	O
reciprocal	O
expression	O
pattern	O
accompanies	O
differentiation	O
towards	O
the	O
Th1	O
cytokine	O
phenotype	O
.	O

In	O
T	O
cells	O
from	O
HDM	O
skin	O
prick	O
test	O
-positive	O
(	O
HDM-SPT+	O
/	O
HDM-IgE+	B-Gene
)	O
volunteers	O
,	O
overnight	O
stimulation	O
results	O
in	O
marked	O
upregulation	O
of	O
GATA-3	B-Gene
expression	O
,	O
compared	O
to	O
an	O
equally	O
marked	O
downregulation	O
of	O
expression	O
in	O
T	O
cells	O
from	O
SPT-	O
/	O
IgE-	B-Gene
subjects	O
.	O

In	O
subjects	O
who	O
are	O
HDM-SPT+	O
but	O
IgE-	B-Gene
,	O
GATA-3	B-Gene
expression	O
levels	O
remained	O
relatively	O
stable	O
during	O
culture	O
with	O
HDM	O
.	O

CONCLUSIONS	O
:	O
Upregulation	O
of	O
GATA-3	B-Gene
expression	O
in	O
PBMC	O
is	O
a	O
hallmark	O
of	O
the	O
early	O
phase	O
of	O
Th2	O
recall	O
responses	O
to	O
specific	O
allergen	O
in	O
atopics	O
.	O

The	O
reciprocal	O
expression	O
pattern	O
observed	O
in	O
HDM-specific	O
recall	O
responses	O
of	O
non-atopics	O
provides	O
independent	O
confirmation	O
of	O
the	O
presence	O
of	O
underlying	O
Th1	O
-like	O
immunity	O
in	O
these	O
subjects	O
.	O

The	O
parallel	O
findings	O
in	O
neonatal	O
T	O
cells	O
suggest	O
that	O
the	O
same	O
approach	O
may	O
be	O
utilized	O
for	O
monitoring	O
the	O
progress	O
of	O
allergen-specific	O
Th1	O
/	O
Th2	O
memory	O
development	O
during	O
early	O
childhood	O
,	O
and	O
hence	O
in	O
assessment	O
of	O
risk	O
for	O
future	O
allergic	O
disease	O
.	O

Copyright	O
2001	O
S	O
.	O

Karger	O
AG	O
,	O
Basel	O

Tumor	B-Disease
cells	O
regulate	O
the	O
lytic	O
activity	O
of	O
tumor-specific	B-Disease
cytotoxic	O
t	O
lymphocytes	O
by	O
modulating	O
the	O
inhibitory	O
natural	O
killer	O
receptor	O
function	O
.	O

Tumor	B-Disease
-infiltrating	O
p58+	B-Gene
T	O
cells	O
from	O
a	O
renal	B-Disease
tumor	I-Disease
were	O
specifically	O
expanded	O
in	O
response	O
to	O
tumor	B-Disease
cell	O
stimulation	O
and	O
cloned	O
.	O

These	O
p58+	B-Gene
T	O
cells	O
were	O
found	O
to	O
express	O
a	O
memory	O
phenotype	O
and	O
corresponded	O
to	O
clonal	O
TCRBV3	O
T-cell	O
expansion	O
.	O

Functionally	O
,	O
p58	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
CTLs	O
displayed	O
a	O
low	O
lytic	O
activity	O
for	O
HLA-A2	B-Gene
tumor	B-Disease
and	O
normal	O
cells	O
.	O

However	O
,	O
this	O
lytic	O
activity	O
was	O
significantly	O
increased	O
after	O
blockade	O
of	O
p58	B-Gene
with	O
specific	O
monoclonal	O
antibodies	O
.	O

Interestingly	O
,	O
we	O
demonstrated	O
that	O
stimulation	O
by	O
tumor	B-Disease
cells	O
was	O
required	O
to	O
trigger	O
the	O
inhibitory	O
effect	O
of	O
p58	B-Gene
on	O
the	O
lytic	O
activity	O
of	O
antigen-specific	O
CTLs	O
and	O
that	O
stimulation	O
of	O
the	O
inhibitory	O
function	O
of	O
p58	B-Gene
by	O
tumor	B-Disease
cells	O
correlated	O
with	O
an	O
inhibition	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
activation	O
in	O
p58+	B-Gene
tumor-specific	B-Disease
CTLS	O
.	O

The	O
heat	O
shock	O
response	O
reduces	O
myelin	B-Gene
oligodendrocyte	I-Gene
glycoprotein	I-Gene
-induced	O
experimental	B-Disease
autoimmune	I-Disease
encephalomyelitis	I-Disease
in	O
mice	O
.	O

The	O
stress	O
response	O
(	O
SR	O
)	O
can	O
block	O
inflammatory	O
gene	O
expression	O
by	O
preventing	O
activation	O
of	O
transcription	B-Gene
factor	I-Gene
nuclear	I-Gene
factor-kappa	I-Gene
B	I-Gene
(	O
NF-kappaB	B-Gene
)	O
.	O

As	O
inflammatory	O
gene	O
expression	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
demyelinating	B-Disease
diseases	I-Disease
,	O
we	O
tested	O
the	O
effects	O
of	O
the	O
SR	O
on	O
the	O
progression	O
of	O
the	O
demyelinating	B-Disease
disease	I-Disease
experimental	B-Disease
autoimmune	I-Disease
encephalomyelitis	I-Disease
(	O
EAE	B-Disease
)	O
.	O

EAE	B-Disease
was	O
actively	O
induced	O
in	O
C57BL	O
/	O
6	O
mice	O
using	O
an	O
encephalitogenic	O
myelin	B-Gene
oligodendrocyte	I-Gene
glycoprotein	I-Gene
(	O
MOG	B-Gene
(	O
35-55	O
)	O
)	O
peptide	O
.	O

Whole	O
body	O
hyperthermia	O
was	O
used	O
to	O
induce	O
a	O
heat	O
shock	O
response	O
(	O
HSR	O
)	O
in	O
immunized	O
mice	O
2	O
days	O
after	O
the	O
booster	O
MOG	B-Gene
(	O
35-55	O
)	O
peptide	O
injection	O
.	O

The	O
HSR	O
reduced	O
the	O
incidence	O
of	O
EAE	B-Disease
by	O
70	O
%	O
,	O
delayed	O
disease	O
onset	O
by	O
6	O
days	O
,	O
and	O
attenuated	O
disease	O
severity	O
.	O

The	O
HSR	O
attenuated	O
leukocyte	O
infiltration	O
into	O
CNS	O
assessed	O
by	O
quantitation	O
of	O
perivascular	O
infiltrates	O
,	O
and	O
by	O
reduced	O
staining	O
for	O
CD4	B-Gene
and	O
CD25	B-Gene
immunopositive	O
T-cells	O
.	O

T-cell	O
activation	O
,	O
assessed	O
by	O
the	O
production	O
of	O
interferon	B-Gene
gamma	I-Gene
(	O
IFNgamma	B-Gene
)	O
in	O
response	O
to	O
MOG	B-Gene
(	O
35-55	O
)	O
,	O
was	O
also	O
decreased	O
by	O
the	O
HSR	O
.	O

The	O
HSR	O
reduced	O
inflammatory	O
gene	O
expression	O
in	O
the	O
brain	O
that	O
normally	O
occurs	O
during	O
EAE	B-Disease
,	O
including	O
the	O
early	O
increase	O
in	O
RANTES	O
(	O
regulated	O
on	O
activation	O
of	O
normal	O
T-cell	O
expressed	O
and	O
secreted	O
)	O
expression	O
,	O
and	O
the	O
later	O
expression	O
of	O
the	O
inducible	O
form	O
of	O
nitric	B-Gene
oxide	I-Gene
synthase	I-Gene
.	O

The	O
early	O
activation	O
of	O
transcription	B-Gene
factor	I-Gene
NF-kappaB	I-Gene
was	O
also	O
blocked	O
by	O
the	O
HSR	O
.	O

The	O
finding	O
that	O
the	O
SR	O
reduces	O
inflammation	O
in	O
the	O
brain	O
and	O
the	O
clinical	O
severity	O
of	O
EAE	B-Disease
opens	O
a	O
novel	O
therapeutic	O
approach	O
for	O
prevention	O
of	O
autoimmune	B-Disease
diseases	I-Disease
.	O

Differential	O
requirement	O
for	O
the	O
transcription	B-Gene
factor	I-Gene
PU.1	I-Gene
in	O
the	O
generation	O
of	O
natural	O
killer	O
cells	O
versus	O
B	O
and	O
T	O
cells	O
.	O

PU.1	B-Gene
is	O
a	O
member	O
of	O
the	O
Ets	B-Gene
family	I-Gene
of	O
transcription	O
factors	O
required	O
for	O
the	O
development	O
of	O
various	O
lymphoid	O
and	O
myeloid	O
cell	O
lineages	O
,	O
but	O
its	O
role	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
development	O
is	O
not	O
known	O
.	O

The	O
study	O
shows	O
that	O
PU.1	B-Gene
is	O
expressed	O
in	O
NK	O
cells	O
and	O
that	O
,	O
on	O
cell	O
transfer	O
into	O
alymphoid	O
Rag2	B-Gene
/	O
gammac	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
hematopoietic	O
progenitors	O
of	O
PU.1	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
fetal	O
liver	O
cells	O
could	O
generate	O
functional	O
NK	O
cells	O
but	O
not	O
B	O
or	O
T	O
cells	O
.	O

Nevertheless	O
,	O
the	O
numbers	O
of	O
bone	O
marrow	O
NK	O
cell	O
precursors	O
and	O
splenic	O
mature	O
NK	O
cells	O
were	O
reduced	O
compared	O
to	O
controls	O
.	O

Moreover	O
,	O
PU.1	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
NK	O
cells	O
displayed	O
reduced	O
expression	O
of	O
the	O
receptors	O
for	O
stem	B-Gene
cell	I-Gene
factor	I-Gene
and	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-7	I-Gene
,	O
suggesting	O
a	O
nonredundant	O
role	O
for	O
PU.1	B-Gene
in	O
regulating	O
the	O
expression	O
of	O
these	O
cytokine	O
receptor	O
genes	O
during	O
NK	O
cell	O
development	O
.	O

PU.1	B-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
NK	O
cells	O
also	O
showed	O
defective	O
expression	O
of	O
inhibitory	O
and	O
activating	O
members	O
of	O
the	O
Ly49	B-Gene
family	I-Gene
and	O
failed	O
to	O
proliferate	O
in	O
response	O
to	O
IL-2	B-Gene
and	O
IL-12	B-Gene
.	O

Thus	O
,	O
despite	O
the	O
less	O
stringent	O
requirement	O
for	O
PU.1	B-Gene
in	O
NK	O
cell	O
development	O
compared	O
to	O
B	O
and	O
T	O
cells	O
,	O
PU.1	B-Gene
regulates	O
NK	O
cell	O
differentiation	O
and	O
homeostasis	O
.	O

The	O
involvement	O
of	O
TNF-alpha	B-Gene
-related	I-Gene
apoptosis	I-Gene
-inducing	I-Gene
ligand	I-Gene
in	O
the	O
enhanced	O
cytotoxicity	O
of	O
IFN-beta	B-Gene
-stimulated	O
human	O
dendritic	O
cells	O
to	O
tumor	B-Disease
cells	O
.	O

TNF-alpha	B-Gene
-related	I-Gene
apoptosis	I-Gene
-inducing	I-Gene
ligand	I-Gene
(	O
TRAIL	B-Gene
)	O
is	O
characterized	O
by	O
its	O
preferential	O
induction	O
of	O
apoptosis	O
of	O
tumor	B-Disease
cells	O
but	O
not	O
normal	O
cells	O
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
,	O
besides	O
their	O
role	O
as	O
APCs	O
,	O
now	O
have	O
been	O
demonstrated	O
to	O
exert	O
cytotoxicity	O
or	O
cytostasis	O
on	O
some	O
tumor	B-Disease
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
both	O
human	B-Gene
CD34	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
stem	O
cell	O
-derived	O
DCs	O
(	O
CD34DCs	B-Gene
)	O
and	O
human	B-Gene
CD14	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
monocyte	O
-derived	O
DCs	O
(	O
MoDCs	O
)	O
express	O
TRAIL	B-Gene
and	O
exhibit	O
cytotoxicity	O
to	O
some	O
types	O
of	O
tumor	B-Disease
cells	O
partially	O
through	O
TRAIL	B-Gene
.	O

Moderate	O
expression	O
of	O
TRAIL	B-Gene
appeared	O
on	O
CD34DCs	B-Gene
from	O
the	O
8th	O
day	O
of	O
culture	O
and	O
was	O
also	O
seen	O
on	O
freshly	O
isolated	O
monocytes	O
.	O

The	O
level	O
of	O
TRAIL	B-Gene
expression	O
remained	O
constant	O
until	O
DC	O
maturation	O
.	O

TRAIL	B-Gene
expression	O
on	O
immature	O
CD34DCs	B-Gene
or	O
MoDCs	O
was	O
greatly	O
up	O
-regulated	O
after	O
IFN-beta	B-Gene
stimulation	O
.	O

Moreover	O
,	O
IFN-beta	B-Gene
could	O
strikingly	O
enhance	O
the	O
ability	O
of	O
CD34DCs	B-Gene
or	O
MoDCs	O
to	O
kill	O
TRAIL	B-Gene
-sensitive	O
tumor	B-Disease
cells	O
,	O
but	O
LPS	B-Chemical
did	O
not	O
have	O
such	O
an	O
effect	O
.	O

The	O
up-regulation	O
of	O
TRAIL	B-Gene
on	O
IFN-beta	B-Gene
-stimulated	O
DCs	O
partially	O
contributed	O
to	O
the	O
increased	O
cytotoxicity	O
of	O
DCS	O
:	O
Pretreatment	O
of	O
TRAIL	B-Gene
-sensitive	O
tumor	B-Disease
cells	O
with	O
caspase-3	B-Gene
inhibitor	I-Gene
could	O
significantly	O
increase	O
their	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
IFN-beta	B-Gene
-stimulated	O
DCS	O
:	O
In	O
contrast	O
,	O
NF-kappaB	B-Gene
inhibitor	I-Gene
could	O
significantly	O
increase	O
the	O
sensitivity	O
of	O
tumor	B-Disease
cells	O
to	O
the	O
killing	O
by	O
nonstimulated	O
or	O
LPS	B-Chemical
-stimulated	O
DCS	O
:	O
Our	O
studies	O
demonstrate	O
that	O
IFN-beta	B-Gene
-stimulated	O
DCs	O
are	O
functionally	O
cytotoxic	O
.	O

Thus	O
,	O
an	O
innate	O
mechanism	O
of	O
DC	O
-mediated	O
antitumor	O
immunity	O
might	O
exist	O
in	O
vivo	O
in	O
which	O
DCs	O
act	O
as	O
effectors	O
to	O
directly	O
kill	O
tumor	B-Disease
cells	O
partially	O
via	O
TRAIL	B-Gene
.	O

Subsequently	O
,	O
DCs	O
act	O
as	O
APCs	O
involved	O
in	O
the	O
uptake	O
,	O
processing	O
,	O
and	O
presentation	O
of	O
apoptotic	O
tumor	B-Disease
Ags	O
to	O
cross-prime	O
CD8	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
CTL	O
cells	O
.	O

Runx2	B-Gene
:	O
a	O
novel	O
oncogenic	O
effector	O
revealed	O
by	O
in	O
vivo	O
complementation	O
and	O
retroviral	O
tagging	O
.	O

The	O
Runx2	B-Gene
(	O
Cbfa1	B-Gene
,	O
Pebp2alphaA	B-Gene
,	O
Aml3	B-Gene
)	O
gene	O
was	O
previously	O
identified	O
as	O
a	O
frequent	O
target	O
for	O
transcriptional	O
activation	O
by	O
proviral	O
insertion	O
in	O
T-cell	B-Disease
lymphomas	I-Disease
of	O
CD2-MYC	B-Gene
transgenic	O
mice	O
.	O

We	O
have	O
recently	O
shown	O
that	O
over-expression	O
of	O
the	O
full-length	O
,	O
most	O
highly	O
expressed	O
Runx2	B-Gene
isoform	I-Gene
in	O
the	O
thymus	O
perturbs	O
T-cell	O
development	O
,	O
leads	O
to	O
development	O
of	O
spontaneous	O
lymphomas	B-Disease
at	O
low	O
frequency	O
and	O
is	O
strongly	O
synergistic	O
with	O
Myc	B-Gene
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
relationship	O
of	O
Runx2	B-Gene
to	O
other	O
lymphomagenic	O
pathways	O
,	O
we	O
tested	O
the	O
effect	O
of	O
combining	O
the	O
CD2-Runx2	B-Gene
transgene	I-Gene
either	O
with	O
a	O
Pim1	B-Gene
transgene	I-Gene
(	O
E	B-Gene
(	I-Gene
mu	I-Gene
)	I-Gene
-Pim1	I-Gene
)	O
or	O
with	O
the	O
p53	B-Gene
null	O
genotype	O
,	O
as	O
each	O
of	O
these	O
displays	O
independent	O
synergy	O
with	O
Myc	B-Gene
.	O

In	O
both	O
cases	O
we	O
observed	O
synergistic	O
tumour	B-Disease
development	O
.	O

However	O
,	O
Runx2	B-Gene
appeared	O
to	O
have	O
a	O
dominant	O
effect	O
on	O
the	O
tumour	B-Disease
phenotype	O
in	O
each	O
case	O
,	O
with	O
most	O
tumours	B-Disease
conforming	O
to	O
the	O
CD3	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
,	O
CD8	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
,	O
CD4	B-Gene
(	I-Gene
+	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
phenotype	O
seen	O
in	O
CD2-Runx2	B-Gene
mice	O
.	O

Neonatal	O
infection	O
of	O
CD2-Runx2	B-Gene
mice	O
with	O
Moloney	O
murine	O
leukaemia	B-Disease
virus	O
(	O
Moloney	O
MLV	O
)	O
also	O
led	O
to	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B-Disease
onset	O
.	O

Analysis	O
of	O
known	O
Moloney	O
MLV	O
target	O
genes	O
in	O
these	O
lymphomas	B-Disease
showed	O
a	O
high	O
frequency	O
of	O
rearrangement	O
at	O
c-Myc	B-Gene
or	O
N-Myc	B-Gene
(	O
82	O
%	O
)	O
,	O
and	O
a	O
significant	O
number	O
at	O
Pim1	B-Gene
or	O
Pim2	B-Gene
(	O
23	O
%	O
)	O
,	O
and	O
at	O
Pal1	B-Gene
/	I-Gene
Gfi1	I-Gene
(	O
18	O
%	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Runx2	B-Gene
makes	O
a	O
distinct	O
contribution	O
to	O
T-cell	B-Disease
lymphoma	I-Disease
development	O
which	O
does	O
not	O
coincide	O
with	O
any	O
of	O
the	O
oncogene	O
complementation	O
groups	O
previously	O
identified	O
by	O
retroviral	O
tagging	O
.	O

Expression	O
of	O
Mad1	B-Gene
in	O
T	O
cells	O
leads	O
to	O
reduced	O
thymic	O
cellularity	O
and	O
impaired	O
mitogen	O
-induced	O
proliferation	O
.	O

To	O
investigate	O
Mad1	B-Gene
function	O
in	O
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
that	O
express	O
a	O
Mad1	B-Gene
transgene	I-Gene
in	O
T	O
lineage	O
cells	O
under	O
the	O
control	O
of	O
the	O
proximal	O
lck	B-Gene
promoter	I-Gene
.	O

Thymus	O
size	O
in	O
lck-Mad1	B-Gene
transgenic	O
mice	O
is	O
drastically	O
reduced	O
although	O
representation	O
of	O
the	O
various	O
thymocyte	O
sub	O
populations	O
appears	O
normal	O
.	O

To	O
investigate	O
more	O
closely	O
any	O
effects	O
of	O
Mad1	B-Gene
expression	O
on	O
thymocytes	O
,	O
we	O
examined	O
thymic	O
selection	O
using	O
MHC	B-Gene
class	I-Gene
I	I-Gene
-restricted	O
H-Y-TCR	B-Gene
transgenic	O
mice	O
.	O

Mad1	B-Gene
expression	O
in	O
vivo	O
reduces	O
the	O
efficiency	O
of	O
positive	O
selection	O
.	O

Furthermore	O
,	O
thymocytes	O
and	O
splenic	O
T	O
cells	O
from	O
lck-Mad1	B-Gene
transgenic	O
mice	O
display	O
a	O
profound	O
proliferative	O
defect	O
in	O
response	O
to	O
activation	O
with	O
either	O
PMA	B-Chemical
/	O
Ionomycin	B-Chemical
or	O
immobilized	O
anti-CD3	B-Gene
/	I-Gene
CD28	I-Gene
antibody	I-Gene
.	O

This	O
proliferative	O
defect	O
is	O
not	O
reversed	O
by	O
addition	O
of	O
exogenous	B-Gene
IL-2	I-Gene
and	O
is	O
p53	B-Gene
-independent	O
.	O

The	O
growth	O
inhibition	O
caused	O
by	O
Mad1	B-Gene
is	O
overcome	O
by	O
expression	O
of	O
active	O
c-Myc	B-Gene
.	O

Caspase	B-Gene
-dependent	O
cleavage	O
of	O
the	O
hematopoietic	B-Gene
specific	I-Gene
adaptor	I-Gene
protein	I-Gene
Gads	I-Gene
alters	O
signalling	O
from	O
the	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
.	O

Gads	B-Gene
is	O
a	O
SH2	O
and	O
SH3	O
domain	O
-containing	O
,	O
hematopoietic-specific	O
adaptor	O
protein	O
that	O
functions	O
in	O
signalling	O
from	O
the	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
.	O

Gads	B-Gene
acts	O
by	O
linking	O
SLP-76	B-Gene
,	O
bound	O
by	O
the	O
carboxy-terminal	O
Gads	B-Gene
SH3	O
domain	O
,	O
to	O
tyrosine	B-Chemical
phosphorylated	O
LAT	B-Gene
which	O
contains	O
binding	O
sites	O
for	O
the	O
Gads	B-Gene
SH2	O
domain	O
.	O

Gads	B-Gene
is	O
distinguished	O
from	O
Grb2	B-Gene
and	O
the	O
closely	O
related	O
Grap	B-Gene
protein	I-Gene
by	O
the	O
presence	O
of	O
a	O
120	O
amino	O
acid	O
unique	O
region	O
between	O
the	O
SH2	O
domain	O
and	O
the	O
carboxy	O
terminal	O
SH3	O
domain	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
unique	O
region	O
of	O
Gads	B-Gene
contains	O
a	O
capase	B-Gene
cleavage	O
site	O
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
results	O
in	O
detectable	O
Gads	B-Gene
cleavage	O
by	O
60	O
min	O
.	O

Gads	B-Gene
cleavage	O
is	O
blocked	O
in	O
vivo	O
by	O
treating	O
cells	O
with	O
a	O
caspase	B-Gene
3	I-Gene
inhibitor	I-Gene
.	O

A	O
putative	O
caspase	B-Gene
3	I-Gene
cleavage	O
site	O
was	O
identified	O
within	O
the	O
unique	O
region	O
and	O
mutation	O
of	O
this	O
site	O
prevented	O
Gads	B-Gene
cleavage	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
.	O

The	O
Gads	B-Gene
cleavage	O
products	O
retained	O
the	O
predicted	O
binding	O
specificity	O
for	O
SLP-76	B-Gene
and	O
LAT	B-Gene
.	O

Expression	O
of	O
the	O
Gads	B-Gene
cleavage	O
products	O
in	O
Jurkat	O
T	O
cells	O
inhibited	O
NFAT	B-Gene
activation	O
following	O
TCR	B-Gene
cross	O
linking	O
.	O

These	O
findings	O
indicate	O
that	O
cleavage	O
of	O
Gads	B-Gene
in	O
vivo	O
could	O
function	O
to	O
alter	O
signalling	O
downstream	O
of	O
the	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
by	O
disrupting	O
cross	O
talk	O
between	O
SLP-76	B-Gene
and	O
LAT	B-Gene
.	O

Comparison	O
of	O
hprt	B-Gene
and	O
lacI	B-Gene
mutant	I-Gene
frequency	O
with	O
DNA	O
adduct	O
formation	O
in	O
N-hydroxy-2-acetylaminofluorene	B-Chemical
-treated	O
Big	O
Blue	O
rats	O
.	O

N-Hydroxy-2-acetylaminofluorene	B-Chemical
(	O
N-OH-AAF	B-Chemical
)	O
is	O
the	O
proximate	O
carcinogenic	O
metabolite	O
of	O
the	O
powerful	O
rat	O
liver	O
carcinogen	O
2-acetylaminofluorene	B-Chemical
.	O

In	O
this	O
study	O
,	O
transgenic	O
Big	O
Blue	O
(	O
R	O
)	O
rats	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
in	O
vivo	O
mutagenicity	O
and	O
DNA	O
adduct	O
formation	O
by	O
N-OH-AAF	B-Chemical
in	O
the	O
target	O
liver	O
compared	O
with	O
that	O
in	O
nontarget	O
tissues	O
.	O

Male	O
rats	O
were	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
25	O
mg	O
N-OH-AAF	B-Chemical
/	O
kg	O
body	O
weight	O
by	O
i.p.	O
injection	O
at	O
4-day	O
intervals	O
,	O
and	O
groups	O
of	O
treated	O
and	O
control	O
rats	O
were	O
euthanized	O
up	O
to	O
10	O
weeks	O
after	O
beginning	O
the	O
dosing	O
.	O

Mutant	O
frequencies	O
were	O
measured	O
in	O
the	O
spleen	O
lymphocyte	O
hprt	B-Gene
gene	I-Gene
,	O
and	O
lacI	B-Gene
mutant	I-Gene
frequencies	O
were	O
determined	O
in	O
the	O
liver	O
and	O
spleen	O
lymphocytes	O
.	O

At	O
6	O
weeks	O
after	O
beginning	O
the	O
dosing	O
,	O
the	O
hprt	B-Gene
mutant	I-Gene
frequency	O
in	O
spleen	O
lymphocytes	O
from	O
the	O
four-dose	O
group	O
was	O
16.5	O
x	O
10	O
(	O
-6	O
)	O
compared	O
with	O
3.2	O
x	O
10	O
(	O
-6	O
)	O
in	O
control	O
animals	O
.	O

Also	O
at	O
6	O
weeks	O
,	O
rats	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
N-OH-AAF	B-Chemical
had	O
lacI	B-Gene
mutant	I-Gene
frequencies	O
in	O
the	O
liver	O
of	O
97.6	O
,	O
155.6	O
,	O
and	O
406.8	O
x	O
10	O
(	O
-6	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
25.7	O
x	O
10	O
(	O
-6	O
)	O
;	O
rats	O
given	O
four	O
doses	O
had	O
lacI	B-Gene
mutant	I-Gene
frequencies	O
in	O
spleen	O
lymphocytes	O
of	O
55.8	O
x	O
10	O
(	O
-6	O
)	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
20.4	O
x	O
10	O
(	O
-6	O
)	O
.	O

Additional	O
rats	O
were	O
evaluated	O
for	O
DNA	O
adduct	O
formation	O
in	O
the	O
liver	O
,	O
spleen	O
lymphocytes	O
,	O
and	O
bone	O
marrow	O
by	O
(	O
32	O
)	O
P	O
-postlabeling	O
.	O

Adduct	O
analysis	O
was	O
conducted	O
1	O
day	O
after	O
one	O
,	O
two	O
,	O
and	O
four	O
treatments	O
with	O
N-OH-AAF	B-Chemical
,	O
5	O
days	O
after	O
one	O
treatment	O
,	O
and	O
9	O
days	O
after	O
two	O
treatments	O
.	O

N-	B-Chemical
(	I-Chemical
Deoxyguanosin-8-yl	I-Chemical
)	I-Chemical
-2-aminofluorene	I-Chemical
was	O
the	O
major	O
DNA	O
adduct	O
identified	O
in	O
all	O
the	O
tissues	O
examined	O
.	O

Adduct	O
concentrations	O
increased	O
with	O
total	O
dose	O
to	O
maximum	O
values	O
in	O
samples	O
taken	O
1	O
day	O
after	O
two	O
doses	O
,	O
and	O
remained	O
essentially	O
the	O
same	O
after	O
four	O
doses	O
.	O

In	O
samples	O
taken	O
after	O
four	O
doses	O
,	O
adduct	O
levels	O
were	O
103	O
,	O
28	O
,	O
and	O
7	O
fmol	O
/	O
microg	O
of	O
DNA	O
in	O
liver	O
,	O
spleen	O
lymphocytes	O
,	O
and	O
bone	O
marrow	O
,	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
the	O
extent	O
of	O
both	O
DNA	O
adduct	O
formation	O
and	O
mutant	O
induction	O
correlates	O
with	O
the	O
organ	O
specificity	O
for	O
N-OH-AAF	B-Chemical
carcinogenesis	O
in	O
the	O
rat	O
.	O

Environ	O
.	O

Mol	O
.	O

Mutagen	O
.	O

37	O
:	O
195-202	O
,	O
2001	O
.	O

Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O

Gene-	O
and	O
tissue-specificity	O
of	O
mutation	O
in	O
Big	O
Blue	O
rats	O
treated	O
with	O
the	O
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	B-Chemical
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
found	O
that	O
treating	O
transgenic	O
Big	O
Blue	O
rats	O
with	O
the	O
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	B-Chemical
(	O
N-OH-AAF	B-Chemical
)	O
produced	O
the	O
same	O
major	O
DNA	O
adduct	O
in	O
the	O
target	O
liver	O
and	O
the	O
nontarget	O
spleen	O
lymphocytes	O
and	O
bone	O
marrow	O
cells	O
,	O
induced	O
lacI	B-Gene
mutants	I-Gene
in	O
the	O
liver	O
,	O
and	O
induced	O
much	O
lower	O
frequencies	O
of	O
l	B-Gene
acI	I-Gene
and	O
hprt	B-Gene
mutants	I-Gene
in	O
spleen	O
lymphocytes	O
.	O

In	O
the	O
present	O
study	O
,	O
sequence	O
analysis	O
was	O
conducted	O
on	O
lacI	B-Gene
DNA	I-Gene
and	O
hprt	B-Gene
cDNA	I-Gene
from	O
the	O
mutants	O
,	O
to	O
determine	O
the	O
mutational	O
specificity	O
of	O
N-OH-AAF	B-Chemical
in	O
the	O
rat	O
.	O

All	O
the	O
mutation	O
spectra	O
from	O
N-OH-AAF	B-Chemical
-treated	O
rats	O
differed	O
significantly	O
from	O
corresponding	O
mutation	O
profiles	O
from	O
untreated	O
animals	O
(	O
P	O
=	O
0.02	O
to	O
P	O
<	O
0.0001	O
)	O
.	O

Although	O
there	O
were	O
similarities	O
among	O
the	O
mutational	O
patterns	O
derived	O
from	O
N-OH-AAF	B-Chemical
-treated	O
rats	O
(	O
e.g.	O
,	O
G	O
:	O
C	O
--	O
>	O
T	O
:	O
A	O
transversion	O
was	O
the	O
most	O
common	O
mutation	O
in	O
all	O
mutation	O
sets	O
)	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
patterns	O
of	O
basepair	O
substitution	O
and	O
frameshift	O
mutation	O
between	O
the	O
liver	O
and	O
spleen	O
lymphocyte	O
lacI	B-Gene
mutants	I-Gene
(	O
P	O
=	O
0.02	O
)	O
and	O
between	O
the	O
spleen	O
lymphocyte	O
lacI	B-Gene
and	O
hprt	B-Gene
mutants	I-Gene
(	O
P	O
=	O
0.04	O
)	O
.	O

Also	O
,	O
multiplex	O
PCR	O
analysis	O
of	O
genomic	O
DNA	O
from	O
the	O
hprt	B-Gene
mutants	I-Gene
indicated	O
that	O
12	O
%	O
of	O
mutants	O
from	O
treated	O
rats	O
had	O
major	O
deletions	O
in	O
the	O
hprt	B-Gene
gene	I-Gene
;	O
no	O
corresponding	O
incidence	O
of	O
large	O
deletions	O
was	O
evident	O
among	O
lacI	B-Gene
mutations	I-Gene
.	O

All	O
the	O
mutation	O
profiles	O
reflect	O
the	O
general	O
mutational	O
specificity	O
of	O
the	O
major	O
DNA	O
adduct	O
formed	O
by	O
N-OH-AAF	B-Chemical
.	O

The	O
differences	O
between	O
N-OH-AAF	B-Chemical
mutation	O
in	O
the	O
endogenous	O
gene	O
and	O
transgene	O
can	O
be	O
partially	O
explained	O
by	O
the	O
structures	O
of	O
the	O
two	O
genes	O
.	O

The	O
tissue-specificity	O
of	O
the	O
mutation	O
spectra	O
may	O
contribute	O
to	O
targeting	O
tumor	B-Disease
formation	O
to	O
the	O
liver	O
.	O

Environ	O
.	O

Mol	O
.	O

Mutagen	O
.	O

37	O
:	O
203-214	O
,	O
2001	O
.	O

Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O

Gene	O
transfer	O
of	O
antisense	O
hypoxia	B-Gene
inducible	I-Gene
factor-1	I-Gene
alpha	I-Gene
enhances	O
the	O
therapeutic	O
efficacy	O
of	O
cancer	B-Disease
immunotherapy	O
.	O

Solid	O
tumors	B-Disease
meet	O
their	O
demands	O
for	O
nascent	O
blood	O
vessels	O
and	O
increased	O
glycolysis	O
,	O
to	O
combat	O
hypoxia	O
,	O
by	O
activating	O
multiple	O
genes	O
involved	O
in	O
angiogenesis	O
and	O
glucose	B-Chemical
metabolism	O
.	O

Hypoxia	B-Gene
inducible	I-Gene
factor-1	I-Gene
(	O
HIF-1	B-Gene
)	O
is	O
a	O
constitutively	O
expressed	O
basic	O
helix-loop-helix	O
transcription	O
factor	O
,	O
formed	O
by	O
the	O
assembly	O
of	O
HIF-1alpha	B-Gene
and	O
HIF-1beta	B-Gene
(	O
Arnt	B-Gene
)	O
,	O
that	O
is	O
stablized	O
in	O
response	O
to	O
hypoxia	O
,	O
and	O
rapidly	O
degraded	O
under	O
normoxic	O
conditions	O
.	O

It	O
activates	O
the	O
transcription	O
of	O
genes	O
important	O
for	O
maintaining	O
oxygen	B-Chemical
homeostasis	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
engineered	O
down-regulation	O
of	O
HIF-1alpha	B-Gene
by	O
intratumoral	O
gene	O
transfer	O
of	O
an	O
antisense	O
HIF-1alpha	B-Gene
plasmid	O
leads	O
to	O
the	O
down-regulation	O
of	O
VEGF	B-Gene
,	O
and	O
decreased	O
tumor	B-Disease
microvessel	O
density	O
.	O

Antisense	O
HIF-1alpha	B-Gene
monotherapy	O
resulted	O
in	O
the	O
complete	O
and	O
permanent	O
rejection	O
of	O
small	O
(	O
0.1	O
cm	O
in	O
diameter	O
)	O
EL-4	O
tumors	B-Disease
,	O
which	O
is	O
unusual	O
for	O
an	O
anti-angiogenic	O
agent	O
where	O
transient	O
suppression	O
of	O
tumor	B-Disease
growth	O
is	O
the	O
norm	O
.	O

It	O
induced	O
NK	O
cell	O
-dependent	O
rejection	O
of	O
tumors	B-Disease
,	O
but	O
failed	O
to	O
stimulate	O
systemic	O
T	O
cell	O
-mediated	O
anti-tumor	B-Disease
immunity	O
,	O
and	O
synergized	O
with	O
B7-1	B-Gene
-mediated	O
immunotherapy	O
to	O
cause	O
the	O
NK	O
cell	O
and	O
CD8	B-Gene
T	O
cell	O
-dependent	O
rejection	O
of	O
larger	O
EL-4	O
tumors	B-Disease
(	O
0.4	O
cm	O
in	O
diameter	O
)	O
that	O
were	O
refractory	O
to	O
monotherapies	O
.	O

Mice	O
cured	O
of	O
their	O
tumors	B-Disease
by	O
combination	O
therapy	O
resisted	O
a	O
rechallenge	O
with	O
parental	O
tumor	B-Disease
cells	O
,	O
indicating	O
systemic	O
antitumor	O
immunity	O
had	O
been	O
achieved	O
.	O

In	O
summary	O
,	O
whilst	O
intensive	O
investigations	O
are	O
in	O
progress	O
to	O
target	O
the	O
many	O
HIF-1	B-Gene
effectors	I-Gene
,	O
the	O
results	O
herein	O
indicate	O
that	O
blocking	O
hypoxia-inducible	O
pathways	O
and	O
enhancing	O
NK	O
-mediated	O
antitumor	O
immunity	O
by	O
targeting	O
HIF-1	B-Gene
itself	O
may	O
be	O
advantageous	O
,	O
especially	O
when	O
combined	O
with	O
cancer	B-Disease
immunotherapy	O
.	O

Molecular	O
pathogenesis	O
of	O
influenza	B-Disease
A	O
virus	O
infection	O
and	O
virus	O
-induced	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
.	O

Despite	O
vaccines	O
and	O
antiviral	O
substances	O
influenza	B-Disease
still	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
world	O
wide	O
.	O

Better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
of	O
influenza	B-Disease
virus	O
replication	O
,	O
pathogenesis	O
and	O
host	O
immune	O
responses	O
is	O
required	O
for	O
the	O
development	O
of	O
more	O
efficient	O
means	O
of	O
prevention	O
and	O
treatment	O
of	O
influenza	B-Disease
.	O

Influenza	B-Disease
A	O
virus	O
,	O
which	O
replicates	O
in	O
epithelial	O
cells	O
and	O
leukocytes	O
,	O
regulates	O
host	O
cell	O
transcriptional	O
and	O
translational	O
systems	O
and	O
activates	O
,	O
as	O
well	O
as	O
downregulates	O
apoptotic	O
pathways	O
.	O

Influenza	B-Disease
A	O
virus	O
infection	O
results	O
in	O
the	O
production	O
of	O
chemotactic	O
(	O
RANTES	B-Gene
,	O
MIP-1	B-Gene
alpha	I-Gene
,	O
MCP-1	B-Gene
,	O
MCP-3	B-Gene
,	O
and	O
IP-10	B-Gene
)	O
,	O
pro-inflammatory	O
(	O
IL-1	B-Gene
beta	I-Gene
,	O
IL-6	B-Gene
,	O
IL-18	B-Gene
,	O
and	O
TNF-alpha	B-Gene
)	O
,	O
and	O
antiviral	O
(	O
IFN-alpha	B-Gene
/	I-Gene
beta	I-Gene
)	O
cytokines	O
.	O

Cytokine	O
gene	O
expression	O
is	O
associated	O
with	O
the	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
,	O
AP-1	B-Gene
,	O
STAT	B-Gene
and	O
IRF	B-Gene
signal	O
transducing	O
molecules	O
in	O
influenza	B-Disease
A	O
virus	O
-infected	O
cells	O
.	O

In	O
addition	O
of	O
upregulating	O
cytokine	O
gene	O
expression	O
,	O
influenza	B-Disease
A	O
virus	O
infection	O
activates	O
caspase-1	B-Gene
enzyme	I-Gene
,	O
which	O
is	O
involved	O
in	O
the	O
proteolytic	O
processing	O
of	O
proIL-1	B-Gene
beta	I-Gene
and	O
proIL-18	B-Gene
into	O
their	O
biologically	O
active	O
forms	O
.	O

Influenza	B-Disease
A	O
virus	O
-induced	O
IFN-alpha	B-Gene
/	I-Gene
beta	I-Gene
is	O
essential	O
in	O
host	O
's	O
antiviral	O
defence	O
by	O
activating	O
the	O
expression	O
of	O
antiviral	B-Gene
Mx	I-Gene
,	O
PKR	B-Gene
and	O
oligoadenylate	B-Gene
synthetase	I-Gene
genes	I-Gene
.	O

IFN-alpha	B-Gene
/	I-Gene
beta	I-Gene
also	O
prolongs	O
T	O
cell	O
survival	O
,	O
upregulates	O
IL-12	B-Gene
and	O
IL-18	B-Gene
receptor	I-Gene
gene	I-Gene
expression	O
and	O
together	O
with	O
IL-18	B-Gene
stimulates	O
NK	O
and	O
T	B-Gene
cell	I-Gene
IFN-gamma	I-Gene
production	O
and	O
the	O
development	O
of	O
Th1-type	O
immune	O
response	O
.	O

Epstein-Barr	O
Virus	O
and	O
its	O
glycoprotein-350	B-Gene
upregulate	O
IL-6	B-Gene
in	O
human	O
B-lymphocytes	O
via	O
CD21	B-Gene
,	O
involving	O
activation	O
of	O
NF-kappaB	B-Gene
and	O
different	O
signaling	O
pathways	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
ubiquitous	O
and	O
highly	O
immunotropic	O
gamma	O
herpesvirus	O
that	O
infects	O
more	O
than	O
90	O
%	O
of	O
humans	O
worldwide	O
.	O

Its	O
pathogenicity	O
leads	O
to	O
a	O
number	O
of	O
diseases	O
including	O
tumors	B-Disease
that	O
result	O
from	O
EBV	O
's	O
ability	O
to	O
readily	O
transform	O
B-lymphocytes	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
epithelial	O
cells	O
.	O

EBV	O
utilizes	O
CD21	B-Gene
/	I-Gene
CR2	I-Gene
as	O
its	O
receptor	O
on	O
B	O
cells	O
to	O
initiate	O
the	O
infection	O
process	O
.	O

EBV	O
binds	O
to	O
CR2	B-Gene
through	O
its	O
major	B-Gene
envelope	I-Gene
glycoprotein-350	I-Gene
(	O
gp350	B-Gene
)	O
and	O
is	O
also	O
a	O
remarkable	O
immunomodulating	O
agent	O
.	O

We	O
had	O
previously	O
shown	O
that	O
EBV	O
is	O
capable	O
of	O
modulating	O
the	O
synthesis	O
of	O
a	O
number	O
of	O
cytokines	O
.	O

We	O
now	O
show	O
that	O
while	O
both	O
purified	O
recombinant	B-Gene
gp350	I-Gene
(	O
rgp350	B-Gene
)	O
and	O
EBV	O
upregulate	O
IL-6	B-Gene
mRNA	I-Gene
synthesis	O
in	O
B	O
cells	O
,	O
EBV	O
-induced	O
IL-6	B-Gene
gene	I-Gene
activation	O
occurs	O
for	O
a	O
significantly	O
longer	O
period	O
of	O
time	O
(	O
i.e.	O
12	O
hours	O
for	O
EBV	O
as	O
compared	O
to	O
6	O
hours	O
for	O
rgp350	B-Gene
)	O
.	O

Moreover	O
,	O
the	O
half-life	O
of	O
EBV	O
-induced	O
IL-6	B-Gene
mRNA	I-Gene
was	O
also	O
significantly	O
longer	O
(	O
10	O
hours	O
)	O
than	O
that	O
of	O
mRNA	O
induced	O
by	O
rgp350	B-Gene
(	O
about	O
6	O
hours	O
)	O
.	O

Both	O
EBV	O
and	O
gp350	B-Gene
enhance	O
the	O
binding	O
of	O
the	O
NF-kappaB	B-Gene
transcription	I-Gene
factor	I-Gene
,	O
as	O
determined	O
by	O
band-shift	O
and	O
augment	O
NF-kappaB	B-Gene
-mediated	O
activation	O
of	O
a	O
CAT	O
reporter	O
plasmid	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
while	O
the	O
activation	O
of	O
IL-6	B-Gene
gene	I-Gene
expression	O
by	O
gp350	B-Gene
is	O
mediated	O
primarily	O
by	O
the	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
pathway	O
,	O
EBV	O
can	O
mediate	O
its	O
effects	O
through	O
multiple	O
signaling	O
pathways	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
showing	O
that	O
the	O
binding	O
of	O
a	O
herpesvirus	O
envelope	O
glycoprotein	O
to	O
CR2	B-Gene
on	O
human	O
B	O
cells	O
results	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-Gene
transcription	I-Gene
factor	I-Gene
leading	O
to	O
the	O
upregulation	O
of	O
IL-6	B-Gene
gene	I-Gene
expression	O
in	O
these	O
lymphocytes	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Autostimulation	O
of	O
the	O
Epstein-Barr	B-Gene
virus	I-Gene
BRLF1	I-Gene
promoter	I-Gene
is	O
mediated	O
through	O
consensus	O
Sp1	B-Gene
and	O
Sp3	B-Gene
binding	O
sites	O
.	O

As	O
an	O
essential	O
step	O
in	O
the	O
lytic	O
cascade	O
,	O
the	O
Rta	B-Gene
homologues	I-Gene
of	O
gammaherpesviruses	O
all	O
activate	O
their	O
own	O
expression	O
.	O

Consistent	O
with	O
this	O
biologic	O
function	O
,	O
the	O
Epstein-Barr	B-Gene
virus	I-Gene
(	I-Gene
EBV	I-Gene
)	I-Gene
Rta	I-Gene
protein	I-Gene
powerfully	O
stimulates	O
the	O
promoter	O
of	O
its	O
own	O
gene	O
,	O
Rp	B-Gene
,	O
in	O
EBV	O
-positive	O
B	O
cells	O
in	O
transient-transfection	O
reporter	O
-based	O
assays	O
.	O

We	O
analyzed	O
the	O
activity	O
of	O
RpCAT	B-Gene
in	O
response	O
to	O
Rta	B-Gene
by	O
deletional	O
and	O
site	O
-directed	O
mutagenesis	O
.	O

Two	O
cognate	O
Sp1	B-Gene
binding	O
sites	O
located	O
at	O
-279	O
and	O
-45	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
proved	O
crucial	O
for	O
Rta	B-Gene
-mediated	O
activation	O
.	O

Previously	O
described	O
binding	O
sites	O
for	O
the	O
cellular	B-Gene
transcription	I-Gene
factor	I-Gene
Zif268	I-Gene
and	O
the	O
viral	B-Gene
transactivator	I-Gene
ZEBRA	I-Gene
were	O
found	O
to	O
be	O
dispensable	O
for	O
activation	O
of	O
RpCAT	B-Gene
by	O
Rta	B-Gene
.	O

Gel	O
shift	O
analysis	O
,	O
using	O
extracts	O
of	O
B	O
cells	O
in	O
latency	O
or	O
induced	O
into	O
the	O
lytic	O
cycle	O
,	O
identified	O
Sp1	B-Gene
and	O
Sp3	B-Gene
as	O
the	O
predominant	O
cellular	O
proteins	O
bound	O
to	O
Rp	B-Gene
near	O
-45	O
.	O

During	O
the	O
lytic	O
cycle	O
,	O
ZEBRA	B-Gene
bound	O
Rp	B-Gene
near	O
the	O
Sp1	B-Gene
/	I-Gene
Sp3	I-Gene
site	O
.	O

The	O
binding	O
of	O
Sp1	B-Gene
and	O
Sp3	B-Gene
to	O
Rp	B-Gene
correlated	O
with	O
the	O
reporter	O
activities	O
in	O
the	O
mutagenesis	O
study	O
,	O
establishing	O
a	O
direct	O
link	O
between	O
transcriptional	O
activation	O
of	O
Rp	B-Gene
by	O
Rta	B-Gene
and	O
DNA	O
binding	O
by	O
Sp1	B-Gene
and	O
/	O
or	O
Sp3	B-Gene
.	O

The	O
relative	O
abundance	O
or	O
functional	O
state	O
of	O
the	O
cellular	B-Gene
Sp1	I-Gene
and	O
Sp3	B-Gene
transcription	I-Gene
factors	I-Gene
may	O
be	O
altered	O
in	O
response	O
to	O
stimuli	O
that	O
induce	O
the	O
BRLF1	B-Gene
promoter	I-Gene
and	O
thereby	O
contribute	O
to	O
the	O
activation	O
of	O
the	O
viral	O
lytic	O
cycle	O
.	O

A	O
genetic	O
investigation	O
of	O
E2A	B-Gene
function	O
in	O
lymphocyte	O
development	O
.	O

Lymphocytes	O
are	O
derived	O
from	O
hematopoietic	O
stem	O
cells	O
(	O
HSC	O
)	O
following	O
a	O
series	O
of	O
regulated	O
differentiation	O
events	O
.	O

Multipotent	O
HSCs	O
become	O
committed	O
to	O
the	O
B	O
cell	O
lineage	O
in	O
bone	O
marrow	O
and	O
the	O
T	O
cell	O
lineage	O
in	O
the	O
thymus	O
after	O
receiving	O
appropriate	O
signals	O
from	O
the	O
corresponding	O
microenvironment	O
.	O

These	O
committed	O
lymphoid	O
cells	O
must	O
then	O
undergo	O
V	O
(	O
D	O
)	O
J	O
recombination	O
at	O
the	O
immunoglobulin	B-Gene
gene	I-Gene
or	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
gene	I-Gene
locus	I-Gene
resulting	O
in	O
clonal	O
production	O
of	O
functional	O
B	O
or	O
T	O
lymphocytes	O
,	O
respectively	O
.	O

Lymphocyte	O
commitment	O
and	O
differentiation	O
are	O
accompanied	O
by	O
programmed	O
gene	O
expression	O
or	O
repression	O
events	O
which	O
are	O
driven	O
by	O
lineage	O
and	O
stage	O
specific	O
transcription	O
factors	O
.	O

The	O
basic-helix-loop-helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
encoded	O
by	O
the	O
E2A	B-Gene
gene	I-Gene
are	O
involved	O
in	O
several	O
differentiation	O
events	O
during	O
B	O
and	O
T	O
cell	O
development	O
,	O
including	O
lineage	O
commitment	O
,	O
initiation	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
and	O
antigen	O
receptor	O
mediated	O
proliferation	O
and	O
differentiation	O
.	O

Several	O
recent	O
reviews	O
have	O
provided	O
a	O
comprehensive	O
discussion	O
of	O
biochemical	O
,	O
cellular	O
,	O
and	O
genetic	O
research	O
on	O
E2A	B-Gene
function	O
in	O
lymphocyte	O
development	O
(	O
1	O
,	O
2	O
)	O
.	O

Here	O
,	O
we	O
only	O
discuss	O
some	O
of	O
the	O
genetic	O
approaches	O
our	O
laboratory	O
(	O
except	O
where	O
it	O
is	O
noted	O
)	O
has	O
undertaken	O
to	O
investigate	O
the	O
molecular	O
pathways	O
mediated	O
by	O
E2A	B-Gene
transcription	I-Gene
factors	I-Gene
in	O
lymphocyte	O
development	O

Oxidized	O
alkyl	O
phospholipids	B-Chemical
are	O
specific	O
,	O
high	O
affinity	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor	I-Gene
gamma	I-Gene
ligands	I-Gene
and	O
agonists	O
.	O

Synthetic	O
high	O
affinity	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor	I-Gene
(	I-Gene
PPAR	I-Gene
)	I-Gene
agonists	I-Gene
are	O
known	O
,	O
but	O
biologic	O
ligands	O
are	O
of	O
low	O
affinity	O
.	O

Oxidized	O
low	O
density	O
lipoprotein	O
(	O
oxLDL	O
)	O
is	O
inflammatory	O
and	O
signals	O
through	O
PPARs	B-Gene
.	O

We	O
showed	O
,	O
by	O
phospholipase	B-Gene
A	I-Gene
(	O
1	O
)	O
digestion	O
,	O
that	O
PPARgamma	B-Gene
agonists	I-Gene
in	O
oxLDL	O
arise	O
from	O
the	O
small	O
pool	O
of	O
alkyl	B-Chemical
phosphatidylcholines	I-Chemical
in	O
LDL	O
.	O

We	O
identified	O
an	O
abundant	O
oxidatively	O
fragmented	O
alkyl	O
phospholipid	B-Chemical
in	O
oxLDL	O
,	O
hexadecyl	B-Chemical
azelaoyl	I-Chemical
phosphatidylcholine	I-Chemical
(	O
azPC	B-Chemical
)	O
,	O
as	O
a	O
high	O
affinity	O
ligand	O
and	O
agonist	O
for	O
PPARgamma	B-Gene
.	O

[	O
(	O
3	O
)	O
H	O
]	O
azPC	B-Chemical
bound	O
recombinant	O
PPARgamma	B-Gene
with	O
an	O
affinity	O
(	O
K	O
(	O
d	O
)	O
(	O
(	O
app	O
)	O
)	O
approximately	O
40	O
nm	O
)	O
that	O
was	O
equivalent	O
to	O
rosiglitazone	B-Chemical
(	O
BRL49653	B-Chemical
)	O
,	O
and	O
competition	O
with	O
rosiglitazone	B-Chemical
showed	O
that	O
binding	O
occurred	O
in	O
the	O
ligand	O
-binding	O
pocket	O
.	O

azPC	B-Chemical
induced	O
PPRE	B-Gene
reporter	O
gene	O
expression	O
,	O
as	O
did	O
rosiglitazone	B-Chemical
,	O
with	O
a	O
half-maximal	O
effect	O
at	O
100	O
nm	O
.	O

Overexpression	O
of	O
PPARalpha	B-Gene
or	O
PPARgamma	B-Gene
revealed	O
that	O
azPC	B-Chemical
was	O
a	O
specific	O
PPARgamma	B-Gene
agonist	I-Gene
.	O

The	O
scavenger	B-Gene
receptor	I-Gene
CD36	I-Gene
is	O
encoded	O
by	O
a	O
PPRE	B-Gene
-responsive	O
gene	O
,	O
and	O
azPC	B-Chemical
enhanced	O
expression	O
of	O
CD36	B-Gene
in	O
primary	O
human	O
monocytes	O
.	O

We	O
found	O
that	O
anti-CD36	B-Gene
inhibited	O
azPC	B-Chemical
uptake	O
,	O
and	O
it	O
inhibited	O
PPRE	B-Gene
reporter	O
induction	O
.	O

Results	O
with	O
a	O
small	O
molecule	O
phospholipid	B-Gene
flippase	I-Gene
mimetic	O
suggest	O
azPC	B-Chemical
acts	O
intracellularly	O
and	O
that	O
cellular	O
azPC	B-Chemical
accumulation	O
was	O
efficient	O
.	O

Thus	O
,	O
certain	O
alkyl	O
phospholipid	B-Chemical
oxidation	O
products	O
in	O
oxLDL	O
are	O
specific	O
,	O
high	O
affinity	O
extracellular	O
ligands	O
and	O
agonists	O
for	O
PPARgamma	B-Gene
that	O
induce	O
PPAR	B-Gene
-responsive	O
genes	O

Ligation	O
of	O
CD11b	B-Gene
and	O
CD11c	B-Gene
beta	I-Gene
(	I-Gene
2	I-Gene
)	I-Gene
integrins	I-Gene
by	O
antibodies	O
or	O
soluble	B-Gene
CD23	I-Gene
induces	O
macrophage	B-Gene
inflammatory	I-Gene
protein	I-Gene
1alpha	I-Gene
(	O
MIP-1alpha	B-Gene
)	O
and	O
MIP-1beta	B-Gene
production	O
in	O
primary	O
human	O
monocytes	O
through	O
a	O
pathway	O
dependent	O
on	O
nuclear	B-Gene
factor-kappaB	I-Gene
.	O

Chemokines	O
and	O
adhesion	O
molecules	O
such	O
as	O
integrins	B-Gene
play	O
a	O
major	O
part	O
in	O
the	O
trafficking	O
,	O
extravasation	O
,	O
and	O
recruitment	O
of	O
leukocytes	O
to	O
inflammatory	O
sites	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
beta	B-Gene
(	I-Gene
2	I-Gene
)	I-Gene
integrin	I-Gene
engagement	O
on	O
chemokine	O
production	O
by	O
freshly	O
isolated	O
human	O
monocytes	O
.	O

We	O
found	O
that	O
ligation	O
of	O
CD11b	B-Gene
or	O
CD11c	B-Gene
but	O
not	O
CD11a	B-Gene
alpha	I-Gene
chains	I-Gene
of	O
beta	B-Gene
(	I-Gene
2	I-Gene
)	I-Gene
integrins	I-Gene
by	O
antibodies	O
or	O
soluble	B-Gene
CD23	I-Gene
(	I-Gene
sCD23	I-Gene
)	I-Gene
fusion	I-Gene
proteins	I-Gene
rapidly	O
induced	O
transcription	O
and	O
secretion	O
of	O
interleukin	B-Gene
8	I-Gene
,	O
macrophage	B-Gene
inflammatory	I-Gene
protein	I-Gene
(	I-Gene
MIP	I-Gene
)	I-Gene
1alpha	I-Gene
,	O
and	O
MIP-1beta	B-Gene
.	O

Because	O
the	O
promoters	O
of	O
these	O
chemokine	O
genes	O
contain	O
kappaB	O
binding	O
sites	O
,	O
we	O
assessed	O
the	O
possible	O
role	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
(	O
NF-kappaB	B-Gene
)	O
in	O
controlling	O
induction	O
of	O
the	O
genes	O
through	O
beta	B-Gene
(	I-Gene
2	I-Gene
)	I-Gene
integrin	I-Gene
engagement	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
sCD23	B-Gene
or	O
antibodies	O
to	O
CD11b	B-Gene
or	O
to	O
CD11c	B-Gene
up	O
-regulated	O
DNA	O
-binding	O
activity	O
of	O
NF-kappaB	B-Gene
.	O

Activation	O
of	O
NF-kappaB	B-Gene
was	O
accompanied	O
by	O
degradation	O
of	O
its	O
cytosolic	B-Gene
inhibitor	I-Gene
IkappaB-alpha	I-Gene
.	O

Blockade	O
of	O
depletion	O
of	O
IkappaB-alpha	B-Gene
by	O
proteasome	O
inhibitors	O
(	O
proteasome	B-Chemical
inhibitor	I-Chemical
I	I-Chemical
or	O
acetyl-leucinyl-leucinyl-norleucinal	B-Chemical
)	O
led	O
to	O
concomitant	O
inhibition	O
of	O
NF-kappaB	B-Gene
DNA	I-Gene
-binding	O
activity	O
and	O
expression	O
of	O
MIP-1alpha	B-Gene
and	O
MIP-1beta	B-Gene
messenger	I-Gene
RNA	I-Gene
induced	O
by	O
beta	B-Gene
(	I-Gene
2	I-Gene
)	I-Gene
integrin	I-Gene
ligation	O
.	O

These	O
results	O
suggest	O
that	O
triggering	O
of	O
CD11b	B-Gene
or	O
CD11c	B-Gene
beta	I-Gene
(	I-Gene
2	I-Gene
)	I-Gene
integrin	I-Gene
on	O
primary	O
human	O
monocytes	O
provides	O
activation	O
signals	O
leading	O
to	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-Gene
and	O
subsequent	O
secretion	O
of	O
MIP-1alpha	B-Gene
and	O
MIP-1beta	B-Gene
that	O
may	O
have	O
an	O
important	O
role	O
in	O
recruitment	O
of	O
other	O
inflammatory	O
cells	O
during	O
initiation	O
of	O
an	O
inflammatory	O
response	O

Functional	O
correction	O
of	O
FA-C	B-Disease
cells	O
with	O
FANCC	B-Gene
suppresses	O
the	O
expression	O
of	O
interferon	B-Gene
gamma-inducible	I-Gene
genes	O
.	O

Because	O
hematopoietic	O
cells	O
derived	O
from	O
Fanconi	B-Disease
anemia	I-Disease
(	O
FA	B-Disease
)	O
patients	O
of	O
the	O
C	O
-complementation	O
group	O
(	O
FA-C	B-Disease
)	O
are	O
hypersensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
interferon	B-Gene
gamma	I-Gene
(	O
IFNgamma	B-Gene
)	O
,	O
the	O
products	O
of	O
certain	O
IFNgamma-inducible	B-Gene
genes	O
known	O
to	O
influence	O
hematopoietic	O
cell	O
survival	O
were	O
quantified	O
.	O

High	O
constitutive	O
expression	O
of	O
the	O
IFNgamma-inducible	B-Gene
genes	O
,	O
IFN	B-Gene
-stimulated	I-Gene
gene	I-Gene
factor	I-Gene
3	I-Gene
gamma	I-Gene
subunit	I-Gene
(	O
ISGF3gamma	B-Gene
)	O
,	O
IFN	B-Gene
regulatory	I-Gene
factor-1	I-Gene
(	O
IRF-1	B-Gene
)	O
,	O
and	O
the	O
cyclin	B-Gene
-dependent	I-Gene
kinase	I-Gene
inhibitor	I-Gene
p21	I-Gene
(	O
WAF1	B-Gene
)	O
was	O
found	O
in	O
FANCC	B-Gene
mutant	I-Gene
B	O
lymphoblasts	O
,	O
low-density	O
bone	O
marrow	O
cells	O
,	O
and	O
murine	O
embryonic	O
fibroblasts	O
.	O

Paradoxically	O
,	O
these	O
cells	O
do	O
not	O
activate	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
(	I-Gene
STAT	I-Gene
)	I-Gene
1	I-Gene
properly	O
.	O

In	O
an	O
attempt	O
to	O
clarify	O
mechanisms	O
by	O
which	O
FA-C	B-Disease
cells	O
overexpress	O
IFNgamma-inducible	B-Gene
genes	O
in	O
the	O
face	O
of	O
defective	O
STAT1	B-Gene
phosphorylation	O
,	O
it	O
was	O
reasoned	O
that	O
decreased	O
levels	O
of	O
activated	O
STAT1	B-Gene
might	O
result	O
in	O
reduced	O
expression	O
of	O
a	O
hematopoietic	B-Gene
IFNgamma	I-Gene
-responsive	I-Gene
protein	I-Gene
that	O
normally	O
modulates	O
expression	O
of	O
other	O
IFNgamma	B-Gene
-responsive	O
genes	O
.	O

Levels	O
of	O
the	O
IFNgamma	B-Gene
-inducible	O
factor	O
IFN	B-Gene
consensus	I-Gene
sequence	I-Gene
binding	I-Gene
protein	I-Gene
(	O
ICSBP	B-Gene
)	O
,	O
a	O
negative	O
trans	O
-acting	O
regulator	O
of	O
some	O
IFNgamma-inducible	B-Gene
genes	O
,	O
were	O
quantified	O
.	O

ICSBP	B-Gene
levels	O
were	O
reduced	O
in	O
FA-C	B-Disease
B	O
lymphoblasts	O
and	O
MEFs	O
.	O

However	O
,	O
enforced	O
expression	O
of	O
ICSBP	B-Gene
failed	O
to	O
down-regulate	O
IRF-1	B-Gene
,	O
ISGF3gamma	B-Gene
,	O
and	O
p21	B-Gene
(	O
WAF1	B-Gene
)	O
.	O

Thus	O
,	O
the	O
FANCC	B-Gene
protein	I-Gene
functions	O
to	O
modulate	O
expression	O
of	O
a	O
family	O
of	O
genes	O
that	O
in	O
normal	O
cells	O
are	O
inducible	O
only	O
by	O
specific	O
environmental	O
cues	O
for	O
apoptosis	O
or	O
mitogenic	O
inhibition	O
,	O
but	O
it	O
does	O
so	O
independently	O
of	O
the	O
classic	O
IFN-STAT1	B-Gene
pathway	O
and	O
is	O
not	O
the	O
direct	O
result	O
of	O
reduced	O
ICSBP	B-Gene
expression	O
.	O

Distinct	O
BMI-1	B-Gene
and	O
EZH2	B-Gene
expression	O
patterns	O
in	O
thymocytes	O
and	O
mature	O
T	O
cells	O
suggest	O
a	O
role	O
for	O
Polycomb	B-Gene
genes	I-Gene
in	O
human	O
T	O
cell	O
differentiation	O
.	O

BMI-1	B-Gene
and	O
EZH2	B-Gene
Polycomb-group	I-Gene
(	I-Gene
PcG	I-Gene
)	I-Gene
proteins	I-Gene
belong	O
to	O
two	O
distinct	O
protein	O
complexes	O
involved	O
in	O
the	O
regulation	O
of	O
hematopoiesis	O
.	O

Using	O
unique	O
PcG-specific	B-Gene
antisera	I-Gene
and	O
triple	O
immunofluorescence	O
,	O
we	O
found	O
that	O
mature	O
resting	O
peripheral	O
T	O
cells	O
expressed	O
BMI-1	B-Gene
,	O
whereas	O
dividing	O
blasts	O
were	O
EZH2	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
.	O

By	O
contrast	O
,	O
subcapsular	O
immature	O
double	O
-negative	O
(	O
DN	O
)	O
(	O
CD4	B-Gene
(	I-Gene
-	I-Gene
)	I-Gene
/	I-Gene
CD8	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
)	O
T	O
cells	O
in	O
the	O
thymus	O
coexpressed	O
BMI-1	B-Gene
and	O
EZH2	B-Gene
or	O
were	O
BMI-1	B-Gene
single	O
positive	O
.	O

Their	O
descendants	O
,	O
double	O
-positive	O
(	O
DP	O
;	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
/	I-Gene
CD8	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
)	O
cortical	O
thymocytes	O
,	O
expressed	O
EZH2	B-Gene
without	O
BMI-1	B-Gene
.	O

Most	O
EZH2	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
DN	O
and	O
DP	O
thymocytes	O
were	O
dividing	O
,	O
while	O
DN	O
BMI-1	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
/	I-Gene
EZH2	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
thymocytes	O
were	O
resting	O
and	O
proliferation	O
was	O
occasionally	O
noted	O
in	O
DN	O
BMI-1	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
/	I-Gene
EZH2	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
.	O

Maturation	O
of	O
DP	O
cortical	O
thymocytes	O
to	O
single	O
-positive	O
(	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
/	I-Gene
CD8	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
or	O
CD8	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
/	I-Gene
CD4	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
)	O
medullar	O
thymocytes	O
correlated	O
with	O
decreased	O
detectability	O
of	O
EZH2	B-Gene
and	O
continued	O
relative	O
absence	O
of	O
BMI-1	B-Gene
.	O

Our	O
data	O
show	O
that	O
BMI-1	B-Gene
and	O
EZH2	B-Gene
expression	O
in	O
mature	O
peripheral	O
T	O
cells	O
is	O
mutually	O
exclusive	O
and	O
linked	O
to	O
proliferation	O
status	O
,	O
and	O
that	O
this	O
pattern	O
is	O
not	O
yet	O
established	O
in	O
thymocytes	O
of	O
the	O
cortex	O
and	O
medulla	O
.	O

T	O
cell	O
stage-specific	O
PcG	B-Gene
expression	O
profiles	O
suggest	O
that	O
PcG	B-Gene
genes	I-Gene
contribute	O
to	O
regulation	O
of	O
T	O
cell	O
differentiation	O
.	O

They	O
probably	O
reflect	O
stabilization	O
of	O
cell	O
type-specific	O
gene	O
expression	O
and	O
irreversibility	O
of	O
lineage	O
choice	O
.	O

The	O
difference	O
in	O
PcG	B-Gene
expression	O
between	O
medullar	O
thymocytes	O
and	O
mature	O
interfollicular	O
T	O
cells	O
indicates	O
that	O
additional	O
maturation	O
processes	O
occur	O
after	O
thymocyte	O
transportation	O
from	O
the	O
thymus	O
.	O

CD45	B-Gene
tyrosine	I-Gene
phosphatase	I-Gene
controls	O
common	B-Gene
gamma-chain	I-Gene
cytokine	I-Gene
-mediated	O
STAT	B-Gene
and	O
extracellular	O
signal	O
-related	O
kinase	O
phosphorylation	O
in	O
activated	O
human	O
lymphoblasts	O
:	O
inhibition	O
of	O
proliferation	O
without	O
induction	O
of	O
apoptosis	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
CD45	B-Gene
signals	O
can	O
influence	O
signaling	O
processes	O
in	O
activated	O
human	O
lymphoblasts	O
.	O

To	O
this	O
end	O
,	O
we	O
generated	O
lymphoblasts	O
which	O
proliferate	O
in	O
response	O
to	O
common	B-Gene
gamma-chain	I-Gene
cytokines	O
,	O
but	O
readily	O
undergo	O
apoptosis	O
after	O
cytokine	O
withdrawal	O
.	O

In	O
experiments	O
with	O
the	O
CD45R0	B-Gene
mAb	I-Gene
UCHL-1	I-Gene
,	O
but	O
not	O
control	O
CD45	B-Gene
mAbs	I-Gene
,	O
we	O
found	O
significant	O
inhibition	O
of	O
proliferation	O
.	O

Interestingly	O
,	O
the	O
pan-CD45	B-Gene
mAb	I-Gene
GAP8.3	O
,	O
which	O
is	O
most	O
effective	O
in	O
inhibition	O
of	O
OKT-3	B-Chemical
-mediated	O
proliferation	O
in	O
quiescent	O
lymphocytes	O
,	O
was	O
ineffective	O
in	O
lymphoblasts	O
.	O

Addition	O
of	O
CD3	B-Gene
mAb	I-Gene
OKT-3	B-Chemical
had	O
no	O
influence	O
on	O
IL-2	B-Gene
-mediated	O
proliferation	O
(	O
with	O
or	O
without	O
UCHL-1	B-Gene
)	O
.	O

In	O
contrast	O
,	O
after	O
addition	O
of	O
OKT-3	B-Chemical
to	O
IL-4	B-Gene
-	O
and	O
IL-7	B-Gene
-stimulated	O
proliferation	O
assays	O
,	O
UCHL-1	B-Gene
signals	O
could	O
not	O
significantly	O
alter	O
cellular	O
proliferation	O
.	O

We	O
did	O
not	O
find	O
induction	O
of	O
apoptosis	O
following	O
CD45R0	B-Gene
signaling	O
.	O

In	O
Western	O
blots	O
using	O
mAbs	O
detecting	O
phosphorylated	B-Gene
STAT-3	I-Gene
,	O
STAT-5	B-Gene
,	O
STAT-6	B-Gene
,	O
or	O
extracellular	B-Gene
signal	I-Gene
-related	I-Gene
kinase	I-Gene
1	I-Gene
/	I-Gene
2	I-Gene
,	O
we	O
found	O
that	O
CD45R0	B-Gene
signaling	O
could	O
effectively	O
diminish	O
phosphorylation	O
of	O
these	O
intracellular	O
signaling	O
components	O
.	O

Using	O
RT-PCR	O
,	O
we	O
found	O
that	O
CD45R0	B-Gene
signaling	O
inhibited	O
IL-2	B-Gene
mRNA	I-Gene
production	O
without	O
major	O
influence	O
on	O
IL-13	B-Gene
,	O
IL-5	B-Gene
,	O
or	O
IFN-gamma	B-Gene
mRNA	I-Gene
levels	O
.	O

Costimulation	O
with	O
OKT-3	B-Chemical
and	O
IL-2	B-Gene
optimally	O
induced	O
secretion	O
of	O
IFN-gamma	B-Gene
,	O
TNF-alpha	B-Gene
,	O
and	O
IL-5	B-Gene
,	O
which	O
was	O
not	O
decreased	O
by	O
CD45	B-Gene
signals	O
.	O

In	O
conclusion	O
,	O
we	O
illustrate	O
that	O
CD45R0	B-Gene
signals	O
control	O
early	O
cytokine	O
receptor	O
-associated	O
signaling	O
processes	O
and	O
mRNA	O
and	O
DNA	O
synthesis	O
in	O
activated	O
human	O
lymphoblasts	O
.	O

Furthermore	O
,	O
we	O
show	O
the	O
existence	O
of	O
CD45	B-Gene
epitopes	O
(	O
GAP8.3	O
)	O
,	O
which	O
are	O
active	O
and	O
critical	O
for	O
signaling	O
in	O
quiescent	O
lymphocytes	O
,	O
but	O
are	O
nonfunctional	O
in	O
activated	O
human	O
lymphoblasts	O
.	O

Positive	O
and	O
negative	O
roles	O
of	O
the	O
trans	O
-acting	O
T	B-Gene
cell	I-Gene
factor-1	I-Gene
for	O
the	O
acquisition	O
of	O
distinct	O
Ly-49	B-Gene
MHC	I-Gene
class	I-Gene
I	I-Gene
receptors	I-Gene
by	O
NK	O
cells	O
.	O

Members	O
of	O
the	O
Ly-49	B-Gene
gene	I-Gene
family	I-Gene
code	O
for	O
class	B-Gene
I	I-Gene
MHC-specific	I-Gene
receptors	I-Gene
that	O
regulate	O
NK	O
cell	O
function	O
.	O

Due	O
to	O
a	O
combinatorial	O
distribution	O
of	O
Ly-49	B-Gene
receptors	I-Gene
,	O
NK	O
cells	O
display	O
considerable	O
clonal	O
heterogeneity	O
.	O

The	O
acquisition	O
of	O
one	O
Ly-49	B-Gene
receptor	I-Gene
,	O
Ly-49A	B-Gene
is	O
strictly	O
dependent	O
on	O
the	O
transcriptional	B-Gene
trans	I-Gene
-acting	I-Gene
factor	I-Gene
T	I-Gene
cell-specific	I-Gene
factor-1	I-Gene
(	O
TCF-1	B-Gene
)	O
.	O

Indeed	O
,	O
TCF-1	B-Gene
binds	O
to	O
two	O
sites	O
in	O
the	O
Ly-49a	B-Gene
promoter	I-Gene
and	O
regulates	O
its	O
activity	O
,	O
suggesting	O
that	O
the	O
Ly-49a	B-Gene
gene	I-Gene
is	O
a	O
direct	O
TCF-1	B-Gene
target	O
.	O

TCF-1	B-Gene
deficiency	O
resulted	O
in	O
the	O
altered	O
usage	O
of	O
additional	O
Ly-49	B-Gene
receptors	I-Gene
.	O

We	O
show	O
in	O
this	O
study	O
,	O
using	O
TCF-1	B-Gene
beta	I-Gene
(	I-Gene
2	I-Gene
)	I-Gene
-microglobulin	I-Gene
double	O
-deficient	O
mice	O
,	O
that	O
these	O
repertoire	O
alterations	O
are	O
not	O
due	O
to	O
Ly-49	B-Gene
/	I-Gene
MHC	I-Gene
class	I-Gene
I	I-Gene
interactions	O
.	O

Our	O
findings	O
rather	O
suggest	O
a	O
TCF-1	B-Gene
-dependent	O
,	O
cell	O
autonomous	O
effect	O
on	O
the	O
acquisition	O
of	O
multiple	O
Ly-49	B-Gene
receptors	I-Gene
.	O

Besides	O
reduced	O
receptor	O
usage	O
(	O
Ly-49A	B-Gene
and	O
D	B-Partial_Gene
)	O
,	O
we	O
also	O
observed	O
no	O
effect	O
(	O
Ly-49C	B-Gene
)	O
and	O
significantly	O
expanded	O
(	O
Ly-49G	B-Gene
and	O
I	B-Partial_Gene
)	O
receptor	O
usage	O
in	O
the	O
absence	O
of	O
TCF-1	B-Gene
.	O

These	O
effects	O
did	O
not	O
in	O
all	O
cases	O
correlate	O
with	O
the	O
presence	O
of	O
TCF	B-Gene
binding	O
sites	O
in	O
the	O
respective	O
proximal	O
promoter	O
.	O

Therefore	O
,	O
besides	O
TCF-1	B-Gene
binding	O
to	O
the	O
proximal	O
promoter	O
,	O
Ly-49	B-Gene
acquisition	O
may	O
also	O
be	O
regulated	O
by	O
TCF-1	B-Gene
binding	O
to	O
more	O
distant	O
cis	O
-acting	O
elements	O
and	O
/	O
or	O
by	O
regulating	O
the	O
expression	O
of	O
additional	O
trans	O
-acting	O
factors	O
.	O

Consistent	O
with	O
the	O
observed	O
differential	O
,	O
positive	O
or	O
negative	O
role	O
of	O
TCF-1	B-Gene
for	O
Ly-49	B-Gene
receptor	I-Gene
acquisition	O
,	O
reporter	O
gene	O
assays	O
revealed	O
the	O
presence	O
of	O
an	O
inducing	O
as	O
well	O
as	O
a	O
repressing	O
TCF	B-Gene
site	O
in	O
certain	O
proximal	O
Ly-49	B-Gene
promoters	I-Gene
.	O

These	O
findings	O
reveal	O
an	O
important	O
role	O
of	O
TCF-1	B-Gene
for	O
the	O
formation	O
of	O
the	O
NK	O
cell	O
receptor	O
repertoire	O
.	O

A	O
prominent	O
role	O
for	O
activator	B-Gene
protein-1	I-Gene
in	O
the	O
transcription	O
of	O
the	O
human	B-Gene
2B4	I-Gene
(	I-Gene
CD244	I-Gene
)	I-Gene
gene	I-Gene
in	O
NK	O
cells	O
.	O

The	O
cell	B-Gene
surface	I-Gene
glycoprotein	I-Gene
2B4	I-Gene
(	O
CD244	B-Gene
)	O
of	O
the	O
Ig	B-Gene
superfamily	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
NK	O
and	O
T	O
lymphocyte	O
functions	O
.	O

We	O
have	O
recently	O
identified	O
CD48	B-Gene
as	O
the	O
high	O
affinity	O
counterreceptor	O
for	O
2B4	B-Gene
in	O
both	O
mice	O
and	O
humans	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
2B4	B-Gene
associates	O
with	O
src	B-Gene
homology	I-Gene
2	I-Gene
domain	I-Gene
-containing	I-Gene
protein	I-Gene
or	O
signaling	B-Gene
lymphocyte	I-Gene
activation	I-Gene
molecule	I-Gene
-associated	I-Gene
protein	I-Gene
,	O
whose	O
mutation	O
is	O
the	O
underlying	O
genetic	O
defect	O
in	O
the	O
X	O
-linked	O
lymphoproliferative	O
syndrome	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
the	O
human	B-Gene
2B4	I-Gene
(	I-Gene
h2B4	I-Gene
)	I-Gene
promoter	I-Gene
.	O

Through	O
primer	O
extension	O
analysis	O
,	O
we	O
found	O
that	O
the	O
transcription	O
of	O
the	O
h2B4	B-Gene
gene	I-Gene
initiates	O
at	O
multiple	O
start	O
sites	O
.	O

We	O
isolated	O
h2B4	B-Gene
genomic	O
clones	O
and	O
PCR	O
amplified	O
the	O
5	O
'untranslated	O
region	O
containing	O
the	O
promoter	O
elements	O
.	O

We	O
have	O
identified	O
a	O
functional	O
AP-1	B-Gene
site	O
that	O
lies	O
between	O
(	O
-106	O
to	O
-100	O
)	O
through	O
transient	O
transfection	O
analysis	O
in	O
YT	O
cells	O
,	O
a	O
human	O
NK	O
cell	O
line	O
.	O

EMSAs	O
with	O
Abs	O
specific	O
for	O
various	O
protein	O
factors	O
of	O
the	O
AP-1	B-Gene
family	I-Gene
revealed	O
that	O
multiple	O
members	O
of	O
the	O
Jun	B-Gene
family	I-Gene
are	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
h2B4	B-Gene
gene	I-Gene
.	O

Mutation	O
of	O
the	O
AP-1	B-Gene
site	O
not	O
only	O
abolishes	O
protein	O
/	O
DNA	O
interactions	O
but	O
also	O
promoter	O
activity	O
.	O

These	O
results	O
demonstrate	O
a	O
significant	O
role	O
for	O
AP-1	B-Gene
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
h2B4	B-Gene
gene	I-Gene
.	O

Stepwise	O
lineage	O
restriction	O
of	O
progenitors	O
in	O
lympho-myelopoiesis	O
.	O

It	O
has	O
long	O
been	O
controversial	O
whether	O
hematopoiesis	O
progresses	O
through	O
ordered	O
stages	O
of	O
determination	O
as	O
in	O
embryonic	O
development	O
.	O

This	O
is	O
due	O
to	O
the	O
absence	O
of	O
a	O
methodology	O
capable	O
of	O
exactly	O
determining	O
the	O
developmental	O
potential	O
of	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
.	O

The	O
multilineage	O
progenitor	O
(	O
MLP	O
)	O
assay	O
enabled	O
us	O
to	O
discriminate	O
among	O
seven	O
types	O
of	O
hematopoietic	O
progenitors	O
,	O
which	O
are	O
multipotent	O
progenitor	O
p-MTB	O
(	O
capable	O
of	O
generating	O
myeloid	O
,	O
T	O
and	O
B	O
cells	O
)	O
,	O
bipotent	O
progenitors	O
p-MT	O
,	O
p-MB	O
and	O
p-TB	O
,	O
and	O
unipotent	O
progenitors	O
p-M	O
,	O
p-T	O
and	O
p-B	O
.	O

Among	O
these	O
seven	O
types	O
,	O
the	O
p-TB	O
type	O
progenitor	O
was	O
found	O
to	O
be	O
absent	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
process	O
of	O
lineage	O
commitment	O
proceeds	O
through	O
an	O
ordered	O
but	O
not	O
random	O
process	O
.	O

By	O
extending	O
the	O
area	O
of	O
investigation	O
to	O
include	O
the	O
erythroid	O
lineage	O
,	O
more	O
convincing	O
evidence	O
for	O
the	O
ordered	O
process	O
was	O
obtained	O
.	O

Detailed	O
and	O
exact	O
illustration	O
of	O
the	O
process	O
of	O
hematopoiesis	O
will	O
provide	O
an	O
opportunity	O
to	O
revive	O
hematopoiesis	O
as	O
one	O
of	O
the	O
most	O
fascinating	O
targets	O
of	O
research	O
in	O
developmental	O
biology	O

Pax5	B-Gene
determines	O
the	O
identity	O
of	O
B	O
cells	O
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
B-lymphopoiesis	O
.	O

Despite	O
being	O
one	O
of	O
the	O
most	O
intensively	O
studied	O
cell	O
types	O
,	O
the	O
molecular	O
basis	O
of	O
B	O
cell	O
specification	O
is	O
largely	O
unknown	O
.	O

The	O
Pax5	B-Gene
gene	I-Gene
encoding	O
the	O
transcription	B-Gene
factor	I-Gene
BSAP	I-Gene
is	O
required	O
for	O
progression	O
of	O
B-lymphopoiesis	O
beyond	O
the	O
pro-B	O
cell	O
stage	O
.	O

Pax5	B-Gene
-deficient	O
pro-B	O
cells	O
are	O
,	O
however	O
,	O
not	O
yet	O
committed	O
to	O
the	O
B-lymphoid	O
lineage	O
,	O
but	O
instead	O
have	O
a	O
broad	O
lymphomyeloid	O
developmental	O
potential	O
.	O

Pax5	B-Gene
appears	O
to	O
mediate	O
B-lineage	O
commitment	O
by	O
repressing	O
the	O
transcription	O
of	O
non-B-lymphoid	O
genes	O
and	O
by	O
simultaneously	O
activating	O
the	O
expression	O
of	O
B-lineage-specific	O
genes	O
.	O

Pax5	B-Gene
thus	O
functions	O
both	O
as	O
a	O
transcriptional	O
repressor	O
and	O
activator	O
,	O
depending	O
on	O
its	O
interactions	O
with	O
corepressors	O
of	O
the	O
Groucho	B-Gene
protein	I-Gene
family	I-Gene
or	O
with	O
positive	O
regulators	O
such	O
as	O
the	O
TATA	B-Gene
-binding	I-Gene
protein	I-Gene
.	O

Once	O
committed	O
to	O
the	O
B-lineage	O
,	O
B	O
cells	O
require	O
Pax5	B-Gene
function	O
to	O
maintain	O
their	O
B-lymphoid	O
identity	O
throughout	O
B	O
cell	O
development	O

Localized	O
pancreatic	O
NF-kappaB	B-Gene
activation	O
and	O
inflammatory	O
response	O
in	O
taurocholate	B-Chemical
-induced	O
pancreatitis	B-Disease
.	O

Transcription	B-Gene
factor	I-Gene
nuclear	I-Gene
factor-kappaB	I-Gene
(	O
NF-kappaB	B-Gene
)	O
is	O
activated	O
in	O
cerulein	O
pancreatitis	B-Disease
and	O
mediates	O
cytokine	O
expression	O
.	O

The	O
role	O
of	O
transcription	O
factor	O
activation	O
in	O
other	O
models	O
of	O
pancreatitis	B-Disease
has	O
not	O
been	O
established	O
.	O

Here	O
we	O
report	O
upregulation	O
of	O
NF-kappaB	B-Gene
and	O
inflammatory	O
molecules	O
,	O
and	O
their	O
correlation	O
with	O
local	O
pancreatic	B-Disease
injury	I-Disease
,	O
in	O
a	O
model	O
of	O
severe	B-Disease
pancreatitis	I-Disease
.	O

Rats	O
received	O
intraductal	O
infusion	O
of	O
taurocholate	B-Chemical
or	O
saline	O
,	O
and	O
the	O
pancreatic	O
head	O
and	O
tail	O
were	O
analyzed	O
separately	O
.	O

NF-kappaB	B-Gene
and	O
activator	B-Gene
protein-1	I-Gene
(	O
AP-1	B-Gene
)	O
activation	O
were	O
assessed	O
by	O
gel	O
shift	O
assay	O
,	O
and	O
mRNA	O
expression	O
of	O
interleukin-6	B-Gene
,	O
tumor	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
,	O
KC	B-Gene
,	O
monocyte	B-Gene
chemoattractant	I-Gene
protein-1	I-Gene
,	O
and	O
inducible	B-Gene
nitric	I-Gene
oxide	I-Gene
synthase	I-Gene
was	O
assessed	O
by	O
semiquantitative	O
RT-PCR	O
.	O

Morphological	O
damage	O
and	O
trypsin	O
activation	O
were	O
much	O
greater	O
in	O
the	O
pancreatic	O
head	O
than	O
tail	O
,	O
in	O
parallel	O
with	O
a	O
stronger	O
activation	O
of	O
NF-kappaB	B-Gene
and	O
cytokine	O
mRNA	O
.	O

Saline	O
infusion	O
mildly	O
affected	O
these	O
parameters	O
.	O

AP-1	B-Gene
was	O
strongly	O
activated	O
in	O
both	O
pancreatic	O
segments	O
after	O
either	O
taurocholate	B-Chemical
or	O
saline	O
infusion	O
.	O

NF-kappaB	B-Gene
inhibition	O
with	O
N-acetylcysteine	B-Chemical
ameliorated	O
the	O
local	O
inflammatory	O
response	O
.	O

Correlation	O
between	O
localized	O
NF-kappaB	B-Gene
activation	O
,	O
cytokine	O
upregulation	O
,	O
and	O
tissue	O
damage	O
suggests	O
a	O
key	O
role	O
for	O
NF-kappaB	B-Gene
in	O
the	O
development	O
of	O
the	O
inflammatory	O
response	O
of	O
acute	B-Disease
pancreatitis	I-Disease
.	O

Stem	B-Gene
cell	I-Gene
factor	I-Gene
and	O
interleukin-3	B-Gene
induce	O
stepwise	O
generation	O
of	O
erythroid	O
precursor	O
cells	O
from	O
a	O
basic	B-Gene
fibroblast	I-Gene
growth	I-Gene
factor	I-Gene
-dependent	O
hematopoietic	O
stem	O
cell	O
line	O
,	O
A-6	O
.	O

A	O
m	O
ultipotent	O
immature	O
myeloid	O
cell	O
population	O
was	O
produced	O
from	O
a	O
basic	B-Gene
fibroblast	I-Gene
growth	I-Gene
factor	I-Gene
(	O
bFGF	B-Gene
)	O
-dependent	O
hematopoietic	O
stem	O
cell	O
line	O
,	O
A-6	O
,	O
when	O
cultured	O
with	O
stem	B-Gene
cell	I-Gene
factor	I-Gene
(	O
SCF	B-Gene
)	O
replacing	O
bFGF	B-Gene
.	O

Those	O
cells	O
were	O
positive	O
for	O
stem	O
cell	O
markers	O
,	O
c-kit	B-Gene
and	O
CD34	B-Gene
,	O
and	O
a	O
myeloid	O
cell	O
marker	O
,	O
F4	B-Gene
/	I-Gene
80	I-Gene
.	O

Some	O
cell	O
fractions	O
were	O
also	O
positive	O
for	O
Mac-1	B-Gene
,	O
a	O
macrophage	O
marker	O
or	O
Gr-1	B-Gene
,	O
a	O
granulocytic	O
maker	O
,	O
but	O
negative	O
for	O
an	O
erythroid	O
marker	O
TER119	B-Gene
.	O

They	O
also	O
showed	O
the	O
expression	O
of	O
mRNA	O
for	O
the	O
myeloid-specific	B-Gene
PU.1	I-Gene
but	O
did	O
not	O
that	O
for	O
the	O
erythroid-specific	B-Gene
GATA-1	I-Gene
.	O

Among	O
various	O
cytokines	O
,	O
interleukin-3	B-Gene
(	O
IL-3	B-Gene
)	O
induced	O
erythroid	O
precursor	O
cells	O
that	O
expressed	O
the	O
erythroid-specific	B-Gene
GATA-1	I-Gene
and	O
beta-major	B-Gene
globin	I-Gene
.	O

The	O
quantitative	O
analysis	O
showed	O
that	O
erythroid	O
precursor	O
cells	O
were	O
newly	O
produced	O
from	O
the	O
immature	O
myeloid	O
cells	O
by	O
cultivation	O
with	O
IL-3	B-Gene
.	O

SCF	B-Gene
and	O
IL-3	B-Gene
induced	O
stepwise	O
generation	O
of	O
erythroid	O
precursor	O
cells	O
from	O
an	O
A-6	O
hematopoietic	O
stem	O
cell	O
line	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Inhibition	O
of	O
the	O
transcription	B-Gene
factors	I-Gene
AP-1	I-Gene
and	O
NF-kappaB	B-Gene
in	O
CD4	B-Gene
T	O
cells	O
by	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor	I-Gene
gamma	I-Gene
ligands	I-Gene
.	O

The	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor	I-Gene
gamma	I-Gene
(	O
PPARgamma	B-Gene
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
hormone	O
receptor	O
superfamily	O
,	O
is	O
essential	O
for	O
adipocyte	O
differentiation	O
and	O
glucose	B-Chemical
homeostasis	O
.	O

PPARgamma	B-Gene
has	O
been	O
found	O
recently	O
to	O
regulate	O
macrophage	O
activation	O
in	O
response	O
to	O
mitogens	O
and	O
inflammation	O
.	O

Our	O
study	O
shows	O
PPARgamma	B-Gene
to	O
be	O
preferentially	O
expressed	O
in	O
the	O
nuclei	O
of	O
resting	O
T	O
cells	O
and	O
to	O
increase	O
upon	O
activation	O
of	O
T	O
cells	O
by	O
either	O
anti-CD3	B-Gene
and	O
anti-CD28	B-Gene
or	O
phorbol	B-Chemical
myristyl	I-Chemical
acetate	I-Chemical
(	O
PMA	B-Chemical
)	O
.	O

We	O
also	O
found	O
the	O
PPARgamma	B-Gene
ligand	I-Gene
ciglitizone	B-Chemical
to	O
attenuate	O
the	O
activation	O
of	O
T	O
cells	O
by	O
inhibiting	O
cytokine	O
gene	O
expression	O
and	O
anti-CD3	B-Gene
and	O
anti-CD28	B-Gene
or	O
PMA	B-Chemical
-induced	O
proliferative	O
responses	O
.	O

Inhibition	O
of	O
both	O
the	O
proliferative	O
response	O
and	O
inflammatory	O
cytokine	O
expression	O
in	O
CD4	B-Gene
T	O
cells	O
was	O
correlated	O
with	O
suppression	O
of	O
the	O
activated	O
transcription	B-Gene
factors	I-Gene
AP1	I-Gene
and	O
NF-kappaB	B-Gene
.	O

PPARgamma	B-Gene
ligands	I-Gene
also	O
strongly	O
inhibited	O
SEA	B-Gene
-induced	O
Vbeta3	B-Gene
T	O
cell	O
activation	O
in	O
vivo	O
.	O

These	O
results	O
,	O
together	O
with	O
previous	O
findings	O
of	O
the	O
inhibitory	O
effect	O
of	O
PPARgamma	B-Gene
ligands	I-Gene
on	O
activated	O
macrophages	O
,	O
provide	O
clear	O
evidence	O
for	O
PPARgamma	B-Gene
as	O
a	O
negative	O
regulator	O
of	O
the	O
inflammatory	O
activation	O
of	O
both	O
macrophage	O
and	O
T	O
cells	O
.	O

PPARgamma	B-Gene
may	O
thus	O
be	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmunity	O
.	O

Androgens	B-Chemical
indirectly	O
accelerate	O
thymocyte	O
apoptosis	O
.	O

Apoptotic	O
processes	O
,	O
or	O
the	O
disturbance	O
of	O
the	O
natural	O
regulation	O
of	O
these	O
processes	O
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	B-Disease
diseases	I-Disease
(	O
AID	B-Disease
)	O
.	O

Women	O
are	O
,	O
in	O
general	O
,	O
more	O
susceptible	O
than	O
men	O
to	O
develop	O
AID	B-Disease
like	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Androgens	B-Chemical
and	O
glucocorticoids	B-Chemical
,	O
in	O
contrast	O
to	O
oestrogens	B-Chemical
,	O
have	O
favourable	O
effects	O
in	O
AID	B-Disease
models	O
as	O
well	O
as	O
in	O
human	O
AID	B-Disease
.	O

It	O
is	O
known	O
that	O
glucocorticoids	B-Chemical
(	O
GC	B-Chemical
)	O
,	O
used	O
for	O
treatment	O
of	O
AID	B-Disease
,	O
increase	O
apoptosis	O
in	O
the	O
thymus	O
resulting	O
in	O
decreased	O
numbers	O
of	O
CD4+	B-Gene
CD8+	I-Gene
thymocytes	O
.	O

It	O
was	O
asked	O
whether	O
androgens	B-Chemical
,	O
in	O
contrast	O
to	O
oestrogens	B-Chemical
,	O
exert	O
their	O
favourable	O
effects	O
in	O
the	O
treatment	O
of	O
AID	B-Disease
by	O
a	O
mechanism	O
comparable	O
to	O
that	O
described	O
for	O
GC	B-Chemical
by	O
eliminating	O
the	O
apoptosis	O
prone	O
CD4+	B-Gene
CD8+	I-Gene
population	O
in	O
the	O
thymus	O
.	O

Although	O
both	O
androgens	B-Chemical
and	O
oestrogens	B-Chemical
proved	O
thymolytic	O
,	O
a	O
significantly	O
decreased	O
percentage	O
of	O
CD4+	B-Gene
CD8+	I-Gene
thymocytes	O
was	O
observed	O
by	O
flow	O
cytometry	O
after	O
treatment	O
of	O
mice	O
with	O
the	O
androgen	B-Chemical
methyltestosterone	I-Chemical
,	O
but	O
not	O
with	O
the	O
oestrogen	B-Chemical
ethinylestradiol	I-Chemical
.	O

To	O
investigate	O
whether	O
the	O
observed	O
thymolytic	O
effects	O
were	O
due	O
to	O
the	O
presence	O
of	O
hormone	O
receptors	O
on	O
thymocytes	O
,	O
cells	O
were	O
isolated	O
from	O
the	O
thymus	O
and	O
incubated	O
with	O
androgens	B-Chemical
or	O
oestrogens	B-Chemical
to	O
measure	O
apoptosis	O
.	O

Several	O
techniques	O
were	O
used	O
to	O
determine	O
thymocyte	O
apoptosis	O
in	O
vitro	O
,	O
but	O
no	O
enhanced	O
apoptotic	O
signal	O
was	O
observed	O
.	O

Using	O
the	O
very	O
sensitive	O
TUNEL	O
assay	O
,	O
no	O
direct	O
effect	O
of	O
androgens	B-Chemical
on	O
thymocytes	O
in	O
vitro	O
could	O
be	O
observed	O
.	O

This	O
is	O
in	O
sharp	O
contrast	O
to	O
the	O
high	O
signal	O
observed	O
with	O
GC	B-Chemical
.	O

Therefore	O
,	O
upon	O
in	O
vivo	O
androgen	O
treatment	O
,	O
other	O
cells	O
containing	O
androgen	B-Gene
receptors	I-Gene
than	O
thymocytes	O
are	O
probably	O
involved	O
in	O
inducing	O
the	O
increase	O
in	O
thymic	O
apoptosis	O
.	O

To	O
study	O
the	O
role	O
of	O
the	O
androgen	B-Gene
receptor	I-Gene
on	O
thymocyte	O
apoptosis	O
,	O
androgen	B-Gene
receptor	I-Gene
mutant	I-Gene
(	O
Tfm	O
/	O
Y	O
)	O
mice	O
were	O
treated	O
with	O
androgens	B-Chemical
.	O

No	O
alterations	O
of	O
thymocyte	O
subpopulations	O
were	O
seen	O
,	O
suggesting	O
that	O
changes	O
in	O
the	O
percentage	O
of	O
CD4+	B-Gene
CD8+	I-Gene
thymocytes	O
after	O
administration	O
of	O
androgens	B-Chemical
depend	O
on	O
the	O
presence	O
of	O
functional	O
androgen	B-Gene
receptors	I-Gene
.	O

Thus	O
,	O
it	O
is	O
concluded	O
that	O
androgens	B-Chemical
indirectly	O
accelerate	O
thymocyte	O
apoptosis	O
in	O
vivo	O
.	O

A	O
transcriptional	O
block	O
in	O
the	O
IL-2	B-Gene
promoter	I-Gene
at	O
the	O
-150	O
AP-1	B-Gene
site	O
in	O
effector	B-Gene
CD8+	I-Gene
T	O
cells	O
.	O

Both	O
CD4+	B-Gene
and	O
CD8+	B-Gene
T	O
cells	O
that	O
produce	O
IL-2	B-Gene
in	O
response	O
to	O
Ag	O
recognition	O
have	O
been	O
isolated	O
.	O

However	O
,	O
most	O
effector	B-Gene
CD8+	I-Gene
T	O
cells	O
recovered	O
after	O
exposure	O
to	O
Ag	O
do	O
not	O
produce	O
sufficient	O
IL-2	B-Gene
to	O
sustain	O
growth	O
,	O
and	O
depend	O
on	O
CD4+	B-Gene
T	O
helper	O
cells	O
for	O
this	O
obligate	O
growth	O
factor	O
.	O

IL-2	B-Gene
expression	O
in	O
CD4+	B-Gene
T	O
cells	O
is	O
primarily	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
,	O
but	O
mechanisms	O
restricting	O
IL-2	B-Gene
production	O
in	O
CD8+	B-Gene
T	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

To	O
evaluate	O
transcriptional	O
regulation	O
of	O
the	O
IL-2	B-Gene
gene	I-Gene
in	O
CD8+	B-Gene
T	O
cells	O
,	O
we	O
stably	O
transfected	O
reporter	O
genes	O
into	O
Ag	O
-specific	O
CD8+	B-Gene
T	O
cell	O
clones	O
.	O

CD28+	B-Gene
CD8	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
unable	O
to	O
transcribe	O
the	O
IL-2	B-Gene
gene	I-Gene
in	O
response	O
to	O
antigenic	O
stimulation	O
had	O
a	O
block	O
in	O
transactivation	O
of	O
the	O
-150	O
CD28	B-Gene
response	I-Gene
element	I-Gene
(	I-Gene
CD28RE	I-Gene
)	I-Gene
/	I-Gene
AP-1	I-Gene
site	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
,	O
but	O
did	O
transactivate	O
the	O
composite	O
NFAT	B-Gene
/	I-Gene
AP-1	I-Gene
and	O
OCT	B-Gene
/	I-Gene
AP-1	I-Gene
sites	O
,	O
and	O
a	O
consensus	O
AP-1	B-Gene
motif	O
.	O

Mutation	O
of	O
the	O
nonconsensus	O
-150	O
AP-1	B-Gene
site	O
to	O
a	O
consensus	O
AP-1	B-Gene
site	O
,	O
or	O
insertion	O
of	O
a	O
CD28RE	B-Gene
/	I-Gene
AP-1	I-Gene
consensus	O
site	O
upstream	O
of	O
the	O
native	O
-150	O
CD28RE	B-Gene
/	I-Gene
AP-1	I-Gene
site	O
restored	O
transactivation	O
of	O
the	O
altered	O
promoter	O
.	O

These	O
results	O
suggest	O
that	O
the	O
defect	O
at	O
the	O
-150	O
site	O
may	O
reflect	O
the	O
absence	O
or	O
inactivity	O
of	O
a	O
required	O
factor	O
rather	O
than	O
repression	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

Tetramer	O
-guided	O
epitope	O
mapping	O
:	O
rapid	O
identification	O
and	O
characterization	O
of	O
immunodominant	O
CD4+	B-Gene
T	O
cell	O
epitopes	O
from	O
complex	O
antigens	O
.	O

T	O
cell	O
responses	O
to	O
Ags	O
involve	O
recognition	O
of	O
selected	O
peptide	O
epitopes	O
contained	O
within	O
the	O
antigenic	O
protein	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
new	O
approach	O
for	O
direct	O
identification	O
of	O
CD4+	B-Gene
T	O
cell	O
epitopes	O
of	O
complex	O
Ags	O
that	O
uses	O
human	B-Gene
class	I-Gene
II	I-Gene
tetramers	O
to	O
identify	O
reactive	O
cells	O
.	O

With	O
a	O
panel	O
of	O
60	O
overlapping	O
peptides	O
covering	O
the	O
entire	O
sequence	O
of	O
the	O
VP16	B-Gene
protein	I-Gene
,	O
a	O
major	O
Ag	O
for	O
HSV-2	O
,	O
we	O
generated	O
a	O
panel	O
of	O
class	B-Gene
II	I-Gene
MHC	I-Gene
tetramers	O
loaded	O
with	O
peptide	O
pools	O
that	O
were	O
used	O
to	O
stain	O
peripheral	O
lymphocytes	O
of	O
an	O
HSV-2	O
infected	O
individual	O
.	O

With	O
this	O
approach	O
,	O
we	O
identified	O
four	O
new	O
DRA1*0101	B-Gene
/	O
DRB1*0401-	B-Gene
and	O
two	O
DRA1*0101	B-Gene
/	O
DRB1*0404	B-Gene
-restricted	O
,	O
VP16-specific	B-Gene
epitopes	O
.	O

By	O
using	O
tetramers	O
to	O
sort	O
individual	O
cells	O
,	O
we	O
easily	O
obtained	O
a	O
large	O
number	O
of	O
clones	O
specific	O
to	O
these	O
epitopes	O
.	O

Although	O
DRA1*0101	B-Gene
/	O
DRB1*0401	B-Gene
and	O
DRA1*0101	B-Gene
/	O
DRB1*0404	B-Gene
are	O
structurally	O
very	O
similar	O
,	O
nonoverlapping	O
VP16	B-Gene
epitopes	O
were	O
identified	O
,	O
illustrating	O
high	O
selectivity	O
of	O
individual	O
allele	O
polymorphisms	O
within	O
common	O
MHC	B-Gene
variants	O
.	O

This	O
rapid	O
approach	O
to	O
detecting	O
CD4+	B-Gene
T	O
cell	O
epitopes	O
from	O
complex	O
Ags	O
can	O
be	O
applied	O
to	O
any	O
known	O
Ag	O
that	O
gives	O
a	O
T	O
cell	O
response	O
.	O

Molecular	O
mechanism	O
of	O
cell	O
cycle	O
progression	O
induced	O
by	O
the	O
oncogene	B-Gene
product	I-Gene
Tax	I-Gene
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
.	O

The	O
trans-activator	B-Gene
protein	I-Gene
Tax	I-Gene
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adult	B-Disease
T-cell	I-Disease
leukemia	I-Disease
through	O
,	O
at	O
least	O
in	O
part	O
,	O
its	O
ability	O
to	O
stimulate	O
cell	O
growth	O
.	O

We	O
previously	O
reported	O
that	O
Tax	B-Gene
induced	O
cell	O
cycle	O
progression	O
from	O
G0	O
/	O
G1	O
phase	O
to	O
S	O
and	O
G2	O
/	O
M	O
phases	O
in	O
human	O
T-cell	O
line	O
Kit	O
225	O
cells	O
.	O

To	O
elucidate	O
molecular	O
mechanism	O
of	O
Tax	B-Gene
-induced	O
cell	O
cycle	O
progression	O
,	O
we	O
systematically	O
examined	O
the	O
effects	O
of	O
Tax	B-Gene
on	O
biochemical	O
events	O
associated	O
with	O
cell	O
cycle	O
progression	O
.	O

Introduction	O
of	O
Tax	B-Gene
into	O
resting	O
Kit	O
225	O
cells	O
induced	O
activation	O
of	O
the	O
G1	O
/	O
S	O
transition	O
regulation	O
cascade	O
consisting	O
of	O
activation	O
of	O
cyclin	B-Gene
dependent	I-Gene
kinase	I-Gene
2	I-Gene
(	O
CDK2	B-Gene
)	O
and	O
CDK4	B-Gene
,	O
phosphorylation	O
of	O
the	O
Rb	B-Gene
family	I-Gene
proteins	I-Gene
and	O
an	O
increase	O
in	O
free	O
E2F	B-Gene
.	O

The	O
kinase	O
activation	O
was	O
found	O
to	O
result	O
from	O
Tax	B-Gene
-induced	O
expression	O
of	O
genes	O
for	O
cell	O
cycle	O
regulatory	O
molecules	O
including	O
cyclin	B-Gene
D2	I-Gene
,	O
cyclin	B-Gene
E	I-Gene
,	O
E2F1	B-Gene
,	O
CDK2	B-Gene
,	O
CDK4	B-Gene
and	O
CDK6	B-Gene
,	O
and	O
Tax	B-Gene
-induced	O
reduction	O
of	O
CDK	B-Gene
inhibitors	I-Gene
p19	I-Gene
(	O
INK4d	B-Gene
)	O
and	O
p27	B-Gene
(	O
Kip1	B-Gene
)	O
.	O

These	O
modulations	O
by	O
Tax	B-Gene
always	O
paralleled	O
the	O
ability	O
of	O
Tax	B-Gene
to	O
activate	O
the	O
NF-kappaB	B-Gene
transcription	O
pathway	O
.	O

These	O
results	O
indicate	O
the	O
important	O
role	O
of	O
Tax	B-Gene
-mediated	O
trans-activation	O
of	O
the	O
genes	O
for	O
cell	O
cycle	O
regulatory	O
molecules	O
in	O
Tax	B-Gene
-induced	O
cell	O
cycle	O
progression	O
.	O

Expression	O
of	O
interferon	B-Gene
consensus	I-Gene
sequence	I-Gene
binding	I-Gene
protein	I-Gene
induces	O
potent	O
immunity	O
against	O
BCR	B-Gene
/	I-Gene
ABL	I-Gene
-induced	O
leukemia	B-Disease
.	O

Mice	O
deficient	O
in	O
the	O
interferon	B-Gene
consensus	I-Gene
sequence	I-Gene
binding	I-Gene
protein	I-Gene
(	O
ICSBP	B-Gene
)	O
develop	O
a	O
disease	O
resembling	O
chronic	B-Disease
myeloid	I-Disease
leukemia	I-Disease
(	O
CML	B-Disease
)	O
,	O
which	O
in	O
humans	O
is	O
caused	O
by	O
the	O
BCR	B-Gene
/	I-Gene
ABL	I-Gene
oncoprotein	I-Gene
.	O

Interferon-alpha	B-Gene
(	O
IFN-alpha	B-Gene
)	O
induces	O
ICSBP	B-Gene
expression	O
and	O
is	O
an	O
effective	O
therapy	O
for	O
CML	B-Disease
.	O

This	O
study	O
examined	O
whether	O
enforced	O
expression	O
of	O
ICSBP	B-Gene
might	O
antagonize	O
BCR	B-Gene
/	I-Gene
ABL	I-Gene
-induced	O
leukemia	B-Disease
;	O
results	O
demonstrated	O
that	O
ICSBP	B-Gene
-modified	O
cells	O
generated	O
a	O
protective	O
CD8	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cytotoxic	O
T-cell	O
response	O
against	O
BCR	B-Gene
/	I-Gene
ABL	I-Gene
-transformed	O
BaF3	O
cells	O
in	O
a	O
murine	O
leukemia	B-Disease
model	O
.	O

ICSBP	B-Gene
expression	O
represents	O
a	O
novel	O
means	O
of	O
stimulating	O
a	O
host	O
immune	O
response	O
to	O
BCR	B-Gene
/	I-Gene
ABL	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
leukemia	B-Disease
cells	O
and	O
a	O
potential	O
strategy	O
for	O
immunotherapy	O
of	O
CML	B-Disease
.	O

(	O
Blood.	O
2001	O
;	O
97	O
:	O
3491-3497	O
)	O

Antigen-receptor	O
cross	O
-linking	O
and	O
lipopolysaccharide	B-Chemical
trigger	O
distinct	O
phosphoinositide	B-Gene
3-kinase	I-Gene
-dependent	O
pathways	O
to	O
NF-kappa	B-Gene
B	I-Gene
activation	O
in	O
primary	O
B	O
cells	O
.	O

The	O
NF-kappaB	B-Gene
/	I-Gene
Rel	I-Gene
transcription	I-Gene
factors	I-Gene
play	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
B	O
cell	O
development	O
,	O
differentiation	O
and	O
function	O
.	O

Nuclear	B-Gene
NF-kappaB	I-Gene
is	O
induced	O
in	O
B	O
cells	O
by	O
engagement	O
of	O
either	O
the	O
BCR	B-Gene
or	O
CD40	B-Gene
or	O
by	O
stimulation	O
with	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
.	O

Despite	O
the	O
importance	O
of	O
NF-kappaB	B-Gene
to	O
B	O
cell	O
function	O
,	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
leading	O
to	O
NF-kappaB	B-Gene
activation	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
role	O
of	O
phosphoinositide	B-Gene
3'-kinase	I-Gene
(	O
PI	B-Gene
3-kinase	I-Gene
)	O
in	O
BCR	B-Gene
-	O
and	O
LPS	B-Chemical
-induced	O
NF-kappaB	B-Gene
activation	O
using	O
populations	O
of	O
primary	O
murine	O
resting	O
B	O
cells	O
.	O

Using	O
the	O
specific	O
pharmacological	O
inhibitors	O
of	O
PI	B-Gene
3-kinase	I-Gene
,	O
Wortmannin	B-Chemical
and	O
LY294002	B-Chemical
,	O
we	O
demonstrate	O
that	O
PI	B-Gene
3-kinase	I-Gene
activity	O
is	O
vital	O
for	O
BCR	B-Gene
-induced	O
NF-kappaB	B-Gene
DNA	I-Gene
-binding	O
activity	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
this	O
is	O
achieved	O
via	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
-dependent	O
degradation	O
of	O
IkappaBalpha	B-Gene
.	O

Similar	O
analyses	O
reveal	O
that	O
PI	B-Gene
3-kinase	I-Gene
is	O
also	O
critical	O
in	O
triggering	O
NF-kappaB	B-Gene
DNA	I-Gene
-binding	O
activity	O
and	O
IkappaBalpha	B-Gene
degradation	O
following	O
LPS	B-Chemical
stimulation	O
.	O

Interestingly	O
,	O
a	O
PKC	B-Gene
inhibitor	I-Gene
which	O
blocked	O
the	O
BCR	B-Gene
-induced	O
IkappaBalpha	B-Gene
degradation	O
had	O
no	O
effect	O
on	O
the	O
degradation	O
of	O
IkappaBalpha	B-Gene
after	O
LPS	B-Chemical
stimulation	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
the	O
involvement	O
of	O
PI	B-Gene
3-kinase	I-Gene
in	O
at	O
least	O
two	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
activation	O
of	O
NF-kappaB	B-Gene
in	O
B	O
cells	O
.	O

The	O
translesion	O
DNA	B-Gene
polymerase	I-Gene
zeta	I-Gene
plays	O
a	O
major	O
role	O
in	O
Ig	B-Gene
and	O
bcl-6	B-Gene
somatic	O
hypermutation	O
.	O

Ig	B-Gene
somatic	O
mutations	O
would	O
be	O
introduced	O
by	O
a	O
polymerase	O
(	O
pol	O
)	O
while	O
repairing	O
DNA	O
outside	O
main	O
DNA	O
replication	O
.	O

We	O
show	O
that	O
human	O
B	O
cells	O
constitutively	O
express	O
the	O
translesion	B-Gene
pol	I-Gene
zeta	I-Gene
,	O
which	O
effectively	O
extends	O
DNA	O
past	O
mismatched	O
bases	O
(	O
mispair	O
extender	O
)	O
,	O
and	O
pol	B-Gene
eta	I-Gene
,	O
which	O
bypasses	O
DNA	O
lesions	O
in	O
an	O
error-free	O
fashion	O
.	O

Upon	O
B	B-Gene
cell	I-Gene
receptor	I-Gene
(	O
BCR	B-Gene
)	O
engagement	O
and	O
coculture	O
with	O
activated	B-Gene
CD4+	I-Gene
T	O
cells	O
,	O
these	O
lymphocytes	O
upregulated	O
pol	B-Gene
zeta	I-Gene
,	O
downregulated	O
pol	B-Gene
eta	I-Gene
,	O
and	O
mutated	O
the	O
Ig	B-Gene
and	O
bcl-6	B-Gene
genes	I-Gene
.	O

Inhibition	O
of	O
the	O
pol	B-Gene
zeta	I-Gene
REV3	I-Gene
catalytic	I-Gene
subunit	I-Gene
by	O
specific	O
phosphorothioate	B-Chemical
-modified	O
oligonucleotides	O
impaired	O
Ig	B-Gene
and	O
bcl-6	B-Gene
hypermutation	I-Gene
and	O
UV	O
damage	O
-induced	O
DNA	O
mutagenesis	O
,	O
without	O
affecting	O
cell	O
cycle	O
or	O
viability	O
.	O

Thus	O
,	O
pol	B-Gene
zeta	I-Gene
plays	O
a	O
critical	O
role	O
in	O
Ig	B-Gene
and	O
bcl-6	B-Gene
hypermutation	I-Gene
,	O
perhaps	O
facilitated	O
by	O
the	O
downregulation	O
of	O
pol	B-Gene
eta	I-Gene
.	O

Requirement	O
for	O
p38	B-Gene
and	O
p44	B-Gene
/	I-Gene
p42	I-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinases	I-Gene
in	O
RAGE	B-Gene
-mediated	O
nuclear	B-Gene
factor-kappaB	I-Gene
transcriptional	O
activation	O
and	O
cytokine	O
secretion	O
.	O

Advanced	B-Gene
glycation	I-Gene
end	I-Gene
product	I-Gene
(	O
AGE	B-Gene
)	O
activation	O
of	O
the	O
signal	B-Gene
-transducing	I-Gene
receptor	I-Gene
for	I-Gene
AGE	I-Gene
(	O
RAGE	B-Gene
)	O
has	O
been	O
linked	O
to	O
a	O
proinflammatory	O
phenotypic	O
change	O
within	O
cells	O
.	O

However	O
,	O
the	O
precise	O
intracellular	O
signaling	O
pathways	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
demonstrate	O
here	O
that	O
human	B-Gene
serum	I-Gene
albumin	I-Gene
modified	O
with	O
N	B-Chemical
(	I-Chemical
varepsilon	I-Chemical
)	I-Chemical
-	I-Chemical
(	I-Chemical
carboxymethyl	I-Chemical
)	I-Chemical
lysine	I-Chemical
(	O
CML	B-Chemical
)	O
,	O
a	O
major	O
AGE	B-Gene
adduct	O
that	O
progressively	O
accumulates	O
with	O
aging	O
,	O
diabetes	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
,	O
induced	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
-driven	O
reporter	O
gene	O
expression	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

The	O
NF-kappaB	B-Gene
response	O
was	O
blocked	O
with	O
a	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
putative	O
ligand	O
-binding	O
domain	O
of	O
RAGE	B-Gene
,	O
with	O
anti-	B-Gene
RAGE	I-Gene
antiserum	I-Gene
,	O
and	O
by	O
coexpression	O
of	O
truncated	O
receptors	O
lacking	O
the	O
intracellular	O
domain	O
.	O

Signal	O
transduction	O
from	O
RAGE	B-Gene
to	O
NF-kappaB	B-Gene
involved	O
the	O
generation	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
,	O
since	O
reporter	O
gene	O
expression	O
was	O
blocked	O
with	O
the	O
antioxidant	O
N-acetyl-L-cysteine	B-Chemical
.	O

CML	B-Chemical
-modified	O
albumin	B-Gene
produced	O
rapid	O
transient	O
activation	O
of	O
tyrosine	B-Chemical
phosphorylation	O
,	O
extracellular	B-Gene
signal	I-Gene
-regulated	I-Gene
kinase	I-Gene
1	I-Gene
and	O
2	B-Partial_Gene
,	O
and	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
MAPK	B-Gene
)	O
,	O
but	O
not	O
c-Jun	B-Gene
NH	I-Gene
(	I-Gene
2	I-Gene
)	I-Gene
-terminal	I-Gene
kinase	I-Gene
.	O

RAGE	B-Gene
-mediated	O
NF-kappaB	B-Gene
activation	O
was	O
suppressed	O
by	O
the	O
selective	O
p38	B-Gene
MAPK	I-Gene
inhibitor	O
SB203580	B-Chemical
and	O
by	O
coexpression	O
of	O
a	O
kinase-dead	O
p38	B-Gene
dominant	O
-negative	O
mutant	O
.	O

Activation	O
of	O
NF-kappaB	B-Gene
by	O
CML	B-Chemical
-modified	O
albumin	B-Gene
increased	O
secretion	O
of	O
proinflammatory	O
cytokines	O
(	O
tumor	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
,	O
interleukin-1beta	B-Gene
,	O
and	O
monocyte	B-Gene
chemoattractant	I-Gene
protein-1	I-Gene
)	O
severalfold	O
,	O
and	O
inhibition	O
of	O
p38	B-Gene
MAPK	I-Gene
blocked	O
these	O
increases	O
.	O

These	O
results	O
indicate	O
that	O
p38	B-Gene
MAPK	I-Gene
activation	O
mediates	O
RAGE	B-Gene
-induced	O
NF-kappaB	B-Gene
-dependent	O
secretion	O
of	O
proinflammatory	O
cytokines	O
and	O
suggest	O
that	O
accelerated	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
cellular	O
activation	O
induced	O
by	O
this	O
receptor	O
.	O

STAT3	B-Gene
is	O
constitutively	O
active	O
in	O
some	O
patients	O
with	O
Polycythemia	B-Disease
rubra	I-Disease
vera	I-Disease
.	O

OBJECTIVE	O
:	O
Polycythemia	B-Disease
vera	I-Disease
is	O
a	O
clonal	O
stem	O
cell	O
disorder	O
characterized	O
by	O
hyperproliferation	O
of	O
the	O
erythroid	O
,	O
myeloid	O
,	O
and	O
megakaryocytic	O
lineages	O
.	O

While	O
it	O
has	O
been	O
shown	O
that	O
progenitor	O
cells	O
of	O
P.	B-Disease
vera	I-Disease
patients	O
are	O
hypersensitive	O
to	O
several	O
growth	O
factors	O
including	O
erythropoietin	B-Gene
,	O
insulin	B-Gene
-like	I-Gene
growth	I-Gene
factor-1	I-Gene
,	O
thrombopoietin	B-Gene
,	O
interleukin-3	B-Gene
,	O
and	O
granulocyte	B-Gene
/	I-Gene
monocyte	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
,	O
the	O
molecular	O
pathogenesis	O
of	O
this	O
disease	O
remains	O
unknown	O
.	O

Growth	O
factor	O
hypersensitivity	B-Disease
could	O
be	O
mediated	O
by	O
changes	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
therefore	O
investigated	O
a	O
common	O
downstream	O
effector	O
of	O
cytokines	O
,	O
the	O
signal	B-Gene
transducers	I-Gene
and	I-Gene
activators	I-Gene
of	I-Gene
transcription	I-Gene
(	O
STATs	B-Gene
)	O
.	O

A	O
constitutive	O
activation	O
of	O
STAT	B-Gene
factors	I-Gene
could	O
explain	O
the	O
increased	O
proliferation	O
of	O
P.	B-Disease
vera	I-Disease
cells	O
even	O
in	O
the	O
absence	O
of	O
growth	O
factor	O
stimulation	O
.	O

METHODS	O
:	O
Peripheral	O
granulocytes	O
from	O
patients	O
with	O
P.	B-Disease
vera	I-Disease
and	O
from	O
healthy	O
volunteers	O
were	O
assayed	O
for	O
STAT1	B-Gene
,	O
3	B-Partial_Gene
,	O
and	O
5	B-Partial_Gene
DNA	O
binding	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Four	O
of	O
14	O
P.	B-Disease
vera	I-Disease
patients	O
analyzed	O
showed	O
constitutive	O
STAT3	B-Gene
DNA	I-Gene
binding	O
in	O
unstimulated	O
peripheral	O
granulocytes	O
,	O
while	O
none	O
of	O
the	O
17	O
healthy	O
volunteers	O
tested	O
did	O
.	O

None	O
of	O
the	O
subjects	O
showed	O
constitutive	O
STAT1	B-Gene
or	O
STAT5	B-Gene
activity	O
.	O

Western	O
blotting	O
demonstrated	O
that	O
,	O
in	O
the	O
three	O
patients	O
,	O
STAT3	B-Gene
is	O
constitutively	O
phosphorylated	O
on	O
Tyr	B-Chemical
705	O
,	O
whereas	O
it	O
is	O
unphosphorylated	O
in	O
the	O
other	O
patients	O
and	O
in	O
controls	O
.	O

Interestingly	O
,	O
constitutive	O
STAT3	B-Gene
activity	O
did	O
not	O
correlate	O
with	O
the	O
duration	O
of	O
disease	O
or	O
the	O
treatment	O
regimen	O
.	O

It	O
was	O
observed	O
in	O
a	O
recently	O
diagnosed	O
patient	O
and	O
in	O
two	O
patients	O
treated	O
only	O
with	O
phlebotomy	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
constitutive	O
phosphorylation	O
and	O
activation	O
of	O
STAT3	B-Gene
is	O
not	O
a	O
secondary	O
event	O
induced	O
by	O
mutagenizing	O
agents	O
or	O
by	O
prolonged	O
hyperproliferation	O
of	O
hematopoietic	O
cells	O
,	O
but	O
rather	O
represents	O
a	O
primary	O
molecular	O
aberration	O
.	O

Constitutively	O
active	O
STAT3	B-Gene
may	O
contribute	O
to	O
the	O
growth	O
factor	O
hypersensitivity	B-Disease
of	O
P.	B-Disease
vera	I-Disease
cells	O
.	O

T	O
helper-cell	O
phenotype	O
regulates	O
atherosclerosis	B-Disease
in	O
mice	O
under	O
conditions	O
of	O
mild	B-Disease
hypercholesterolemia	I-Disease
.	O

BACKGROUND	O
:	O
T	O
cells	O
are	O
implicated	O
in	O
atherosclerosis	B-Disease
,	O
but	O
little	O
is	O
known	O
about	O
the	O
genetic	O
control	O
or	O
molecular	O
pathways	O
,	O
especially	O
under	O
conditions	O
of	O
mild	B-Disease
hypercholesterolemia	I-Disease
.	O

METHODS	O
AND	O
RESULTS	O
:	O
BALB	O
/	O
c	O
mice	O
,	O
making	O
a	O
CD4+	B-Gene
Th2	O
(	O
IL-4+	B-Gene
)	O
cell	O
response	O
,	O
express	O
both	O
MHC	B-Gene
class	I-Gene
II	I-Gene
antigens	I-Gene
(	O
IA	O
(	O
d	O
)	O
,	O
IE	O
(	O
d	O
)	O
)	O
and	O
are	O
atherosclerosis	B-Disease
-resistant	O
.	O

C57Bl	O
/	O
6	O
mice	O
produce	O
a	O
CD4+	B-Gene
Th1	O
(	O
interferon	B-Gene
[	I-Gene
IFN	I-Gene
]	I-Gene
gamma+	I-Gene
)	O
response	O
,	O
express	O
IA	O
(	O
b	O
)	O
but	O
no	O
IE	O
,	O
and	O
are	O
atherosclerosis-prone	B-Disease
.	O

To	O
evaluate	O
T	O
helper-cell	O
phenotype	O
in	O
fatty	O
streak	O
formation	O
,	O
wild-type	O
C57Bl	O
/	O
6	O
mice	O
(	O
IA	O
(	O
b	O
)	O
+IE-	O
)	O
and	O
transgenic	O
mice	O
,	O
either	O
AB	O
(	O
o	O
)	O
,	O
IA	O
(	O
b	O
)	O
-IE-	O
;	O
ABEalpha	O
,	O
IA-IE	O
(	O
k	O
)	O
+	O
;	O
or	O
BL	O
:	O
TG	O
:	O
Ealpha	O
,	O
IA	O
(	O
b	O
)	O
+IE	O
(	O
k	O
)	O
+	O
,	O
were	O
fed	O
a	O
high-cholesterol	B-Chemical
diet	O
for	O
16	O
weeks	O
and	O
evaluated	O
histomorphometrically	O
for	O
aortic	B-Disease
lesions	I-Disease
.	O

Lesion	O
size	O
in	O
AB	O
(	O
o	O
)	O
,	O
ABEalpha	O
,	O
and	O
BL	O
:	O
TG	O
:	O
Ealpha	O
strains	O
was	O
decreased	O
by	O
54	O
%	O
,	O
79	O
%	O
,	O
and	O
82	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
wild-type	O
,	O
correlating	O
with	O
decreased	O
Th1	O
and	O
increased	O
Th2	O
expression	O
and	O
suggesting	O
that	O
T	O
helper-cell	O
phenotype	O
is	O
important	O
in	O
fatty	O
lesion	O
development	O
.	O

Decreasing	O
Th1	O
cells	O
by	O
antibodies	O
(	O
alpha-CD4	B-Gene
)	O
or	O
cytokines	O
(	O
IL-4	B-Gene
)	O
also	O
caused	O
>	O
/	O
=80	O
%	O
reductions	O
in	O
lesion	O
size	O
.	O

Immunohistology	O
revealed	O
IFN-gamma	B-Gene
,	O
but	O
not	O
IL-4	B-Gene
,	O
colocalized	O
with	O
activated	O
macrophages	O
.	O

Confirming	O
these	O
findings	O
in	O
a	O
different	O
mouse	O
strain	O
,	O
BALB	O
/	O
c	O
Stat	B-Gene
6	I-Gene
knockout	O
mice	O
(	O
Th2	O
cell	O
-deficient	O
)	O
developed	O
aortic	B-Disease
lesions	I-Disease
comparable	O
to	O
C57Bl	O
/	O
6	O
mice	O
on	O
the	O
same	O
diet	O
.	O

CONCLUSIONS	O
:	O
In	O
mildly	O
hypercholesterolemic	O
C57Bl	O
/	O
6	O
mice	O
,	O
presence	O
of	O
IA	O
(	O
b	O
)	O
and	O
absence	O
of	O
IE	O
regulated	O
CD4+	B-Gene
T	O
helper-cell	O
phenotype	O
;	O
fatty	O
lesions	O
were	O
proportional	O
to	O
IFNgamma+	B-Gene
Th1	O
cells	O
in	O
both	O
C57Bl	O
/	O
6	O
and	O
BALB	O
/	O
c	O
strains	O
.	O

IFN-gamma	B-Gene
may	O
participate	O
through	O
macrophage	O
activation	O
,	O
whereas	O
IL-4	B-Gene
may	O
act	O
to	O
limit	O
Th1-cell	O
response	O
.	O

Smad3	B-Gene
and	O
Smad4	B-Gene
mediate	O
transforming	B-Gene
growth	I-Gene
factor-beta1	I-Gene
-induced	O
IgA	B-Gene
expression	O
in	O
murine	O
B	O
lymphocytes	O
.	O

Transforming	B-Gene
growth	I-Gene
factor	I-Gene
(	I-Gene
TGF	I-Gene
)	I-Gene
-beta1	I-Gene
is	O
well	O
established	O
as	O
a	O
critical	O
IgA	B-Gene
isotype	O
switching	O
factor	O
and	O
Smad	B-Gene
molecules	O
have	O
been	O
reported	O
to	O
act	O
as	O
transducers	O
and	O
transcriptional	O
factors	O
in	O
the	O
expression	O
of	O
TGF-beta1	B-Gene
-targeted	O
genes	O
.	O

We	O
examined	O
the	O
involvement	O
of	O
Smad	B-Gene
proteins	I-Gene
in	O
TGF-beta1	B-Gene
-induced	O
IgA	B-Gene
expression	O
.	O

First	O
,	O
we	O
found	O
that	O
TGF-beta1	B-Gene
significantly	O
increases	O
endogenous	O
germ-line	O
(	O
GL	O
)	O
alpha	O
transcripts	O
by	O
LPS	B-Chemical
-stimulated	O
CH12.LX.4933	O
(	O
mu	O
(	O
+	O
)	O
)	O
B	B-Disease
lymphoma	I-Disease
cells	O
.	O

To	O
investigate	O
its	O
signaling	O
mechanisms	O
,	O
the	O
lymphoma	B-Disease
cell	O
line	O
was	O
transfected	O
with	O
pFL3	O
that	O
contains	O
the	O
TGF-beta	B-Gene
-responsive	I-Gene
element	I-Gene
of	O
the	O
GLalpha	O
promoter	O
,	O
and	O
stimulated	O
with	O
TGF-beta1	B-Gene
.	O

Similar	O
to	O
endogenous	O
GLalpha	O
transcripts	O
,	O
TGF-beta1	B-Gene
induces	O
GLalpha	O
promoter	O
activity	O
and	O
overexpression	O
of	O
Smad3	B-Gene
markedly	O
enhances	O
the	O
promoter	O
activity	O
.	O

This	O
activity	O
is	O
further	O
augmented	O
by	O
cotransfected	O
Smad4	B-Gene
.	O

On	O
the	O
other	O
hand	O
,	O
Smad7	B-Gene
substantially	O
abrogates	O
the	O
synergistic	O
effect	O
of	O
Smad3	B-Gene
/	I-Gene
4	I-Gene
on	O
GLalpha	O
promoter	O
activity	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
Smad3	B-Gene
/	I-Gene
4	I-Gene
enhances	O
TGF-beta1	B-Gene
-induced	O
endogenous	O
GLalpha	O
transcripts	O
in	O
normal	O
spleen	O
B	O
cell	O
s	O
.	O

Finally	O
,	O
in	O
the	O
presence	O
of	O
TGF-beta1	B-Gene
,	O
overexpression	O
of	O
Smad3	B-Gene
/	I-Gene
4	I-Gene
selectively	O
increases	O
both	O
surface	O
IgA	B-Gene
expression	O
and	O
IgA	B-Gene
production	O
.	O

The	O
results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
Smad3	B-Gene
,	O
Smad4	B-Gene
,	O
and	O
Smad7	B-Gene
,	O
at	O
least	O
in	O
part	O
,	O
serve	O
as	O
mediators	O
linking	O
TGF-beta1	B-Gene
to	O
transcriptional	O
regulation	O
of	O
IgA	B-Gene
switching	O
related	O
gene	O
and	O
regulation	O
of	O
IgA	B-Gene
class	O
switching	O
.	O

The	O
effect	O
of	O
HIV-1	O
regulatory	O
proteins	O
on	O
cellular	O
genes	O
:	O
derepression	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
by	O
Tat	B-Gene
.	O

In	O
HIV	O
-infected	O
individuals	O
dysregulation	O
of	O
the	O
immune	O
system	O
is	O
characterized	O
by	O
severe	O
disorders	O
of	O
the	O
cytokine	O
network	O
.	O

Increase	O
secretion	O
of	O
IL-2	B-Gene
,	O
the	O
major	O
T	O
cell	O
growth	O
and	O
differentiation	O
cytokine	O
,	O
may	O
play	O
a	O
decisive	O
role	O
in	O
sensitization	O
of	O
T	O
cells	O
for	O
activation	O
induced	O
apoptosis	O
and	O
indirect	O
death	O
of	O
activated	O
T	O
cells	O
through	O
augmented	O
virus	O
replication	O
.	O

We	O
investigated	O
the	O
cause	O
of	O
enhanced	O
IL-2	B-Gene
secretion	O
and	O
found	O
that	O
the	O
HIV	B-Gene
Tat	I-Gene
induces	O
this	O
effect	O
.	O

We	O
demonstrate	O
that	O
increased	O
IL-2	B-Gene
secretion	O
is	O
due	O
to	O
Tat	B-Gene
-enhanced	O
IL-2	B-Gene
promoter	I-Gene
activation	O
.	O

Tat	B-Gene
derepresses	O
and	O
activates	O
the	O
distal	O
AP-1	B-Gene
site	O
(	O
position	O
-185	O
to	O
-177	O
)	O
in	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

In	O
nonstimulated	O
T	O
cells	O
a	O
repressor	O
complex	O
containing	O
NF-IL6	B-Gene
,	O
JunB	B-Gene
,	O
c-Fos	B-Gene
and	O
Fra-1	B-Gene
is	O
formed	O
on	O
the	O
AP-1	B-Gene
(	O
IL-2	B-Gene
/	I-Gene
d	I-Gene
)	O
site	O
and	O
represses	O
IL-2	B-Gene
promoter	I-Gene
activity	O
.	O

After	O
T	O
cell	O
activation	O
,	O
a	O
heterodimeric	O
activator	O
containing	O
p65	B-Gene
and	O
c-Jun	B-Gene
binds	O
to	O
the	O
AP-1	B-Gene
(	O
IL-2	B-Gene
/	I-Gene
d	I-Gene
)	O
site	O
.	O

HIV	B-Gene
Tat	I-Gene
enhances	O
activation	O
of	O
NF-kappaB	B-Gene
and	O
consequently	O
,	O
activates	O
the	O
AP-1	B-Gene
(	O
IL-2	B-Gene
/	I-Gene
d	I-Gene
)	O
site	O
.	O

Our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
mechanism	O
by	O
which	O
HIV	B-Gene
Tat	I-Gene
dysregulates	O
IL-2	B-Gene
production	O
and	O
therefore	O
may	O
contribute	O
to	O
the	O
HIV-1	O
infection	O
in	O
a	O
way	O
yet	O
to	O
be	O
clarified	O
.	O

Plasmin	B-Gene
-induced	O
expression	O
of	O
cytokines	O
and	O
tissue	B-Gene
factor	I-Gene
in	O
human	O
monocytes	O
involves	O
AP-1	B-Gene
and	O
IKKbeta	B-Gene
-mediated	O
NF-kappaB	B-Gene
activation	O
.	O

It	O
was	O
previously	O
shown	O
that	O
plasmin	B-Gene
activates	O
human	O
peripheral	O
monocytes	O
in	O
terms	O
of	O
lipid	O
mediator	O
release	O
and	O
chemotactic	O
migration	O
.	O

Here	O
it	O
is	O
demonstrated	O
that	O
plasmin	B-Gene
induces	O
proinflammatory	O
cytokine	O
release	O
and	O
tissue	B-Gene
factor	I-Gene
(	O
TF	B-Gene
)	O
expression	O
by	O
monocytes	O
.	O

Plasmin	B-Gene
0.043	O
to	O
1.43	O
CTA	O
U	O
/	O
mL	O
,	O
but	O
not	O
active	O
site	O
-blocked	O
plasmin	B-Gene
,	O
triggered	O
concentration	O
-dependent	O
expression	O
of	O
mRNA	O
for	O
interleukin-1alpha	B-Gene
(	O
IL-1alpha	B-Gene
)	O
,	O
IL-1beta	B-Gene
,	O
tumor	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
,	O
and	O
TF	B-Gene
with	O
maximum	O
responses	O
after	O
4	O
hours	O
.	O

Plasmin	B-Gene
-mediated	O
mRNA	O
expression	O
was	O
inhibited	O
in	O
a	O
concentration	O
-dependent	O
manner	O
by	O
the	O
lysine	B-Chemical
analogue	O
trans-4-	B-Chemical
(	I-Chemical
aminomethyl	I-Chemical
)	I-Chemical
cyclohexane-1-carboxylic	I-Chemical
acid	I-Chemical
(	O
t-AMCA	B-Chemical
)	O
.	O

Increases	O
in	O
mRNA	O
levels	O
were	O
followed	O
by	O
concentration-	O
and	O
time	O
-dependent	O
release	O
of	O
IL-1alpha	B-Gene
,	O
IL-1beta	B-Gene
and	O
TNF-alpha	B-Gene
and	O
by	O
TF	B-Gene
expression	O
on	O
monocyte	O
surfaces	O
.	O

Neither	O
cytokines	O
nor	O
TF	B-Gene
could	O
be	O
detected	O
when	O
monocytes	O
were	O
preincubated	O
with	O
actinomycin	B-Chemical
D	I-Chemical
or	O
cycloheximide	B-Chemical
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
plasmin	B-Gene
-induced	O
activation	O
of	O
NF-kappaB	B-Gene
;	O
DNA	O
-binding	O
complexes	O
were	O
composed	O
of	O
p50	B-Gene
,	O
p65	B-Gene
,	O
and	O
c-Rel	B-Gene
,	O
as	O
shown	O
by	O
supershift	O
experiments	O
.	O

Nuclear	O
translocation	O
of	O
NF-kappaB	B-Gene
/	I-Gene
Rel	I-Gene
proteins	I-Gene
coincided	O
with	O
IkappaBalpha	B-Gene
degradation	O
.	O

At	O
variance	O
with	O
endotoxic	O
lipopolysaccharide	B-Chemical
,	O
plasmin	B-Gene
elicited	O
the	O
rapid	O
degradation	O
of	O
another	O
cytoplasmic	B-Gene
NF-kappaB	I-Gene
inhibitor	I-Gene
,	O
p105	B-Gene
.	O

Proteolysis	O
of	O
NF-kappaB	B-Gene
inhibitors	I-Gene
was	O
apparently	O
due	O
to	O
transient	O
activation	O
of	O
IkappaB	B-Gene
kinase	I-Gene
(	I-Gene
IKK	I-Gene
)	I-Gene
beta	I-Gene
that	O
reached	O
maximum	O
activity	O
at	O
1	O
hour	O
after	O
plasmin	B-Gene
stimulation	O
.	O

In	O
addition	O
,	O
AP-1	B-Gene
binding	O
was	O
increased	O
in	O
plasmin	B-Gene
-treated	O
monocytes	O
,	O
with	O
most	O
complexes	O
composed	O
of	O
JunD	B-Gene
,	O
c-Fos	B-Gene
,	O
and	O
FosB	B-Gene
.	O

These	O
findings	O
further	O
substantiate	O
the	O
role	O
of	O
plasmin	B-Gene
as	O
a	O
proinflammatory	O
activator	O
of	O
human	O
monocytes	O
and	O
reveal	O
an	O
important	O
new	O
link	O
between	O
the	O
plasminogen-plasmin	B-Gene
system	O
and	O
inflammation	O
.	O

(	O
Blood.	O
2001	O
;	O
97	O
:	O
3941-3950	O
)	O

Treatment	O
of	O
allergic	O
airway	B-Disease
inflammation	I-Disease
and	O
hyperresponsiveness	O
by	O
antisense	O
-induced	O
local	O
blockade	O
of	O
GATA-3	B-Gene
expression	O
.	O

Recent	O
studies	O
in	O
transgenic	O
mice	O
have	O
revealed	O
that	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
GATA-3	I-Gene
in	O
T	O
cells	O
can	O
prevent	O
T	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
-mediated	O
allergic	O
airway	B-Disease
inflammation	I-Disease
in	O
mice	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
GATA-3	B-Gene
plays	O
a	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
airway	B-Disease
inflammation	I-Disease
and	O
whether	O
antagonizing	O
the	O
expression	O
and	O
/	O
or	O
function	O
of	O
GATA-3	B-Gene
can	O
be	O
used	O
for	O
the	O
therapy	O
of	O
allergic	O
airway	B-Disease
inflammation	I-Disease
and	O
hyperresponsiveness	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
locally	O
antagonizing	O
GATA-3	B-Gene
function	O
in	O
a	O
murine	O
model	O
of	O
asthma	B-Disease
.	O

We	O
could	O
suppress	O
GATA-3	B-Gene
expression	O
in	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-4	I-Gene
-producing	O
T	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
an	O
antisense	O
phosphorothioate	O
oligonucleotide	O
overlapping	O
the	O
translation	O
start	O
site	O
of	O
GATA-3	B-Gene
,	O
whereas	O
nonsense	O
control	O
oligonucleotides	O
were	O
virtually	O
inactive	O
.	O

In	O
a	O
murine	O
model	O
of	O
asthma	B-Disease
associated	O
with	O
allergic	B-Disease
pulmonary	I-Disease
inflammation	I-Disease
and	O
hyperresponsiveness	O
in	O
ovalbumin	B-Gene
(	O
OVA	B-Gene
)	O
-sensitized	O
mice	O
,	O
local	O
intranasal	O
administration	O
of	O
fluorescein	O
isothiocyanate	O
-labeled	O
GATA-3	B-Gene
antisense	O
oligonucleotides	O
led	O
to	O
DNA	O
uptake	O
in	O
lung	O
cells	O
associated	O
with	O
a	O
reduction	O
of	O
intracellular	B-Gene
GATA-3	I-Gene
expression	O
.	O

Such	O
intrapulmonary	O
blockade	O
of	O
GATA-3	B-Gene
expression	O
caused	O
an	O
abrogation	O
of	O
signs	O
of	O
lung	B-Disease
inflammation	I-Disease
including	O
infiltration	O
of	O
eosinophils	O
and	O
Th2	O
cytokine	O
production	O
.	O

Furthermore	O
,	O
treatment	O
with	O
antisense	O
but	O
not	O
nonsense	O
oligonucleotides	O
induced	O
a	O
significant	O
reduction	O
of	O
airway	B-Disease
hyperresponsiveness	I-Disease
in	O
OVA	B-Gene
-sensitized	O
mice	O
to	O
levels	O
comparable	O
to	O
saline	O
-treated	O
control	O
mice	O
,	O
as	O
assessed	O
by	O
both	O
enhanced	O
pause	O
(	O
PenH	O
)	O
responses	O
and	O
pulmonary	O
resistance	O
determined	O
by	O
body	O
plethysmography	O
.	O

These	O
data	O
indicate	O
a	O
critical	O
role	O
for	O
GATA-3	B-Gene
in	O
the	O
effector	O
phase	O
of	O
a	O
murine	O
asthma	B-Disease
model	O
and	O
suggest	O
that	O
local	O
delivery	O
of	O
GATA-3	B-Gene
antisense	O
oligonucleotides	O
may	O
be	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
airway	B-Disease
hyperresponsiveness	I-Disease
such	O
as	O
in	O
asthma	B-Disease
.	O

This	O
approach	O
has	O
the	O
potential	O
advantage	O
of	O
suppressing	O
the	O
expression	O
of	O
various	O
proinflammatory	O
Th2	O
cytokines	O
simultaneously	O
rather	O
than	O
suppressing	O
the	O
activity	O
of	O
a	O
single	O
cytokine	O
.	O

Pharmacokinetic	O
differences	O
between	O
a	O
T	O
cell	O
-tolerizing	O
and	O
a	O
T	O
cell	O
-activating	O
peptide	O
.	O

Vaccination	O
with	O
a	O
peptide	O
representing	O
a	O
CTL	O
epitope	O
from	O
the	O
human	B-Gene
papillomavirus	I-Gene
(	I-Gene
HPV	I-Gene
)	I-Gene
16	I-Gene
E7	I-Gene
protein	I-Gene
induces	O
a	O
specific	O
CTL	O
response	O
that	O
prevents	O
the	O
outgrowth	O
of	O
HPV16	B-Gene
E7	I-Gene
-expressing	O
tumors	B-Disease
.	O

In	O
contrast	O
,	O
vaccination	O
with	O
a	O
peptide	O
encoding	O
an	O
adenovirus	B-Gene
type	I-Gene
5	I-Gene
(	I-Gene
Ad5	I-Gene
)	I-Gene
E1A	I-Gene
CTL	O
epitope	O
results	O
in	O
CTL	O
tolerance	O
and	O
enhanced	O
growth	O
of	O
an	O
Ad5	B-Gene
E1A	I-Gene
-expressing	O
tumor	B-Disease
.	O

It	O
is	O
unclear	O
why	O
these	O
peptides	O
induce	O
such	O
opposite	O
effects	O
.	O

To	O
determine	O
whether	O
a	O
difference	O
in	O
pharmacokinetics	O
can	O
explain	O
the	O
functional	O
contrasts	O
,	O
tritiated	O
Ad5	B-Gene
E1A	I-Gene
and	O
HPV16	B-Gene
E7	I-Gene
peptides	O
were	O
injected	O
into	O
mice	O
.	O

Results	O
show	O
that	O
the	O
tolerizing	O
peptide	O
spread	O
through	O
the	O
body	O
16	O
times	O
faster	O
than	O
the	O
activating	O
peptide	O
and	O
was	O
cleared	O
at	O
least	O
2	O
times	O
faster	O
.	O

The	O
HPV16	B-Gene
E7	I-Gene
peptide	O
kinetics	O
correlated	O
with	O
the	O
kinetics	O
of	O
HPV16	B-Gene
E7	I-Gene
-specific	O
CTL	O
induction	O
.	O

In	O
contrast	O
,	O
Ad5	B-Gene
E1A	I-Gene
peptide	O
injection	O
resulted	O
in	O
physical	O
deletion	O
of	O
preexisting	O
Ad5	B-Gene
E1A	I-Gene
-specific	O
CTLs	O
within	O
24	O
h	O
after	O
injection	O
.	O

This	O
tolerization	O
occurred	O
at	O
the	O
time	O
when	O
the	O
peptide	O
reached	O
its	O
maximum	O
peptide	O
concentration	O
in	O
the	O
organs	O
.	O

These	O
data	O
suggest	O
that	O
ubiquitous	O
expression	O
of	O
the	O
tolerizing	O
Ad5	B-Gene
E1A	I-Gene
peptide	O
within	O
a	O
short	O
period	O
of	O
time	O
causes	O
activation	O
-induced	O
cell	O
death	O
of	O
Ad5	B-Gene
E1A	I-Gene
-specific	O
CTLs	O
.	O

Therefore	O
,	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
peptides	O
is	O
vital	O
for	O
the	O
safety	O
and	O
efficacy	O
of	O
peptide	O
-based	O
vaccines	O
.	O

Stat6	B-Gene
is	O
necessary	O
and	O
sufficient	O
for	O
IL-4	B-Gene
's	O
role	O
in	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
.	O

IL-4	B-Gene
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
T	O
CR	O
-stimulated	O
naive	O
CD4	B-Gene
T	O
cells	O
to	O
the	O
Th2	O
phenotype	O
.	O

In	O
response	O
to	O
IL-4	B-Gene
,	O
the	O
IL-4R	B-Gene
activates	O
a	O
set	O
of	O
phosphotyrosine	B-Chemical
binding	O
domain	O
-containing	O
proteins	O
,	O
including	O
insulin	B-Gene
receptor	I-Gene
substrate	I-Gene
1	I-Gene
/	I-Gene
2	I-Gene
,	O
Shc	B-Gene
,	O
and	O
IL-4R	B-Gene
interacting	I-Gene
protein	I-Gene
,	O
as	O
well	O
as	O
Stat6	B-Gene
.	O

Stat6	B-Gene
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
Th2	O
differentiation	O
.	O

To	O
determine	O
the	O
roles	O
of	O
the	O
phosphotyrosine	B-Chemical
binding	O
adaptors	O
in	O
Th2	O
differentiation	O
,	O
we	O
prepared	O
a	O
retrovirus	O
containing	O
a	O
mutant	O
of	O
the	O
human	B-Gene
(	I-Gene
h	I-Gene
)	I-Gene
IL-4R	I-Gene
alpha-chain	I-Gene
,	O
Y497F	O
,	O
which	O
is	O
unable	O
to	O
recruit	O
these	O
adaptors	O
.	O

The	O
mutant	O
hIL-4Ralpha	B-Gene
,	O
as	O
well	O
as	O
the	O
wild-type	O
(	O
WT	O
)	O
hIL-4Ralpha	B-Gene
,	O
was	O
introduced	O
into	O
naive	O
CD4	B-Gene
T	O
cells	O
.	O

Upon	O
hIL-4	B-Gene
stimulation	O
,	O
Y497F	O
worked	O
as	O
well	O
as	O
the	O
WT	O
hIL-4Ralpha	B-Gene
in	O
driving	O
Th2	O
differentiation	O
,	O
as	O
measured	O
by	O
Gata3	B-Gene
up-regulation	O
and	O
IL-4	B-Gene
production	O
.	O

Furthermore	O
,	O
IL-4-driven	B-Gene
cell	O
expansion	O
was	O
also	O
normal	O
in	O
the	O
cells	O
infected	O
with	O
Y497F	O
,	O
although	O
cells	O
infected	O
with	O
Y497F	O
were	O
not	O
capable	O
of	O
phosphorylating	O
insulin	B-Gene
receptor	I-Gene
substrate	I-Gene
2	I-Gene
.	O

These	O
results	O
suggest	O
that	O
the	O
signal	O
pathway	O
mediated	O
by	O
Y497	O
is	O
dispensable	O
for	O
both	O
IL-4	B-Gene
-driven	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
.	O

Both	O
WT	O
and	O
Y497F	O
hIL-4Ralpha	B-Gene
lose	O
the	O
ability	O
to	O
drive	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
in	O
Stat6-knockout	B-Gene
CD4	B-Gene
T	O
cells	O
.	O

A	O
constitutively	O
activated	O
form	O
of	O
Stat6	B-Gene
introduced	O
into	O
CD4	B-Gene
T	O
cells	O
resulted	O
in	O
both	O
Th2	O
differentiation	O
and	O
enhanced	O
cell	O
expansion	O
.	O

Thus	O
,	O
activated	B-Gene
Stat6	I-Gene
is	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
both	O
IL-4	B-Gene
-driven	O
Th2	O
differentiation	O
and	O
cell	O
expansion	O
in	O
CD4	B-Gene
T	O
cells	O
.	O

Cytokine	O
production	O
by	O
Vgamma	O
(	O
+	O
)	O
-T-cell	O
subsets	O
is	O
an	O
important	O
factor	O
determining	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-Th-cell	O
phenotype	O
and	O
susceptibility	O
of	O
BALB	O
/	O
c	O
mice	O
to	O
coxsackievirus	O
B3	O
-induced	O
myocarditis	B-Disease
.	O

Two	O
coxsackievirus	O
B3	O
(	O
CVB3	O
)	O
variants	O
(	O
H3	O
and	O
H310A1	O
)	O
differ	O
by	O
a	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
VP2	B-Gene
capsid	I-Gene
protein	I-Gene
.	O

H3	O
induces	O
severe	B-Disease
myocarditis	I-Disease
in	O
BALB	O
/	O
c	O
mice	O
,	O
but	O
H310A1	O
is	O
amyocarditic	O
.	O

Infection	O
with	O
H3	O
,	O
but	O
not	O
H310A1	O
,	O
preferentially	O
activates	O
Vgamma4	O
Vdelta4	O
cells	O
,	O
which	O
are	O
strongly	O
positive	O
for	O
gamma	B-Gene
interferon	I-Gene
(	O
IFN-gamma	B-Gene
)	O
,	O
whereas	O
Vgamma1	O
Vdelta4	O
cells	O
are	O
increased	O
in	O
both	O
H3	O
and	O
H310A1	O
virus	O
-infected	O
animals	O
.	O

Depletion	O
of	O
Vgamma1	O
(	O
+	O
)	O
cells	O
using	O
monoclonal	O
anti-Vgamma1	O
antibody	O
enhanced	O
myocarditis	B-Disease
and	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-	O
,	O
IFN-gamma	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-cell	O
responses	O
in	O
both	O
H3-	O
and	O
H310A1	O
-infected	O
mice	O
yet	O
decreased	O
the	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-	O
,	O
IL-4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-cell	O
response	O
.	O

Depleting	O
Vgamma4	O
(	O
+	O
)	O
cells	O
suppressed	O
myocarditis	B-Disease
and	O
reduced	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
IFN-gamma	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
but	O
increased	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
IL-4	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
.	O

The	O
role	O
of	O
cytokine	O
production	O
by	O
Vgamma1	O
(	O
+	O
)	O
and	O
Vgamma4	O
(	O
+	O
)	O
T	O
cells	O
was	O
investigated	O
by	O
adoptively	O
transferring	O
these	O
cells	O
isolated	O
from	O
H3	O
-infected	O
BALB	O
/	O
c	O
Stat4	B-Gene
knockout	O
(	O
Stat4ko	B-Gene
)	O
(	O
defective	O
in	O
IFN-gamma	B-Gene
expression	O
)	O
or	O
BALB	O
/	O
c	O
Stat6ko	B-Gene
(	O
defective	O
in	O
IL-4	B-Gene
expression	O
)	O
mice	O
into	O
H3	O
virus	O
-infected	O
wild-type	O
BALB	O
/	O
c	O
recipients	O
.	O

Vgamma4	O
and	O
Vgamma1	O
(	O
+	O
)	O
T	O
cells	O
from	O
Stat4ko	B-Gene
mice	O
expressed	O
IL-4	B-Gene
but	O
no	O
or	O
minimal	O
IFN-gamma	B-Gene
,	O
whereas	O
these	O
cell	O
populations	O
derived	O
from	O
Stat6ko	B-Gene
mice	O
expressed	O
IFN-gamma	B-Gene
but	O
no	O
IL-4	B-Gene
.	O

Stat4ko	B-Gene
Vgamma1	O
(	O
+	O
)	O
cells	O
(	O
IL-4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
)	O
suppress	O
myocarditis	B-Disease
.	O

Stat6ko	B-Gene
Vgamma1	O
(	O
+	O
)	O
cells	O
(	O
IFN-gamma	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
)	O
were	O
not	O
inhibitory	O
.	O

Stat6ko	B-Gene
Vgamma4	O
(	O
+	O
)	O
cells	O
(	O
IFN-gamma	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
)	O
significantly	O
enhanced	O
myocarditis	B-Disease
.	O

Stat4ko	B-Gene
Vgamma4	O
(	O
+	O
)	O
cells	O
(	O
IL-4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
)	O
neither	O
inhibited	O
nor	O
enhanced	O
disease	O
.	O

These	O
results	O
show	O
that	O
distinct	O
gammadelta-T-cell	O
subsets	O
control	O
myocarditis	B-Disease
susceptibility	O
and	O
bias	O
the	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-Th-cell	O
response	O
.	O

The	O
cytokines	O
produced	O
by	O
the	O
Vgamma	O
subpopulation	O
have	O
a	O
significant	O
influence	O
on	O
the	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-Th-cell	O
phenotype	O
.	O

Inhaled	O
nitric	B-Chemical
oxide	I-Chemical
down-regulates	O
intrapulmonary	O
nitric	B-Chemical
oxide	I-Chemical
production	O
in	O
lipopolysaccharide	B-Chemical
-induced	O
acute	B-Disease
lung	I-Disease
injury	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
examine	O
whether	O
inhaled	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	O
)	O
affected	O
the	O
intrapulmonary	O
production	O
of	O
NO	O
,	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
,	O
and	O
nuclear	B-Gene
factor-kappaB	I-Gene
in	O
a	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
-induced	O
model	O
of	O
acute	B-Disease
lung	I-Disease
injury	I-Disease
.	O

DESIGN	O
:	O
Prospective	O
,	O
randomized	O
,	O
laboratory	O
study	O
.	O

SETTING	O
:	O
Experimental	O
laboratory	O
at	O
a	O
biomedical	O
institute	O
.	O

SUBJECTS	O
:	O
Twenty	O
male	O
rabbits	O
weighing	O
2.5-3.5	O
kg	O
.	O

INTERVENTIONS	O
:	O
Saline	O
or	O
LPS	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
was	O
administered	O
intravenously	O
with	O
or	O
without	O
NO	O
inhalation	O
(	O
10	O
ppm	O
)	O
in	O
each	O
group	O
of	O
five	O
rabbits	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
LPS	B-Chemical
increased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	O
and	O
NO	O
levels	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
NO	O
levels	O
produced	O
by	O
resting	O
and	O
stimulated	O
alveolar	O
macrophages	O
.	O

Inhaled	O
NO	O
decreased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	O
and	O
NO	O
levels	O
as	O
measured	O
by	O
nitrite	B-Chemical
levels	O
in	O
the	O
lavage	O
fluid	O
,	O
and	O
NO	O
produced	O
by	O
the	O
resting	O
and	O
stimulated	O
alveolar	O
macrophages	O
.	O

Inhaled	O
NO	O
also	O
blocked	O
the	O
activities	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
and	O
nuclear	B-Gene
factor-kappaB	I-Gene
binding	O
to	O
DNA	O
in	O
lavage	O
cells	O
and	O
in	O
alveolar	O
macrophages	O
.	O

CONCLUSION	O
:	O
Inhaled	O
NO	O
attenuates	O
LPS	B-Chemical
-induced	O
acute	B-Disease
lung	I-Disease
injury	I-Disease
,	O
possibly	O
by	O
decreasing	O
NO	O
production	O
in	O
the	O
lungs	O
.	O

The	O
mechanism	O
of	O
reducing	O
NO	O
production	O
resulting	O
from	O
inhaled	O
NO	O
may	O
involve	O
,	O
in	O
part	O
,	O
the	O
activities	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
and	O
/	O
or	O
nuclear	B-Gene
factor-kappaB	I-Gene
.	O

Role	O
of	O
T-bet	B-Gene
in	O
commitment	O
of	O
TH1	O
cells	O
before	O
IL-12	B-Gene
-dependent	O
selection	O
.	O

How	O
cytokines	O
control	O
differentiation	O
of	O
helper	O
T	O
(	O
TH	O
)	O
cells	O
is	O
controversial	O
.	O

We	O
show	O
that	O
T-bet	B-Gene
,	O
without	O
apparent	O
assistance	O
from	O
interleukin	B-Gene
12	I-Gene
(	I-Gene
IL-12	I-Gene
)	I-Gene
/	I-Gene
STAT4	I-Gene
,	O
specifies	O
TH1	O
effector	O
fate	O
by	O
targeting	O
chromatin	O
remodeling	O
to	O
individual	O
interferon-gamma	B-Gene
(	I-Gene
IFN-gamma	I-Gene
)	I-Gene
alleles	I-Gene
and	O
by	O
inducing	O
IL-12	B-Gene
receptor	I-Gene
beta2	I-Gene
expression	O
.	O

Subsequently	O
,	O
it	O
appears	O
that	O
IL-12	B-Gene
/	I-Gene
STAT4	I-Gene
serves	O
two	O
essential	O
functions	O
in	O
the	O
development	O
of	O
TH1	O
cells	O
:	O
as	O
growth	O
signal	O
,	O
inducing	O
survival	O
and	O
cell	O
division	O
;	O
and	O
as	O
trans-activator	O
,	O
prolonging	O
IFN-gamma	B-Gene
synthesis	O
through	O
a	O
genetic	O
interaction	O
with	O
the	O
coactivator	O
,	O
CREB	B-Gene
-binding	I-Gene
protein	I-Gene
.	O

These	O
results	O
suggest	O
that	O
a	O
cytokine	O
does	O
not	O
simply	O
induce	O
TH	O
fate	O
choice	O
but	O
instead	O
may	O
act	O
as	O
an	O
essential	O
secondary	O
stimulus	O
that	O
mediates	O
selective	O
survival	O
of	O
a	O
lineage	O
.	O

Transcriptional	O
activation	O
by	O
a	O
matrix	O
associating	O
region	O
-binding	O
protein	O
.	O

contextual	O
requirements	O
for	O
the	O
function	O
of	O
bright	B-Gene
.	O

Bright	B-Gene
(	O
B	B-Gene
cell	I-Gene
regulator	I-Gene
of	I-Gene
IgH	I-Gene
transcription	I-Gene
)	O
is	O
a	O
B	O
cell	O
-specific	O
,	O
matrix	O
associating	O
region	O
-binding	O
protein	O
that	O
transactivates	O
gene	O
expression	O
from	O
the	O
IgH	B-Gene
intronic	I-Gene
enhancer	I-Gene
(	O
E	B-Gene
mu	I-Gene
)	O
.	O

We	O
show	O
here	O
that	O
Bright	B-Gene
has	O
multiple	O
contextual	O
requirements	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

Bright	B-Gene
can	O
not	O
transactivate	O
via	O
out	O
of	O
context	O
,	O
concatenated	O
binding	O
sites	O
.	O

Transactivation	O
is	O
maximal	O
on	O
integrated	O
substrates	O
.	O

Two	O
of	O
the	O
three	O
previously	O
identified	O
binding	O
sites	O
in	O
E	B-Gene
mu	I-Gene
are	O
required	O
for	O
full	O
Bright	B-Gene
transactivation	O
.	O

The	O
Bright	B-Gene
DNA	I-Gene
binding	O
domain	O
defined	O
a	O
new	O
family	O
,	O
which	O
includes	O
SWI1	B-Gene
,	O
a	O
component	O
of	O
the	O
SWI.SNF	B-Gene
complex	I-Gene
shown	O
to	O
have	O
high	O
mobility	O
group	O
-like	O
DNA	O
binding	O
characteristics	O
.	O

Similar	O
to	O
one	O
group	O
of	O
high	B-Gene
mobility	I-Gene
group	I-Gene
box	I-Gene
proteins	I-Gene
,	O
Bright	B-Gene
distorts	O
E	B-Gene
mu	I-Gene
binding	O
site	O
-containing	O
DNA	O
on	O
binding	O
,	O
supporting	O
the	O
concept	O
that	O
it	O
mediates	O
E	B-Gene
mu	I-Gene
remodeling	O
.	O

Transfection	O
studies	O
further	O
implicate	O
Bright	B-Gene
in	O
facilitating	O
spatially	O
separated	O
promoter-enhancer	O
interactions	O
in	O
both	O
transient	O
and	O
stable	O
assays	O
.	O

Finally	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Bright	B-Gene
leads	O
to	O
enhanced	O
DNase	B-Gene
I	I-Gene
sensitivity	O
of	O
the	O
endogenous	B-Gene
E	I-Gene
mu	I-Gene
matrix	O
associating	O
regions	O
.	O

These	O
data	O
further	O
suggest	O
that	O
Bright	B-Gene
may	O
contribute	O
to	O
increased	O
gene	O
expression	O
by	O
remodeling	O
the	O
immunoglobulin	B-Gene
locus	I-Gene
during	O
B	O
cell	O
development	O
.	O

Synergistic	O
transcriptional	O
activation	O
of	O
human	B-Gene
Acyl-coenzyme	I-Gene
A	I-Gene
:	I-Gene
cholesterol	I-Gene
acyltransterase-1	I-Gene
gene	I-Gene
by	O
interferon-gamma	B-Gene
and	O
all-trans-retinoic	B-Chemical
acid	I-Chemical
THP-1	O
cells	O
.	O

Acyl-coenzyme	B-Gene
A	I-Gene
:	I-Gene
cholesterol	I-Gene
acyltransferase	I-Gene
(	O
ACAT	B-Gene
)	O
is	O
an	O
intracellular	O
enzyme	O
involved	O
in	O
cellular	O
cholesterol	B-Chemical
homeostasis	O
and	O
in	O
atherosclerotic	O
foam	O
cell	O
formation	O
.	O

Human	B-Gene
ACAT-1	I-Gene
gene	I-Gene
contains	O
two	O
promoters	O
(	O
P1	B-Gene
and	O
P7	B-Gene
)	O
,	O
each	O
located	O
in	O
a	O
different	O
chromosome	O
(	O
1	O
and	O
7	O
)	O
(	O
Li	O
,	O
B.	O
L.	O
,	O
Li	O
,	O
X.	O
L.	O
,	O
Duan	O
,	O
Z.	O
J.	O
,	O
Lee	O
,	O
O.	O
,	O
Lin	O
,	O
S.	O
,	O
Ma	O
,	O
Z.	O
M.	O
,	O
Chang	O
,	O
C.	O
C.	O
,	O
Yang	O
,	O
X.	O
Y.	O
,	O
Park	O
,	O
J.	O
P.	O
,	O
Mohandas	O
,	O
T.	O
K.	O
,	O
Noll	O
,	O
W.	O
,	O
Chan	O
,	O
L.	O
,	O
and	O
Chang	O
,	O
T.	O
Y.	O
(	O
1999	O
)	O
J.	O
Biol	O
Chem.	O
274	O
,	O
11060-11071	O
)	O
.	O

Interferon-gamma	B-Gene
(	O
IFN-gamma	B-Gene
)	O
,	O
a	O
cytokine	O
that	O
exerts	O
many	O
pro-atherosclerotic	O
effects	O
in	O
vivo	O
,	O
causes	O
up-regulation	O
of	O
ACAT-1	B-Gene
mRNA	I-Gene
in	O
human	O
blood	O
monocyte	O
-derived	O
macrophages	O
and	O
macrophage	O
-like	O
cells	O
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

To	O
examine	O
the	O
molecular	O
nature	O
of	O
this	O
observation	O
,	O
we	O
identified	O
within	O
the	O
ACAT-1	B-Gene
P1	I-Gene
promoter	I-Gene
a	O
159-base	O
pair	O
core	O
region	O
.	O

This	O
region	O
contains	O
4	O
Sp1	B-Gene
elements	I-Gene
and	O
an	O
IFN-gamma	B-Gene
activated	O
sequence	O
(	O
GAS	O
)	O
that	O
overlaps	O
with	O
the	O
second	O
Sp1	B-Gene
element	I-Gene
.	O

In	O
the	O
monocytic	O
cell	O
line	O
THP-1	O
cell	O
,	O
the	O
combination	O
of	O
IFN-gamma	B-Gene
and	O
all-trans-retinoic	B-Chemical
acid	I-Chemical
(	O
a	O
known	O
differentiation	O
agent	O
)	O
enhances	O
the	O
ACAT-1	B-Gene
P1	I-Gene
promoter	I-Gene
but	O
not	O
the	O
P7	B-Gene
promoter	I-Gene
.	O

Additional	O
experiments	O
showed	O
that	O
all-trans-retinoic	B-Chemical
acid	I-Chemical
causes	O
large	O
induction	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
STAT1	I-Gene
,	O
while	O
IFN-gamma	B-Gene
causes	O
activation	O
of	O
STAT1	B-Gene
such	O
that	O
it	O
binds	O
to	O
the	O
GAS	O
/	O
Sp1	B-Gene
site	O
in	O
the	O
ACAT-1	B-Gene
P1	I-Gene
promoter	I-Gene
.	O

Our	O
work	O
provides	O
a	O
molecular	O
mechanism	O
to	O
account	O
for	O
the	O
effect	O
of	O
IFN-gamma	B-Gene
in	O
causing	O
transcriptional	O
activation	O
of	O
ACAT-1	B-Gene
in	O
macrophage	O
-like	O
cells	O
.	O

Partners	O
in	O
transcription	O
:	O
NFAT	B-Gene
and	O
AP-1	B-Gene
.	O

Combinatorial	O
regulation	O
is	O
a	O
powerful	O
mechanism	O
that	O
enables	O
tight	O
control	O
of	O
gene	O
expression	O
,	O
via	O
integration	O
of	O
multiple	O
signaling	O
pathways	O
that	O
induce	O
different	O
transcription	O
factors	O
required	O
for	O
enhanceosome	O
assembly	O
.	O

The	O
four	O
calcium	B-Chemical
-regulated	O
transcription	O
factors	O
of	O
the	O
NFAT	B-Gene
family	I-Gene
act	O
synergistically	O
with	O
AP-1	B-Gene
(	I-Gene
Fos	I-Gene
/	I-Gene
Jun	I-Gene
)	I-Gene
proteins	I-Gene
on	O
composite	O
DNA	O
elements	O
which	O
contain	O
adjacent	O
NFAT	B-Gene
and	O
AP-1	B-Gene
binding	O
sites	O
,	O
where	O
they	O
form	O
highly	O
stable	O
ternary	O
complexes	O
to	O
regulate	O
the	O
expression	O
of	O
diverse	O
inducible	O
genes	O
.	O

Concomitant	O
induction	O
of	O
NFAT	B-Gene
and	O
AP-1	B-Gene
requires	O
concerted	O
activation	O
of	O
two	O
different	O
signaling	O
pathways	O
:	O
calcium	B-Chemical
/	O
calcineurin	B-Gene
,	O
which	O
promotes	O
NFAT	B-Gene
dephosphorylation	O
,	O
nuclear	O
translocation	O
and	O
activation	O
;	O
and	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	I-Gene
PKC	I-Gene
)	I-Gene
/	I-Gene
Ras	I-Gene
,	O
which	O
promotes	O
the	O
synthesis	O
,	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Fos	B-Gene
and	O
Jun	B-Gene
families	I-Gene
of	O
transcription	O
factors	O
.	O

A	O
fifth	O
member	O
of	O
the	O
NFAT	B-Gene
family	I-Gene
,	O
NFAT5	B-Gene
,	O
controls	O
the	O
cellular	O
response	O
to	O
osmotic	O
stress	O
,	O
by	O
a	O
mechanism	O
that	O
requires	O
dimer	O
formation	O
and	O
is	O
independent	O
of	O
calcineurin	B-Gene
or	O
of	O
interaction	O
with	O
AP-1	B-Gene
.	O

Pharmacological	O
interference	O
with	O
theNFAT	B-Gene
:	O
AP-1	B-Gene
interaction	O
may	O
be	O
useful	O
in	O
selective	O
manipulation	O
of	O
the	O
immune	O
response	O
.	O

Balanced	O
activation	O
of	O
NFAT	B-Gene
and	O
AP-1	B-Gene
is	O
known	O
to	O
be	O
required	O
for	O
productive	O
immune	O
responses	O
,	O
but	O
the	O
role	O
of	O
NFAT	B-Gene
:	O
AP-1	B-Gene
interactions	O
in	O
other	O
cell	O
types	O
and	O
biological	O
processes	O
remains	O
to	O
be	O
understood	O
.	O

D609	B-Chemical
inhibits	O
ionizing	O
radiation	O
-induced	O
oxidative	O
damage	O
by	O
acting	O
as	O
a	O
potent	O
antioxidant	O
.	O

Tricyclodecan-9-yl	B-Chemical
-xanthogenate	I-Chemical
(	O
D609	B-Chemical
)	O
has	O
been	O
extensively	O
studied	O
in	O
biological	O
systems	O
and	O
exhibits	O
a	O
variety	O
of	O
biological	O
functions	O
,	O
including	O
antiviral	O
,	O
antitumor	O
,	O
and	O
anti-inflammatory	O
activities	O
.	O

Most	O
of	O
these	O
activities	O
have	O
been	O
largely	O
attributed	O
to	O
the	O
inhibitory	O
effect	O
of	O
D609	B-Chemical
on	O
phosphatidylcholine-specific	B-Chemical
phospholipase	B-Gene
C	I-Gene
.	O

However	O
,	O
as	O
a	O
xanthate	B-Chemical
derivative	O
,	O
D609	B-Chemical
is	O
a	O
strong	O
electrolyte	O
and	O
readily	O
dissociates	O
to	O
xanthate	B-Chemical
anions	O
and	O
cations	O
of	O
alkali	O
metals	O
in	O
solution	O
.	O

Xanthate	B-Chemical
anions	O
and	O
protonated	O
xanthic	B-Chemical
acid	I-Chemical
contain	O
a	O
free	O
thiol	B-Chemical
moiety	O
and	O
are	O
highly	O
reductive	O
.	O

This	O
implies	O
that	O
D609	B-Chemical
and	O
other	O
xanthate	B-Chemical
derivatives	O
may	O
function	O
as	O
potent	O
antioxidants	O
.	O

Indeed	O
,	O
we	O
found	O
that	O
D609	B-Chemical
inhibited	O
the	O
Fenton	O
reaction	O
-induced	O
oxidation	O
of	O
dihydrorhodamine	B-Chemical
123	I-Chemical
in	O
a	O
dose	O
-dependent	O
manner	O
similar	O
to	O
that	O
of	O
pyrrolidinedithiocarbamate	B-Chemical
,	O
a	O
well	O
known	O
antioxidant	O
.	O

In	O
addition	O
,	O
D609	B-Chemical
inhibited	O
the	O
formation	O
of	O
the	O
alpha-phenyl-tert-butylnitrone-free	B-Chemical
radical	O
spin	O
adducts	O
and	O
lipid	O
peroxidation	O
of	O
synaptosomal	O
membranes	O
by	O
the	O
Fenton	O
reagents	O
.	O

Furthermore	O
,	O
preincubation	O
of	O
lymphocytes	O
with	O
D609	B-Chemical
resulted	O
in	O
a	O
significant	O
diminution	O
of	O
ionizing	O
radiation	O
(	O
IR	O
)	O
-induced	O
1	O
)	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
;	O
2	O
)	O
decrease	O
in	O
intracellular	O
reduced	O
glutathione	B-Chemical
;	O
3	O
)	O
oxidative	O
damage	O
to	O
proteins	O
and	O
lipids	B-Chemical
;	O
and	O
4	O
)	O
activation	O
of	O
nuclear	B-Gene
factor-kappaB	I-Gene
.	O

Moreover	O
,	O
when	O
D609	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
i.v.	O
)	O
was	O
administered	O
to	O
mice	O
10	O
min	O
prior	O
to	O
total	O
body	O
IR	O
(	O
6.5	O
and	O
8.5	O
Gy	O
)	O
,	O
it	O
protected	O
the	O
mice	O
from	O
IR	O
-induced	O
lethality	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
D609	B-Chemical
is	O
a	O
potent	O
antioxidant	O
and	O
has	O
the	O
ability	O
to	O
inhibit	O
IR	O
-induced	O
cellular	O
oxidative	O
stress	O
.	O

The	O
role	O
of	O
Epstein-Barr	O
virus	O
in	O
neoplastic	O
transformation	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
new	O
data	O
from	O
basic	O
,	O
translational	O
and	O
clinical	O
research	O
relating	O
to	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Beside	O
its	O
well-known	O
tropism	O
for	O
B	O
lymphocytes	O
and	O
epithelial	O
cells	O
,	O
EBV	O
also	O
infects	O
T	O
lymphocytes	O
,	O
monocytes	O
and	O
granulocytes	O
.	O

After	O
primary	O
infection	O
,	O
EBV	O
persists	O
throughout	O
the	O
life	O
span	O
in	O
resting	O
memory	O
B	O
cells	O
,	O
from	O
where	O
it	O
is	O
reactivated	O
upon	O
breakdown	O
of	O
cellular	O
immunity	O
.	O

In	O
the	O
process	O
of	O
neoplastic	O
transformation	O
,	O
the	O
EBV	B-Gene
-encoded	I-Gene
latent	I-Gene
membrane	I-Gene
protein	I-Gene
1	I-Gene
(	I-Gene
LMP1	I-Gene
)	I-Gene
oncogene	I-Gene
represents	O
the	O
major	O
driving	O
force	O
.	O

LMP1	B-Gene
acts	O
like	O
a	O
constitutively	O
activated	O
receptor	O
of	O
the	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
receptor	I-Gene
family	I-Gene
and	O
allows	O
the	O
amplification	O
or	O
bypassing	O
of	O
physiological	O
regulatory	O
signals	O
through	O
direct	O
and	O
indirect	O
interactions	O
with	O
proteins	O
of	O
the	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
receptor	I-Gene
-associated	I-Gene
factor	I-Gene
(	I-Gene
TRAF	I-Gene
)	I-Gene
family	I-Gene
.	O

TRAF2	B-Gene
-mediated	O
NF-kappaB	B-Gene
activation	O
,	O
AP-1	B-Gene
induction	O
and	O
JAK3	B-Gene
/	I-Gene
STAT	I-Gene
activation	O
may	O
result	O
in	O
sustained	O
proliferation	O
leading	O
to	O
lymphoma	B-Disease
.	O

The	O
ability	O
of	O
LMP1	B-Gene
to	O
suppress	O
germinal	O
center	O
formation	O
and	O
its	O
capacity	O
to	O
mediate	O
its	O
own	O
transcriptional	O
activation	O
shed	O
new	O
light	O
on	O
the	O
pathogenesis	O
of	O
EBV	O
-associated	O
latency	O
type	O
II	O
lymphoproliferations	O
like	O
Hodgkin	B-Disease
's	I-Disease
disease	I-Disease
and	O
angioimmunoblastic	B-Disease
lymphadenopathy	I-Disease
.	O

The	O
carboxy	O
terminus	O
of	O
LMP1	B-Gene
is	O
also	O
a	O
reliable	O
marker	O
for	O
individual	O
EBV	O
strain	O
identification	O
and	O
thus	O
offers	O
new	O
possibilities	O
in	O
tracing	O
the	O
molecular	O
events	O
leading	O
to	O
posttransplant	O
lymphoproliferative	B-Disease
disorders	I-Disease
(	O
PTLDs	B-Disease
)	O
.	O

Cytotoxic	O
T	O
lymphocytes	O
directed	O
against	O
well	O
-characterized	O
epitopes	O
of	O
EBV	B-Gene
latency	I-Gene
genes	I-Gene
represent	O
an	O
already	O
successful	O
and	O
promising	O
therapeutic	O
approach	O
to	O
EBV	O
-associated	O
lymphomas	B-Disease
,	O
in	O
particular	O
PTLDs	B-Disease

The	O
Friend	B-Gene
of	I-Gene
GATA	I-Gene
proteins	I-Gene
U	I-Gene
-shaped	I-Gene
,	O
FOG-1	B-Gene
,	O
and	O
FOG-2	B-Gene
function	O
as	O
negative	O
regulators	O
of	O
blood	O
,	O
heart	O
,	O
and	O
eye	O
development	O
in	O
Drosophila	O
.	O

Friend	B-Gene
of	I-Gene
GATA	I-Gene
(	I-Gene
FOG	I-Gene
)	I-Gene
proteins	I-Gene
regulate	O
GATA	B-Gene
factor	I-Gene
-activated	O
gene	O
transcription	O
.	O

During	O
vertebrate	O
hematopoiesis	O
,	O
FOG	B-Gene
and	O
GATA	B-Gene
proteins	I-Gene
cooperate	O
to	O
promote	O
erythrocyte	O
and	O
megakaryocyte	O
differentiation	O
.	O

The	O
Drosophila	B-Gene
FOG	I-Gene
homologue	I-Gene
U	I-Gene
-shaped	I-Gene
(	O
Ush	B-Gene
)	O
is	O
expressed	O
similarly	O
in	O
the	O
blood	O
cell	O
anlage	O
during	O
embryogenesis	O
.	O

During	O
hematopoiesis	O
,	O
the	O
acute	B-Gene
myeloid	I-Gene
leukemia	I-Gene
1	I-Gene
homologue	I-Gene
Lozenge	I-Gene
and	O
Glial	B-Gene
cells	I-Gene
missing	I-Gene
are	O
required	O
for	O
the	O
production	O
of	O
crystal	O
cells	O
and	O
plasmatocytes	O
,	O
respectively	O
.	O

However	O
,	O
additional	O
factors	O
have	O
been	O
predicted	O
to	O
control	O
crystal	O
cell	O
proliferation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Ush	B-Gene
is	O
expressed	O
in	O
hemocyte	O
precursors	O
and	O
plasmatocytes	O
throughout	O
embryogenesis	O
and	O
larval	O
development	O
,	O
and	O
the	O
GATA	B-Gene
factor	I-Gene
Serpent	I-Gene
is	O
essential	O
for	O
Ush	B-Gene
embryonic	O
expression	O
.	O

Furthermore	O
,	O
loss	O
of	O
ush	B-Gene
function	O
results	O
in	O
an	O
overproduction	O
of	O
crystal	O
cells	O
,	O
whereas	O
forced	O
expression	O
of	O
Ush	B-Gene
reduces	O
this	O
cell	O
population	O
.	O

Murine	B-Gene
FOG-1	I-Gene
and	O
FOG-2	B-Gene
also	O
can	O
repress	O
crystal	O
cell	O
production	O
,	O
but	O
a	O
mutant	O
version	O
of	O
FOG-2	B-Gene
lacking	O
a	O
conserved	O
motif	O
that	O
binds	O
the	O
corepressor	O
C-terminal	O
binding	O
protein	O
fails	O
to	O
affect	O
the	O
cell	O
lineage	O
.	O

The	O
GATA	B-Gene
factor	I-Gene
Pannier	I-Gene
(	O
Pnr	B-Gene
)	O
is	O
required	O
for	O
eye	O
and	O
heart	O
development	O
in	O
Drosophila	O
.	O

When	O
Ush	B-Gene
,	O
FOG-1	B-Gene
,	O
FOG-2	B-Gene
,	O
or	O
mutant	B-Gene
FOG-2	I-Gene
is	O
coexpressed	O
with	O
Pnr	B-Gene
during	O
these	O
developmental	O
processes	O
,	O
severe	O
eye	O
and	O
heart	O
phenotypes	O
result	O
,	O
consistent	O
with	O
a	O
conserved	O
negative	O
regulation	O
of	O
Pnr	B-Gene
function	O
.	O

These	O
results	O
indicate	O
that	O
the	O
fly	O
and	O
mouse	B-Gene
FOG	I-Gene
proteins	I-Gene
function	O
similarly	O
in	O
three	O
distinct	O
cellular	O
contexts	O
in	O
Drosophila	O
,	O
but	O
may	O
use	O
different	O
mechanisms	O
to	O
regulate	O
genetic	O
events	O
in	O
blood	O
vs	O
.	O
cardial	O
or	O
eye	O
cell	O
lineages	O

Constitutive	O
expression	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
genes	I-Gene
in	O
melanoma	B-Disease
cell	O
lines	O
results	O
from	O
the	O
transcription	O
of	O
class	B-Gene
II	I-Gene
transactivator	I-Gene
abnormally	O
initiated	O
from	O
its	O
B	O
cell-specific	O
promoter	O
.	O

In	O
melanoma	B-Disease
cell	O
lines	O
,	O
two	O
different	O
patterns	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
expression	O
have	O
been	O
described	O
,	O
either	O
an	O
IFN	B-Gene
gamma-inducible	I-Gene
expression	O
of	O
HLA-DR	B-Gene
and	O
HLA-DP	B-Gene
,	O
with	O
a	O
faint	O
or	O
null	O
expression	O
of	O
HLA-DQ	B-Gene
,	O
resembling	O
that	O
described	O
for	O
melanocytes	O
,	O
or	O
a	O
constitutive	O
expression	O
,	O
i.e.	O
,	O
IFN-gamma	B-Gene
independent	O
,	O
of	O
all	O
three	O
HLA-D	B-Gene
isotypes	O
.	O

As	O
this	O
latter	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
more	O
rapid	O
progression	O
of	O
melanoma	B-Disease
tumors	I-Disease
,	O
we	O
have	O
analyzed	O
in	O
different	O
melanoma	B-Disease
cell	O
lines	O
the	O
molecular	O
mechanisms	O
leading	O
to	O
this	O
abnormal	O
pattern	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
expression	O
.	O

In	O
agreement	O
with	O
the	O
evidence	O
of	O
a	O
coordinate	O
transcription	O
of	O
the	O
HLA-D	B-Gene
genes	I-Gene
in	O
these	O
cell	O
lines	O
,	O
we	O
have	O
shown	O
the	O
constitutive	O
expression	O
of	O
CIITA	B-Gene
(	I-Gene
class	I-Gene
II	I-Gene
transactivator	I-Gene
)	I-Gene
transcripts	I-Gene
,	O
CIITA	B-Gene
being	O
known	O
as	O
the	O
master	O
switch	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
expression	O
.	O

Unexpectedly	O
,	O
these	O
transcripts	O
initiate	O
from	O
promoter	O
III	O
of	O
the	O
CIITA	B-Gene
gene	I-Gene
,	O
a	O
promoter	O
that	O
is	O
mainly	O
used	O
constitutively	O
in	O
B	O
lymphocytes	O
.	O

This	O
expression	O
was	O
further	O
shown	O
to	O
occur	O
through	O
factor	O
(	O
s	O
)	O
acting	O
on	O
the	O
enhancer	O
located	O
upstream	O
of	O
CIITA	B-Gene
promoter	I-Gene
III	I-Gene
,	O
which	O
was	O
previously	O
described	O
in	O
epithelioid	O
cells	O
as	O
an	O
IFN-gamma-response	B-Gene
sequence	O
.	O

The	O
hypothesis	O
of	O
a	O
general	O
abnormality	O
of	O
the	O
IFN-gamma	B-Gene
transduction	O
pathway	O
was	O
dismissed	O
.	O

Constitutive	O
transcription	O
of	O
CIITA	B-Gene
from	O
promoter	O
III	O
having	O
been	O
observed	O
in	O
unrelated	O
melanoma	B-Disease
cell	O
lines	O
,	O
we	O
propose	O
the	O
hypothesis	O
that	O
this	O
phenomenon	O
might	O
not	O
be	O
a	O
random	O
event	O
,	O
but	O
could	O
be	O
linked	O
to	O
the	O
neoplasic	O
state	O
of	O
the	O
melanoma	B-Disease
cells	O

Signal	O
thresholds	O
and	O
modular	O
synergy	O
during	O
expression	O
of	O
costimulatory	O
molecules	O
in	O
B	O
lymphocytes	O
.	O

We	O
analyzed	O
intracellular	O
pathways	O
modulating	O
surface	O
densities	O
of	O
CD80	B-Gene
and	O
CD86	B-Gene
in	O
B	O
cells	O
activated	O
through	O
ligation	O
of	O
the	O
Ag	O
receptor	O
,	O
and	O
the	O
adhesion	O
molecule	O
CD54	B-Gene
.	O

Whereas	O
B	B-Gene
cell	I-Gene
Ag	I-Gene
receptor	I-Gene
(	O
BCR	B-Gene
)	O
cross	O
-linking	O
alone	O
stimulated	O
increased	O
expression	O
of	O
CD86	B-Gene
,	O
up-regulation	O
of	O
CD80	B-Gene
required	O
dual	O
stimulation	O
with	O
anti-IgM	B-Gene
and	O
anti-CD54	B-Gene
.	O

The	O
principal	O
downstream	O
component	O
contributed	O
by	O
BCR	B-Gene
signaling	O
,	O
toward	O
both	O
CD80	B-Gene
and	O
CD86	B-Gene
induction	O
,	O
was	O
the	O
elevated	O
concentration	O
of	O
free	O
cytoplasmic	O
Ca	O
(	O
2+	O
)	O
,	O
recruited	O
by	O
way	O
of	O
capacitative	O
influx	O
.	O

This	O
alone	O
was	O
sufficient	O
to	O
generate	O
an	O
increase	O
in	O
CD86	B-Gene
levels	O
.	O

However	O
,	O
CD80	B-Gene
enhancement	O
required	O
the	O
concerted	O
action	O
of	O
both	O
intracellular	O
Ca	O
(	O
2+	O
)	O
concentration	O
and	O
CD54	B-Gene
-initiated	O
pathways	O
.	O

The	O
nexus	O
between	O
anti-IgM	B-Gene
and	O
anti-CD54	B-Gene
stimulation	O
,	O
in	O
the	O
context	O
of	O
CD80	B-Gene
regulation	O
,	O
was	O
identified	O
to	O
involve	O
a	O
self	O
-propagating	O
process	O
of	O
sequential	O
synergy	O
.	O

The	O
first	O
step	O
involved	O
amplified	O
accumulation	O
of	O
intracellular	O
cAMP	B-Chemical
,	O
as	O
a	O
result	O
of	O
cross-talk	O
between	O
BCR	B-Gene
-mobilized	O
Ca	O
(	O
2+	O
)	O
and	O
CD54	B-Gene
-derived	O
signals	O
.	O

This	O
then	O
facilitated	O
a	O
second	O
synergistic	O
interaction	O
between	O
Ca	O
(	O
2+	O
)	O
and	O
cAMP	B-Chemical
,	O
culminating	O
in	O
CD80	B-Gene
expression	O
.	O

Our	O
findings	O
of	O
distinct	O
signal	O
transducer	O
requirements	O
,	O
with	O
the	O
added	O
consequences	O
of	O
cross-talk	O
,	O
offers	O
an	O
explanation	O
for	O
variable	O
modulation	O
of	O
costimulatory	O
molecule	O
expression	O
in	O
response	O
to	O
diverse	O
physiological	O
stimuli	O
.	O

Importantly	O
,	O
these	O
results	O
also	O
reveal	O
how	O
concentration	O
threshold	O
barriers	O
for	O
recruitment	O
of	O
individual	O
second	O
messengers	O
can	O
be	O
overcome	O
by	O
constructive	O
convergence	O
of	O
signaling	O
modules	O
.	O

Down-regulation	O
of	O
IL-12	B-Gene
p40	I-Gene
gene	I-Gene
in	O
Plasmodium	O
berghei	O
-infected	O
mice	O
.	O

We	O
analyzed	O
the	O
mechanism	O
that	O
causes	O
suppression	O
of	O
IL-12	B-Gene
p40	I-Gene
gene	I-Gene
induction	O
during	O
Plasmodium	O
berghei	O
infection	O
.	O

Although	O
IL-12	B-Gene
together	O
with	O
IFN-gamma	B-Gene
plays	O
an	O
important	O
role	O
in	O
protection	O
against	O
pathogenic	O
infection	O
,	O
the	O
IL-12	B-Gene
p70	I-Gene
protein	I-Gene
production	O
of	O
infected	O
macrophages	O
is	O
lower	O
than	O
that	O
by	O
the	O
uninfected	O
macrophages	O
.	O

We	O
showed	O
in	O
the	O
present	O
study	O
that	O
the	O
induction	O
of	O
IL-12	B-Gene
p40	I-Gene
gene	I-Gene
but	O
not	O
IL-12	B-Gene
p35	I-Gene
gene	I-Gene
in	O
macrophages	O
of	O
P.	O
berghei	O
-infected	O
mice	O
was	O
profoundly	O
inhibited	O
.	O

The	O
inhibition	O
was	O
induced	O
by	O
interaction	O
with	O
macrophages	O
that	O
had	O
contacted	O
with	O
P.	O
berghei	O
-infected	O
erythrocytes	O
and	O
was	O
mediated	O
by	O
a	O
soluble	O
factor	O
,	O
IL-10	B-Gene
.	O

There	O
was	O
comparable	O
activation	O
of	O
NF-kappaB	B-Gene
in	O
uninfected	O
and	O
infected	O
cells	O
.	O

The	O
induction	O
of	O
IFN-regulatory	B-Gene
factor-1	I-Gene
gene	I-Gene
was	O
comparable	O
in	O
transcription	O
level	O
in	O
uninfected	O
and	O
infected	O
cells	O
,	O
while	O
the	O
unidentified	O
complex	O
formation	O
of	O
IFN-regulatory	B-Gene
factor-1	I-Gene
was	O
observed	O
in	O
infected	O
cells	O
.	O

Therefore	O
,	O
the	O
inhibition	O
of	O
the	O
IL-12	B-Gene
p40	I-Gene
gene	I-Gene
induction	O
appeared	O
to	O
be	O
regulated	O
at	O
transcriptional	O
regulation	O
level	O
of	O
the	O
gene	O
.	O

Transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
regulates	O
Ig	B-Gene
lambda	I-Gene
light	I-Gene
chain	I-Gene
gene	I-Gene
rearrangement	O
.	O

The	O
tissue-	O
and	O
stage-specific	O
assembly	O
of	O
Ig	B-Gene
and	O
TCR	B-Gene
genes	I-Gene
is	O
mediated	O
by	O
a	O
common	O
V	B-Gene
(	I-Gene
D	I-Gene
)	I-Gene
J	I-Gene
recombinase	I-Gene
complex	I-Gene
in	O
precursor	O
lymphocytes	O
.	O

Directed	O
alterations	O
in	O
the	O
accessibility	O
of	O
V	B-Partial_Gene
,	O
D	B-Partial_Gene
,	O
and	O
J	B-Gene
gene	I-Gene
segments	O
target	O
the	O
recombinase	B-Gene
to	O
specific	O
Ag	O
receptor	O
loci	O
.	O

Accessibility	O
within	O
a	O
given	O
locus	O
is	O
regulated	O
by	O
the	O
functional	O
interaction	O
of	O
transcription	O
factors	O
with	O
cognate	O
enhancer	O
elements	O
and	O
correlates	O
with	O
the	O
transcriptional	O
activity	O
of	O
unrearranged	O
gene	O
segments	O
.	O

As	O
demonstrated	O
in	O
our	O
prior	O
studies	O
,	O
rearrangement	O
of	O
the	O
Igkappa	B-Gene
locus	I-Gene
is	O
regulated	O
by	O
the	O
inducible	O
transcription	B-Gene
factor	I-Gene
NF-kappaB	I-Gene
.	O

In	O
contrast	O
to	O
the	O
Igkappa	B-Gene
locus	I-Gene
,	O
known	O
transcriptional	O
control	O
elements	O
in	O
the	O
Iglambda	B-Gene
locus	I-Gene
lack	O
functional	O
NF-kappaB	B-Gene
binding	O
sites	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
the	O
expression	O
of	O
assembled	O
Iglambda	B-Gene
genes	I-Gene
in	O
mature	O
B	O
cells	O
has	O
been	O
shown	O
to	O
be	O
NF-kappaB	B-Gene
independent	O
.	O

Nonetheless	O
,	O
we	O
now	O
show	O
that	O
specific	O
repression	O
of	O
NF-kappaB	B-Gene
inhibits	O
germline	O
transcription	O
and	O
recombination	O
of	O
Iglambda	B-Gene
gene	I-Gene
segments	O
in	O
precursor	O
B	O
cells	O
.	O

Molecular	O
analyses	O
indicate	O
that	O
the	O
block	O
in	O
NF-kappaB	B-Gene
impairs	O
Iglambda	B-Gene
rearrangement	O
at	O
the	O
level	O
of	O
recombinase	B-Gene
accessibility	O
.	O

In	O
contrast	O
,	O
the	O
activities	O
of	O
known	O
Iglambda	B-Gene
promoter	I-Gene
and	O
enhancer	O
elements	O
are	O
unaffected	O
in	O
the	O
same	O
cellular	O
background	O
.	O

These	O
findings	O
expand	O
the	O
range	O
of	O
NF-kappaB	B-Gene
action	O
in	O
precursor	O
B	O
cells	O
beyond	O
Igkappa	B-Gene
to	O
include	O
the	O
control	O
of	O
recombinational	O
accessibility	O
at	O
both	O
L	O
chain	O
loci	O
.	O

Moreover	O
,	O
our	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
Iglambda	B-Gene
regulatory	I-Gene
element	I-Gene
that	O
is	O
either	O
directly	O
or	O
indirectly	O
activated	O
by	O
NF-kappaB	B-Gene
during	O
the	O
early	O
stages	O
of	O
B	O
cell	O
development	O
.	O

Adipophilin	B-Gene
is	O
a	O
sensitive	O
marker	O
for	O
lipid	B-Chemical
loading	O
in	O
human	O
blood	O
monocytes	O
.	O

Adipophilin	B-Gene
,	O
a	O
marker	O
of	O
lipid	B-Chemical
accumulation	O
initially	O
described	O
in	O
adipocytes	O
,	O
was	O
recently	O
shown	O
to	O
be	O
induced	O
in	O
macrophage	O
foam	O
cells	O
.	O

We	O
found	O
that	O
even	O
freshly	O
isolated	O
blood	O
monocytes	O
express	O
adipophilin	B-Gene
and	O
that	O
the	O
amount	O
of	O
adipophilin	B-Gene
protein	I-Gene
is	O
variable	O
in	O
monocytes	O
from	O
different	O
healthy	O
individuals	O
.	O

However	O
,	O
the	O
physiological	O
expression	O
of	O
adipophilin	B-Gene
does	O
not	O
correlate	O
with	O
the	O
levels	O
of	O
free	O
fatty	B-Chemical
acids	I-Chemical
,	O
cholesterylesters	O
or	O
free	O
cholesterol	B-Chemical
.	O

Enzymatically	O
modified	O
low-density	O
lipoprotein	O
(	O
E-LDL	O
)	O
induces	O
rapid	O
foam	O
cell	O
formation	O
in	O
monocytes	O
and	O
upregulates	O
adipophilin	B-Gene
mRNA	I-Gene
and	O
protein	O
within	O
2	O
h	O
of	O
incubation	O
.	O

This	O
rapid	O
induction	O
of	O
adipophilin	B-Gene
is	O
accompanied	O
by	O
a	O
significant	O
increase	O
of	O
free	O
fatty	B-Chemical
acids	I-Chemical
in	O
monocytes	O
incubated	O
with	O
E-LDL	O
.	O

Adipophilin	B-Gene
facilitates	O
the	O
uptake	O
of	O
free	O
fatty	B-Chemical
acids	I-Chemical
,	O
and	O
here	O
we	O
demonstrate	O
that	O
free	O
fatty	B-Chemical
acids	I-Chemical
increase	O
is	O
related	O
to	O
the	O
early	O
upregulation	O
of	O
adipophilin	B-Gene
expression	O
in	O
blood	O
monocytes	O
.	O

Fatty	O
acids	O
are	O
ligands	O
for	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor-gamma	I-Gene
(	O
PPARgamma	B-Gene
)	O
,	O
and	O
the	O
upregulation	O
of	O
adipophilin	B-Gene
mRNA	I-Gene
by	O
PPARgamma	B-Gene
agonists	I-Gene
like	O
15d-PGJ	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
and	O
ciglitazone	B-Chemical
indicates	O
that	O
PPARgamma	B-Gene
may	O
mediate	O
the	O
induction	O
of	O
adipophilin	B-Gene
expression	O
in	O
human	O
blood	O
monocytes	O
.	O

Hepatic	O
ischemia-reperfusion	B-Disease
injury	I-Disease
.	O

BACKGROUND	O
:	O
The	O
morbidity	O
associated	O
with	O
liver	O
transplantation	O
and	O
major	O
hepatic	O
resections	O
is	O
partly	O
a	O
result	O
of	O
ischemia-reperfusion	B-Disease
injury	I-Disease
.	O

DATA	O
SOURCES	O
:	O
The	O
entire	O
world	O
literature	O
on	O
the	O
subject	O
was	O
searched	O
via	O
Medline	O
.	O

Keywords	O
included	O
reperfusion	B-Disease
injury	I-Disease
,	O
transplantation	O
,	O
liver	O
resection	O
,	O
nitric	B-Chemical
oxide	I-Chemical
,	O
endothelin	B-Gene
,	O
cytokines	O
,	O
Kupffer	O
cells	O
,	O
ischemic	O
/	O
ischaemic	O
preconditioning	O
,	O
and	O
nuclear	B-Gene
factor-kappa	I-Gene
B	I-Gene
.	O

CONCLUSIONS	O
:	O
An	O
imbalance	O
between	O
endothelin	B-Gene
and	O
nitric	B-Chemical
oxide	I-Chemical
levels	O
results	O
in	O
failure	O
of	O
the	O
hepatic	O
microcirculation	O
at	O
the	O
onset	O
of	O
reperfusion	O
.	O

Activation	O
of	O
nuclear	B-Gene
factor-kappa	I-Gene
B	I-Gene
in	O
the	O
liver	O
promotes	O
proinflammatory	O
cytokine	O
and	O
adhesion	O
molecule	O
synthesis	O
.	O

These	O
result	O
in	O
oxygen	B-Chemical
-derived	O
free	O
radical	O
production	O
and	O
neutrophil	O
recruitment	O
,	O
further	O
contributing	O
to	O
cellular	O
injury	O
.	O

Various	O
therapeutic	O
modalities	O
acting	O
on	O
the	O
above	O
mediators	O
have	O
been	O
successfully	O
used	O
to	O
attenuate	O
reperfusion	B-Disease
injury	I-Disease
in	O
animal	O
models	O
of	O
hepatic	O
transplantation	O
and	O
resection	O
.	O

Application	O
of	O
the	O
knowledge	O
gained	O
from	O
animal	O
models	O
of	O
hepatic	O
ischemia-reperfusion	O
to	O
the	O
clinical	O
setting	O
will	O
improve	O
the	O
outcome	O
of	O
hepatic	O
surgery	O
.	O

Troglitazone	B-Chemical
,	O
a	O
PPARgamma	B-Gene
ligand	I-Gene
,	O
inhibits	O
osteopontin	B-Gene
gene	I-Gene
expression	O
in	O
human	O
monocytes	O
/	O
macrophage	O
THP-1	O
cells	O
.	O

Peroxizome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor-gamma	I-Gene
(	O
PPARgamma	B-Gene
)	O
is	O
a	O
member	O
of	O
the	O
nuclear	B-Gene
receptor	I-Gene
family	I-Gene
of	O
transcription	O
factors	O
that	O
regulate	O
adipocyte	O
differentiation	O
.	O

Recent	O
studies	O
indicate	O
that	O
liganded	B-Gene
PPARgamma	I-Gene
not	O
only	O
promotes	O
differentiation	O
but	O
also	O
inhibits	O
the	O
activation	O
of	O
macrophages	O
.	O

Osteopontin	B-Gene
,	O
a	O
component	O
of	O
extracellular	O
matrix	O
,	O
is	O
synthesized	O
by	O
macrophages	O
in	O
atherosclerotic	O
plaques	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
PPARgamma	B-Gene
ligand	I-Gene
regulates	O
osteopontin	B-Gene
gene	I-Gene
expression	O
in	O
THP-1	O
cells	O
,	O
a	O
cell	O
line	O
derived	O
from	O
human	O
monocytic	O
leukemia	B-Disease
cells	O
which	O
can	O
differentiate	O
to	O
macrophage	O
upon	O
stimulation	O
with	O
phorbol	B-Chemical
ester	I-Chemical
PMA	I-Chemical
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
osteopontin	B-Gene
expression	O
is	O
markedly	O
induced	O
in	O
response	O
to	O
PMA	B-Chemical
.	O

Troglitazone	B-Chemical
,	O
a	O
PPARgamma	B-Gene
ligand	I-Gene
,	O
dramatically	O
attenuated	O
the	O
PMA	B-Chemical
-induced	O
osteopontin	B-Gene
expression	O
.	O

Transient	O
transfection	O
assays	O
of	O
the	O
human	B-Gene
osteopontin	I-Gene
promoter	I-Gene
/	O
luciferase	O
construct	O
which	O
contains	O
a	O
5'-flanking	O
region	O
between	O
-1500	O
and	O
+87	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
demonstrate	O
that	O
either	O
treatment	O
with	O
troglitazone	B-Chemical
or	O
cotransfection	O
of	O
PPARgamma	B-Gene
expression	O
vector	O
inhibits	O
osteopontin	B-Gene
promoter	I-Gene
activity	O
.	O

These	O
data	O
indicate	O
that	O
troglitazone	B-Chemical
reduces	O
osteopontin	B-Gene
gene	I-Gene
expression	O
at	O
transcriptional	O
level	O
through	O
PPARgamma	B-Gene
activation	O
,	O
and	O
suggest	O
the	O
role	O
of	O
troglitazone	B-Chemical
in	O
inhibiting	O
the	O
ability	O
of	O
macrophages	O
to	O
produce	O
extracellular	O
matrix	O
,	O
which	O
is	O
particularly	O
relevant	O
to	O
atherosclerotic	O
plaque	O
formation	O
.	O

Regulation	O
of	O
the	O
human	B-Gene
MAT2B	I-Gene
gene	I-Gene
encoding	O
the	O
regulatory	O
beta	O
subunit	O
of	O
methionine	B-Gene
adenosyltransferase	I-Gene
,	O
MAT	B-Gene
II	I-Gene
.	O

Methionine	B-Gene
adenosyltransferase	I-Gene
(	O
MAT	B-Gene
)	O
catalyzes	O
the	O
biosynthesis	O
of	O
S-adenosylmethionine	B-Chemical
(	O
AdoMet	B-Chemical
)	O
,	O
a	O
key	O
molecule	O
in	O
transmethylation	O
reactions	O
and	O
polyamine	B-Chemical
biosynthesis	O
.	O

The	O
MAT	B-Gene
II	I-Gene
isozyme	I-Gene
consists	O
of	O
a	O
catalytic	O
alpha2	O
and	O
a	O
regulatory	O
beta	O
subunit	O
.	O

Down-regulation	O
of	O
the	O
MAT	B-Gene
II	I-Gene
beta	I-Gene
subunit	I-Gene
expression	O
causes	O
a	O
6-10-fold	O
increase	O
in	O
intracellular	O
AdoMet	B-Chemical
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
the	O
beta	O
subunit	O
expression	O
is	O
regulated	O
,	O
we	O
cloned	O
the	O
MAT2B	B-Gene
gene	I-Gene
,	O
determined	O
its	O
organization	O
,	O
characterized	O
its	O
5'-flanking	O
sequences	O
,	O
and	O
elucidated	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
regulation	O
of	O
its	O
promoter	O
.	O

Transcription	O
of	O
the	O
MAT2B	B-Gene
gene	I-Gene
initiates	O
at	O
position	O
-203	O
relative	O
to	O
the	O
translation	O
start	O
site	O
.	O

Promoter	O
deletion	O
analysis	O
defined	O
a	O
minimal	O
promoter	O
between	O
positions	O
+52	O
and	O
+93	O
base	O
pairs	O
,	O
a	O
GC-rich	O
region	O
.	O

Inclusion	O
of	O
the	O
sequences	O
between	O
-4	O
and	O
+52	O
enhanced	O
promoter	O
activity	O
;	O
this	O
was	O
primarily	O
because	O
of	O
an	O
Sp1	B-Gene
recognition	O
site	O
at	O
+9	O
/	O
+15	O
.	O

The	O
inclusion	O
of	O
sequences	O
up	O
to	O
position	O
-115	O
provided	O
full	O
activity	O
;	O
this	O
was	O
attributed	O
to	O
a	O
TATA	O
at	O
-32	O
.	O

The	O
Sp1	B-Gene
site	O
at	O
position	O
+9	O
was	O
key	O
for	O
the	O
formation	O
of	O
protein.DNA	O
complexes	O
.	O

Mutation	O
of	O
both	O
the	O
Sp1	B-Gene
site	O
at	O
+9	O
and	O
the	O
TATA	O
at	O
-32	O
reduced	O
promoter	O
activity	O
to	O
its	O
minimal	O
level	O
.	O

Supershift	O
assays	O
showed	O
no	O
effect	O
of	O
the	O
anti-Sp1	B-Gene
antibody	I-Gene
on	O
complex	O
formation	O
,	O
whereas	O
the	O
anti-Sp3	B-Gene
antibody	I-Gene
had	O
a	O
strong	O
effect	O
on	O
protein.DNA	O
complex	O
formation	O
,	O
suggesting	O
that	O
Sp3	B-Gene
is	O
one	O
of	O
the	O
main	O
factors	O
binding	O
to	O
this	O
Sp1	B-Gene
site	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
supported	O
the	O
involvement	O
of	O
both	O
Sp1	B-Gene
and	O
Sp3	B-Gene
in	O
complexes	O
formed	O
on	O
the	O
MAT2B	B-Gene
promoter	I-Gene
.	O

The	O
data	O
show	O
that	O
the	O
5'-untranslated	O
sequences	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
MAT2B	B-Gene
gene	I-Gene
and	O
identifies	O
the	O
Sp1	B-Gene
site	O
at	O
+9	O
as	O
a	O
potential	O
target	O
for	O
modulating	O
MAT2B	B-Gene
expression	O
,	O
a	O
process	O
that	O
can	O
have	O
a	O
major	O
effect	O
on	O
intracellular	O
AdoMet	B-Chemical
levels	O
.	O

Tumour-stromal	B-Disease
interactions	O
.	O

Role	O
of	O
the	O
stroma	O
in	O
mammary	O
development	O
.	O

Mammary	O
development	O
depends	O
on	O
branching	O
morphogenesis	O
,	O
namely	O
the	O
bifurcation	O
and	O
extension	O
of	O
ductal	O
growth	O
points	O
(	O
end	O
buds	O
)	O
and	O
secretory	O
lobules	O
into	O
a	O
more	O
or	O
less	O
fatty	O
stroma	O
.	O

Because	O
breast	B-Disease
carcinomas	I-Disease
are	O
overwhelmingly	O
ductal	O
in	O
origin	O
,	O
this	O
review	O
focuses	O
on	O
stromal	O
influences	O
guiding	O
postnatal	O
ductal	O
development	O
and	O
there	O
is	O
only	O
the	O
briefest	O
account	O
of	O
the	O
role	O
of	O
embryonic	O
stroma	O
(	O
mesenchyme	O
)	O
.	O

The	O
stroma	O
as	O
the	O
necessary	O
target	O
for	O
endocrine	O
mammogens	O
and	O
the	O
source	O
of	O
stimulatory	O
growth	O
factors	O
is	O
described	O
and	O
the	O
importance	O
of	O
mammary	O
epithelium	O
-induced	O
modifications	O
of	O
the	O
periductal	O
stroma	O
is	O
emphasized	O
.	O

Evidence	O
is	O
presented	O
that	O
if	O
they	O
are	O
to	O
grow	O
,	O
end	O
buds	O
must	O
condition	O
proximal	O
fatty	O
stroma	O
by	O
recruiting	O
white	O
blood	O
cells	O
as	O
well	O
as	O
inducing	O
stromal	O
cell	O
division	O
and	O
,	O
possibly	O
,	O
estrogen	B-Gene
receptors	I-Gene
.	O

The	O
induction	O
of	O
a	O
fibrous	O
stromal	O
tunic	O
around	O
the	O
end	O
bud	O
is	O
described	O
and	O
its	O
likely	O
role	O
as	O
a	O
complex	O
ductal	O
morphogen	O
is	O
discussed	O
;	O
a	O
possible	O
role	O
in	O
growth	O
inhibition	O
is	O
also	O
considered	O
.	O

Although	O
the	O
signals	O
governing	O
fibrotic	O
induction	O
,	O
ductal	O
morphogenesis	O
,	O
and	O
growth	O
inhibition	O
are	O
unknown	O
,	O
a	O
role	O
for	O
transforming	B-Gene
growth	I-Gene
factor-beta	I-Gene
is	O
highly	O
likely	O
and	O
is	O
discussed	O
.	O

Finally	O
,	O
a	O
need	O
for	O
new	O
conceptual	O
and	O
experimental	O
approaches	O
to	O
understanding	O
stromal-epithelial	O
signaling	O
is	O
discussed	O
.	O

Biomechanical	O
strain	O
induces	O
class	B-Gene
a	I-Gene
scavenger	I-Gene
receptor	I-Gene
expression	O
in	O
human	O
monocyte	O
/	O
macrophages	O
and	O
THP-1	O
cells	O
:	O
a	O
potential	O
mechanism	O
of	O
increased	O
atherosclerosis	B-Disease
in	O
hypertension	B-Disease
.	O

BACKGROUND	O
:	O
Although	O
hypertension	B-Disease
is	O
an	O
important	O
risk	O
factor	O
for	O
the	O
development	O
of	O
atherosclerosis	B-Disease
,	O
the	O
mechanisms	O
for	O
this	O
interaction	O
are	O
incompletely	O
described	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
biomechanical	O
strain	O
regulates	O
macrophage	O
phenotype	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
biomechanical	O
strain	O
can	O
induce	O
expression	O
of	O
the	O
class	B-Gene
A	I-Gene
scavenger	I-Gene
receptor	I-Gene
(	O
SRA	B-Gene
)	O
,	O
an	O
important	O
lipoprotein	O
receptor	O
in	O
atherogenesis	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Human	O
monocyte	O
/	O
macrophages	O
or	O
THP-1	O
cells	O
were	O
cultured	O
in	O
a	O
device	O
that	O
imposes	O
uniform	O
biaxial	O
cyclic	O
1-Hz	O
strains	O
of	O
0	O
%	O
,	O
1	O
%	O
,	O
2	O
%	O
,	O
or	O
3	O
%	O
,	O
and	O
SRA	B-Gene
expression	O
was	O
analyzed	O
.	O

Mechanical	O
strains	O
induced	O
SRA	B-Gene
mRNA	I-Gene
(	O
3.5+	O
/	O
-0.6-fold	O
at	O
3	O
%	O
strain	O
for	O
48	O
hours	O
,	O
P	O
<	O
0.01	O
)	O
and	O
SRA	B-Gene
protein	I-Gene
in	O
THP-1	O
cells	O
in	O
an	O
amplitude	O
-dependent	O
manner	O
.	O

This	O
induction	O
was	O
accompanied	O
by	O
augmented	O
expression	O
of	O
the	O
class	B-Gene
B	I-Gene
scavenger	I-Gene
receptor	I-Gene
CD36	I-Gene
(	O
2.8+	O
/	O
-0.3-fold	O
,	O
P	O
<	O
0.001	O
)	O
but	O
not	O
by	O
increased	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptor-gamma	I-Gene
expression	O
.	O

To	O
evaluate	O
this	O
effect	O
in	O
vivo	O
,	O
apolipoprotein	B-Gene
E	I-Gene
(	I-Gene
-	I-Gene
/	I-Gene
-	I-Gene
)	I-Gene
mice	O
were	O
randomly	O
assigned	O
to	O
receive	O
standard	O
chow	O
,	O
a	O
high-cholesterol	B-Chemical
diet	O
,	O
or	O
a	O
high-cholesterol	B-Chemical
diet	O
with	O
hypertension	B-Disease
induced	O
by	O
angiotensin	B-Gene
II	I-Gene
infusion	O
for	O
8	O
weeks	O
.	O

Immunohistochemistry	O
revealed	O
that	O
among	O
macrophages	O
in	O
atherosclerotic	O
lesions	O
of	O
the	O
aorta	O
,	O
the	O
proportion	O
of	O
macrophages	O
with	O
SRA	B-Gene
expression	O
was	O
highest	O
in	O
hypertensive	B-Disease
animals	O
on	O
a	O
high-cholesterol	B-Chemical
diet	O
(	O
43.9+	O
/	O
-0.7	O
%	O
,	O
versus	O
12.0+	O
/	O
-2.0	O
%	O
for	O
normotensive	O
animals	O
on	O
a	O
high-cholesterol	B-Chemical
diet	O
and	O
4.7+	O
/	O
-4.7	O
%	O
for	O
animals	O
on	O
standard	O
chow	O
;	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Biomechanical	O
strain	O
induces	O
SRA	B-Gene
expression	O
by	O
monocyte	O
/	O
macrophages	O
,	O
suggesting	O
a	O
novel	O
mechanism	O
for	O
promotion	O
of	O
atherosclerosis	B-Disease
in	O
hypertensive	B-Disease
patients	O
.	O

Long-term	O
-impaired	O
expression	O
of	O
nuclear	B-Gene
factor-kappa	I-Gene
B	I-Gene
and	O
I	B-Gene
kappa	I-Gene
B	I-Gene
alpha	I-Gene
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
trauma	B-Disease
patients	O
.	O

Nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappa	I-Gene
B	I-Gene
expression	O
and	O
dimer	O
characteristics	O
were	O
studied	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
major-trauma	B-Disease
patients	O
and	O
healthy	O
controls	O
.	O

Analysis	O
of	O
PBMCs	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
10	O
after	O
trauma	B-Disease
revealed	O
that	O
expression	O
of	O
both	O
p65p50	B-Gene
heterodimers	O
and	O
p50p50	B-Gene
homodimers	O
was	O
significantly	O
reduced	O
compared	O
with	O
that	O
in	O
controls	O
.	O

In	O
vitro	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
stimulation	O
of	O
PBMCs	O
induced	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
.	O

However	O
,	O
throughout	O
the	O
survey	O
,	O
p65p50	B-Gene
activation	O
remained	O
significantly	O
lower	O
in	O
trauma	B-Disease
patients	O
than	O
in	O
controls	O
.	O

After	O
LPS	B-Chemical
stimulation	O
in	O
vitro	O
,	O
the	O
p65p50	B-Gene
/	I-Gene
p50p50	I-Gene
ratio	O
was	O
significantly	O
lower	O
in	O
PBMCs	O
from	O
trauma	B-Disease
patients	O
than	O
from	O
healthy	O
controls	O
.	O

The	O
ex	O
vivo	O
expression	O
of	O
I	B-Gene
kappa	I-Gene
B	I-Gene
alpha	I-Gene
was	O
higher	O
in	O
PBMCs	O
of	O
controls	O
than	O
of	O
trauma	B-Disease
patients	O
.	O

LPS	B-Chemical
did	O
not	O
induce	O
I	B-Gene
kappa	I-Gene
B	I-Gene
expression	O
in	O
PBMCs	O
from	O
trauma	B-Disease
patients	O
,	O
but	O
strong	O
induction	O
was	O
obtained	O
with	O
staphylococci	O
,	O
suggesting	O
that	O
this	O
defect	O
is	O
not	O
universal	O
and	O
depends	O
on	O
the	O
nature	O
of	O
the	O
activating	O
signal	O
.	O

Although	O
no	O
direct	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
interleukin-10	B-Gene
or	O
transforming	B-Gene
growth	I-Gene
factor-beta	I-Gene
and	O
NF-kappa	B-Gene
B	I-Gene
,	O
these	O
immunosuppressive	O
cytokines	O
were	O
significantly	O
elevated	O
in	O
trauma	B-Disease
patients	O
by	O
10	O
days	O
after	O
admission	O
.	O

The	O
long-term	O
low-basal	O
and	O
LPS	B-Chemical
-induced	O
nuclear	O
translocation	O
of	O
NF-kappa	B-Gene
B	I-Gene
recalled	O
long-term	O
immunoparalysis	O
observed	O
in	O
patients	O
with	O
severe	O
inflammatory	O
stress	O
such	O
as	O
trauma	B-Disease
.	O

OX40	B-Gene
stimulation	O
by	O
gp34	B-Gene
/	I-Gene
OX40	I-Gene
ligand	I-Gene
enhances	O
productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
.	O

OX40	B-Gene
is	O
a	O
member	O
of	O
the	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
(	I-Gene
TNF	I-Gene
)	I-Gene
receptor	I-Gene
superfamily	O
and	O
known	O
to	O
be	O
an	O
important	O
costimulatory	O
molecule	O
expressed	O
on	O
activated	O
T	O
cells	O
.	O

To	O
investigate	O
the	O
role	O
of	O
costimulation	O
of	O
OX40	B-Gene
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
by	O
its	O
natural	O
ligand	O
,	O
gp34	B-Gene
,	O
the	O
OX40	B-Gene
-transfected	O
ACH-2	O
cell	O
line	O
,	O
ACH-2	O
/	O
OX40	B-Gene
,	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
was	O
cocultured	O
with	O
paraformaldehyde	B-Chemical
(	O
PFA	B-Chemical
)	O
-fixed	O
gp34	B-Gene
-transfected	O
mouse	O
cell	O
line	O
,	O
SV-T2	O
/	O
gp34	B-Gene
.	O

The	O
results	O
showed	O
that	O
HIV-1	O
production	O
was	O
strongly	O
induced	O
.	O

This	O
was	O
followed	O
by	O
apparent	O
apoptosis	O
,	O
and	O
both	O
processes	O
were	O
specifically	O
inhibited	O
by	O
the	O
gp34	B-Gene
-specific	O
neutralizing	O
monoclonal	O
antibody	O
5A8	O
.	O

Endogenous	O
TNF	B-Gene
alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
and	O
TNF-beta	B-Gene
production	O
were	O
not	O
involved	O
in	O
the	O
enhanced	O
HIV-1	O
production	O
.	O

Furthermore	O
,	O
enhanced	O
HIV-1	O
transcription	O
in	O
gp34	B-Gene
-stimulated	O
ACH-2	O
/	O
OX40	B-Gene
cells	O
was	O
dependent	O
on	O
the	O
kappa	O
B	O
site	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
,	O
and	O
the	O
OX40-gp34	B-Gene
interaction	O
activated	O
NF-kappa	B-Gene
B	I-Gene
consisting	O
of	O
p50	B-Gene
and	O
p65	B-Gene
subunits	I-Gene
.	O

When	O
primary	O
activated	B-Gene
CD4	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
acutely	O
infected	O
with	O
HIV-1	O
(	O
NL4-3	O
)	O
(	O
CXCR4	B-Gene
-using	O
T-cell-line-tropic	O
)	O
were	O
cocultured	O
with	O
PFA	B-Chemical
-fixed	O
gp34	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
1	O
-bearing	O
MT-2	O
cells	O
or	O
SV-T2	O
/	O
gp34	B-Gene
cells	O
,	O
HIV-1	O
production	O
was	O
also	O
markedly	O
enhanced	O
.	O

The	O
enhancement	O
was	O
again	O
significantly	O
inhibited	O
by	O
5A8	O
.	O

The	O
present	O
study	O
first	O
shows	O
that	O
OX40-gp34	B-Gene
interaction	O
stimulates	O
HIV-1	O
expression	O
and	O
suggests	O
that	O
OX40	B-Gene
triggering	O
by	O
gp34	B-Gene
may	O
play	O
an	O
important	O
role	O
in	O
enhancing	O
HIV-1	O
production	O
in	O
both	O
acutely	O
and	O
latently	O
infected	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
in	O
vivo	O
.	O

Transcriptional	O
regulation	O
of	O
galectin-10	B-Gene
(	O
eosinophil	B-Gene
Charcot-Leyden	I-Gene
crystal	I-Gene
protein	I-Gene
)	O
:	O
a	O
GC	O
box	O
(	O
-44	O
to	O
-50	O
)	O
controls	O
butyric	B-Chemical
acid	I-Chemical
induction	O
of	O
gene	O
expression	O
.	O

Galectin-10	B-Gene
(	O
gal-10	B-Gene
,	O
also	O
known	O
as	O
Charcot-Leyden	B-Gene
crystal	I-Gene
protein	I-Gene
)	O
is	O
a	O
member	O
of	O
the	O
galectin	B-Gene
family	I-Gene
of	O
beta-galactoside	B-Gene
binding	I-Gene
proteins	I-Gene
that	O
is	O
expressed	O
uniquely	O
in	O
eosinophilic	O
and	O
basophilic	O
leukocytes	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
galectin	B-Gene
gene	I-Gene
expression	O
,	O
we	O
present	O
an	O
analysis	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
gal-10	B-Gene
.	O

Analysis	O
of	O
the	O
minimal	O
promoter	O
revealed	O
nine	O
consensus	O
-binding	O
sites	O
for	O
transcription	O
factors	O
,	O
including	O
several	O
that	O
are	O
also	O
found	O
in	O
the	O
minimal	O
promoters	O
of	O
galectins	B-Gene
-1	I-Gene
,	O
-2	B-Partial_Gene
,	O
and	O
-3	B-Partial_Gene
.	O

The	O
decrease	O
in	O
gal-10	B-Gene
promoter	I-Gene
activity	O
after	O
disruption	O
of	O
either	O
the	O
GC	O
box	O
(	O
-44	O
to	O
-50	O
)	O
or	O
the	O
Oct	B-Gene
site	O
(	O
-255	O
to	O
-261	O
)	O
suggests	O
that	O
these	O
sites	O
,	O
along	O
with	O
the	O
previously	O
characterized	O
GATA	B-Gene
and	O
EoTF	O
sites	O
,	O
are	O
necessary	O
for	O
full	O
promoter	O
activity	O
.	O

By	O
supershift	O
analysis	O
,	O
we	O
demonstrate	O
binding	O
of	O
the	O
transcription	B-Gene
factors	I-Gene
Sp1	I-Gene
and	O
Oct1	B-Gene
to	O
the	O
consensus	O
GC	O
box	O
and	O
the	O
Oct	B-Gene
site	O
,	O
respectively	O
.	O

Similar	O
to	O
gal-1	B-Gene
,	O
gal-10	B-Gene
expression	O
is	O
induced	O
by	O
butyric	B-Chemical
acid	I-Chemical
,	O
an	O
effect	O
that	O
is	O
lost	O
upon	O
ablation	O
of	O
the	O
GC	O
box	O
.	O

Additionally	O
,	O
we	O
demonstrate	O
AML3	B-Gene
binding	O
to	O
the	O
consensus	O
AML	B-Gene
site	O
and	O
YY1	B-Gene
binding	O
to	O
the	O
Inr	O
sequence	O
,	O
both	O
elements	O
functioning	O
as	O
silencers	O
in	O
the	O
gal-10	B-Gene
promoter	I-Gene
.	O

Nuclear	B-Gene
peroxisome	I-Gene
proliferator	I-Gene
-activated	I-Gene
receptors	I-Gene
alpha	I-Gene
and	O
gamma	B-Partial_Gene
have	O
opposing	O
effects	O
on	O
monocyte	O
chemotaxis	O
in	O
endometriosis	B-Disease
.	O

The	O
peroxisome	B-Gene
proliferator	I-Gene
-activated	I-Gene
receptors	I-Gene
(	I-Gene
PPARs	I-Gene
)	I-Gene
alpha	I-Gene
and	O
gamma	B-Partial_Gene
are	O
nuclear	O
receptors	O
that	O
play	O
important	O
roles	O
in	O
inflammatory	O
diseases	O
like	O
ulcerative	B-Disease
colitis	I-Disease
and	O
arthritis	B-Disease
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
possible	O
role	O
of	O
PPARs	B-Gene
in	O
macrophage	O
attraction	O
into	O
the	O
peritoneal	O
cavity	O
of	O
patients	O
with	O
endometriosis	B-Disease
.	O

We	O
identified	O
PPAR-alpha	B-Gene
and	O
-gamma	B-Partial_Gene
messenger	I-Partial_Gene
RNA	I-Partial_Gene
by	O
RT-PCR	O
and	O
protein	O
by	O
immunoblotting	O
of	O
lysates	O
of	O
peritoneal	O
macrophages	O
and	O
monocytic	O
U937	O
cells	O
.	O

Using	O
immunocytochemistry	O
,	O
we	O
localized	O
PPAR-alpha	B-Gene
and	O
-gamma	B-Partial_Gene
within	O
the	O
nuclei	O
of	O
both	O
cell	O
types	O
.	O

Monocyte	O
chemotactic	O
activity	O
of	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	B-Disease
was	O
quantified	O
in	O
Boyden	O
chambers	O
.	O

Migration	O
of	O
U937	O
cells	O
was	O
increased	O
by	O
WY	B-Chemical
14643	I-Chemical
and	O
reduced	O
by	O
rosiglitazone	B-Chemical
.	O

Peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	B-Disease
activated	O
U937	O
cells	O
transiently	O
transfected	O
with	O
a	O
PPAR-alpha	B-Gene
/	I-Gene
GAL4	I-Gene
luciferase	O
reporter	O
.	O

By	O
contrast	O
,	O
peritoneal	O
fluid	O
did	O
not	O
cause	O
significant	O
activation	O
of	O
PPAR-gamma	B-Gene
/	I-Gene
GAL4	I-Gene
constructs	O
.	O

The	O
U937	O
cells	O
transiently	O
transfected	O
with	O
a	O
PPAR	B-Gene
response	I-Gene
element	I-Gene
luciferase	O
reporter	O
showed	O
disease	O
stage	O
-dependent	O
up-regulation	O
when	O
treated	O
with	O
peritoneal	O
fluid	O
from	O
patients	O
with	O
endometriosis	B-Disease
.	O

Treatment	O
with	O
peritoneal	O
fluid	O
from	O
healthy	O
controls	O
down	O
-regulated	O
PPAR	B-Gene
response	I-Gene
element	I-Gene
transactivation	O
.	O

We	O
conclude	O
that	O
peritoneal	O
fluid	O
of	O
endometriosis	B-Disease
patients	O
contains	O
activators	O
of	O
PPAR-alpha	B-Gene
that	O
stimulate	O
macrophage	O
chemotaxis	O
.	O

Inhibitors	O
of	O
PPAR-alpha	B-Gene
or	O
activators	O
of	O
PPAR-gamma	B-Gene
could	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
inflammation	O
associated	O
with	O
endometriosis	B-Disease
.	O

Nuclear	B-Gene
factor-kappaB	I-Gene
suppressive	O
and	O
inhibitor-kappaB	B-Gene
stimulatory	O
effects	O
of	O
troglitazone	B-Chemical
in	O
obese	O
patients	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
:	O
evidence	O
of	O
an	O
antiinflammatory	O
action	O
?	O

It	O
has	O
been	O
shown	O
recently	O
that	O
troglitazone	B-Chemical
exerts	O
an	O
anti-inflammatory	O
effect	O
,	O
in	O
vitro	O
,	O
and	O
in	O
experimental	O
animals	O
.	O

To	O
test	O
these	O
properties	O
in	O
humans	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
troglitazone	B-Chemical
on	O
the	O
proinflammatory	B-Gene
transcription	I-Gene
factor	I-Gene
nuclear	I-Gene
factor-kappaB	I-Gene
and	O
its	O
inhibitory	B-Gene
protein	I-Gene
IkappaB	I-Gene
in	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
and	O
plasma	B-Gene
soluble	I-Gene
intracellular	I-Gene
adhesion	I-Gene
molecule-1	I-Gene
,	O
monocyte	B-Gene
chemoattractant	I-Gene
protein-1	I-Gene
,	O
plasminogen	B-Gene
activator	I-Gene
inhibitor-1	I-Gene
,	O
and	O
C	B-Gene
-reactive	I-Gene
protein	I-Gene
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
troglitazone	B-Chemical
on	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
generation	O
,	O
p47	B-Gene
(	I-Gene
phox	I-Gene
)	I-Gene
subunit	I-Gene
expression	O
,	O
9-hydroxyoctadecadienoic	B-Chemical
acid	I-Chemical
(	O
9-HODE	B-Chemical
)	O
,	O
13-HODE	B-Chemical
,	O
o-tyrosine	B-Chemical
,	O
and	O
m-tyrosine	B-Chemical
in	O
obese	O
patients	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
.	O

Seven	O
obese	O
patients	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
were	O
treated	O
with	O
troglitazone	B-Chemical
(	O
400	O
mg	O
/	O
day	O
)	O
for	O
4	O
weeks	O
.	O

Blood	O
samples	O
were	O
obtained	O
at	O
weekly	O
intervals	O
.	O

Nuclear	B-Gene
factor-kappaB	I-Gene
binding	O
activity	O
in	O
MNC	O
nuclear	O
extracts	O
was	O
significantly	O
inhibited	O
after	O
troglitazone	B-Chemical
treatment	O
at	O
week	O
1	O
and	O
continued	O
to	O
be	O
inhibited	O
up	O
to	O
week	O
4	O
.	O

On	O
the	O
other	O
hand	O
,	O
IkappaB	B-Gene
protein	I-Gene
levels	O
increased	O
significantly	O
after	O
troglitazone	B-Chemical
treatment	O
at	O
week	O
1	O
,	O
and	O
this	O
increase	O
persisted	O
throughout	O
the	O
study	O
.	O

Plasma	B-Gene
monocyte	I-Gene
chemoattractant	I-Gene
protein-1	I-Gene
and	O
soluble	B-Gene
intracellular	I-Gene
adhesion	I-Gene
molecule-1	I-Gene
concentrations	O
did	O
not	O
decrease	O
significantly	O
after	O
troglitazone	B-Chemical
treatment	O
,	O
although	O
there	O
was	O
a	O
trend	O
toward	O
inhibition	O
.	O

Reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
generation	O
by	O
polymorphonuclear	O
cells	O
and	O
MNC	O
,	O
p47	B-Gene
(	I-Gene
phox	I-Gene
)	I-Gene
subunit	I-Gene
protein	I-Gene
quantities	O
,	O
plasminogen	B-Gene
activator	I-Gene
inhibitor-1	I-Gene
,	O
and	O
C	B-Gene
-reactive	I-Gene
protein	I-Gene
levels	O
decreased	O
significantly	O
after	O
troglitazone	B-Chemical
intake	O
.	O

13-HODE	B-Chemical
/	O
linoleic	B-Chemical
acid	I-Chemical
and	O
9-HODE	B-Chemical
/	O
linoleic	B-Chemical
acid	I-Chemical
ratios	O
also	O
decreased	O
after	O
troglitazone	B-Chemical
intake	O
.	O

However	O
,	O
o-tyrosine	B-Chemical
/	O
phenylalanine	B-Chemical
and	O
m-tyrosine	B-Chemical
/	O
phenylalanine	B-Chemical
ratios	O
did	O
not	O
change	O
significantly	O
.	O

These	O
data	O
show	O
that	O
troglitazone	B-Chemical
has	O
profound	O
antiinflammatory	O
effects	O
in	O
addition	O
to	O
antioxidant	O
effects	O
in	O
obese	O
type	O
2	O
diabetics	O
;	O
these	O
effects	O
may	O
be	O
relevant	O
to	O
the	O
recently	O
described	O
beneficial	O
antiatherosclerotic	O
effects	O
of	O
troglitazone	B-Chemical
at	O
the	O
vascular	O
level	O
.	O

GRbeta	B-Gene
expression	O
in	O
nasal	B-Disease
polyp	I-Disease
inflammatory	O
cells	O
and	O
its	O
relationship	O
to	O
the	O
anti-inflammatory	O
effects	O
of	O
intranasal	O
fluticasone	B-Chemical
.	O

BACKGROUND	O
:	O
Nasal	B-Disease
polyposis	I-Disease
disease	I-Disease
is	O
an	O
inflammatory	O
disorder	O
with	O
intense	O
eosinophilic	O
infiltration	O
of	O
respiratory	O
mucosa	O
that	O
is	O
often	O
difficult	O
to	O
control	O
with	O
topical	O
steroids	B-Chemical
.	O

Recent	O
evidence	O
suggests	O
that	O
overexpression	O
of	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
splice	O
variant	O
GRbeta	B-Gene
in	O
inflammatory	O
cells	O
might	O
contribute	O
to	O
steroid	B-Chemical
insensitivity	O
in	O
diseases	O
such	O
as	O
asthma	B-Disease
.	O

OBJECTIVE	O
:	O
The	O
purposes	O
of	O
this	O
investigation	O
were	O
to	O
determine	O
whether	O
nasal	B-Disease
polyp	I-Disease
(	O
NP	B-Disease
)	O
inflammatory	O
cells	O
overexpress	O
GRbeta	B-Gene
and	O
to	O
examine	O
whether	O
GRbeta	B-Gene
overexpression	O
is	O
associated	O
with	O
insensitivity	O
to	O
the	O
potent	O
topical	O
steroid	O
fluticasone	B-Chemical
propionate	I-Chemical
(	O
FP	B-Chemical
)	O
.	O

METHODS	O
:	O
Biopsies	O
were	O
obtained	O
from	O
10	O
subjects	O
with	O
NPs	B-Disease
before	O
and	O
4	O
weeks	O
after	O
treatment	O
with	O
intranasal	O
FP	B-Chemical
.	O

Middle	O
turbinates	O
biopsies	O
from	O
6	O
healthy	O
,	O
nonallergic	O
subjects	O
served	O
as	O
normal	O
controls	O
.	O

Biopsies	O
were	O
immunostained	O
for	O
inflammatory	O
cell	O
markers	O
as	O
well	O
as	O
GRbeta	B-Gene
and	O
probed	O
for	O
various	O
cytokine	O
mRNA	O
.	O

The	O
anti-inflammatory	O
response	O
to	O
FP	B-Chemical
was	O
examined	O
in	O
relation	O
to	O
pretreatment	O
levels	O
of	O
GRbeta	B-Gene
expression	O
.	O

RESULTS	O
:	O
The	O
total	O
numbers	O
of	O
inflammatory	O
cells	O
were	O
increased	O
in	O
NPs	B-Disease
.	O

The	O
percentage	O
of	O
inflammatory	O
cells	O
expressing	O
GRbeta	B-Gene
was	O
also	O
increased	O
(	O
40.5	O
%	O
+	O
/	O
-	O
19.2	O
%	O
vs	O
16.1	O
%	O
+	O
/	O
-	O
4.0	O
%	O
,	O
P	O
=.009	O
)	O
.	O

GRbeta	B-Gene
expression	O
in	O
NPs	B-Disease
was	O
almost	O
exclusive	O
to	O
T	O
lymphocytes	O
,	O
eosinophils	O
,	O
and	O
macrophages	O
.	O

An	O
inverse	O
correlation	O
was	O
observed	O
between	O
the	O
baseline	O
inflammatory	O
cell	O
GRbeta	B-Gene
expression	O
and	O
the	O
reduction	O
after	O
FP	B-Chemical
treatment	O
in	O
EG2	O
-positive	O
eosinophils	O
,	O
CD4	B-Gene
-positive	O
T	O
lymphocytes	O
,	O
endothelial	O
VCAM-1	B-Gene
expression	O
,	O
and	O
IL-4	B-Gene
mRNA	I-Gene
-positive	O
cells	O
.	O

NPs	B-Disease
that	O
were	O
``	O
FP	B-Chemical
-insensitive	O
''in	O
terms	O
of	O
suppression	O
of	O
eosinophil	O
numbers	O
(	O
major	O
basic	O
protein	O
-positive	O
)	O
had	O
a	O
significantly	O
greater	O
percentage	O
of	O
GRbeta	B-Gene
-positive	O
inflammatory	O
cells	O
,	O
a	O
higher	O
ratio	O
of	O
GRbeta	B-Gene
-positive	O
/	O
GRalpha	B-Gene
-positive	O
cells	O
,	O
and	O
increased	O
numbers	O
of	O
GRbeta	B-Gene
-positive	O
eosinophils	O
and	O
macrophages	O
in	O
comparison	O
with	O
those	O
that	O
were	O
``	O
FP	B-Chemical
-sensitive	O
.	O

''	O

``	O
FP	B-Chemical
-insensitive	O
''NPs	B-Disease
also	O
demonstrated	O
a	O
higher	O
percentage	O
of	O
IL-5	B-Gene
-positive	O
inflammatory	O
cells	O
expressing	O
GRbeta	B-Gene
before	O
and	O
after	O
FP	B-Chemical
treatment	O
.	O

CONCLUSION	O
:	O
GRbeta	B-Gene
expression	O
appears	O
to	O
be	O
a	O
marker	O
of	O
steroid	B-Chemical
insensitivity	O
in	O
NPs	B-Disease
.	O

Expression	O
of	O
GRbeta	B-Gene
by	O
NP	B-Disease
inflammatory	O
cells	O
,	O
particularly	O
T	O
cells	O
and	O
eosinophils	O
,	O
might	O
render	O
them	O
resistant	O
to	O
suppression	O
by	O
topical	O
steroids	B-Chemical
and	O
thereby	O
contribute	O
to	O
persistent	O
NP	B-Disease
inflammation	O
.	O

Macrophage	O
stimulation	O
with	O
Murabutide	B-Chemical
,	O
an	O
HIV	O
-suppressive	O
muramyl	O
peptide	O
derivative	O
,	O
selectively	O
activates	O
extracellular	B-Gene
signal	I-Gene
-regulated	I-Gene
kinases	I-Gene
1	I-Gene
and	O
2	B-Partial_Gene
,	O
C	B-Gene
/	I-Gene
EBPbeta	I-Gene
and	O
STAT1	B-Gene
:	O
role	O
of	O
CD14	B-Gene
and	O
Toll	B-Gene
-like	I-Gene
receptors	I-Gene
2	I-Gene
and	O
4	B-Partial_Gene
.	O

The	O
smallest	O
unit	O
of	O
bacterial	O
peptidoglycans	O
known	O
to	O
be	O
endowed	O
with	O
biological	O
activities	O
is	O
muramyl	B-Chemical
dipeptide	I-Chemical
(	O
MDP	B-Chemical
)	O
.	O

A	O
clinically	O
acceptable	O
synthetic	O
derivative	O
of	O
MDP	B-Chemical
,	O
namely	O
murabutide	B-Chemical
(	O
MB	B-Chemical
)	O
,	O
has	O
been	O
found	O
to	O
present	O
interesting	O
pharmacological	O
properties	O
and	O
to	O
suppress	O
HIV-1	O
replication	O
in	O
monocyte	O
-derived	O
macrophages	O
(	O
MDM	O
)	O
.	O

We	O
have	O
addressed	O
the	O
signaling	O
events	O
activated	O
in	O
MDM	O
following	O
stimulation	O
with	O
either	O
MB	B-Chemical
or	O
the	O
potent	O
immunostimulant	O
LPS	B-Chemical
.	O

We	O
also	O
examined	O
whether	O
signaling	O
by	O
muramyl	B-Chemical
peptides	I-Chemical
involves	O
the	O
use	O
of	O
cell	O
surface	O
receptors	O
,	O
including	O
CD14	B-Gene
and	O
Toll	B-Gene
-like	I-Gene
receptor	I-Gene
2	I-Gene
(	O
TLR2	B-Gene
)	O
or	O
TLR4	B-Gene
that	O
are	O
known	O
to	O
be	O
signal	O
-transducing	O
receptors	O
for	O
other	O
bacterial	O
cell	O
wall	O
components	O
.	O

We	O
demonstrate	O
that	O
,	O
unlike	O
LPS	B-Chemical
,	O
the	O
safe	O
immunomodulator	O
MB	B-Chemical
selectively	O
activates	O
extracellular	B-Gene
signal	I-Gene
-regulated	I-Gene
kinases	I-Gene
(	I-Gene
Erk	I-Gene
)	I-Gene
1	I-Gene
/	I-Gene
2	I-Gene
,	O
in	O
the	O
absence	O
of	O
detectable	O
Jun	B-Gene
N-terminal	I-Gene
kinase	I-Gene
(	O
JNK	B-Gene
)	O
or	O
p38	B-Gene
mitogen	I-Gene
-activated	I-Gene
kinase	I-Gene
activation	O
.	O

Furthermore	O
,	O
STAT1	B-Gene
activation	O
but	O
weak	O
or	O
no	O
activation	O
of	O
STAT3	B-Gene
or	O
STAT5	B-Gene
respectively	O
,	O
could	O
be	O
detected	O
in	O
MB	B-Chemical
-stimulated	O
MDM	O
.	O

Using	O
MonoMac6	O
cells	O
,	O
we	O
observed	O
high	O
C	B-Gene
/	I-Gene
EBPbeta	I-Gene
and	O
AP-1	B-Gene
but	O
weaker	O
and	O
transient	O
NF-kappaB	B-Gene
activation	O
by	O
MB	B-Chemical
.	O

Moreover	O
,	O
the	O
truncated	O
form	O
of	O
C	B-Gene
/	I-Gene
EBPbeta	I-Gene
,	O
known	O
to	O
repress	O
HIV-1	O
transcription	O
,	O
was	O
detected	O
in	O
extracts	O
from	O
MB	B-Chemical
-treated	O
THP-1	O
cells	O
.	O

Surprisingly	O
,	O
neither	O
MB	B-Chemical
nor	O
MDP	B-Chemical
were	O
able	O
to	O
transduce	O
signals	O
via	O
CD14	B-Gene
and	O
TLR2	B-Gene
or	O
4	B-Partial_Gene
.	O

These	O
findings	O
present	O
major	O
differences	O
in	O
the	O
early	O
cell	O
activation	O
process	O
between	O
LPS	B-Chemical
and	O
muramyl	B-Chemical
peptides	I-Chemical
,	O
and	O
strongly	O
argue	O
for	O
the	O
implication	O
of	O
co-receptors	O
other	O
than	O
TLR2	B-Gene
and	O
TLR4	B-Gene
in	O
mediating	O
the	O
signaling	O
events	O
induced	O
by	O
defined	O
subunits	O
of	O
bacterial	O
peptidoglycans	O
.	O

Type	B-Gene
I	I-Gene
interferons	I-Gene
and	O
IL-12	B-Gene
:	O
convergence	O
and	O
cross-regulation	O
among	O
mediators	O
of	O
cellular	O
immunity	O
.	O

Therapeutic	O
use	O
of	O
type	B-Gene
I	I-Gene
IFN	I-Gene
(	O
IFN-alpha	B-Gene
/	I-Gene
beta	I-Gene
)	O
has	O
become	O
common	O
.	O

Many	O
of	O
the	O
diverse	O
diseases	O
targeted	O
are	O
marked	O
by	O
pathogenetic	O
abnormalities	O
in	O
cell	O
-mediated	O
immunity	O
(	O
CMI	O
)	O
,	O
these	O
cellular	O
immune	O
responses	O
either	O
causing	O
injury	O
to	O
the	O
host	O
,	O
lacking	O
sufficient	O
vigor	O
for	O
virus	O
or	O
tumor	B-Disease
clearance	O
,	O
or	O
both	O
.	O

In	O
general	O
,	O
therapeutic	O
efficacy	O
is	O
limited	O
.	O

It	O
is	O
thus	O
notable	O
that	O
the	O
pleiotropic	O
effects	O
of	O
type	B-Gene
I	I-Gene
IFN	I-Gene
on	O
CMI	O
remain	O
poorly	O
understood	O
.	O

We	O
characterized	O
the	O
effects	O
of	O
type	B-Gene
I	I-Gene
IFN	I-Gene
on	O
the	O
production	O
of	O
IL-12	B-Gene
,	O
the	O
central	O
immunoregulatory	O
cytokine	O
of	O
the	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cell	O
arm	O
of	O
CMI	O
.	O

We	O
show	O
that	O
type	B-Gene
I	I-Gene
IFN	I-Gene
are	O
potent	O
inhibitors	O
of	O
IL-12	B-Gene
production	O
by	O
human	O
monocytes	O
/	O
macrophages	O
.	O

The	O
underlying	O
mechanism	O
involves	O
transcriptional	O
inhibition	O
of	O
the	O
IL-12p40	B-Gene
gene	I-Gene
,	O
marked	O
by	O
down-regulation	O
of	O
PU.1	B-Gene
binding	O
activity	O
at	O
the	O
upstream	O
Ets	B-Gene
site	O
of	O
the	O
IL-12p40	B-Gene
promoter	I-Gene
.	O

Type	B-Gene
I	I-Gene
IFN	I-Gene
have	O
previously	O
been	O
shown	O
to	O
be	O
able	O
to	O
substitute	O
for	O
IL-12	B-Gene
in	O
driving	O
IFN-gamma	B-Gene
production	O
from	O
T	O
and	O
NK	O
cells	O
.	O

The	O
ability	O
of	O
IFN-alpha	B-Gene
/	I-Gene
beta	I-Gene
to	O
suppress	O
IL-12	B-Gene
production	O
while	O
up	O
-regulating	O
IFN-gamma	B-Gene
production	O
suggests	O
a	O
possible	O
mechanistic	O
basis	O
for	O
the	O
difficulties	O
of	O
employing	O
these	O
cytokines	O
in	O
diseases	O
involving	O
abnormalities	O
of	O
CMI	O
.	O

Glucocorticoid	B-Chemical
-regulated	O
transcription	O
factors	O
.	O

Glucocorticoids	B-Chemical
are	O
the	O
most	O
effective	O
antiinflammatory	O
drugs	O
used	O
in	O
the	O
treatment	O
of	O
asthma	B-Disease
.	O

They	O
act	O
by	O
binding	O
to	O
a	O
specific	O
receptor	O
(	O
GR	B-Gene
)	O
that	O
,	O
upon	O
activation	O
,	O
translocates	O
to	O
the	O
nucleus	O
and	O
either	O
increases	O
(	O
transactivates	O
)	O
or	O
decreases	O
(	O
transrepresses	O
)	O
gene	O
expression	O
.	O

Inhibition	O
of	O
pro-inflammatory	O
transcription	O
factors	O
such	O
as	O
activator	B-Gene
protein	I-Gene
(	I-Gene
AP	I-Gene
)	I-Gene
-1	I-Gene
,	O
signal	B-Gene
transducers	I-Gene
and	I-Gene
activators	I-Gene
of	I-Gene
transcription	I-Gene
(	O
STATs	B-Gene
)	O
,	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T	I-Gene
cells	I-Gene
(	O
NFAT	B-Gene
)	O
and	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappa	I-Gene
B	I-Gene
is	O
thought	O
to	O
be	O
a	O
major	O
action	O
of	O
glucocorticoids	B-Chemical
.	O

Acetylation	O
of	O
histones	B-Gene
allows	O
unwinding	O
of	O
the	O
local	O
DNA	O
structure	O
and	O
enables	O
RNA	B-Gene
polymerase	I-Gene
II	I-Gene
to	O
enhance	O
gene	O
transcription	O
.	O

Histone	B-Gene
acetylation	O
is	O
regulated	O
by	O
a	O
balance	O
between	O
the	O
activity	O
of	O
histone	B-Gene
acetyltransferases	I-Gene
(	O
HATs	B-Gene
)	O
and	O
histone	B-Gene
deacetylases	I-Gene
(	O
HDACs	B-Gene
)	O
.	O

GR	B-Gene
acts	O
as	O
a	O
direct	O
inhibitor	O
of	O
NF-kappa	B-Gene
B	I-Gene
-induced	O
HAT	B-Gene
activity	O
and	O
also	O
by	O
recruiting	O
HDAC2	B-Gene
to	O
the	O
NF-kappa	B-Gene
B	I-Gene
/	I-Gene
HAT	I-Gene
complex	I-Gene
.	O

A	O
sub-group	O
of	O
patients	O
with	O
glucocorticoid	B-Chemical
-insensitive	O
asthma	B-Disease
have	O
an	O
inability	O
to	O
induce	O
histone	B-Gene
acetylation	O
in	O
response	O
to	O
dexamethasone	B-Chemical
suggesting	O
reduced	O
expression	O
of	O
a	O
GR-specific	B-Gene
HAT	B-Gene
.	O

This	O
suggests	O
that	O
pharmacological	O
manipulation	O
of	O
specific	O
histone	B-Gene
acetylation	O
status	O
is	O
a	O
potentially	O
useful	O
approach	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O

Identification	O
of	O
the	O
precise	O
mechanism	O
by	O
which	O
activated	O
GR	B-Gene
recruits	O
HDAC2	B-Gene
may	O
reveal	O
new	O
targets	O
for	O
the	O
development	O
of	O
drugs	O
that	O
may	O
dissociate	O
the	O
antiinflammatory	O
actions	O
of	O
glucocorticoids	B-Chemical
from	O
their	O
side	O
effects	O
that	O
are	O
largely	O
due	O
to	O
gene	O
induction	O
.	O

Copyright	O
Academic	O
Press	O
.	O

Targeting	O
of	O
p300	B-Gene
to	O
the	O
interleukin-2	B-Gene
promoter	I-Gene
via	O
CREB-Rel	B-Gene
cross-talk	O
during	O
mitogen	O
and	O
oncogenic	O
molecular	O
signaling	O
in	O
activated	O
T-cells	O
.	O

In	O
this	O
report	O
,	O
we	O
explore	O
the	O
mechanisms	O
of	O
targeting	O
of	O
p300	B-Gene
to	O
the	O
interleukin-2	B-Gene
(	I-Gene
IL-2	I-Gene
)	I-Gene
promoter	I-Gene
in	O
response	O
to	O
mitogenic	O
and	O
oncogenic	O
molecular	O
signals	O
.	O

Recruitment	O
of	O
p300	B-Gene
by	O
cAMP	B-Gene
-responsive	I-Gene
element	I-Gene
-binding	I-Gene
protein-Rel	I-Gene
cross-talk	O
at	O
the	O
composite	O
CD28	B-Gene
response	I-Gene
element	I-Gene
(	O
CD28RE	O
)	O
-	O
TRE	O
element	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
is	O
essential	O
for	O
promoter	O
inducibility	O
during	O
T-cell	O
activation	O
,	O
and	O
CD28RE-TRE	B-Gene
is	O
the	O
exclusive	O
target	O
of	O
the	O
human	B-Gene
T-cell	I-Gene
lymphotropic	I-Gene
virus	I-Gene
type	I-Gene
I	I-Gene
oncoprotein	I-Gene
Tax	I-Gene
.	O

The	O
intrinsic	O
histone	B-Gene
acetyltransferase	I-Gene
activity	O
of	O
p300	B-Gene
is	O
dispensable	O
for	O
activation	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
,	O
and	O
the	O
N-terminal	O
743	O
residues	O
contain	O
the	O
minimal	O
structural	O
requirements	O
for	O
synergistic	O
transactivation	O
of	O
the	O
CD28RE-TRE	B-Gene
,	O
the	O
IL-2	B-Gene
promoter	I-Gene
,	O
and	O
endogenous	B-Gene
IL-2	I-Gene
gene	I-Gene
expression	O
.	O

Mutational	O
analysis	O
of	O
p300	B-Gene
reveals	O
differential	O
structural	O
requirements	O
for	O
the	O
N-terminal	O
p300	B-Gene
module	O
by	O
individual	O
cis	O
-elements	O
within	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

These	O
findings	O
provide	O
evidence	O
that	O
p300	B-Gene
assembles	O
at	O
the	O
IL-2	B-Gene
promoter	I-Gene
to	O
form	O
an	O
enhanceosome	O
-like	O
signal	O
transduction	O
target	O
that	O
is	O
centrally	O
integrated	O
at	O
the	O
CD28RE-TRE	B-Gene
element	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
through	O
specific	O
protein	O
module	O
-targeted	O
associations	O
in	O
activated	O
T-cells	O
.	O

Cot	B-Gene
kinase	I-Gene
induces	O
cyclooxygenase-2	B-Gene
expression	O
in	O
T	O
cells	O
through	O
activation	O
of	O
the	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T	I-Gene
cells	I-Gene
.	O

Cyclooxygenase-2	B-Gene
(	O
COX-2	B-Gene
)	O
is	O
induced	O
in	O
human	O
T	O
lymphocytes	O
upon	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
triggering	O
.	O

Here	O
we	O
report	O
that	O
Cot	B-Gene
kinase	I-Gene
,	O
a	O
mitogen	B-Gene
-activated	I-Gene
protein	I-Gene
kinase	I-Gene
kinase	I-Gene
kinase	I-Gene
involved	O
in	O
T	O
cell	O
activation	O
,	O
up-regulates	O
COX-2	B-Gene
gene	I-Gene
expression	O
in	O
Jurkat	O
T	O
cells	O
.	O

Induction	O
of	O
COX-2	B-Gene
promoter	I-Gene
activity	O
by	O
Cot	B-Gene
kinase	I-Gene
occurred	O
mainly	O
through	O
activation	O
of	O
the	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T	I-Gene
cells	I-Gene
(	O
NFAT	B-Gene
)	O
.	O

Mutation	O
of	O
the	O
distal	O
(	O
-105	O
/	O
-97	O
)	O
and	O
proximal	O
(	O
-76	O
/	O
-61	O
)	O
NFAT	B-Gene
response	I-Gene
elements	I-Gene
in	O
the	O
COX-2	B-Gene
promoter	I-Gene
abolished	O
the	O
activation	O
induced	O
by	O
Cot	B-Gene
kinase	I-Gene
.	O

Even	O
more	O
,	O
coexpression	O
of	O
a	O
dominant	O
negative	O
version	O
of	O
NFAT	B-Gene
inhibited	O
Cot	B-Gene
kinase	I-Gene
-mediated	O
COX-2	B-Gene
promoter	I-Gene
activation	O
,	O
whereas	O
cotransfection	O
of	O
a	O
constitutively	O
active	O
version	O
of	O
the	O
calcium	B-Gene
-dependent	I-Gene
phosphatase	I-Gene
calcineurin	I-Gene
synergizes	O
with	O
Cot	B-Gene
kinase	I-Gene
in	O
the	O
up-regulation	O
of	O
COX-2	B-Gene
promoter	I-Gene
-driven	O
transcription	O
.	O

Strikingly	O
,	O
Cot	B-Gene
kinase	I-Gene
increased	O
transactivation	O
mediated	O
by	O
a	O
GAL4-NFAT	B-Gene
fusion	I-Gene
protein	I-Gene
containing	O
the	O
N-terminal	O
transactivation	O
domain	O
of	O
NFATp	B-Gene
.	O

In	O
contrast	O
to	O
phorbol	B-Chemical
ester	I-Chemical
plus	O
calcium	B-Chemical
ionophore	O
A23187	B-Chemical
,	O
Cot	B-Gene
kinase	I-Gene
increases	O
both	O
COX-2	B-Gene
promoter	I-Gene
activity	O
and	O
NFAT	B-Gene
-mediated	O
transactivation	O
in	O
a	O
cyclosporin	B-Chemical
A	I-Chemical
-independent	O
manner	O
.	O

These	O
data	O
indicate	O
that	O
Cot	B-Gene
kinase	I-Gene
up-regulates	O
COX-2	B-Gene
promoter	I-Gene
-driven	O
transcription	O
through	O
the	O
NFAT	B-Gene
response	I-Gene
elements	I-Gene
,	O
being	O
the	O
Cot	B-Gene
kinase	I-Gene
-induced	O
NFAT	B-Gene
-dependent	O
transactivation	O
presumably	O
implicated	O
in	O
this	O
up-regulation	O
.	O

Invariant	O
chain	O
induces	O
B	O
cell	O
maturation	O
by	O
activating	O
a	O
TAF	B-Gene
(	I-Gene
II	I-Gene
)	I-Gene
105-NF-kappaB	I-Gene
-dependent	O
transcription	O
program	O
.	O

Early	O
stages	O
of	O
B	O
cell	O
development	O
occur	O
in	O
the	O
bone	O
marrow	O
,	O
resulting	O
in	O
formation	O
of	O
immature	O
B	O
cells	O
.	O

From	O
there	O
these	O
immature	O
cells	O
migrate	O
to	O
the	O
spleen	O
where	O
they	O
differentiate	O
to	O
mature	O
cells	O
.	O

This	O
final	O
maturation	O
step	O
is	O
crucial	O
for	O
the	O
B	O
cells	O
to	O
become	O
responsive	O
to	O
antigens	O
and	O
to	O
participate	O
in	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
invariant	O
chain	O
(	O
Ii	O
)	O
,	O
a	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
class	I-Gene
II	I-Gene
chaperone	I-Gene
,	O
as	O
well	O
as	O
the	O
transcription	B-Gene
factors	I-Gene
c-Rel	I-Gene
and	O
p65	B-Gene
/	I-Gene
RelA	I-Gene
,	O
were	O
found	O
to	O
play	O
a	O
role	O
in	O
the	O
final	O
antigen	O
-independent	O
differentiation	O
stage	O
of	O
B	O
cells	O
in	O
the	O
spleen	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
possible	O
link	O
between	O
Ii	O
-dependent	O
B	O
cell	O
maturation	O
and	O
the	O
NF-kappaB	B-Gene
pathway	O
.	O

Our	O
studies	O
indicate	O
that	O
Ii	O
-induced	O
B	O
cell	O
maturation	O
involves	O
activation	O
of	O
transcription	O
mediated	O
by	O
the	O
NF-kappaB	B-Gene
p65	I-Gene
/	I-Gene
RelA	I-Gene
homodimer	O
and	O
requires	O
the	O
B	B-Gene
cell	I-Gene
-enriched	I-Gene
coactivator	I-Gene
TBP	I-Gene
-associated	I-Gene
factor	I-Gene
(	I-Gene
II	I-Gene
)	I-Gene
105	I-Gene
.	O

Constitutively	O
activated	B-Gene
Akt-1	I-Gene
is	O
vital	O
for	O
the	O
survival	O
of	O
human	O
monocyte	O
-differentiated	O
macrophages	O
.	O

Role	O
of	O
Mcl-1	B-Gene
,	O
independent	O
of	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
,	O
Bad	B-Gene
,	O
or	O
caspase	B-Gene
activation	O
.	O

Recent	O
data	O
from	O
mice	O
deficient	O
for	O
phosphatase	B-Gene
and	I-Gene
tensin	I-Gene
homologue	I-Gene
deleted	O
from	O
chromosome	O
10	O
or	O
src	B-Gene
homology	I-Gene
2	I-Gene
domain	I-Gene
-containing	I-Gene
5	I-Gene
'inositol	I-Gene
phosphatase	I-Gene
,	O
phosphatases	B-Gene
that	O
negatively	O
regulate	O
the	O
phosphatidylinositol	B-Gene
3-kinase	I-Gene
(	O
PI3K	B-Gene
)	O
pathway	O
,	O
revealed	O
an	O
increased	O
number	O
of	O
macrophages	O
in	O
these	O
animals	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
the	O
PI3K	B-Gene
pathway	O
for	O
macro-phage	O
survival	O
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
PI3K	B-Gene
-regulated	O
serine	B-Gene
/	I-Gene
threonine	I-Gene
kinase	I-Gene
Akt-1	I-Gene
in	O
modulating	O
macrophage	O
survival	O
.	O

Akt-1	B-Gene
was	O
constitutively	O
activated	O
in	O
human	O
macrophages	O
and	O
addition	O
of	O
the	O
PI3K	B-Gene
inhibitor	O
,	O
LY294002	B-Chemical
,	O
suppressed	O
the	O
activation	O
of	O
Akt-1	B-Gene
and	O
induced	O
cell	O
death	O
.	O

Furthermore	O
,	O
suppression	O
of	O
Akt-1	B-Gene
by	O
inhibition	O
of	O
PI3K	B-Gene
or	O
a	O
dominant	O
negative	O
(	O
DN	O
)	O
Akt-1	B-Gene
resulted	O
in	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
,	O
activation	O
of	O
caspases-9	B-Gene
and	O
-3	B-Partial_Gene
,	O
and	O
DNA	O
fragmentation	O
.	O

The	O
effects	O
of	O
PI3K	B-Gene
inhibition	O
were	O
reversed	O
by	O
the	O
ectopic	O
expression	O
of	O
constitutively	O
activated	B-Gene
Akt-1	I-Gene
or	O
Bcl-x	B-Gene
(	I-Gene
L	I-Gene
)	I-Gene
.	O

Inhibition	O
of	O
PI3K	B-Gene
/	I-Gene
Akt-1	I-Gene
pathway	O
either	O
by	O
LY294002	B-Chemical
or	O
DN	O
Akt-1	B-Gene
had	O
no	O
effect	O
on	O
the	O
constitutive	O
or	O
inducible	O
activation	O
of	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
in	O
human	O
macrophages	O
.	O

However	O
,	O
after	O
inhibition	O
of	O
the	O
PI3K	B-Gene
/	I-Gene
Akt-1	I-Gene
pathway	O
,	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	O
molecule	O
Mcl-1	B-Gene
,	O
but	O
not	O
other	O
Bcl-2	B-Gene
family	I-Gene
members	O
was	O
observed	O
,	O
and	O
Mcl-1	B-Gene
rescued	O
macrophages	O
from	O
LY294002	B-Chemical
-induced	O
cell	O
death	O
.	O

Further	O
,	O
inhibition	O
of	O
Mcl-1	B-Gene
by	O
antisense	O
oligonucleotides	O
,	O
also	O
resulted	O
in	O
macrophage	O
apoptosis	O
.	O

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
the	O
constitutive	O
activation	O
of	O
Akt-1	B-Gene
regulates	O
macrophage	O
survival	O
through	O
Mcl-1	B-Gene
,	O
which	O
is	O
independent	O
of	O
caspases	B-Gene
,	O
NF-kappaB	B-Gene
,	O
or	O
Bad	B-Gene
.	O

Regulation	O
of	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-18	I-Gene
receptor	I-Gene
alpha	I-Gene
chain	I-Gene
expression	O
on	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
during	O
T	O
helper	O
(	O
Th	O
)	O
1	O
/	O
Th2	O
differentiation	O
.	O

Critical	O
downregulatory	O
role	O
of	O
IL-4	B-Gene
.	O

Interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-18	I-Gene
has	O
been	O
well	O
characterized	O
as	O
a	O
costimulatory	O
factor	O
for	O
the	O
induction	O
of	O
IL-12	B-Gene
-mediated	O
interferon	B-Gene
(	I-Gene
IFN	I-Gene
)	I-Gene
-gamma	I-Gene
production	O
by	O
T	O
helper	O
(	O
Th	O
)	O
1	O
cells	O
,	O
but	O
also	O
can	O
induce	O
IL-4	B-Gene
production	O
and	O
thus	O
facilitate	O
the	O
differentiation	O
of	O
Th2	O
cells	O
.	O

To	O
determine	O
the	O
mechanisms	O
by	O
which	O
IL-18	B-Gene
might	O
regulate	O
these	O
diametrically	O
distinct	O
immune	O
responses	O
,	O
we	O
have	O
analyzed	O
the	O
role	O
of	O
cytokines	O
in	O
the	O
regulation	O
of	O
IL-18	B-Gene
receptor	I-Gene
alpha	I-Gene
chain	I-Gene
(	O
IL-18Ralpha	B-Gene
)	O
expression	O
.	O

The	O
majority	O
of	O
peripheral	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
constitutively	O
expressed	O
the	O
IL-18Ralpha	B-Gene
.	O

Upon	O
antigen	O
stimulation	O
in	O
the	O
presence	O
of	O
IL-12	B-Gene
,	O
marked	O
enhancement	O
of	O
IL-18Ralpha	B-Gene
expression	O
was	O
observed	O
.	O

IL-12	B-Gene
-mediated	O
upregulation	O
of	O
IL-18Ralpha	B-Gene
required	O
IFN-gamma	B-Gene
.	O

Activated	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
T	O
cells	O
that	O
expressed	O
low	O
levels	O
of	O
IL-18Ralpha	B-Gene
could	O
produce	O
IFN-gamma	B-Gene
when	O
stimulated	O
with	O
the	O
combination	O
of	O
IL-12	B-Gene
and	O
IL-18	B-Gene
,	O
while	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
cells	O
which	O
expressed	O
high	O
levels	O
of	O
IL-18Ralpha	B-Gene
could	O
respond	O
to	O
IL-18	B-Gene
alone	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
stimulation	O
in	O
the	O
presence	O
of	O
IL-4	B-Gene
resulted	O
in	O
a	O
downregulation	O
of	O
IL-18Ralpha	B-Gene
expression	O
.	O

Both	O
IL-4	B-Gene
(	O
-	O
/	O
)	O
-	O
and	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
(	I-Gene
Stat	I-Gene
)	I-Gene
6	I-Gene
(	O
-	O
/	O
)	O
-	O
T	O
cells	O
expressed	O
higher	O
levels	O
of	O
IL-18Ralpha	B-Gene
after	O
TCR	B-Gene
stimulation	O
.	O

Furthermore	O
,	O
activated	O
T	O
cells	O
from	O
Stat6	B-Gene
(	O
-	O
/	O
)	O
-	O
mice	O
produced	O
more	O
IFN-gamma	B-Gene
in	O
response	O
to	O
IL-18	B-Gene
than	O
wild-type	O
controls	O
.	O

Thus	O
,	O
positive	O
/	O
negative	O
regulation	O
of	O
the	O
IL-18Ralpha	B-Gene
by	O
the	O
major	O
inductive	O
cytokines	O
(	O
IL-12	B-Gene
and	O
IL-4	B-Gene
)	O
determines	O
the	O
capacity	O
of	O
IL-18	B-Gene
to	O
polarize	O
an	O
immune	O
response	O
.	O

Dendritic	O
cell	O
development	O
from	O
common	O
myeloid	O
progenitors	O
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
professional	O
antigen	O
-presenting	O
cells	O
which	O
both	O
initiate	O
adaptive	O
immune	O
responses	O
and	O
control	O
tolerance	O
to	O
self-antigens	O
.	O

It	O
has	O
been	O
suggested	O
that	O
these	O
different	O
effects	O
on	O
responder	O
cells	O
depend	O
on	O
subsets	O
of	O
DCs	O
arising	O
from	O
either	O
myeloid	O
or	O
lymphoid	O
hematopoietic	O
origins	O
.	O

In	O
this	O
model	O
,	O
CD8	B-Gene
alpha+	I-Gene
Mac-1-	I-Gene
DCs	O
are	O
supposed	O
to	O
be	O
of	O
lymphoid	O
while	O
CD8	B-Gene
alpha-	I-Gene
Mac-1+	I-Gene
DCs	O
are	O
supposed	O
to	O
be	O
of	O
myeloid	O
origin	O
.	O

Here	O
we	O
summarize	O
our	O
findings	O
that	O
both	O
CD8	B-Gene
alpha+	I-Gene
and	O
CD8	B-Gene
alpha-	I-Gene
DCs	O
can	O
arise	O
from	O
clonogenic	O
common	O
myeloid	O
progenitors	O
(	O
CMPs	O
)	O
in	O
both	O
thymus	O
and	O
spleen	O
.	O

Therefore	O
CD8	B-Gene
alpha	I-Gene
expression	O
DCs	O
does	O
not	O
indicate	O
a	O
lymphoid	O
origin	O
and	O
differences	O
among	O
CD8	B-Gene
alpha+	I-Gene
and	O
CD8	B-Gene
alpha-	I-Gene
DCs	O
might	O
rather	O
reflect	O
maturation	O
status	O
than	O
ontogeny	O
.	O

On	O
the	O
basis	O
of	O
transplantation	O
studies	O
,	O
it	O
seems	O
likely	O
that	O
most	O
of	O
the	O
DCs	O
in	O
secondary	O
lymphoid	O
organs	O
and	O
a	O
substantial	O
fraction	O
of	O
thymic	O
DCs	O
are	O
myeloid	O
-derived	O
.	O

Down-regulation	O
of	O
TDT	B-Gene
transcription	O
in	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
CD8	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
thymocytes	O
by	O
Ikaros	B-Gene
proteins	I-Gene
in	O
direct	O
competition	O
with	O
an	O
Ets	B-Gene
activator	I-Gene
.	O

Ikaros	B-Gene
is	O
a	O
unique	O
regulator	O
of	O
lymphopoiesis	O
that	O
associates	O
with	O
pericentromeric	O
heterochromatin	O
and	O
has	O
been	O
implicated	O
in	O
heritable	O
gene	O
inactivation	O
.	O

Binding	O
and	O
competition	O
experiments	O
demonstrate	O
that	O
Ikaros	B-Gene
dimers	O
compete	O
with	O
an	O
Ets	B-Gene
activator	I-Gene
for	O
occupancy	O
of	O
the	O
lymphocyte-specific	B-Gene
TdT	I-Gene
promoter	I-Gene
.	O

Mutations	O
that	O
selectively	O
disrupt	O
Ikaros	B-Gene
binding	O
to	O
an	O
integrated	O
TdT	B-Gene
promoter	I-Gene
had	O
no	O
effect	O
on	O
promoter	O
function	O
in	O
a	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
CD8	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
thymocyte	O
line	O
.	O

However	O
,	O
these	O
mutations	O
abolished	O
down-regulation	O
on	O
differentiation	O
,	O
providing	O
evidence	O
that	O
Ikaros	B-Gene
plays	O
a	O
direct	O
role	O
in	O
repression	O
.	O

Reduced	O
access	O
to	O
restriction	O
enzyme	O
cleavage	O
suggested	O
that	O
chromatin	O
alterations	O
accompany	O
down-regulation	O
.	O

The	O
Ikaros	B-Gene
-dependent	O
down-regulation	O
event	O
and	O
the	O
observed	O
chromatin	O
alterations	O
appear	O
to	O
precede	O
pericentromeric	O
repositioning	O
.	O

Current	O
models	O
propose	O
that	O
the	O
functions	O
of	O
Ikaros	B-Gene
should	O
be	O
disrupted	O
by	O
a	O
small	O
isoform	O
that	O
retains	O
the	O
dimerization	O
domain	O
and	O
lacks	O
the	O
DNA	O
-binding	O
domain	O
.	O

Surprisingly	O
,	O
in	O
the	O
CD4	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
CD8	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
thymocyte	O
line	O
,	O
overexpression	O
of	O
a	O
small	O
Ikaros	B-Gene
isoform	I-Gene
had	O
no	O
effect	O
on	O
differentiation	O
or	O
on	O
the	O
pericentromeric	O
targeting	O
and	O
DNA	O
-binding	O
properties	O
of	O
Ikaros	B-Gene
.	O

Rather	O
,	O
the	O
small	O
isoform	O
assembled	O
into	O
multimeric	O
complexes	O
with	O
DNA-bound	O
Ikaros	B-Gene
at	O
the	O
pericentromeric	O
foci	O
.	O

The	O
capacity	O
for	O
in	O
vivo	O
multimer	O
formation	O
suggests	O
that	O
interactions	O
between	O
Ikaros	B-Gene
dimers	O
bound	O
to	O
the	O
TdT	B-Gene
promoter	I-Gene
and	O
those	O
bound	O
to	O
pericentromeric	O
repeat	O
sequences	O
may	O
contribute	O
to	O
the	O
pericentromeric	O
repositioning	O
of	O
the	O
inactive	O
gene	O
.	O

CD28	B-Gene
costimulation	O
is	O
required	O
not	O
only	O
to	O
induce	O
IL-12	B-Gene
receptor	I-Gene
but	O
also	O
to	O
render	O
janus	B-Gene
kinases	I-Gene
/	I-Gene
STAT4	I-Gene
responsive	O
to	O
IL-12	B-Gene
stimulation	O
in	O
TCR	B-Gene
-triggered	O
T	O
cells	O
.	O

The	O
activation	O
of	O
resting	O
T	O
cells	O
for	O
the	O
acquisition	O
of	O
various	O
functions	O
depends	O
on	O
whether	O
CD28	B-Gene
costimulatory	O
signals	O
are	O
provided	O
upon	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
stimulation	O
.	O

Here	O
,	O
we	O
investigated	O
how	O
CD28	B-Gene
costimulation	O
functions	O
to	O
allow	O
TCR	B-Gene
-triggered	O
resting	O
T	O
cells	O
to	O
acquire	O
IL-12	B-Gene
responsiveness	O
.	O

When	O
T	O
cells	O
are	O
stimulated	O
with	O
low	O
doses	O
of	O
anti-CD3	B-Gene
mAb	I-Gene
,	O
CD28	B-Gene
costimulation	O
was	O
required	O
for	O
the	O
optimal	O
levels	O
of	O
IL-12	B-Gene
receptor	I-Gene
(	O
IL-12R	B-Gene
)	O
expression	O
.	O

However	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
high	O
doses	O
of	O
anti-CD3	B-Gene
alone	O
induced	O
comparable	O
levels	O
of	O
IL-12R	B-Gene
expression	O
to	O
those	O
induced	O
upon	O
CD28	B-Gene
costimulation	O
.	O

Nevertheless	O
,	O
there	O
was	O
a	O
substantial	O
difference	O
in	O
IL-12	B-Gene
responsiveness	O
between	O
these	O
two	O
groups	O
of	O
T	O
cells	O
:	O
compared	O
to	O
anti-CD28	B-Gene
-costimulated	O
T	O
cells	O
,	O
T	O
cells	O
that	O
were	O
not	O
costimulated	O
with	O
anti-CD28	B-Gene
exhibited	O
decreased	O
levels	O
of	O
Janus	B-Gene
kinases	I-Gene
(	I-Gene
JAK	I-Gene
)	I-Gene
JAK2	I-Gene
/	I-Gene
TYK2	I-Gene
and	O
STAT4	B-Gene
phosphorylation	O
and	O
IFN-y	B-Gene
production	O
following	O
IL-12	B-Gene
stimulation	O
.	O

Importantly	O
,	O
STAT6	B-Gene
phosphorylation	O
following	O
IL-4	B-Gene
stimulation	O
was	O
not	O
decreased	O
in	O
anti-CD28	B-Gene
-uncostimulated	O
T	O
cells	O
.	O

These	O
resutls	O
indicate	O
that	O
CD28	B-Gene
costimulation	O
not	O
only	O
contributes	O
to	O
up	O
-regulating	O
IL-12R	B-Gene
expression	O
but	O
is	O
also	O
required	O
to	O
render	O
JAKs	B-Gene
/	I-Gene
STAT4	I-Gene
responsive	O
to	O
IL-12	B-Gene
stimulation	O
.	O

Single	O
dose	O
intranasal	O
administration	O
of	O
retinal	O
autoantigen	O
generates	O
a	O
rapid	O
accumulation	O
and	O
cell	O
activation	O
in	O
draining	O
lymph	O
node	O
and	O
spleen	O
:	O
implications	O
for	O
tolerance	O
therapy	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
A	O
single	O
intranasal	O
delivery	O
of	O
retinal	O
autoantigen	O
suppresses	O
effectively	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
EAU	O
)	O
.	O

To	O
further	O
unravel	O
underlying	O
mechanisms	O
the	O
authors	O
wished	O
to	O
determine	O
,	O
firstly	O
,	O
the	O
kinetics	O
of	O
antigen	O
delivery	O
and	O
,	O
secondly	O
,	O
the	O
early	O
cellular	O
responses	O
involved	O
in	O
the	O
initial	O
stages	O
of	O
nasal	O
mucosal	O
tolerance	O
induction	O
.	O

METHODS	O
:	O
Flow	O
cytometry	O
,	O
cell	O
proliferation	O
assays	O
,	O
and	O
microscopy	O
were	O
used	O
to	O
track	O
antigen	O
following	O
a	O
single	O
,	O
intranasal	O
dose	O
of	O
Alexa-488	O
labelled	O
retinal	O
antigen	O
.	O

RESULTS	O
:	O
A	O
rapid	O
accumulation	O
of	O
antigen	O
within	O
both	O
superficial	O
cervical	O
lymph	O
nodes	O
(	O
SCLN	O
)	O
and	O
spleen	O
was	O
observed	O
after	O
30	O
minutes	O
.	O

Significant	O
proliferative	O
responses	O
to	O
IRBP	B-Gene
were	O
elicited	O
by	O
48	O
hours	O
indicating	O
that	O
systemic	O
priming	O
of	O
naive	O
T	O
cells	O
to	O
retinal	O
antigen	O
had	O
occurred	O
.	O

Cell	O
activation	O
was	O
further	O
confirmed	O
by	O
immunoprecipitation	O
studies	O
,	O
which	O
demonstrated	O
phosphorylation	O
of	O
STAT4	B-Gene
but	O
not	O
STAT6	B-Gene
in	O
both	O
lymph	O
nodes	O
and	O
spleen	O
.	O

However	O
,	O
at	O
24	O
hours	O
,	O
STAT4	B-Gene
heterodimerisation	O
with	O
STAT	B-Gene
3	I-Gene
was	O
only	O
observed	O
in	O
spleen	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
provide	O
novel	O
evidence	O
that	O
following	O
a	O
single	O
intranasal	O
application	O
rapid	O
transfer	O
of	O
antigen	O
occurs	O
.	O

Resulting	O
T	O
cell	O
proliferation	O
develops	O
consequent	O
to	O
differential	O
cell	O
signalling	O
in	O
SCLN	O
and	O
spleen	O
.	O

Further	O
understanding	O
of	O
these	O
underlying	O
cellular	O
mechanisms	O
,	O
in	O
particular	O
as	O
is	O
inferred	O
by	O
the	O
results	O
the	O
contribution	O
of	O
local	O
versus	O
systemic	O
tolerance	O
induction	O
,	O
may	O
assist	O
in	O
strategies	O
to	O
clinically	O
apply	O
mucosal	O
tolerance	O
therapy	O
successfully	O
.	O

Identification	O
of	O
phosphorylation	O
sites	O
for	O
Bruton	B-Gene
's	I-Gene
tyrosine	I-Gene
kinase	I-Gene
within	O
the	O
transcriptional	B-Gene
regulator	I-Gene
BAP	I-Gene
/	I-Gene
TFII-I	I-Gene
.	O

Bruton	B-Gene
's	I-Gene
tyrosine	I-Gene
kinase	I-Gene
(	O
Btk	B-Gene
)	O
,	O
a	O
member	O
of	O
the	O
Tec	B-Gene
family	I-Gene
of	O
cytosolic	O
kinases	O
,	O
is	O
essential	O
for	O
B	O
cell	O
development	O
and	O
function	O
.	O

BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
,	O
a	O
protein	O
implicated	O
in	O
transcriptional	O
regulation	O
,	O
is	O
associated	O
with	O
Btk	B-Gene
in	O
B	O
cells	O
and	O
is	O
transiently	O
phosphorylated	O
on	O
tyrosine	B-Chemical
following	O
B	B-Gene
cell	I-Gene
receptor	I-Gene
engagement	O
.	O

BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
is	O
a	O
substrate	O
for	O
Btk	B-Gene
in	O
vitro	O
and	O
is	O
hyperphosphorylated	O
on	O
tyrosine	B-Chemical
upon	O
coexpression	O
with	O
Btk	B-Gene
in	O
mammalian	O
cells	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
physiologic	O
consequences	O
of	O
BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
tyrosine	B-Chemical
phosphorylation	O
following	O
B	B-Gene
cell	I-Gene
receptor	I-Gene
stimulation	O
,	O
site	O
-directed	O
mutagenesis	O
and	O
phosphopeptide	O
mapping	O
were	O
used	O
to	O
locate	O
the	O
predominant	O
sites	O
of	O
BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
phosphorylation	O
by	O
Btk	B-Gene
in	O
vitro	O
.	O

These	O
residues	O
,	O
Tyr248	B-Chemical
,	O
Tyr357	B-Chemical
,	O
and	O
Tyr462	B-Chemical
,	O
were	O
also	O
found	O
to	O
be	O
the	O
major	O
sites	O
for	O
Btk	B-Gene
-dependent	O
phosphorylation	O
of	O
BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
in	O
vivo	O
.	O

Residues	O
Tyr357	B-Chemical
and	O
Tyr462	B-Chemical
are	O
contained	O
within	O
the	O
loop	O
regions	O
of	O
adjacent	O
helix-loop-helix	O
-like	O
repeats	O
within	O
BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
.	O

Mutation	O
of	O
either	O
Tyr248	B-Chemical
,	O
Tyr357	B-Chemical
,	O
or	O
Tyr462	B-Chemical
to	O
phenylalanine	B-Chemical
reduced	O
transcription	O
from	O
a	O
c-fos	B-Gene
promoter	I-Gene
relative	O
to	O
wild-type	O
BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
in	O
transfected	O
COS-7	O
cells	O
,	O
consistent	O
with	O
the	O
interpretation	O
that	O
phosphorylation	O
at	O
these	O
sites	O
contributes	O
to	O
transcriptional	O
activation	O
.	O

Phosphorylation	O
of	O
BAP	B-Gene
/	I-Gene
TFII-I	I-Gene
by	O
Btk	B-Gene
may	O
link	O
engagement	O
of	O
receptors	O
such	O
as	O
surface	B-Gene
immunoglobulin	I-Gene
to	O
modulation	O
of	O
gene	O
expression	O
.	O

Activation	O
of	O
the	O
p21	B-Gene
(	I-Gene
CIP1	I-Gene
/	I-Gene
WAF1	I-Gene
)	I-Gene
promoter	I-Gene
by	O
bone	B-Gene
morphogenetic	I-Gene
protein-2	I-Gene
in	O
mouse	O
B	O
lineage	O
cells	O
.	O

BMPs	B-Gene
exert	O
a	O
negative	O
growth	O
effect	O
on	O
various	O
types	O
of	O
cells	O
.	O

We	O
have	O
previously	O
reported	O
that	O
BMP-2	B-Gene
inhibited	O
the	O
growth	O
of	O
HS-72	O
mouse	O
hybridoma	O
cells	O
by	O
inducing	O
p21	B-Gene
(	O
CIP1	B-Gene
/	I-Gene
WAF1	I-Gene
)	O
expression	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
BMP-2	B-Gene
activated	O
the	O
mouse	B-Gene
p21	I-Gene
(	I-Gene
CIP1	I-Gene
/	I-Gene
WAF1	I-Gene
)	I-Gene
promoter	I-Gene
in	O
HS-72	O
cells	O
,	O
and	O
that	O
a	O
29-base	O
pair	O
(	O
b	O
)	O
region	O
of	O
the	O
promoter	O
(	O
-1928	O
/	O
-1900	O
relative	O
to	O
the	O
TATA	O
box	O
)	O
,	O
conserved	O
between	O
mice	O
and	O
humans	O
,	O
was	O
responsive	O
to	O
BMP-2	B-Gene
as	O
well	O
as	O
expression	O
of	O
Smad1	B-Gene
,	O
Smad4	B-Gene
,	O
and	O
constitutively	O
active	O
mutants	O
of	O
BMP	B-Gene
type	I-Gene
I	I-Gene
receptors	I-Gene
.	O

Furthermore	O
,	O
an	O
oligonucleotide	O
containing	O
the	O
29-b	O
region	O
was	O
found	O
to	O
be	O
associated	O
with	O
Smad4	B-Gene
and	O
phosphorylated	B-Gene
Smad1	I-Gene
in	O
the	O
nuclear	O
extract	O
of	O
BMP-2	B-Gene
-stimulated	O
HS-72	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
BMP-2	B-Gene
might	O
activate	O
p21	B-Gene
(	O
CIP1	B-Gene
/	I-Gene
WAF1	I-Gene
)	O
transcription	O
by	O
inducing	O
a	O
binding	O
of	O
Smad4	B-Gene
and	O
Smad1	B-Gene
to	O
the	O
29-b	O
region	O
in	O
HS-72	O
cells	O
.	O

TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
ligand	I-Gene
selectively	O
induces	O
apoptosis	O
and	O
overcomes	O
drug	O
resistance	O
in	O
multiple	B-Disease
myeloma	I-Disease
:	O
therapeutic	O
applications	O
.	O

Multiple	B-Disease
myeloma	I-Disease
(	O
MM	B-Disease
)	O
remains	O
incurable	O
and	O
novel	O
treatments	O
are	O
urgently	O
needed	O
.	O

Preclinical	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluations	O
were	O
performed	O
to	O
assess	O
the	O
potential	O
therapeutic	O
applications	O
of	O
human	B-Gene
recombinant	I-Gene
tumor	I-Gene
necrosis	I-Gene
factor	I-Gene
(	I-Gene
TNF	I-Gene
)	I-Gene
-related	I-Gene
apoptosis	I-Gene
-inducing	I-Gene
ligand	I-Gene
/	I-Gene
Apo2	I-Gene
ligand	I-Gene
(	O
TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
)	O
in	O
MM	B-Disease
.	O

TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
potently	O
induced	O
apoptosis	O
of	O
MM	B-Disease
cells	O
from	O
patients	O
and	O
the	O
majority	O
of	O
MM	B-Disease
cell	O
lines	O
,	O
including	O
cells	O
sensitive	O
or	O
resistant	O
to	O
dexamethasone	B-Chemical
(	O
Dex	B-Chemical
)	O
,	O
doxorubicin	B-Chemical
(	O
Dox	B-Chemical
)	O
,	O
melphalan	B-Chemical
,	O
and	O
mitoxantrone	B-Chemical
.	O

TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
also	O
overcame	O
the	O
survival	O
effect	O
of	O
interleukin	B-Gene
6	I-Gene
on	O
MM	B-Disease
cells	O
and	O
did	O
not	O
affect	O
the	O
survival	O
of	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
mononuclear	O
cells	O
and	O
purified	O
B	O
cells	O
from	O
healthy	O
donors	O
.	O

The	O
status	O
of	O
the	O
TRAIL	B-Gene
receptors	I-Gene
(	O
assessed	O
by	O
immunoblotting	O
and	O
flow	O
cytometry	O
)	O
could	O
not	O
predict	O
TRAIL	B-Gene
sensitivity	O
of	O
MM	B-Disease
cells	O
.	O

The	O
anti-MM	B-Disease
activity	O
of	O
TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
was	O
confirmed	O
in	O
nu	O
/	O
xid	O
/	O
bg	O
mice	O
xenografted	O
with	O
human	O
MM	B-Disease
cells	O
;	O
TRAIL	B-Gene
(	O
500	O
microg	O
intraperitoneally	O
daily	O
for	O
14	O
days	O
)	O
was	O
well	O
tolerated	O
and	O
significantly	O
suppressed	O
the	O
growth	O
of	O
plasmacytomas	O
.	O

Dox	B-Chemical
up	O
-regulated	O
the	O
expression	O
of	O
the	O
TRAIL	B-Gene
receptor	I-Gene
death	I-Gene
receptor	I-Gene
5	I-Gene
(	O
DR5	B-Gene
)	O
and	O
synergistically	O
enhanced	O
the	O
effect	O
of	O
TRAIL	B-Gene
not	O
only	O
against	O
MM	B-Disease
cells	O
sensitive	O
to	O
,	O
but	O
also	O
against	O
those	O
resistant	O
to	O
,	O
Dex-	B-Chemical
or	O
Dox	B-Chemical
-induced	O
apoptosis	O
.	O

Nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappaB	I-Gene
inhibitors	O
,	O
such	O
as	O
SN50	B-Chemical
(	O
a	O
cell-permeable	O
inhibitor	O
of	O
the	O
nuclear	O
translocation	O
and	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-Gene
)	O
or	O
the	O
proteasome	O
inhibitor	O
PS-341	B-Chemical
,	O
enhanced	O
the	O
proapoptotic	O
activity	O
of	O
TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
against	O
TRAIL	B-Gene
-sensitive	O
MM	B-Disease
cells	O
,	O
whereas	O
SN50	B-Chemical
reversed	O
the	O
TRAIL	B-Gene
resistance	O
of	O
ARH-77	O
and	O
IM-9	O
MM	B-Disease
cells	O
.	O

Importantly	O
,	O
normal	O
B	O
lymphocytes	O
were	O
not	O
sensitized	O
to	O
TRAIL	B-Gene
by	O
either	O
Dox	B-Chemical
,	O
SN50	B-Chemical
,	O
or	O
PS-341	B-Chemical
.	O

These	O
preclinical	O
studies	O
suggest	O
that	O
TRAIL	B-Gene
/	I-Gene
Apo2L	I-Gene
can	O
overcome	O
conventional	O
drug	O
resistance	O
and	O
provide	O
the	O
basis	O
for	O
clinical	O
trials	O
of	O
TRAIL	B-Gene
-based	O
treatment	O
regimens	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
MM	B-Disease
.	O

(	O
Blood.	O
2001	O
;	O
98	O
:	O
795-804	O
)	O

HTLV-1	B-Gene
p12	I-Gene
(	I-Gene
I	I-Gene
)	I-Gene
protein	I-Gene
enhances	O
STAT5	B-Gene
activation	O
and	O
decreases	O
the	O
interleukin-2	B-Gene
requirement	O
for	O
proliferation	O
of	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

The	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
protein	I-Gene
,	O
encoded	O
by	O
the	O
pX	O
open	O
reading	O
frame	O
I	O
of	O
the	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
is	O
a	O
hydrophobic	O
protein	O
that	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
Golgi	O
.	O

Although	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
contains	O
4	O
minimal	O
proline-rich	B-Chemical
,	O
src	B-Gene
homology	O
3	O
-binding	O
motifs	O
(	O
PXXP	O
)	O
,	O
a	O
characteristic	O
commonly	O
found	O
in	O
proteins	O
involved	O
in	O
signaling	O
pathways	O
,	O
it	O
has	O
not	O
been	O
known	O
whether	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
has	O
a	O
role	O
in	O
modulating	O
intracellular	O
signaling	O
pathways	O
.	O

This	O
study	O
demonstrated	O
that	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
binds	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
interleukin-2	B-Gene
receptor	I-Gene
(	I-Gene
IL-2R	I-Gene
)	I-Gene
beta	I-Gene
chain	I-Gene
that	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
Jak1	B-Gene
and	O
Jak3	B-Gene
kinases	I-Gene
.	O

As	O
a	O
result	O
of	O
this	O
interaction	O
,	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
increases	O
signal	B-Gene
transducers	I-Gene
and	I-Gene
activators	I-Gene
of	I-Gene
transcription	I-Gene
5	I-Gene
(	O
STAT5	B-Gene
)	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
and	O
this	O
effect	O
depends	O
on	O
the	O
presence	O
of	O
both	O
IL-2R	B-Gene
beta	I-Gene
and	O
gamma	B-Partial_Gene
(	I-Partial_Gene
c	I-Partial_Gene
)	I-Partial_Gene
chains	I-Partial_Gene
and	O
Jak3	B-Gene
.	O

Transduction	O
of	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
-based	O
retroviral	O
vector	O
expressing	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
also	O
resulted	O
in	O
increased	O
STAT5	B-Gene
phosphorylation	O
and	O
DNA	O
binding	O
.	O

However	O
,	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
could	O
increase	O
proliferation	O
of	O
human	O
PBMCs	O
only	O
after	O
stimulation	O
of	O
T-cell	B-Gene
receptors	I-Gene
by	O
treatment	O
of	O
cells	O
with	O
low	O
concentrations	O
of	O
alphaCD3	B-Gene
and	O
alphaCD28	B-Gene
antibodies	I-Gene
.	O

In	O
addition	O
,	O
the	O
proliferative	O
advantage	O
of	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
-transduced	O
PBMCs	O
was	O
evident	O
mainly	O
at	O
low	O
concentrations	O
of	O
IL-2	B-Gene
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
p12	B-Gene
(	I-Gene
I	I-Gene
)	I-Gene
may	O
confer	O
a	O
proliferative	O
advantage	O
on	O
HTLV-1	O
-infected	O
cells	O
in	O
the	O
presence	O
of	O
suboptimal	O
antigen	O
stimulation	O
and	O
that	O
this	O
event	O
may	O
account	O
for	O
the	O
clonal	O
proliferation	O
of	O
infected	O
T	O
cells	O
in	O
vivo	O
.	O

(	O
Blood.	O
2001	O
;	O
98	O
:	O
823-829	O
)	O

Maturation	O
of	O
human	O
dendritic	O
cells	O
as	O
sulfasalazine	B-Chemical
target	O
.	O

AIM	O
:	O
Sulfasalazine	B-Chemical
,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
,	O
is	O
effective	O
in	O
treating	O
some	O
autoimmune	B-Disease
diseases	I-Disease
,	O
but	O
its	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

To	O
determine	O
whether	O
dendritic	O
cells	O
could	O
be	O
a	O
possible	O
target	O
of	O
the	O
drug	O
,	O
we	O
studied	O
the	O
effects	O
of	O
sulfasalazine	B-Chemical
and	O
its	O
metabolites	O
,	O
aminosalicylate	B-Chemical
and	O
sulfapyridine	B-Chemical
,	O
on	O
in	O
vitro	O
maturation	O
(	O
terminal	O
differentiation	O
)	O
of	O
human	O
myeloid	O
dendritic	O
cells	O
.	O

METHODS	O
:	O
We	O
prepared	O
immature	O
dendritic	O
cells	O
by	O
incubating	O
CD14	B-Gene
-positive	O
cells	O
in	O
the	O
presence	O
of	O
granulocyte-	B-Gene
macrophage	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
and	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-4	I-Gene
.	O

The	O
cells	O
were	O
matured	O
by	O
addition	O
of	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
(	I-Gene
TNF	I-Gene
)	I-Gene
-a	I-Gene
,	O
IL-1	B-Gene
beta	I-Gene
,	O
and	O
prostaglandin	B-Chemical
E2	I-Chemical
in	O
the	O
presence	O
of	O
sulfasalazine	B-Chemical
or	O
its	O
metabolites	O
--	O
aminosalicylate	B-Chemical
and	O
sulfapyridine	B-Chemical
,	O
or	O
their	O
combinations	O
.	O

We	O
quantified	O
the	O
effect	O
of	O
drugs	O
on	O
the	O
dendritic	O
cell	O
characteristics	O
,	O
such	O
as	O
stimulation	O
of	O
autologous	O
and	O
allogeneic	O
pan-T	O
cell	O
proliferation	O
,	O
surface	O
marker	O
phenotype	O
,	O
IL-12	B-Gene
p40	I-Gene
subunit	I-Gene
secretion	O
,	O
and	O
activation	O
of	O
nuclear	B-Gene
transcription	I-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappa	I-Gene
B	I-Gene
.	O

RESULTS	O
:	O
Dendritic	O
cells	O
treated	O
with	O
sulfasalazine	B-Chemical
(	O
1.25	O
micromol	O
/	O
L	O
or	O
2.5	O
micromol	O
/	O
L	O
)	O
could	O
not	O
stimulate	O
T	O
cells	O
(	O
p	O
<	O
0.028	O
,	O
two	O
-sided	O
paired	O
t-test	O
)	O
.	O

In	O
distinction	O
to	O
drug-free	O
maturing	O
dendritic	O
cells	O
,	O
2.5	O
micromol	O
/	O
L	O
sulfasalazine	B-Chemical
upregulated	O
the	O
levels	O
of	O
CD14	B-Gene
and	O
CD68	B-Gene
and	O
downregulated	O
the	O
levels	O
of	O
CD40	B-Gene
,	O
CD80	B-Gene
,	O
and	O
CD83	B-Gene
(	O
for	O
all	O
CD	O
markers	O
,	O
p	O
<	O
0.03	O
for	O
difference	O
between	O
measurements	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
sulfasalazine	B-Chemical
)	O
.	O

From	O
concentration	O
-dependent	O
changes	O
in	O
CD83	B-Gene
expression	O
,	O
we	O
found	O
an	O
apparent	O
ID50	O
>	O
>	O
1.5	O
micromol	O
/	O
L	O
sulfasalazine	B-Chemical
.	O

The	O
apparent	O
ID50	O
value	O
for	O
aminosalicylate	B-Chemical
-inhibited	O
maturation	O
was	O
4	O
micromol	O
/	O
L	O
.	O

Sulfapyridine	B-Chemical
had	O
no	O
effect	O
.	O

At	O
1.25	O
micromol	O
/	O
L	O
,	O
sulfasalazine	B-Chemical
largely	O
inhibited	O
NF-kB	B-Gene
activation	O
in	O
dendritic	O
cells	O
.	O

CONCLUSION	O
:	O
Maturing	O
human	O
dendritic	O
cells	O
are	O
hundred-fold	O
more	O
sensitive	O
to	O
sulfasalazine	B-Chemical
than	O
T	O
cells	O
and	O
NK	O
cells	O
and	O
the	O
most	O
sensitive	O
human	O
cells	O
described	O
so	O
far	O
.	O

Thus	O
,	O
dendritic	O
cell	O
maturation	O
is	O
an	O
important	O
target	O
of	O
sulfasalazine	B-Chemical
.	O

Because	O
of	O
the	O
role	O
of	O
dendritic	O
cells	O
in	O
(	O
auto	O
)	O
immunity	O
,	O
inhibition	O
of	O
their	O
maturation	O
might	O
provide	O
a	O
target	O
for	O
further	O
optimization	O
of	O
sulfasalazine	B-Chemical
therapy	O
.	O

Suppression	O
of	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
production	O
by	O
cAMP	B-Chemical
in	O
human	O
monocytes	O
:	O
dissociation	O
with	O
mRNA	O
level	O
and	O
independent	O
of	O
interleukin-10	B-Gene
.	O

BACKGROUND	O
:	O
Elevation	O
of	O
cellular	O
cAMP	B-Chemical
inhibits	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
-stimulated	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	O
TNF-alpha	B-Gene
)	O
production	O
and	O
increases	O
the	O
expression	O
of	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-10	I-Gene
in	O
mononuclear	O
cells	O
.	O

TNF-alpha	B-Gene
gene	I-Gene
expression	O
obligates	O
activation	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
nuclear	I-Gene
factor	I-Gene
kappaB	I-Gene
(	O
NF-kappaB	B-Gene
)	O
.	O

Exogenous	B-Gene
IL-10	I-Gene
inhibits	O
NF-kappaB	B-Gene
in	O
monocytes	O
and	O
thus	O
attenuates	O
TNF-alpha	B-Gene
production	O
.	O

We	O
examined	O
the	O
role	O
of	O
endogenous	B-Gene
IL-10	I-Gene
in	O
the	O
regulation	O
of	O
NF-kappaB	B-Gene
activation	O
and	O
TNF-alpha	B-Gene
production	O
in	O
human	O
monocytes	O
by	O
cAMP	B-Chemical
.	O

METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	O
Escherichia	O
coli	O
LPS	B-Chemical
(	O
100	O
ng	O
/	O
ml	O
)	O
with	O
and	O
without	O
forskolin	B-Chemical
(	O
FSK	B-Chemical
,	O
50	O
microM	O
)	O
or	O
dibutyryl	B-Chemical
cyclic	I-Chemical
AMP	I-Chemical
(	O
dbcAMP	B-Chemical
,	O
100	O
microM	O
)	O
.	O

Cytokine	O
(	O
TNF-alpha	B-Gene
and	O
IL-10	B-Gene
)	O
release	O
was	O
measured	O
by	O
immunoassay	O
.	O

TNF-alpha	B-Gene
mRNA	I-Gene
was	O
measured	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
and	O
NF-kappaB	B-Gene
DNA	I-Gene
binding	O
activity	O
was	O
assessed	O
by	O
gel	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
cAMP	B-Chemical
-elevating	O
agents	O
inhibited	O
LPS	B-Chemical
-stimulated	O
TNF-alpha	B-Gene
release	O
(	O
0.77	O
+	O
/	O
-	O
0.13	O
ng	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
LPS	B-Chemical
+	O
dbcAMP	B-Chemical
and	O
0.68	O
+	O
/	O
-	O
0.19	O
ng	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
LPS	B-Chemical
+	O
FSK	B-Chemical
,	O
both	O
P	O
<	O
0.05	O
vs	O
1.61	O
+	O
/	O
-	O
0.34	O
ng	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
LPS	B-Chemical
alone	O
)	O
.	O

Conversely	O
,	O
cAMP	B-Chemical
enhanced	O
LPS	B-Chemical
-stimulated	O
IL-10	B-Gene
release	O
(	O
100	O
+	O
/	O
-	O
21.5	O
pg	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
LPS	B-Chemical
+	O
dbcAMP	B-Chemical
and	O
110	O
+	O
/	O
-	O
25.2	O
pg	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
LPS	B-Chemical
+	O
FSK	B-Chemical
,	O
both	O
P	O
<	O
0.05	O
vs	O
53.3	O
+	O
/	O
-	O
12.8	O
pg	O
/	O
10	O
(	O
6	O
)	O
cells	O
in	O
LPS	B-Chemical
alone	O
)	O
.	O

Neither	O
TNF-alpha	B-Gene
mRNA	I-Gene
expression	O
nor	O
NF-kappaB	B-Gene
activation	O
stimulated	O
by	O
LPS	B-Chemical
was	O
inhibited	O
by	O
the	O
cAMP	B-Chemical
-elevating	O
agents	O
.	O

Neutralization	O
of	O
IL-10	B-Gene
with	O
a	O
specific	O
antibody	O
did	O
not	O
attenuate	O
the	O
effect	O
of	O
cAMP	B-Chemical
-elevating	O
agents	O
on	O
TNF-alpha	B-Gene
production	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
cAMP	B-Chemical
inhibits	O
LPS	B-Chemical
-stimulated	O
TNF-alpha	B-Gene
production	O
through	O
a	O
posttranscriptional	O
mechanism	O
that	O
is	O
independent	O
of	O
endogenous	B-Gene
IL-10	I-Gene
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Inhibition	O
of	O
AP-1	B-Gene
by	O
the	O
glucocorticoid-inducible	B-Chemical
protein	O
GILZ	B-Gene
.	O

The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	B-Chemical
arise	O
largely	O
by	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
,	O
which	O
has	O
been	O
ascribed	O
to	O
interference	O
between	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
and	O
transcription	O
factors	O
such	O
as	O
AP-1	B-Gene
and	O
NF-kappa	B-Gene
B	I-Gene
as	O
well	O
as	O
by	O
competition	O
for	O
common	O
coactivators	O
.	O

Here	O
we	O
show	O
that	O
glucocorticoid	B-Chemical
-induced	O
inhibition	O
of	O
interleukin-2	B-Gene
mRNA	I-Gene
expression	O
in	O
activated	O
normal	O
T	O
cells	O
required	O
new	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
this	O
phenomenon	O
is	O
secondary	O
to	O
expression	O
of	O
glucocorticoid	B-Chemical
-regulated	O
genes	O
.	O

One	O
of	O
the	O
most	O
prominent	O
glucocorticoid	B-Chemical
-induced	O
genes	O
is	O
glucocorticoid	B-Gene
-induced	I-Gene
leucine	I-Gene
zipper	I-Gene
(	O
GILZ	B-Gene
)	O
,	O
which	O
has	O
been	O
reported	O
to	O
inhibit	O
activation	O
-induced	O
up-regulation	O
of	O
Fas	B-Gene
ligand	I-Gene
(	I-Gene
FasL	I-Gene
)	I-Gene
mRNA	I-Gene
.	O

Indeed	O
,	O
transient	O
expression	O
of	O
GILZ	B-Gene
in	O
Jurkat	O
T	O
cells	O
blocked	O
induction	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
FasL	B-Gene
promoter	I-Gene
.	O

This	O
could	O
be	O
accounted	O
for	O
by	O
GILZ	B-Gene
-mediated	O
inhibition	O
of	O
Egr-2	B-Gene
and	O
Egr-3	B-Gene
,	O
NFAT	B-Gene
/	I-Gene
AP-1	I-Gene
-inducible	O
transcription	O
factors	O
that	O
bind	O
a	O
regulatory	O
element	O
in	O
the	O
FasL	B-Gene
promoter	I-Gene
and	O
up-regulate	O
FasL	B-Gene
expression	O
.	O

GILZ	B-Gene
also	O
potently	O
inhibited	O
AP-1-driven	B-Gene
and	O
IL-2	B-Gene
promoter-driven	I-Gene
reporter	O
constructs	O
,	O
and	O
recombinant	O
GILZ	B-Gene
specifically	O
interacted	O
with	O
c-Fos	B-Gene
and	O
c-Jun	B-Gene
in	O
vitro	O
and	O
inhibited	O
the	O
binding	O
of	O
active	O
AP-1	B-Gene
to	O
its	O
target	O
DNA	O
.	O

Whereas	O
homodimerization	O
of	O
GILZ	B-Gene
required	O
the	O
presence	O
of	O
its	O
leucine	B-Chemical
zipper	O
,	O
the	O
interaction	O
with	O
c-Fos	B-Gene
and	O
c-Jun	B-Gene
occurred	O
through	O
the	O
N-terminal	O
60-amino	O
acid	O
region	O
of	O
GILZ	B-Gene
.	O

Thus	O
,	O
GILZ	B-Gene
represents	O
a	O
glucocorticoid	B-Chemical
-induced	O
gene	O
product	O
that	O
can	O
inhibit	O
a	O
variety	O
of	O
activation	O
-induced	O
events	O
,	O
at	O
least	O
in	O
part	O
by	O
direct	O
interference	O
with	O
AP-1	B-Gene
,	O
and	O
is	O
therefore	O
a	O
candidate	O
for	O
a	O
mediator	O
of	O
glucocorticoid	B-Chemical
-induced	O
immunosuppression	O
.	O

Transcription	B-Gene
factor	I-Gene
LKLF	I-Gene
is	O
sufficient	O
to	O
program	O
T	O
cell	O
quiescence	O
via	O
a	O
c-Myc	B-Gene
--	O
dependent	O
pathway	O
.	O

T	O
lymphocytes	O
circulate	O
in	O
a	O
quiescent	O
state	O
until	O
they	O
encounter	O
cognate	O
antigen	O
bound	O
to	O
the	O
surface	O
of	O
an	O
antigen	O
-presenting	O
cell	O
.	O

The	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
quiescence	O
remain	O
largely	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
forced	O
expression	O
of	O
the	O
lung	B-Gene
Kruppel	I-Gene
-like	I-Gene
transcription	I-Gene
factor	I-Gene
(	O
LKLF	B-Gene
)	O
in	O
Jurkat	O
T	O
cells	O
is	O
sufficient	O
to	O
program	O
a	O
quiescent	O
phenotype	O
characterized	O
by	O
decreased	O
proliferation	O
,	O
reduced	O
cell	O
size	O
and	O
protein	O
synthesis	O
and	O
decreased	O
surface	O
expression	O
of	O
activation	O
markers	O
.	O

Conversely	O
,	O
LKLF	B-Gene
-deficient	O
peripheral	O
T	O
cells	O
produced	O
by	O
gene	O
targeting	O
showed	O
increased	O
proliferation	O
,	O
increased	O
cell	O
size	O
and	O
enhanced	O
expression	O
of	O
surface	O
activation	O
markers	O
in	O
vivo	O
.	O

LKLF	B-Gene
appeared	O
to	O
function	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
decreasing	O
expression	O
of	O
the	O
proto-oncogene	O
encoding	O
c-Myc	B-Gene
.	O

Forced	O
expression	O
of	O
LKLF	B-Gene
was	O
associated	O
with	O
markedly	O
decreased	O
c-Myc	B-Gene
expression	O
.	O

In	O
addition	O
,	O
many	O
effects	O
of	O
LKLF	B-Gene
expression	O
were	O
mimicked	O
by	O
expression	O
of	O
the	O
dominant	O
-negative	O
MadMyc	B-Gene
protein	I-Gene
and	O
rescued	O
by	O
overexpression	O
of	O
c-Myc	B-Gene
.	O

Thus	O
,	O
LKLF	B-Gene
is	O
both	O
necessary	O
and	O
sufficient	O
to	O
program	O
quiescence	O
in	O
T	O
cells	O
and	O
functions	O
,	O
in	O
part	O
,	O
by	O
negatively	O
regulating	O
a	O
c-Myc	B-Gene
--	O
dependent	O
pathway	O
.	O

The	O
RING	B-Gene
finger	I-Gene
protein	I-Gene
Siah-1	I-Gene
regulates	O
the	O
level	O
of	O
the	O
transcriptional	B-Gene
coactivator	I-Gene
OBF-1	I-Gene
.	O

The	O
transcriptional	B-Gene
coactivator	I-Gene
OBF-1	I-Gene
,	O
which	O
interacts	O
with	O
Oct-1	B-Gene
and	O
Oct-2	B-Gene
and	O
the	O
octamer	O
site	O
DNA	O
,	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
development	O
of	O
a	O
normal	O
immune	O
response	O
and	O
the	O
formation	O
of	O
germinal	O
centers	O
in	O
secondary	O
lymphoid	O
organs	O
.	O

Here	O
we	O
have	O
identified	O
the	O
RING	B-Gene
finger	I-Gene
protein	I-Gene
Siah-1	I-Gene
as	O
a	O
protein	O
interacting	O
specifically	O
with	O
OBF-1	B-Gene
.	O

This	O
interaction	O
is	O
mediated	O
by	O
the	O
C-terminal	O
part	O
of	O
Siah-1	B-Gene
and	O
by	O
residues	O
in	O
the	O
N-terminus	O
of	O
OBF-1	B-Gene
,	O
partly	O
distinct	O
from	O
the	O
residues	O
required	O
for	O
formation	O
of	O
a	O
complex	O
with	O
the	O
Oct	B-Gene
POU	O
domains	O
and	O
the	O
DNA	O
.	O

Interaction	O
between	O
Siah-1	B-Gene
and	O
OBF-1	B-Gene
leads	O
to	O
downregulation	O
of	O
OBF-1	B-Gene
protein	I-Gene
level	O
but	O
not	O
mRNA	O
,	O
and	O
to	O
a	O
corresponding	O
reduction	O
in	O
octamer	O
site	O
-dependent	O
transcription	O
activation	O
.	O

Inhibition	O
of	O
the	O
ubiquitin-proteasome	B-Gene
pathway	O
in	O
B	O
cells	O
leads	O
to	O
elevated	O
levels	O
of	O
OBF-1	B-Gene
protein	I-Gene
.	O

Furthermore	O
,	O
in	O
immunized	O
mice	O
,	O
OBF-1	B-Gene
protein	I-Gene
amounts	O
are	O
dramatically	O
increased	O
in	O
primary	O
activated	O
B	O
cells	O
,	O
without	O
concomitant	O
increase	O
in	O
OBF-1	B-Gene
mRNA	I-Gene
.	O

These	O
data	O
suggest	O
that	O
Siah-1	B-Gene
is	O
part	O
of	O
a	O
novel	O
regulatory	O
loop	O
controlling	O
the	O
level	O
of	O
OBF-1	B-Gene
protein	I-Gene
in	O
B	O
cells	O
.	O

Transcription	B-Gene
factor	I-Gene
STAT5A	I-Gene
is	O
a	O
substrate	O
of	O
Bruton	B-Gene
's	I-Gene
tyrosine	I-Gene
kinase	I-Gene
in	O
B	O
cells	O
.	O

STAT5A	B-Gene
is	O
a	O
molecular	O
regulator	O
of	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
in	O
lymphohematopoietic	O
cells	O
.	O

Here	O
we	O
show	O
that	O
STAT5A	B-Gene
can	O
serve	O
as	O
a	O
functional	O
substrate	O
of	O
Bruton	B-Gene
's	I-Gene
tyrosine	I-Gene
kinase	I-Gene
(	O
BTK	B-Gene
)	O
.	O

Purified	O
recombinant	B-Gene
BTK	I-Gene
was	O
capable	O
of	O
directly	O
binding	O
purified	O
recombinant	B-Gene
STAT5A	I-Gene
with	O
high	O
affinity	O
(	O
K	O
(	O
d	O
)	O
=	O
44	O
nm	O
)	O
,	O
as	O
determined	O
by	O
surface	O
plasmon	O
resonance	O
using	O
a	O
BIAcore	O
biosensor	O
system	O
.	O

BTK	B-Gene
was	O
also	O
capable	O
of	O
tyrosine	B-Chemical
-phosphorylating	O
ectopically	O
expressed	O
recombinant	B-Gene
STAT5A	I-Gene
on	O
Tyr	B-Chemical
(	O
694	O
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
a	O
Janus	B-Gene
kinase	I-Gene
3	I-Gene
-independent	O
fashion	O
.	O

BTK	B-Gene
phosphorylated	O
the	O
Y665F	O
,	O
Y668F	O
,	O
and	O
Y682F	O
,	O
Y683F	O
mutants	O
but	O
not	O
the	O
Y694F	O
mutant	O
of	O
STAT5A	B-Gene
.	O

STAT5A	B-Gene
mutations	O
in	O
the	O
Src	B-Gene
homology	O
2	O
(	O
SH2	O
)	O
and	O
SH3	O
domains	O
did	O
not	O
alter	O
the	O
BTK	B-Gene
-mediated	O
tyrosine	B-Chemical
phosphorylation	O
.	O

Recombinant	B-Gene
BTK	I-Gene
proteins	I-Gene
with	O
mutant	B-Gene
pleckstrin	I-Gene
homology	O
,	O
SH2	O
,	O
or	O
SH3	O
domains	O
were	O
capable	O
of	O
phosphorylating	O
STAT5A	B-Gene
,	O
whereas	O
recombinant	B-Gene
BTK	I-Gene
proteins	I-Gene
with	O
SH1	B-Gene
/	O
kinase	O
domain	O
mutations	O
were	O
not	O
.	O

In	O
pull-down	O
experiments	O
,	O
only	O
full-length	O
BTK	B-Gene
and	O
its	O
SH1	B-Gene
/	O
kinase	O
domain	O
(	O
but	O
not	O
the	O
pleckstrin	B-Gene
homology	O
,	O
SH2	O
,	O
or	O
SH3	O
domains	O
)	O
were	O
capable	O
of	O
binding	O
STAT5A	B-Gene
.	O

Ectopically	O
expressed	O
BTK	B-Gene
kinase	I-Gene
domain	O
was	O
capable	O
of	O
tyrosine	B-Chemical
-phosphorylating	O
STAT5A	B-Gene
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

BTK	B-Gene
-mediated	O
tyrosine	B-Chemical
phosphorylation	O
of	O
ectopically	O
expressed	O
wild	O
type	O
(	O
but	O
not	O
Tyr	B-Chemical
(	O
694	O
)	O
mutant	O
)	O
STAT5A	B-Gene
enhanced	O
its	O
DNA	O
binding	O
activity	O
.	O

In	O
BTK	B-Gene
-competent	O
chicken	O
B	O
cells	O
,	O
anti-IgM	B-Gene
-stimulated	O
tyrosine	B-Chemical
phosphorylation	O
of	O
STAT5	B-Gene
protein	I-Gene
was	O
prevented	O
by	O
pretreatment	O
with	O
the	O
BTK	B-Gene
inhibitor	O
LFM-A13	B-Chemical
but	O
not	O
by	O
pretreatment	O
with	O
the	O
JAK3	B-Gene
inhibitor	O
HI-P131	B-Chemical
.	O

B	B-Gene
cell	I-Gene
antigen	I-Gene
receptor	I-Gene
ligation	O
resulted	O
in	O
enhanced	O
tyrosine	B-Chemical
phosphorylation	O
of	O
STAT5	B-Gene
in	O
BTK	B-Gene
-deficient	O
chicken	O
B	O
cells	O
reconstituted	O
with	O
wild	B-Gene
type	I-Gene
human	I-Gene
BTK	I-Gene
but	O
not	O
in	O
BTK	B-Gene
-deficient	O
chicken	O
B	O
cells	O
reconstituted	O
with	O
kinase	O
-inactive	O
mutant	B-Gene
BTK	I-Gene
.	O

Similarly	O
,	O
anti-IgM	B-Gene
stimulation	O
resulted	O
in	O
enhanced	O
tyrosine	B-Chemical
phosphorylation	O
of	O
STAT5A	B-Gene
in	O
BTK	B-Gene
-competent	O
B	O
cells	O
from	O
wild	O
type	O
mice	O
but	O
not	O
in	O
BTK	B-Gene
-deficient	O
B	O
cells	O
from	O
XID	O
mice	O
.	O

In	O
contrast	O
to	O
B	O
cells	O
from	O
XID	O
mice	O
,	O
B	O
cells	O
from	O
JAK3	B-Gene
knockout	O
mice	O
showed	O
a	O
normal	O
STAT5A	B-Gene
phosphorylation	O
response	O
to	O
anti-IgM	B-Gene
stimulation	O
.	O

These	O
findings	O
provide	O
unprecedented	O
experimental	O
evidence	O
that	O
BTK	B-Gene
plays	O
a	O
nonredundant	O
and	O
pivotal	O
role	O
in	O
B	B-Gene
cell	I-Gene
antigen	I-Gene
receptor	I-Gene
-mediated	O
STAT5A	B-Gene
activation	O
in	O
B	O
cells	O

Corticosteroid	B-Chemical
-induced	O
lymphopenia	O
,	O
immunosuppression	O
,	O
and	O
body	O
defense	O
.	O

The	O
apparent	O
paradox	O
of	O
heightened	O
adrenal	O
corticosteroid	B-Chemical
levels	O
associated	O
with	O
reduction	O
in	O
the	O
competence	O
of	O
the	O
body	O
's	O
defensive	O
apparatus	O
to	O
cope	O
with	O
exposure	O
to	O
new	O
microbial	O
antigens	O
is	O
considered	O
.	O

The	O
question	O
is	O
asked	O
how	O
this	O
lowered	O
defensive	O
capability	O
,	O
which	O
occurs	O
in	O
the	O
face	O
of	O
a	O
threat	O
to	O
body	O
integrity	O
,	O
is	O
consistent	O
with	O
Cannon	O
's	O
principals	O
of	O
the	O
``	O
wisdom	O
of	O
the	O
body	O
.	O

''	O

The	O
suggestion	O
is	O
offered	O
that	O
the	O
immunologic	O
response	O
to	O
self-antigens	O
exposed	O
by	O
disease	O
or	O
trauma	O
may	O
be	O
suppressed	O
by	O
corticosteroid	B-Chemical
to	O
offset	O
the	O
likelihood	O
of	O
autoimmune	O
attack	O
.	O

Chronic	B-Disease
lymphatic	I-Disease
leukaemia	I-Disease
:	O
cellular	O
effects	O
of	O
glucocorticoids	B-Chemical
in	O
vitro	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
levels	O
and	O
steroid	B-Chemical
induced	O
inhibition	O
of	O
nucleic	O
acid	O
precursors	O
have	O
been	O
examined	O
in	O
lymphocytes	O
from	O
27	O
patients	O
at	O
different	O
stages	O
of	O
chronic	B-Disease
lymphatic	I-Disease
leukaemia	I-Disease
.	O

No	O
correlation	O
can	O
be	O
found	O
between	O
the	O
level	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
the	O
stage	O
of	O
the	O
disease	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0.02	O
)	O
was	O
found	O
between	O
stage	O
O	O
and	O
stage	O
III	O
/	O
IV	O
patients	O
,	O
in	O
terms	O
of	O
the	O
in	O
vitro	O
effect	O
of	O
dexamethasone	B-Chemical
on	O
[	O
3H	O
]	O
uridine	B-Chemical
incorporation	O
.	O

Interaction	O
of	O
glucocorticoids	B-Chemical
with	O
macrophages	O
.	O

Identification	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
monocytes	O
and	O
macrophages	O
.	O

Glucocorticoid	B-Chemical
binding	O
was	O
measured	O
in	O
resident	O
and	O
thioglycollate	B-Chemical
-elicited	O
mouse	O
peritoneal	O
macrophages	O
,	O
rabbit	O
alveolar	O
macrophages	O
,	O
and	O
human	O
monocytes	O
.	O

Two	O
assays	O
of	O
binding	O
were	O
used	O
--	O
an	O
assay	O
with	O
intact	O
cells	O
in	O
suspension	O
or	O
monolayers	O
,	O
and	O
an	O
assay	O
of	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

The	O
mononuclear	O
phagocytes	O
contained	O
approximately	O
equal	O
to	O
4	O
--	O
10	O
X	O
10	O
(	O
3	O
)	O
high	O
affinity	O
receptor	O
sites	O
per	O
cell	O
,	O
with	O
dissociation	O
constants	O
of	O
approximately	O
equal	O
to	O
2	O
--	O
8	O
nM	O
dexamethasone	B-Chemical
.	O

The	O
binding	O
to	O
the	O
saturable	O
sites	O
was	O
specific	O
for	O
steroids	B-Chemical
with	O
glucocorticoid	B-Chemical
or	O
antiglucocorticoid	B-Chemical
activity	O
.	O

Cortisol	B-Chemical
,	O
corticosterone	B-Chemical
,	O
and	O
progesterone	B-Chemical
competed	O
with	O
dexamethasone	B-Chemical
for	O
binding	O
,	O
whereas	O
estradiol	B-Chemical
,	O
dihydrotestosterone	B-Chemical
,	O
and	O
11-epicortisol	B-Chemical
competed	O
very	O
little	O
.	O

Binding	O
of	O
dexamethasone	B-Chemical
to	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
the	O
receptor	O
complex	O
and	O
temperature	O
-sensitive	O
translocation	O
of	O
cytosol	O
forms	O
to	O
nuclear	O
forms	O
were	O
shown	O
.	O

At	O
37	O
degrees	O
C	O
the	O
predominant	O
form	O
of	O
the	O
hormone-receptor	B-Gene
complex	I-Gene
was	O
nuclear	O
.	O

These	O
results	O
demonstrate	O
that	O
corticosteroids	B-Chemical
interact	O
with	O
macrophages	O
at	O
physiological	O
concentrations	O
.	O

Nuclear	O
glucocorticoid	B-Chemical
binding	O
in	O
chronic	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
lymphocytes	O
.	O

A	O
reliable	O
procedure	O
is	O
described	O
for	O
isolating	O
3H-triamcinolone	B-Gene
acetonide	I-Gene
(	I-Gene
3H-TA	I-Gene
)	I-Gene
receptor	I-Gene
complexes	I-Gene
from	O
purified	O
chronic	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
(	O
CLL	B-Disease
)	O
lymphocyte	O
nuclei	O
,	O
based	O
on	O
the	O
use	O
of	O
carbobenzoxy-L-phenylalanine	B-Chemical
(	O
CBZ-L-phe	B-Chemical
)	O
to	O
prevent	O
breakdown	O
of	O
hormone-receptor	O
complexes	O
during	O
extraction	O
of	O
nuclei	O
with	O
0.6M	O
KCl	O
.	O

Using	O
this	O
method	O
,	O
specific	O
nuclear	O
glucocorticoid	B-Chemical
binding	O
was	O
demonstrated	O
in	O
14	O
/	O
14	O
patients	O
with	O
untreated	O
CLL	B-Disease
.	O

No	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
nuclear	O
-associated	O
3H-TA	B-Chemical
and	O
peripheral	O
white	O
blood	O
cell	O
count	O
or	O
rosetting	O
ability	O
of	O
circulating	O
lymphocytes	O
.	O

The	O
leukocyte	O
migration	O
inhibition	O
response	O
to	O
certain	O
breast	B-Disease
cancer	I-Disease
-related	O
antigens	O
(	O
MCF-7	O
and	O
MuMTV	O
)	O
:	O
their	O
potential	O
as	O
discriminants	O
.	O

Certain	O
oncogenic	O
viruses	O
have	O
been	O
implicated	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
,	O
including	O
the	O
murine	O
mammary	B-Disease
tumor	I-Disease
virus	O
(	O
MuMTV	O
)	O
and	O
the	O
Mason-Pfizer	O
monkey	O
virus	O
(	O
MPMV	O
)	O
.	O

We	O
have	O
used	O
the	O
leukocyte	O
migration	O
inhibition	O
(	O
LMI	O
)	O
response	O
to	O
assay	O
the	O
response	O
to	O
several	O
potential	O
breast	B-Disease
cancer	I-Disease
-related	O
antigens	O
,	O
including	O
MuMTV	O
,	O
MPMV	O
,	O
and	O
a	O
breast	B-Disease
cancer	I-Disease
cultured	O
cell	O
line	O
,	O
MCF-7	O
,	O
in	O
96	O
breast	B-Disease
cancer	I-Disease
patients	O
,	O
in	O
32	O
women	O
with	O
benign	O
breast	B-Disease
disease	I-Disease
,	O
and	O
in	O
67	O
normal	O
women	O
.	O

The	O
lowest	O
tenth	O
percentile	O
of	O
control	O
(	O
LMI	O
)	O
responses	O
was	O
used	O
as	O
the	O
cutoff	O
point	O
to	O
designate	O
responders	O
.	O

Breast	B-Disease
cancer	I-Disease
patients	O
showed	O
significant	O
responses	O
to	O
MuMTV	O
(	O
49	O
%	O
and	O
to	O
MCF-7	O
(	O
50	O
%	O
)	O
,	O
but	O
not	O
to	O
MPMV	O
(	O
29	O
%	O
)	O
.	O

In	O
a	O
paired-antigen	O
study	O
using	O
MuMTV	O
and	O
MCF-7	O
,	O
75	O
%	O
of	O
the	O
breast	B-Disease
cancer	I-Disease
patients	O
responded	O
,	O
versus	O
18	O
%	O
of	O
the	O
normal	O
women	O
(	O
P	O
less	O
than	O
0.0050	O
)	O
.	O

The	O
potential	O
for	O
this	O
assay	O
to	O
distinguish	O
``	O
normal	O
''from	O
``	O
breast	B-Disease
cancer	I-Disease
''was	O
analyzed	O
using	O
a	O
migration	O
index	O
derived	O
from	O
discriminant	O
analysis	O
.	O

The	O
ability	O
of	O
the	O
assay	O
to	O
discriminate	O
``	O
normal	O
''from	O
``	O
cancer	B-Disease
''was	O
significant	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
showed	O
a	O
sensitivity	O
of	O
detecting	O
``	O
cancer	B-Disease
''of	O
75	O
%	O
.	O

The	O
overall	O
responses	O
to	O
MuMTV	O
and	O
MCF-7	O
were	O
analyzed	O
with	O
reference	O
to	O
certain	O
prognostic	O
factors	O
,	O
but	O
showed	O
no	O
relation	O
to	O
age	O
,	O
menstrual	O
status	O
,	O
estrogen	B-Gene
receptor	I-Gene
status	O
,	O
or	O
stage	O
of	O
disease	O
.	O

The	O
above	O
reactions	O
suggest	O
that	O
a	O
large	O
proportion	O
of	O
breast	B-Disease
cancer	I-Disease
patients	O
exhibit	O
presensitization	O
to	O
antigenfs	O
found	O
in	O
MuMTV	O
and	O
MCF-7	O
,	O
which	O
may	O
be	O
cross	O
-reactive	O
with	O
antigens	O
in	O
the	O
primary	O
cancer	B-Disease
.	O

These	O
responses	O
appear	O
to	O
be	O
independent	O
of	O
major	O
prognostic	O
variables	O
.	O

Further	O
refinement	O
of	O
this	O
assay	O
may	O
yield	O
one	O
which	O
is	O
more	O
highly	O
discriminating	O
for	O
breast	B-Disease
cancer	I-Disease
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
and	O
actions	O
in	O
rat	O
thymocytes	O
and	O
immunologically	O
stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O

After	O
reviewing	O
briefly	O
our	O
earlier	O
studies	O
on	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
mechanisms	O
in	O
thymus	O
cells	O
,	O
we	O
have	O
outlined	O
results	O
from	O
the	O
following	O
two	O
areas	O
of	O
current	O
interest	O
in	O
our	O
laboratories	O
:	O
the	O
``	O
life-cycle	O
''of	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
complexes	O
in	O
thymus	O
cells	O
,	O
and	O
the	O
levels	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
sensitivity	O
in	O
immunologically	O
stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O

Several	O
of	O
our	O
results	O
on	O
energetics	O
and	O
kinetics	O
of	O
hormone	O
binding	O
to	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
rat	O
thymus	O
cells	O
seem	O
to	O
require	O
extension	O
of	O
the	O
simplest	O
model	O
of	O
hormone-receptor	O
transformations	O
in	O
intact	O
cells	O
.	O

ATP-depletion	B-Chemical
experiments	O
suggest	O
the	O
existence	O
of	O
a	O
nonbinding	O
form	O
of	O
the	O
receptor	O
;	O
``	O
chase	O
''experiments	O
suggest	O
reaction	O
of	O
hormone	O
directly	O
with	O
nuclear-bound	O
receptor	O
;	O
experiments	O
on	O
depletion	O
and	O
replenishment	O
of	O
cytoplasmic	O
receptor	O
using	O
cortisol	B-Chemical
and	O
dexamethasone	B-Chemical
suggest	O
the	O
existence	O
of	O
at	O
least	O
two	O
subpopulations	O
of	O
nuclear-bound	O
hormone-receptor	O
complex	O
.	O

We	O
have	O
found	O
that	O
mitogen	O
or	O
immunologic	O
stimulation	O
of	O
human	O
peripheral	O
lymphocytes	O
in	O
culture	O
leads	O
within	O
24	O
h	O
or	O
so	O
to	O
a	O
striking	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
per	O
cell	O
.	O

We	O
believe	O
this	O
increase	O
may	O
be	O
due	O
to	O
partial	O
synchronization	O
of	O
the	O
cell	O
population	O
in	O
a	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
which	O
receptor	O
content	O
is	O
high	O
.	O

Contrary	O
to	O
the	O
widely	O
held	O
view	O
that	O
mitogen	O
-stimulated	O
cells	O
become	O
insensitive	O
to	O
glucocorticoids	B-Chemical
,	O
our	O
experiments	O
show	O
that	O
with	O
respect	O
to	O
inhibition	O
of	O
thymidine	B-Chemical
and	O
uridine	B-Chemical
incorporation	O
and	O
glucose	B-Chemical
uptake	O
,	O
the	O
cells	O
are	O
highly	O
sensitive	O
to	O
dexamethasone	B-Chemical
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
after	O
stimulation	O
with	O
concanavalin	B-Gene
A	I-Gene
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
in	O
cytosol	O
and	O
nuclear	O
extract	O
of	O
human	O
leukocytes	O
.	O

Cortisol	B-Chemical
binding	O
by	O
cytosol	O
and	O
0.4	O
M	O
KCl	O
extract	O
of	O
the	O
nuclear	O
fraction	O
of	O
human	O
leukocytes	O
were	O
studied	O
by	O
gel	O
chromatography	O
and	O
ion	O
exchange	O
filtration	O
on	O
DEAE	B-Chemical
cellulose	O
.	O

The	O
cytoplasmic	O
cortisol	B-Gene
binding	I-Gene
protein	I-Gene
has	O
a	O
molecular	O
weight	O
95	O
000	O
and	O
the	O
soluble	O
nuclear	O
binding	O
protein	O
50	O
000	O
.	O

The	O
absence	O
of	O
the	O
uptake	O
of	O
radioactive	O
cortisol	B-Chemical
by	O
isolated	O
nuclei	O
and	O
the	O
apparent	O
requirement	O
of	O
the	O
cytosol	O
for	O
glucocorticoid	B-Chemical
specific	O
binding	O
in	O
nuclear	O
receptor	O
sites	O
was	O
observed	O
.	O

The	O
association	O
constant	O
characterising	O
the	O
binding	O
of	O
cortisol	B-Chemical
to	O
cytosol	O
was	O
KA	O
=	O
3.5	O
.	O

10	O
(	O
9	O
)	O
l	O
/	O
mol	O
.	O

Glucocorticoids	B-Chemical
and	O
lymphocytes	O
.	O

I	O
.	O

Increased	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
in	O
antigen	O
-stimulated	O
lymphocytes	O
.	O

Recently	O
a	O
2-	O
to	O
3-fold	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
human	O
peripheral	O
lymphocytes	O
has	O
been	O
noted	O
after	O
in	O
vitro	O
mitogen	O
stimulation	O
.	O

Here	O
,	O
we	O
extend	O
these	O
observations	O
to	O
in	O
vivo	O
immunization	O
.	O

After	O
unilateral	O
immunization	O
of	O
adrenalectomized	O
male	O
rats	O
,	O
a	O
50	O
%	O
increase	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
per	O
cell	O
,	O
determined	O
by	O
binding	O
of	O
dexamethasone	B-Chemical
,	O
was	O
observed	O
in	O
cell	O
suspensions	O
of	O
homolateral	O
lymph	O
nodes	O
over	O
those	O
from	O
the	O
contralateral	O
nonimmunized	O
side	O
of	O
the	O
same	O
animal	O
.	O

The	O
association	O
constant	O
for	O
dexamethasone	B-Chemical
was	O
similar	O
in	O
both	O
groups	O
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
various	O
steroids	B-Chemical
,	O
the	O
time	O
course	O
of	O
cytoplasmic	O
and	O
nuclear	O
association	O
,	O
and	O
cytoplasmic-to-nuclear	O
translocation	O
.	O

Despite	O
a	O
50	O
%	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
per	O
cell	O
,	O
the	O
cells	O
from	O
the	O
homolateral	O
and	O
controlateral	O
lymph	O
nodes	O
were	O
equally	O
sensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
dexamethasone	B-Chemical
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
,	O
RNA	O
,	O
and	O
DNA	O
,	O
or	O
measurements	O
of	O
in	O
vitro	O
cell	O
survival	O
.	O

Glucocorticoids	B-Chemical
and	O
lymphocytes	O
.	O

II	O
.	O

Cell	O
cycle	O
-dependent	O
changes	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
.	O

To	O
study	O
variations	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
during	O
the	O
cell	O
cycle	O
,	O
we	O
have	O
separated	O
mitogen	O
-stimulated	O
human	O
peripheral	O
lymphocytes	O
and	O
rat	O
lymph	O
node	O
cells	O
by	O
unit	O
gravity	O
sedimentation	O
and	O
measured	O
glucocorticoid	B-Chemical
binding	O
in	O
the	O
resultant	O
fractions	O
.	O

By	O
morphologic	O
criteria	O
and	O
thymidine	B-Chemical
incorporation	O
,	O
the	O
fractions	O
were	O
separated	O
into	O
populations	O
of	O
G0	O
and	O
G1	O
phase	O
and	O
S	O
and	O
post-S	O
phase	O
cells	O
.	O

A	O
2-	O
to	O
3-fold	O
increase	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
per	O
cell	O
,	O
for	O
cells	O
in	O
the	O
S	O
and	O
post-S	O
phase	O
over	O
those	O
in	O
G0	O
and	O
G1	O
,	O
was	O
observed	O
with	O
both	O
nonstimulated	O
rat	O
lymph	O
node	O
cell	O
suspensions	O
and	O
concanavalin	B-Gene
A	I-Gene
-stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O

These	O
observations	O
together	O
with	O
those	O
from	O
other	O
studies	O
indicate	O
that	O
formation	O
of	O
new	O
glucocorticoid	B-Gene
receptors	I-Gene
near	O
the	O
S	O
phase	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
proliferating	O
cells	O
.	O

We	O
propose	O
that	O
this	O
increase	O
in	O
glucocorticoid	B-Gene
receptors	I-Gene
during	O
the	O
cell	O
cycle	O
may	O
explain	O
the	O
increase	O
in	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
mitogen	O
-stimulated	O
lymphocytes	O
.	O

Heterogeneity	O
of	O
the	O
in	O
vitro	O
responses	O
to	O
glucocorticoids	B-Chemical
in	O
acute	B-Disease
leukemia	I-Disease
.	O

In	O
leukocyte	O
population	O
freshly	O
isolated	O
from	O
the	O
blood	O
of	O
26	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
,	O
we	O
have	O
measured	O
several	O
parameters	O
including	O
glucocorticoid	B-Gene
receptors	I-Gene
,	O
nucleoside	O
incorporation	O
,	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
,	O
and	O
steroid	B-Chemical
-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
in	O
some	O
cases	O
,	O
the	O
short-term	O
response	O
to	O
steroid	B-Chemical
therapy	O
was	O
determined	O
.	O

Although	O
,	O
in	O
all	O
the	O
patients	O
studied	O
,	O
leukocytes	O
were	O
found	O
to	O
contain	O
glucocorticoid	B-Gene
receptors	I-Gene
,	O
we	O
failed	O
to	O
demonstrate	O
any	O
correlation	O
between	O
the	O
level	O
of	O
binding	O
sites	O
and	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
response	O
to	O
glucocorticoids	B-Chemical
.	O

This	O
absence	O
of	O
correlation	O
could	O
be	O
in	O
part	O
explained	O
by	O
the	O
marked	O
heterogeneity	O
of	O
the	O
steroid	B-Chemical
response	O
demonstrated	O
in	O
leukocyte	O
subpopulations	O
.	O

It	O
appears	O
,	O
however	O
,	O
that	O
the	O
degree	O
of	O
steroid	B-Chemical
action	O
in	O
vitro	O
as	O
well	O
as	O
the	O
extent	O
of	O
spontaneous	O
and	O
dexamethasone	B-Chemical
-induced	O
cell	O
death	O
may	O
be	O
related	O
to	O
the	O
number	O
of	O
cells	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

'Activation-labile	O
'glucocorticoid-receptor	B-Gene
complexes	I-Gene
of	O
a	O
steroid	B-Chemical
-resistant	O
variant	O
of	O
CEM-C7	O
human	O
lymphoid	O
cells	O
.	O

For	O
cytoplasmic	B-Gene
glucocorticoid-receptor	I-Gene
complexes	I-Gene
to	O
enter	O
and	O
accumulate	O
in	O
the	O
nucleus	O
a	O
temperature	O
-dependent	O
event	O
,	O
'activation	O
'is	O
required	O
.	O

Activation	O
can	O
be	O
achieved	O
in	O
vitro	O
by	O
increased	O
ionic	O
strength	O
,	O
dilution	O
or	O
gel	O
filtration	O
and	O
is	O
manifested	O
by	O
an	O
increased	O
affinity	O
of	O
steroid-receptor	B-Gene
complex	I-Gene
for	O
DNA	O
and	O
an	O
altered	O
elution	O
profile	O
from	O
ion-exchange	O
resins	O
.	O

Munck	O
and	O
Foley	O
have	O
shown	O
that	O
activated	O
complexes	O
isolated	O
from	O
thymocytes	O
elute	O
from	O
DEAE-cellulose	O
in	O
a	O
manner	O
identical	O
to	O
complexes	O
activated	O
in	O
vitro	O
.	O

We	O
report	O
here	O
that	O
DEAE-cellulose	O
chromatography	O
of	O
steroid-receptor	B-Gene
complexes	I-Gene
from	O
CEM-C7	O
,	O
a	O
cloned	O
human	O
leukaemic	O
T-cell	O
line	O
sensitive	O
to	O
the	O
cytolytic	O
action	O
of	O
glucocorticoids	B-Chemical
,	O
and	O
its	O
steroid	B-Chemical
-resistant	O
subclone	O
4R4	O
demonstrated	O
that	O
steroid	B-Gene
receptors	I-Gene
of	O
clone	O
4R4	O
can	O
not	O
form	O
stable	O
activated	O
complexes	O
.	O

This	O
defines	O
a	O
new	O
defect	O
in	O
receptor	O
action	O
,	O
activation	O
lability	O
(	O
r	O
+	O
act1	O
)	O
,	O
which	O
is	O
unlike	O
either	O
the	O
r-	O
,	O
r	O
+	O
nt-	O
,	O
or	O
r	O
+	O
nti	O
phenotypes	O
previously	O
described	O
for	O
mouse	O
lymphoid	O
variants	O
.	O

Immunochemical	O
differences	O
between	O
glucocorticoid	B-Gene
receptors	I-Gene
from	O
corticoid	B-Chemical
-sensitive	O
and	O
-resistant	O
malignant	O
lymphocytes	O
.	O

We	O
have	O
explored	O
the	O
possibility	O
of	O
using	O
antibodies	O
against	O
purified	B-Gene
rat	I-Gene
liver	I-Gene
glucocorticoid	I-Gene
receptors	I-Gene
to	O
study	O
the	O
immunochemical	O
properties	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
from	O
murine	O
and	O
human	O
malignant	O
lymphocytes	O
.	O

For	O
this	O
purpose	O
,	O
purified	B-Gene
immune	I-Gene
immunoglobulin	I-Gene
G	I-Gene
was	O
covalently	O
linked	O
to	O
Sepharose	O
CL-4B	O
.	O

We	O
then	O
examined	O
the	O
ability	O
of	O
the	O
affinity	O
gel	O
to	O
recognize	O
cytosolic	B-Gene
[	I-Gene
3H	I-Gene
]	I-Gene
triamcinolone	I-Gene
acetonide-receptor	I-Gene
complexes	I-Gene
from	O
the	O
corticoid	B-Chemical
-sensitive	O
(	O
CS	O
)	O
and	O
-resistant	O
strains	O
of	O
mouse	O
lymphoma	B-Disease
P1798	O
,	O
from	O
CS	O
lymphocytes	O
of	O
patients	O
with	O
chronic	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
,	O
and	O
from	O
a	O
CS	O
clone	O
of	O
human	O
leukemic	O
lymphoblasts	O
in	O
tissue	O
culture	O
(	O
CH6	O
)	O
.	O

Mouse	O
thymus	O
was	O
used	O
as	O
a	O
source	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
from	O
normal	O
CS	O
lymphocytes	O
.	O

Whereas	O
the	O
immunoaffinity	O
column	O
retained	O
70	O
to	O
84	O
%	O
of	O
the	O
58-	O
to	O
62-A	O
(	O
Stokes	O
radius	O
)	O
[	B-Gene
3H	I-Gene
]	I-Gene
triamcinolone	I-Gene
acetonide-receptor	I-Gene
complexes	I-Gene
characteristic	O
of	O
the	O
CS	O
mouse	O
and	O
human	O
lymphocytes	O
,	O
it	O
failed	O
to	O
recognize	O
the	O
27-	O
to	O
28-A	O
(	O
Stokes	O
radius	O
)	O
glucocorticoid	B-Gene
receptor	I-Gene
present	O
in	O
corticoid	B-Chemical
-resistant	O
mouse	O
lymphoma	B-Disease
P1798	O
cells	O
.	O

Therefore	O
,	O
under	O
appropriate	O
experimental	O
conditions	O
,	O
it	O
was	O
possible	O
to	O
demonstrate	O
cross-reactivity	O
between	O
the	O
antiserum	O
against	O
rat	B-Gene
liver	I-Gene
glucocorticoid	I-Gene
receptor	I-Gene
and	O
the	O
58-	O
to	O
62-A	O
(	O
Stokes	O
radius	O
)	O
glucocorticoid	B-Gene
receptor	I-Gene
from	O
species	O
as	O
diverse	O
as	O
mouse	O
and	O
humans	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
activation	O
and	O
inactivation	O
in	O
c	O
ultured	O
human	O
lymphocytes	O
.	O

Although	O
glucocorticoids	B-Chemical
are	O
not	O
cytolytic	O
for	O
and	O
do	O
not	O
inhibit	O
the	O
growth	O
of	O
the	O
IM-9	O
line	O
of	O
cultured	O
human	O
lymphoblasts	O
,	O
these	O
cells	O
have	O
a	O
high	O
steroid	B-Chemical
-binding	O
capacity	O
.	O

We	O
have	O
used	O
IM-9	O
cells	O
in	O
order	O
to	O
examine	O
whether	O
unoccupied	O
glucocorticoid	B-Gene
receptors	I-Gene
are	O
inactivated	O
and	O
activated	O
in	O
intact	O
cells	O
.	O

when	O
IM-9	O
cells	O
are	O
incubated	O
in	O
glucose-free	B-Chemical
medium	O
in	O
a	O
nitrogen	B-Chemical
atmosphere	O
,	O
both	O
their	O
ability	O
to	O
bind	O
triamcinolone	B-Chemical
acetonide	I-Chemical
and	O
their	O
ATP	B-Chemical
levels	O
decline	O
and	O
,	O
when	O
glucose	B-Chemical
and	O
oxygen	B-Chemical
are	O
reintroduced	O
,	O
ATP	B-Chemical
levels	O
and	O
receptor	O
activity	O
return	O
.	O

The	O
specific	O
glucocorticoid	B-Chemical
-binding	O
activity	O
of	O
cytosol	O
prepared	O
from	O
cells	O
exposed	O
to	O
various	O
degrees	O
of	O
energy	O
limitation	O
is	O
directly	O
correlated	O
with	O
the	O
ATP	B-Chemical
content	O
.	O

Receptor	O
activation	O
in	O
intact	O
cells	O
is	O
rapid	O
and	O
independent	O
of	O
protein	O
synthesis	O
.	O

Cytosol	O
prepared	O
from	O
inactivated	O
cells	O
can	O
not	O
be	O
activated	O
by	O
addition	O
of	O
ATP	B-Chemical
.	O

The	O
inactivation	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
that	O
occurs	O
when	O
cytosol	O
from	O
normal	O
IM-9	O
cells	O
is	O
incubated	O
at	O
25	O
degrees	O
C	O
is	O
inhibited	O
by	O
molybdate	B-Chemical
,	O
vanadate	B-Chemical
,	O
fluoride	B-Chemical
,	O
ATP	B-Chemical
,	O
and	O
several	O
other	O
nucleotides	O
.	O

The	O
experiments	O
with	O
intact	O
human	O
lymphoblasts	O
suggest	O
that	O
assays	O
of	O
specific	O
glucocorticoid	B-Chemical
-binding	O
capacity	O
do	O
not	O
necessarily	O
reflect	O
the	O
cellular	O
content	O
of	O
receptor	O
protein	O
.	O

Influence	O
of	O
sex	B-Gene
hormone	I-Gene
binding	I-Gene
globulin	I-Gene
and	O
serum	B-Gene
albumin	I-Gene
on	O
the	O
conversion	O
of	O
androstenedione	B-Chemical
to	O
testosterone	B-Chemical
by	O
human	O
erythrocytes	O
.	O

The	O
influence	O
of	O
human	B-Gene
serum	I-Gene
albumin	I-Gene
and	O
sex	B-Gene
hormone	I-Gene
binding	I-Gene
globulin	I-Gene
(	O
SHBG	B-Gene
)	O
on	O
the	O
enzymic	O
conversion	O
of	O
androstenedione	B-Chemical
to	O
testosterone	B-Chemical
in	O
human	O
erythrocytes	O
was	O
investigated	O
in	O
vitro	O
.	O

Total	O
plasma	O
and	O
albumin	B-Gene
delayed	O
the	O
conversion	O
rate	O
of	O
androstenedione	B-Chemical
,	O
while	O
SHBG	B-Gene
increased	O
it	O
markedly	O
.	O

The	O
effect	O
of	O
SHBG	B-Gene
was	O
largely	O
abolished	O
by	O
heating	O
to	O
60	O
degrees	O
C	O
for	O
1	O
h	O
and	O
by	O
saturating	O
its	O
binding	O
sites	O
by	O
DHT	B-Chemical
.	O

The	O
effect	O
of	O
both	O
proteins	O
was	O
found	O
to	O
be	O
related	O
to	O
their	O
concentration	O
.	O

It	O
appears	O
that	O
the	O
binding	O
sites	O
of	O
albumin	B-Gene
provide	O
a	O
mechanism	O
for	O
retarding	O
androstenedione	B-Chemical
uptake	O
by	O
the	O
erythrocytes	O
and	O
that	O
the	O
high	O
binding	O
affinity	O
of	O
SHBG	B-Gene
for	O
testosterone	B-Chemical
facilitates	O
the	O
diffusion	O
of	O
this	O
steroid	B-Chemical
out	O
of	O
the	O
cell	O
and	O
thus	O
,	O
displaces	O
the	O
chemical	O
equilibrium	O
within	O
the	O
cell	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
and	O
glucocorticoid	B-Chemical
sensitivity	O
of	O
human	O
leukemic	O
cells	O
.	O

We	O
have	O
established	O
optimal	O
conditions	O
for	O
the	O
measurement	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GR	B-Gene
)	O
in	O
human	O
white	O
cells	O
using	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
as	O
the	O
ligand	O
,	O
and	O
the	O
subsequent	O
determination	O
of	O
the	O
GR	B-Gene
content	O
in	O
normal	O
human	O
lymphocytes	O
and	O
in	O
leukemic	O
cells	O
of	O
patients	O
with	O
various	O
forms	O
of	O
acute	O
and	O
chronic	B-Disease
leukemia	I-Disease
.	O

A	O
number	O
of	O
leukemia	B-Disease
cell	O
lines	O
in	O
continuous	O
culture	O
were	O
also	O
subjected	O
to	O
the	O
GR	B-Gene
assay	O
,	O
and	O
the	O
results	O
were	O
correlated	O
with	O
the	O
sensitivity	O
of	O
these	O
cell	O
lines	O
to	O
glucocorticoid	B-Chemical
steroids	B-Chemical
in	O
vitro	O
.	O

The	O
GR	B-Gene
content	O
of	O
normal	O
human	O
lymphocytes	O
amounted	O
to	O
4	O
,	O
850	O
+	O
/	O
-	O
1	O
,	O
340	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
receptors	O
/	O
cell	O
.	O

The	O
mean	O
equilibrium	O
dissociation	O
constant	O
(	O
KD	O
)	O
of	O
the	O
interaction	O
of	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
with	O
the	O
GR	B-Gene
was	O
1.2	O
x	O
10	O
(	O
-8	O
)	O
M	O
.	O

Steroidal	O
compounds	O
with	O
a	O
known	O
glucocorticoid	B-Chemical
potency	O
effectively	O
competed	O
for	O
the	O
binding	O
,	O
whereas	O
steroids	B-Chemical
devoid	O
of	O
glucocorticoid	B-Chemical
activity	O
(	O
e.g.	O
estradiol-17	B-Chemical
beta	I-Chemical
and	O
testosterone	B-Chemical
)	O
were	O
ineffective	O
.	O

The	O
GR	B-Gene
content	O
of	O
the	O
blast	O
cells	O
obtained	O
from	O
eight	O
patients	O
suffering	O
from	O
acute	B-Disease
leukemia	I-Disease
and	O
four	O
patients	O
with	O
a	O
blast	O
crisis	O
of	O
chronic	B-Disease
myelocytic	I-Disease
leukemia	I-Disease
was	O
found	O
to	O
be	O
highly	O
variable	O
(	O
3	O
,	O
230-29	O
,	O
900	O
receptors	O
/	O
cell	O
)	O
,	O
while	O
the	O
lymphocytes	O
of	O
six	O
patients	O
with	O
chronic	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
contained	O
a	O
rather	O
stable	O
GR	B-Gene
content	O
(	O
2	O
,	O
930-5	O
,	O
120	O
receptors	O
/	O
cell	O
)	O
,	O
which	O
was	O
comparable	O
with	O
that	O
of	O
normal	O
lymphocytes	O
.	O

GR	B-Gene
was	O
identified	O
in	O
all	O
the	O
12	O
malignant	O
continuous	O
white	O
cell	O
lines	O
studied	O
.	O

Large	O
cells	O
contained	O
more	O
GR	B-Gene
than	O
the	O
smaller	O
ones	O
.	O

There	O
was	O
no	O
apparent	O
correlation	O
between	O
the	O
GR	B-Gene
concentration	O
and	O
the	O
sensitivity	O
of	O
the	O
cells	O
in	O
vitro	O
to	O
glucocorticoids	B-Chemical
as	O
judged	O
by	O
[	O
3H	O
]	O
thymidine	B-Chemical
incorporation	O
studies	O
.	O

Distribution	O
of	O
the	O
surface	O
markers	O
in	O
the	O
leukemic	O
cell	O
lines	O
did	O
not	O
relate	O
to	O
the	O
GR	B-Gene
concentration	O
.	O

We	O
conclude	O
that	O
the	O
presence	O
of	O
GR	B-Gene
is	O
probably	O
a	O
universal	O
feature	O
of	O
the	O
leukemic	O
cells	O
,	O
and	O
,	O
from	O
a	O
clinical	O
standpoint	O
,	O
probably	O
does	O
not	O
alone	O
imply	O
steroid	B-Chemical
responsiveness	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
content	O
of	O
T	O
lymphocytes	O
:	O
evidence	O
for	O
heterogeneity	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
were	O
measured	O
in	O
T	O
lymphocytes	O
that	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
either	O
nylon	B-Chemical
wool	O
filtration	O
or	O
E-rosette	O
sedimentation	O
.	O

T	O
cells	O
isolated	O
by	O
nylon	B-Chemical
wool	O
filtration	O
specifically	O
bind	O
6.7	O
+	O
/	O
-	O
0.2	O
fmol	O
of	O
dexamethasone	B-Chemical
per	O
million	O
cells	O
(	O
equivalent	O
to	O
4000	O
+	O
/	O
-	O
200	O
receptors	O
per	O
cell	O
)	O
,	O
whereas	O
T	O
cells	O
isolated	O
by	O
E-rosette	O
sedimentation	O
bind	O
12.0	O
+	O
/	O
-	O
0.7	O
fmol	O
of	O
dexamethasone	B-Chemical
per	O
million	O
cells	O
(	O
equivalent	O
to	O
7200	O
+	O
/	O
-	O
400	O
receptors	O
per	O
cell	O
)	O
.	O

This	O
difference	O
in	O
the	O
amount	O
of	O
dexamethasone	B-Chemical
bound	O
by	O
the	O
two	O
T	O
cell	O
preparations	O
was	O
significant	O
(	O
p	O
less	O
than	O
.001	O
)	O
and	O
was	O
present	O
immediately	O
after	O
cell	O
isolation	O
.	O

The	O
binding	O
affinities	O
of	O
the	O
different	O
T	O
cell	O
preparations	O
for	O
dexamethasone	B-Chemical
were	O
similar	O
.	O

T	O
cells	O
that	O
are	O
isolated	O
by	O
a	O
combination	O
of	O
nylon	B-Chemical
wool	O
filtration	O
followed	O
by	O
E-rosette	O
sedimentation	O
bind	O
the	O
same	O
amount	O
of	O
dexamethasone	B-Chemical
as	O
T	O
cells	O
isolated	O
by	O
nylon	B-Chemical
wool	O
filtration	O
alone	O
.	O

T	O
cells	O
isolated	O
by	O
a	O
combination	O
of	O
E-rosette	O
sedimentation	O
following	O
by	O
nylon	B-Chemical
wool	O
filtration	O
bind	O
less	O
dexamethasone	B-Chemical
than	O
do	O
T	O
cells	O
isolated	O
by	O
E-rosette	O
sedimentation	O
alone	O
.	O

These	O
findings	O
suggest	O
that	O
T	O
cells	O
are	O
heterogeneous	O
with	O
respect	O
to	O
their	O
quantity	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

Isolation	O
of	O
T	O
cells	O
by	O
E-rosette	O
sedimentation	O
enriches	O
for	O
T	O
cells	O
that	O
have	O
a	O
greater	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
,	O
and	O
isolation	O
of	O
T	O
cells	O
by	O
nylon	B-Chemical
wool	O
filtration	O
enriches	O
for	O
T	O
cells	O
that	O
have	O
a	O
lesser	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
and	O
sensitivity	O
in	O
leukemias	B-Disease
.	O

In	O
an	O
attempt	O
to	O
investigate	O
the	O
utility	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
determination	O
to	O
predict	O
clinical	O
responsiveness	O
in	O
human	O
leukemias	B-Disease
we	O
have	O
studied	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
the	O
leukemic	O
cells	O
from	O
46	O
patients	O
and	O
in	O
the	O
lymphocytes	O
from	O
18	O
normal	O
donors	O
.	O

In	O
the	O
normal	O
lymphocytes	O
there	O
were	O
3	O
,	O
875	O
(	O
Median	O
)	O
specific	O
binding	O
sites	O
per	O
cell	O
.	O

The	O
blasts	O
from	O
17	O
patients	O
with	O
ANLL	B-Disease
had	O
on	O
average	O
higher	O
levels	O
of	O
binding	O
sites	O
per	O
cell	O
(	O
Median	O
=	O
7	O
,	O
250	O
,	O
range	O
:	O
0	O
to	O
15	O
,	O
295	O
)	O
than	O
the	O
other	O
leukemias	B-Disease
.	O

Of	O
the	O
15	O
patients	O
with	O
CLL	B-Disease
,	O
six	O
had	O
received	O
glucocorticoid	B-Chemical
treatment	O
for	O
3	O
to	O
5	O
years	O
.	O

Their	O
lymphocytes	O
had	O
lower	O
number	O
of	O
receptors	O
(	O
Median	O
=	O
2	O
,	O
000	O
)	O
than	O
the	O
other	O
cases	O
which	O
were	O
newly	O
diagnosed	O
(	O
Median	O
=	O
4	O
,	O
500	O
)	O
.	O

Four	O
patients	O
had	O
ALL	B-Disease
/	O
AUL	B-Disease
,	O
three	O
patients	O
had	O
blast	O
crisis	O
as	O
terminal	O
phase	O
of	O
CML	B-Disease
,	O
and	O
seven	O
had	O
leukemic	O
Non-Hodgkin	B-Disease
lymphomas	I-Disease
(	O
Median	O
=	O
3	O
,	O
500	O
sites	O
/	O
cell	O
)	O
.	O

In	O
24	O
patients	O
we	O
have	O
also	O
studied	O
the	O
in	O
vitro	O
sensitivity	O
of	O
the	O
leukemic	O
cells	O
to	O
dexamethasone	B-Chemical
.	O

There	O
was	O
no	O
marked	O
correlation	O
between	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
and	O
in	O
vitro	O
sensitivity	O
.	O

An	O
attempt	O
to	O
correlate	O
receptor	O
levels	O
with	O
clinical	O
responsiveness	O
demonstrated	O
that	O
glucocorticoid	B-Gene
receptor	I-Gene
determination	O
might	O
be	O
of	O
value	O
in	O
patients	O
with	O
lymphoid	O
malignancies	B-Disease
but	O
probably	O
not	O
in	O
patients	O
with	O
other	O
leukemias	B-Disease
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
concentrations	O
and	O
terminal	B-Gene
transferase	I-Gene
activity	O
as	O
indicators	O
of	O
prognosis	O
in	O
acute	O
non-lymphocytic	B-Disease
leukaemia	I-Disease
.	O

Activity	O
of	O
terminal	B-Gene
deoxynucleotidyl	I-Gene
transferase	I-Gene
(	O
TdT	B-Gene
)	O
,	O
adenosine	B-Gene
deaminase	I-Gene
,	O
and	O
5'nucleotidase	B-Gene
and	O
the	O
cellular	O
concentration	O
of	O
glucocorticoid	B-Gene
(	I-Gene
dexamethasone	I-Gene
)	I-Gene
receptor	I-Gene
were	O
determined	O
in	O
25	O
patients	O
with	O
acute	O
non-lymphocytic	B-Disease
leukaemia	I-Disease
.	O

All	O
patients	O
were	O
treated	O
according	O
to	O
a	O
common	O
protocol	O
.	O

Increased	O
activity	O
of	O
TdT	B-Gene
(	O
greater	O
than	O
0.1	O
unit	O
/	O
microgram	O
DNA	O
)	O
was	O
found	O
in	O
11	O
patients	O
.	O

This	O
group	O
of	O
patients	O
was	O
shown	O
to	O
have	O
higher	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.06	O
)	O
compared	O
with	O
patients	O
with	O
low	O
activity	O
of	O
TdT	B-Gene
.	O

The	O
glucocorticoid	B-Gene
receptor	I-Gene
concentration	O
of	O
the	O
leukaemic	O
blast	O
cells	O
ranged	O
from	O
0	O
to	O
0.94	O
fmol	O
/	O
microgram	O
DNA	O
.	O

Thirteen	O
patients	O
had	O
blast	O
cells	O
with	O
a	O
glucocorticoid	B-Gene
receptor	I-Gene
concentration	O
over	O
0.22	O
fmol	O
/	O
microgram	O
DNA	O
.	O

These	O
patients	O
had	O
significantly	O
increased	O
remission	O
and	O
survival	O
rates	O
(	O
p	O
=	O
0.006	O
)	O
compared	O
with	O
those	O
with	O
a	O
low	O
receptor	O
concentration	O
.	O

This	O
finding	O
can	O
not	O
be	O
explained	O
by	O
a	O
difference	O
in	O
sensitivity	O
to	O
glucocorticoids	B-Chemical
since	O
these	O
were	O
not	O
used	O
as	O
therapeutic	O
agents	O
.	O

Adenosine	B-Gene
deaminase	I-Gene
and	O
5'nucleotidase	B-Gene
activities	O
both	O
varied	O
within	O
two	O
orders	O
of	O
magnitude	O
.	O

No	O
correlation	O
could	O
be	O
found	O
between	O
activities	O
of	O
these	O
enzymes	O
and	O
remission	O
or	O
survival	O
rate	O
.	O

These	O
results	O
show	O
that	O
measurements	O
of	O
TdT	B-Gene
activity	O
and	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
concentration	O
yield	O
valuable	O
prognostic	O
information	O
in	O
acute	O
non-lymphocytic	B-Disease
leukaemia	I-Disease

Immunoglobulin	B-Gene
localization	O
in	O
benign	O
and	O
malignant	O
lesions	O
of	O
the	O
human	O
mammary	O
gland	O
.	O

Using	O
direct	O
imunofluorescence	O
,	O
lesions	O
from	O
266	O
human	O
breast	O
specimens	O
were	O
studied	O
for	O
the	O
presence	O
of	O
IgA	B-Gene
,	O
IgM	B-Gene
,	O
or	O
IgG	B-Gene
localization	O
.	O

The	O
lesions	O
included	O
benign	O
elements	O
from	O
66	O
subcutaneous	O
mastectomy	O
specimens	O
in	O
which	O
the	O
absence	O
of	O
simultaneous	O
breast	B-Disease
malignancy	I-Disease
was	O
documented	O
,	O
primary	O
breast	B-Disease
carcinomas	I-Disease
from	O
153	O
mastectomy	O
specimens	O
,	O
and	O
47	O
biopsies	O
containing	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O

A	O
statistically	O
significant	O
association	O
of	O
IgA	B-Gene
and	O
IgM	B-Gene
with	O
benign	O
lesions	O
was	O
contrasted	O
to	O
the	O
association	O
of	O
IgG	B-Gene
with	O
malignant	O
lesions	O
.	O

In	O
both	O
primary	O
and	O
metastatic	O
lesions	O
,	O
IgG	B-Gene
localization	O
was	O
associated	O
with	O
estrogen-receptor-poor	B-Gene
primary	O
cancers	B-Disease
as	O
compared	O
with	O
estrogen-receptor-rich	B-Gene
primary	O
cancers	B-Disease
.	O

Among	O
primary	O
breast	B-Disease
cancer	I-Disease
patients	O
,	O
IgG	B-Gene
localization	O
in	O
the	O
tumor	B-Disease
correlated	O
with	O
relative	O
lymphopenia	B-Disease
.	O

A	O
shorter	O
disease-free	O
interval	O
was	O
noted	O
in	O
association	O
with	O
IgG	B-Gene
localization	O
among	O
the	O
metastatic	O
breast	O
lesions	O
.	O

No	O
statistically	O
significant	O
association	O
between	O
stage	O
of	O
disease	O
and	O
immunoglobulin	B-Gene
presence	O
was	O
demonstrable	O
.	O

Moderate-to-severe	B-Disease
intraductal	I-Disease
epithelial	I-Disease
hyperplasias	I-Disease
were	O
more	O
often	O
associated	O
with	O
immunoglobulin	B-Gene
G	I-Gene
localization	O
that	O
were	O
other	O
benign	O
lesions	O

Evidence	O
for	O
a	O
steroid	B-Gene
receptor	I-Gene
in	O
rheumatoid	O
synovial	O
tissue	O
cells	O
.	O

One	O
mechanism	O
by	O
which	O
glucocorticoids	B-Chemical
could	O
exert	O
their	O
anti-inflammatory	O
action	O
is	O
via	O
rapidly	O
saturable	O
,	O
stereo-specific	O
cytoplasmic	O
protein	O
receptors	O
.	O

This	O
report	O
is	O
of	O
an	O
investigation	O
into	O
such	O
a	O
possibility	O
in	O
synovial	O
cells	O
.	O

Synovium	O
,	O
obtained	O
from	O
knee	O
joints	O
of	O
rheumatoid	O
patients	O
undergoing	O
surgery	O
,	O
was	O
incubated	O
with	O
clostridiopeptidase	B-Gene
A	I-Gene
and	O
trypsin-EDTA	B-Chemical
to	O
obtain	O
cell	O
suspensions	O
.	O

These	O
,	O
together	O
with	O
cells	O
obtained	O
from	O
synovial	O
fluid	O
aspirated	O
from	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
were	O
identified	O
by	O
electron	O
microscopy	O
.	O

Duplicate	O
samples	O
of	O
these	O
cell	O
suspensions	O
were	O
incubated	O
with	O
increasing	O
concentrations	O
of	O
H3Dexamethasone	B-Chemical
(	O
1	O
x	O
10	O
(	O
-10	O
)	O
M-1	O
x	O
10	O
(	O
-9	O
)	O
M	O
)	O
for	O
30	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

Analysis	O
of	O
the	O
proportion	O
of	O
steroid	B-Chemical
bound	O
to	O
whole	O
cells	O
showed	O
evidence	O
for	O
specific	O
,	O
rapidly	O
saturable	O
,	O
receptors	O
in	O
the	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
,	O
but	O
this	O
was	O
not	O
found	O
in	O
synovial	O
fluid	O
cells	O
.	O

Electron	O
micrographs	O
showed	O
that	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
consisted	O
of	O
synovial	O
fibroblast	O
-	O
and	O
macrophage-types	O
,	O
lymphocytes	O
,	O
monocytes	O
and	O
macrophages	O
.	O

Polymorphonuclear	O
leucocytes	O
appeared	O
to	O
be	O
absent	O
.	O

However	O
,	O
in	O
synovial	O
fluid	O
cell	O
type	O
polymorphonuclear	O
leucocytes	O
were	O
the	O
predominant	O
cell	O
type	O
.	O

We	O
concluded	O
from	O
this	O
,	O
that	O
one	O
or	O
more	O
of	O
the	O
cell	O
types	O
present	O
in	O
synovial	O
tissue	O
contain	O
a	O
specific	O
steroid	B-Gene
receptor	I-Gene
,	O
but	O
that	O
this	O
is	O
lacking	O
in	O
synovial	O
fluid	O
polymorphonuclear	O
leucocytes	O
.	O

Human	O
lymphoid	O
cell	O
lines	O
and	O
glucocorticoids	B-Chemical
:	O
II	O
.	O

Whole	O
cell	O
and	O
cytoplasmic	O
binding	O
properties	O
of	O
lymphoblastoid	O
,	O
leukaemia	B-Disease
and	O
lymphoma	B-Disease
lines	O
.	O

The	O
glucocorticoid	B-Chemical
binding	O
properties	O
of	O
18	O
human	O
lymphoid	O
cell	O
lines	O
(	O
HLCL	O
)	O
have	O
been	O
investigated	O
.	O

The	O
specificity	O
of	O
steroid	B-Chemical
binding	O
was	O
confirmed	O
with	O
various	O
glucocorticoid	B-Chemical
agonists	O
and	O
antagonists	O
.	O

A	O
gradation	O
in	O
whole	O
cell	O
and	O
cytoplasmic	O
glucocorticoid	B-Chemical
binding	O
capacity	O
was	O
observed	O
in	O
the	O
different	O
cell	O
line	O
types	O
:	O
lymphoblastoid	O
greater	O
than	O
lymphoma	B-Disease
greater	O
than	O
leukaemia	B-Disease
.	O

The	O
cytoplasmic	O
receptors	O
of	O
leukaemia	B-Disease
and	O
lymphoblastoid	O
lines	O
appeared	O
to	O
contain	O
both	O
proteinaceous	O
and	O
phospholipid	B-Chemical
components	O
.	O

Cytoplasmic	B-Gene
steroid-receptor	I-Gene
complexes	I-Gene
exhibited	O
a	O
wide	O
range	O
of	O
sedimentation	O
coefficients	O
(	O
8.5-11.3S	O
)	O
in	O
low	O
ionic	O
strength	O
buffer	O
but	O
there	O
was	O
no	O
correlation	O
with	O
cell	O
line	O
type	O
or	O
glucocorticoid	B-Chemical
sensitivity	O
.	O

Activation	O
of	O
these	O
complexes	O
by	O
heat	O
(	O
37	O
degrees	O
C	O
)	O
or	O
exposure	O
to	O
high	O
ionic	O
strength	O
buffer	O
(	O
0.3	O
M	O
NaCl	O
)	O
induced	O
nuclear	O
binding	O
of	O
steroid	B-Chemical
but	O
only	O
complexes	O
in	O
high	O
ionic	O
strength	O
buffer	O
manifested	O
changes	O
in	O
sedimentation	O
coefficient	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
the	O
level	O
or	O
nature	O
of	O
glucocorticoid	B-Chemical
binding	O
and	O
the	O
cytolethal	O
or	O
cytostatic	O
responsiveness	O
of	O
HLCL	O
to	O
glucocorticoid	B-Chemical
treatment	O
in	O
vitro	O
.	O

The	O
resistance	O
to	O
cytolethal	O
effects	O
can	O
not	O
be	O
ascribed	O
to	O
a	O
failure	O
of	O
cells	O
to	O
take	O
up	O
and	O
bind	O
steroid	B-Chemical
or	O
to	O
significant	O
differences	O
in	O
the	O
molecular	O
species	O
of	O
cytoplasmic	O
receptors	O
present	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
glucocorticoids	B-Chemical
achieve	O
cytolethal	O
responses	O
in	O
human	O
lymphoid	O
cells	O

Glucocorticoid	B-Gene
receptors	I-Gene
and	O
in	O
vitro	O
corticosensitivity	O
of	O
peanut	O
-positive	O
and	O
peanut	O
-negative	O
human	O
thymocyte	O
subpopulations	O
.	O

In	O
6	O
human	O
thymus	O
glands	O
,	O
the	O
immature	O
subset	O
of	O
thymocytes	O
was	O
separated	O
from	O
the	O
more	O
mature	O
one	O
,	O
by	O
differential	O
peanut	B-Gene
lectin	I-Gene
agglutination	O
.	O

These	O
2	O
cell	O
subpopulations	O
were	O
analyzed	O
for	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
by	O
using	O
a	O
whole	O
cell	O
assay	O
,	O
with	O
(	O
3H	O
)	O
-triamcinolone	B-Chemical
acetonide	I-Chemical
as	O
tracer	O
.	O

The	O
unagglutinated	O
thymocytes	O
(	O
peanut	O
negative	O
)	O
contained	O
about	O
2	O
times	O
more	O
receptor	O
sites	O
per	O
cell	O
than	O
agglutinated	O
(	O
peanut	O
positive	O
)	O
ones	O
(	O
7650	O
+	O
/	O
-	O
1550	O
S.D.	O
verus	O
3195	O
+	O
/	O
-	O
896	O
S.D.	O
)	O
.	O

The	O
affinity	O
for	O
steroid	B-Chemical
was	O
similar	O
in	O
both	O
cell	O
subsets	O
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
glucocorticoids	O
,	O
the	O
time-course	O
of	O
steroid-receptor	B-Gene
association	O
,	O
and	O
cytoplasmic	O
to	O
nuclear	O
translocation	O
.	O

Despite	O
the	O
greater	O
number	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
,	O
the	O
peanut	O
-negative	O
thymocyte	O
subpopulation	O
did	O
not	O
differ	O
from	O
the	O
peanut	O
-positive	O
one	O
in	O
its	O
sensitivity	O
to	O
the	O
inhibitory	O
effects	O
of	O
triamcinolone	B-Chemical
acetonide	I-Chemical
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
and	O
DNA	O
.	O

Moreover	O
,	O
the	O
peanut	O
-negative	O
subset	O
appeared	O
more	O
resistant	O
in	O
vitro	O
to	O
the	O
steroid	B-Chemical
-induced	O
cell	O
lysis	O
as	O
compared	O
to	O
the	O
peanut	O
-positive	O
one	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
glucocorticoid	B-Gene
receptor	I-Gene
density	O
and	O
corticosensitivity	O
are	O
not	O
directly	O
correlated	O
and	O
that	O
the	O
number	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
may	O
be	O
dependent	O
on	O
the	O
degree	O
of	O
immunologic	O
maturation	O

[	O
Tumor	B-Disease
histology	O
and	O
steroid	B-Gene
receptors	I-Gene
in	O
breast	B-Disease
carcinoma	I-Disease
]	O

In	O
Specimens	O
of	O
115	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
4	O
tumorparameters	O
(	O
tumorsize	O
,	O
tumorboder	O
,	O
nucleargrade	O
,	O
lymphocytic	O
stromal	O
reaction	O
)	O
3	O
features	O
of	O
regional	O
lymphnodes	O
(	O
sinushistiocytosis	O
,	O
T-cellreaction	O
,	O
lymphnode	O
metastases	O
)	O
and	O
estrogen	B-Chemical
and	O
progesteron	B-Gene
receptors	I-Gene
were	O
determined	O
.	O

A	O
strong	O
sinushistiocytosis	O
and	O
T-cellreaction	O
could	O
be	O
verified	O
mainly	O
in	O
metastases	O
in	O
free	O
lymphnodes	O
.	O

The	O
steroid	B-Gene
receptor	I-Gene
content	O
does	O
not	O
correlate	O
with	O
histological	O
parameters	O

Glucocorticoid	B-Gene
receptors	I-Gene
in	O
lymphoid	B-Disease
tumors	I-Disease
.	O

There	O
is	O
a	O
range	O
of	O
levels	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
numbers	O
seen	O
in	O
the	O
various	O
subclasses	O
of	O
acute	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
.	O

This	O
variability	O
can	O
not	O
be	O
explained	O
by	O
the	O
known	O
correlation	O
between	O
active	O
cell	O
proliferation	O
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
receptors	O
,	O
since	O
the	O
tumors	B-Disease
with	O
the	O
highest	O
growth	O
fraction	O
(	O
i.e.	O
,	O
Burkitt	B-Disease
's	I-Disease
lymphoma	I-Disease
and	O
T-cell	B-Disease
leukemia	I-Disease
)	O
tend	O
to	O
have	O
lower	O
average	O
receptor	O
numbers	O
than	O
do	O
tumors	B-Disease
with	O
lower	O
growth	O
fractions	O
such	O
as	O
common	O
ALL	B-Disease
.	O

All	O
clinical	O
specimens	O
from	O
patients	O
with	O
lymphatic	B-Disease
leukemia	I-Disease
have	O
some	O
measurable	O
level	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
;	O
therefore	O
,	O
the	O
resistance	O
seen	O
in	O
vivo	O
can	O
not	O
be	O
explained	O
by	O
the	O
lack	O
of	O
receptors	O
.	O

However	O
,	O
there	O
has	O
been	O
a	O
positive	O
correlation	O
,	O
in	O
our	O
hands	O
,	O
with	O
receptor	O
level	O
and	O
prognosis	O
.	O

On	O
the	O
basis	O
of	O
in	O
vitro	O
models	O
,	O
it	O
is	O
proposed	O
that	O
perhaps	O
the	O
high	O
receptor	O
cell	O
lines	O
(	O
i.e.	O
,	O
common	O
ALL	B-Disease
of	O
childhood	O
)	O
have	O
relative	O
stability	O
of	O
their	O
genetic	O
material	O
making	O
glucocorticoid	B-Chemical
-resistant	O
mutations	O
less	O
likely	O
to	O
occur	O
in	O
patients	O
with	O
these	O
cells	O
than	O
in	O
low-receptor	O
cell	O
lines	O
(	O
i.e.	O
,	O
T-cell	B-Disease
leukemia	I-Disease
)	O
.	O

This	O
greater	O
genetic	O
variability	O
in	O
the	O
low-receptor	O
lines	O
could	O
account	O
for	O
the	O
earlier	O
emergence	O
of	O
clinical	O
glucocorticoid	B-Chemical
resistance	O
in	O
these	O
patients	O
.	O

[	O
Glucocorticoid	B-Gene
receptor	I-Gene
level	O
in	O
the	O
blood	O
leukocytes	O
in	O
different	O
acute	O
diseases	O
]	O

Content	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
cytosol	O
of	O
blood	O
leukocytes	O
,	O
concentration	O
of	O
cortisol	B-Chemical
and	O
amount	O
of	O
leukocytes	O
in	O
blood	O
were	O
studied	O
in	O
20	O
patients	O
with	O
acute	O
impairments	O
within	O
the	O
second	O
day	O
of	O
the	O
disease	O
.	O

Content	O
of	O
receptors	O
in	O
cytosol	O
of	O
blood	O
leukocytes	O
was	O
studied	O
using	O
3H-triamcinolone	B-Chemical
acetonide	I-Chemical
.	O

Distinct	O
increase	O
in	O
amount	O
of	O
the	O
leukocyte	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
was	O
found	O
in	O
patients	O
with	O
poisoning	B-Disease
by	O
dichlorethane	O
and	O
hypnotic	O
drugs	O
under	O
conditions	O
of	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

In	O
acute	B-Disease
pancreatitis	I-Disease
content	O
of	O
the	O
leukocyte	O
receptors	O
was	O
not	O
altered	O
as	O
compared	O
with	O
controls	O
.	O

Concentration	O
of	O
endogenous	O
cortisol	B-Chemical
was	O
increased	O
in	O
blood	O
of	O
all	O
the	O
patients	O
,	O
except	O
of	O
the	O
cases	O
of	O
acetate	B-Chemical
intoxication	O
.	O

Reverse	O
correlation	O
was	O
observed	O
between	O
concentration	O
of	O
cortisol	B-Chemical
in	O
blood	O
and	O
content	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
leukocytes	O
.	O

But	O
in	O
the	O
patients	O
with	O
acute	B-Disease
pancreatitis	I-Disease
the	O
decrease	O
in	O
content	O
of	O
leukocyte	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
was	O
not	O
observed	O
although	O
there	O
was	O
an	O
increase	O
in	O
cortisol	B-Chemical
concentration	O
in	O
blood	O
.	O

The	O
role	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
immunological	O
processes	O
under	O
conditions	O
of	O
purulent	O
complications	O
and	O
possibility	O
to	O
regulate	O
the	O
metabolism	O
in	O
leukocytes	O

Decreased	O
glucocorticoid	B-Gene
receptor	I-Gene
binding	O
in	O
adrenal	B-Disease
insufficiency	I-Disease
.	O

To	O
examine	O
the	O
effect	O
of	O
glucocorticoid	B-Chemical
deficiency	O
on	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
,	O
we	O
examine	O
the	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
to	O
lymphocytes	O
in	O
normal	O
subjects	O
and	O
patients	O
with	O
adrenal	B-Disease
insufficiency	I-Disease
before	O
and	O
after	O
glucocorticoid	B-Chemical
replacement	O
therapy	O
.	O

Using	O
a	O
whole	O
cell	O
competitive	O
binding	O
assay	O
,	O
normal	O
human	O
lymphocytes	O
had	O
5977	O
+	O
/	O
-	O
1487	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
binding	O
sites	O
/	O
cell	O
and	O
a	O
dissociation	O
constant	O
of	O
10	O
+	O
/	O
-	O
2	O
nM	O
.	O

Lymphocytes	O
from	O
patients	O
with	O
untreated	O
adrenal	B-Disease
insufficiency	I-Disease
had	O
fewer	O
binding	O
sites	O
(	O
3364	O
+	O
/	O
-322	O
)	O
and	O
a	O
2-fold	O
increase	O
in	O
binding	O
affinity	O
(	O
5.4	O
+	O
/	O
-	O
0.9	O
mM	O
)	O
.	O

The	O
administration	O
of	O
conventional	O
replacement	O
doses	O
of	O
cortisone	B-Chemical
acetate	I-Chemical
for	O
6	O
months	O
caused	O
no	O
change	O
in	O
receptor	O
number	O
,	O
but	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
affinity	O
toward	O
normal	O
.	O

After	O
long	O
term	O
glucocorticoid	B-Chemical
replacement	O
therapy	O
,	O
binding	O
parameters	O
were	O
similar	O
to	O
those	O
in	O
patients	O
before	O
treatment	O
.	O

The	O
physiological	O
implications	O
of	O
the	O
decreased	O
receptor	O
number	O
and	O
increased	O
binding	O
affinity	O
in	O
adrenal	B-Disease
insufficiency	I-Disease
remain	O
to	O
be	O
elucidated	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
and	O
in	O
vitro	O
sensitivity	O
to	O
steroid	B-Chemical
hormones	I-Chemical
in	O
human	O
lymphoproliferative	B-Disease
diseases	I-Disease
and	O
myeloid	B-Disease
leukemia	I-Disease
.	O

The	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
quantitation	O
by	O
a	O
whole-cell	O
assay	O
and	O
/	O
or	O
cytosol	O
technique	O
and	O
the	O
in	O
vitro	O
sensitivity	O
to	O
steroids	B-Chemical
have	O
been	O
assessed	O
in	O
peripheral	O
blood	O
cells	O
from	O
normal	O
donors	O
and	O
patients	O
with	O
chronic	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
(	O
CLL	B-Disease
)	O
,	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
,	O
lymphosarcoma	B-Disease
cell	I-Disease
leukemia	I-Disease
(	O
LSCL	B-Disease
)	O
,	O
acute	B-Disease
nonlymphatic	I-Disease
leukemia	I-Disease
(	O
ANLL	B-Disease
)	O
,	O
and	O
chronic	B-Disease
myeloid	I-Disease
leukemia	I-Disease
(	O
CML	B-Disease
)	O
.	O

Within	O
the	O
lymphoproliferative	B-Disease
diseases	I-Disease
,	O
ALL	B-Disease
cells	O
exhibited	O
the	O
highest	O
GR	B-Gene
concentration	O
(	O
regardless	O
of	O
the	O
method	O
used	O
)	O
and	O
the	O
highest	O
in	O
vitro	O
inhibition	O
of	O
spontaneous	O
[	O
3H	O
]	O
thymidine	B-Chemical
(	O
[	O
3H	O
]	O
TdR	B-Chemical
)	O
uptake	O
by	O
glucocorticoids	B-Chemical
.	O

A	O
significant	O
relationship	O
between	O
GR	B-Gene
concentration	O
(	O
whole-cell	O
assay	O
)	O
and	O
in	O
vitro	O
sensitivity	O
to	O
dexamethasone	B-Chemical
was	O
also	O
found	O
.	O

On	O
the	O
contrary	O
,	O
CLL	B-Disease
cells	O
presented	O
the	O
highest	O
sensitivity	O
to	O
glucocorticoids	B-Chemical
in	O
PHA	B-Gene
-stimulated	O
cell	O
cultures	O
.	O

Cells	O
from	O
the	O
only	O
two	O
ALL	B-Disease
patients	O
who	O
did	O
not	O
undergo	O
a	O
remission	O
after	O
glucocorticoid	B-Chemical
-inclusive	O
chemotherapy	O
had	O
both	O
the	O
lowest	O
in	O
vitro	O
sensitivity	O
to	O
dexamethasone	B-Chemical
and	O
the	O
lowest	O
GR	B-Gene
concentration	O
with	O
whole-cell	O
assay	O
.	O

Concerning	O
myeloid	B-Disease
leukemia	I-Disease
,	O
ANLL	B-Disease
patients	O
had	O
GR	B-Gene
concentrations	O
slightly	O
higher	O
than	O
those	O
found	O
in	O
the	O
ALL	B-Disease
group	O
but	O
exhibited	O
the	O
lowest	O
degree	O
of	O
inhibition	O
of	O
spontaneous	O
[	O
3H	O
]	O
TdR	B-Chemical
uptake	O
by	O
dexamethasone	B-Chemical
(	O
stimulatory	O
effects	O
occurred	O
in	O
some	O
cases	O
)	O
.	O

CML	B-Disease
cells	O
exhibited	O
an	O
inhibition	O
degree	O
by	O
in	O
vitro	O
glucocorticoids	B-Chemical
significantly	O
higher	O
than	O
that	O
of	O
ANLL	B-Disease
cells	O
but	O
not	O
different	O
from	O
that	O
of	O
lymphoproliferative	B-Disease
diseases	I-Disease
.	O

No	O
clear	O
relationship	O
among	O
GR	B-Gene
pattern	O
,	O
in	O
vitro	O
cell	O
sensitivity	O
to	O
glucocorticoids	B-Chemical
,	O
and	O
clinicohematologic	O
parameters	O
was	O
observed	O
in	O
myeloid	B-Disease
leukemia	I-Disease
-bearing	O
patients	O
.	O

Metabolic	O
and	O
ultrastructural	O
aspects	O
of	O
the	O
in	O
vitro	O
lysis	O
of	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
cells	O
by	O
glucocorticoids	B-Chemical
.	O

Human	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
(	O
CLL	B-Disease
)	O
cells	O
like	O
prothymocytes	O
and	O
immunoactivated	O
T-lymphocytes	O
are	O
readily	O
lysed	O
in	O
vitro	O
by	O
pharmacological	O
concentrations	O
of	O
glucocorticoids	B-Chemical
such	O
as	O
cortisol	B-Chemical
,	O
whereas	O
peripheral	O
blood	O
lymphocytes	O
and	O
thymocytes	O
are	O
unaffected	O
by	O
the	O
hormone	O
.	O

In	O
this	O
study	O
,	O
metabolic	O
and	O
ultrastructural	O
aspects	O
of	O
the	O
cortisol	B-Chemical
-induced	O
killing	O
process	O
of	O
CLL	B-Disease
cells	O
are	O
recorded	O
.	O

In	O
vitro	O
lysis	O
was	O
found	O
to	O
be	O
temperature	O
dependent	O
and	O
was	O
detected	O
only	O
after	O
6	O
to	O
8	O
hr	O
incubation	O
with	O
cortisol	B-Chemical
by	O
means	O
of	O
the	O
trypan	O
blue	O
exclusion	O
test	O
.	O

However	O
,	O
30	O
min	O
of	O
incubation	O
with	O
cortisol	B-Chemical
at	O
either	O
37	O
degrees	O
or	O
4	O
degrees	O
followed	O
by	O
the	O
removal	O
of	O
the	O
hormone	O
was	O
still	O
sufficient	O
to	O
induce	O
the	O
lytic	O
process	O
.	O

Ultrastructural	O
studies	O
demonstrated	O
sequential	O
changes	O
in	O
the	O
cytoplasm	O
,	O
including	O
swelling	O
of	O
mitochondria	O
and	O
cytoplasmic	O
decompartmentalization	O
,	O
followed	O
by	O
loss	O
of	O
surface	O
microvilli	O
with	O
the	O
appearance	O
of	O
``	O
holes	O
''in	O
the	O
cell	O
membrane	O
,	O
and	O
subsequent	O
condensation	O
of	O
nuclear	O
chromatin	O
.	O

The	O
large	O
holes	O
in	O
the	O
membrane	O
appearing	O
after	O
6	O
hr	O
of	O
incubation	O
with	O
the	O
hormone	O
may	O
be	O
the	O
cause	O
for	O
the	O
penetration	O
of	O
the	O
viable	O
stain	O
into	O
the	O
dead	O
cells	O
,	O
as	O
seen	O
by	O
light	O
microscopy	O
.	O

Addition	O
of	O
metabolic	O
inhibitors	O
including	O
actinomycin	B-Chemical
D	I-Chemical
,	O
puromycin	B-Chemical
,	O
and	O
cycloheximide	B-Chemical
following	O
administration	O
of	O
cortisol	B-Chemical
resulted	O
in	O
inhibition	O
of	O
the	O
cell	O
lysis	O
.	O

An	O
excess	O
of	O
an	O
antagonist	O
such	O
as	O
cortexolone	B-Chemical
was	O
found	O
to	O
inhibit	O
the	O
cortisol	B-Chemical
-induced	O
cytolysis	O
of	O
the	O
CLL	B-Disease
cells	O
.	O

It	O
is	O
suggested	O
that	O
the	O
glucocorticoid	B-Chemical
-induced	O
lysis	O
of	O
human	O
CLL	B-Disease
cells	O
is	O
similar	O
to	O
the	O
phenomenon	O
observed	O
in	O
rat	O
or	O
murine	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
interaction	O
of	O
the	O
steroid	B-Chemical
molecule	O
with	O
the	O
cytoplasmic	O
receptor	O
.	O

The	O
resulting	O
complex	O
appears	O
to	O
activate	O
specific	O
gene	O
(	O
s	O
)	O
the	O
products	O
of	O
which	O
eventually	O
cause	O
cytolysis	O
.	O

Regulation	O
of	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
in	O
human	O
lymphocytes	O
.	O

The	O
presence	O
of	O
a	O
glucocorticoid	B-Gene
receptor	I-Gene
in	O
human	O
lymphocytes	O
is	O
well	O
established	O
,	O
but	O
factors	O
affecting	O
its	O
regulation	O
have	O
not	O
been	O
described	O
.	O

Using	O
a	O
competitive	O
binding	O
whole	O
cell	O
assay	O
,	O
we	O
have	O
examined	O
the	O
binding	O
of	O
[	O
3H	O
]	O
-dexamethasone	B-Chemical
at	O
24	O
and	O
37	O
degrees	O
C	O
in	O
untreated	O
normal	O
subjects	O
and	O
in	O
healthy	O
subjects	O
taking	O
various	O
glucocorticoid	B-Chemical
preparations	O
.	O

At	O
24	O
degrees	O
C	O
normal	O
human	O
lymphocytes	O
had	O
6000	O
binding	O
sites	O
/	O
cell	O
and	O
a	O
dissociation	O
constant	O
of	O
4	O
x	O
10	O
(	O
-9	O
)	O
M	O
.	O

The	O
administration	O
of	O
1	O
mg	O
of	O
dexamethasone	B-Chemical
,	O
5	O
mg	O
of	O
prednisone	B-Chemical
,	O
and	O
37.5	O
mg	O
of	O
cortisone	B-Chemical
acetate	I-Chemical
resulted	O
in	O
a	O
30	O
%	O
decrease	O
in	O
binding	O
sites	O
after	O
1	O
week	O
with	O
no	O
change	O
in	O
binding	O
affinity	O
.	O

No	O
changes	O
in	O
the	O
number	O
of	O
binding	O
sites	O
was	O
noted	O
before	O
1	O
week	O
and	O
the	O
diminished	O
number	O
persisted	O
for	O
1	O
week	O
after	O
discontinuation	O
of	O
glucocorticoid	B-Chemical
treatment	O
.	O

Lymphocytes	O
from	O
hospitalized	O
patients	O
taking	O
40-60	O
mg	O
of	O
dexamethasone	B-Chemical
daily	O
demonstrated	O
the	O
same	O
change	O
in	O
number	O
of	O
binding	O
sites	O
that	O
was	O
seen	O
in	O
normal	O
subjects	O
taking	O
1	O
mg	O
of	O
dexamethasone	B-Chemical
.	O

When	O
binding	O
assays	O
were	O
carried	O
out	O
at	O
physiologic	O
temperature	O
there	O
was	O
the	O
same	O
decrease	O
in	O
number	O
of	O
binding	O
sites	O
after	O
dexamethasone	B-Chemical
administration	O
,	O
and	O
in	O
addition	O
,	O
there	O
was	O
a	O
two-fold	O
increase	O
in	O
binding	O
affinity	O
.	O

Glucocorticoid	B-Chemical
administration	O
results	O
in	O
a	O
time	O
-dependent	O
decrease	O
in	O
the	O
number	O
of	O
lymphocyte	O
glucocorticoid	B-Chemical
binding	O
sites	O
that	O
is	O
independent	O
of	O
the	O
type	O
of	O
glucocorticoid	B-Chemical
administered	O
.	O

This	O
is	O
the	O
first	O
in	O
vivo	O
demonstration	O
that	O
glucocorticoids	B-Chemical
modulate	O
their	O
own	O
receptors	O
in	O
man	O
.	O

Serum	O
sex	O
steroid	B-Chemical
and	O
peptide	O
hormone	O
concentrations	O
,	O
and	O
endometrial	O
estrogen	B-Chemical
and	O
progestin	B-Gene
receptor	I-Gene
levels	O
during	O
administration	O
of	O
human	B-Gene
leukocyte	I-Gene
interferon	I-Gene
.	O

Five	O
normally	O
cycling	O
healthy	O
women	O
were	O
given	O
daily	O
subcutaneous	O
injections	O
of	O
human	B-Gene
leukocyte	I-Gene
interferon	I-Gene
(	O
3	O
X	O
10	O
(	O
6	O
)	O
units	O
/	O
day	O
)	O
from	O
the	O
3rd	O
through	O
23rd	O
day	O
of	O
the	O
menstrual	O
cycle	O
,	O
and	O
serum	O
steroid	B-Chemical
and	O
peptide	O
hormone	O
concentrations	O
monitored	O
at	O
3-day	O
intervals	O
during	O
the	O
treatment	O
and	O
the	O
preceding	O
control	O
cycle	O
.	O

Concentrations	O
of	O
cytosol	O
and	O
nuclear	B-Gene
estrogen	I-Gene
receptors	I-Gene
(	O
ERC	B-Gene
and	O
ERN	B-Gene
,	O
respectively	O
)	O
and	O
progestin	B-Gene
receptors	I-Gene
(	O
PRC	B-Gene
and	O
PRN	B-Gene
)	O
were	O
also	O
measured	O
from	O
endometrial	O
biopsies	O
taken	O
on	O
the	O
24th	O
day	O
of	O
the	O
control	O
and	O
treatment	O
cycle	O
.	O

In	O
addition	O
,	O
an	O
extensive	O
monitoring	O
of	O
clinical	O
chemical	O
and	O
hematological	O
tests	O
from	O
the	O
blood	O
samples	O
were	O
performed	O
.	O

Serum	O
estradiol	B-Chemical
and	O
progesterone	B-Chemical
concentrations	O
were	O
significantly	O
decreased	O
during	O
the	O
treatment	O
cycle	O
,	O
suggesting	O
that	O
interferon	B-Gene
interacts	O
in	O
vivo	O
with	O
the	O
function	O
of	O
both	O
FSH	B-Gene
and	O
LH	B-Gene
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
serum	O
peptide	O
hormone	O
concentrations	O
measured	O
(	O
FSH	B-Gene
,	O
LH	B-Gene
,	O
prolactin	B-Gene
,	O
insulin	B-Gene
,	O
growth	B-Gene
hormone	I-Gene
and	O
TSH	B-Gene
)	O
;	O
neither	O
were	O
the	O
levels	O
of	O
endometrial	B-Gene
ERC	I-Gene
,	O
ERN	B-Gene
,	O
PRC	B-Gene
and	O
PRN	B-Gene
affected	O
by	O
interferon	B-Gene
administration	O
.	O

As	O
expected	O
,	O
interferon	B-Gene
administration	O
resulted	O
in	O
decreased	O
leukocyte	O
counts	O
.	O

Moreover	O
,	O
an	O
increasing	O
tendency	O
in	O
the	O
activities	O
of	O
serum	B-Gene
alkaline	I-Gene
phosphatase	I-Gene
and	O
gamma-glutamyltransferase	B-Gene
during	O
the	O
interferon	B-Gene
therapy	O
shows	O
that	O
interferon	B-Gene
may	O
slightly	O
interfere	O
with	O
the	O
liver	O
function	O
.	O

These	O
results	O
suggest	O
that	O
one	O
of	O
the	O
mechanisms	O
by	O
which	O
interferon	B-Gene
treatment	O
may	O
affect	O
the	O
growth	O
of	O
hormone	O
-dependent	O
neoplasms	B-Disease
could	O
be	O
the	O
interaction	O
with	O
production	O
and	O
/	O
or	O
function	O
of	O
circulating	O
hormonal	O
compounds	O
.	O

Clinical	O
implications	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
human	O
leukemia	B-Disease
.	O

Normal	O
lymphoid	O
cells	O
contain	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

A	O
variety	O
of	O
stimuli	O
that	O
activate	O
these	O
cells	O
also	O
induce	O
increases	O
in	O
receptor	O
concentration	O
.	O

Similar	O
glucocorticoid	B-Gene
receptors	I-Gene
can	O
be	O
detected	O
in	O
lymphoid	O
cells	O
from	O
patients	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
.	O

Absence	O
of	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
usually	O
found	O
in	O
treated	O
patients	O
)	O
predicts	O
lack	O
of	O
glucocorticoid	B-Chemical
responsiveness	O
.	O

Furthermore	O
,	O
in	O
our	O
hands	O
,	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
correlate	O
with	O
the	O
duration	O
of	O
complete	O
remission	O
in	O
ALL	B-Disease
(	O
though	O
not	O
in	O
other	O
forms	O
of	O
leukemia	B-Disease
)	O
.	O

This	O
association	O
is	O
independent	O
of	O
cell	O
type	O
,	O
age	O
,	O
sex	O
,	O
or	O
initial	O
leukocyte	O
count	O
.	O

The	O
level	O
of	O
receptor	O
shows	O
a	O
negative	O
correlation	O
with	O
increasing	O
aggressiveness	O
of	O
the	O
tumor	B-Disease
(	O
null-cell	O
leukemia	B-Disease
greater	O
than	O
T-cell	B-Disease
leukemia	I-Disease
greater	O
than	O
Burkitt	B-Disease
's	I-Disease
lymphoma	I-Disease
)	O
.	O

Corticosteroid	B-Chemical
-mediated	O
immunoregulation	O
in	O
man	O
.	O

Glucocorticoids	B-Chemical
have	O
profound	O
and	O
complex	O
effects	O
on	O
the	O
human	O
immune	O
response	O
.	O

However	O
,	O
the	O
precise	O
mechanisms	O
of	O
the	O
corticosteroid	B-Chemical
-induced	O
immunoregulation	O
in	O
man	O
have	O
not	O
been	O
precisely	O
defined	O
.	O

Intracytoplasmic	O
corticosteroid-specific	B-Chemical
receptors	O
appear	O
to	O
be	O
an	O
important	O
common	O
pathway	O
for	O
steroid	B-Chemical
-induced	O
changes	O
,	O
but	O
variations	O
of	O
receptor	O
parameters	O
do	O
not	O
account	O
for	O
the	O
multifaceted	O
effects	O
on	O
the	O
immune	O
system	O
.	O

Human	O
circulating	O
mononuclear	O
cells	O
redistribute	O
out	O
of	O
the	O
intravascular	O
compartment	O
following	O
treatment	O
with	O
corticosteroids	B-Chemical
.	O

Although	O
certain	O
components	O
at	O
this	O
redistribution	O
phenomenon	O
have	O
been	O
well	O
-characterized	O
,	O
the	O
importance	O
of	O
this	O
compartmental	O
cellular	O
shift	O
with	O
respect	O
to	O
the	O
mechanisms	O
of	O
corticosteroid	B-Chemical
-induced	O
immunoregulation	O
are	O
less	O
well	O
-defined	O
.	O

Recent	O
observations	O
that	O
activated	O
lymphocytes	O
may	O
be	O
sensitive	O
to	O
the	O
lytic	O
effects	O
of	O
glucocorticoids	B-Chemical
suggest	O
that	O
under	O
certain	O
situations	O
the	O
elimination	O
of	O
selected	O
subsets	O
of	O
cells	O
may	O
be	O
a	O
relevant	O
mechanism	O
of	O
corticosteroid	B-Chemical
-mediated	O
immunoregulation	O
in	O
man	O
.	O

Corticosteroid	B-Chemical
-mediated	O
effects	O
on	O
monocyte	O
function	O
may	O
be	O
an	O
important	O
mechanism	O
of	O
drug	O
-induced	O
immunoregulation	O
in	O
monocyte	O
-dependent	O
responses	O
.	O

In	O
some	O
experimental	O
conditions	O
,	O
corticosteroids	B-Chemical
inhibit	O
Interleukin	B-Gene
1	I-Gene
production	O
by	O
monocytes	O
.	O

The	O
immunoregulatory	O
effects	O
of	O
corticosteroids	B-Chemical
on	O
lymphocyte	O
immune	O
responses	O
are	O
complex	O
.	O

In	O
vitro	O
corticosteroids	B-Chemical
appear	O
to	O
selectively	O
affect	O
early	O
immunoregulatory	O
events	O
as	O
opposed	O
to	O
altering	O
an	O
established	O
response	O
.	O

Multiple	O
sites	O
of	O
steroid	B-Chemical
-induced	O
modulations	O
of	O
human	O
B	O
cell	O
responses	O
have	O
been	O
defined	O
.	O

Reduced	O
level	O
of	O
cellular	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
in	O
patients	O
with	O
anorexia	B-Disease
nervosa	I-Disease
.	O

Specific	O
glucocorticoid	B-Gene
receptors	I-Gene
were	O
measured	O
in	O
circulating	O
mononuclear	O
leukocytes	O
from	O
12	O
patients	O
with	O
anorexia	B-Disease
nervosa	I-Disease
and	O
21	O
healthy	O
control	O
subjects	O
.	O

Cells	O
from	O
patients	O
were	O
found	O
to	O
contain	O
a	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
lower	O
level	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
3830	O
+	O
/	O
-	O
210	O
sites	O
/	O
cell	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
than	O
those	O
from	O
controls	O
(	O
4930	O
+	O
/	O
-	O
250	O
sites	O
/	O
cell	O
)	O
.	O

A	O
partial	O
glucocorticoid	B-Gene
receptor	I-Gene
defect	O
may	O
well	O
explain	O
the	O
abnormal	O
cortisol	B-Chemical
metabolism	O
and	O
glucocorticoid	B-Chemical
resistance	O
commonly	O
found	O
in	O
patients	O
with	O
anorexia	B-Disease
nervosa	I-Disease
.	O

Administration	O
of	O
fibroblast	B-Gene
interferon	I-Gene
to	O
patients	O
with	O
advanced	O
breast	B-Disease
cancer	I-Disease
:	O
possible	O
effects	O
on	O
skin	O
metastasis	O
and	O
on	O
hormone	O
receptors	O
.	O

Eleven	O
patients	O
with	O
metastasized	O
breast	B-Disease
cancer	I-Disease
received	O
8	O
intramuscular	O
injections	O
of	O
6	O
x	O
10	O
(	O
6	O
)	O
units	O
of	O
human	B-Gene
fibroblast	I-Gene
interferon	I-Gene
over	O
a	O
period	O
of	O
40	O
days	O
.	O

The	O
injections	O
did	O
not	O
cause	O
local	O
irritation	O
or	O
inflammation	O
.	O

Fever	O
occurred	O
in	O
only	O
1	O
of	O
the	O
11	O
patients	O
.	O

Although	O
several	O
types	O
of	O
metastases	O
were	O
monitored	O
,	O
only	O
skin	O
nodules	O
consistently	O
(	O
10	O
out	O
of	O
11	O
patients	O
)	O
exhibited	O
changes	O
that	O
were	O
suggestive	O
of	O
a	O
therapeutic	O
effect	O
of	O
the	O
treatment	O
regimen	O
:	O
either	O
a	O
simple	O
decrease	O
in	O
size	O
of	O
some	O
nodules	O
or	O
central	O
necrosis	O
accompanied	O
by	O
an	O
inflammatory	O
reaction	O
.	O

NK-activity	O
of	O
peripheral	O
blood	O
leukocytes	O
was	O
significantly	O
increased	O
after	O
administration	O
of	O
the	O
first	O
dose	O
;	O
the	O
effect	O
of	O
subsequent	O
injections	O
was	O
less	O
clear	O
.	O

Receptors	O
for	O
estrogens	B-Chemical
and	O
progestogens	B-Chemical
were	O
increased	O
in	O
the	O
tumor	B-Disease
biopsies	O
of	O
2	O
out	O
of	O
2	O
and	O
5	O
out	O
of	O
6	O
patients	O
tested	O
respectively	O
.	O

Effects	O
of	O
chronic	O
glucocorticoid	B-Chemical
excess	O
in	O
man	O
on	O
insulin	B-Gene
binding	O
to	O
circulating	O
cells	O
:	O
differences	O
between	O
endogenous	O
and	O
exogenous	O
hypercorticism	B-Disease
.	O

We	O
measured	O
[	O
125I	O
]	O
insulin	B-Gene
binding	O
to	O
circulating	O
monocytes	O
or	O
erythrocytes	O
from	O
16	O
patients	O
with	O
chronic	O
glucocorticoid	B-Chemical
excess	O
,	O
9	O
chronically	O
treated	O
with	O
prednisone	B-Chemical
and	O
7	O
with	O
adrenocortical	B-Disease
hyperfunction	I-Disease
.	O

With	O
monocytes	O
,	O
[	O
125I	O
]	O
insulin	B-Gene
binding	O
was	O
iincreased	O
in	O
all	O
patients	O
.	O

Analysis	O
of	O
binding	O
data	O
indicated	O
that	O
increased	O
binding	O
in	O
patients	O
treated	O
with	O
prednisone	B-Chemical
was	O
due	O
to	O
an	O
ncrease	O
in	O
receptor	O
concentration	O
,	O
whereas	O
in	O
patients	O
with	O
adrenocortical	B-Disease
hyperfunction	I-Disease
,	O
it	O
was	O
due	O
to	O
an	O
increase	O
in	O
receptor	O
affinity	O
.	O

With	O
erythrocytes	O
from	O
patients	O
with	O
adrenocortical	B-Disease
hyperfunction	I-Disease
there	O
was	O
an	O
increase	O
in	O
receptor	O
affinity	O
and	O
a	O
decrease	O
in	O
receptor	O
concentration	O
,	O
so	O
that	O
the	O
binding	O
of	O
[	O
125I	O
]	O
insulin	B-Gene
was	O
normal	O
.	O

The	O
disparity	O
of	O
results	O
between	O
endogenous	O
and	O
exogenous	O
hypercorticism	B-Disease
,	O
between	O
the	O
two	O
cell	O
types	O
,	O
and	O
between	O
the	O
present	O
studies	O
and	O
previous	O
studies	O
suggest	O
that	O
the	O
effects	O
of	O
glucocorticoid	B-Chemical
excess	O
on	O
the	O
insulin	B-Gene
receptor	I-Gene
are	O
extremely	O
complex	O
and	O
wide	O
-ranging	O
and	O
that	O
in	O
this	O
condition	O
,	O
extrapolations	O
in	O
humans	O
from	O
data	O
with	O
circulating	O
cells	O
to	O
liver	O
and	O
muscle	O
may	O
not	O
be	O
appropriate	O
.	O

Immunosuppressive	O
effect	O
of	O
serum	O
progesterone	B-Chemical
during	O
pregnancy	O
depends	O
on	O
the	O
progesterone	B-Chemical
binding	O
capacity	O
of	O
the	O
lymphocytes	O
.	O

Cytotoxic	O
activity	O
and	O
progesterone	B-Chemical
binding	O
capacity	O
of	O
the	O
lymphocytes	O
,	O
together	O
with	O
serum	O
progesterone	B-Chemical
concentrations	O
,	O
were	O
determined	O
in	O
women	O
with	O
normal	O
pregnancy	O
or	O
with	O
a	O
clinical	O
diagnosis	O
of	O
threatened	O
abortion	O
or	O
threatened	O
premature	O
labour	O
.	O

The	O
lymphocytes	O
of	O
women	O
with	O
threatened	O
abortion	O
or	O
threatened	O
premature	O
labour	O
showed	O
significantly	O
higher	O
cytotoxic	O
activity	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
significantly	O
lower	O
progesterone	B-Chemical
binding	O
capacity	O
(	O
P	O
less	O
than	O
0.001	O
)	O
than	O
did	O
lymphocytes	O
obtained	O
from	O
the	O
healthy	O
pregnant	O
women	O
.	O

Significant	O
inverse	O
correlation	O
was	O
found	O
between	O
progesterone	B-Chemical
binding	O
capacity	O
and	O
cytotoxic	O
activity	O
of	O
the	O
lymphocytes	O
(	O
P	O
less	O
than	O
0.001	O
)	O
,	O
but	O
the	O
progesterone	B-Chemical
concentration	O
of	O
the	O
pregnancy	O
serum	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
other	O
two	O
parameters	O
.	O

The	O
findings	O
indicate	O
that	O
intact	O
progesterone	B-Chemical
binding	O
capacity	O
of	O
the	O
lymphocytes	O
is	O
an	O
essential	O
factor	O
for	O
the	O
manifestation	O
of	O
the	O
blocking	O
effect	O
exerted	O
by	O
pregnancy	O
serum	O
on	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O

The	O
association	O
of	O
cytosol	B-Chemical
oestrogen	I-Chemical
and	O
progesterone	B-Gene
receptors	I-Gene
with	O
histological	O
features	O
of	O
breast	B-Disease
cancer	I-Disease
and	O
early	O
recurrence	O
of	O
disease	O
.	O

Two	O
hundred	O
and	O
eighty-eight	O
primary	O
breast	B-Disease
tumours	I-Disease
were	O
examined	O
for	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-Chemical
(	O
REc	B-Chemical
)	O
and	O
progesterone	B-Gene
(	I-Gene
RPc	I-Gene
)	I-Gene
receptors	I-Gene
.	O

Analysis	O
has	O
shown	O
a	O
relative	O
interdependence	O
between	O
the	O
steroid	B-Gene
receptor	I-Gene
status	O
of	O
primary	O
breast	B-Disease
cancer	I-Disease
and	O
other	O
prognostic	O
variables	O
such	O
as	O
histological	O
grade	O
,	O
lymphocytic	O
infiltration	O
and	O
tumour	B-Disease
elastosis	I-Disease
.	O

There	O
were	O
significant	O
associations	O
between	O
epithelial	O
cellularity	O
,	O
stromal	O
fibrosis	O
and	O
the	O
value	O
of	O
REc	B-Chemical
in	O
those	O
tumours	B-Disease
in	O
which	O
the	O
receptor	O
was	O
present	O
.	O

Cellularity	O
and	O
fibrosis	O
were	O
unrelated	O
to	O
the	O
presence	O
or	O
absence	O
of	O
oestrogen	B-Gene
receptor	I-Gene
.	O

By	O
contrast	O
,	O
neither	O
the	O
presence	O
or	O
absence	O
nor	O
the	O
value	O
of	O
RPc	B-Chemical
could	O
be	O
related	O
to	O
cellularity	O
or	O
fibrosis	O
.	O

The	O
value	O
of	O
REc	B-Chemical
and	O
RPc	B-Chemical
analysis	O
as	O
an	O
indicator	O
of	O
prognosis	O
was	O
examined	O
in	O
a	O
sub-group	O
of	O
175	O
patients	O
receiving	O
no	O
additional	O
treatment	O
following	O
mastectomy	O
.	O

Overall	O
relapse-free	O
survival	O
(	O
RFS	O
)	O
was	O
no	O
different	O
for	O
those	O
patients	O
with	O
receptors	O
compared	O
to	O
those	O
without	O
them	O
(	O
REc	B-Chemical
P	O
=	O
0.11	O
,	O
RPc	B-Chemical
P	O
=	O
0.7	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
RFS	O
of	O
receptor	O
positive	O
and	O
negative	O
tumours	B-Disease
when	O
the	O
axillary	O
node	O
status	O
was	O
taken	O
into	O
account	O
.	O

Specific	O
estrogen	B-Chemical
binding	O
sites	O
in	O
human	O
lymphoid	O
cells	O
and	O
thymic	O
cells	O
.	O

The	O
binding	O
of	O
estrogen	B-Chemical
in	O
preparations	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
as	O
well	O
as	O
by	O
splenic	O
and	O
thymic	O
cells	O
is	O
demonstrated	O
by	O
three	O
different	O
approaches	O
(	O
Dextran	B-Chemical
-coated	O
charcoal	O
method	O
,	O
whole	O
cell	O
assay	O
,	O
and	O
gel	O
filtration	O
on	O
a	O
sepharose	O
4B	O
column	O
)	O
.	O

Scatchard	O
's	O
analysis	O
of	O
[	O
3H	O
]	O
-moxestrol	B-Chemical
(	O
R2858	B-Chemical
)	O
and	O
[	O
3H	O
]	O
-estradiol	B-Chemical
binding	O
proves	O
the	O
existence	O
of	O
a	O
single	O
class	O
of	O
receptor	O
sites	O
having	O
a	O
dissociation	O
constant	O
of	O
0.18-2.4	O
X	O
10	O
(	O
-9	O
)	O
M	O
.	O

Physicochemical	O
properties	O
of	O
the	O
binder	O
,	O
including	O
binding	O
capacity	O
and	O
steroid	B-Chemical
specificity	O
,	O
are	O
quite	O
similar	O
to	O
those	O
reported	O
for	O
the	O
thymus	O
of	O
small	O
mammalian	O
species	O
or	O
human	O
thymoma	B-Disease
.	O

Binding	O
of	O
progestins	B-Chemical
to	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

Correlation	O
to	O
their	O
glucocorticoid	B-Chemical
-like	O
effects	O
on	O
in	O
vitro	O
functions	O
of	O
human	O
mononuclear	O
leukocytes	O
.	O

A	O
number	O
of	O
physiological	O
and	O
synthetic	O
progestins	B-Chemical
were	O
tested	O
for	O
their	O
ability	O
to	O
compete	O
with	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
for	O
the	O
binding	O
to	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
of	O
human	O
mononuclear	O
leukocytes	O
and	O
their	O
ability	O
to	O
elicit	O
glucocorticoid	B-Chemical
-like	O
effects	O
on	O
the	O
same	O
cells	O
.	O

As	O
compared	O
to	O
the	O
reference	O
compound	O
dexamethasone	B-Chemical
(	O
relative	O
receptor	O
binding	O
affinity	O
defined	O
as	O
100	O
%	O
)	O
,	O
two	O
potent	O
synthetic	O
progestins	B-Chemical
with	O
a	O
pregnane-type	B-Chemical
structure	O
,	O
megestrol	B-Chemical
acetate	I-Chemical
and	O
medroxyprogesterone	B-Chemical
acetate	I-Chemical
,	O
were	O
found	O
to	O
display	O
a	O
considerable	O
binding	O
affinity	O
towards	O
the	O
receptor	O
(	O
46	O
and	O
42	O
%	O
,	O
respectively	O
)	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
the	O
naturally	O
occurring	O
ligand	O
,	O
cortisol	B-Chemical
,	O
to	O
the	O
receptor	O
was	O
clearly	O
lower	O
(	O
25	O
%	O
)	O
.	O

The	O
effective	O
binding	O
of	O
medroxyprogesterone	B-Chemical
acetate	I-Chemical
to	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
was	O
confirmed	O
by	O
direct	O
binding	O
studies	O
utilizing	O
a	O
tritiated	O
derivative	O
of	O
this	O
steroid	B-Chemical
.	O

No	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
specific	O
progesterone	B-Gene
receptor	I-Gene
in	O
human	O
mononuclear	O
leukocytes	O
was	O
obtained	O
as	O
judged	O
by	O
the	O
results	O
of	O
competition	O
experiments	O
where	O
a	O
progesterone	B-Gene
receptor-specific	I-Gene
ligand	O
[	O
3H	O
]	O
Org	B-Chemical
2058	I-Chemical
was	O
used	O
.	O

Medroxyprogesterone	B-Chemical
acetate	I-Chemical
and	O
megestrol	B-Chemical
acetate	I-Chemical
also	O
induced	O
glucocorticoid	B-Chemical
-like	O
effects	O
on	O
the	O
lymphocyte	O
functions	O
.	O

These	O
included	O
inhibition	O
of	O
the	O
proliferative	O
responses	O
to	O
the	O
T-cell	O
mitogens	O
concanavalin	B-Gene
A	I-Gene
and	O
phytohaemagglutinin	B-Gene
and	O
an	O
enhanced	O
accumulation	O
of	O
immunoglobulin	B-Gene
secreting	O
cells	O
in	O
pokeweed	O
mitogen	O
-stimulated	O
cultures	O
.	O

The	O
progestin	B-Chemical
effect	O
appears	O
to	O
be	O
mediated	O
through	O
a	O
radiosensitive	O
(	O
suppressor	O
)	O
subpopulation	O
of	O
T	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
the	O
synthetic	O
progestins	B-Chemical
related	O
structurally	O
to	O
19-nortestosterone	B-Chemical
,	O
norethisterone	B-Chemical
and	O
d-norgestrel	B-Chemical
,	O
were	O
virtually	O
devoid	O
of	O
binding	O
affinity	O
towards	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
nor	O
did	O
they	O
measurably	O
influence	O
the	O
in	O
vitro	O
lymphocyte	O
functions	O
.	O

These	O
studies	O
demonstrate	O
that	O
certain	O
progestins	B-Chemical
in	O
common	O
clinical	O
use	O
probably	O
possess	O
inherent	O
glucocorticoid	B-Chemical
activity	O
and	O
suggest	O
that	O
side	O
effects	O
attributable	O
to	O
this	O
character	O
(	O
e.g.	O
suppression	O
of	O
the	O
pituitary-adrenal	O
axis	O
)	O
might	O
be	O
expected	O
when	O
these	O
compounds	O
are	O
used	O
in	O
pharmacological	O
doses	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
and	O
cortico-sensitivity	O
in	O
a	O
human	O
clonal	O
monocytic	O
cell	O
line	O
,	O
CM-SM	O
.	O

CM-SM	O
is	O
a	O
clonal	O
line	O
of	O
human	O
precursor	O
mononuclear	O
phagocytes	O
inducible	O
to	O
macrophage	O
differentiation	O
in	O
response	O
to	O
the	O
tumor	B-Disease
promoter	O
phorbol	B-Chemical
ester	I-Chemical
12-O-tetradecanoyl-phorbol-13-acetate	I-Chemical
(	O
TPA	B-Chemical
)	O
.	O

Untreated	O
CM-SM	O
cells	O
contain	O
single	O
class	O
,	O
high-affinity	O
(	O
KD	O
=	O
4.0	O
X	O
10	O
(	O
-9	O
)	O
M	O
)	O
glucocorticoid-specific	B-Gene
receptor	I-Gene
sites	O
(	O
approximately	O
60	O
,	O
000	O
per	O
cell	O
)	O
,	O
as	O
measured	O
by	O
a	O
whole	O
cell	O
assay	O
,	O
at	O
37	O
degrees	O
C	O
,	O
using	O
[	O
3H	O
]	O
triamcinolone	B-Chemical
acetonide	I-Chemical
(	O
TA	B-Chemical
)	O
.	O

Exposure	O
of	O
CM-SM	O
to	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)	O
produced	O
a	O
progressive	O
,	O
dose-	O
and	O
time	O
-related	O
series	O
of	O
changes	O
in	O
CM-SM	O
cell	O
growth	O
,	O
saturation	O
density	O
,	O
morphology	O
,	O
and	O
functional	O
properties	O
,	O
with	O
half-maximal	O
effects	O
at	O
about	O
10	O
(	O
-9	O
)	O
M	O
for	O
DEX	B-Chemical
.	O

TA-receptor	B-Chemical
sites	O
rapidly	O
decreased	O
(	O
about	O
70	O
%	O
)	O
after	O
DEX	B-Chemical
treatment	O
,	O
without	O
any	O
apparent	O
change	O
in	O
steroid	B-Chemical
specificity	O
and	O
affinity	O
.	O

After	O
5	O
days	O
in	O
culture	O
with	O
a	O
saturating	O
concentration	O
(	O
3.6	O
X	O
10	O
(	O
-8	O
)	O
M	O
)	O
of	O
hormone	O
,	O
the	O
cells	O
reached	O
a	O
saturation	O
density	O
of	O
about	O
9.0	O
X	O
10	O
(	O
6	O
)	O
viable	O
cells	O
/	O
ml	O
(	O
about	O
4.0	O
X	O
10	O
(	O
6	O
)	O
viable	O
cells	O
/	O
ml	O
in	O
the	O
controls	O
)	O
,	O
while	O
the	O
modal	O
volume	O
of	O
the	O
resulting	O
cell	O
population	O
was	O
approximately	O
60	O
%	O
,	O
as	O
compared	O
to	O
the	O
volume	O
of	O
untreated	O
cells	O
.	O

DEX	B-Chemical
-treated	O
cells	O
appeared	O
less	O
differentiated	O
than	O
controls	O
,	O
as	O
assessed	O
by	O
combined	O
morphologic	O
,	O
antigenic	O
,	O
and	O
cytoenzymatic	O
analyses	O
.	O

DEX	B-Chemical
almost	O
completely	O
inhibited	O
TPA	B-Chemical
activation	O
of	O
the	O
following	O
macrophage	O
functions	O
:	O
adherency	O
to	O
the	O
culture	O
plate	O
,	O
expression	O
of	O
lysosomal	O
enzymes	O
,	O
Fc	B-Gene
and	O
C3	B-Gene
receptors	I-Gene
,	O
and	O
stimulation	O
of	O
phagocytosis	O
.	O

After	O
removal	O
of	O
DEX	B-Chemical
,	O
the	O
cells	O
,	O
within	O
a	O
few	O
passages	O
,	O
returned	O
to	O
a	O
state	O
apparently	O
identical	O
to	O
the	O
untreated	O
controls	O
and	O
could	O
be	O
induced	O
to	O
macrophage	O
differentiation	O
in	O
response	O
to	O
TPA	B-Chemical
.	O

Human	O
breast	B-Disease
cancer	I-Disease
and	O
impaired	O
NK	O
cell	O
function	O
.	O

Recent	O
advances	O
in	O
tumor	B-Disease
immunology	O
have	O
led	O
to	O
the	O
discovery	O
of	O
a	O
new	O
lymphoid	O
cell	O
with	O
unique	O
antitumor	O
activity	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
form	O
an	O
antitumor	O
surveillance	O
system	O
and	O
appear	O
to	O
be	O
vital	O
in	O
preventing	O
tumor	B-Disease
growth	O
and	O
metastasis	O
in	O
animal	O
models	O
.	O

We	O
studied	O
NK	O
activity	O
in	O
patients	O
with	O
benign	O
and	O
malignant	O
breast	B-Disease
disease	I-Disease
,	O
using	O
a	O
chromium-51	B-Chemical
release	O
microtiter	O
cytotoxicity	O
assay	O
with	O
K562	O
cells	O
as	O
targets	O
.	O

Compared	O
with	O
benign	O
controls	O
,	O
patients	O
with	O
malignancies	B-Disease
had	O
significantly	O
depressed	O
NK	O
-mediated	O
lysis	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Furthermore	O
,	O
lysis	O
in	O
those	O
with	O
advanced	O
disease	O
(	O
stages	O
II	O
,	O
III	O
,	O
and	O
IV	O
)	O
was	O
significantly	O
less	O
than	O
in	O
those	O
with	O
limited	O
disease	O
(	O
stage	O
I	O
)	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

NK	O
activity	O
was	O
not	O
correlated	O
to	O
estrogen	B-Chemical
or	O
progesterone	B-Gene
receptor	I-Gene
states	O
.	O

Positive	O
correlation	O
of	O
a	O
depressed	O
natural	O
killer	O
activity	O
with	O
the	O
extent	O
of	O
tumor	B-Disease
spread	O
supports	O
the	O
concept	O
of	O
an	O
NK	O
cell	O
immune	O
surveillance	O
system	O
in	O
breast	B-Disease
cancer	I-Disease
and	O
emphasizes	O
its	O
importance	O
in	O
this	O
malignancy	B-Disease
.	O

Covalent	O
labeling	O
of	O
rat	O
thymocyte	O
and	O
human	B-Gene
lymphoid	I-Gene
glucocorticoid	I-Gene
receptor	I-Gene
.	O

Lymphoid	O
cells	O
contain	O
specific	O
receptors	O
for	O
glucocorticoids	B-Chemical
.	O

We	O
have	O
used	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	B-Chemical
to	O
label	O
covalently	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
rat	O
thymic	O
lymphocytes	O
and	O
in	O
neoplastic	O
cells	O
obtained	O
from	O
patients	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
and	O
malignant	B-Disease
lymphoma	I-Disease
.	O

The	O
covalently	O
labeled	O
glucocorticoid	B-Gene
receptors	I-Gene
were	O
identified	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
in	O
the	O
presence	O
of	O
0.1	O
%	O
sodium	O
dodecyl	O
sulfate	O
)	O
.	O

In	O
cytosolic	O
fractions	O
prepared	O
from	O
rat	O
thymic	O
lymphocytes	O
,	O
[	O
3H	O
]	O
-dexamethasone-21-mesylate	B-Chemical
labels	O
a	O
protein	O
(	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
)	O
which	O
was	O
identified	O
as	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
by	O
the	O
following	O
criteria	O
:	O
(	O
a	O
)	O
labeling	O
of	O
this	O
moiety	O
is	O
inhibited	O
by	O
treatment	O
with	O
a	O
100-fold	O
molar	O
excess	O
of	O
glucocorticoids	B-Chemical
,	O
such	O
as	O
dexamethasone	B-Chemical
and	O
triamcinolone	B-Chemical
acetonide	I-Chemical
;	O
and	O
(	O
b	O
)	O
the	O
covalently	O
labeled	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
protein	O
is	O
activated	O
(	O
by	O
heating	O
at	O
20	O
degrees	O
for	O
30	O
min	O
)	O
to	O
a	O
form	O
that	O
binds	O
to	O
DNA-cellulose	O
.	O

When	O
intact	O
thymocytes	O
are	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	B-Chemical
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
is	O
also	O
labeled	O
covalently	O
.	O

Approximately	O
35	O
%	O
of	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
can	O
be	O
labeled	O
covalently	O
when	O
intact	O
thymocytes	O
are	O
treated	O
with	O
100	O
nM	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	B-Chemical
for	O
30	O
min	O
at	O
4	O
degrees	O
.	O

Neoplastic	O
cells	O
from	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
and	O
malignant	B-Disease
lymphoma	I-Disease
were	O
treated	O
with	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	B-Chemical
.	O

In	O
all	O
samples	O
,	O
an	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
moiety	O
was	O
labeled	O
covalently	O
;	O
labeling	O
was	O
inhibited	O
by	O
excess	O
glucocorticoid	B-Chemical
.	O

Smaller	O
moieties	O
were	O
also	O
identified	O
by	O
competition	O
experiments	O
;	O
these	O
may	O
represent	O
proteolytic	O
fragments	O
of	O
the	O
Mr	O
approximately	O
equal	O
to	O
95	O
,	O
000	O
receptor	O
.	O

Thus	O
,	O
in	O
rat	O
and	O
human	O
lymphoid	O
cells	O
,	O
[	O
3H	O
]	O
dexamethasone-21-mesylate	B-Chemical
can	O
be	O
used	O
to	O
label	O
covalently	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

Specific	O
high-affinity	O
receptors	O
for	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
:	O
presence	O
in	O
monocytes	O
and	O
induction	O
in	O
T	O
lymphocytes	O
following	O
activation	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
have	O
high	O
affinity	O
binding	O
sites	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
Kd	O
0.14	O
nM	O
,	O
sedimentation	O
coefficient	O
3.7S	O
)	O
.	O

Resting	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
however	O
,	O
do	O
not	O
have	O
a	O
demonstrable	O
1	B-Gene
,	I-Gene
25-	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
.	O

After	O
activation	O
with	O
phytohemagglutinin	B-Gene
the	O
T	O
cells	O
exhibit	O
the	O
receptor	O
within	O
24	O
h	O
,	O
and	O
this	O
expression	O
is	O
blocked	O
by	O
cycloheximide	B-Chemical
.	O

The	O
receptor	O
in	O
activated	O
T	O
lymphocytes	O
has	O
a	O
sedimentation	O
coefficient	O
of	O
3.7S	O
and	O
a	O
high	O
affinity	O
(	O
Kd	O
0.10	O
nM	O
)	O
for	O
the	O
ligand	O
.	O

[	O
Glucocorticoid	B-Gene
receptors	I-Gene
in	O
normal	O
human	O
lymphocytes	O
]	O

Glucocorticoid	B-Gene
(	I-Gene
GC	I-Gene
)	I-Gene
receptors	I-Gene
were	O
studied	O
in	O
intact	O
lymphocytes	O
from	O
11	O
donors	O
.	O

GC	B-Chemical
binding	O
parameters	O
were	O
found	O
to	O
be	O
highly	O
reproducible	O
in	O
repeated	O
experiments	O
with	O
lymphocytes	O
.	O

It	O
was	O
shown	O
that	O
GC	B-Gene
receptors	I-Gene
in	O
donors	O
'lymphocytes	O
could	O
be	O
distributed	O
into	O
two	O
different	O
classes	O
similarly	O
to	O
the	O
pattern	O
seen	O
in	O
skin	O
fibroblasts	O
.	O

Human	O
lymphocytes	O
are	O
an	O
adequate	O
object	O
for	O
studying	O
genetically	O
determined	O
variability	O
of	O
GC	B-Gene
receptors	I-Gene
and	O
its	O
clinical	O
importance	O
.	O

Presence	O
and	O
steroid	B-Chemical
inducibility	O
of	O
glutamine	B-Gene
synthetase	I-Gene
in	O
human	O
leukemic	O
cells	O
.	O

Glutamine	B-Gene
synthetase	I-Gene
(	O
EC	O
6.3.1.2	O
;	O
GS	B-Gene
)	O
is	O
present	O
in	O
lymphoblasts	O
from	O
patients	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
as	O
well	O
as	O
in	O
normal	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
16	O
out	O
of	O
20	O
ALL	B-Disease
patients	O
studied	O
exposure	O
of	O
the	O
cells	O
to	O
physiological	O
concentrations	O
of	O
dexamethasone	B-Chemical
in	O
vitro	O
increased	O
enzyme	O
activity	O
above	O
the	O
control	O
levels	O
.	O

The	O
increase	O
was	O
specific	O
for	O
glucocorticoid	B-Gene
receptor	I-Gene
ligands	I-Gene
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
magnitude	O
of	O
glucocorticoid	B-Chemical
-mediated	O
increase	O
of	O
GS	B-Gene
activity	O
and	O
the	O
cellular	O
levels	O
of	O
specific	O
glucocorticoid	B-Gene
receptors	I-Gene
assayed	O
in	O
the	O
same	O
cell	O
specimen	O
.	O

Moreover	O
,	O
the	O
basal	O
levels	O
of	O
the	O
enzyme	O
measured	O
in	O
cells	O
prior	O
to	O
exposure	O
to	O
dexamethasone	B-Chemical
correlated	O
negatively	O
with	O
receptor	O
density	O
.	O

It	O
is	O
suggested	O
that	O
the	O
presence	O
of	O
steroid-inducible	B-Chemical
GS	B-Gene
in	O
ALL	B-Disease
cells	O
may	O
prove	O
to	O
be	O
a	O
marker	O
for	O
functional	O
receptor	O
sites	O
.	O

Effect	O
of	O
cell	O
cycle	O
position	O
on	O
dexamethasone	B-Chemical
binding	O
by	O
mouse	O
and	O
human	O
lymphoid	O
cell	O
lines	O
:	O
correlation	O
between	O
an	O
increase	O
in	O
dexamethasone	B-Chemical
binding	O
during	O
S	O
phase	O
and	O
dexamethasone	B-Chemical
sensitivity	O
.	O

We	O
determined	O
the	O
effect	O
of	O
cell	O
cycle	O
position	O
on	O
the	O
amount	O
of	O
dexamethasone	B-Chemical
that	O
was	O
specifically	O
bound	O
by	O
mouse	O
and	O
human	O
lymphoid	O
cell	O
lines	O
.	O

Cell	O
lines	O
that	O
were	O
either	O
sensitive	O
or	O
resistant	O
to	O
growth	O
inhibition	O
by	O
dexamethasone	B-Chemical
were	O
compared	O
.	O

Exponentially	O
growing	O
cells	O
were	O
separated	O
by	O
centrifugal	O
elutriation	O
into	O
fractions	O
that	O
corresponded	O
to	O
different	O
positions	O
in	O
the	O
cell	O
cycle	O
.	O

The	O
cell	O
cycle	O
phase	O
distribution	O
of	O
each	O
fraction	O
was	O
estimated	O
by	O
flow	O
cytometry	O
and	O
autoradiography	O
.	O

The	O
amount	O
of	O
dexamethasone	B-Chemical
bound	O
per	O
cell	O
in	O
each	O
fraction	O
was	O
measured	O
by	O
a	O
whole	O
cell	O
binding	O
assay	O
.	O

In	O
three	O
dexamethasone	B-Chemical
-sensitive	O
cell	O
lines	O
(	O
two	O
mouse	O
and	O
one	O
human	O
)	O
,	O
we	O
found	O
that	O
the	O
amount	O
of	O
dexamethasone	B-Chemical
bound	O
per	O
cell	O
increased	O
2-4-fold	O
between	O
G1	O
phase	O
and	O
S	O
phase	O
,	O
and	O
then	O
decreased	O
during	O
G2	O
/	O
M	O
phase	O
.	O

Results	O
were	O
the	O
same	O
when	O
the	O
amount	O
of	O
dexamethasone	B-Chemical
bound	O
per	O
milligram	O
of	O
cell	O
protein	O
was	O
measured	O
.	O

Binding	O
affinity	O
was	O
the	O
same	O
during	O
G1	O
phase	O
and	O
S	O
phase	O
,	O
but	O
the	O
proportion	O
of	O
bound	O
dexamethasone	B-Chemical
that	O
translocated	O
to	O
the	O
nucleus	O
was	O
greater	O
during	O
S	O
phase	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
the	O
amount	O
of	O
dexamethasone	B-Chemical
bound	O
per	O
cell	O
by	O
three	O
dexamethasone	B-Chemical
-resistant	O
cell	O
lines	O
(	O
two	O
mouse	O
and	O
one	O
human	O
)	O
did	O
not	O
increase	O
during	O
S	O
phase	O
.	O

Our	O
results	O
indicate	O
that	O
cell	O
cycle	O
changes	O
in	O
dexamethasone	B-Chemical
binding	O
are	O
not	O
simply	O
related	O
to	O
changes	O
in	O
cell	O
protein	O
or	O
cell	O
volume	O
during	O
the	O
cell	O
cycle	O
.	O

An	O
increase	O
in	O
dexamethasone	B-Chemical
binding	O
during	O
S	O
phase	O
may	O
be	O
required	O
for	O
dexamethasone	B-Chemical
to	O
inhibit	O
cell	O
growth	O
,	O
and	O
a	O
failure	O
of	O
dexamethasone	B-Chemical
binding	O
to	O
increase	O
during	O
S	O
phase	O
might	O
represent	O
a	O
new	O
mechanism	O
of	O
dexamethasone	B-Chemical
resistance	O
in	O
lymphoid	O
cells	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
and	O
steroid	B-Chemical
sensitivity	O
in	O
normal	O
and	O
neoplastic	O
human	O
lymphoid	O
tissues	O
:	O
a	O
review	O
.	O

The	O
determination	O
of	O
estrogen	B-Chemical
and	O
progesterone	B-Gene
receptors	I-Gene
in	O
breast	B-Disease
cancer	I-Disease
has	O
been	O
shown	O
to	O
be	O
useful	O
in	O
predicting	O
the	O
response	O
to	O
endocrine	O
therapy	O
.	O

Given	O
their	O
well-known	O
inhibitory	O
effects	O
on	O
lymphoid	O
tissue	O
,	O
glucocorticoids	B-Chemical
have	O
been	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
leukemia	B-Disease
.	O

Given	O
these	O
facts	O
,	O
over	O
the	O
last	O
10	O
years	O
,	O
several	O
investigators	O
have	O
measured	O
the	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
to	O
see	O
whether	O
their	O
number	O
correlated	O
with	O
glucocorticoid	B-Chemical
responsiveness	O
in	O
vitro	O
or	O
in	O
vivo	O
.	O

No	O
clear	O
correlation	O
could	O
be	O
established	O
between	O
the	O
level	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
and	O
the	O
in	O
vitro	O
action	O
of	O
steroids	B-Chemical
in	O
normal	O
and	O
neoplastic	O
lymphoid	O
tissue	O
.	O

In	O
contrast	O
,	O
attempts	O
to	O
correlate	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
in	O
acute	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
to	O
in	O
vivo	O
steroid	B-Chemical
responsiveness	O
and	O
immunological	O
type	O
using	O
the	O
whole-cell	O
-binding	O
assay	O
for	O
receptor	O
determination	O
and	O
selecting	O
the	O
patients	O
according	O
to	O
age	O
and	O
immunological	O
criteria	O
have	O
been	O
more	O
successful	O
.	O

Effect	O
of	O
thymosin	B-Gene
on	O
glucocorticoid	B-Gene
receptor	I-Gene
activity	O
and	O
glucocorticoid	B-Chemical
sensitivity	O
of	O
human	O
thymocytes	O
.	O

Incubation	O
with	O
thymosin	B-Gene
fraction	O
5	O
,	O
(	O
TMS	B-Gene
F5	O
at	O
300	O
micrograms	O
/	O
ml	O
)	O
a	O
partially	O
purified	O
thymic	O
factor	O
,	O
reduced	O
the	O
steroid	B-Chemical
binding	O
activity	O
of	O
human	O
infant	O
thymocytes	O
from	O
9.6	O
+	O
/	O
-	O
2.1	O
fmole	O
/	O
ml	O
to	O
5.0	O
+	O
/	O
-	O
2.0	O
fmole	O
/	O
ml	O
.	O

The	O
glucocorticoid	B-Gene
receptor	I-Gene
activity	O
in	O
normal	O
infant	O
thymocytes	O
was	O
found	O
to	O
be	O
2	O
,	O
146	O
+	O
/	O
-	O
726	O
(	O
s.d.	O
)	O
sites	O
per	O
cell	O
with	O
dissociation	O
constant	O
of	O
1.4	O
+	O
/	O
-	O
0.6	O
X	O
10	O
(	O
-8	O
)	O
M	O
.	O

TMS	B-Gene
F5	O
also	O
increased	O
the	O
resistance	O
of	O
human	O
thymocytes	O
to	O
the	O
cytolytic	O
effect	O
of	O
dexamethasone	B-Chemical
(	O
2.5	O
X	O
10	O
(	O
-8	O
)	O
M	O
)	O
to	O
168.6	O
+	O
/	O
-	O
30.2	O
%	O
of	O
control	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

In	O
animals	O
,	O
medullary	O
and	O
peripheral	O
blood	O
T	O
cells	O
are	O
more	O
resistant	O
to	O
glucocorticoids	B-Chemical
than	O
immature	O
thymic	O
T	O
cells	O
.	O

The	O
results	O
show	O
that	O
thymosin	B-Gene
can	O
induce	O
changes	O
consistent	O
with	O
differentiation	O
in	O
human	O
thymocytes	O
.	O

These	O
in	O
vitro	O
results	O
are	O
consistent	O
with	O
a	O
physiological	O
role	O
of	O
thymosin	B-Gene
in	O
intrathymic	O
T	O
cell	O
maturation	O
in	O
man	O
.	O

Incubation	O
of	O
a	O
human	O
malignant	O
thymus	O
derived	O
T	O
cell	O
line	O
(	O
MOLT	O
3	O
)	O
with	O
TMS	B-Gene
F5	O
also	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
number	O
of	O
steroid	B-Chemical
binding	O
sites	O
to	O
44.2	O
+	O
/	O
-	O
15.3	O
%	O
of	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
but	O
TMS	B-Gene
F5	O
did	O
not	O
significantly	O
reduce	O
the	O
glucocorticoid	B-Chemical
sensitivity	O
of	O
MOLT	O
3	O
cells	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
number	O
and	O
intracellular	O
water	O
space	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
relationship	O
between	O
cell	O
water	O
content	O
and	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
,	O
eleven	O
normal	O
and	O
malignant	O
lymphoid	O
or	O
myelomonocytic	O
cell	O
types	O
originating	O
from	O
mouse	O
,	O
rat	O
and	O
man	O
were	O
investigated	O
.	O

The	O
cellular	O
water	O
space	O
was	O
measured	O
with	O
3H2O	O
,	O
and	O
glucocorticoid	B-Gene
receptor	I-Gene
number	O
was	O
measured	O
in	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
at	O
30	O
and	O
37	O
degrees	O
C	O
.	O

The	O
intracellular	O
water	O
phase	O
concentration	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
around	O
40	O
nmol	O
/	O
l	O
cell	O
water	O
)	O
,	O
and	O
the	O
dependence	O
of	O
receptor	O
affinity	O
on	O
temperature	O
were	O
similar	O
in	O
normal	O
and	O
malignant	O
rodent	O
and	O
human	O
cells	O
.	O

It	O
is	O
concluded	O
that	O
comparisons	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
are	O
best	O
made	O
on	O
the	O
basis	O
of	O
intracellular	O
receptor	O
concentrations	O
.	O

Thermodynamics	O
of	O
steroid	B-Chemical
binding	O
to	O
the	O
human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
.	O

The	O
thermodynamics	O
of	O
the	O
interaction	O
of	O
glucocorticoids	B-Chemical
with	O
their	O
receptor	O
were	O
studied	O
in	O
cytosol	O
from	O
human	O
lymphoblastoid	O
cells	O
.	O

The	O
rate	O
and	O
affinity	O
constants	O
of	O
dexamethasone	B-Chemical
and	O
cortisol	B-Chemical
between	O
0	O
degree	O
and	O
25	O
degrees	O
C	O
were	O
calculated	O
by	O
curve	O
-fitting	O
from	O
time-course	O
and	O
equilibrium	O
kinetics	O
.	O

The	O
data	O
were	O
consistent	O
with	O
a	O
simple	O
reversible	O
bimolecular	O
interaction	O
.	O

Arrhenius	O
and	O
Va	O
n't	O
Hoff	O
plots	O
were	O
curvilinear	O
for	O
both	O
steroids	B-Chemical
.	O

At	O
equilibrium	O
,	O
the	O
solution	O
for	O
the	O
equation	O
delta	O
G	O
=	O
delta	O
H	O
-	O
T	O
X	O
delta	O
S	O
(	O
eqn.	O
1	O
)	O
was	O
(	O
in	O
kJ	O
X	O
mol-1	O
)	O
-47	O
=	O
36	O
-	O
83	O
(	O
dexamethasone	B-Chemical
)	O
and	O
-42	O
=	O
-9	O
-	O
33	O
(	O
cortisol	B-Chemical
)	O
at	O
0	O
degree	O
C	O
.	O

Enthalpy	O
and	O
entropy	O
changes	O
decreased	O
quasi-linearly	O
with	O
temperature	O
such	O
that	O
,	O
at	O
25	O
degrees	O
C	O
,	O
the	O
respective	O
values	O
were	O
-50	O
=	O
-75	O
+	O
25	O
and	O
-43	O
=	O
-48	O
+	O
5	O
.	O

Thus	O
,	O
for	O
both	O
steroids	B-Chemical
,	O
the	O
interaction	O
was	O
entropy-driven	O
at	O
low	O
temperature	O
and	O
became	O
entirely	O
enthalpy-driven	O
at	O
20	O
degrees	O
C	O
.	O

Thermodynamic	O
values	O
for	O
the	O
transition	O
state	O
were	O
calculated	O
from	O
the	O
rate	O
constants	O
.	O

For	O
the	O
forward	O
reaction	O
,	O
eqn	O
.	O

(	O
1	O
)	O
gave	O
45	O
=	O
84	O
-	O
39	O
(	O
dexamethasone	B-Chemical
)	O
and	O
46	O
=	O
60	O
-	O
14	O
(	O
cortisol	B-Chemical
)	O
at	O
0	O
degree	O
C	O
,	O
and	O
44	O
=	O
24	O
+	O
20	O
(	O
dexamethasone	B-Chemical
)	O
and	O
46	O
=	O
28	O
+	O
18	O
(	O
cortisol	B-Chemical
)	O
at	O
25	O
degrees	O
C	O
.	O

These	O
data	O
fit	O
quite	O
well	O
with	O
a	O
two-step	O
model	O
[	O
Ross	O
&	O
Subramanian	O
(	O
1981	O
)	O
Biochemistry	O
20	O
,	O
3096-3102	O
]	O
proposed	O
for	O
ligand-protein	O
interactions	O
,	O
which	O
involves	O
a	O
partial	O
immobilization	O
of	O
the	O
reacting	O
species	O
governed	O
by	O
hydrophobic	O
forces	O
,	O
followed	O
by	O
stabilization	O
of	O
the	O
complex	O
by	O
short-range	O
interactions	O
.	O

On	O
the	O
basis	O
of	O
this	O
model	O
,	O
an	O
analysis	O
of	O
the	O
transition-state	O
thermodynamics	O
led	O
to	O
the	O
conclusion	O
that	O
no	O
more	O
than	O
half	O
of	O
the	O
steroid	B-Chemical
molecular	O
area	O
is	O
engaged	O
in	O
the	O
binding	O
process	O
.	O

Cell	O
cycle	O
-related	O
changes	O
in	O
number	O
of	O
T-lymphocyte	B-Gene
receptors	I-Gene
for	O
glucocorticoids	B-Chemical
and	O
insulin	B-Gene
.	O

Enriched	O
human	O
peripheral	O
T-lymphocytes	O
were	O
stimulated	O
with	O
PHA	B-Gene
and	O
examined	O
for	O
variations	O
in	O
insulin	B-Gene
and	O
glucocorticoid	B-Gene
(	I-Gene
dexamethasone	I-Gene
)	I-Gene
receptor	I-Gene
numbers	O
during	O
the	O
early	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

Cells	O
in	O
G0	O
,	O
G1a	O
and	O
G1b	O
phases	O
,	O
where	O
the	O
G1a	O
-	O
G1b	O
transition	O
is	O
an	O
Interleukin	B-Gene
2	I-Gene
dependent	O
event	O
,	O
were	O
quantitated	O
by	O
flow	O
cytometry	O
.	O

Few	O
but	O
significant	O
numbers	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
2700	O
/	O
cell	O
)	O
and	O
no	O
insulin	B-Gene
receptors	I-Gene
(	O
-1	O
/	O
cell	O
)	O
were	O
found	O
in	O
the	O
resting	O
(	O
G0	O
)	O
phase	O
.	O

As	O
cells	O
entered	O
the	O
G1a	O
phase	O
the	O
specific	O
binding	O
of	O
dexamethasone	B-Chemical
increased	O
and	O
of	O
insulin	B-Gene
took	O
place	O
.	O

Although	O
the	O
specific	O
binding	O
further	O
increased	O
as	O
T-cells	O
entered	O
the	O
G1b	O
phase	O
(	O
as	O
measured	O
at	O
44	O
h	O
of	O
incubation	O
and	O
using	O
hydroxyurea	B-Chemical
-treated	O
cells	O
)	O
,	O
the	O
major	O
changes	O
in	O
the	O
specific	O
binding	O
of	O
dexamethasone	B-Chemical
took	O
place	O
during	O
the	O
period	O
16	O
-	O
20	O
h	O
after	O
stimulation	O
.	O

Based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
both	O
receptor	O
types	O
(	O
cell	O
membrane	O
and	O
cytoplasmic	O
receptors	O
)	O
are	O
being	O
formed	O
and	O
increased	O
at	O
G1	O
phase	O
prior	O
to	O
cell	O
proliferation	O
,	O
indicating	O
the	O
importance	O
of	O
G1	O
phase	O
in	O
immunoregulation	O
.	O

Specific	O
uptake	O
of	O
1	B-Chemical
,	I-Chemical
25-dihydroxycholecalciferol	I-Chemical
by	O
human	O
chronic	B-Disease
myeloid	I-Disease
leukemia	I-Disease
cells	O
.	O

We	O
have	O
examined	O
mononuclear	O
cell	O
preparations	O
from	O
patients	O
with	O
chronic	B-Disease
myeloid	I-Disease
leukemia	I-Disease
[	O
CML	B-Disease
]	O
for	O
binding	O
of	O
and	O
response	O
to	O
1	B-Chemical
,	I-Chemical
25-dihydroxycholecalciferol	I-Chemical
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
.	O

Whole	O
cells	O
specifically	O
took	O
up	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
with	O
high	O
affinity	O
(	O
Kd	O
3.6	O
X	O
10	O
(	O
-11	O
)	O
M	O
)	O
and	O
low	O
capacity	O
.	O

Subcellular	O
fractionation	O
of	O
labeled	O
cells	O
showed	O
that	O
binding	O
was	O
restricted	O
to	O
cytosols	O
and	O
nuclei	O
.	O

Sucrose	O
gradient	O
centrifugation	O
of	O
cells	O
preincubated	O
with	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
revealed	O
a	O
single	O
3.6S	O
peak	O
which	O
was	O
totally	O
displaced	O
with	O
100-fold	O
excess	O
nonradioactive	O
hormone	O
.	O

However	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
specific	O
binding	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
postlabeling	O
standard	O
cytosol	O
preparations	O
.	O

In	O
addition	O
,	O
cytosols	O
prepared	O
from	O
a	O
mixture	O
of	O
CML	B-Disease
cells	O
and	O
1	B-Gene
,	I-Gene
25-	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
-positive	O
T47D	O
(	O
human	O
breast	B-Disease
cancer	I-Disease
)	O
cells	O
had	O
less	O
than	O
10	O
%	O
of	O
the	O
binding	O
measured	O
in	O
T47D	O
cytosol	O
alone	O
.	O

However	O
,	O
the	O
levels	O
of	O
binding	O
in	O
T47D	O
cytosols	O
were	O
not	O
reduced	O
if	O
the	O
receptors	O
were	O
occupied	O
with	O
[	O
3H	O
]	O
-1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
prior	O
to	O
the	O
addition	O
of	O
the	O
CML	B-Disease
cytosols	O
.	O

Thus	O
,	O
CML	B-Disease
cells	O
appear	O
to	O
contain	O
both	O
the	O
receptor	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
and	O
an	O
unknown	O
substance	O
which	O
prevents	O
its	O
detection	O
following	O
the	O
preparation	O
of	O
cytosol	O
.	O

Cells	O
from	O
patients	O
with	O
CML	B-Disease
in	O
the	O
chronic	O
phase	O
specifically	O
bound	O
more	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
[	O
18.0	O
+	O
/	O
-	O
3.2	O
(	O
S.E.	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
]	O
than	O
did	O
those	O
in	O
acute	O
myeloid	O
transformation	O
[	O
7.2	O
+	O
/	O
-	O
1.5	O
]	O
or	O
than	O
did	O
cells	O
from	O
patients	O
with	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
[	O
2.6	O
+	O
/	O
-	O
0.8	O
]	O
.	O

Only	O
cells	O
from	O
the	O
first	O
group	O
of	O
patients	O
responded	O
to	O
the	O
addition	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
differentiating	O
along	O
the	O
monocyte-macrophage	O
pathway	O
.	O

We	O
conclude	O
that	O
the	O
differentiation-induction	O
effect	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
is	O
likely	O
to	O
depend	O
on	O
adequate	O
levels	O
of	O
receptor	O
and	O
that	O
intact	O
cells	O
rather	O
than	O
cytosol	O
preparations	O
should	O
be	O
studied	O
before	O
cells	O
of	O
a	O
particular	O
tissue	O
are	O
designated	O
as	O
receptor	O
negative	O
.	O

Multiple	O
forms	O
and	O
fragments	O
of	O
cytosolic	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
from	O
human	O
leukemic	O
cells	O
and	O
normal	O
lymphocytes	O
.	O

Therapy	O
with	O
glucocorticoids	B-Chemical
is	O
generally	O
more	O
effective	O
in	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
than	O
in	O
other	O
types	O
of	O
human	O
leukemia	B-Disease
.	O

Previous	O
studies	O
,	O
however	O
,	O
have	O
not	O
revealed	O
any	O
consistent	O
relationship	O
between	O
clinical	O
responsiveness	O
and	O
the	O
cellular	O
or	O
cytosolic	O
concentration	O
of	O
glucocorticoid	B-Chemical
-binding	O
sites	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
whether	O
there	O
are	O
intrinsic	O
structural	O
differences	O
among	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
various	O
types	O
of	O
leukemic	O
cells	O
and	O
normal	O
lymphocytes	O
and	O
to	O
investigate	O
the	O
role	O
of	O
endogenous	O
peptidases	B-Gene
in	O
receptor	O
degradation	O
.	O

Cytosols	O
were	O
prepared	O
from	O
fresh	O
or	O
rapidly	O
frozen	O
leukocytes	O
from	O
6	O
healthy	O
adults	O
and	O
35	O
high-risk	O
leukemia	B-Disease
patients	O
(	O
median	O
white	O
blood	O
cell	O
count	O
,	O
150	O
,	O
000	O
cells	O
/	O
microliter	O
;	O
median	O
age	O
,	O
13	O
years	O
)	O
.	O

Receptors	O
were	O
labeled	O
with	O
[	O
3H	O
]	O
triamcinolone	B-Chemical
acetonide	I-Chemical
and	O
quantitated	O
by	O
charcoal-dextran	B-Chemical
treatment	O
or	O
Sephadex	O
LH-20	O
chromatography	O
.	O

Mean	O
and	O
median	O
cytosolic	O
receptor	O
concentrations	O
in	O
12	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
specimens	O
lacking	O
the	O
standard	O
B-cell	O
or	O
T-cell	O
markers	O
(	O
``	O
null	O
cells	O
''	O
)	O
were	O
approximately	O
4-fold	O
higher	O
than	O
in	O
23	O
other	O
leukemic	O
cell	O
specimens	O
.	O

No	O
other	O
consistent	O
differences	O
in	O
receptor	O
content	O
were	O
observed	O
.	O

Agarose	B-Chemical
filtration	O
and	O
ultracentrifugation	O
in	O
hypotonic	O
buffers	O
containing	O
20	O
mM	O
Na2MoO4	O
revealed	O
complexes	O
of	O
similar	O
size	O
and	O
shape	O
in	O
all	O
clinical	O
specimens	O
tested	O
and	O
two	O
established	O
leukemic	O
cell	O
lines	O
.	O

They	O
had	O
Stokes	O
radii	O
(	O
Rs	O
)	O
of	O
8.1	O
+	O
/	O
-	O
0.5	O
(	O
S.D.	O
)	O
nm	O
(	O
n	O
=	O
50	O
)	O
,	O
sedimentation	O
coefficients	O
of	O
9.5	O
+	O
/	O
-	O
0.3S	O
(	O
n	O
=	O
40	O
)	O
,	O
molecular	O
weights	O
of	O
approximately	O
330	O
,	O
000	O
,	O
and	O
axial	O
ratios	O
(	O
a	O
/	O
b	O
)	O
of	O
approximately	O
12	O
.	O

In	O
hypertonic	O
,	O
molybdate-free	B-Chemical
buffer	O
,	O
these	O
oligomeric	O
complexes	O
were	O
dissociated	O
into	O
subunits	O
with	O
Rs	O
of	O
5.9	O
+	O
/	O
-	O
0.3	O
nm	O
(	O
n	O
=	O
12	O
)	O
and	O
a	O
/	O
b	O
of	O
11	O
to	O
12	O
,	O
as	O
observed	O
previously	O
for	O
other	O
receptors	O
.	O

Fragmentation	O
of	O
the	O
oligomer	O
and	O
the	O
subunit	O
was	O
evident	O
in	O
some	O
cytosols	O
.	O

High	O
activities	O
of	O
peptidases	B-Gene
of	O
various	O
specificities	O
were	O
detected	O
in	O
leukemic	O
cell	O
cytosols	O
,	O
as	O
in	O
other	O
cytosols	O
,	O
by	O
fluorometric	O
assays	O
with	O
derivatives	O
of	O
7-amino-4-methylcoumarin	B-Chemical
.	O

Receptor	O
cleavage	O
by	O
these	O
and	O
other	O
endogenous	O
enzymes	O
may	O
account	O
for	O
previous	O
observations	O
of	O
``	O
abnormal	O
''receptors	O
in	O
cytosols	O
from	O
some	O
leukemic	O
specimens	O
.	O

We	O
conclude	O
that	O
intrinsic	O
structural	O
defects	O
in	O
the	O
receptors	O
are	O
unlikely	O
explanations	O
for	O
the	O
unresponsiveness	O
of	O
some	O
types	O
of	O
leukemia	B-Disease
to	O
steroid	B-Chemical
therapy	O
.	O

Identification	O
of	O
human	B-Gene
leukemic	I-Gene
glucocorticoid	I-Gene
receptors	I-Gene
using	O
affinity	O
labeling	O
and	O
anti-human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
antibodies	I-Gene
.	O

Antisera	O
raised	O
against	O
human	B-Gene
lymphoid	I-Gene
glucocorticoid	I-Gene
receptors	I-Gene
were	O
used	O
in	O
combination	O
with	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
affinity	O
label	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
21-mesylate	I-Chemical
[	O
(	O
3H	O
]	O
DM	B-Chemical
)	O
to	O
identify	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
of	O
the	O
human	O
B-lymphoblastoid	O
cell	O
line	O
IM-9	O
and	O
the	O
human	O
T-cell	O
leukemic	O
cell	O
line	O
CEM-C7	O
.	O

Antisera	O
were	O
obtained	O
following	O
immunization	O
of	O
New	O
Zealand	O
White	O
rabbits	O
with	O
[	O
3H	O
]	O
triamcinolone	B-Gene
acetonide	I-Gene
[	I-Gene
(	I-Gene
3H	I-Gene
]	I-Gene
TA	I-Gene
)	I-Gene
-glucocorticoid	I-Gene
receptor	I-Gene
complexes	I-Gene
partially	O
purified	O
by	O
two-stage	O
DNA-cellulose	O
chromatography	O
.	O

The	O
presence	O
of	O
anti-human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
antibodies	I-Gene
was	O
verified	O
by	O
:	O
(	O
a	O
)	O
adsorption	O
of	O
[	O
3H	O
]	O
TA-receptor-antibody	B-Gene
complexes	I-Gene
to	O
Protein	O
A	O
;	O
(	O
b	O
)	O
a	O
shift	O
to	O
higher	O
apparent	O
molecular	O
weight	O
in	O
the	O
elution	O
position	O
from	O
Sephacryl	O
S300	O
of	O
[	O
3H	O
]	O
TA-receptor	B-Gene
complexes	I-Gene
incubated	O
with	O
immune	O
serum	O
;	O
and	O
(	O
c	O
)	O
the	O
ability	O
of	O
immune	O
serum	O
to	O
displace	O
[	O
3H	O
]	O
TA-receptor	B-Gene
complexes	I-Gene
on	O
sucrose	B-Chemical
gradients	O
.	O

These	O
antibodies	O
also	O
recognized	O
rat	O
liver	O
and	O
murine	O
S49	O
cell	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

Sodium	B-Chemical
dodecyl	I-Chemical
sulfate-polyacrylamide	I-Chemical
gel	O
electrophoresis	O
of	O
[	O
3H	O
]	O
DM	B-Chemical
-labeled	O
IM-9	O
cytosol	O
identified	O
a	O
major	O
competable	O
band	O
with	O
a	O
molecular	O
weight	O
of	O
approximately	O
90	O
,	O
000	O
,	O
three	O
minor	O
competable	O
components	O
with	O
molecular	O
weights	O
of	O
approximately	O
78	O
,	O
000	O
,	O
approximately	O
51	O
,	O
000	O
,	O
and	O
approximately	O
38	O
,	O
500	O
,	O
and	O
at	O
least	O
21	O
other	O
noncompetable	O
components	O
.	O

Following	O
immunoprecipitation	O
of	O
[	O
3H	O
]	O
DM	B-Chemical
-labeled	O
cytosol	O
with	O
immune	O
serum	O
,	O
only	O
the	O
Mr	O
90	O
,	O
000	O
and	O
78	O
,	O
000	O
components	O
were	O
seen	O
.	O

Sodium	B-Chemical
dodecyl	I-Chemical
sulfate-polyacrylamide	I-Chemical
gel	O
electrophoresis	O
of	O
[	O
3H	O
]	O
DM	B-Chemical
-labeled	O
CEM-C7	O
cytosol	O
revealed	O
a	O
larger	O
number	O
of	O
[	O
3H	O
]	O
DM	B-Chemical
-labeled	O
components	O
.	O

However	O
,	O
after	O
immunoprecipitation	O
of	O
[	O
3H	O
]	O
DM	B-Chemical
-labeled	O
CEM-C7	O
cytosol	O
,	O
a	O
predominant	O
competable	O
component	O
with	O
a	O
molecular	O
weight	O
of	O
90	O
,	O
000	O
was	O
easily	O
identified	O
.	O

This	O
component	O
was	O
markedly	O
diminished	O
when	O
cytosols	O
from	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
-deficient	O
cell	O
line	O
ICR-27	O
were	O
used	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
affinity	O
labeling	O
and	O
anti-human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
antibodies	I-Gene
is	O
capable	O
of	O
providing	O
direct	O
physical	O
identification	O
of	O
human	B-Gene
lymphoid	I-Gene
glucocorticoid	I-Gene
receptors	I-Gene
.	O

1	B-Chemical
,	I-Chemical
25-Dihydroxyvitamin	I-Chemical
D3	I-Chemical
inhibits	O
antigen	O
-induced	O
T	O
cell	O
activation	O
.	O

The	O
proliferative	O
response	O
of	O
murine	O
spleen	O
and	O
thymus	O
cells	O
to	O
antigen	O
but	O
not	O
to	O
lectin	B-Gene
was	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
vitamin	B-Chemical
D3	I-Chemical
,	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

To	O
directly	O
examine	O
the	O
effect	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
on	O
T	O
cell	O
activation	O
in	O
the	O
absence	O
of	O
other	O
complicating	O
interactions	O
,	O
we	O
utilized	O
a	O
panel	O
of	O
cloned	O
Ia	O
-restricted	O
T	O
cell	O
hybridomas	O
that	O
secrete	O
IL	B-Gene
2	I-Gene
on	O
activation	O
by	O
cloned	O
Ia	O
-bearing	O
stimulator	O
cells	O
(	O
TA3	O
)	O
or	O
when	O
stimulated	O
by	O
mitogen	O
.	O

Physiologic	O
concentrations	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
0.01	O
to	O
0.1	O
nm	O
)	O
inhibited	O
the	O
antigen	O
-induced	O
secretion	O
of	O
IL	B-Gene
2	I-Gene
by	O
several	O
of	O
these	O
T	O
cell	O
hybridomas	O
.	O

This	O
inhibition	O
was	O
dependent	O
on	O
the	O
concentration	O
of	O
the	O
free	O
hormone	O
and	O
could	O
be	O
overcome	O
by	O
increasing	O
the	O
number	O
of	O
Ia	O
-bearing	O
stimulator	O
cells	O
used	O
.	O

Pretreatment	O
of	O
the	O
T	O
hybridoma	O
but	O
not	O
the	O
TA3	O
stimulator	O
cell	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
resulted	O
in	O
inhibition	O
of	O
activation	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
finding	O
that	O
specific	O
1	B-Gene
,	I-Gene
25-	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
are	O
present	O
on	O
the	O
T	O
cell	O
hybridomas	O
but	O
are	O
lacking	O
in	O
TA3	O
cells	O
.	O

1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
failed	O
,	O
however	O
,	O
to	O
inhibit	O
the	O
activation	O
of	O
the	O
T	O
cell	O
hybridomas	O
by	O
lectin	B-Gene
or	O
by	O
an	O
anti-Thy-1	B-Gene
antibody	I-Gene
.	O

These	O
findings	O
suggest	O
that	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
may	O
be	O
interfering	O
with	O
early	O
events	O
of	O
antigen	O
-induced	O
T	O
cell	O
activation	O
,	O
perhaps	O
by	O
hindering	O
T	O
cell	O
recognition	O
of	O
the	O
relevant	O
antigen	O
on	O
stimulator	O
cell	O
surfaces	O
.	O

This	O
system	O
should	O
prove	O
useful	O
in	O
studying	O
the	O
molecular	O
mechanisms	O
by	O
which	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
acts	O
to	O
inhibit	O
T	O
cell	O
activation	O
and	O
subsequent	O
IL	B-Gene
2	I-Gene
production	O
.	O

Short-term	O
and	O
long-term	O
effects	O
of	O
estrogen	B-Chemical
on	O
lymphoid	O
tissues	O
and	O
lymphoid	O
cells	O
with	O
some	O
remarks	O
on	O
the	O
significance	O
for	O
carcinogenesis	O
.	O

Estrogens	B-Chemical
have	O
long	O
been	O
thought	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
immune	O
system	O
.	O

The	O
difference	O
in	O
some	O
types	O
of	O
immune	O
responses	O
between	O
males	O
and	O
females	O
is	O
well-known	O
,	O
as	O
is	O
the	O
pronounced	O
thymic	O
involution	O
induced	O
by	O
exogenous	O
estrogens	B-Chemical
.	O

Estrogens	B-Chemical
stimulate	O
some	O
aspects	O
of	O
macrophage	O
activity	O
and	O
,	O
depending	O
on	O
dose	O
and	O
mitogen	O
,	O
inhibit	O
or	O
stimulate	O
lymphocyte	O
proliferative	O
response	O
in	O
vitro	O
.	O

Another	O
example	O
is	O
the	O
estrogen	B-Chemical
effect	O
on	O
the	O
delayed	O
type	O
hypersensitivity	B-Disease
response	O
.	O

A	O
broad	O
review	O
is	O
given	O
of	O
such	O
estrogen	B-Chemical
effects	O
on	O
lymphoid	O
tissue	O
and	O
immune	O
response	O
.	O

Most	O
of	O
the	O
studies	O
published	O
so	O
far	O
are	O
phenomenological	O
.	O

However	O
,	O
the	O
recent	O
description	O
of	O
estrogen	B-Gene
receptors	I-Gene
in	O
the	O
thymus	O
and	O
in	O
some	O
lymphocyte	O
subpopulations	O
,	O
as	O
well	O
as	O
a	O
deeper	O
understanding	O
of	O
regulating	O
factors	O
in	O
the	O
immune	O
system	O
,	O
open	O
the	O
possibility	O
of	O
a	O
more	O
detailed	O
understanding	O
of	O
the	O
estrogen	B-Chemical
mechanism	O
of	O
interference	O
.	O

Estrogen	B-Chemical
effects	O
in	O
adults	O
are	O
reversible	O
.	O

After	O
treating	O
neonatal	O
mice	O
with	O
the	O
synthetic	O
estrogen	B-Chemical
diethylstilbestrol	B-Chemical
(	O
DES	B-Chemical
)	O
,	O
disturbances	O
are	O
induced	O
in	O
lymphocyte	O
populations	O
and	O
lymphocyte	O
functions	O
which	O
are	O
permanent	O
and	O
irreversible	O
.	O

Lymphocytes	O
from	O
adult	O
,	O
neonatally	O
DES	B-Chemical
-treated	O
female	O
mice	O
have	O
a	O
reduced	O
mitogen	O
response	O
to	O
ConA	B-Gene
and	O
LPS	B-Chemical
(	O
T	O
and	O
B	O
cell	O
mitogen	O
)	O
and	O
the	O
delayed	O
type	O
hypersensitivity	B-Disease
response	O
is	O
depressed	O
.	O

A	O
detailed	O
analysis	O
demonstrated	O
a	O
decreased	O
T	O
helper	O
cell	O
population	O
.	O

The	O
activity	O
of	O
Natural	O
Killer	O
cells	O
is	O
permanently	O
reduced	O
and	O
this	O
functional	O
impairment	O
is	O
related	O
to	O
a	O
decreased	O
number	O
of	O
these	O
cells	O
,	O
in	O
turn	O
determined	O
at	O
the	O
bone	O
marrow	O
level	O
.	O

The	O
same	O
animals	O
have	O
an	O
increased	O
sensitivity	O
to	O
chemical	O
carcinogens	O
(	O
methylcholanthrene	B-Chemical
)	O
and	O
they	O
spontaneously	O
develop	O
epithelial	O
changes	O
in	O
the	O
uterine	O
cervix	O
which	O
morphologically	O
are	O
similar	O
to	O
adenocarcinoma	B-Disease
.	O

The	O
association	O
between	O
estrogen	B-Chemical
-associated	O
malignancy	B-Disease
and	O
estrogen	B-Chemical
effects	O
in	O
lymphocyte	O
functions	O
deserves	O
further	O
study	O
.	O

Structure	O
and	O
regulation	O
of	O
the	O
glucocorticoid	B-Gene
hormone	I-Gene
receptor	I-Gene
.	O

The	O
glucocorticoid	B-Gene
receptor	I-Gene
is	O
an	O
intracellular	O
protein	O
which	O
possesses	O
three	O
distinct	O
domains	O
,	O
one	O
that	O
binds	O
agonist	O
and	O
antagonist	O
steroids	B-Chemical
,	O
one	O
that	O
binds	O
DNA	O
,	O
and	O
one	O
that	O
binds	O
anti-receptor	O
antibodies	O
and	O
is	O
required	O
for	O
glucocorticoid	B-Chemical
modulation	O
of	O
gene	O
expression	O
.	O

In	O
intact	O
cells	O
,	O
receptor	O
number	O
,	O
affinity	O
and	O
activity	O
can	O
change	O
in	O
response	O
to	O
factors	O
that	O
bind	O
to	O
the	O
receptor	O
,	O
or	O
that	O
act	O
indirectly	O
through	O
ill	O
-defined	O
mechanisms	O
which	O
may	O
include	O
resumption	O
or	O
arrest	O
of	O
cell	O
cycling	O
and	O
variations	O
in	O
intracellular	O
calcium	B-Chemical
ion	O
concentrations	O
.	O

Some	O
of	O
these	O
factors	O
appear	O
to	O
exert	O
their	O
effect	O
by	O
controlling	O
critical	O
receptor	O
properties	O
such	O
as	O
ATP	B-Chemical
-dependent	O
phosphorylation	O
,	O
integrity	O
of	O
thiol	B-Chemical
groups	O
,	O
and	O
exposure	O
of	O
key	O
amino	O
acid	O
residues	O
.	O

Glucocorticoid	B-Chemical
agonists	O
promote	O
the	O
'transformation	O
'of	O
the	O
receptor	O
into	O
the	O
DNA	O
-binding	O
state	O
,	O
which	O
is	O
competent	O
for	O
modulating	O
gene	O
expression	O
.	O

Glucocorticoid	B-Chemical
antagonists	O
are	O
steroids	B-Chemical
that	O
interact	O
with	O
the	O
receptor	O
but	O
either	O
fail	O
to	O
produce	O
a	O
stable	O
complex	O
or	O
produce	O
a	O
stable	O
but	O
inefficient	O
complex	O
.	O

Although	O
substituent	O
groups	O
that	O
confer	O
agonist	O
or	O
antagonist	O
activity	O
to	O
the	O
steroid	B-Chemical
have	O
been	O
identified	O
,	O
the	O
molecular	O
determinants	O
of	O
this	O
difference	O
at	O
the	O
receptor	O
level	O
remain	O
unknown	O
.	O

Most	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
on	O
receptor	O
regulation	O
can	O
be	O
accommodated	O
by	O
postulating	O
the	O
existence	O
of	O
an	O
intracellular	O
cycle	O
that	O
involves	O
five	O
states	O
of	O
the	O
receptor	O
.	O

The	O
active	O
free	O
receptor	O
is	O
phosphorylated	O
,	O
reduced	O
,	O
and	O
presumably	O
oligomeric	O
(	O
state	O
A	O
)	O
.	O

Following	O
binding	O
of	O
an	O
agonist	O
(	O
state	O
B	O
)	O
,	O
it	O
can	O
become	O
transformed	O
by	O
dissociation	O
into	O
its	O
subunits	O
and	O
dephosphorylation	O
(	O
state	O
C	O
)	O
.	O

The	O
transformed	O
receptor	O
then	O
interacts	O
with	O
chromatin	O
(	O
state	O
D	O
)	O
.	O

Dissociation	O
of	O
the	O
steroid	B-Chemical
and	O
oxidation	O
of	O
receptor	O
thiol	B-Chemical
group	O
(	O
s	O
)	O
lead	O
to	O
the	O
inactive	O
receptor	O
form	O
(	O
state	O
E	O
)	O
.	O

Reduction	O
and	O
rephosphorylation	O
of	O
the	O
receptor	O
enable	O
it	O
to	O
bind	O
steroids	B-Chemical
again	O
so	O
that	O
the	O
cycle	O
is	O
closed	O
.	O

Drugs	O
affecting	O
the	O
hormonal	O
receptors	O
of	O
normal	O
and	O
leukaemic	O
peripheral	O
leucocytes	O
.	O

The	O
authors	O
investigated	O
the	O
behaviour	O
of	O
steroid	B-Chemical
hormone	I-Chemical
uptake	O
in	O
leukaemic	O
cells	O
(	O
CML	B-Disease
,	O
CLL	B-Disease
,	O
AML	B-Disease
,	O
ALL	B-Disease
)	O
,	O
in	O
basal	O
conditions	O
and	O
after	O
incubation	O
with	O
drugs	O
which	O
modify	O
the	O
cellular	O
concentration	O
of	O
cAMP	B-Chemical
,	O
PGE	B-Chemical
and	O
PGF	B-Chemical
.	O

The	O
results	O
demonstrated	O
the	O
presence	O
in	O
leukaemic	O
cells	O
of	O
an	O
alteration	O
in	O
the	O
incorporation	O
of	O
steroid	B-Chemical
hormones	I-Chemical
.	O

This	O
alteration	O
was	O
scarcely	O
modified	O
by	O
incubation	O
with	O
theophylline	B-Chemical
,	O
which	O
increases	O
cellular	O
concentration	O
of	O
cAMP	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
was	O
moderately	O
counteracted	O
by	O
thioproline	B-Chemical
and	O
was	O
evidently	O
inhibited	O
by	O
flurbiprofen	B-Chemical
,	O
which	O
also	O
reduced	O
cellular	O
concentrations	O
of	O
prostaglandins	B-Chemical
,	O
particularly	O
PGE2	B-Chemical
,	O
with	O
the	O
exception	O
of	O
PGF2	B-Chemical
which	O
showed	O
a	O
poor	O
response	O
.	O

Differences	O
were	O
observed	O
in	O
the	O
behavior	O
of	O
hormonal	O
uptake	O
of	O
CML	B-Disease
,	O
in	O
contrast	O
to	O
that	O
of	O
AML	B-Disease
,	O
CLL	B-Disease
and	O
ALL	B-Disease
peripheral	O
leucocytes	O
.	O

Characterization	O
of	O
aldosterone	B-Chemical
binding	O
sites	O
in	O
circulating	O
human	O
mononuclear	O
leukocytes	O
.	O

Aldosterone	B-Chemical
binding	O
sites	O
in	O
human	O
mononuclear	O
leukocytes	O
were	O
characterized	O
after	O
separation	O
of	O
cells	O
from	O
blood	O
by	O
a	O
Percoll	O
gradient	O
.	O

After	O
washing	O
and	O
resuspension	O
in	O
RPMI-1640	O
medium	O
,	O
cells	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
1	O
h	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
aldosterone	B-Chemical
plus	O
a	O
100-fold	O
concentration	O
of	O
RU-26988	B-Chemical
(	O
11	B-Chemical
alpha	I-Chemical
,	I-Chemical
17	I-Chemical
alpha-dihydroxy-17	I-Chemical
beta-propynylandrost-1	I-Chemical
,	I-Chemical
4	I-Chemical
,	I-Chemical
6-trien-3-one	I-Chemical
)	O
,	O
with	O
or	O
without	O
an	O
excess	O
of	O
unlabeled	O
aldosterone	B-Chemical
.	O

Aldosterone	B-Chemical
binds	O
to	O
a	O
single	O
class	O
of	O
receptors	O
with	O
an	O
affinity	O
of	O
2.7	O
+	O
/	O
-	O
0.5	O
nM	O
(	O
means	O
+	O
/	O
-	O
SD	O
,	O
n	O
=	O
14	O
)	O
and	O
a	O
capacity	O
of	O
290	O
+	O
/	O
-	O
108	O
sites	O
/	O
cell	O
(	O
n	O
=	O
14	O
)	O
.	O

The	O
specificity	O
data	O
show	O
a	O
hierarchy	O
of	O
affinity	O
of	O
desoxycorticosterone	B-Chemical
=	O
corticosterone	B-Chemical
=	O
aldosterone	B-Chemical
greater	O
than	O
hydrocortisone	B-Chemical
greater	O
than	O
dexamethasone	B-Chemical
.	O

The	O
results	O
indicate	O
that	O
mononuclear	O
leukocytes	O
could	O
be	O
useful	O
for	O
studying	O
the	O
physiological	O
significance	O
of	O
these	O
mineralocorticoid	B-Gene
receptors	I-Gene
and	O
their	O
regulation	O
in	O
humans	O
.	O

Primary	O
cortisol	B-Chemical
resistance	O
accompanied	O
by	O
a	O
reduction	O
in	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
two	O
members	O
of	O
the	O
same	O
family	O
.	O

This	O
report	O
describes	O
studies	O
of	O
a	O
man	O
suspected	O
of	O
having	O
primary	O
cortisol	B-Chemical
resistance	O
.	O

This	O
conclusion	O
is	O
based	O
on	O
his	O
high	O
plasma	O
cortisol	B-Chemical
levels	O
and	O
high	O
24-h	O
urinary	O
17-hydroxycorticosteroid	B-Chemical
and	O
cortisol	B-Chemical
excretion	O
,	O
plus	O
the	O
fact	O
that	O
he	O
had	O
no	O
manifestations	O
of	O
Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
.	O

Among	O
family	O
members	O
tested	O
,	O
his	O
mother	O
also	O
had	O
hypercortisolemia	B-Disease
.	O

Both	O
mother	O
and	O
son	O
had	O
high	O
levels	O
of	O
unbound	O
plasma	O
cortisol	B-Chemical
,	O
but	O
their	O
plasma	B-Gene
ACTH	I-Gene
concentrations	O
were	O
within	O
the	O
normal	O
range	O
.	O

Both	O
were	O
partially	O
resistant	O
to	O
dexamethasone	B-Chemical
adrenal	O
suppression	O
,	O
and	O
both	O
had	O
mild	B-Disease
hypertension	I-Disease
without	O
hypokalemia	O
.	O

To	O
study	O
this	O
apparent	O
end-organ	O
resistance	O
to	O
cortisol	B-Chemical
,	O
we	O
examined	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
peripheral	O
mononuclear	O
cells	O
.	O

Using	O
whole	O
cell	O
assays	O
,	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
both	O
patients	O
were	O
found	O
to	O
have	O
reduced	O
total	O
binding	O
capacity	O
.	O

We	O
conclude	O
that	O
these	O
two	O
patients	O
,	O
members	O
of	O
the	O
same	O
family	O
,	O
have	O
primary	O
cortisol	B-Chemical
resistance	O
accompanied	O
by	O
a	O
reduced	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

Plasmacytoid	O
blast	O
crisis	O
in	O
B-cell	B-Disease
chronic	I-Disease
lymphocytic	I-Disease
leukemia	I-Disease
:	O
effect	O
of	O
estradiol	B-Chemical
on	O
growth	O
and	O
differentiation	O
in	O
vitro	O
.	O

Evolution	O
of	O
a	O
case	O
of	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
(	O
CLL	B-Disease
)	O
into	O
blast	O
crisis	O
was	O
found	O
to	O
be	O
characterized	O
by	O
three	O
unusual	O
features	O
(	O
1	O
)	O
the	O
phenotype	O
of	O
the	O
emerging	O
blast	O
cells	O
was	O
that	O
of	O
pre-plasmacytoid	O
cells	O
as	O
shown	O
by	O
plasma	O
cell	O
morphology	O
and	O
an	O
immunological	O
phenotype	O
corresponding	O
partially	O
with	O
CLL-	B-Disease
or	O
intermediate	O
B-cells	O
,	O
partially	O
with	O
plasma	O
cells	O
(	O
terminal	B-Gene
transferase	I-Gene
-	O
,	O
common	B-Gene
acute	I-Gene
lymphocytic	I-Gene
leukemia	I-Gene
antigen	I-Gene
-	O
,	O
Ia+	B-Gene
,	O
surface	B-Gene
immunoglobulin	I-Gene
heavy	I-Gene
chains	I-Gene
-	O
,	O
surface	O
kappa	O
light	O
chains	O
+	O
,	O
intracytoplasmic	B-Gene
immunoglobulin	I-Gene
A+	I-Gene
and	O
G+	B-Partial_Gene
,	O
BA-1+	B-Gene
,	O
polyclonal	B-Gene
gammaglobulin	I-Gene
production	O
)	O
;	O
(	O
2	O
)	O
cytogenetic	O
analysis	O
of	O
spontaneous	O
metaphases	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
typical	O
CLL	B-Disease
abnormality	O
,	O
trisomy	O
12	O
,	O
in	O
all	O
of	O
the	O
cells	O
,	O
an	O
additional	O
translocation	O
between	O
chromosomes	O
14	O
and	O
17	O
was	O
present	O
in	O
40	O
%	O
with	O
a	O
presumptive	O
breakpoint	O
on	O
chromosome	O
14	O
(	O
q12-3	O
)	O
never	O
described	O
before	O
(	O
commonly	O
q32	O
)	O
and	O
(	O
3	O
)	O
the	O
progression	O
of	O
the	O
disease	O
was	O
associated	O
with	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
by	O
the	O
transformed	O
cells	O
of	O
specific	O
binding	O
sites	O
for	O
estradiol	B-Chemical
(	O
E2	B-Chemical
)	O
due	O
to	O
an	O
actual	O
increase	O
in	O
total	O
cellular	O
receptor	O
proteins	O
and	O
not	O
to	O
a	O
change	O
in	O
receptor	O
affinity	O
for	O
E2	B-Chemical
.	O

The	O
functional	O
status	O
of	O
the	O
steroid	B-Gene
receptors	I-Gene
was	O
confirmed	O
by	O
nuclear	O
transfer	O
of	O
the	O
cytoplasmic	O
hormone-receptor	O
complex	O
upon	O
temperature	O
activation	O
.	O

Since	O
the	O
rise	O
in	O
E2-receptor	B-Gene
display	O
paralleled	O
a	O
large	O
increase	O
in	O
the	O
proliferative	O
activity	O
of	O
the	O
cells	O
as	O
well	O
as	O
a	O
change	O
in	O
their	O
maturation	O
status	O
the	O
question	O
was	O
raised	O
as	O
to	O
whether	O
the	O
E2-receptor	B-Gene
should	O
be	O
considered	O
as	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
of	O
cellular	O
differentiation	O
.	O

Exposure	O
of	O
the	O
patient	O
's	O
blast	O
cells	O
to	O
E2	B-Chemical
in	O
vitro	O
resulted	O
in	O
cessation	O
of	O
cell	O
growth	O
following	O
at	O
least	O
one	O
mitosis	O
after	O
addition	O
of	O
the	O
inducer	O
as	O
seen	O
from	O
the	O
replacement	O
of	O
the	O
large	O
blasts	O
by	O
small	O
CLL	B-Disease
-like	O
cells	O
without	O
definite	O
signs	O
of	O
alteration	O
of	O
the	O
differentiation	O
status	O
.	O

This	O
suggests	O
the	O
association	O
of	O
E2-receptor	B-Gene
expression	O
with	O
control	O
of	O
growth	O
rather	O
than	O
cell	O
maturation	O
.	O

Mononuclear	O
cells	O
infiltrating	O
human	O
mammary	B-Disease
carcinomas	I-Disease
:	O
immunohistochemical	O
analysis	O
with	O
monoclonal	O
antibodies	O
.	O

Breast	B-Disease
carcinomas	I-Disease
were	O
examined	O
by	O
the	O
immunoperoxidase	O
technique	O
using	O
antisera	O
specific	O
for	O
lymphocyte	O
subsets	O
,	O
monocytes	O
,	O
NK	O
cells	O
and	O
major	B-Gene
histocompatibility	I-Gene
antigens	I-Gene
(	O
HLA-A	B-Gene
,	O
-B	B-Partial_Gene
,	O
-C	B-Partial_Gene
;	O
Ia	B-Partial_Gene
-like	I-Partial_Gene
)	O
.	O

Sixty-four	O
per	O
cent	O
of	O
the	O
patients	O
had	O
a	O
moderate	O
or	O
strong	O
mononuclear	O
cell	O
infiltration	O
,	O
77	O
%	O
of	O
the	O
patients	O
without	O
mononuclear	O
cell	O
infiltration	O
had	O
receptors	O
for	O
estrogens	B-Chemical
as	O
compared	O
to	O
51	O
%	O
of	O
the	O
patients	O
with	O
infiltration	O
.	O

The	O
majority	O
of	O
the	O
infiltrating	O
mononuclear	O
cells	O
were	O
T	O
cells	O
;	O
generally	O
the	O
OKT8	O
cells	O
were	O
predominant	O
.	O

The	O
Leu	O
3A	O
/	O
OKT8	O
cell	O
ratio	O
was	O
not	O
related	O
to	O
histological	O
type	O
,	O
tumor	B-Disease
size	O
,	O
age	O
of	O
the	O
patient	O
or	O
presence	O
of	O
metastases	O
.	O

Some	O
of	O
the	O
T	O
cells	O
had	O
the	O
Ia	O
antigen	O
and	O
were	O
thus	O
probably	O
activated	O
.	O

The	O
B	O
cells	O
were	O
either	O
absent	O
or	O
less	O
numerous	O
than	O
the	O
T	O
cells	O
.	O

There	O
was	O
no	O
relation	O
between	O
their	O
distribution	O
and	O
the	O
various	O
parameters	O
studied	O
.	O

A	O
few	O
monocytes	O
were	O
heterogeneous	O
according	O
to	O
their	O
markers	O
(	O
OKM	O
I	O
and	O
acid	B-Gene
phosphatase	I-Gene
)	O
.	O

In	O
6	O
cases	O
only	O
there	O
was	O
a	O
strong	O
infiltration	O
of	O
mononuclear	O
cells	O
positive	O
for	O
acid	B-Gene
phosphatase	I-Gene
.	O

The	O
number	O
of	O
the	O
natural	O
killer	O
cells	O
was	O
also	O
low	O
.	O

Only	O
a	O
few	O
mononuclear	O
infiltrating	O
cells	O
had	O
receptors	O
for	O
transferrin	B-Gene
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
inflammatory	O
infiltration	O
and	O
the	O
presence	O
of	O
HLA	B-Gene
class-I	I-Gene
antigens	I-Gene
on	O
tumor	B-Disease
cell	O
s	O
.	O

Some	O
of	O
the	O
antisera	O
specific	O
for	O
lymphocyte	O
subsets	O
also	O
stained	O
the	O
breast	B-Disease
carcinoma	I-Disease
cells	O
.	O

The	O
great	O
variations	O
in	O
the	O
subsets	O
of	O
mononuclear	O
cells	O
in	O
breast	B-Disease
carcinomas	I-Disease
may	O
correspond	O
to	O
various	O
systems	O
of	O
defense	O
against	O
neoplasm	O
.	O

Interleukin	B-Gene
2	I-Gene
receptor	I-Gene
(	O
Tac	B-Gene
antigen	I-Gene
)	O
expression	O
in	O
HTLV-I	O
-associated	O
adult	B-Disease
T-cell	I-Disease
leukemia	I-Disease
.	O

Interleukin-2	B-Gene
(	O
IL-2	B-Gene
)	O
is	O
a	O
lymphokine	O
synthesized	O
by	O
some	O
T-cells	O
following	O
activation	O
.	O

Resting	O
T-cells	O
do	O
not	O
express	O
IL-2	B-Gene
receptors	I-Gene
,	O
but	O
receptors	O
are	O
rapidly	O
expressed	O
on	O
T-cells	O
following	O
interaction	O
of	O
antigens	O
,	O
mitogens	O
,	O
or	O
monoclonal	O
antibodies	O
with	O
the	O
antigen-specific	O
T-cell	B-Gene
receptor	I-Gene
complex	I-Gene
.	O

Using	O
anti-Tac	B-Gene
,	O
a	O
monoclonal	O
antibody	O
that	O
recognizes	O
the	O
IL-2	B-Gene
receptor	I-Gene
,	O
the	O
receptor	O
has	O
been	O
purified	O
and	O
shown	O
to	O
be	O
a	O
Mr	O
33	O
,	O
000	O
peptide	O
that	O
is	O
posttranslationally	O
glycosylated	O
to	O
a	O
Mr	O
55	O
,	O
000	O
mature	O
form	O
.	O

Normal	O
resting	O
T-cells	O
and	O
most	O
leukemic	O
T-cell	O
populations	O
do	O
not	O
express	O
IL-2	B-Gene
receptors	I-Gene
;	O
however	O
,	O
the	O
leukemic	O
cells	O
of	O
the	O
11	O
patients	O
examined	O
who	O
had	O
human	O
T-cell	O
lymphotropic	O
virus	O
-associated	O
adult	B-Disease
T-cell	I-Disease
leukemia	I-Disease
expressed	O
the	O
Tac	B-Gene
antigen	I-Gene
.	O

In	O
human	O
T-cell	O
lymphotropic	O
virus-I	O
infected	O
cells	O
,	O
the	O
Mr	O
42	O
,	O
000	O
long	O
open	O
reading	O
frame	O
protein	O
encoded	O
in	O
part	O
by	O
the	O
pX	B-Gene
region	O
of	O
this	O
virus	O
may	O
act	O
as	O
a	O
transacting	O
transcriptional	O
activator	O
that	O
induces	O
IL-2	B-Gene
receptor	I-Gene
gene	I-Gene
transcription	O
,	O
thus	O
providing	O
an	O
explanation	O
for	O
the	O
constant	O
association	O
of	O
IL-2	B-Gene
receptor	I-Gene
expression	O
with	O
adult	O
T-cell	O
lymphotropic	O
virus-I	O
infection	O
of	O
lymphoid	O
cells	O
.	O

The	O
constant	O
expression	O
of	O
large	O
numbers	O
of	O
IL-2	B-Gene
receptors	I-Gene
which	O
may	O
be	O
aberrant	O
may	O
play	O
a	O
role	O
in	O
the	O
uncontrolled	O
growth	O
of	O
adult	B-Disease
T-cell	I-Disease
leukemia	I-Disease
cells	O
.	O

Two	O
patients	O
with	O
Tac	B-Gene
-positive	O
adult	B-Disease
T-cell	I-Disease
leukemia	I-Disease
have	O
been	O
treated	O
with	O
the	O
anti-Tac	B-Gene
.	O

One	O
of	O
the	O
patients	O
had	O
6-	O
and	O
3-mo	O
remissions	O
of	O
his	O
leukemia	B-Disease
following	O
two	O
courses	O
of	O
therapy	O
with	O
this	O
monoclonal	O
antibody	O
directed	O
toward	O
this	O
growth	O
factor	O
receptor	O
.	O

A	O
controlled	O
pore	O
glass	O
bead	O
assay	O
for	O
the	O
measurement	O
of	O
cytoplasmic	O
and	O
nuclear	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
.	O

An	O
assay	O
for	O
the	O
quantitation	O
of	O
cytoplasmic	O
and	O
nuclear	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
in	O
lymphoid	O
tissue	O
has	O
been	O
developed	O
using	O
controlled	O
pore	O
glass	O
(	O
CPG	B-Chemical
)	O
beads	O
.	O

Soluble	O
receptor	O
--	O
3H-steroid	B-Gene
complex	I-Gene
(	O
cytosol	O
or	O
nuclear	O
extract	O
)	O
is	O
adsorbed	O
quantitatively	O
within	O
the	O
crevasses	O
of	O
porous	O
glass	O
beads	O
.	O

Excess	O
labeled	O
steroid	B-Chemical
as	O
well	O
as	O
most	O
non-specifically	O
bound	O
steroid	B-Chemical
is	O
easily	O
washed	O
away	O
,	O
leaving	O
the	O
hormone-receptor	O
complex	O
retained	O
by	O
the	O
beads	O
.	O

Bound	O
3H-steroid	B-Gene
is	O
eluted	O
with	O
ethanol	B-Chemical
and	O
measured	O
for	O
radioactivity	O
.	O

This	O
procedure	O
which	O
is	O
simple	O
,	O
rapid	O
,	O
and	O
highly	O
reproducible	O
is	O
carried	O
out	O
using	O
frozen	O
samples	O
(	O
stable	O
for	O
many	O
months	O
)	O
containing	O
as	O
few	O
as	O
1	O
X	O
10	O
(	O
7	O
)	O
cells	O
.	O

A	O
comparison	O
of	O
the	O
CPG	B-Chemical
assay	O
to	O
dextran	B-Chemical
coated	O
charcoal	B-Chemical
and	O
a	O
whole	O
cell	O
assay	O
demonstrates	O
that	O
CPG	B-Chemical
and	O
dextran	B-Chemical
coated	O
charcoal	B-Chemical
give	O
equivalent	O
measurements	O
of	O
cytosolic	O
receptor	O
concentration	O
,	O
while	O
the	O
CPG	B-Chemical
and	O
whole	O
cell	O
assays	O
provide	O
equivalent	O
values	O
for	O
total	O
receptor	O
content	O
.	O

[	O
3H	O
]	O
cortivazol	B-Chemical
:	O
a	O
unique	O
high	O
affinity	O
ligand	O
for	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

Cortivazol	B-Chemical
(	O
CVZ	B-Chemical
)	O
and	O
deacylcortivazol	B-Chemical
(	O
DAC	B-Chemical
)	O
are	O
pyrazolosteroids	B-Chemical
with	O
potent	O
glucocorticoid	B-Chemical
activity	O
.	O

In	O
previous	O
work	O
we	O
showed	O
that	O
DAC	B-Chemical
is	O
40-fold	O
more	O
potent	O
than	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)	O
in	O
lysing	O
leukemic	O
lymphoblasts	O
.	O

To	O
assess	O
the	O
interaction	O
between	O
these	O
atypical	O
steroids	B-Chemical
and	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
,	O
we	O
examined	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	B-Chemical
to	O
cytosol	O
from	O
glucocorticoid	B-Chemical
-sensitive	O
and	O
-resistant	O
variants	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
C7	O
.	O

In	O
glucocorticoid	B-Chemical
-sensitive	O
cells	O
[	O
3H	O
]	O
CVZ	B-Chemical
causes	O
a	O
2-fold	O
induction	O
of	O
glutamine	B-Gene
synthetase	I-Gene
and	O
binds	O
to	O
a	O
protein	O
in	O
the	O
4.6	O
S	O
region	O
of	O
high	O
salt	O
sucrose	O
gradients	O
.	O

On	O
DEAE-cellulose	O
chromatography	O
,	O
[	O
3H	O
]	O
CVZ-receptor	B-Chemical
complexes	O
show	O
a	O
shift	O
from	O
high	O
(	O
0.25	O
M	O
KP	O
)	O
to	O
low	O
salt	O
(	O
0.09	O
M	O
KP	O
)	O
eluting	O
forms	O
upon	O
activation	O
.	O

CVZ	B-Chemical
competes	O
for	O
a	O
97	O
,	O
000-dalton	O
protein	O
labeled	O
by	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
mesylate	I-Chemical
.	O

Scatchard	O
analysis	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	B-Chemical
in	O
glucocorticoid	B-Chemical
-sensitive	O
cells	O
revealed	O
a	O
curvilinear	O
plot	O
which	O
resolved	O
into	O
high	O
(	O
0.4	O
nM	O
)	O
and	O
low	O
(	O
11	O
nM	O
)	O
affinity	O
components	O
.	O

The	O
receptor	O
concentration	O
of	O
the	O
low	O
affinity	O
site	O
(	O
0.30	O
pmol	O
/	O
mg	O
protein	O
)	O
was	O
approximately	O
twice	O
that	O
of	O
the	O
high	O
affinity	O
site	O
(	O
0.14	O
pmol	O
/	O
mg	O
protein	O
)	O
.	O

Dissociation	O
experiments	O
with	O
dilution	O
and	O
/	O
or	O
excess	O
unlabeled	O
CVZ	B-Chemical
supported	O
the	O
presence	O
of	O
independent	O
sites	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
[	O
3H	O
]	O
DEX	B-Chemical
to	O
C7	O
cytosol	O
revealed	O
a	O
single	O
class	O
of	O
binding	O
sites	O
(	O
Kd	O
=	O
1.9	O
nM	O
;	O
receptor	O
concentration	O
,	O
0.46	O
pmol	O
/	O
mg	O
protein	O
)	O
.	O

Examination	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
CVZ	B-Chemical
using	O
10	O
(	O
-5	O
)	O
M	O
DEX	B-Chemical
as	O
the	O
competing	O
ligand	O
showed	O
that	O
DEX	B-Chemical
binds	O
only	O
to	O
the	O
low	O
affinity	O
site	O
detected	O
by	O
[	O
3H	O
]	O
CVZ	B-Chemical
.	O

In	O
cytosol	O
from	O
a	O
glucocorticoid	B-Chemical
-resistant	O
cell	O
line	O
with	O
virtually	O
no	O
[	O
3H	O
]	O
DEX	B-Chemical
binding	O
,	O
[	O
3H	O
]	O
CVZ	B-Chemical
detected	O
a	O
single	O
high	O
affinity	O
binding	O
site	O
that	O
was	O
similar	O
in	O
dissociation	O
constant	O
(	O
0.8	O
nM	O
)	O
and	O
receptor	O
concentration	O
(	O
0.13	O
pmol	O
/	O
mg	O
protein	O
)	O
to	O
the	O
high	O
affinity	O
site	O
detected	O
in	O
the	O
glucocorticoid	B-Chemical
-sensitive	O
cell	O
line	O
C7	O
.	O

Differential	O
protection	O
of	O
normal	O
and	O
malignant	O
human	O
myeloid	O
progenitors	O
(	O
CFU-GM	O
)	O
from	O
Ara-C	B-Chemical
toxicity	O
using	O
cycloheximide	B-Chemical
.	O

Cycloheximide	B-Chemical
,	O
a	O
reversible	O
protein	O
synthesis	O
inhibitor	O
,	O
is	O
thought	O
to	O
block	O
DNA	O
replication	O
in	O
normal	O
cells	O
by	O
preventing	O
synthesis	O
of	O
a	O
labile	O
protein	O
.	O

In	O
animal	O
systems	O
,	O
cycloheximide	B-Chemical
protects	O
normal	O
cells	O
from	O
cytotoxic	O
S-phase	O
specific	O
agents	O
,	O
such	O
as	O
cytosine	B-Chemical
arabinoside	I-Chemical
(	O
Ara-C	B-Chemical
)	O
.	O

Malignant	O
cells	O
appear	O
not	O
to	O
be	O
susceptible	O
to	O
cycloheximide	B-Chemical
-induced	O
cycle	O
arrest	O
and	O
,	O
subsequently	O
,	O
may	O
not	O
be	O
protected	O
from	O
Ara-C	B-Chemical
cytotoxicity	O
.	O

The	O
effect	O
of	O
cycloheximide	B-Chemical
on	O
granulocyte	O
/	O
macrophage	O
progenitors	O
(	O
CFU-GM	O
)	O
after	O
in	O
vitro	O
Ara-C	B-Chemical
exposure	O
was	O
examined	O
using	O
normal	O
human	O
bone	O
marrow	O
,	O
malignant	O
progenitors	O
from	O
patients	O
with	O
chronic	B-Disease
myelogenous	I-Disease
leukemia	I-Disease
(	O
CML	B-Disease
)	O
,	O
and	O
clonogenic	O
cells	O
from	O
the	O
human	O
acute	B-Disease
nonlymphocytic	I-Disease
leukemia	I-Disease
cell	O
lines	O
HL-60	O
and	O
KG-1	O
.	O

Mononuclear	O
or	O
clonogenic	O
cells	O
were	O
incubated	O
for	O
one	O
hour	O
with	O
cycloheximide	B-Chemical
,	O
followed	O
by	O
the	O
addition	O
,	O
for	O
three	O
or	O
17	O
hours	O
,	O
of	O
Ara-C	B-Chemical
before	O
being	O
plated	O
in	O
a	O
methylcellulose	O
culture	O
system	O
.	O

CFU-GM	O
survival	O
was	O
significantly	O
increase	O
if	O
normal	O
cells	O
were	O
treated	O
with	O
cycloheximide	B-Chemical
before	O
Ara-C	B-Chemical
exposure	O
.	O

Similar	O
cycloheximide	B-Chemical
pretreatment	O
of	O
CML	B-Disease
progenitors	O
and	O
clonogenic	O
HL-60	O
and	O
KG-1	O
cells	O
failed	O
to	O
protect	O
CFU-GM	O
from	O
Ara-C	B-Chemical
-induced	O
cytotoxicity	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
of	O
mononuclear	O
leukocytes	O
from	O
myasthenia	B-Disease
gravis	I-Disease
patients	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
analyse	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
binding	O
in	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
from	O
39	O
myasthenia	B-Disease
gravis	I-Disease
(	O
MG	B-Disease
)	O
patients	O
(	O
unoperated	O
patients	O
(	O
n	O
=	O
13	O
)	O
,	O
thymectomized	O
patients	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
receiving	O
glucocorticoids	B-Chemical
:	O
thymectomized	O
(	O
n	O
=	O
11	O
)	O
and	O
unoperated	O
(	O
n	O
=	O
6	O
]	O
.	O

A	O
whole	O
cell	O
binding	O
assay	O
with	O
3	O
(	O
H	O
)	O
dexamethasone	B-Chemical
was	O
used	O
.	O

GR	B-Gene
mean	O
values	O
were	O
significantly	O
higher	O
in	O
the	O
MNL	O
of	O
MG	B-Disease
patients	O
(	O
thymectomized	O
or	O
not	O
)	O
not	O
receiving	O
glucocorticoid	B-Chemical
than	O
in	O
the	O
MNL	O
of	O
healthy	O
donors	O
.	O

Affinity	O
was	O
within	O
the	O
normal	O
range	O
.	O

Sex	O
,	O
age	O
or	O
clinical	O
forms	O
of	O
illness	O
did	O
not	O
influence	O
the	O
results	O
.	O

In	O
patients	O
receiving	O
prednisone	B-Chemical
(	O
Pd	B-Chemical
)	O
the	O
GR	B-Gene
values	O
were	O
significantly	O
lower	O
than	O
in	O
MG	B-Disease
patients	O
without	O
Pd	B-Chemical
therapy	O
,	O
independent	O
of	O
Pd	B-Chemical
dose	O
or	O
time	O
of	O
administration	O
.	O

No	O
differences	O
in	O
receptor	O
binding	O
between	O
normal	O
subjects	O
and	O
MG	B-Disease
patients	O
receiving	O
Pd	B-Chemical
have	O
been	O
found	O
.	O

Correlation	O
of	O
steroid	B-Gene
receptors	I-Gene
with	O
histologic	O
differentiation	O
in	O
mammary	B-Disease
carcinoma	I-Disease
.	O

A	O
Singapore	O
experience	O
.	O

Cancer	B-Disease
of	O
the	O
breast	O
is	O
the	O
most	O
common	O
tumor	B-Disease
in	O
females	O
in	O
Singapore	O
,	O
with	O
the	O
rate	O
of	O
20.7	O
per	O
100	O
,	O
000	O
per	O
year	O
(	O
1977	O
estimate	O
)	O
,	O
which	O
is	O
predicted	O
to	O
increase	O
to	O
29.8	O
per	O
100	O
,	O
000	O
women	O
per	O
year	O
by	O
1995	O
.	O

A	O
detailed	O
histopathologic	O
review	O
of	O
50	O
primary	O
breast	B-Disease
cancer	I-Disease
tumors	I-Disease
analyzed	O
for	O
estrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
level	O
was	O
carried	O
out	O
and	O
a	O
variety	O
of	O
morphologic	O
features	O
correlated	O
with	O
ER	B-Gene
results	O
to	O
identify	O
any	O
factors	O
that	O
will	O
improve	O
the	O
management	O
and	O
prognosis	O
for	O
breast	B-Disease
cancer	I-Disease
.	O

Cytosol	O
was	O
incubated	O
with	O
3H-estradiol	B-Chemical
in	O
the	O
presence	O
and	O
absence	O
of	O
cold	O
diethylstilbestrol	B-Chemical
,	O
and	O
bound	O
and	O
free	O
hormone	O
were	O
separated	O
by	O
Dextran	O
-coated	O
charcoal	O
method	O
.	O

Tumors	B-Disease
binding	O
more	O
than	O
5	O
fmol	O
/	O
mg	O
cytosol	O
protein	O
were	O
classified	O
as	O
ER	B-Gene
-positive	O
.	O

Progesterone	B-Gene
receptor	I-Gene
(	O
PR	B-Gene
)	O
level	O
was	O
analyzed	O
in	O
some	O
specimens	O
with	O
the	O
use	O
of	O
a	O
similar	O
method	O
.	O

Most	O
of	O
the	O
patients	O
were	O
Chinese	O
(	O
90	O
%	O
)	O
.	O

Three	O
patients	O
were	O
Malays	O
,	O
one	O
was	O
Indian	O
,	O
and	O
one	O
was	O
European	O
in	O
this	O
series	O
.	O

Results	O
indicated	O
that	O
there	O
was	O
strong	O
correlation	O
between	O
ER	B-Gene
level	O
,	O
age	O
,	O
and	O
histologic	O
grade	O
of	O
the	O
tumors	B-Disease
.	O

No	O
correlation	O
existed	O
between	O
absence	O
or	O
presence	O
of	O
lymph	O
node	O
metastases	O
and	O
ER	B-Gene
.	O

Although	O
there	O
was	O
a	O
trend	O
for	O
ER	B-Gene
-positive	O
tumors	B-Disease
to	O
have	O
a	O
low-grade	O
lymphocytic	O
infiltration	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Mineralocorticoid	B-Chemical
and	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
circulating	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
primary	B-Disease
hyperaldosteronism	I-Disease
.	O

Mineralocorticoid	B-Chemical
and	O
glucocorticoid	B-Gene
receptors	I-Gene
were	O
measured	O
in	O
circulating	O
mononuclear	O
leukocytes	O
in	O
5	O
patients	O
affected	O
by	O
Conn	B-Disease
's	I-Disease
syndrome	I-Disease
(	O
3	O
cases	O
of	O
bilateral	O
adrenal	B-Disease
hyperplasia	I-Disease
and	O
2	O
cases	O
of	O
adenoma	B-Disease
plus	O
unilateral	O
hyperplasia	O
)	O
.	O

The	O
number	O
of	O
the	O
binding	O
sites	O
per	O
cell	O
resulted	O
significantly	O
lower	O
(	O
189	O
+	O
/	O
-	O
114	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
,	O
as	O
compared	O
with	O
the	O
normal	O
controls	O
(	O
298	O
+	O
/	O
-	O
105	O
)	O
.	O

The	O
affinity	O
of	O
aldosterone	B-Chemical
for	O
the	O
receptor	O
was	O
found	O
to	O
be	O
not	O
different	O
than	O
that	O
of	O
healthy	O
control	O
subjects	O
.	O

The	O
capacity	O
and	O
the	O
affinity	O
of	O
dexamethasone	B-Chemical
for	O
glucocorticoid	B-Gene
receptors	I-Gene
ranged	O
in	O
the	O
normal	O
values	O
.	O

These	O
data	O
suggest	O
a	O
possible	O
down-regulation	O
of	O
mineralocorticoid	B-Gene
receptors	I-Gene
in	O
humans	O
.	O

Therapeutic	O
concentrations	O
of	O
glucocorticoids	B-Chemical
suppress	O
the	O
antimicrobial	O
activity	O
of	O
human	O
macrophages	O
without	O
impairing	O
their	O
responsiveness	O
to	O
gamma	B-Gene
interferon	I-Gene
.	O

By	O
exposing	O
human	O
blood	O
-derived	O
macrophages	O
and	O
alveolar	O
macrophages	O
in	O
vitro	O
to	O
dexamethasone	B-Chemical
,	O
we	O
showed	O
in	O
these	O
studies	O
that	O
glucocorticoids	B-Chemical
markedly	O
suppress	O
the	O
antimicrobial	O
activity	O
of	O
macrophages	O
but	O
not	O
macrophage	O
activation	O
by	O
lymphokines	O
.	O

As	O
little	O
as	O
2.5	O
X	O
10	O
(	O
-8	O
)	O
mol	O
/	O
liter	O
of	O
dexamethasone	B-Chemical
prevented	O
macrophages	O
from	O
inhibiting	O
germination	O
of	O
Aspergillus	O
spores	O
or	O
from	O
eliminating	O
ingested	O
bacteria	O
such	O
as	O
Listeria	O
,	O
Nocardia	O
,	O
or	O
Salmonella	O
.	O

Damage	O
to	O
macrophage	O
function	O
was	O
inhibited	O
by	O
progesterone	B-Chemical
and	O
appeared	O
to	O
be	O
receptor	O
-mediated	O
.	O

In	O
accordance	O
with	O
in	O
vivo	O
observations	O
,	O
dexamethasone	B-Chemical
required	O
24-36	O
h	O
to	O
suppress	O
antimicrobial	O
activity	O
.	O

While	O
glucocorticoids	B-Chemical
interfered	O
with	O
base-line	O
activity	O
of	O
macrophages	O
,	O
dexamethasone	B-Chemical
concentrations	O
comparable	O
to	O
drug	O
levels	O
in	O
patients	O
had	O
no	O
effect	O
on	O
macrophage	O
activation	O
.	O

Proliferating	O
lymphocytes	O
and	O
gamma-interferon	B-Gene
thus	O
increased	O
the	O
antimicrobial	O
activity	O
of	O
phagocytes	O
exposed	O
to	O
glucocorticoids	B-Chemical
over	O
that	O
of	O
control	O
cells	O
.	O

Macrophage	O
activation	O
and	O
correction	O
of	O
the	O
dexamethasone	B-Chemical
effect	O
by	O
gamma-interferon	B-Gene
,	O
however	O
,	O
was	O
dependent	O
on	O
the	O
pathogen	O
.	O

The	O
lymphokine	O
enhanced	O
the	O
antimicrobial	O
activity	O
of	O
dexamethasone	B-Chemical
-treated	O
macrophages	O
against	O
Listeria	O
and	O
Salmonella	O
but	O
not	O
against	O
Aspergillus	O
or	O
Nocardia	O
.	O

Dexamethasone	B-Chemical
-induced	O
damage	O
to	O
the	O
antimicrobial	O
activity	O
of	O
human	O
macrophages	O
in	O
vitro	O
parallels	O
observations	O
that	O
glucocorticoids	B-Chemical
render	O
laboratory	O
animals	O
susceptible	O
to	O
listeriosis	O
and	O
aspergillosis	O
by	O
damaging	O
resident	O
macrophages	O
.	O

Suppression	O
of	O
macrophage	O
antimicrobial	O
activity	O
should	O
thus	O
be	O
considered	O
when	O
treating	O
patients	O
with	O
glucocorticoids	B-Chemical
;	O
its	O
prevention	O
by	O
gamma-interferon	B-Gene
might	O
be	O
beneficial	O
for	O
some	O
but	O
not	O
all	O
pathogens	O
.	O

Defective	O
binding	O
and	O
function	O
of	O
1	B-Gene
,	I-Gene
25-dihydroxyvitamin	I-Gene
D3	I-Gene
receptors	I-Gene
in	O
peripheral	O
mononuclear	O
cells	O
of	O
patients	O
with	O
end-organ	O
resistance	O
to	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D	I-Chemical
.	O

Lectin	B-Gene
-induced	O
DNA	O
synthesis	O
by	O
peripheral	O
mononuclear	O
cells	O
from	O
17	O
normal	O
donors	O
was	O
inhibited	O
(	O
40-60	O
%	O
)	O
by	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
at	O
physiological	O
concentrations	O
(	O
10	O
(	O
-10	O
)	O
-10	O
(	O
-9	O
)	O
M	O
)	O
.	O

The	O
lymphocytes	O
acquire	O
specific	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
upon	O
activation	O
by	O
the	O
lectins	B-Gene
.	O

This	O
process	O
precedes	O
the	O
inhibitory	O
effect	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
studied	O
lymphocytes	O
from	O
six	O
patients	O
from	O
four	O
different	O
kindreds	O
with	O
the	O
syndrome	O
of	O
hereditary	O
end-organ	O
resistance	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
(	O
the	O
so	O
-called	O
vitamin	B-Disease
D	I-Disease
-dependent	I-Disease
rickets	I-Disease
type	I-Disease
II	I-Disease
)	O
.	O

In	O
five	O
patients	O
(	O
three	O
kindreds	O
)	O
peripheral	O
blood	O
mononuclear	O
cells	O
did	O
not	O
acquire	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
upon	O
phytohemagglutinin	B-Gene
-induced	O
activation	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
normal	O
lymphocytes	O
,	O
the	O
mitogenic	O
stimulation	O
of	O
these	O
patients	O
'lymphocytes	O
by	O
phytohemagglutinin	B-Gene
and	O
concanavalin	B-Gene
A	I-Gene
was	O
not	O
inhibited	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Activated	O
lymphocytes	O
of	O
the	O
sixth	O
patient	O
from	O
a	O
fourth	O
kindred	O
exhibited	O
normal	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
but	O
the	O
hormone	O
failed	O
to	O
inhibit	O
the	O
mitogenic	O
stimulation	O
.	O

A	O
similar	O
pattern	O
of	O
the	O
vitamin	B-Chemical
D	I-Chemical
effector	O
system	O
was	O
previously	O
observed	O
in	O
fibroblasts	O
cultured	O
from	O
skin	O
biopsies	O
of	O
the	O
same	O
group	O
of	O
patients	O
.	O

The	O
conclusions	O
from	O
these	O
findings	O
are	O
:	O
(	O
a	O
)	O
the	O
inhibition	O
of	O
mitogenic	O
stimulation	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
mediated	O
by	O
specific	O
functional	O
receptors	O
to	O
the	O
hormone	O
;	O
and	O
(	O
b	O
)	O
the	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
mononuclear	O
cells	O
are	O
probably	O
controlled	O
genetically	O
by	O
the	O
same	O
mechanisms	O
as	O
the	O
effector	O
system	O
in	O
well	O
-characterized	O
target	O
organs	O
of	O
the	O
hormone	O
,	O
such	O
as	O
intestine	O
and	O
kidney	O
.	O

Aldosterone-receptor	B-Gene
deficiency	O
in	O
pseudohypoaldosteronism	B-Disease
.	O

Pseudohypoaldosteronism	B-Disease
,	O
a	O
syndrome	O
characterized	O
by	O
salt	O
wasting	O
and	O
failure	O
to	O
thrive	O
,	O
usually	O
presents	O
in	O
infancy	O
as	O
high	O
urinary	O
levels	O
of	O
sodium	B-Chemical
despite	O
hyponatremia	B-Disease
,	O
hyperkalemia	B-Disease
,	O
hyperreninemia	B-Disease
,	O
and	O
elevated	O
aldosterone	B-Chemical
levels	O
.	O

We	O
have	O
investigated	O
this	O
syndrome	O
for	O
the	O
possibility	O
of	O
abnormal	O
Type	O
I	O
or	O
``	O
mineralocorticoid	B-Chemical
-like	O
''receptors	O
,	O
which	O
have	O
intrinsic	O
steroid	B-Chemical
specificity	O
indistinguishable	O
from	O
that	O
of	O
renal	B-Gene
mineralocorticoid	I-Gene
receptors	I-Gene
and	O
are	O
found	O
in	O
many	O
tissues	O
and	O
cells	O
,	O
including	O
mononuclear	O
leukocytes	O
.	O

We	O
have	O
studied	O
three	O
patients	O
with	O
pseudohypoaldosteronism	B-Disease
:	O
the	O
28-year-old	O
index	O
case	O
in	O
Melbourne	O
(	O
Patient	O
1	O
)	O
and	O
two	O
siblings	O
in	O
Munich	O
,	O
eight	O
and	O
two	O
years	O
of	O
age	O
(	O
Patients	O
2	O
and	O
3	O
)	O
;	O
clinically	O
,	O
Patient	O
3	O
had	O
a	O
less	O
severe	O
case	O
than	O
his	O
sister	O
.	O

Percoll	B-Chemical
-separated	O
control	O
monocytes	O
bound	O
[	O
3H	O
]	O
aldosterone	B-Chemical
with	O
high	O
affinity	O
(	O
Kd	O
approximately	O
3	O
nM	O
)	O
and	O
limited	O
capacity	O
(	O
150	O
to	O
600	O
sites	O
per	O
cell	O
)	O
.	O

On	O
repeated	O
examination	O
,	O
no	O
[	O
3H	O
]	O
aldosterone	B-Chemical
binding	O
was	O
found	O
in	O
monocytes	O
from	O
Patients	O
1	O
and	O
2	O
;	O
in	O
Patient	O
3	O
,	O
the	O
levels	O
were	O
62	O
sites	O
per	O
cell	O
,	O
more	O
than	O
2	O
S.D.	O
below	O
those	O
of	O
the	O
control	O
.	O

Levels	O
in	O
the	O
parents	O
of	O
the	O
Munich	O
patients	O
(	O
first	O
cousins	O
)	O
were	O
normal	O
.	O

It	O
appears	O
that	O
pseudohypoaldosteronism	B-Disease
is	O
caused	O
by	O
a	O
Type	O
I	O
receptor	O
defect	O
,	O
that	O
the	O
defect	O
may	O
be	O
complete	O
or	O
partial	O
,	O
that	O
transmission	O
may	O
be	O
autosomal	O
recessive	O
,	O
and	O
that	O
the	O
study	O
of	O
patients	O
with	O
pseudohypoaldosteronism	B-Disease
may	O
indicate	O
physiologic	O
roles	O
for	O
Type	O
I	O
receptors	O
in	O
nonepithelial	O
tissues	O
.	O

A	O
nuclear	O
factor	O
that	O
binds	O
to	O
a	O
conserved	O
sequence	O
motif	O
in	O
transcriptional	O
control	O
elements	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

Trans	O
-acting	O
factors	O
that	O
mediate	O
B-cell	O
specific	O
transcription	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
have	O
been	O
postulated	O
based	O
on	O
an	O
analysis	O
of	O
the	O
expression	O
of	O
exogenously	O
introduced	O
immunoglobulin	B-Gene
gene	I-Gene
recombinants	O
in	O
lymphoid	O
and	O
non-lymphoid	O
cells	O
.	O

Two	O
B-cell-specific	O
,	O
cis	O
-acting	O
transcriptional	O
regulatory	O
elements	O
have	O
been	O
identified	O
.	O

One	O
element	O
is	O
located	O
in	O
the	O
intron	O
between	O
the	O
variable	O
(	O
V	O
)	O
and	O
constant	O
(	O
C	O
)	O
regions	O
of	O
both	O
heavy	O
and	O
kappa	O
light-chain	O
genes	O
and	O
acts	O
as	O
a	O
transcriptional	O
enhancer	O
.	O

The	O
second	O
element	O
is	O
found	O
upstream	O
of	O
both	O
heavy	O
and	O
kappa	O
light-chain	O
gene	O
promoters	O
.	O

This	O
element	O
directs	O
lymphoid-specific	O
transcription	O
even	O
in	O
the	O
presence	O
of	O
viral	O
enhancers	O
.	O

We	O
have	O
sought	O
nuclear	O
factors	O
that	O
might	O
bind	O
specifically	O
to	O
these	O
two	O
regulatory	O
elements	O
by	O
application	O
of	O
a	O
modified	O
gel	O
electrophoresis	O
DNA	O
binding	O
assay	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
human	O
B-cell	O
nuclear	O
factor	O
(	O
IgNF-A	O
)	O
that	O
binds	O
to	O
DNA	O
sequences	O
in	O
the	O
upstream	O
regions	O
of	O
both	O
the	O
mouse	O
heavy	O
and	O
kappa	O
light-chain	O
gene	O
promoters	O
and	O
also	O
to	O
the	O
mouse	O
heavy-chain	O
gene	O
enhancer	O
.	O

This	O
sequence-specific	O
binding	O
is	O
probably	O
mediated	O
by	O
a	O
highly	O
conserved	O
sequence	O
motif	O
,	O
ATTTGCAT	O
,	O
present	O
in	O
all	O
three	O
transcriptional	O
elements	O
.	O

Interestingly	O
,	O
a	O
factor	O
showing	O
similar	O
binding	O
specificity	O
to	O
IgNF-A	O
is	O
also	O
present	O
in	O
human	O
HeLa	O
cells	O
.	O

Lymphocyte	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
binding	O
in	O
depressed	O
patients	O
with	O
hypercortisolemia	B-Disease
.	O

Despite	O
elevated	O
levels	O
of	O
serum	O
and	O
urinary	O
cortisol	B-Chemical
,	O
patients	O
with	O
depressive	O
illness	O
manifest	O
none	O
of	O
the	O
clinical	O
stigmata	O
of	O
glucocorticoid	B-Chemical
excess	O
.	O

This	O
hypercortisolemia	B-Disease
in	O
the	O
absence	O
of	O
clinical	O
effects	O
suggests	O
a	O
state	O
of	O
hormone	O
resistance	O
and	O
could	O
be	O
mediated	O
by	O
alterations	O
in	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

Earlier	O
studies	O
have	O
shown	O
that	O
small	O
doses	O
of	O
glucocorticoids	B-Chemical
cause	O
a	O
decrease	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
binding	O
in	O
normal	O
human	O
lymphocytes	O
.	O

White	O
cells	O
from	O
depressed	O
patients	O
with	O
significant	O
hypercortisolemia	B-Disease
would	O
be	O
expected	O
to	O
show	O
a	O
similar	O
change	O
in	O
receptor	O
concentration	O
if	O
peripheral	O
tissues	O
are	O
adequately	O
exposed	O
to	O
and	O
sensitive	O
to	O
the	O
hormone	O
.	O

In	O
this	O
study	O
we	O
compared	O
the	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
to	O
lymphocytes	O
from	O
normal	O
subjects	O
and	O
depressed	O
patients	O
with	O
hypercortisolemia	B-Disease
.	O

Lymphocytes	O
from	O
normal	O
subjects	O
had	O
a	O
mean	O
receptor	O
concentration	O
of	O
10.2	O
+	O
/	O
-	O
0.66	O
fm	O
/	O
10	O
(	O
6	O
)	O
cells	O
(	O
S.E.M.	O
)	O
and	O
a	O
dissociation	O
constant	O
of	O
4.8	O
+	O
/	O
-	O
0.47	O
nM	O
.	O

Lymphocytes	O
from	O
depressed	O
patients	O
with	O
abnormal	O
0800	O
h	O
serum	O
cortisol	B-Chemical
after	O
dexamethasone	B-Chemical
had	O
a	O
mean	O
receptor	O
concentration	O
of	O
8.8	O
+	O
/	O
-	O
0.75	O
fm	O
/	O
10	O
(	O
6	O
)	O
cells	O
,	O
which	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
or	O
from	O
depressed	O
subjects	O
with	O
normal	O
post-dexamethasone	B-Chemical
cortisol	I-Chemical
levels	O
(	O
9.4	O
+	O
/	O
-	O
0.95	O
fm	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
.	O

Lymphocytes	O
from	O
depressed	O
patients	O
with	O
elevated	O
urinary	O
free	O
cortisol	B-Chemical
excretion	O
(	O
UFC	O
)	O
also	O
had	O
normal	O
receptor	O
concentration	O
and	O
binding	O
affinity	O
for	O
dexamethasone	B-Chemical
.	O

The	O
lack	O
of	O
a	O
change	O
in	O
lymphocyte	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
concentration	O
in	O
the	O
presence	O
of	O
cortisol	B-Chemical
excess	O
suggests	O
the	O
possibility	O
that	O
hypercortisolemia	B-Disease
in	O
depressive	O
illness	O
represents	O
a	O
state	O
of	O
peripheral	O
glucocorticoid	B-Chemical
resistance	O
.	O

Immunological	O
interference	O
of	O
high	O
dose	O
corticosteroids	B-Chemical
.	O

High-dose	O
corticosteroids	B-Chemical
(	O
HDC	O
)	O
will	O
influence	O
cellular	O
as	O
well	O
as	O
humoral	O
participants	O
of	O
the	O
immune	O
response	O
.	O

The	O
lymphoid	O
tissue	O
will	O
decrease	O
in	O
size	O
and	O
weight	O
after	O
prolonged	O
treatment	O
with	O
HDC	O
.	O

Lymphocyte	O
functions	O
will	O
be	O
impaired	O
.	O

Reduced	O
synthesis	O
of	O
B-	O
as	O
well	O
as	O
T-lymphocytes	O
will	O
be	O
seen	O
.	O

The	O
inhibitory	O
effect	O
on	O
B-cell	O
function	O
can	O
be	O
observed	O
both	O
as	O
decreased	O
serum	O
levels	O
of	O
immunoglobulins	O
and	O
as	O
impaired	O
binding	O
of	O
antibodies	O
and	O
complement	O
to	O
the	O
cellular	O
surface	O
.	O

Reduced	O
T-cell	O
function	O
indicated	O
by	O
impaired	O
stimulation	O
by	O
PHA	B-Gene
and	O
porkweed	O
as	O
well	O
as	O
by	O
impaired	O
lymphokinin	B-Gene
effects	O
on	O
leukocyte	O
migration	O
inhibition	O
has	O
been	O
reported	O
.	O

Reduced	O
lymphocyte	O
adherence	O
to	O
antigen	O
and	O
suppressed	O
lymphocyte	O
reaction	O
have	O
also	O
been	O
observed	O
.	O

Humoral	O
factors	O
involved	O
in	O
chemotaxis	O
,	O
opsonisation	O
,	O
phagocytosis	O
,	O
vascular	O
permeability	O
leading	O
to	O
leakage	O
of	O
fluid	O
and	O
cells	O
and	O
factors	O
involved	O
in	O
lysis	O
of	O
antigens	O
are	O
impaired	O
.	O

This	O
can	O
be	O
explained	O
partly	O
by	O
the	O
observed	O
reduced	O
complement	O
activation	O
via	O
the	O
alternative	O
as	O
well	O
as	O
the	O
classical	O
pathway	O
in	O
association	O
with	O
HDC	O
therapy	O
.	O

Acute	O
processes	O
with	O
increased	O
vascular	O
permeability	O
and	O
accumulation	O
of	O
leukocytes	O
as	O
impairing	O
factors	O
could	O
be	O
influenced	O
beneficially	O
by	O
HDC	O
therapy	O
.	O

This	O
positive	O
effect	O
can	O
be	O
seen	O
in	O
treatment	O
of	O
septic	O
shock	O
or	O
rejection	O
of	O
a	O
transplant	O
.	O

However	O
,	O
if	O
sepsis	O
or	O
rejection	O
is	O
not	O
rapidly	O
reversed	O
,	O
complications	O
such	O
as	O
multisystem	O
organ	O
failure	O
and	O
bacteremia	O
are	O
prone	O
to	O
appear	O
.	O

[	O
Glucocorticoid	B-Gene
receptors	I-Gene
and	O
response	O
to	O
polychemotherapy	O
in	O
acute	B-Disease
lymphatic	I-Disease
leukemia	I-Disease
]	O

Glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
levels	O
were	O
quantified	O
in	O
leukemic	O
blasts	O
from	O
peripheral	O
blood	O
of	O
86	O
patients	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O

The	O
subsequent	O
achievement	O
of	O
complete	O
remission	O
after	O
combination	O
chemotherapy	O
was	O
correlated	O
with	O
high	O
receptor	O
levels	O
.	O

Forty-seven	O
of	O
50	O
patients	O
with	O
leukemic	O
cells	O
containing	O
more	O
than	O
6	O
,	O
000	O
receptor	O
sites	O
and	O
22	O
of	O
36	O
patients	O
with	O
cells	O
containing	O
less	O
than	O
6	O
,	O
000	O
receptor	O
sites	O
achieved	O
remission	O
.	O

The	O
study	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
leukemic	O
cells	O
may	O
predict	O
response	O
to	O
combination	O
chemotherapy	O
in	O
patients	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O

The	O
new	O
world	O
primates	O
as	O
animal	O
models	O
of	O
glucocorticoid	B-Chemical
resistance	O
.	O

Many	O
New	O
World	O
primate	O
species	O
have	O
greatly	O
increased	O
plasma	O
cortisol	B-Chemical
concentrations	O
,	O
decreased	O
plasma	B-Gene
cortisol	I-Gene
binding	I-Gene
globulin	I-Gene
capacity	O
and	O
affinity	O
,	O
marked	O
resistance	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
to	O
suppression	O
by	O
dexamethasone	B-Chemical
,	O
and	O
no	O
biological	O
evidence	O
of	O
glucocorticoid	B-Chemical
excess	O
.	O

These	O
primates	O
also	O
have	O
high	O
levels	O
of	O
circulating	O
progesterone	B-Chemical
,	O
estrogen	B-Chemical
,	O
mineralocorticoid	B-Chemical
,	O
androgen	B-Chemical
and	O
vitamin	B-Chemical
D	I-Chemical
.	O

The	O
glucocorticoid	B-Chemical
target	O
tissues	O
that	O
have	O
been	O
examined	O
(	O
circulating	O
mononuclear	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
)	O
have	O
normal	O
concentrations	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
with	O
decreased	O
affinity	O
for	O
dexamethasone	B-Chemical
.	O

Transformation	O
of	O
B-lymphocytes	O
with	O
the	O
Epstein-Barr	O
virus	O
leads	O
to	O
glucocorticoid	B-Gene
receptor	I-Gene
induction	O
that	O
is	O
less	O
than	O
that	O
observed	O
with	O
cells	O
from	O
Old	O
World	O
primates	O
.	O

The	O
receptor	O
in	O
these	O
cells	O
has	O
a	O
low	O
affinity	O
for	O
dexamethasone	B-Chemical
.	O

The	O
low	O
affinity	O
leads	O
to	O
an	O
increased	O
loss	O
of	O
specific	O
bound	O
ligand	O
during	O
thermal	O
activation	O
.	O

Meroreceptor	O
generation	O
is	O
normal	O
.	O

The	O
molecular	O
weight	O
of	O
the	O
receptor	O
,	O
determined	O
by	O
SDS-PAGE	O
,	O
is	O
similar	O
to	O
that	O
of	O
Old	O
World	O
primates	O
(	O
approximately	O
92	O
,	O
000	O
)	O
and	O
the	O
activation	O
pattern	O
per	O
se	O
,	O
examined	O
in	O
vitro	O
by	O
heating	O
cytosol	O
and	O
performing	O
phosphocellulose	O
chromatography	O
,	O
appears	O
similar	O
to	O
that	O
of	O
human	O
controls	O
.	O

The	O
ratios	O
of	O
nuclear	O
to	O
cytosolic	O
hormone-receptor-complexes	O
and	O
of	O
cytosolic	O
activated	O
to	O
unactivated	O
receptor	O
complexes	O
in	O
intact	O
cells	O
are	O
similar	O
to	O
Old	O
World	O
primates	O
.	O

Results	O
from	O
mixing	O
studies	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
a	O
binding	O
inhibitor	O
(	O
s	O
)	O
or	O
a	O
deficient	O
cytosolic	O
positive	O
modifier	O
(	O
s	O
)	O
of	O
binding	O
underlies	O
the	O
findings	O
in	O
these	O
primates	O
.	O

The	O
New	O
World	O
primates	O
,	O
unlike	O
men	O
with	O
the	O
syndrome	O
of	O
primary	O
cortisol	B-Chemical
resistance	O
,	O
have	O
compensated	O
for	O
their	O
condition	O
with	O
intra-adrenal	O
and	O
mineralocorticoid	B-Gene
receptor	I-Gene
adaptations	O
.	O

Thus	O
,	O
unlike	O
Old	O
World	O
primates	O
,	O
cortisol	B-Chemical
in	O
New	O
World	O
primates	O
has	O
only	O
weak	O
sodium	B-Chemical
-retaining	O
potency	O
because	O
the	O
aldosterone	B-Gene
receptor	I-Gene
has	O
a	O
low	O
affinity	O
for	O
cortisol	B-Chemical
.	O

The	O
common	O
element	O
that	O
would	O
explain	O
the	O
apparent	O
resistance	O
to	O
six	O
steroid	B-Chemical
hormones	I-Chemical
in	O
New	O
World	O
primates	O

Preferential	O
transcription	O
of	O
HTLV-I	O
LTR	O
in	O
cell-free	O
extracts	O
of	O
human	O
T	O
cells	O
producing	O
HTLV-I	O
viral	O
proteins	O
.	O

The	O
promoters	O
of	O
the	O
adenovirus	B-Gene
2	I-Gene
major	I-Gene
late	I-Gene
gene	I-Gene
,	O
the	O
mouse	B-Gene
beta-globin	I-Gene
gene	I-Gene
,	O
the	O
mouse	B-Gene
immunoglobulin	I-Gene
VH	I-Gene
gene	I-Gene
and	O
the	O
LTR	O
of	O
the	O
human	O
T-lymphotropic	O
retrovirus	O
type	O
I	O
were	O
tested	O
for	O
their	O
transcription	O
activities	O
in	O
cell-free	O
extracts	O
of	O
four	O
cell	O
lines	O
;	O
HeLa	O
,	O
CESS	O
(	O
Epstein-Barr	O
virus	O
-transformed	O
human	O
B	O
cell	O
line	O
)	O
,	O
MT-1	O
(	O
HTLV-I	O
-infected	O
human	O
T	O
cell	O
line	O
without	O
viral	O
protein	O
synthesis	O
)	O
,	O
and	O
MT-2	O
(	O
HTLV-I	O
-infected	O
human	O
T	O
cell	O
line	O
producing	O
viral	O
proteins	O
)	O
.	O

LTR	O
was	O
preferentially	O
transcribed	O
in	O
the	O
extracts	O
of	O
MT-2	O
although	O
the	O
other	O
three	O
genes	O
were	O
transcribed	O
with	O
relatively	O
constant	O
efficiencies	O
in	O
different	O
extracts	O
.	O

The	O
results	O
agree	O
well	O
with	O
the	O
previous	O
in	O
vivo	O
studies	O
on	O
the	O
promoter	O
activity	O
of	O
HTLV-I	O
LTR	O
.	O

Mixing	O
of	O
HeLa	O
and	O
MT-2	O
extracts	O
revealed	O
the	O
presence	O
of	O
a	O
LTR-specific	O
stimulating	O
activity	O
in	O
MT-2	O
extracts	O
.	O

Inhibition	O
by	O
cortisol	B-Chemical
of	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
.	O

The	O
effects	O
of	O
cortisol	B-Chemical
on	O
the	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
(	O
PBM	O
)	O
cells	O
were	O
studied	O
in	O
vitro	O
using	O
a	O
direct	O
4-h	O
51Cr-release	O
assay	O
and	O
K	O
562	O
cell	O
line	O
as	O
a	O
target	O
.	O

Preincubation	O
for	O
20	O
h	O
of	O
PBM	O
cells	O
drawn	O
from	O
healthy	O
donors	O
with	O
1	O
X	O
10	O
(	O
-8	O
)	O
to	O
1	O
X	O
10	O
(	O
-5	O
)	O
M	O
cortisol	B-Chemical
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
NK	O
cell	O
activity	O
.	O

The	O
magnitude	O
of	O
the	O
suppression	O
was	O
directly	O
related	O
to	O
the	O
steroid	B-Chemical
concentration	O
and	O
inversely	O
related	O
to	O
the	O
number	O
of	O
effector	O
cells	O
.	O

Cortisol	B-Chemical
was	O
able	O
to	O
minimize	O
the	O
enhancement	O
of	O
NK	O
cytotoxicity	O
obtainable	O
in	O
the	O
presence	O
of	O
immune	O
interferon	B-Gene
(	O
IFN-gamma	B-Gene
)	O
.	O

A	O
significantly	O
higher	O
suppression	O
was	O
achieved	O
after	O
sequential	O
exposure	O
of	O
PBM	O
cells	O
to	O
cortisol	B-Chemical
and	O
equimolar	O
levels	O
of	O
prostaglandin	B-Chemical
E2	I-Chemical
(	O
PgE2	B-Chemical
)	O
.	O

The	O
concomitant	O
incubation	O
with	O
theophylline	B-Chemical
and	O
isobutyl	B-Chemical
-methylxanthine	I-Chemical
failed	O
to	O
enhance	O
the	O
cortisol	B-Chemical
-induced	O
suppression	O
,	O
whereas	O
PgE2	B-Chemical
-dependent	O
inhibition	O
significantly	O
increased	O
after	O
exposure	O
of	O
PBM	O
cells	O
to	O
methyl	B-Chemical
-xanthines	I-Chemical
.	O

The	O
inhibitory	O
effect	O
of	O
cortisol	B-Chemical
was	O
partially	O
or	O
totally	O
prevented	O
by	O
the	O
concomitant	O
incubation	O
with	O
equimolar	O
amounts	O
of	O
11-deoxycortisol	B-Chemical
and	O
RU	B-Chemical
486	I-Chemical
but	O
not	O
of	O
progesterone	B-Chemical
.	O

Treatment	O
of	O
NK	O
effectors	O
with	O
a	O
monoclonal	B-Gene
anti-human	I-Gene
corticosteroid	I-Gene
-binding	I-Gene
globulin	I-Gene
(	I-Gene
CBG	I-Gene
)	I-Gene
antibody	I-Gene
produced	O
an	O
enhancement	O
of	O
the	O
spontaneous	O
NK	O
activity	O
and	O
a	O
partial	O
suppression	O
of	O
cortisol	B-Chemical
-mediated	O
effects	O
.	O

Our	O
results	O
suggest	O
that	O
endogenous	O
glucocorticoids	B-Chemical
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
NK	O
cell	O
-mediated	O
cytotoxicity	O
.	O

Since	O
the	O
effect	O
of	O
cortisol	B-Chemical
was	O
additive	O
to	O
that	O
of	O
PgE2	B-Chemical
and	O
was	O
not	O
changed	O
by	O
phosphodiesterase	B-Gene
inhibitors	I-Gene
,	O
it	O
is	O
conceivable	O
that	O
the	O
hormone	O
acts	O
at	O
a	O
level	O
different	O
from	O
the	O
adenylate	B-Gene
cyclase	I-Gene
-	I-Gene
phosphodiesterase	I-Gene
system	O
.	O

Data	O
obtained	O
with	O
the	O
use	O
of	O
antiglucocorticoids	O
and	O
the	O
anti-CBG	B-Gene
antibody	I-Gene
are	O
compatible	O
with	O
a	O
role	O
both	O
of	O
high-affinity	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
of	O
CBG	B-Gene
in	O
mediating	O
cortisol	B-Chemical
action	O
on	O
the	O
human	O
NK	O
cell	O
activity	O
.	O

Altered	O
interaction	O
between	O
triiodothyronine	B-Chemical
and	O
its	O
nuclear	O
receptors	O
in	O
absence	O
of	O
cortisol	B-Chemical
:	O
a	O
proposed	O
mechanism	O
for	O
increased	O
thyrotropin	B-Gene
secretion	O
in	O
corticosteroid	B-Chemical
deficiency	O
states	O
.	O

Thyroid	O
hormones	O
occasionally	O
appear	O
less	O
effective	O
when	O
administered	O
alone	O
to	O
patients	O
with	O
panhypopituitarism	B-Disease
,	O
and	O
manifestations	O
suggestive	O
of	O
hypothyroidism	B-Disease
have	O
been	O
reported	O
in	O
patients	O
suffering	O
from	O
untreated	O
Addison	B-Disease
's	I-Disease
disease	I-Disease
.	O

In	O
the	O
latter	O
condition	O
,	O
thyrotropin	B-Gene
secretion	O
is	O
increased	O
:	O
this	O
occurs	O
already	O
after	O
as	O
little	O
as	O
2	O
days	O
of	O
temporary	O
withdrawal	O
of	O
therapy	O
with	O
substitution	O
doses	O
of	O
corticosteroids	B-Chemical
while	O
circulating	O
levels	O
of	O
thyroid	B-Chemical
hormones	I-Chemical
remain	O
within	O
normal	O
limits	O
.	O

Therefore	O
,	O
a	O
possible	O
role	O
of	O
cortisol	B-Chemical
in	O
interaction	O
between	O
triiodothyronine	B-Chemical
and	O
its	O
nuclear	O
receptors	O
was	O
examined	O
at	O
the	O
level	O
of	O
circulating	O
lymphocytes	O
obtained	O
from	O
patients	O
with	O
primary	O
or	O
secondary	B-Disease
adrenocortical	I-Disease
failure	I-Disease
.	O

The	O
affinity	O
of	O
these	O
receptors	O
was	O
found	O
to	O
be	O
decreased	O
,	O
by	O
more	O
than	O
50	O
%	O
on	O
average	O
,	O
in	O
the	O
absence	O
of	O
cortisol	B-Chemical
treatments	O
.	O

This	O
change	O
was	O
promptly	O
corrected	O
upon	O
resumption	O
of	O
therapy	O
.	O

The	O
number	O
of	O
binding	O
sites	O
was	O
not	O
significantly	O
modified	O
.	O

The	O
influence	O
of	O
cortisol	B-Chemical
on	O
thyroid	B-Gene
hormone	I-Gene
receptors	I-Gene
discussed	O
here	O
might	O
account	O
for	O
the	O
clinical	O
observations	O
mentioned	O
above	O
.	O

Granulocyte-macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
.	O

Sensitive	O
and	O
receptor	O
-mediated	O
regulation	O
by	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
in	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

We	O
show	O
that	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
[	I-Chemical
OH	I-Chemical
]	I-Chemical
2D3	I-Chemical
)	O
,	O
the	O
most	O
hormonally	O
active	O
metabolite	O
of	O
vitamin	B-Chemical
D3	I-Chemical
,	O
modulates	O
sensitively	O
and	O
specifically	O
both	O
the	O
protein	O
and	O
messenger	O
RNA	O
accumulation	O
of	O
the	O
multilineage	B-Gene
growth	I-Gene
factor	I-Gene
granulocyte-macrophage	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
GM-CSF	B-Gene
)	O
.	O

The	O
regulation	O
of	O
GM-CSF	B-Gene
expression	O
is	O
seen	O
in	O
both	O
normal	O
human	O
mitogen	O
-activated	O
T	O
lymphocytes	O
and	O
T	O
lymphocytes	O
from	O
a	O
line	O
(	O
S-LB1	O
)	O
transformed	O
with	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
1	O
(	O
HTLV-1	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
a	O
HTLV-1	O
transformed	O
T	O
lymphocyte	O
line	O
(	O
Ab-VDR	O
)	O
established	O
from	O
a	O
patient	O
with	O
vitamin	B-Disease
D	I-Disease
-resistant	I-Disease
rickets	I-Disease
type	I-Disease
II	I-Disease
with	O
undetectable	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
cellular	I-Gene
receptors	I-Gene
are	O
resistant	O
to	O
the	O
action	O
of	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D3	I-Chemical
.	O

Inhibition	O
of	O
GM-CSF	B-Gene
expression	O
by	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D3	I-Chemical
can	O
occur	O
independently	O
of	O
interleukin	B-Gene
2	I-Gene
regulation	O
and	O
is	O
probably	O
mediated	O
through	O
cellular	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
.	O

We	O
conclude	O
that	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D3	I-Chemical
may	O
be	O
important	O
in	O
the	O
physiology	O
of	O
hematopoiesis	O
.	O

Decreased	O
deoxyribonucleic	O
acid	O
binding	O
of	O
glucocorticoid-receptor	B-Gene
complex	I-Gene
in	O
cultured	O
skin	O
fibroblasts	O
from	O
a	O
patient	O
with	O
the	O
glucocorticoid	B-Chemical
resistance	O
syndrome	O
.	O

A	O
patient	O
with	O
the	O
syndrome	O
of	O
glucocorticoid	B-Chemical
resistance	O
was	O
studied	O
.	O

A	O
27-yr-old	O
woman	O
initially	O
was	O
diagnosed	O
as	O
having	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
,	O
based	O
on	O
the	O
findings	O
of	O
high	O
plasma	B-Gene
ACTH	I-Gene
and	O
serum	O
cortisol	B-Chemical
levels	O
,	O
increased	O
urinary	O
cortisol	B-Chemical
secretion	O
,	O
resistance	O
to	O
adrenal	O
suppression	O
with	O
dexamethasone	B-Chemical
,	O
and	O
bilateral	O
adrenal	B-Disease
hyperplasia	I-Disease
by	O
computed	O
tomography	O
and	O
scintigraphy	O
of	O
the	O
adrenal	O
glands	O
.	O

However	O
,	O
she	O
had	O
no	O
signs	O
or	O
symptoms	O
of	O
Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
.	O

During	O
a	O
5-yr	O
follow-up	O
,	O
no	O
clinical	O
abnormalities	O
developed	O
,	O
although	O
hypercortisolism	B-Disease
persisted	O
.	O

End-organ	O
resistance	O
to	O
cortisol	B-Chemical
was	O
suspected	O
.	O

To	O
explain	O
the	O
end-organ	O
resistance	O
to	O
cortisol	B-Chemical
,	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GR	B-Gene
)	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
a	O
forearm	O
skin	O
biopsy	O
were	O
characterized	O
and	O
compared	O
with	O
the	O
results	O
of	O
similar	O
studies	O
in	O
normal	O
subjects	O
.	O

The	O
patient	O
's	O
GR	B-Gene
in	O
whole	O
cell	O
assays	O
had	O
an	O
increased	O
dissociation	O
constant	O
(	O
Kd	O
)	O
.	O

In	O
the	O
cytosol	O
of	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
patient	O
,	O
there	O
was	O
also	O
decreased	O
binding	O
capacity	O
.	O

The	O
thermal	O
stability	O
and	O
the	O
sedimentation	O
coefficient	O
in	O
a	O
sucrose	O
density	O
gradient	O
of	O
the	O
receptors	O
in	O
the	O
cytosol	O
of	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
patient	O
and	O
normal	O
subjects	O
were	O
similar	O
.	O

GR	B-Gene
complex	I-Gene
activation	O
,	O
analyzed	O
by	O
DEAE-cellulose	O
chromatography	O
,	O
was	O
decreased	O
in	O
the	O
patient	O
.	O

DNA	O
binding	O
of	O
the	O
GR	B-Gene
complex	I-Gene
after	O
temperature	O
-induced	O
activation	O
was	O
lower	O
in	O
the	O
patient	O
than	O
in	O
normal	O
subjects	O
.	O

Nuclear	O
translocation	O
of	O
GR	B-Gene
complexes	I-Gene
from	O
the	O
patient	O
was	O
also	O
slightly	O
decreased	O
.	O

These	O
results	O
suggest	O
that	O
the	O
patient	O
's	O
glucocorticoid	B-Chemical
resistance	O
was	O
due	O
to	O
a	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
glucocorticoids	B-Chemical
and	O
a	O
decrease	O
in	O
the	O
binding	O
of	O
the	O
GR	B-Gene
complex	I-Gene
to	O
DNA	O
.	O

Identification	O
and	O
purification	O
of	O
a	O
human	B-Gene
lymphoid-specific	I-Gene
octamer	I-Gene
-binding	I-Gene
protein	I-Gene
(	O
OTF-2	B-Gene
)	O
that	O
activates	O
transcription	O
of	O
an	O
immunoglobulin	B-Gene
promoter	I-Gene
in	O
vitro	O
.	O

The	O
octamer	O
sequence	O
5'-ATGCAAAT	O
,	O
in	O
either	O
orientation	O
,	O
serves	O
as	O
an	O
upstream	O
element	O
in	O
a	O
variety	O
of	O
promoters	O
and	O
also	O
occurs	O
as	O
a	O
modular	O
enhancer	O
element	O
.	O

It	O
is	O
of	O
particular	O
interest	O
in	O
immunoglobulin	B-Gene
genes	I-Gene
since	O
it	O
is	O
found	O
in	O
the	O
upstream	O
regions	O
of	O
all	O
heavy	O
and	O
light	O
chain	O
promoters	O
and	O
in	O
the	O
heavy	O
chain	O
enhancer	O
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
necessary	O
for	O
cell-specific	O
expression	O
.	O

We	O
report	O
here	O
the	O
chromatographic	O
separation	O
of	O
ubiquitous	O
and	O
B	B-Gene
cell-specific	I-Gene
octamer	I-Gene
-binding	I-Gene
proteins	I-Gene
.	O

The	O
B	O
cell	O
factor	O
was	O
purified	O
to	O
homogeneity	O
using	O
affinity	O
chromatography	O
and	O
consists	O
of	O
three	O
peptides	O
of	O
62	O
,	O
61	O
,	O
and	O
58.5	O
+	O
/	O
-	O
1.5	O
kd	O
.	O

Each	O
of	O
the	O
polypeptides	O
was	O
renatured	O
after	O
SDS-PAGE	O
and	O
shown	O
to	O
bind	O
to	O
the	O
octamer	O
sequence	O
.	O

The	O
specific	O
DNA	O
binding	O
activity	O
of	O
the	O
pure	O
B	O
cell-specific	O
factor	O
was	O
indistinguishable	O
from	O
that	O
of	O
the	O
affinity	O
-purified	O
ubiquitous	O
factor	O
.	O

This	O
B	B-Gene
cell-specific	I-Gene
octamer	I-Gene
-binding	I-Gene
factor	I-Gene
,	O
in	O
pure	O
form	O
,	O
activated	O
transcription	O
from	O
a	O
kappa	O
light	O
chain	O
promoter	O
in	O
vitro	O
,	O
thus	O
demonstrating	O
that	O
it	O
is	O
indeed	O
a	O
B	O
cell-specific	O
transcription	O
factor	O
for	O
this	O
gene	O
.	O

In	O
addition	O
to	O
the	O
ubiquitous	O
and	O
B	B-Gene
cell-specific	I-Gene
octamer	I-Gene
-binding	I-Gene
factors	I-Gene
,	O
we	O
identified	O
several	O
additional	O
proteins	O
,	O
one	O
of	O
which	O
is	O
B	O
cell	O
-specific	O
,	O
that	O
interact	O
with	O
the	O
kappa	O
promoter	O
.	O

Lymphocyte	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
binding	O
in	O
depression	B-Disease
:	O
normal	O
values	O
following	O
recovery	O
.	O

The	O
number	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
in	O
lymphocytes	O
and	O
plasma	O
cortisol	B-Chemical
concentrations	O
were	O
measured	O
in	O
20	O
patients	O
who	O
had	O
recovered	O
from	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
and	O
20	O
healthy	O
control	O
subjects	O
.	O

The	O
number	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
sites	O
in	O
lymphocytes	O
from	O
the	O
recovered	O
depressed	O
group	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

Although	O
the	O
mean	O
plasma	O
cortisol	B-Chemical
concentration	O
in	O
recovered	O
depressives	O
was	O
higher	O
than	O
in	O
control	O
subjects	O
,	O
the	O
difference	O
only	O
just	O
reached	O
significance	O
.	O

This	O
study	O
shows	O
that	O
the	O
reduction	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
numbers	O
which	O
occurs	O
during	O
acute	B-Disease
depressive	I-Disease
illness	I-Disease
does	O
not	O
persist	O
on	O
recovery	O
and	O
is	O
,	O
therefore	O
,	O
state	O
-dependent	O
.	O

Identification	O
and	O
purification	O
of	O
a	O
human	B-Gene
immunoglobulin-enhancer	I-Gene
-binding	I-Gene
protein	I-Gene
(	O
NF-kappa	B-Gene
B	I-Gene
)	O
that	O
activates	O
transcription	O
from	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
promoter	O
in	O
vitro	O
.	O

The	O
enhancer	B-Gene
-binding	I-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
,	O
which	O
is	O
found	O
only	O
in	O
cells	O
that	O
transcribe	O
immunoglobulin	B-Gene
light	I-Gene
chain	I-Gene
genes	I-Gene
,	O
has	O
been	O
purified	O
from	O
nuclear	O
extracts	O
of	O
Namalwa	O
cells	O
(	O
human	O
Burkitt	B-Disease
lymphoma	I-Disease
cells	O
)	O
by	O
sequence-specific	O
DNA	O
affinity	O
chromatography	O
.	O

The	O
purified	B-Gene
NF-kappa	I-Gene
B	I-Gene
has	O
been	O
identified	O
as	O
a	O
51-kDa	O
polypeptide	O
by	O
UV	O
-crosslinking	O
analysis	O
.	O

``	O
Footprint	O
''and	O
methylation-interference	O
analyses	O
have	O
shown	O
that	O
purified	B-Gene
NF-kappa	I-Gene
B	I-Gene
has	O
a	O
binding	O
activity	O
specific	O
for	O
the	O
kappa	O
light	O
chain	O
enhancer	O
sequence	O
.	O

The	O
purified	O
factor	O
activated	O
in	O
vitro	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
I	O
promoter	O
by	O
binding	O
to	O
an	O
upstream	O
NF-kappa	B-Gene
B	I-Gene
-binding	O
site	O

Inhibition	O
of	O
interleukin	B-Gene
2	I-Gene
-induced	O
proliferation	O
of	O
cloned	O
murine	O
T	O
cells	O
by	O
glucocorticoids	B-Chemical
.	O

Possible	O
involvement	O
of	O
an	O
inhibitory	O
protein	O
.	O

The	O
ability	O
of	O
glucocorticoids	B-Chemical
to	O
inhibit	O
interleukin	B-Gene
2	I-Gene
(	O
IL	B-Gene
2	I-Gene
)	O
-induced	O
T	O
cell	O
proliferation	O
in	O
two	O
cytotoxic	O
T	O
cell	O
(	O
CTL	O
)	O
clones	O
has	O
been	O
studied	O
.	O

A	O
complete	O
inhibition	O
of	O
DNA	O
synthesis	O
by	O
dexamethasone	B-Chemical
(	O
Dx	B-Chemical
)	O
could	O
be	O
observed	O
when	O
IL	B-Gene
2	I-Gene
-depleted	O
cultures	O
of	O
CTL	O
were	O
either	O
incubated	O
for	O
6	O
h	O
with	O
the	O
hormone	O
prior	O
to	O
the	O
addition	O
of	O
IL	B-Gene
2	I-Gene
or	O
treated	O
simultaneously	O
with	O
Dx	B-Chemical
and	O
a	O
low	O
concentration	O
of	O
IL	B-Gene
2	I-Gene
.	O

No	O
significant	O
reduction	O
in	O
the	O
number	O
and	O
affinity	O
of	O
IL	B-Gene
2	I-Gene
receptors	I-Gene
was	O
seen	O
after	O
6	O
h	O
incubation	O
with	O
Dx	B-Chemical
.	O

The	O
order	O
of	O
potency	O
observed	O
with	O
the	O
different	O
steroids	B-Chemical
indicated	O
that	O
this	O
inhibitory	O
effect	O
was	O
mediated	O
through	O
binding	O
to	O
a	O
specific	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

The	O
action	O
of	O
these	O
hormones	O
possibly	O
involves	O
the	O
synthesis	O
of	O
an	O
inhibitory	O
protein	O
(	O
s	O
)	O
,	O
since	O
the	O
presence	O
of	O
cycloheximide	B-Chemical
during	O
the	O
incubation	O
with	O
Dx	B-Chemical
prevented	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

Furthermore	O
,	O
supernatant	O
from	O
Dx	B-Chemical
-treated	O
CTL	O
contained	O
a	O
nondialyzable	O
factor	O
which	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	O
growth	O
of	O
CTL	O
clones	O
induced	O
by	O
IL	B-Gene
2	I-Gene
.	O

Blocking	O
of	O
IL	B-Gene
2	I-Gene
synthesis	O
and	O
IL	B-Gene
2	I-Gene
receptor	I-Gene
formation	O
have	O
been	O
proposed	O
as	O
one	O
of	O
the	O
major	O
mechanisms	O
of	O
glucocorticoid	B-Chemical
-induced	O
immunosuppression	O
.	O

Our	O
results	O
indicate	O
that	O
these	O
hormones	O
may	O
also	O
affect	O
T	O
cell	O
proliferation	O
by	O
inhibiting	O
IL	B-Gene
2	I-Gene
activity	O
.	O

Octamer	B-Gene
-binding	I-Gene
proteins	I-Gene
from	O
B	O
or	O
HeLa	O
cells	O
stimulate	O
transcription	O
of	O
the	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
promoter	I-Gene
in	O
vitro	O
.	O

The	O
B-cell	O
-type	O
specificity	O
of	O
the	O
immunoglobulin	B-Gene
(	I-Gene
Ig	I-Gene
)	I-Gene
heavy-chain	I-Gene
and	O
light-chain	B-Gene
promoters	I-Gene
is	O
mediated	O
by	O
an	O
octanucleotide	O
(	O
OCTA	O
)	O
element	O
,	O
ATGCAAAT	O
,	O
that	O
is	O
also	O
a	O
functional	O
component	O
of	O
other	O
RNA	B-Gene
polymerase	I-Gene
II	I-Gene
promoters	I-Gene
,	O
such	O
as	O
snRNA	O
and	O
histone	B-Gene
H2B	I-Gene
promoters	I-Gene
.	O

Two	O
nuclear	O
proteins	O
that	O
bind	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
the	O
OCTA	O
element	O
have	O
been	O
identified	O
.	O

NF-A1	B-Gene
is	O
present	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
whereas	O
the	O
presence	O
of	O
NF-A2	B-Gene
is	O
essentially	O
confined	O
to	O
B	O
cells	O
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
NF-A2	B-Gene
activates	O
cell-type-specific	O
transcription	O
of	O
the	O
Ig	B-Gene
promoter	I-Gene
and	O
NF-A1	B-Gene
mediates	O
the	O
other	O
responses	O
of	O
the	O
OCTA	O
element	O
.	O

Extracts	O
of	O
the	O
B-cell	O
line	O
,	O
BJA-B	O
,	O
contain	O
high	O
levels	O
of	O
NF-A2	B-Gene
and	O
specifically	O
transcribe	O
Ig	B-Gene
promoters	I-Gene
.	O

In	O
contrast	O
,	O
extracts	O
from	O
HeLa	O
cells	O
transcribed	O
the	O
Ig	B-Gene
promoter	I-Gene
poorly	O
.	O

Surprisingly	O
,	O
addition	O
of	O
either	O
affinity	O
-enriched	O
NF-A2	B-Gene
or	O
NF-A1	B-Gene
to	O
either	O
a	O
HeLa	O
extract	O
or	O
a	O
partially	O
purified	O
reaction	O
system	O
specifically	O
stimulates	O
the	O
Ig	B-Gene
promoter	I-Gene
.	O

This	O
suggests	O
that	O
the	O
constitutive	O
OCTA	B-Gene
-binding	I-Gene
factor	I-Gene
NF-A1	I-Gene
can	O
activate	O
transcription	O
of	O
the	O
Ig	B-Gene
promoter	I-Gene
and	O
that	O
B-cell	O
-specific	O
transcription	O
of	O
this	O
promoter	O
,	O
at	O
least	O
in	O
vitro	O
,	O
is	O
partially	O
due	O
to	O
a	O
quantitative	O
difference	O
in	O
the	O
amount	O
of	O
OCTA	B-Gene
-binding	I-Gene
protein	I-Gene
.	O

Because	O
NF-A1	B-Gene
can	O
stimulate	O
Ig	B-Gene
transcription	O
,	O
the	O
inability	O
of	O
this	O
factor	O
to	O
activate	O
in	O
vivo	O
the	O
Ig	B-Gene
promoter	I-Gene
to	O
the	O
same	O
degree	O
as	O
the	O
snRNA	O
promoters	O
probably	O
reflects	O
a	O
difference	O
in	O
the	O
context	O
of	O
the	O
OCTA	O
element	O
in	O
these	O
two	O
types	O
of	O
promoters	O
.	O

[	O
Determination	O
of	O
the	O
sensitivity	O
to	O
glucocorticoids	B-Chemical
in	O
vitro	O
]	O

A	O
modified	O
method	O
for	O
the	O
determination	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
human	O
lymphocytes	O
is	O
suggested	O
.	O

The	O
principal	O
distinction	O
of	O
the	O
method	O
is	O
standardization	O
by	O
the	O
lymphocyte	O
count	O
in	O
a	O
sample	O
(	O
1	O
mln	O
)	O
and	O
the	O
labeled	O
hormone	O
concentration	O
.	O

The	O
modification	O
saves	O
time	O
and	O
money	O
,	O
limits	O
the	O
range	O
of	O
the	O
data	O
variations	O
,	O
and	O
makes	O
use	O
of	O
a	O
lesser	O
volume	O
of	O
blood	O
.	O

Examinations	O
of	O
70	O
children	O
aged	O
4	O
to	O
15	O
suffering	O
from	O
the	O
nephrotic	O
form	O
of	O
glomerulonephritis	B-Disease
have	O
made	O
it	O
possible	O
to	O
distinguish	O
two	O
groups	O
of	O
patients	O
:	O
with	O
relatively	O
high	O
values	O
of	O
specific	O
binding	O
X	O
=	O
6820.1	O
+	O
/	O
-	O
530.0	O
(	O
n	O
=	O
30	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
2.04	O
)	O
,	O
this	O
corresponding	O
to	O
a	O
clinical	O
form	O
of	O
hormone	O
-sensitive	O
glomerulonephritis	B-Disease
,	O
and	O
with	O
relatively	O
low	O
values	O
of	O
specific	O
binding	O
X	O
=	O
1815.2	O
+	O
/	O
-	O
302.8	O
(	O
n	O
=	O
40	O
,	O
p	O
=	O
0.95	O
,	O
t	O
=	O
1.96	O
)	O
,	O
that	O
corresponds	O
to	O
hormone	O
-resistant	O
glomerulonephritis	B-Disease
.	O

Dynamic	O
studies	O
have	O
not	O
shown	O
any	O
statistically	O
significant	O
changes	O
in	O
the	O
specific	O
binding	O
values	O
.	O

These	O
results	O
permit	O
regarding	O
the	O
specific	O
binding	O
value	O
as	O
a	O
prognostic	O
criterion	O
in	O
the	O
assessment	O
of	O
corticosteroid	B-Chemical
therapy	O
;	O
this	O
allows	O
a	O
wide	O
employment	O
of	O
the	O
described	O
method	O
in	O
practical	O
nephrology	O
.	O

Association	O
of	O
increased	O
lytic	O
effector	O
cell	O
function	O
with	O
high	O
estrogen	B-Gene
receptor	I-Gene
levels	O
in	O
tumor	B-Disease
-bearing	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

Tumor	B-Disease
-bearing	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
were	O
assayed	O
for	O
their	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
and	O
for	O
the	O
function	O
of	O
activated	O
cytotoxic	O
T-cells	O
,	O
as	O
assessed	O
by	O
lectin	B-Gene
-dependent	O
cellular	O
cytotoxicity	O
(	O
LDCC	O
)	O
.	O

Tumor	B-Disease
-bearing	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
had	O
a	O
significant	O
increase	O
in	O
NK	O
activity	O
and	O
in	O
LDCC	O
,	O
as	O
compared	O
with	O
healthy	O
control	O
individuals	O
.	O

Although	O
the	O
enhanced	O
NK	O
cell	O
activity	O
and	O
LDCC	O
were	O
closely	O
associated	O
with	O
high	O
levels	O
(	O
greater	O
than	O
31	O
fmol	O
/	O
mg	O
)	O
of	O
estrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
content	O
in	O
the	O
primary	O
tumor	B-Disease
,	O
no	O
other	O
clinical	O
or	O
histologic	O
correlation	O
between	O
the	O
increase	O
in	O
either	O
parameter	O
of	O
cytotoxic	O
effector	O
cell	O
function	O
could	O
be	O
found	O
.	O

Thus	O
,	O
ER	B-Gene
levels	O
greater	O
than	O
31	O
fmol	O
/	O
mg	O
might	O
be	O
associated	O
with	O
increased	O
cytotoxic	O
effector	O
cell	O
function	O
in	O
tumor	B-Disease
-bearing	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

Properties	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
Epstein-Barr	O
virus	O
-transformed	O
lymphocytes	O
from	O
patients	O
with	O
familial	O
cortisol	B-Chemical
resistance	O
.	O

In	O
a	O
previous	O
report	O
of	O
two	O
patients	O
with	O
familial	O
glucocorticoid	B-Chemical
resistance	O
due	O
to	O
reduced	O
numbers	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GR	B-Gene
)	O
,	O
we	O
have	O
shown	O
decreased	O
numbers	O
of	O
GR	B-Gene
in	O
peripheral	O
mononuclear	O
cells	O
and	O
cultured	O
fibroblasts	O
but	O
normal	O
affinity	O
of	O
GR	B-Gene
in	O
both	O
patients	O
.	O

In	O
this	O
study	O
,	O
peripheral	O
lymphocytes	O
from	O
these	O
patients	O
,	O
one	O
patient	O
's	O
son	O
and	O
daughter	O
,	O
and	O
normal	O
subjects	O
were	O
transformed	O
with	O
Epstein-Barr	O
virus	O
.	O

Reduced	O
numbers	O
and	O
normal	O
affinity	O
of	O
GR	B-Gene
were	O
found	O
in	O
the	O
Epstein-Barr	O
virus	O
-transformed	O
lymphocytes	O
from	O
both	O
patients	O
while	O
the	O
son	O
and	O
daughter	O
had	O
normal	O
numbers	O
and	O
affinity	O
of	O
GR	B-Gene
.	O

The	O
thermal	O
stability	O
of	O
GR	B-Gene
and	O
thermal	O
activation	O
of	O
cytosolic	O
receptors	O
in	O
both	O
patients	O
were	O
found	O
to	O
be	O
normal	O
.	O

Although	O
the	O
percentages	O
of	O
nuclear	O
bound	O
GR	B-Gene
were	O
similar	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
,	O
the	O
absolute	O
amounts	O
of	O
nuclear	O
bound	O
GR	B-Gene
of	O
the	O
patients	O
were	O
about	O
one-half	O
that	O
of	O
normal	O
controls	O
.	O

These	O
abnormal	O
properties	O
of	O
GR	B-Gene
(	O
reduced	O
numbers	O
of	O
GR	B-Gene
)	O
were	O
preserved	O
in	O
the	O
transformed	O
cells	O
from	O
the	O
patients	O
.	O

Novel	O
region	O
within	O
the	O
V	B-Gene
kappa	I-Gene
gene	I-Gene
promoter	I-Gene
is	O
responsible	O
for	O
tissue	O
and	O
stage-specific	O
expression	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
in	O
human	O
lymphoid	O
neoplasms	O
.	O

Immunoglobulin	B-Gene
gene-specific	I-Gene
transacting	I-Gene
factors	I-Gene
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
lymphoid	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

The	O
role	O
of	O
these	O
factors	O
in	O
B-cell	O
differentiation	O
and	O
stage-specific	O
expression	O
of	O
these	O
genes	O
is	O
,	O
however	O
,	O
not	O
fully	O
understood	O
.	O

We	O
have	O
used	O
a	O
model	O
of	O
human	O
lymphoid	O
neoplasia	B-Disease
to	O
address	O
this	O
question	O
.	O

Different	O
fragments	O
of	O
unrearranged	O
human	O
variable	O
region	O
of	O
immunoglobulin	B-Gene
kappa	I-Gene
gene	I-Gene
(	O
V	B-Gene
kappa	I-Gene
)	O
were	O
used	O
for	O
cell-free	O
in	O
vitro	O
transcription	O
and	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Previously	O
described	O
enhancement	O
of	O
in	O
vitro	O
transcription	O
that	O
was	O
only	O
seen	O
with	O
nuclear	O
extracts	O
derived	O
from	O
B-cell	O
neoplasms	O
corresponding	O
to	O
the	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
actions	O
of	O
these	O
factor	O
(	O
s	O
)	O
on	O
the	O
DNA	O
region	O
within	O
the	O
V	B-Gene
kappa	I-Gene
gene	I-Gene
promoter	I-Gene
.	O

This	O
region	O
is	O
located	O
within	O
the	O
920	O
bp	O
fragment	O
located	O
210	O
bp	O
upstream	O
from	O
the	O
coding	O
region	O
and	O
this	O
fragment	O
represents	O
a	O
possible	O
novel	O
DNA	O
region	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
stage-	O
and	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

Identification	O
of	O
a	O
novel	O
lymphoid	B-Gene
specific	I-Gene
octamer	I-Gene
binding	I-Gene
protein	I-Gene
(	O
OTF-2B	B-Gene
)	O
by	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
found	O
in	O
the	O
promoters	O
of	O
immunoglobulin	B-Gene
(	I-Gene
Ig	I-Gene
)	I-Gene
heavy	I-Gene
and	I-Gene
light	I-Gene
chain	I-Gene
genes	I-Gene
and	O
in	O
the	O
heavy	O
chain	O
enhancer	O
and	O
is	O
a	O
major	O
determinant	O
of	O
the	O
cell	O
type	O
specific	O
expression	O
of	O
Ig	B-Gene
genes	I-Gene
in	O
B	O
cells	O
.	O

An	O
apparent	O
paradox	O
is	O
that	O
the	O
same	O
sequence	O
serves	O
as	O
an	O
upstream	O
promoter	O
or	O
enhancer	O
element	O
in	O
a	O
variety	O
of	O
housekeeping	O
genes	O
such	O
as	O
the	O
histone	B-Gene
H2B	I-Gene
and	O
U	B-Gene
snRNA	I-Gene
genes	I-Gene
.	O

The	O
differential	O
usage	O
of	O
this	O
regulatory	O
sequence	O
motif	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
different	O
species	O
of	O
octamer	B-Gene
binding	I-Gene
proteins	I-Gene
.	O

One	O
species	O
of	O
100	O
kd	O
,	O
designated	O
OTF-1	B-Gene
,	O
is	O
present	O
in	O
all	O
cell	O
types	O
and	O
may	O
exert	O
its	O
activating	O
function	O
only	O
when	O
it	O
can	O
interact	O
with	O
additional	O
adjacent	O
transcription	O
factors	O
.	O

The	O
lymphoid	B-Gene
cell	I-Gene
specific	I-Gene
octamer	I-Gene
binding	I-Gene
protein	I-Gene
of	O
60	O
kd	O
(	O
OTF-2A	B-Gene
)	O
specifically	O
stimulates	O
Ig	B-Gene
promoters	I-Gene
which	O
consist	O
essentially	O
of	O
a	O
TATA-box	O
and	O
an	O
octamer	O
sequence	O
upstream	O
of	O
it	O
.	O

Here	O
we	O
present	O
evidence	O
for	O
yet	O
another	O
B	B-Gene
cell	I-Gene
specific	I-Gene
octamer	I-Gene
binding	I-Gene
protein	I-Gene
of	O
75	O
kd	O
(	O
OTF-2B	B-Gene
)	O
.	O

From	O
several	O
findings	O
,	O
including	O
the	O
absence	O
of	O
OTF-2B	B-Gene
(	O
but	O
not	O
OTF-2A	B-Gene
)	O
from	O
a	O
lymphocyte	O
line	O
that	O
can	O
not	O
respond	O
to	O
the	O
IgH	B-Gene
enhancer	I-Gene
,	O
we	O
propose	O
a	O
role	O
of	O
the	O
novel	O
octamer	O
factor	O
in	O
the	O
long	O
range	O
activation	O
by	O
the	O
IgH	B-Gene
enhancer	I-Gene
.	O

We	O
have	O
used	O
the	O
proteolytic	O
clipping	O
bandshift	O
assay	O
(	O
PCBA	O
)	O
technique	O
to	O
distinguish	O
the	O
three	O
different	O
forms	O
found	O
in	O
B	O
cells	O
.	O

This	O
analysis	O
indicates	O
that	O
the	O
75	O
kd-species	O
OTF-2B	B-Gene
is	O
closely	O
related	O
to	O
the	O
60	O
kd	O
species	O
OTF-2A	B-Gene
.	O

Octamer	B-Gene
transcription	I-Gene
factors	I-Gene
1	I-Gene
and	O
2	B-Partial_Gene
each	O
bind	O
to	O
two	O
different	O
functional	O
elements	O
in	O
the	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
promoter	I-Gene
.	O

Immunoglobulin	B-Gene
heavy-chain	I-Gene
genes	I-Gene
contain	O
two	O
conserved	O
sequence	O
elements	O
5	O
'to	O
the	O
site	O
of	O
transcription	O
initiation	O
:	O
the	O
octamer	O
ATGCAAAT	O
and	O
the	O
heptamer	O
CTCATGA	O
.	O

Both	O
of	O
these	O
elements	O
are	O
required	O
for	O
normal	O
cell-specific	O
promoter	O
function	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
both	O
the	O
ubiquitous	O
and	O
lymphoid-cell-specific	B-Gene
octamer	I-Gene
transcription	I-Gene
factors	I-Gene
(	O
OTF-1	B-Gene
and	O
OTF-2	B-Gene
,	O
respectively	O
)	O
interact	O
specifically	O
with	O
each	O
of	O
the	O
two	O
conserved	O
sequence	O
elements	O
,	O
forming	O
either	O
homo-	O
or	O
heterodimeric	O
complexes	O
.	O

This	O
was	O
surprising	O
,	O
since	O
the	O
heptamer	O
and	O
octamer	O
sequence	O
motifs	O
bear	O
no	O
obvious	O
similarity	O
to	O
each	O
other	O
.	O

Binding	O
of	O
either	O
factor	O
to	O
the	O
octamer	O
element	O
occurred	O
independently	O
.	O

However	O
,	O
OTF	B-Gene
interaction	O
with	O
the	O
heptamer	O
sequence	O
appeared	O
to	O
require	O
the	O
presence	O
of	O
an	O
intact	O
octamer	O
motif	O
and	O
occurred	O
with	O
a	O
spacing	O
of	O
either	O
2	O
or	O
14	O
base	O
pairs	O
between	O
the	O
two	O
elements	O
,	O
suggesting	O
coordinate	O
binding	O
resulting	O
from	O
protein-protein	O
interactions	O
.	O

The	O
degeneracy	O
in	O
sequences	O
recognized	O
by	O
the	O
OTFs	B-Gene
may	O
be	O
important	O
in	O
widening	O
the	O
range	O
over	O
which	O
gene	O
expression	O
can	O
be	O
modulated	O
and	O
in	O
establishing	O
cell	O
type	O
specificity	O
.	O

Kappa	O
B-specific	O
DNA	O
binding	O
proteins	O
:	O
role	O
in	O
the	O
regulation	O
of	O
human	B-Gene
interleukin-2	I-Gene
gene	I-Gene
expression	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-Gene
interleukin-2	I-Gene
(	I-Gene
IL-2	I-Gene
)	I-Gene
gene	I-Gene
,	O
like	O
induction	O
of	O
the	O
IL-2	B-Gene
receptor	I-Gene
alpha	I-Gene
(	I-Gene
IL-2R	I-Gene
alpha	I-Gene
)	I-Gene
gene	I-Gene
and	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
,	O
is	O
shown	O
to	O
be	O
modulated	O
by	O
a	O
kappa	O
B	O
-like	O
enhancer	O
element	O
.	O

Mutation	O
of	O
a	O
kappa	O
B	O
core	O
sequence	O
identified	O
in	O
the	O
IL-2	B-Gene
promoter	I-Gene
(	O
-206	O
to	O
-195	O
)	O
partially	O
inhibits	O
both	O
mitogen-	O
and	O
HTLV-I	B-Gene
Tax	I-Gene
-mediated	O
activation	O
of	O
this	O
transcription	O
unit	O
and	O
blocks	O
the	O
specific	O
binding	O
of	O
two	O
inducible	O
cellular	O
factors	O
.	O

These	O
kappa	O
B-specific	O
proteins	O
(	O
80	O
to	O
90	O
and	O
50	O
to	O
55	O
kilodaltons	O
)	O
similarly	O
interact	O
with	O
the	O
functional	O
kappa	O
B	O
enhancer	O
present	O
in	O
the	O
IL-2R	B-Gene
alpha	I-Gene
promoter	I-Gene
.	O

These	O
data	O
suggest	O
that	O
these	O
kappa	O
B-specific	O
proteins	O
have	O
a	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
this	O
growth	O
factor-growth	O
factor	O
receptor	O
gene	O
system	O
that	O
controls	O
T	O
cell	O
proliferation	O
.	O

Tumor	B-Disease
and	O
serum	B-Gene
beta-2-microglobulin	I-Gene
expression	O
in	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

To	O
investigate	O
whether	O
the	O
tumor	B-Disease
expression	O
of	O
beta-2-microglobulin	B-Gene
(	O
beta	B-Gene
2-M	I-Gene
)	O
could	O
serve	O
as	O
a	O
marker	O
of	O
tumor	B-Disease
biologic	O
behavior	O
,	O
the	O
authors	O
studied	O
specimens	O
of	O
breast	B-Disease
carcinomas	I-Disease
from	O
60	O
consecutive	O
female	O
patients	O
.	O

Presence	O
of	O
beta	B-Gene
2-M	I-Gene
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

No	O
significant	O
correlations	O
were	O
found	O
between	O
tumor	B-Gene
beta	I-Gene
2-M	I-Gene
expression	O
and	O
several	O
histologic	O
attributes	O
such	O
as	O
type	O
,	O
histologic	O
and	O
nuclear	O
grades	O
,	O
mitotic	O
index	O
,	O
necrosis	O
,	O
vascular	O
invasion	O
,	O
and	O
lymphocytic	O
infiltration	O
.	O

Likewise	O
,	O
beta	B-Gene
2-M	I-Gene
was	O
not	O
associated	O
with	O
markers	O
of	O
disease	O
extension	O
such	O
as	O
TNM	O
,	O
(	O
UICC	O
,	O
classification	O
of	O
malignant	B-Disease
tumors	I-Disease
)	O
staging	O
and	O
axillary	O
lymph	O
node	O
involvement	O
or	O
with	O
estrogen	B-Chemical
,	O
progesterone	B-Chemical
,	O
and	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
.	O

However	O
,	O
there	O
was	O
a	O
significantly	O
positive	O
association	O
between	O
tumor	B-Gene
beta	I-Gene
2-M	I-Gene
expression	O
and	O
the	O
degree	O
of	O
lymphocytic	O
infiltration	O
in	O
the	O
tumor	B-Disease
tissue	O
.	O

Beta	B-Gene
2-M	I-Gene
serum	I-Gene
levels	O
were	O
determined	O
by	O
an	O
enzyme	O
-linked	O
immunosorbent	O
assay	O
in	O
samples	O
from	O
22	O
of	O
the	O
above	O
women	O
.	O

Although	O
some	O
of	O
the	O
highest	O
values	O
had	O
been	O
obtained	O
in	O
women	O
with	O
larger	O
(	O
T4	O
)	O
primary	O
tumors	B-Disease
,	O
the	O
authors	O
failed	O
to	O
detect	O
any	O
statistical	O
relationship	O
between	O
beta	B-Gene
2-M	I-Gene
expression	O
in	O
the	O
tumor	B-Disease
with	O
serum	O
levels	O
or	O
between	O
serum	B-Gene
beta	I-Gene
2-M	I-Gene
and	O
the	O
above	O
histologic	O
,	O
laboratory	O
,	O
and	O
clinical	O
factors	O
.	O

Estradiol	B-Gene
receptors	I-Gene
in	O
the	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
hepatitis	B-Disease
B	I-Disease
virus	O
carriers	O
treated	O
with	O
interferon-alpha	B-Gene
.	O

Estradiol	B-Gene
receptors	I-Gene
in	O
the	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
the	O
effects	O
of	O
interferon-alpha	B-Gene
(	O
IFN-alpha	B-Gene
)	O
on	O
estradiol	B-Gene
receptors	I-Gene
were	O
studied	O
in	O
asymptomatic	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
carriers	O
,	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
and	O
normal	O
controls	O
.	O

The	O
level	O
of	O
estradiol	B-Gene
receptors	I-Gene
in	O
the	O
cytosol	O
of	O
mononuclear	O
cells	O
was	O
significantly	O
lower	O
in	O
asymptomatic	O
HBV	O
carriers	O
and	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
,	O
compared	O
to	O
normal	O
controls	O
.	O

This	O
low	O
level	O
of	O
cytosol	B-Gene
estradiol	I-Gene
receptors	I-Gene
in	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
was	O
increased	O
by	O
the	O
administration	O
of	O
IFN-alpha	B-Gene
.	O

In	O
addition	O
,	O
when	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
were	O
incubated	O
with	O
IFN-alpha	B-Gene
in	O
vitro	O
,	O
the	O
level	O
of	O
cytosol	B-Gene
estradiol	I-Gene
receptors	I-Gene
also	O
increased	O
by	O
increasing	O
the	O
concentration	O
of	O
IFN-alpha	B-Gene
.	O

We	O
previously	O
reported	O
that	O
the	O
response	O
of	O
mononuclear	O
cells	O
to	O
estrogen	B-Chemical
is	O
impaired	O
in	O
HBV	O
carriers	O
,	O
and	O
our	O
present	O
results	O
suggested	O
that	O
this	O
may	O
be	O
due	O
to	O
the	O
low	O
level	O
of	O
estradiol	B-Gene
receptors	I-Gene
in	O
the	O
cytosol	O
of	O
mononuclear	O
cells	O
.	O

In	O
vivo	O
responsiveness	O
to	O
glucocorticoid	B-Chemical
correlated	O
with	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
normal	O
humans	O
.	O

Dexamethasone	B-Chemical
loading	O
tests	O
(	O
0.1	O
mg	O
dexamethasone	B-Chemical
/	O
kg	O
,	O
iv	O
)	O
were	O
performed	O
in	O
18	O
normal	O
males	O
to	O
evaluate	O
the	O
individual	O
responsiveness	O
to	O
glucocorticoid	B-Chemical
.	O

There	O
were	O
inter-individual	O
differences	O
in	O
increase	O
in	O
peripheral	O
blood	O
polymorphonuclear	O
leukocyte	O
count	O
,	O
decrease	O
in	O
peripheral	O
blood	O
lymphocyte	O
count	O
,	O
and	O
increase	O
in	O
plasma	O
free	O
fatty	B-Chemical
acids	I-Chemical
levels	O
after	O
dexamethasone	B-Chemical
injection	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	O
leukocytes	O
and	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	O
(	O
r	O
=	O
0.7514	O
,	O
p	O
less	O
than	O
0.0003	O
)	O
.	O

Simultaneous	O
measurements	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
by	O
whole-cell	O
assay	O
revealed	O
that	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
in	O
polymorphonuclear	O
leukocytes	O
linearly	O
correlated	O
with	O
that	O
in	O
the	O
corresponding	O
lymphocytes	O
(	O
r	O
=	O
0.9482	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O

There	O
were	O
also	O
significant	O
correlations	O
between	O
the	O
maximum	O
increase	O
in	O
polymorphonuclear	O
leukocytes	O
and	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
in	O
polymorphonuclear	O
leukocytes	O
(	O
r	O
=	O
0.7239	O
,	O
p	O
less	O
than	O
0.0007	O
)	O
,	O
and	O
between	O
the	O
maximum	O
decrease	O
in	O
lymphocytes	O
and	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
in	O
lymphocytes	O
(	O
r	O
=	O
0.7703	O
,	O
p	O
less	O
than	O
0.0002	O
)	O
.	O

These	O
results	O
suggest	O
that	O
individual	O
differences	O
are	O
preserved	O
both	O
in	O
glucocorticoid	B-Chemical
responsiveness	O
and	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
content	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
normal	O
humans	O
.	O

[	O
Preliminary	O
observation	O
of	O
level	O
free-form	O
E	O
receptor	O
levels	O
in	O
serum	O
of	O
normal	O
childbearing	O
-aged	O
and	O
pregnant	O
women	O
]	O

In	O
137	O
cases	O
of	O
childbearing	O
-aged	O
and	O
pregnant	O
women	O
,	O
free	O
form	O
E	O
receptor	O
levels	O
(	O
sE	O
)	O
in	O
serum	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
level	O
of	O
sE	O
was	O
significantly	O
decreased	O
during	O
the	O
first	O
trimester	O
,	O
slightly	O
higher	O
in	O
the	O
second	O
trimester	O
,	O
and	O
recovered	O
to	O
normal	O
in	O
the	O
third	O
trimester	O
.	O

The	O
level	O
remained	O
lower	O
in	O
29	O
PIH	O
women	O
but	O
appeared	O
higher	O
in	O
overdue	O
pregnancies	O
as	O
compared	O
with	O
the	O
normal	O
3rd	O
trimester	O
range	O
.	O

The	O
results	O
indicate	O
that	O
there	O
is	O
a	O
relationship	O
between	O
a	O
change	O
in	O
T	O
cell	O
function	O
and	O
pregnancy	O
.	O

Congenital	O
immunodeficiencies	O
associated	O
with	O
absence	O
of	O
HLA	B-Gene
class	I-Gene
II	I-Gene
antigens	I-Gene
on	O
lymphocytes	O
result	O
from	O
distinct	O
mutations	O
in	O
trans	O
-acting	O
factors	O
.	O

Coordinate	O
regulation	O
of	O
HLA	B-Gene
class	I-Gene
II	I-Gene
gene	I-Gene
expression	O
during	O
development	O
and	O
coinduction	O
of	O
class	O
II	O
genes	O
by	O
soluble	O
factors	O
suggests	O
that	O
common	O
trans	O
-acting	O
factor	O
(	O
s	O
)	O
control	O
expression	O
of	O
these	O
genes	O
.	O

In	O
B-lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
two	O
independent	O
class	B-Disease
II	I-Disease
-deficient	I-Disease
bare	I-Disease
lymphocyte	I-Disease
syndrome	I-Disease
patients	O
,	O
we	O
observed	O
a	O
drastic	O
decrease	O
in	O
transcription	O
rates	O
of	O
the	O
class	O
II	O
genes	O
.	O

When	O
these	O
cell	O
lines	O
are	O
fused	O
,	O
class	O
II	O
genes	O
are	O
reexpressed	O
,	O
indicating	O
that	O
immunodeficiencies	O
in	O
bare	B-Disease
lymphocyte	I-Disease
syndrome	I-Disease
patients	O
are	O
the	O
result	O
of	O
two	O
distinct	O
mutations	O
.	O

Further	O
studies	O
show	O
that	O
genes	O
governing	O
the	O
expression	O
of	O
class	O
II	O
antigens	O
fall	O
into	O
at	O
least	O
three	O
complementation	O
groups	O
;	O
two	O
of	O
these	O
were	O
previously	O
unidentified	O
in	O
mutant	O
cell	O
lines	O
generated	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
discrete	O
complexes	O
,	O
NFX1.1	B-Gene
and	O
NFX1.2	B-Gene
,	O
that	O
bind	O
to	O
the	O
DRA	O
X	O
consensus	O
element	O
.	O

Though	O
the	O
mutation	O
in	O
at	O
least	O
one	O
mutant	O
line	O
generated	O
in	O
vitro	O
(	O
RJ2.2.5	O
)	O
affects	O
products	O
functioning	O
via	O
interaction	O
with	O
the	O
X	O
box	O
,	O
clear	O
alterations	O
in	O
either	O
NFX1.1	B-Gene
or	O
NFX1.2	B-Gene
are	O
not	O
found	O
in	O
any	O
of	O
the	O
mutant	O
cell	O
lines	O
.	O

Number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
lymphocytes	O
and	O
their	O
sensitivity	O
to	O
hormone	O
action	O
.	O

The	O
study	O
demonstrated	O
a	O
decreased	O
level	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GR	B-Gene
)	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
hypercholesterolemic	O
subjects	O
,	O
and	O
an	O
elevated	O
level	O
in	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

In	O
the	O
lymphocytes	O
with	O
a	O
high	O
GR	B-Gene
number	O
,	O
dexamethasone	B-Chemical
inhibited	O
[	O
3H	O
]	O
-thymidine	B-Chemical
and	O
[	O
3H	O
]	O
-acetate	B-Chemical
incorporation	O
into	O
DNA	O
and	O
cholesterol	B-Chemical
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
control	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
decreased	O
GR	B-Gene
number	O
resulted	O
in	O
a	O
less	O
efficient	O
dexamethasone	B-Chemical
inhibition	O
of	O
the	O
incorporation	O
of	O
labeled	O
compounds	O
.	O

These	O
data	O
showed	O
that	O
the	O
sensitivity	O
of	O
lymphocytes	O
to	O
glucocorticoids	B-Chemical
changed	O
only	O
with	O
a	O
decrease	O
of	O
GR	B-Gene
level	O
.	O

Anti-Ro	B-Gene
(	I-Gene
SSA	I-Gene
)	I-Gene
autoantibodies	I-Gene
are	O
associated	O
with	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
beta	I-Gene
genes	I-Gene
in	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
patients	O
.	O

Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	O
.	O

Associations	O
between	O
HLA	B-Gene
class	I-Gene
II	I-Gene
antigens	I-Gene
and	O
autoantibodies	O
to	O
the	O
ribonucleoproteins	B-Gene
Ro	I-Gene
(	O
SSA	B-Gene
)	O
and	O
La	B-Gene
(	O
SSB	B-Gene
)	O
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O

Because	O
HLA	B-Gene
class	I-Gene
II	I-Gene
molecules	O
present	O
antigen	O
to	O
T	B-Gene
cell	I-Gene
receptors	I-Gene
(	O
TCRs	B-Gene
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	B-Gene
gene	I-Gene
associated	O
with	O
the	O
production	O
of	O
anti-Ro	B-Gene
(	I-Gene
SSA	I-Gene
)	I-Gene
antibodies	I-Gene
.	O

A	O
pair	O
of	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-Gene
constant	I-Gene
region	I-Gene
C	I-Gene
beta	I-Gene
1	I-Gene
and	O
the	O
other	O
to	O
the	O
C	B-Partial_Gene
beta	I-Partial_Gene
2	I-Partial_Gene
gene	I-Partial_Gene
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B-Gene
beta	I-Gene
locus	I-Gene
.	O

This	O
RFLP	O
pair	O
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-Gene
(	O
SSA	B-Gene
)	O
precipitins	O
,	O
84	O
%	O
of	O
anti-	B-Gene
Ro	I-Gene
(	I-Gene
SSA	I-Gene
)	I-Gene
-positive	O
patients	O
lacking	O
La	B-Gene
(	O
SSB	B-Gene
)	O
precipitins	O
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	O
(	O
P	O
=	O
0.0004	O
)	O
.	O

This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	B-Disease
patients	O
indicates	O
that	O
these	O
RFLPs	O
are	O
not	O
disease	O
susceptibility	O
markers	O
,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	B-Gene
genes	I-Gene
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti-Ro	B-Gene
(	I-Gene
SSA	I-Gene
)	I-Gene
antibodies	I-Gene
.	O

The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	O
and	O
HLA	B-Gene
class	I-Gene
II	I-Gene
antigens	I-Gene
previously	O
associated	O
with	O
the	O
anti-	B-Gene
Ro	I-Gene
(	I-Gene
SSA	I-Gene
)	I-Gene
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	O
occur	O
in	O
response	O
to	O
Ro	B-Gene
(	O
SSA	B-Gene
)	O
.	O

Reactivity	O
of	O
lymphocytes	O
to	O
a	O
progesterone	B-Gene
receptor-specific	I-Gene
monoclonal	O
antibody	O
.	O

In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	O
lymphocytes	O
,	O
but	O
not	O
nonpregnancy	O
lymphocytes	O
,	O
with	O
the	O
progesterone	B-Gene
receptor-specific	I-Gene
monoclonal	I-Gene
antibody	I-Gene
mPRI	I-Gene
.	O

Using	O
an	O
avidin	B-Gene
-biotin	I-Gene
peroxidase	I-Gene
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+	O
/	O
-	O
3.7	O
%	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	O
lymphocytes	O
,	O
while	O
only	O
0.47	O
+	O
/	O
-	O
0.33	O
%	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	O
lymphocytes	O
reacted	O
with	O
the	O
antibody	O
.	O

To	O
characterize	O
the	O
receptor	O
-bearing	O
subset	O
,	O
CD8+	B-Gene
and	O
CD4+	B-Gene
cells	O
were	O
depleted	O
by	O
complement	O
-dependent	O
lysis	O
.	O

Depletion	O
of	O
CD8+	B-Gene
cells	O
was	O
accompanied	O
by	O
62	O
+	O
/	O
-	O
18	O
%	O
loss	O
of	O
progesterone	B-Gene
receptor	I-Gene
-bearing	O
cells	O
,	O
while	O
depletion	O
of	O
CD4+	B-Gene
cells	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	O
.	O

In	O
nonpregnancy	O
lymphocytes	O
a	O
3-day	O
PHA	B-Gene
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor	O
-containing	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	O
contain	O
progesterone	B-Chemical
binding	O
structures	O
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O

Characterization	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
-binding	O
proteins	O
from	O
the	O
human	O
T-cell	O
line	O
Jurkat	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	O
proteins	O
that	O
bind	O
to	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Among	O
the	O
protein	O
-binding	O
regions	O
of	O
the	O
HIV-1	O
LTR	O
is	O
the	O
transcription-enhancer	O
region	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	O
,	O
C1	B-Gene
,	O
and	O
one	O
constitutive	O
,	O
C2	B-Gene
,	O
protein	O
can	O
bind	O
to	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
cells	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	O
domain	O
.	O

Both	O
C1	B-Gene
and	O
C2	B-Gene
proteins	I-Gene
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-Gene
alpha-subunit	I-Gene
enhancer	I-Gene
.	O

The	O
inducible	O
C1	B-Gene
protein	I-Gene
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross	O
-linking	O
as	O
a	O
47	O
kDa	O
protein	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	B-Gene
Ig	I-Gene
heavy	I-Gene
chain	I-Gene
enhancer	I-Gene
only	O
in	O
lymphocytes	O
is	O
a	O
ubiquitously	O
active	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	B-Gene
heavy	I-Gene
chain	I-Gene
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

Like	O
other	O
enhancers	O
,	O
the	O
Ig	B-Gene
heavy	I-Gene
chain	I-Gene
enhancer	I-Gene
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	O
transcription	O
factors	O
.	O

Each	O
binding	O
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	O
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B-Gene
heavy	I-Gene
chain	I-Gene
enhancer	I-Gene
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	O
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	O
cells	O
and	O
non-B	O
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-Gene
Ig	I-Gene
heavy	I-Gene
chain	I-Gene
enhancer	I-Gene
in	O
non-lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF-muE3	O
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	O
in	O
non-B	O
cells	O
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type-specific	O
transcription	O
in	O
B	O
lymphocytes	O
:	O
(	O
a	O
)	O
cell-specific	O
factors	O
such	O
as	O
Oct-2A	B-Gene
and	O
Oct-2B	B-Gene
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	O
factors	O
such	O
as	O
NF-kappa	B-Gene
B	I-Gene
that	O
are	O
constitutively	O
active	O
in	O
B	O
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	O
active	O
factors	O
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	O
sequence	O
motif	O
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-Gene
Ig	I-Gene
heavy	I-Gene
chain	I-Gene
enhancer	I-Gene
in	O
non-B	O
cells	O
,	O
perhaps	O
due	O
to	O
a	O
non	O
-permissive	O
chromatin	O
structure	O
of	O
the	O
Ig	B-Gene
heavy	I-Gene
chain	I-Gene
locus	I-Gene
.	O

Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	B-Gene
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

AP-1	B-Gene
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	B-Gene
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	B-Chemical
esters	I-Chemical
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	B-Chemical
(	O
TPA	B-Chemical
)	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	B-Chemical
on	O
the	O
regulation	O
of	O
c-jun	B-Gene
gene	I-Gene
expression	O
in	O
HL-60	O
cells	O
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c-jun	B-Gene
transcripts	I-Gene
were	O
detectable	O
in	O
untreated	O
HL-60	O
leukemic	O
cells	O
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	B-Chemical
.	O

Similar	O
kinetics	O
of	O
c-jun	B-Gene
induction	O
by	O
TPA	B-Chemical
were	O
observed	O
in	O
human	O
U-937	O
and	O
THP-1	O
monocytic	O
leukemia	B-Disease
cells	O
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	B-Chemical
1	I-Chemical
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	B-Gene
expression	O
.	O

TPA	B-Chemical
treatment	O
of	O
HL-60	O
cells	O
in	O
the	O
presence	O
of	O
cycloheximide	B-Chemical
was	O
associated	O
with	O
superinduction	O
of	O
c-jun	B-Gene
transcripts	I-Gene
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B-Gene
gene	I-Gene
transcription	O
in	O
untreated	O
HL-60	O
cells	O
,	O
and	O
that	O
exposure	O
to	O
TPA	B-Chemical
increases	O
this	O
rate	O
3.3-fold	O
.	O

Treatment	O
of	O
HL-60	O
cells	O
with	O
both	O
TPA	B-Chemical
and	O
cycloheximide	B-Chemical
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	B-Gene
transcription	O
.	O

The	O
half-life	O
of	O
c-jun	B-Gene
RNA	I-Gene
as	O
determined	O
by	O
treating	O
HL-60	O
cells	O
with	O
TPA	B-Chemical
and	O
actinomycin	B-Chemical
D	I-Chemical
was	O
30	O
min	O
.	O

In	O
contrast	O
,	O
the	O
half-life	O
of	O
c-jun	B-Gene
RNA	I-Gene
in	O
TPA	B-Chemical
-treated	O
HL-60	O
cells	O
exposed	O
to	O
cycloheximide	B-Chemical
and	O
actinomycin	B-Chemical
D	I-Chemical
was	O
greater	O
than	O
2	O
h	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c-jun	B-Gene
RNA	I-Gene
observed	O
during	O
TPA	B-Chemical
-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

NF-kappa	B-Gene
B	I-Gene
as	O
inducible	O
transcriptional	O
activator	O
of	O
the	O
granulocyte-macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
gene	I-Gene
.	O

The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
GM-CSF	B-Gene
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	O
cells	O
with	O
phytohemagglutinin	B-Gene
and	O
active	O
phorbolester	B-Chemical
and	O
upon	O
expression	O
of	O
tax1	B-Gene
,	O
a	O
transactivating	O
protein	O
of	O
the	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
.	O

The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	B-Gene
receptor	I-Gene
alpha-chain	I-Gene
and	O
interleukin-2	B-Gene
genes	I-Gene
,	O
depending	O
on	O
promoter	O
elements	O
that	O
bind	O
the	O
inducible	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
(	O
or	O
an	O
NF-kappa	B-Gene
B	I-Gene
-like	O
factor	O
)	O
.	O

We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	B-Gene
gene	I-Gene
is	O
also	O
regulated	O
by	O
a	O
cognate	O
motif	O
for	O
the	O
NF-kappa	B-Gene
B	I-Gene
transcription	I-Gene
factor	I-Gene
.	O

A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al	O
.	O

(	O
S.	O
Miyatake	O
,	O
M.	O
Seiki	O
,	O
M.	O
Yoshida	O
,	O
and	O
K.	O
Arai	O
,	O
Mol.	O
Cell.	O
Biol.	O
8	O
:	O
5581-5587	O
,	O
1988	O
)	O
described	O
a	O
short	O
promoter	O
region	O
in	O
the	O
GM-CSF	B-Gene
gene	I-Gene
that	O
conferred	O
strong	O
inducibility	O
by	O
T-cell	O
-activating	O
signals	O
and	O
tax1	B-Gene
,	O
but	O
no	O
NF-kappa	B-Gene
B	I-Gene
-binding	O
motifs	O
were	O
identified	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	B-Gene
NF-kappa	I-Gene
B	I-Gene
and	O
of	O
the	O
NF-kappa	B-Gene
B	I-Gene
activated	O
in	O
Jurkat	O
T	O
cells	O
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	B-Gene
promoter	I-Gene
element	I-Gene
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell	O
-activating	O
signals	O
and	O
tax1	B-Gene
.	O

As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	B-Gene
NF-kappa	I-Gene
B	I-Gene
binds	O
at	O
positions	O
-82	O
to	O
-91	O
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	B-Gene
promoter	I-Gene
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	O
functional	O
kappa	O
B	O
motif	O
in	O
the	O
beta	B-Gene
interferon	I-Gene
promoter	I-Gene
(	O
GGGAAATTCC	O
)	O
.	O

Two	O
kappa	O
B	O
-like	O
motifs	O
at	O
positions	O
-98	O
to	O
-108	O
of	O
the	O
GM-CSF	B-Gene
promoter	I-Gene
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O

Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM-CSF	B-Gene
gene	I-Gene
following	O
T-cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF-kappa	B-Gene
B	I-Gene
transcription	I-Gene
factor	I-Gene
to	O
a	O
high-affinity	O
binding	O
site	O
in	O
the	O
GM-CSF	B-Gene
promoter	I-Gene
.	O

The	O
ubiquitous	B-Gene
octamer	I-Gene
-binding	I-Gene
protein	I-Gene
(	I-Gene
s	I-Gene
)	I-Gene
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

All	O
immunoglobulin	B-Gene
genes	I-Gene
contain	O
a	O
conserved	O
octanucleotide	O
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	O
encoding	O
octamer	B-Gene
-binding	I-Gene
proteins	I-Gene
have	O
been	O
cloned	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	B-Gene
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	B-Gene
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
is	O
unclear	O
.	O

We	O
have	O
identified	O
two	O
human	O
pre-B-cell	O
lines	O
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	B-Gene
yet	O
still	O
express	O
high	O
levels	O
of	O
steady-state	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
mRNA	I-Gene
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	B-Gene
gene	I-Gene
in	O
vitro	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	B-Gene
made	O
from	O
one	O
of	O
these	O
pre-B	O
cells	O
or	O
from	O
HeLa	O
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	B-Gene
gene	I-Gene
.	O

Furthermore	O
,	O
OFT-1	B-Gene
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	B-Gene
when	O
normalized	O
for	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
OTF-1	B-Gene
,	O
without	O
OTF-2	B-Gene
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
and	O
that	O
OTF-2	B-Gene
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B-Gene
gene	I-Gene
expression	O
.	O

Perceived	O
social	O
support	O
and	O
tumor	B-Disease
estrogen	B-Gene
/	I-Gene
progesterone	I-Gene
receptor	I-Gene
status	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	B-Disease
cancer	I-Disease
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O

All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O
their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O

A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
``	O
stress	O
''buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O

In	O
the	O
main	O
model	O
reported	O
here	O
,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O
by	O
five	O
variables	O
.	O

Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	B-Gene
receptor	I-Gene
-negative	O
tumor	B-Disease
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O

Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	B-Disease
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity	O
.	O

Octamer	B-Gene
transcription	I-Gene
factors	I-Gene
and	O
the	O
cell	O
type-specificity	O
of	O
immunoglobulin	B-Gene
gene	I-Gene
expression	O
.	O

Antibodies	O
are	O
produced	O
exclusively	O
in	O
B	O
lymphocytes	O
.	O

The	O
expression	O
of	O
the	O
antibody	O
-encoding	O
genes	O
,	O
the	O
immunoglobulin	B-Gene
(	I-Gene
Ig	I-Gene
)	I-Gene
genes	I-Gene
,	O
is	O
also	O
restricted	O
to	O
B	O
cells	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	O
and	O
the	O
enhancer	O
of	O
Ig	B-Gene
genes	I-Gene
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O

This	O
sequence	O
motif	O
is	O
a	O
binding	O
site	O
for	O
nuclear	O
proteins	O
,	O
the	O
so	O
-called	O
octamer	B-Gene
transcription	I-Gene
factors	I-Gene
(	O
Oct	B-Gene
or	O
OTF	B-Gene
factors	I-Gene
)	O
.	O

The	O
Oct-1	B-Gene
protein	I-Gene
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct-2A	B-Gene
and	O
Oct-2B	B-Gene
are	O
found	O
mainly	O
in	O
B	O
lymphocytes	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B-Gene
genes	I-Gene
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	O
Oct	B-Gene
factors	I-Gene
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B-Gene
and	O
Oct-2	B-Gene
factors	I-Gene
.	O

Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	O
factor	O
variants	O
were	O
identified	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	O
transcript	O
of	O
one	O
Oct	B-Gene
factor	I-Gene
gene	I-Gene
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

Pseudohypoaldosteronism	B-Disease
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

Pseudohypoaldosteronism	B-Disease
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	B-Disease
and	O
hyperkalemia	B-Disease
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	B-Chemical
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	B-Chemical
;	O
however	O
,	O
sodium	B-Chemical
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	B-Gene
I	I-Gene
aldosterone	I-Gene
receptors	I-Gene
in	O
peripheral	O
mononuclear	O
leucocytes	O
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	B-Chemical
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	O
receptor	O
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	O
mononuclear	O
leucocytes	O
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	B-Disease
.	O

Steroid	B-Chemical
mediated	O
lysis	O
of	O
lymphoblasts	O
requires	O
the	O
DNA	O
binding	O
region	O
of	O
the	O
steroid	B-Gene
hormone	I-Gene
receptor	I-Gene
.	O

Glucocorticoids	B-Chemical
kill	O
certain	O
types	O
of	O
lymphoblasts	O
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O

It	O
is	O
clear	O
that	O
sufficient	O
numbers	O
of	O
functional	O
glucocorticoid	B-Gene
receptors	I-Gene
are	O
required	O
to	O
mediate	O
lysis	O
,	O
but	O
whether	O
they	O
do	O
so	O
through	O
the	O
classical	O
model	O
of	O
steroid	B-Chemical
hormone	I-Chemical
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established	O
.	O

In	O
this	O
report	O
we	O
have	O
asked	O
which	O
region	O
(	O
s	O
)	O
of	O
the	O
steroid	B-Gene
receptor	I-Gene
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	O
T	O
lymphoblasts	O
.	O

CEM-ICR	O
27	O
leukemic	O
lymphoblasts	O
,	O
a	O
clone	O
of	O
CEM	O
cells	O
which	O
lack	O
functional	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	B-Chemical
nor	O
capable	O
of	O
showing	O
glutamine	B-Gene
synthetase	I-Gene
induction	O
,	O
were	O
provided	O
with	O
steroid	B-Gene
receptors	I-Gene
by	O
DNA	O
transfections	O
of	O
various	O
receptor	O
gene	O
constructs	O
.	O

We	O
measured	O
steroid	B-Chemical
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B-Gene
synthetase	I-Gene
in	O
the	O
transfected	O
cells	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
lysis	O
mechanism	O
in	O
the	O
ICR27	O
lymphoblasts	O
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored	O
.	O

The	O
DNA	O
binding	O
region	O
specifying	O
high	O
affinity	O
for	O
GRE	O
sites	O
is	O
required	O
.	O

Lysis	O
is	O
mediated	O
by	O
any	O
steroid	B-Chemical
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region	O
.	O

Our	O
data	O
support	O
the	O
view	O
that	O
steroid	B-Chemical
-mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid-receptor	B-Gene
complexes	I-Gene
with	O
the	O
genome	O
.	O

Definition	O
of	O
T-cell	O
specific	O
DNA	O
-binding	O
factors	O
that	O
interact	O
with	O
a	O
3'-silencer	O
in	O
the	O
CD4+	B-Gene
T-cell	I-Gene
gene	I-Gene
Rpt-1	I-Gene
.	O

Analysis	O
of	O
the	O
region	O
3	O
'to	O
the	O
CD4+	B-Gene
T-cell	I-Gene
gene	I-Gene
Rpt-1	I-Gene
(	O
encoding	O
regulatory	B-Gene
protein	I-Gene
T-lymphocyte	I-Gene
1	I-Gene
)	O
led	O
to	O
the	O
definition	O
of	O
a	O
silencer	O
element	O
that	O
inhibits	O
heterologous	O
gene	O
expression	O
in	O
certain	O
CD4+	B-Gene
T-cell	O
lines	O
but	O
not	O
in	O
B-cell	O
or	O
non-lymphoid	O
cell	O
lines	O
.	O

Functional	O
silencer	O
activity	O
in	O
vivo	O
was	O
associated	O
with	O
the	O
presence	O
of	O
a	O
specific	O
silencer-DNA-protein	O
complex	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
T-cell	O
extracts	O
.	O

Formation	O
of	O
this	O
complex	O
was	O
selectively	O
inhibited	O
by	O
the	O
region	O
in	O
HIV-1	O
containing	O
a	O
silencer	O
element	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
DNA	O
-binding	O
factors	O
may	O
coregulate	O
HIV-1	O
and	O
Rpt-1	B-Gene
gene	I-Gene
expression	O
through	O
a	O
common	O
transcriptional	O
silencer	O
element	O
.	O

Constitutive	O
expression	O
of	O
HIV-1	B-Gene
tat	I-Gene
protein	I-Gene
in	O
human	O
Jurkat	O
T	O
cells	O
using	O
a	O
BK	O
virus	O
vector	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	O
cell	O
lines	O
that	O
constitutively	O
express	O
functional	O
human	B-Gene
immune	I-Gene
deficiency	I-Gene
virus	I-Gene
type	I-Gene
1	I-Gene
(	I-Gene
HIV-1	I-Gene
)	I-Gene
tat	I-Gene
protein	I-Gene
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	B-Gene
tat	I-Gene
cDNA	I-Gene
,	O
is	O
described	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	O
cell	O
lines	O
as	O
compared	O
with	O
control	O
cell	O
lines	O
was	O
observed	O
.	O

Tax	B-Gene
-independent	O
binding	O
of	O
multiple	O
cellular	O
factors	O
to	O
Tax-response	B-Gene
element	I-Gene
DNA	I-Gene
of	O
HTLV-I	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
promoter	O
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	O
(	O
Tax-response	B-Gene
element	I-Gene
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	O
encoded	O
transactivator	B-Gene
protein	I-Gene
Tax	I-Gene
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	O
proteins	O
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	O
immortalized	O
Tax	B-Gene
-expressing	O
human	O
T-lymphocyte	O
line	O
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	O
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax-protein	B-Gene
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O

Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O

First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	O
proteins	O
were	O
specifically	O
cross	O
-linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE-DNA	B-Gene
fragment	O
.	O

Second	O
,	O
TRE-DNA	O
binding	O
proteins	O
sedimented	O
through	O
a	O
glycerol	B-Chemical
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Third	O
,	O
only	O
the	O
50	O
kD	O
protein	O
was	O
retained	O
on	O
a	O
biotinylated	B-Gene
DNA-streptavidin	I-Gene
matrix	I-Gene
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE-DNA	O
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	O
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	O
,	O
36	O
to	O
42	O
and	O
110	O
kD	O
proteins	O
and	O
to	O
less	O
extent	O
the	O
50	O
kD	O
factor	O
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	B-Chemical
[	I-Chemical
d	I-Chemical
(	I-Chemical
I-C	I-Chemical
)	I-Chemical
]	I-Chemical
in	O
all	O
reactions	O
.	O

The	O
cAMP-response	B-Chemical
element	O
CRE	O
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	O
base-pair	O
sequence	O
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	O
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	B-Gene
response	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
,	O
CREB	B-Gene
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	O
complex	O
and	O
in	O
mediating	O
the	O
Tax	B-Gene
response	O
.	O

[	O
1	B-Gene
,	I-Gene
25-Dihydroxyvitamin	I-Gene
D3	I-Gene
receptors	I-Gene
in	O
lymphocytes	O
and	O
T-	O
and	O
B-lymphocyte	O
count	O
in	O
patients	O
with	O
glomerulonephritis	B-Disease
]	O

Content	O
of	O
receptors	O
to	O
hormonal	O
form	O
of	O
vitamin	B-Chemical
D3	I-Chemical
,	O
1.25	O
(	O
OH	O
)	O
2D3	O
,	O
constituted	O
27.3	O
fmole	O
/	O
mg	O
of	O
protein	O
in	O
lymphocytes	O
of	O
peripheric	O
blood	O
of	O
children	O
with	O
glomerulonephritis	B-Disease
.	O

In	O
the	O
patients	O
concentration	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
was	O
decreased	O
down	O
to	O
2.04	O
mmole	O
/	O
L	O
and	O
1.09	O
mmole	O
/	O
L	O
,	O
respectively	O
,	O
while	O
an	O
increase	O
in	O
parathormone	B-Gene
(	O
PTH	B-Gene
)	O
by	O
36	O
%	O
and	O
a	O
distinct	O
decrease	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
lower	O
than	O
1.25	O
ng	O
/	O
ml	O
)	O
was	O
found	O
in	O
blood	O
;	O
content	O
of	O
cAMP	B-Chemical
was	O
also	O
decreased	O
in	O
lymphocytes	O
by	O
33	O
%	O
.	O

At	O
the	O
same	O
time	O
,	O
total	O
content	O
of	O
T	O
lymphocytes	O
was	O
decreased	O
1.5-fold	O
in	O
peripheric	O
blood	O
.	O

Treatment	O
with	O
I-hydroxyvitamin	B-Chemical
D3	I-Chemical
(	O
1-1.5	O
mg	O
daily	O
,	O
within	O
4	O
weeks	O
)	O
led	O
to	O
normalization	O
of	O
total	O
and	O
ionized	O
form	O
of	O
Ca2+	O
and	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
but	O
did	O
not	O
affect	O
the	O
PTH	B-Gene
content	O
in	O
blood	O
.	O

Concentration	O
of	O
the	O
receptors	O
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
was	O
elevated	O
up	O
to	O
39.7	O
fmole	O
/	O
mg	O
after	O
I	O
week	O
of	O
the	O
treatment	O
,	O
whereas	O
it	O
was	O
decreased	O
to	O
the	O
initial	O
level	O
24.8	O
fmole	O
/	O
mg	O
within	O
4	O
weeks	O
;	O
simultaneous	O
alteration	O
in	O
the	O
cAMP	B-Chemical
content	O
was	O
observed	O
in	O
lymphocytes	O
.	O

Treatment	O
with	O
1-	O
(	O
OH	O
)	O
D3	O
normalized	O
also	O
the	O
T	O
lymphocytes	O
content	O
in	O
peripheric	O
blood	O
.	O

The	O
data	O
obtained	O
suggest	O
that	O
under	O
conditions	O
of	O
glomerulonephritis	B-Disease
only	O
high	O
content	O
of	O
receptors	O
to	O
1.25	O
(	O
OH	O
)	O
2D3	O
in	O
lymphocytes	O
enabled	O
to	O
perform	O
the	O
cell	O
response	O
to	O
the	O
hormone	O
effect	O
.	O

Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	B-Disease
treated	O
by	O
conservation	O
therapy	O
.	O

Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I-II	O
patients	O
with	O
infiltrating	O
ductal	B-Disease
carcinomas	I-Disease
(	O
median	O
follow-up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate	O
/	O
marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	B-Disease
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B-Gene
receptor	I-Gene
negativity	O
,	O
anatomic	O
tumor	B-Disease
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O

Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR	O
/	O
EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	B-Disease
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O
EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O

For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	B-Disease
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

High-risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O

Effects	O
of	O
aldosterone	B-Chemical
on	O
intralymphocytic	O
sodium	B-Chemical
and	O
potassium	B-Chemical
in	O
patients	O
with	O
essential	O
hypertension	B-Disease
.	O

In	O
vitro	O
binding	O
of	O
aldosterone	B-Chemical
to	O
mineralocorticoid	B-Gene
receptors	I-Gene
on	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	B-Chemical
and	O
potassium	B-Chemical
concentrations	O
of	O
HML	O
have	O
already	O
been	O
described	O
.	O

In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	B-Disease
.	O

In	O
only	O
four	O
patients	O
sodium	B-Chemical
in	O
HML	O
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O

A	O
decrease	O
of	O
intracellular	O
sodium	B-Chemical
or	O
potassium	B-Chemical
occurred	O
during	O
incubation	O
without	O
aldosterone	B-Chemical
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	B-Chemical
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O

Plasma	B-Gene
renin	I-Gene
activity	O
and	O
aldosterone	B-Chemical
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O

The	O
number	O
of	O
mineralocorticoid	B-Gene
receptors	I-Gene
/	O
cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O

The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	B-Chemical
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B-Gene
receptors	I-Gene
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	B-Chemical
effector	O
mechanism	O
in	O
the	O
HML	O
of	O
patients	O
with	O
essential	O
hypertension	B-Disease
.	O

Megakaryocytic	O
and	O
erythrocytic	O
lineages	O
share	O
specific	O
transcription	O
factors	O
.	O

Erythroid-specific	O
genes	O
contain	O
binding	O
sites	O
for	O
NF-E1	B-Gene
(	O
also	O
called	O
GF-1	B-Gene
and	O
Eryf-1	B-Gene
;	O
refs	O
1-3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA	O
-binding	O
protein	O
of	O
the	O
erythrocytic	O
lineage	O
.	O

NF-E1	B-Gene
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	O
lineage	O
.	O

A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	O
megakaryocytic	O
cell	O
line	O
and	O
purified	O
human	O
megakaryocytes	O
;	O
it	O
binds	O
to	O
promoter	O
regions	O
of	O
two	O
megakaryocytic-specific	O
genes	O
.	O

The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	O
protein	O
;	O
also	O
,	O
NF-E1	B-Gene
messenger	I-Gene
RNA	I-Gene
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	O
and	O
erythroid	O
cell	O
lines	O
.	O

Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF-E1	B-Gene
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic-specific	O
promoter	O
.	O

We	O
also	O
find	O
that	O
NF-E2	B-Gene
,	O
another	O
trans	O
-acting	O
factor	O
of	O
the	O
erythrocytic	O
lineage	O
,	O
is	O
present	O
in	O
megakaryocytes	O
.	O

Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans	O
-acting	O
factors	O
.	O

Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	O
and	O
the	O
megakaryocytic	O
lineages	O
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	O
and	O
megakaryocytic	O
lineages	O
in	O
most	O
erythroblastic	O
and	O
megakaryoblastic	O
permanent	O
cell	O
lines	O
.	O

A	O
new	O
member	O
of	O
the	O
leucine	B-Chemical
zipper	O
class	O
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-Gene
DR	I-Gene
alpha	I-Gene
promoter	I-Gene
.	O

Several	O
mutants	O
derived	O
from	O
transformed	O
human	O
B	O
cell	O
lines	O
are	O
defective	O
in	O
expressing	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
(	I-Gene
MHC	I-Gene
)	I-Gene
class	I-Gene
II	I-Gene
genes	I-Gene
.	O

The	O
failure	O
to	O
express	O
a	O
class	O
II	O
gene	O
in	O
at	O
least	O
one	O
such	O
mutant	O
line	O
has	O
been	O
mapped	O
to	O
the	O
MHC	B-Gene
class	I-Gene
II	I-Gene
X	O
box	O
,	O
a	O
conserved	O
transcriptional	O
element	O
in	O
the	O
promoter	O
region	O
.	O

A	O
complementary	O
DNA	O
encoding	O
a	O
DNA	O
-binding	O
protein	O
(	O
human	B-Gene
X	I-Gene
box	I-Gene
binding	I-Gene
protein	I-Gene
,	O
hXBP-1	B-Gene
)	O
whose	O
target	O
is	O
the	O
human	O
DR	O
alpha	O
X	O
box	O
and	O
the	O
3	O
'flanking	O
region	O
has	O
now	O
been	O
cloned	O
.	O

This	O
complementary	O
DNA	O
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c-jun	B-Gene
proto-oncogene	I-Gene
product	I-Gene
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	O
target	O
sequence	O
of	O
c-jun	B-Gene
.	O

Mutation	O
of	O
the	O
hXBP-1	B-Gene
DNA	I-Gene
target	O
sequence	O
decreased	O
DR	B-Gene
alpha	I-Gene
promoter	I-Gene
activity	O
in	O
vivo	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
hXBP-1	B-Gene
protein	I-Gene
acts	O
as	O
a	O
transcription	O
factor	O
in	O
B	O
cells	O
.	O

Identification	O
of	O
a	O
novel	O
factor	O
that	O
interacts	O
with	O
an	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
promoter	I-Gene
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B-Gene
cell-specific	I-Gene
factor	I-Gene
OTF2	I-Gene
.	O

The	O
tissue-specific	O
expression	O
of	O
the	O
MOPC	O
141	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
gene	I-Gene
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

B-cell-specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	O
element	O
5'-ATGCAAAG-3',	O
located	O
in	O
the	O
upstream	O
region	O
of	O
this	O
promoter	O
and	O
in	O
the	O
promoters	O
of	O
all	O
other	O
immunoglobulin	B-Gene
heavy-	I-Gene
and	O
light-chain	B-Partial_Gene
genes	I-Partial_Gene
.	O

The	O
interaction	O
of	O
purified	O
octamer	B-Gene
transcription	I-Gene
factors	I-Gene
1	I-Gene
and	O
2	B-Partial_Gene
(	O
OTF1	B-Gene
and	O
OTF2	B-Gene
)	O
with	O
the	O
MOPC	O
141	O
promoter	O
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	O
I	O
footprinting	O
.	O

Purified	B-Gene
OTF1	I-Gene
from	O
HeLa	O
cells	O
and	O
OTF1	B-Gene
and	O
OTF2	B-Gene
from	O
B	O
cells	O
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	O
promoter	O
.	O

The	O
OTF	B-Gene
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	O
element	O
5'-CTCAGGA-3',	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	O
factors	O
involves	O
cooperation	O
between	O
octamer	O
and	O
heptamer	O
sites	O
in	O
this	O
promoter	O
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	O
element	O
,	O
the	O
N	O
element	O
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O

The	O
N	O
element	O
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	O
element	O
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O

The	O
N	O
element	O
bound	O
a	O
transcription	O
factor	O
,	O
NTF	B-Gene
,	O
that	O
is	O
ubiquitous	O
in	O
cell-type	O
distribution	O
,	O
and	O
NTF	B-Gene
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	O
described	O
proteins	O
that	O
bind	O
to	O
similar	O
sequences	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	B-Gene
and	O
OTF2	B-Gene
interactions	O
(	O
both	O
with	O
their	O
cognate	O
DNA	O
elements	O
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

Effects	O
of	O
1	B-Chemical
alpha	I-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
on	O
the	O
human	O
chronic	B-Disease
myelogenous	I-Disease
leukemia	I-Disease
cell	O
line	O
RWLeu-4	O
.	O

The	O
effects	O
of	O
1	B-Chemical
alpha	I-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
VD3	B-Chemical
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	O
chromosome	O
-positive	O
chronic	B-Disease
myelogenous	I-Disease
leukemia	I-Disease
cell	O
line	O
,	O
RWLeu-4	O
,	O
were	O
investigated	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
VD3	B-Chemical
was	O
saturable	O
,	O
with	O
approximately	O
2000-3000	O
sites	O
/	O
cell	O
,	O
and	O
half-maximal	O
binding	O
occurring	O
at	O
0.21-0.33	O
nM	O
.	O

Treatment	O
of	O
RWLeu-4	O
cells	O
with	O
VD3	B-Chemical
induced	O
24R-hydroxylase	B-Gene
activity	O
,	O
a	O
marker	O
of	O
vitamin	B-Chemical
D3	I-Chemical
responsiveness	O
in	O
many	O
tissues	O
.	O

Exposure	O
of	O
RWLeu-4	O
cells	O
to	O
VD3	B-Chemical
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	B-Chemical
treatment	O
.	O

Exposure	O
of	O
RWLeu-4	O
cells	O
to	O
5	O
nM	O
VD3	B-Chemical
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage	O
/	O
monocyte	O
type	O
cells	O
as	O
judged	O
by	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
staining	O
and	O
adherence	O
to	O
plastic	O
.	O

Progressive	O
expression	O
of	O
cell	O
surface	O
maturation-specific	O
antigens	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	O
cells	O
with	O
VD3	B-Chemical
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

c-myc	B-Gene
RNA	I-Gene
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	O
cells	O
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	B-Chemical
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	B-Gene
kinase	I-Gene
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-Gene
oncogene	I-Gene
product	I-Gene
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	B-Chemical
treatment	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	B-Chemical
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	B-Chemical
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	B-Disease
myelogenous	I-Disease
leukemia	I-Disease
.	O

Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	O
infiltrates	O
in	O
breast	B-Disease
carcinomas	I-Disease
--	O
correlation	O
with	O
tumour	B-Disease
differentiation	O
.	O

Inflammatory	O
infiltrates	O
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	B-Disease
carcinomas	I-Disease
by	O
counting	O
the	O
percentage	O
of	O
macrophages	O
,	O
IgA+	B-Gene
and	O
IgG+	B-Gene
plasma	O
cells	O
,	O
T	O
cells	O
with	O
their	O
subpopulations	O
,	O
and	O
natural	O
killer	O
cells	O
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O

These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	B-Disease
differentiation	O
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	B-Gene
receptor	I-Gene
(	O
OR	B-Gene
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
as	O
well	O
as	O
inflammation	O
and	O
progesterone	B-Gene
receptor	I-Gene
(	O
PR	B-Gene
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
percentage	O
of	O
the	O
OKT8+	B-Gene
suppressor	O
/	O
cytotoxic	O
T	O
cells	O
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8+	B-Gene
T	O
cells	O
(	O
P	O
less	O
than	O
0.04	O
)	O
and	O
the	O
Leu-7+	B-Gene
natural	O
killer	O
cells	O
(	O
P	O
less	O
than	O
0.03	O
)	O
.	O

Mapping	O
of	O
B-cell	O
epitopes	O
of	O
the	O
human	B-Gene
hepatitis	I-Gene
B	I-Gene
virus	I-Gene
X	I-Gene
protein	I-Gene
.	O

The	O
immune	O
response	O
to	O
the	O
X	B-Gene
protein	I-Gene
of	O
human	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B-Gene
fusion	I-Gene
proteins	I-Gene
and	O
synthetic	O
peptides	O
.	O

Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O

Each	O
serum	O
contained	O
antibodies	O
to	O
a	O
different	O
set	O
of	O
epitopes	O
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B-Gene
sequence	O
.	O

Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	O
proteins	O
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme	O
-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O

The	O
carboxy-terminal	O
half	O
of	O
the	O
HBx	B-Gene
protein	I-Gene
was	O
preferentially	O
recognized	O
by	O
antibodies	O
from	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
and	O
contained	O
a	O
short	O
immunodominant	O
antigenic	O
region	O
with	O
at	O
least	O
two	O
major	O
nonoverlapping	O
epitopes	O
.	O

Anti-	B-Gene
HBx	I-Gene
antibody	I-Gene
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	B-Gene
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B-Gene
-specific	O
peptide	O
ELISAs	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O

The	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
ORI1yt	O
enhancer	O
is	O
not	O
B-cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B-Gene
transcription	I-Gene
factors	I-Gene
R	I-Gene
and	O
Z	B-Gene
.	O

The	O
Epstein-Barr	O
virus	O
DR	O
promoter	O
is	O
located	O
upstream	O
of	O
the	O
PstI	O
repeats	O
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	O
box	O
,	O
it	O
contains	O
an	O
upstream	O
region	O
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B-Gene
(	O
Z	B-Gene
)	O
(	O
the	O
BZLF1	B-Gene
-encoded	O
transcription	O
factor	O
)	O
and	O
an	O
enhancer	O
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	O
.	O

Domain	O
B	O
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B-Gene
EB1	I-Gene
-responsive	I-Gene
element	I-Gene
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040-3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	B-Gene
and	O
R	B-Gene
,	O
an	O
EBV	O
early	O
product	O
encoded	O
by	O
the	O
open	O
reading	O
frame	O
BRLF1	B-Gene
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313-321	O
,	O
1990	O
)	O
.	O

We	O
show	O
here	O
that	O
domain	O
B	O
is	O
an	O
R	B-Gene
-responsive	I-Gene
element	I-Gene
in	O
HeLa	O
cells	O
and	O
is	O
therefore	O
not	O
an	O
EB1	B-Gene
-responsive	I-Gene
B-cell-specific	I-Gene
element	I-Gene
.	O

However	O
,	O
there	O
is	O
an	O
EB1	B-Gene
-binding	O
site	O
(	O
ZRE-B	O
)	O
located	O
within	O
the	O
R	B-Gene
-responsive	I-Gene
enhancer	I-Gene
region	O
.	O

ZRE-B	O
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R	B-Gene
-dependent	I-Gene
enhancer	I-Gene
activity	O
.	O

Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B-Gene
and	O
EB1	B-Gene
when	O
activating	O
the	O
B	O
domain	O
(	O
ZRE-B	O
plus	O
the	O
R	B-Gene
-responsive	I-Gene
element	I-Gene
)	O
positioned	O
as	O
an	O
enhancer	O
.	O

ZRE-B	O
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B-Gene
inducible	O
enhancer	O
.	O

We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	O
enhancer	O
B	O
domain	O
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R	B-Gene
-activating	O
signal	O
to	O
the	O
rabbit	B-Gene
beta-globin	I-Gene
promoter	I-Gene
.	O

We	O
found	O
that	O
the	O
R	B-Gene
-responsive	I-Gene
element	I-Gene
is	O
composed	O
of	O
four	O
protoenhancers	O
that	O
span	O
the	O
whole	O
B	O
domain	O
.	O

These	O
protoenhancers	O
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B-Gene
.	O

One	O
of	O
the	O
protoenhancers	O
contains	O
the	O
overlapping	O
palindromes	O
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O

However	O
,	O
one	O
palindrome	O
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	O
palindromes	O
did	O
not	O
respond	O
to	O
R	B-Gene
.	O

Human	B-Gene
immunodeficiency	I-Gene
virus	I-Gene
vpr	I-Gene
product	O
is	O
a	O
virion	O
-associated	O
regulatory	O
protein	O
.	O

The	O
vpr	B-Gene
product	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	O
cells	O
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-Gene
protein	I-Gene
.	O

The	O
vpr	B-Gene
product	O
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	B-Gene
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O

Type	O
II	O
estrogen	B-Chemical
binding	O
sites	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O

We	O
have	O
previously	O
reported	O
that	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
contain	O
type	O
II	O
estrogen	B-Chemical
binding	O
sites	O
(	O
type	O
II	O
EBS	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
fluctuations	O
of	O
type	O
II	O
EBS	O
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O

Approximately	O
3	O
times	O
higher	O
levels	O
of	O
type	O
II	O
EBS	O
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O

In	O
postmenopausal	O
women	O
the	O
mean	O
type	O
II	O
EBS	O
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O

However	O
,	O
in	O
3	O
postmenopausal	O
patients	O
a	O
short	O
course	O
of	O
estrogen	B-Chemical
or	O
tamoxifen	B-Chemical
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	O
II	O
EBS	O
levels	O
.	O

Tamoxifen	B-Chemical
was	O
also	O
found	O
to	O
compete	O
with	O
17	B-Chemical
beta-estradiol	I-Chemical
for	O
type	O
II	O
EBS	O
in	O
PBMC	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	B-Chemical
.	O

Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	B-Chemical
action	O
in	O
human	O
tonsillar	O
T-lymphocytes	O
.	O

The	O
treatment	O
of	O
human	O
tonsillar	O
T-lymphocytes	O
with	O
4-phorbol	B-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
(	O
PMA	B-Chemical
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O

This	O
increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	B-Chemical
.	O

Alone	O
,	O
PMA	B-Chemical
and	O
calcium	B-Chemical
ionophore	O
A23187	B-Chemical
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	B-Gene
(	O
PHA	B-Gene
)	O
,	O
leucine	B-Chemical
and	O
,	O
in	O
particular	O
,	O
thymidine	B-Chemical
incorporation	O
.	O

PMA	B-Chemical
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B-Gene
.	O

Alone	O
,	O
these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O
dexamethasone	B-Chemical
on	O
thymidine	B-Chemical
and	O
leucine	B-Chemical
incorporation	O
;	O
however	O
,	O
PMA-A23187	B-Chemical
and	O
PMA	B-Chemical
-PHA	B-Gene
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	B-Chemical
.	O

Lymphocyte	O
cell	O
lines	O
from	O
vitamin	B-Disease
D	I-Disease
-dependent	I-Disease
rickets	I-Disease
type	I-Disease
II	I-Disease
show	O
functional	O
defects	O
in	O
the	O
1	B-Gene
alpha	I-Gene
,	I-Gene
25-dihydroxyvitamin	I-Gene
D3	I-Gene
receptor	I-Gene
.	O

Lymphocyte	O
cell	O
lines	O
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	B-Disease
D	I-Disease
-dependent	I-Disease
rickets	I-Disease
,	I-Disease
type	I-Disease
II	I-Disease
(	O
VDDR-II	B-Disease
)	O
.	O

These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T-lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
1	B-Chemical
alpha	I-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T-lymphocyte	O
cell	O
line	O
(	O
S-LB1	O
)	O
from	O
a	O
normal	O
individual	O
.	O

The	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
of	O
S-LB1	O
was	O
comparable	O
to	O
the	O
well	O
-characterized	O
chick	B-Gene
intestinal	I-Gene
1	I-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5-20	O
%	O
sucrose	B-Chemical
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA-cellulose	O
.	O

Three	O
cell	O
lines	O
established	O
from	O
patients	O
with	O
VDDR-II	B-Disease
(	O
Rh-	O
VDR	O
,	O
Sh-	O
VDR	O
,	O
and	O
Ab-	O
VDR	O
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	O
and	O
treatment	O
of	O
the	O
cultured	O
cells	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	B-Chemical
,	I-Chemical
25-dihydroxy-vitamin	I-Chemical
D3	I-Chemical
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
.	O

In	O
a	O
fourth	O
cell	O
line	O
,	O
A1-VDR	O
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
D3-24-hydroxylase	I-Gene
activity	O
was	O
not	O
detectable	O
.	O

Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	O
line	O
,	O
designated	O
Ro-VDR	O
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	O
cell	O
line	O
from	O
a	O
normal	O
donor	O
.	O

The	O
capacity	O
of	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro-VDR	O
.	O

In	O
all	O
cell	O
lines	O
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	O
was	O
detectable	O
,	O
the	O
receptor	O
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O
on	O
sucrose	B-Chemical
density	O
gradient	O
analysis	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	O
and	O
A1-VDR	O
cells	O
where	O
elution	O
from	O
DNA-cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
.	O

While	O
Ro-VDR	O
cells	O
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	O
from	O
A1-VDR	O
cells	O
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O

In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	O
coding	O
for	O
both	O
the	O
c-myc	B-Gene
oncogene	I-Gene
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte-monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
status	O
of	O
these	O
cells	O
.	O

Use	O
of	O
these	O
cell	O
lines	O
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	B-Disease
D	I-Disease
-dependent	I-Disease
rickets	I-Disease
type	I-Disease
II	I-Disease
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid-specific	O
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
gene	I-Gene
expression	O
.	O

To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	O
(	O
OCTA	O
)	O
-nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
(	I-Gene
IgH	I-Gene
)	I-Gene
gene	I-Gene
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	O
site	O
for	O
a	O
putative	O
additional	O
lymphoid-specific	O
transcription	O
factor	O
,	O
designated	O
NF-microB	O
,	O
in	O
the	O
murine	O
IgH	B-Gene
enhancer	I-Gene
.	O

We	O
demonstrate	O
that	O
the	O
NF-microB	O
-binding	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	B-Gene
enhancer	I-Gene
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	B-Gene
enhancer	I-Gene
in	O
cells	O
of	O
the	O
B-cell	O
lineage	O
but	O
not	O
in	O
nonlymphoid	O
cells	O
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	O
site	O
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	O
and	O
OCTA	O
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	O
or	O
E3	O
site	O
in	O
a	O
70-base-pair	O
fragment	O
of	O
the	O
IgH	B-Gene
enhancer	I-Gene
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	O
motif	O
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	O
protein	O
binds	O
to	O
the	O
microB	O
DNA	O
motif	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	O
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	B-Gene
gene	I-Gene
but	O
that	O
interaction	O
with	O
another	O
enhancer	O
element	O
is	O
essential	O
for	O
its	O
activity	O
.	O

Heterogeneity	O
of	O
antigen	O
molecules	O
recognized	O
by	O
anti-tax1	B-Gene
monoclonal	I-Gene
antibody	I-Gene
Lt-4	I-Gene
in	O
cell	O
lines	O
bearing	O
human	O
T	B-Disease
cell	I-Disease
leukemia	I-Disease
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
,	O
Lt-4	B-Gene
,	O
directed	O
against	O
human	B-Gene
T	I-Gene
cell	I-Gene
leukemia	I-Gene
virus	I-Gene
type	I-Gene
I	I-Gene
(	I-Gene
HTLV-I	I-Gene
)	I-Gene
trans-activator	I-Gene
(	I-Gene
tax1	I-Gene
)	I-Gene
antigen	I-Gene
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-Gene
and	O
related	O
antigens	O
in	O
a	O
variety	O
of	O
T	O
cell	O
lines	O
bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	B-Disease
cell	I-Disease
leukemia	I-Disease
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O

Lt-4	B-Gene
reacted	O
with	O
all	O
HTLV-I	O
-bearing	O
cell	O
lines	O
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	O
cell	O
lines	O
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O
HTLV-II	O
-bearing	O
cell	O
line	O
.	O

Lt-4	B-Gene
detected	O
40	O
kd	O
tax1	B-Gene
antigen	I-Gene
molecules	O
in	O
most	O
HTLV-I	O
-bearing	O
cell	O
lines	O
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	O
kd	O
tax1	B-Gene
antigen	I-Gene
.	O

In	O
the	O
STLV-I	O
-bearing	O
T	O
cell	O
lines	O
,	O
tax1	B-Gene
-related	O
antigen	O
molecules	O
detected	O
by	O
Lt-4	B-Gene
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd	O
.	O

The	O
expression	O
of	O
c-fos	B-Gene
,	O
c-jun	B-Gene
,	O
and	O
c-myc	B-Gene
genes	I-Gene
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	O
lymphoid	O
cells	O
.	O

The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	B-Gene
protooncogenes	I-Gene
c-fos	I-Gene
,	O
c-jun	B-Gene
,	O
and	O
c-myc	B-Gene
was	O
studied	O
in	O
human	O
lymphoid	O
cells	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	B-Gene
and	O
c-jun	B-Gene
mRNA	I-Gene
levels	O
and	O
a	O
decrease	O
in	O
c-myc	B-Gene
mRNA	I-Gene
levels	O
in	O
pre-B	O
(	O
Hyon	O
)	O
and	O
T	O
(	O
DND-41	O
)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	O
in	O
Hyon	O
cells	O
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O

Altered	O
transcription	O
of	O
c-fos	B-Gene
and	O
c-myc	B-Gene
genes	I-Gene
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O

Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	O
cells	O
stabilized	O
the	O
c-myc	B-Gene
mRNA	I-Gene
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O

The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	B-Gene
mRNA	I-Gene
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	O
protooncogenes	O
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	O
protooncogenes	O
in	O
the	O
stress	O
response	O
of	O
lymphoid	O
cells	O
.	O

A	O
novel	O
T-cell	O
protein	O
which	O
recognizes	O
a	O
palindromic	O
sequence	O
in	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

Two	O
major	O
protein	O
-binding	O
sites	O
within	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
have	O
been	O
identified	O
.	O

One	O
(	O
site	O
B	O
)	O
contained	O
a	O
palindromic	O
sequence	O
with	O
homology	O
to	O
steroid	B-Chemical
/	O
thyroid	B-Chemical
hormone	I-Chemical
response	O
elements	O
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O

A	O
novel	O
T-cell	O
protein	O
recognized	O
the	O
palindromic	O
sequence	O
within	O
site	O
B	O
and	O
also	O
bound	O
estrogen-	B-Chemical
or	O
thyroid	B-Chemical
hormone-response	I-Chemical
elements	O
with	O
lower	O
affinity	O
.	O

A	O
7-base-pair	O
mutation	O
in	O
the	O
site	O
B	O
palindrome	O
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Epstein-Barr	B-Gene
virus	I-Gene
nuclear	I-Gene
antigen	I-Gene
2	I-Gene
transactivates	O
latent	B-Gene
membrane	I-Gene
protein	I-Gene
LMP1	I-Gene
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B-Gene
virus	I-Gene
(	I-Gene
EBV	I-Gene
)	I-Gene
nuclear	I-Gene
antigen	I-Gene
2	I-Gene
(	O
EBNA-2	B-Gene
)	O
or	O
leader	O
protein	O
(	O
EBNA-LP	B-Gene
)	O
affects	O
expression	O
of	O
the	O
EBV	B-Gene
latent	I-Gene
infection	I-Gene
membrane	I-Gene
protein	I-Gene
LMP1	I-Gene
.	O

We	O
now	O
demonstrate	O
the	O
following	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B-Gene
under	O
control	O
of	O
simian	O
virus	O
40	O
or	O
Moloney	B-Gene
murine	I-Gene
leukemia	I-Gene
virus	I-Gene
promoters	I-Gene
resulted	O
in	O
increased	O
LMP1	B-Gene
expression	O
in	O
P3HR-1	O
-infected	O
Burkitt	B-Disease
's	I-Disease
lymphoma	I-Disease
cells	O
and	O
the	O
P3HR-1	O
or	O
Daudi	O
cell	O
line	O
.	O

(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA-LP	B-Gene
alone	O
had	O
no	O
effect	O
on	O
LMP1	B-Gene
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	B-Gene
to	O
affect	O
LMP1	B-Gene
expression	O
.	O

(	O
iii	O
)	O
LMP1	B-Gene
expression	O
in	O
Daudi	O
and	O
P3HR-1	O
-infected	O
cells	O
was	O
controlled	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
EBNA-2	B-Gene
expression	O
in	O
Daudi	O
cells	O
increased	O
LMP1	B-Gene
mRNA	I-Gene
.	O

(	O
iv	O
)	O
No	O
other	O
EBV	O
genes	O
were	O
required	O
for	O
EBNA-2	B-Gene
transactivation	O
of	O
LMP1	B-Gene
since	O
cotransfection	O
of	O
recombinant	B-Gene
EBNA-2	I-Gene
expression	O
vectors	O
and	O
genomic	O
LMP1	B-Gene
DNA	I-Gene
fragments	O
enhanced	O
LMP1	B-Gene
expression	O
in	O
the	O
EBV	O
-negative	O
B-lymphoma	O
cell	O
lines	O
BJAB	O
,	O
Louckes	O
,	O
and	O
BL30	O
.	O

(	O
v	O
)	O
An	O
EBNA-2	B-Gene
-responsive	O
element	O
was	O
found	O
within	O
the	O
-512	O
to	O
+40	O
LMP1	B-Gene
DNA	I-Gene
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	B-Gene
expression	O
vector	O
.	O

(	O
vi	O
)	O
The	O
EBV	B-Gene
type	I-Gene
2	I-Gene
EBNA-2	I-Gene
transactivated	O
LMP1	B-Gene
as	O
well	O
as	O
the	O
EBV	B-Gene
type	I-Gene
1	I-Gene
EBNA-2	I-Gene
.	O

(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B-Gene
gene	I-Gene
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-Gene
,	O
whereas	O
a	O
transformation	O
-competent	O
EBNA-2	B-Gene
deletion	O
mutant	O
did	O
transactivate	O
LMP1	B-Gene
.	O

LMP1	B-Gene
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B-Gene
to	O
induce	O
cellular	O
CD23	B-Gene
gene	I-Gene
expression	O
.	O

Thus	O
,	O
EBNA-2	B-Gene
transactivation	O
of	O
LMP1	B-Gene
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	B-Gene
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV	O
-induced	O
growth	O
transformation	O
.	O

Involvement	O
of	O
cyclic	B-Gene
AMP	I-Gene
-dependent	I-Gene
protein	I-Gene
kinases	I-Gene
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	B-Gene
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-Gene
AMP	I-Gene
-dependent	I-Gene
protein	I-Gene
kinases	I-Gene
in	O
interleukin-1	B-Gene
(	O
IL-1	B-Gene
)	O
-responsive	O
cells	O
blocked	O
IL-1	B-Gene
-induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-Gene
immunoglobulin	I-Gene
enhancer	I-Gene
or	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B-Gene
AMP	I-Gene
-dependent	I-Gene
protein	I-Gene
kinases	I-Gene
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	B-Gene
in	O
a	O
number	O
of	O
responsive	O
cell	O
types	O
.	O

Protein	B-Gene
kinase	I-Gene
inhibitor	O
H-7	B-Chemical
blocks	O
accumulation	O
of	O
unspliced	O
mRNA	O
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O

Rex	B-Gene
,	O
the	O
post-transcriptional	O
regulator	O
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	O
viral	O
gag-pol	B-Gene
mRNA	I-Gene
.	O

Rex	B-Gene
is	O
a	O
phosphoprotein	O
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B-Gene
function	O
by	O
using	O
a	O
protein	B-Gene
kinase	I-Gene
inhibitor	I-Gene
,	O
H-7	B-Chemical
[	O
1-	B-Chemical
(	I-Chemical
5-isoquinolinyl-sulfonyl	I-Chemical
)	I-Chemical
-2-methylpiperazine	I-Chemical
]	O
.	O

Treatment	O
of	O
an	O
HTLV-I	O
infected	O
human	O
T-cell	O
line	O
with	O
H-7	B-Chemical
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	O
gag-pol	B-Gene
mRNA	I-Gene
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-Gene
protein	I-Gene
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B-Gene
.	O

In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H-7	B-Chemical
used	O
.	O

Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B-Gene
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV-I	O
.	O

Increased	O
glucocorticoid	B-Chemical
responsiveness	O
of	O
CD4+	B-Gene
T-cell	O
clonal	O
lines	O
grown	O
in	O
serum-free	O
media	O
.	O

CEM-C7	O
,	O
a	O
human	B-Gene
leukemic	I-Gene
CD4+	I-Gene
T-lymphocyte	O
cell	O
line	O
and	O
three	O
of	O
its	O
subclones	O
,	O
CEM-4R4	O
,	O
CEM-3R43	O
,	O
and	O
ICR-27	O
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
5	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum-free	O
media	O
.	O

The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms	O
/	O
ml	O
each	O
transferrin	B-Gene
and	O
insulin	B-Gene
+	O
5	O
ng	O
/	O
ml	O
sodium	B-Chemical
selenite	I-Chemical
+	O
/	O
-	O
0.1	O
%	O
bovine	B-Gene
serum	I-Gene
albumin	I-Gene
.	O

While	O
growing	O
either	O
with	O
or	O
without	O
albumin	B-Gene
,	O
the	O
several	O
clonal	O
lines	O
of	O
CEM	O
cells	O
displayed	O
growth	O
similar	O
to	O
serum	O
-supplemented	O
cultures	O
.	O

Cell	O
proliferation	O
of	O
CEM-C7	O
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O

with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum	O
-supplemented	O
and	O
serum-free	O
cultures	O
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O

Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O

The	O
expression	O
of	O
CD4	B-Gene
,	O
a	O
marker	O
for	O
T	O
-derived	O
lymphoid	O
cells	O
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O

When	O
grown	O
in	O
serum-free	O
medium	O
,	O
CEM-C7	O
cells	O
exhibited	O
increased	O
steroid	B-Chemical
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B-Gene
receptor	I-Gene
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	B-Gene
synthetase	I-Gene
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	B-Chemical
.	O

Receptor	O
mutant	O
subclones	O
of	O
CEM-C7	O
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	B-Chemical
when	O
grown	O
in	O
serum	O
-supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O

The	O
increased	O
sensitivity	O
of	O
CEM-C7	O
cells	O
and	O
its	O
subclones	O
to	O
dexamethasone	B-Chemical
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum	O
-containing	O
medium	O
.	O

Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	B-Chemical
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	B-Chemical
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O

Lipopolysaccharide	B-Chemical
is	O
a	O
potent	O
monocyte	O
/	O
macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
potently	O
stimulates	O
human	O
immunodeficiency	O
virus	O
type	O
1-long	O
terminal	O
repeat	O
(	O
HIV-1-LTR	O
)	O
CAT	O
constructs	O
transfected	O
into	O
monocyte	O
/	O
macrophage	O
-like	O
cell	O
lines	O
but	O
not	O
a	O
T	O
cell	O
line	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NF-kappa	B-Gene
B	I-Gene
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	B-Chemical
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-Gene
B	I-Gene
in	O
U937	O
and	O
THP-1	O
cells	O
.	O

LPS	B-Chemical
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	O
infected	O
monocyte	O
/	O
macrophage	O
-like	O
cloned	O
cell	O
line	O
,	O
U1	O
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte	B-Gene
/	I-Gene
macrophage	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
GM-CSF	B-Gene
)	O
before	O
treatment	O
with	O
LPS	B-Chemical
.	O

This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	O
RNA	O
and	O
and	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
.	O

LPS	B-Chemical
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	O
cell	O
line	O
.	O

The	O
effect	O
of	O
LPS	B-Chemical
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O

Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV-2	O
transactivator	O
gene	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O

The	O
transactivator	B-Gene
(	I-Gene
IE-2	I-Gene
)	I-Gene
gene	I-Gene
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV-2	B-Gene
tat	I-Gene
gene	I-Gene
and	O
T-cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	B-Gene
CD4+	I-Gene
lymphocytes	O
.	O

While	O
the	O
HIV-2	O
and	O
HIV-1	B-Gene
tat	I-Gene
genes	I-Gene
and	O
T-cell	O
activators	O
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	O
transactivator	O
in	O
combination	O
with	O
the	O
HIV-2	B-Gene
tat	I-Gene
or	O
T-cell	O
activators	O
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O

Both	O
HIV-2	O
and	O
CMV	O
transactivators	O
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	O
transactivator	O
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

A	O
significant	O
proportion	O
of	O
transcripts	O
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	O
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	B-Gene
CD4+	I-Gene
lymphocytes	O
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	O
enhancer	O
element	O
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	B-Gene
ets-1	I-Gene
defines	O
a	O
transcriptional	O
activator	O
sequence	O
within	O
the	O
long	O
terminal	O
repeat	O
of	O
the	O
Moloney	O
murine	O
sarcoma	B-Disease
virus	O
.	O

The	O
ets	B-Gene
proto-oncogene	I-Gene
family	I-Gene
is	O
a	O
group	O
of	O
sequence	O
-related	O
genes	O
whose	O
normal	O
cellular	O
function	O
is	O
unknown	O
.	O

In	O
a	O
study	O
of	O
cellular	O
proteins	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	O
lymphocytes	O
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	B-Gene
gene	I-Gene
family	I-Gene
encodes	O
a	O
sequence-specific	O
DNA	O
-binding	O
protein	O
.	O

A	O
mouse	B-Gene
ets-1	I-Gene
cDNA	I-Gene
clone	I-Gene
was	O
obtained	O
by	O
screening	O
a	O
mouse	O
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double	O
-stranded	O
oligonucleotide	O
probe	O
representing	O
20	O
bp	O
of	O
the	O
Moloney	O
murine	O
sarcoma	B-Disease
virus	O
(	O
MSV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

The	O
cDNA	O
sequence	O
has	O
an	O
813-bp	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6	O
%	O
identical	O
to	O
the	O
272	O
carboxy-terminal	O
amino	O
acids	O
of	O
the	O
human	B-Gene
ets-1	I-Gene
protein	I-Gene
.	O

The	O
ORF	O
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	O
protein	O
product	O
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
by	O
mobility-shift	O
assays	O
,	O
Southwestern	O
blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O

A	O
mutant	O
LTR	O
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	B-Gene
binding	O
site	O
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O

Transcriptional	O
efficiency	O
of	O
the	O
MSV	O
LTR	O
promoter	O
containing	O
this	O
disrupted	O
ets-1	B-Gene
binding	O
site	O
was	O
compared	O
to	O
the	O
activity	O
of	O
a	O
wild-type	O
promoter	O
in	O
mouse	O
T	O
lymphocytes	O
in	O
culture	O
,	O
and	O
15-	O
to	O
20-fold	O
reduction	O
in	O
expression	O
of	O
a	O
reporter	O
gene	O
was	O
observed	O
.	O

We	O
propose	O
that	O
ets-1	B-Gene
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets	B-Gene
-related	O
genes	O
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	O
DNA	O
-binding	O
proteins	O
.	O

Cloning	O
of	O
a	O
transcriptionally	O
active	O
human	B-Gene
TATA	I-Gene
binding	I-Gene
factor	I-Gene
.	O

Transcription	B-Gene
factor	I-Gene
IID	I-Gene
(	O
TFIID	B-Gene
)	O
binds	O
to	O
the	O
TATA	O
box	O
promoter	O
element	O
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	O
genes	O
transcribed	O
by	O
RNA	B-Gene
polymerase	I-Gene
II	I-Gene
.	O

Complementary	O
DNA	O
(	O
cDNA	O
)	O
encoding	O
a	O
human	B-Gene
TFIID	I-Gene
protein	I-Gene
has	O
been	O
cloned	O
.	O

The	O
human	B-Gene
TFIID	I-Gene
polypeptide	I-Gene
has	O
339	O
amino	O
acids	O
and	O
a	O
molecular	O
size	O
of	O
37	O
,	O
745	O
daltons	O
.	O

The	O
carboxyl-terminal	B-Chemical
181	O
amino	O
acids	O
of	O
the	O
human	B-Gene
TFIID	I-Gene
protein	I-Gene
shares	O
80	O
%	O
identity	O
with	O
the	O
TFIID	B-Gene
protein	I-Gene
from	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
amino	O
terminus	O
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	B-Chemical
residues	I-Chemical
and	O
an	O
X-Thr-Pro	B-Chemical
repeat	O
.	O

Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O

Mononuclear	B-Gene
leukocyte	I-Gene
glucocorticoid	I-Gene
receptor	I-Gene
binding	O
characteristics	O
and	O
down-regulation	O
in	O
major	B-Disease
depression	I-Disease
.	O

Some	O
patients	O
with	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
(	O
MDD	B-Disease
)	O
have	O
elevated	O
plasma	O
cortisol	B-Chemical
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	B-Chemical
secretion	O
upon	O
administration	O
of	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	B-Chemical
(	O
GC	B-Chemical
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX	B-Chemical
-binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	B-Gene
receptor	I-Gene
affinity	O
(	O
1	O
/	O
Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	O
leukocytes	O
of	O
11	O
MDD	B-Disease
patients	O
and	O
15	O
control	O
subjects	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	B-Disease
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	B-Chemical
in	O
the	O
MDD	B-Disease
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

DEX	B-Chemical
(	O
1.0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	O
GC	B-Gene
receptor	I-Gene
down-regulation	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down	O
-regulated	O
Bmax	O
after	O
DEX	B-Chemical
.	O

By	O
paired	O
t-test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O

Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down-regulation	O
,	O
severity	O
of	O
depression	B-Disease
or	O
cortisol	B-Chemical
concentrations	O
across	O
all	O
the	O
subjects	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	B-Chemical
resistance	O
in	O
MDD	B-Disease
results	O
from	O
a	O
GC	B-Gene
receptor	I-Gene
-binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	B-Chemical
-mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	B-Chemical
resistance	O
.	O

The	O
Epstein-Barr	B-Gene
virus	I-Gene
(	I-Gene
EBV	I-Gene
)	I-Gene
BMRF1	I-Gene
promoter	I-Gene
for	O
early	O
antigen	O
(	O
EA-D	B-Gene
)	O
is	O
regulated	O
by	O
the	O
EBV	O
transactivators	O
,	O
BRLF1	B-Gene
and	O
BZLF1	B-Gene
,	O
in	O
a	O
cell-specific	O
manner	O
.	O

The	O
Epstein-Barr	B-Gene
virus	I-Gene
early	I-Gene
antigen	I-Gene
diffuse	O
component	O
(	O
EA-D	B-Gene
)	O
is	O
essential	O
for	O
Epstein-Barr	B-Gene
virus	I-Gene
DNA	I-Gene
polymerase	I-Gene
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	O
(	O
BMRF1	B-Gene
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	O
viral	O
transactivators	O
,	O
BZLF1	B-Gene
(	O
Z	B-Gene
)	O
and	O
BRLF1	B-Gene
(	O
R	B-Gene
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	O
cells	O
and	O
epithelial	O
cells	O
.	O

In	O
lymphoid	O
cells	O
,	O
Z	B-Gene
or	O
R	B-Gene
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA-D	B-Gene
promoter	I-Gene
activity	O
,	O
whereas	O
both	O
transactivators	O
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O

In	O
epithelial	O
cells	O
,	O
the	O
Z	B-Gene
transactivator	I-Gene
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B-Gene
promoter	I-Gene
;	O
the	O
effect	O
of	O
R	B-Gene
and	O
Z	B-Gene
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B-Gene
alone	O
.	O

Deletional	O
analysis	O
and	O
site	O
-directed	O
mutagenesis	O
of	O
the	O
EA-D	B-Gene
promoter	I-Gene
demonstrated	O
that	O
in	O
epithelial	O
cells	O
the	O
potential	O
AP-1	B-Gene
binding	O
site	O
plays	O
an	O
essential	O
role	O
in	O
Z	B-Gene
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O

In	O
lymphoid	O
cells	O
,	O
only	O
the	O
upstream	O
sequences	O
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z	B-Gene
/	I-Gene
R	I-Gene
combination	O
,	O
and	O
the	O
AP-1	B-Gene
site	O
is	O
dispensable	O
.	O

These	O
data	O
suggest	O
that	O
EA-D	B-Gene
(	I-Gene
BMRF1	I-Gene
)	I-Gene
promoter	I-Gene
regulation	O
by	O
Z	B-Gene
and	O
R	B-Gene
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O

Inducible	O
nuclear	O
factor	O
binding	O
to	O
the	O
kappa	O
B	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	B-Chemical
A	I-Chemical
in	O
a	O
signal	O
-dependent	O
manner	O
.	O

Cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	O
genes	O
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B-Gene
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	B-Chemical
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	O
factors	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	O
DNA	O
-binding	O
complexes	O
,	O
the	O
kappa	O
B	O
complex	O
within	O
the	O
HIV	B-Gene
enhancer	I-Gene
and	O
the	O
NFAT-1	B-Gene
complex	I-Gene
within	O
the	O
interleukin-2	B-Gene
enhancer	I-Gene
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	B-Chemical
.	O

The	O
kappa	O
B	O
-binding	O
activity	O
with	O
the	O
HIV	B-Gene
enhancer	I-Gene
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	O
phytohemagglutinin	B-Gene
whereas	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	O
B	O
complexes	O
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	B-Chemical
.	O

Two	O
distinct	O
forms	O
of	O
active	O
transcription	B-Gene
factor	I-Gene
CREB	I-Gene
(	O
cAMP	B-Gene
response	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
)	O
.	O

Mammalian	O
cells	O
express	O
two	O
distinct	O
forms	O
of	O
transcription	B-Gene
factor	I-Gene
CREB	I-Gene
(	O
cAMP	B-Gene
response	I-Gene
element	I-Gene
binding	I-Gene
protein	I-Gene
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-Gene
gene	I-Gene
transcript	I-Gene
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14-amino	O
acid	O
serine-rich	B-Chemical
insertion	O
present	O
in	O
one	O
of	O
the	O
CREB	B-Gene
isoforms	I-Gene
.	O

We	O
show	O
that	O
both	O
CREB	B-Gene
isoforms	I-Gene
are	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
mammalian	O
species	O
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	B-Chemical
response	O
element	O
in	O
vitro	O
.	O

As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B-Gene
proteins	I-Gene
bind	O
DNA	O
as	O
dimers	O
.	O

Both	O
proteins	O
impart	O
cAMP	B-Chemical
-regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	O
DNA	O
-binding	O
domain	O
,	O
showing	O
that	O
cAMP	B-Chemical
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B-Gene
.	O

The	O
presence	O
of	O
multiple	O
CREB	B-Gene
isoforms	I-Gene
with	O
identical	O
DNA	O
-binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	O
domain	O
raises	O
the	O
possibility	O
that	O
CREB	B-Gene
proteins	I-Gene
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Complementary	O
DNA	O
encoding	O
the	O
human	B-Gene
T-cell	I-Gene
FK506	I-Gene
-binding	I-Gene
protein	I-Gene
,	O
a	O
peptidylprolyl	B-Gene
cis-trans	I-Gene
isomerase	I-Gene
distinct	O
from	O
cyclophilin	B-Gene
.	O

The	O
recently	O
discovered	O
macrolide	O
FK506	B-Chemical
has	O
been	O
demonstrated	O
to	O
have	O
potent	O
immunosuppressive	O
activity	O
at	O
concentrations	O
100-fold	O
lower	O
than	O
cyclosporin	B-Chemical
A	I-Chemical
,	O
a	O
cyclic	O
undecapeptide	O
that	O
is	O
used	O
to	O
prevent	O
rejection	O
after	O
transplantation	O
of	O
bone	O
marrow	O
and	O
organs	O
,	O
such	O
as	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
.	O

After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B-Gene
A	I-Gene
-binding	I-Gene
protein	I-Gene
cyclophilin	I-Gene
is	O
identical	O
to	O
peptidylprolyl	B-Gene
cis-trans	I-Gene
isomerase	I-Gene
,	O
a	O
cellular	O
binding	O
protein	O
for	O
FK506	B-Chemical
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	B-Gene
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	O
coding	O
for	O
FK506	B-Gene
-binding	I-Gene
protein	I-Gene
(	O
FKBP	B-Gene
)	O
from	O
human	O
peripheral	O
blood	O
T	O
cells	O
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	B-Chemical
,	O
reported	O
for	O
bovine	B-Gene
FKBP	I-Gene
.	O

The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O

The	O
first	O
40	O
residues	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
were	O
identical	O
to	O
those	O
of	O
the	O
reported	O
amino-terminal	O
sequence	O
of	O
bovine	B-Gene
FKBP	I-Gene
,	O
indicating	O
that	O
the	O
DNA	O
sequence	O
isolated	O
represents	O
the	O
gene	O
coding	O
for	O
FKBP	B-Gene
.	O

Computer	O
-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	B-Gene
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	B-Gene
.	O

This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins	O
,	O
cyclophilin	B-Gene
and	O
FKBP	B-Gene
,	O
evolved	O
independently	O
.	O

In	O
Northern	O
blot	O
analysis	O
,	O
mRNA	O
species	O
of	O
approximately	O
1.8	O
kilobases	O
that	O
hybridized	O
with	O
human	B-Gene
FKBP	I-Gene
cDNA	I-Gene
were	O
detected	O
in	O
poly	O
(	O
A	O
)	O
+	O
RNAs	O
from	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
and	O
placental	O
cells	O
and	O
leukocytes	O
.	O

Induction	O
of	O
Jurkat	O
leukemic	O
T	O
cells	O
with	O
phorbol	B-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
and	O
ionomycin	B-Chemical
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B-Gene
mRNA	I-Gene
.	O

Southern	O
blot	O
analysis	O
of	O
human	O
genomic	O
DNA	O
digested	O
with	O
different	O
restriction	O
enzymes	O
suggests	O
the	O
existence	O
of	O
only	O
a	O
few	O
copies	O
of	O
the	O
DNA	O
sequence	O
encoding	O
FKBP	B-Gene
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O
as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	B-Gene
gene	I-Gene
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	O
genome	O
.	O

[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	B-Chemical
on	O
the	O
chemotactic	O
migration	O
of	O
human	O
leukocytes	O
]	O

Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	O
leukocytes	O
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O

Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O

Leukocytes	O
migrated	O
most	O
rapidly	O
at	O
night	O
.	O

The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	B-Chemical
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
which	O
was	O
dose	O
-dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	B-Chemical
.	O

The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-5	O
)	O
mol	O
/	O
L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	B-Chemical
,	O
but	O
only	O
partially	O
.	O

It	O
is	O
suggested	O
that	O
glucocorticoids	B-Chemical
(	O
GC	B-Chemical
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	O
and	O
its	O
inhibitory	O
action	O
on	O
ChtM	O
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	B-Chemical
of	O
pharmacological	O
doses	O
.	O

The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	B-Chemical
may	O
be	O
mediated	O
by	O
low	O
affinity	O
specific	O
binding	O
sites	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

The	O
56-59-kilodalton	O
protein	O
identified	O
in	O
untransformed	O
steroid	B-Gene
receptor	I-Gene
complexes	I-Gene
is	O
a	O
unique	O
protein	O
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B-Partial_Gene
and	O
90-kilodalton	B-Gene
heat	I-Gene
shock	I-Gene
proteins	I-Gene
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	O
,	O
untransformed	O
progestin	B-Chemical
,	O
estrogen	B-Chemical
,	O
androgen	B-Chemical
,	O
and	O
glucocorticoid	B-Gene
receptor	I-Gene
complexes	I-Gene
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	O
protein	O
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O
N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269-5275	O
]	O
.	O

In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	O
antibody	O
KN	O
382	O
/	O
EC1	O
raised	O
against	O
the	O
rabbit	O
59-kDa	O
protein	O
reacts	O
with	O
9S	O
,	O
untransformed	O
glucocorticoid	B-Gene
receptor	I-Gene
complexes	I-Gene
in	O
cytosol	O
prepared	O
from	O
human	O
IM-9	O
lymphocytes	O
but	O
not	O
with	O
4S	O
salt	O
-transformed	O
receptors	O
.	O

The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B-Gene
antibody	I-Gene
is	O
a	O
56-kDa	B-Gene
protein	I-Gene
(	O
p56	B-Gene
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O

There	O
are	O
at	O
least	O
six	O
isomorphs	O
of	O
p56	B-Gene
by	O
two-dimensional	O
gel	O
analysis	O
.	O

N-Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	B-Gene
is	O
a	O
unique	O
human	O
protein	O
.	O

When	O
p56	B-Gene
is	O
immunoadsorbed	O
from	O
IM-9	O
cell	O
cytosol	O
,	O
both	O
the	O
70-	B-Partial_Gene
and	O
90-kDa	B-Gene
heat	I-Gene
shock	I-Gene
proteins	I-Gene
are	O
coadsorbed	O
in	O
an	O
immune-specific	O
manner	O
.	O

Neither	O
heat	B-Gene
shock	I-Gene
protein	I-Gene
reacts	O
directly	O
with	O
the	O
EC1	B-Gene
antibody	I-Gene
.	O

We	O
conclude	O
that	O
p56	B-Gene
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B-Gene
and	O
hsp90	B-Gene
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	O
steroid	B-Gene
receptors	I-Gene
.	O

Tandem	O
AP-1	B-Gene
-binding	O
sites	O
within	O
the	O
human	B-Gene
beta-globin	I-Gene
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	O
DNA	O
segment	O
located	O
11	O
kb	O
5	O
'to	O
the	O
human	B-Gene
epsilon-globin	I-Gene
gene	I-Gene
within	O
the	O
dominant	O
control	O
or	O
locus	O
-activating	O
region	O
.	O

This	O
enhancer	O
is	O
inducible	O
in	O
K562	O
human	O
erythroleukemia	B-Disease
cells	O
,	O
increasing	O
linked	O
gamma-globin	B-Gene
promoter	I-Gene
/	O
luciferase	O
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	O
construct	O
.	O

The	O
enhancer	O
consists	O
of	O
tandem	O
AP-1	B-Gene
-binding	O
sites	O
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O

DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	O
molecular	O
weight	O
complex	O
on	O
the	O
enhancer	O
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	B-Gene
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O

Induction	O
of	O
the	O
enhancer	O
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	B-Gene
gene	I-Gene
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	B-Gene
and	O
fos	B-Gene
families	I-Gene
to	O
tandem	O
AP-1	B-Gene
consensus	O
sequences	O
.	O

Detection	O
in	O
non-erythroid	O
cells	O
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	O
cell	O
transcription	B-Gene
factor	I-Gene
EF1	I-Gene
.	O

The	O
erythroid	O
transcription	B-Gene
factor	I-Gene
erythroid	I-Gene
factor-1	I-Gene
(	O
EF1	B-Gene
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid-specific	O
genes	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence-specific	O
DNA	O
-binding	O
characteristics	O
of	O
EF1	B-Gene
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	O
cell	O
types	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B-Gene
-like	O
activity	O
in	O
non-erythroid	O
cells	O
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
expressed	O
in	O
such	O
cells	O
.	O

Nuclear	B-Gene
3	I-Gene
,	I-Gene
5	I-Gene
,	I-Gene
3'-triiodothyronine	I-Gene
receptors	I-Gene
(	O
T3R	B-Gene
)	O
of	O
circulating	O
human	O
lymphocytes	O
in	O
hyper-	O
and	O
hypothyroidism	B-Disease
and	O
nonthyroidal	O
diseases	O
.	O

The	O
clinical	O
implications	O
of	O
nuclear	B-Gene
T3R	I-Gene
alterations	O
of	O
circulating	O
lymphocytes	O
in	O
hyperthyroidism	B-Disease
,	O
hypothyroidism	B-Disease
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O

Nuclear	B-Gene
T3R	I-Gene
in	O
lymphocytes	O
was	O
determined	O
by	O
radio-ligand	O
binding	O
analysis	O
.	O

The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O

In	O
hyperthyroidism	B-Disease
nuclear	O
T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered	O
,	O
whereas	O
in	O
hypothyroidism	B-Disease
the	O
MBC	O
was	O
significantly	O
increased	O
.	O

In	O
the	O
patients	O
with	O
diabetes	B-Disease
mellitus	I-Disease
,	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
hepatic	B-Disease
cirrhosis	I-Disease
,	O
the	O
nuclear	B-Gene
T3R	I-Gene
MBC	O
of	O
lymphocytes	O
was	O
about	O
1.5-1.6	O
times	O
of	O
the	O
normal	O
controls	O
.	O

It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B-Gene
T3R	I-Gene
,	O
and	O
up-regulation	O
was	O
seen	O
in	O
hypothyroidism	B-Disease
and	O
low	O
T3	O
syndrome	O
.	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B-Gene
(	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T-cells	I-Gene
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	O
factor	O
.	O

Nuclear	B-Gene
factor	I-Gene
of	I-Gene
activated	I-Gene
T-cells	I-Gene
(	O
NFAT-1	B-Gene
)	O
is	O
a	O
transcription	O
factor	O
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	B-Gene
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	B-Gene
binding	O
motif	O
that	O
directs	O
transcription	O
of	O
SV40	B-Gene
T-antigen	I-Gene
in	O
transgenic	O
mice	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

NFAT-1	B-Gene
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	O
T-lymphocytes	O
upon	O
release	O
of	O
intracellular	O
calcium	B-Chemical
.	O

By	O
targeting	O
NFAT-1	B-Gene
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B-Gene
activity	O
.	O

Besides	O
in	O
T-lymphocytes	O
NFAT-1	B-Gene
activity	O
could	O
also	O
be	O
induced	O
in	O
T-lymphocyte	O
-depleted	O
spleen	O
cells	O
and	O
purified	O
B-lymphocytes	O
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	B-Chemical
and	O
activate	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	B-Gene
activity	O
between	O
T-lymphocytes	O
and	O
non-T-lymphocytes	O
was	O
revealed	O
.	O

Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O

Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	B-Gene
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR	B-Gene
/	I-Gene
tat	I-Gene
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606-611	O
)	O
.	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	B-Gene
has	O
been	O
shown	O
to	O
bind	O
functional	O
sequences	O
in	O
HIV-LTR	O
suggest	O
a	O
role	O
for	O
NFAT-1	B-Gene
in	O
dermal	O
activation	O
of	O
the	O
HIV-LTR	O
.	O

Induction	O
of	O
immediate	O
early	O
response	O
genes	O
by	O
macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
in	O
normal	O
human	O
monocytes	O
.	O

A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	O
,	O
cytoskeletal	O
,	O
and	O
extracellular	O
matrix	O
genes	O
have	O
been	O
termed	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	O
factor	O
-stimulated	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	B-Gene
(	O
M-CSF	B-Gene
)	O
in	O
human	O
monocytes	O
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M-CSF	B-Gene
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

Normal	O
human	O
monocytes	O
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	B-Chemical
bovine	I-Chemical
serum	I-Chemical
-containing	O
medium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	O
cells	O
were	O
stimulated	O
with	O
M-CSF	B-Gene
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
control	O
resting	O
cells	O
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	B-Gene
,	O
fibronectin	B-Gene
receptor	I-Gene
,	O
and	O
actin	B-Gene
mRNA	I-Gene
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	B-Gene
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O

The	O
c-jun	B-Gene
gene	I-Gene
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	B-Gene
addition	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	B-Gene
and	O
fibronectin	B-Gene
receptor	I-Gene
mRNA	I-Gene
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	B-Gene
addition	O
.	O

We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	O
specific	O
tyrosine	B-Gene
kinase	I-Gene
hck	I-Gene
gene	I-Gene
simultaneously	O
with	O
the	O
other	O
immediate	O
early	O
response	O
genes	O
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	B-Chemical
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super	O
-induced	O
the	O
expression	O
of	O
c-jun	B-Gene
and	O
hck	B-Gene
.	O

Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	B-Gene
,	O
hck	B-Gene
,	O
and	O
actin	B-Gene
genes	I-Gene
.	O

Therefore	O
,	O
in	O
normal	O
human	B-Gene
monocytes	I-Gene
M-CSF	I-Gene
induces	O
immediate	O
early	O
response	O
genes	O
without	O
inducing	O
cell	O
proliferation	O
.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	B-Gene
.	O

Cell-specific	O
differences	O
in	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
regulatory	I-Gene
elements	I-Gene
of	O
human	O
immunodeficiency	O
virus	O
and	O
beta	B-Gene
interferon	I-Gene
promoters	I-Gene
by	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

Tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	I-Gene
TNF-alpha	I-Gene
)	I-Gene
mRNA	I-Gene
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	O
U937	O
cells	O
and	O
in	O
a	O
chronically	O
HIV	O
infected	O
U937	O
cell	O
line	O
(	O
U9-IIIB	O
)	O
.	O

TNF-alpha	B-Gene
RNA	I-Gene
was	O
undetectable	O
in	O
U937	O
cells	O
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	O
cells	O
.	O

Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-Gene
RNA	I-Gene
in	O
U9-IIIB	O
cells	O
compared	O
with	O
U937	O
cells	O
,	O
suggesting	O
that	O
HIV	O
-infected	O
monocytic	O
cells	O
produced	O
higher	O
levels	O
of	O
TNF-alpha	B-Gene
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

The	O
effects	O
of	O
TNF-alpha	B-Gene
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	O
chloramphenicol	O
acetyltransferase	O
plasmids	O
linked	O
to	O
regulatory	O
elements	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
the	O
beta	B-Gene
interferon	I-Gene
promoter	I-Gene
.	O

In	O
U937	O
and	O
Jurkat	O
T	O
lymphoid	O
cells	O
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	O
promoters	O
by	O
TNF-alpha	B-Gene
or	O
phorbol	B-Chemical
ester	I-Chemical
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	B-Gene
B	I-Gene
-containing	O
plasmids	O
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	B-Gene
B	I-Gene
DNA	I-Gene
-binding	O
activity	O
.	O

Although	O
the	O
intact	O
beta	B-Gene
interferon	I-Gene
promoter	I-Gene
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	B-Chemical
ester	I-Chemical
or	O
TNF-alpha	B-Gene
,	O
multimers	O
of	O
the	O
PRDII	O
NF-kappa	B-Gene
B	I-Gene
-binding	O
domain	O
were	O
inducible	O
by	O
both	O
agents	O
.	O

TNF-alpha	B-Gene
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	O
LTR	O
in	O
T	O
cells	O
,	O
but	O
in	O
monocytic	O
cells	O
,	O
TNF-alpha	B-Gene
did	O
not	O
induce	O
the	O
HIV	O
LTR	O
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O

This	O
level	O
of	O
NF-kappa	B-Gene
B	I-Gene
-independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF-alpha	B-Gene
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
viral	O
RNA	O
production	O
in	O
U937	O
cells	O
.	O

However	O
,	O
in	O
Jurkat	O
cells	O
,	O
TNF-alpha	B-Gene
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	O
RNA	O
synthesis	O
,	O
indicating	O
that	O
in	O
T	O
cells	O
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF-alpha	B-Gene
treatment	O
.	O

The	O
internal	O
methionine	B-Chemical
codons	O
of	O
human	B-Gene
T-cell	I-Gene
leukemia	I-Gene
virus	I-Gene
type	I-Gene
II	I-Gene
rex	I-Gene
gene	I-Gene
are	O
not	O
required	O
for	O
p24rex	B-Gene
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	O
trans	O
-acting	O
regulatory	O
genes	O
,	O
tax	B-Gene
and	O
rex	B-Gene
,	O
located	O
in	O
the	O
3	O
'region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
tax	B-Gene
gene	I-Gene
product	I-Gene
(	O
HTLV-I	B-Gene
p40tax	I-Gene
and	O
HTLV-II	B-Gene
p37tax	I-Gene
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
.	O

The	O
rex	B-Gene
gene	I-Gene
encodes	O
two	O
protein	O
products	O
,	O
p27rex	B-Gene
/	I-Gene
p21rex	I-Gene
and	O
p26rex	B-Gene
/	I-Gene
p24rex	I-Gene
in	O
HTLV-I	O
and	O
HTLV-II	O
,	O
respectively	O
.	O

Rex	B-Gene
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full-length	O
gag	B-Gene
/	I-Gene
pol	I-Gene
and	O
singly	O
spliced	O
env	B-Gene
mRNA	I-Gene
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-infected	O
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-Gene
gene	I-Gene
is	O
critical	O
for	O
Rex	B-Gene
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B-Gene
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	B-Gene
rex	I-Gene
gene	I-Gene
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B-Gene
,	O
and	O
by	O
analogy	O
HTLV-II	B-Gene
p24rex	I-Gene
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax	B-Gene
/	I-Gene
rex	I-Gene
mRNA	I-Gene
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-Gene
gene	I-Gene
on	O
Rex	B-Gene
protein	I-Gene
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B-Gene
of	O
HTLV-II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	B-Chemical
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-Gene
gene	I-Gene
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

Interferon	B-Gene
affects	O
nuclear	O
proteins	O
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	B-Disease
myelogenous	I-Disease
leukemia	I-Disease
patients	O
.	O

Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B-Disease
myelogenous	I-Disease
leukemia	I-Disease
(	O
CML	B-Disease
)	O
cells	O
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	O
proteins	O
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	B-Gene
(	O
IFN	B-Gene
)	O
-inducible	O
genes	O
.	O

Exposure	O
of	O
CML	B-Disease
cells	O
to	O
IFN-alpha	B-Gene
diminished	O
the	O
effect	O
of	O
the	O
CML	B-Disease
cytoplasmic	O
proteins	O
on	O
these	O
nuclear	O
protein-DNA	O
complexes	O
.	O

The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN-alpha	B-Gene
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	B-Gene
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	O
protein-DNA	O
complexes	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	B-Gene
in	O
CML	B-Disease
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	O
proteins	O
.	O

Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	O
genes	O
in	O
primary	O
lymphoid	O
cells	O
:	O
assaying	O
for	O
a	O
viral	O
transactivator	O
activity	O
in	O
normal	O
and	O
malignant	O
cells	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	O
promoter	O
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	B-Disease
disorders	I-Disease
.	O

The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	O
lymphoid	O
cells	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
a	O
histone	B-Gene
promoter-driven	I-Gene
beta-galactosidase	I-Gene
gene	I-Gene
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta-galactosidase	B-Gene
in	O
50	O
%	O
to	O
100	O
%	O
of	O
the	O
cells	O
.	O

A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B-Gene
gene	I-Gene
with	O
an	O
adenovirus	O
E2	O
promoter	O
,	O
results	O
in	O
beta-galactosidase	B-Gene
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	O
and	O
primary	O
cells	O
.	O

Since	O
the	O
adenovirus	O
E2	O
promoter	O
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	O
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	O
gene	O
products	O
.	O

[	O
Glucocorticoid	B-Gene
receptors	I-Gene
on	O
human	O
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GCR	B-Gene
)	O
on	O
peripheral	O
mixed	O
leucocytes	O
in	O
patients	O
with	O
Yang-deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	O
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	O
(	O
MNL	O
)	O
and	O
polymorphonuclear	O
(	O
PML	O
)	O
leucocytes	O
,	O
and	O
GCR	B-Gene
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	O
.	O

GCR	B-Gene
on	O
MNL	O
and	O
PML	O
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+	O
/	O
-	O
413	O
and	O
4433	O
+	O
/	O
-	O
651	O
sites	O
/	O
cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+	O
/	O
-	O
962	O
and	O
5622	O
+	O
/	O
-	O
782	O
sites	O
/	O
cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

GCR	B-Gene
on	O
MNL	O
,	O
PML	O
and	O
mixed	O
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+	O
/	O
-	O
370	O
,	O
4986	O
+	O
/	O
-	O
419	O
and	O
4524	O
+	O
/	O
-	O
852	O
sites	O
/	O
cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B-Gene
on	O
MNL	O
and	O
highest	O
on	O
PML	O
.	O

Two	O
glucocorticoid	B-Chemical
binding	O
sites	O
on	O
the	O
human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
.	O

Glucocorticoids	B-Chemical
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	O
cells	O
via	O
interactions	O
with	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
.	O

Cortisol	B-Chemical
and	O
various	O
synthetic	O
glucocorticoids	B-Chemical
bind	O
to	O
the	O
GR	B-Gene
with	O
one-site	O
kinetics	O
.	O

Cortivazol	B-Chemical
(	O
CVZ	B-Chemical
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	B-Chemical
,	O
which	O
has	O
a	O
phenylpyrazol	B-Chemical
fused	O
to	O
the	O
A	O
-ring	O
of	O
the	O
steroid	B-Chemical
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	O
C7	O
cells	O
(	O
a	O
human	O
acute	O
lymphoblastic	O
T-cell	O
line	O
)	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	B-Chemical
.	O

The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	B-Chemical
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	B-Chemical
's	O
enhanced	O
biological	O
effects	O
.	O

In	O
mutant	O
leukemic	O
cells	O
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	B-Chemical
,	O
CVZ	B-Chemical
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	O
C7	O
cells	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	O
affinity	O
CVZ	B-Chemical
binding	O
site	O
.	O

We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	B-Chemical
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B-cell	O
line	O
,	O
IM-9	O
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	B-Chemical
38486	I-Chemical
is	O
able	O
to	O
block	O
both	O
CVZ	B-Chemical
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	B-Chemical
's	O
binding	O
sites	O
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	B-Gene
GR	I-Gene
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ	B-Chemical
-resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	B-Chemical
.	O

These	O
data	O
indicate	O
that	O
CVZ	B-Chemical
is	O
recognizing	O
two	O
glucocorticoid	B-Chemical
binding	O
sites	O
on	O
the	O
human	B-Gene
GR	I-Gene
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

[	O
The	O
role	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
and	O
HLA	B-Gene
antigens	I-Gene
in	O
the	O
pathogenesis	O
of	O
Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
]	O

Lymphocytic	O
levels	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko	O
-Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
.	O

Incidence	O
of	O
HLA	B-Gene
antigens	I-Gene
was	O
determined	O
in	O
94	O
of	O
them	O
.	O

A	O
significant	O
rise	O
of	O
A10	O
and	O
B27	O
antigen	O
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko	O
-Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
.	O

The	O
levels	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
lymphocytes	O
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

The	O
patients	O
carrying	O
B27	O
antigen	O
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O

Antigen	O
B27	O
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
blood	O
lymphocytes	O
.	O

Astrocytes	O
and	O
glioblastoma	B-Disease
cells	O
express	O
novel	O
octamer-DNA	O
binding	O
proteins	O
distinct	O
from	O
the	O
ubiquitous	O
Oct-1	B-Gene
and	O
B	O
cell	O
type	O
Oct-2	B-Gene
proteins	I-Gene
.	O

The	O
'octamer	O
'sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
in	O
B-lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	O
genes	O
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	O
,	O
the	O
octamer	B-Gene
-binding	I-Gene
protein	I-Gene
Oct-2A	I-Gene
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B-cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	B-Gene
protein	I-Gene
Oct-1	I-Gene
seems	O
to	O
control	O
general	O
octamer	O
site	O
-dependent	O
transcription	O
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	B-Gene
and	O
MHC	B-Gene
class	I-Gene
II	I-Gene
genes	I-Gene
,	O
contain	O
an	O
octamer	O
sequence	O
in	O
the	O
promoter	O
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer	B-Gene
-binding	I-Gene
proteins	I-Gene
in	O
the	O
latter	O
cells	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B-Gene
binding	I-Gene
proteins	I-Gene
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	O
mouse	O
astrocytes	O
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	O
glioblastoma	B-Disease
and	O
neuroblastoma	B-Disease
cell	O
lines	O
.	O

The	O
nervous	O
system	O
-derived	O
(	O
N-Oct	B-Gene
)	O
proteins	O
bound	O
to	O
the	O
octamer	O
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	B-Gene
and	O
Oct-2A	B-Gene
proteins	I-Gene
.	O

The	O
relationship	O
of	O
the	O
N-Oct	B-Gene
proteins	I-Gene
to	O
Oct-1	B-Gene
and	O
Oct-2A	B-Gene
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	B-Gene
Oct-1	I-Gene
and	O
Oct-2A	B-Gene
proteins	I-Gene
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N-Oct-factors	B-Gene
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	O
Oct-1	B-Gene
and	O
the	O
lymphoid-specific	B-Gene
Oct-2A	I-Gene
proteins	I-Gene
.	O

In	O
melanoma	B-Disease
cells	O
that	O
contain	O
the	O
N-Oct-3	B-Gene
factor	I-Gene
,	O
a	O
transfected	O
lymphocyte-specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	B-Gene
expression	O
vector	O
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct-3	B-Gene
and	O
other	O
N-Oct	B-Gene
factors	I-Gene
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Progesterone	B-Chemical
suppression	O
of	O
pregnancy	O
lymphocytes	O
is	O
not	O
mediated	O
by	O
glucocorticoid	B-Chemical
effect	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	B-Chemical
on	O
pregnancy	O
lymphocytes	O
is	O
mediated	O
by	O
specific	O
progesterone	B-Gene
receptors	I-Gene
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	B-Chemical
antagonist	O
(	O
RU486	B-Chemical
)	O
and	O
a	O
specific	O
glucocorticoid	B-Gene
receptor	I-Gene
blocker	O
(	O
RU43044	B-Chemical
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	O
factor	O
by	O
progesterone	B-Chemical
-treated	O
pregnancy	O
lymphocytes	O
.	O

RU	B-Chemical
486	I-Chemical
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	B-Chemical
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	O
factor	O
,	O
while	O
RU	B-Chemical
43044	I-Chemical
was	O
without	O
effect	O
.	O

These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	B-Chemical
acts	O
on	O
specific	O
progesterone	B-Gene
receptors	I-Gene
and	O
glucocorticoid	B-Chemical
binding	O
sites	O
are	O
not	O
involved	O
.	O

Decreased	O
concentration	O
of	O
1	B-Gene
,	I-Gene
25-dihydroxyvitamin	I-Gene
D3	I-Gene
receptors	I-Gene
in	O
peripheral	O
mononuclear	O
cells	O
of	O
patients	O
with	O
X	B-Disease
-linked	I-Disease
hypophosphatemic	I-Disease
rickets	I-Disease
:	O
effect	O
of	O
phosphate	B-Chemical
supplementation	O
.	O

Abnormal	O
renal	O
tubular	O
phosphate	B-Chemical
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X	B-Disease
-linked	I-Disease
hypophosphatemic	I-Disease
rickets	I-Disease
(	O
XLH	B-Disease
)	O
.	O

However	O
,	O
the	O
resistance	O
to	O
vitamin	B-Chemical
D	I-Chemical
treatment	O
in	O
XLH	B-Disease
can	O
not	O
be	O
explained	O
by	O
hypophosphatemia	B-Disease
alone	O
.	O

Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	B-Chemical
D	I-Chemical
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B-Gene
)	O
,	O
abnormalities	O
of	O
VDR	B-Gene
have	O
been	O
postulated	O
in	O
XLH	B-Disease
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B-Gene
in	O
PHA	B-Gene
-activated	O
peripheral	O
mononuclear	O
cells	O
from	O
10	O
XLH	B-Disease
patients	O
.	O

Patients	O
without	O
phosphate	B-Chemical
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21.7	O
+	O
/	O
-	O
5.1	O
fmol	O
/	O
mg	O
protein	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60.7	O
+	O
/	O
-	O
4.0	O
)	O
.	O

On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate	B-Chemical
-supplemented	O
patients	O
(	O
58.3	O
+	O
/	O
-	O
2.7	O
)	O
and	O
controls	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B-Gene
concentration	O
and	O
serum	O
phosphate	B-Chemical
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
two	O
patients	O
,	O
VDR	B-Gene
was	O
increased	O
after	O
daily	O
phosphate	B-Chemical
supplementation	O
was	O
started	O
.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-Gene
secondary	O
to	O
persistent	O
hypophosphatemia	B-Disease
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	B-Chemical
D	I-Chemical
resistance	O
in	O
XLH	B-Disease
.	O

Characterization	O
of	O
defensin	B-Gene
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B-Gene
virulence	I-Gene
regulon	I-Gene
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	B-Gene
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP	B-Gene
/	I-Gene
phoQ	I-Gene
two	I-Gene
-component	I-Gene
virulence	I-Gene
regulon	I-Gene
were	O
tested	O
by	O
using	O
purified	B-Gene
defensins	I-Gene
NP-1	I-Gene
and	O
NP-2	B-Gene
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	O
pair	O
(	O
phoP	B-Gene
[	O
transcriptional	O
activator	O
]	O
or	O
phoQ	B-Gene
[	O
membrane	B-Gene
sensor	I-Gene
kinase	I-Gene
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	B-Gene
.	O

The	O
predicted	O
periplasmic	O
domain	O
of	O
the	O
PhoQ	B-Gene
protein	I-Gene
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	O
proteins	O
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B-Gene
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	B-Gene
are	O
polar	O
on	O
phoQ	B-Gene
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B-Gene
protein	I-Gene
in	O
the	O
absence	O
of	O
PhoP	B-Gene
to	O
test	O
whether	O
resistance	O
to	O
defensin	B-Gene
requires	O
only	O
the	O
phoQ	B-Gene
gene	I-Gene
product	I-Gene
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	B-Gene
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B-Gene
without	O
PhoP	B-Gene
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	B-Gene
.	O

This	O
implied	O
that	O
a	O
pag	B-Gene
(	I-Gene
phoP	I-Gene
-activated	I-Gene
gene	I-Gene
)	I-Gene
product	I-Gene
is	O
responsible	O
for	O
defensin	B-Gene
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B-Gene
NP-1	I-Gene
,	O
NP-5	B-Gene
,	O
and	O
HNP-1	B-Gene
to	O
activate	O
pag	B-Gene
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

Defensin	B-Gene
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP-PhoQ	B-Gene
regulon	I-Gene
because	O
mutations	O
in	O
pagC	B-Gene
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B-Gene
locus	I-Gene
that	O
resulted	O
in	O
constitutive	O
pag	B-Gene
activation	O
(	O
phenotype	O
PhoPc	B-Gene
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	B-Gene
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	O
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-Gene
-phoQ	I-Gene
two	O
-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	O
proteins	O
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	O
.	O

Adherence	O
-dependent	O
increase	O
in	O
human	B-Gene
monocyte	I-Gene
PDGF	I-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
is	O
associated	O
with	O
increases	O
in	O
c-fos	B-Gene
,	O
c-jun	B-Gene
,	O
and	O
EGR2	B-Gene
mRNA	I-Gene
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	O
monocyte	O
to	O
a	O
tissue	O
macrophage	O
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	O
factors	O
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	O
encoding	O
profibrotic	O
growth	O
factors	O
such	O
as	O
platelet	B-Gene
-derived	I-Gene
growth	I-Gene
factor	I-Gene
B	I-Gene
subunit	I-Gene
(	O
PDGF	B-Gene
[	I-Gene
B	I-Gene
]	I-Gene
)	O
and	O
transforming	B-Gene
growth	I-Gene
factor-beta	I-Gene
(	O
TGF-beta	B-Gene
)	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

No	O
increase	O
in	O
TGF-beta	B-Gene
mRNA	I-Gene
was	O
observed	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	B-Chemical
D	I-Chemical
.	O

The	O
6-h	O
increase	O
in	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	B-Chemical
.	O

Adherence	O
to	O
either	O
fibronectin	B-Gene
or	O
collagen	B-Gene
-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
accumulation	O
.	O

The	O
increased	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	O
of	O
the	O
early	B-Gene
growth	I-Gene
response	I-Gene
genes	I-Gene
c-fos	I-Gene
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	B-Gene
,	O
and	O
EGR2	B-Gene
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O

The	O
increase	O
in	O
c-jun	B-Gene
and	O
EGR2	B-Gene
,	O
but	O
not	O
c-fos	B-Gene
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	B-Chemical
D	I-Chemical
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-Gene
,	O
c-jun	B-Gene
,	O
EGR2	B-Gene
,	O
and	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
mRNA	I-Gene
.	O

In	O
addition	O
,	O
the	O
increases	O
in	O
c-jun	B-Gene
,	O
EGR2	B-Gene
,	O
and	O
PDGF	B-Gene
(	I-Gene
B	I-Gene
)	I-Gene
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

NF-X2	B-Gene
that	O
binds	O
to	O
the	O
DRA	B-Gene
X2-box	O
is	O
activator	B-Gene
protein	I-Gene
1	I-Gene
.	O

Expression	O
cloning	O
of	O
c-Jun	B-Gene
.	O

Human	B-Gene
class	I-Gene
II	I-Gene
MHC	I-Gene
Ag	I-Gene
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN-gamma	B-Gene
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O

In	O
the	O
DRA	B-Gene
promoter	I-Gene
,	O
one	O
of	O
these	O
cis	O
-acting	O
regulatory	O
motifs	O
is	O
the	O
X2-box	O
to	O
which	O
nuclear	B-Gene
factor	I-Gene
X2	I-Gene
(	O
NF-X2	B-Gene
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	O
cDNA	O
clone	O
encoding	O
NF-X2	B-Gene
.	O

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	B-Gene
c-Jun	I-Gene
protein	I-Gene
,	O
which	O
together	O
with	O
c-Fos	B-Gene
forms	O
the	O
heterodimeric	O
activator	B-Gene
protein-1	I-Gene
transcription	I-Gene
complex	I-Gene
.	O

Whereas	O
c-Fos	B-Gene
/	I-Gene
c-Jun	I-Gene
heterodimers	O
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O

Thus	O
,	O
c-Fos	B-Gene
/	I-Gene
c-Jun	I-Gene
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-Gene
gene	I-Gene
expression	O
.	O

Immunohistochemical	O
study	O
of	O
steroid	B-Chemical
hormones	I-Chemical
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	O
soft	O
tissue	O
tumors	B-Disease
.	O

Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	B-Chemical
hormone	I-Chemical
anti-sera	O
(	O
estradiol	B-Chemical
,	O
estriol	B-Chemical
,	O
cortisol	B-Chemical
,	O
progesterone	B-Chemical
and	O
testosterone	B-Chemical
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	O
soft	O
tissue	O
tumors	B-Disease
(	O
fibrosarcoma	B-Disease
:	O
8	O
,	O
malignant	B-Disease
fibrous	I-Disease
histiocytoma	I-Disease
:	O
6	O
,	O
rhabdomyosarcoma	B-Disease
:	O
10	O
,	O
leiomyosarcoma	B-Disease
:	O
10	O
,	O
liposarcoma	B-Disease
:	O
5	O
)	O
.	O

Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	B-Chemical
hormones	I-Chemical
.	O

Immunostained	O
tumor	B-Disease
cells	O
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	B-Disease
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O

The	O
majority	O
of	O
the	O
positive	O
cases	O
occurred	O
in	O
female	O
cases	O
.	O

Furthermore	O
,	O
the	O
existence	O
of	O
estrogen	B-Gene
receptor	I-Gene
(	O
estrogen	B-Chemical
binding	O
activity	O
)	O
was	O
examined	O
histochemically	O
in	O
39	O
cases	O
and	O
it	O
was	O
detected	O
in	O
8	O
.	O

We	O
concluded	O
that	O
steroid	B-Chemical
hormones	I-Chemical
might	O
be	O
closely	O
related	O
to	O
tumor	B-Disease
cell	O
infiltration	O
of	O
some	O
malignant	O
soft	O
tissue	O
tumors	B-Disease
.	O

Interferon-gamma	B-Gene
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	B-Disease
diseases	I-Disease
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	B-Gene
interferon-gamma	I-Gene
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Sex	O
steroid	B-Chemical
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	O
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

Cloning	O
of	O
a	O
mitogen-inducible	O
gene	O
encoding	O
a	O
kappa	O
B	O
DNA	O
-binding	O
protein	O
with	O
homology	O
to	O
the	O
rel	B-Gene
oncogene	I-Gene
and	O
to	O
cell-cycle	O
motifs	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	O
gene	O
isolated	O
from	O
human	O
T	O
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	O
amino	O
acids	O
.	O

The	O
amino-terminal	O
domain	O
has	O
regions	O
homologous	O
to	O
the	O
oncogene	B-Gene
rel	I-Gene
and	O
to	O
the	O
developmentally	O
important	O
gene	B-Gene
dorsal	I-Gene
of	O
Drosophila	O
.	O

The	O
carboxy-terminal	O
domain	O
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell-cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	O
human	B-Gene
oncogene	I-Gene
bcl-3	I-Gene
and	O
in	O
the	O
ankyrin	B-Gene
protein	I-Gene
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA	O
-binding	O
protein	O
which	O
interacts	O
specifically	O
with	O
the	O
kappa	O
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	O
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Stimulation	O
of	O
a	O
human	O
T-cell	O
clone	O
with	O
anti-CD3	B-Gene
or	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
induces	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer	O
-dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	O
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	B-Gene
enhancer	I-Gene
-binding	I-Gene
protein	I-Gene
NF-kappa	I-Gene
B	I-Gene
were	O
analyzed	O
in	O
two	O
human	O
T-cell	O
clones	O
stimulated	O
through	O
their	O
T-cell	B-Gene
receptor	I-Gene
complex	I-Gene
or	O
by	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
or	O
phorbol	B-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	O
LTR	O
or	O
the	O
HIV	O
enhancer	O
.	O

Interleukin	B-Gene
2	I-Gene
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
or	O
LTR	O
transactivation	O
.	O

Phorbol	B-Chemical
ester	I-Chemical
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	O
LTR	O
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
or	O
antibody	O
to	O
CD3	B-Gene
did	O
not	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	B-Chemical
ester	I-Chemical
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B-Gene
B	I-Gene
by	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
or	O
antibody	O
to	O
CD3	B-Gene
is	O
not	O
sufficient	O
to	O
induce	O
HIV	O
enhancer	O
-dependent	O
transcription	O
in	O
cloned	O
T	O
cells	O
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	O
T-cell	O
lines	O
and	O
indicates	O
that	O
normal	O
T	O
lymphocytes	O
differ	O
from	O
tumoral	O
T	O
cells	O
in	O
terms	O
of	O
requirements	O
for	O
HIV	O
LTR	O
activation	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-Gene
B	I-Gene
complex	I-Gene
with	O
the	O
HIV	O
enhancer	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double	O
-stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	O
regulatory	O
proteins	O
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Inhibition	O
of	O
sequence-specific	O
DNA	O
-binding	O
proteins	O
was	O
achieved	O
with	O
double	O
-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	O
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B-Gene
transcription	I-Gene
factor	I-Gene
or	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappa	I-Gene
B	I-Gene
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O

Octamer	O
-dependent	O
activation	O
of	O
a	O
reporter	O
plasmid	O
or	O
NF-kappa	B-Gene
B	I-Gene
-dependent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	O
transfected	O
B	O
cell	O
line	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	O
consensus	O
to	O
Jurkat	O
T	B-Disease
leukemia	I-Disease
cells	O
inhibited	O
interleukin-2	B-Gene
(	O
IL-2	B-Gene
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	O
site	O
in	O
the	O
IL-2	B-Gene
enhancer	I-Gene
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

[	O
The	O
effect	O
of	O
24	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
dioxyvit	B-Chemical
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	B-Disease
kidney	I-Disease
failure	I-Disease
]	O

Active	O
metabolite	O
of	O
vitamin	B-Chemical
D3	I-Chemical
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	B-Chemical
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	B-Disease
disease	I-Disease
of	I-Disease
kidney	I-Disease
and	O
with	O
chronic	O
glomerulonephritis	B-Disease
under	O
conditions	O
of	O
kidney	B-Disease
insufficiency	I-Disease
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	B-Chemical
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	B-Gene
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	O
and	O
0-lymphocytes	O
.	O

Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	O
under	O
conditions	O
of	O
chronic	B-Disease
kidney	I-Disease
insufficiency	I-Disease
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	B-Chemical
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	B-Disease
.	O

Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	B-Chemical
with	O
simultaneous	O
correction	O
of	O
vitamin	B-Chemical
D	I-Chemical
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	B-Chemical
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	B-Disease
kidney	I-Disease
insufficiency	I-Disease
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	O
factor	O
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	B-Gene
antigen	I-Gene
receptor	I-Gene
.	O

Stimulation	O
of	O
T	O
lymphocytes	O
through	O
their	O
antigen	O
receptor	O
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
NF-AT	B-Gene
and	O
NF-kappa	B-Gene
B	I-Gene
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	O
factor	O
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence	O
-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	B-Gene
(	O
beta-gal	B-Gene
)	O
.	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	B-Gene
transcriptional	O
activity	O
among	O
T	O
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT	B-Gene
-binding	O
site	O
directs	O
transcription	O
of	O
the	O
lacZ	B-Gene
gene	I-Gene
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	O
stably	O
transfected	O
Jurkat	O
T	O
cells	O
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	B-Gene
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta-gal	B-Gene
and	O
others	O
express	O
high	O
levels	O
.	O

This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell-cycle	O
position	O
or	O
heritable	O
variation	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta-gal	B-Gene
activity	O
is	O
correlated	O
with	O
NF-AT	B-Gene
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B-Gene
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	B-Gene
concentration	O
-dependent	O
assembly	O
of	O
transcription	O
complexes	O
at	O
the	O
promoter	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-Gene
B	I-Gene
or	O
the	O
entire	O
interleukin-2	B-Gene
enhancer	I-Gene
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	O
factors	O
may	O
be	O
a	O
common	O
property	O
of	O
inducible	O
genes	O
.	O

Type-II	O
estrogen	B-Chemical
binding	O
sites	O
in	O
a	O
lymphoblastoid	O
cell	O
line	O
and	O
growth-inhibitory	O
effect	O
of	O
estrogen	B-Chemical
,	O
anti-estrogen	B-Chemical
and	O
bioflavonoids	B-Chemical
.	O

Type-II	O
estrogen	B-Chemical
-binding	O
sites	O
(	O
type-II	O
EBS	O
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	O
lymphoblastoid	O
cell	O
line	O
IM-9	O
using	O
a	O
whole-cell	O
assay	O
with	O
(	O
6	O
,	O
7-3H	O
)	O
estradiol	B-Chemical
(	O
3H-E2	B-Chemical
)	O
as	O
tracer	O
.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	B-Chemical
tamoxifen	B-Chemical
and	O
the	O
flavonoids	B-Chemical
quercetin	I-Chemical
and	O
rutin	B-Chemical
competed	O
for	O
(	O
3H	O
)	O
-E2	B-Chemical
binding	O
to	O
type-II	O
EBS	O
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	B-Chemical
(	O
DES	B-Chemical
)	O
tamoxifen	B-Chemical
(	O
TAM	B-Chemical
)	O
,	O
quercetin	B-Chemical
and	O
rutin	B-Chemical
exerted	O
a	O
reversible	O
dose	O
-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	B-Chemical
,	O
rutin	B-Chemical
,	O
DES	B-Chemical
and	O
TAM	B-Chemical
for	O
type-II	O
EBS	O
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover	O
,	O
hesperidin	B-Chemical
,	O
a	O
flavonoid	B-Chemical
which	O
does	O
not	O
bind	O
to	O
type-II	O
EBS	O
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	B-Chemical
,	O
TAM	B-Chemical
or	O
quercetin	B-Chemical
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
estrogen	B-Chemical
and	O
anti-estrogen	B-Chemical
concentrations	O
and	O
flavonoids	B-Chemical
may	O
regulate	O
IM-9	O
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type-II	O
EBS	O
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	O
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B-Gene
and	O
either	O
FK506	B-Chemical
or	O
rapamycin	B-Chemical
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	O
lymphocytes	O
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	O
receptor	O
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	B-Chemical
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	B-Gene
2	I-Gene
(	O
IL-2	B-Gene
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	B-Chemical
but	O
not	O
by	O
FK506	B-Chemical
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	B-Gene
(	O
immunosuppressant	O
binding	O
protein	O
)	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	B-Chemical
to	O
the	O
FK506	B-Gene
binding	I-Gene
protein	I-Gene
FKBP	I-Gene
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	B-Chemical
to	O
FKBP	B-Gene
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However	O
,	O
an	O
excess	O
of	O
rapamycin	B-Chemical
is	O
needed	O
to	O
revert	O
FK506	B-Chemical
-mediated	O
inhibition	O
of	O
IL-2	B-Gene
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	B-Gene
,	O
a	O
T-cell-specific	O
transcription	O
factor	O
necessary	O
for	O
IL-2	B-Gene
gene	I-Gene
activation	O
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	B-Chemical
is	O
needed	O
to	O
revert	O
rapamycin	B-Chemical
-mediated	O
inhibition	O
of	O
IL-2	B-Gene
-induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	B-Gene
FKBP	I-Gene
.	O

FKBP	B-Gene
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	O
amide	O
bond	O
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	B-Chemical
,	O
like	O
FK506	B-Chemical
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	B-Gene
activity	O
of	O
FKBP	B-Gene
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O

Neither	O
FKBP	B-Gene
binding	O
nor	O
inhibition	O
of	O
rotamase	B-Gene
activity	O
of	O
FKBP	B-Gene
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O

Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	B-Gene
bound	O
to	O
FK506	B-Chemical
interferes	O
with	O
antigen	O
receptor	O
-induced	O
signals	O
,	O
while	O
rapamycin	B-Chemical
bound	O
to	O
the	O
immunophilin	B-Gene
interferes	O
with	O
IL-2	B-Gene
-induced	O
signals	O
.	O

Disruption	O
of	O
the	O
human	B-Gene
SCL	I-Gene
locus	I-Gene
by	O
``	O
illegitimate	O
''V-	B-Gene
(	I-Gene
D	I-Gene
)	I-Gene
-J	I-Gene
recombinase	I-Gene
activity	O
.	O

A	O
fusion	O
complementary	O
DNA	O
in	O
the	O
T	O
cell	O
line	O
HSB-2	O
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	B-Gene
transcription	I-Gene
factor	I-Gene
SCL	I-Gene
.	O

The	O
fusion	O
cDNA	O
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	O
locus	O
,	O
SIL	B-Gene
(	O
SCL	B-Gene
interrupting	I-Gene
locus	I-Gene
)	O
,	O
and	O
the	O
5	O
'untranslated	O
region	O
of	O
SCL	B-Gene
.	O

Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-Gene
5	O
'regulatory	O
region	O
.	O

This	O
event	O
is	O
probably	O
mediated	O
by	O
V-	B-Gene
(	I-Gene
D	I-Gene
)	I-Gene
-J	I-Gene
recombinase	I-Gene
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	B-Gene
or	O
a	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
.	O

Two	O
other	O
T	O
cell	O
lines	O
,	O
CEM	O
and	O
RPMI	O
8402	O
,	O
have	O
essentially	O
identical	O
deletions	O
.	O

Thus	O
,	O
in	O
lymphocytes	O
,	O
growth	O
-affecting	O
genes	O
other	O
than	O
immune	O
receptors	O
risk	O
rearrangements	O
.	O

Differences	O
in	O
transcriptional	O
enhancers	O
of	O
HIV-1	O
and	O
HIV-2	O
.	O

Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
comprise	O
the	O
transcriptional	O
enhancer	O
,	O
which	O
contains	O
two	O
conserved	O
binding	O
sites	O
for	O
the	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	B-Disease
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
binding	O
site	O
.	O

We	O
demonstrate	O
that	O
the	O
HIV-1	O
LTR	O
responds	O
better	O
than	O
the	O
HIV-2	O
LTR	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	O
or	O
HIV-2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	O
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	O
transcriptional	O
enhancer	O
.	O

Instead	O
of	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
,	O
the	O
activator	B-Gene
protein	I-Gene
3	I-Gene
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O

In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O

Induction	O
of	O
NF-KB	B-Gene
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	O
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	B-Chemical
acid	I-Chemical
or	O
PMA	B-Chemical
,	O
and	O
in	O
purified	O
human	O
monocytes	O
and	O
macrophages	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B-Gene
transactivation	I-Gene
factor	I-Gene
NF-KB	I-Gene
to	O
the	O
double	O
repeat-KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

PMA	B-Chemical
treatment	O
,	O
and	O
not	O
retinoic	B-Chemical
acid	I-Chemical
treatment	O
of	O
the	O
U937	O
cells	O
acts	O
in	O
inducing	O
NF-KB	B-Gene
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF-KB	B-Gene
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O

When	O
U937	O
cells	O
were	O
infected	O
with	O
HIV-1	O
,	O
no	O
induction	O
of	O
NF-KB	B-Gene
factor	I-Gene
was	O
detected	O
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	O
cell	O
lineage	O
,	O
HIV-1	O
could	O
mimic	O
some	O
differentiation	O
/	O
activation	O
stimuli	O
allowing	O
nuclear	B-Gene
NF-KB	I-Gene
expression	O
.	O

Activation	O
of	O
human	B-Gene
CD4	I-Gene
T	O
lymphocytes	O
.	O

Interaction	O
of	O
fibronectin	B-Gene
with	O
VLA-5	B-Gene
receptor	I-Gene
on	O
CD4	B-Gene
cells	O
induces	O
the	O
AP-1	B-Gene
transcription	I-Gene
factor	I-Gene
.	O

Fibronectin	B-Gene
synergized	O
with	O
anti-CD3	B-Gene
antibody	I-Gene
to	O
promote	O
CD4	B-Gene
cell	O
proliferation	O
in	O
a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-Gene
cells	O
were	O
cultured	O
with	O
anti-CD3	B-Gene
alone	O
or	O
fibronectin	B-Gene
alone	O
.	O

In	O
addition	O
,	O
anti-CD29	B-Gene
(	O
integrin	B-Gene
beta	I-Gene
1	I-Gene
)	O
as	O
well	O
as	O
anti-VLA-5	B-Gene
(	I-Gene
human	I-Gene
fibronectin	I-Gene
receptor	I-Gene
)	I-Gene
antibodies	I-Gene
blocked	O
this	O
CD4	B-Gene
cell	O
activation	O
in	O
this	O
system	O
.	O

Although	O
anti-CD3	B-Gene
alone	O
or	O
fibronectin	B-Gene
alone	O
can	O
not	O
induce	O
IL-2	B-Gene
message	O
by	O
CD4	B-Gene
cells	O
,	O
the	O
combination	O
of	O
anti-CD3	B-Gene
plus	O
fibronectin	B-Gene
induced	O
IL-2	B-Gene
message	O
by	O
CD4	B-Gene
cells	O
.	O

In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B-Gene
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-Gene
-VLA-5	I-Gene
fibronectin	I-Gene
receptor	I-Gene
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B-Gene
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-Gene
transcriptional	I-Gene
factor	I-Gene
.	O

Thus	O
the	O
VLA-5	B-Gene
fibronectin	I-Gene
receptor	I-Gene
on	O
CD4	B-Gene
cells	O
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	B-Gene
-	I-Gene
TCR	I-Gene
-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B-Gene
.	O

TAR	O
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	B-Chemical
ester	I-Chemical
stimulated	O
T	O
lymphocytes	O
.	O

Multiple	O
regulatory	O
elements	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
(	O
HIV	O
LTR	O
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O

Previous	O
transfection	O
studies	O
of	O
HIV	O
LTR	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	B-Gene
acetyltransferase	I-Gene
gene	I-Gene
indicated	O
that	O
multiple	O
regulatory	O
regions	O
including	O
the	O
enhancer	O
,	O
SP1	B-Gene
,	O
TATA	O
and	O
TAR	O
regions	O
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O

To	O
characterize	O
these	O
regulatory	O
elements	O
further	O
,	O
mutations	O
in	O
these	O
regions	O
were	O
inserted	O
into	O
both	O
the	O
5	O
'and	O
3	O
'HIV	O
LTRs	O
and	O
infectious	O
proviral	O
constructs	O
were	O
assembled	O
.	O

These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	O
cells	O
,	O
Jurkat	O
cells	O
or	O
U937	O
cells	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	B-Chemical
esters	I-Chemical
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O

Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B-Gene
gag	I-Gene
protein	I-Gene
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O

Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	B-Gene
,	O
TATA	O
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	O
motif	O
or	O
TAR	O
primary	O
sequence	O
resulted	O
in	O
only	O
slight	O
decreases	O
.	O

However	O
,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	O
loop	O
sequences	O
or	O
stem	O
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	O
cells	O
,	O
gave	O
nearly	O
wild-type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	B-Chemical
ester	I-Chemical
-treated	O
Jurkat	O
cells	O
but	O
not	O
in	O
phorbol	B-Chemical
ester	I-Chemical
-treated	O
HeLa	O
or	O
U937	O
cells	O
.	O

High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	O
mutant	O
constructs	O
in	O
phorbol	B-Chemical
ester	I-Chemical
-treated	O
Jurkat	O
cells	O
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	O
region	O
or	O
by	O
disruption	O
of	O
the	O
tat	B-Gene
gene	I-Gene
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
actions	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

Cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	O
produced	O
by	O
T	O
lymphocytes	O
.	O

Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	O
protein	O
,	O
cyclophilin	B-Gene
and	O
FKBP	B-Gene
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O

Using	O
constructs	O
in	O
which	O
mRNA	O
production	O
controlled	O
by	O
a	O
specific	O
transcription	O
factor	O
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	B-Gene
,	O
NFIL2	B-Gene
A	I-Gene
,	O
NFIL2	B-Gene
B	I-Gene
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
.	O

Cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O

However	O
,	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O
dependent	O
expression	O
of	O
c-fos	B-Gene
mRNA	I-Gene
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
on	O
six	O
different	O
transcription	O
factors	O
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	O
factors	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	O
early	O
region	O
3	O
promoter	O
is	O
mediated	O
by	O
NF-kappa	B-Gene
B	I-Gene
binding	O
motifs	O
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	O
control	O
elements	O
and	O
the	O
cellular	O
factors	O
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	O
has	O
not	O
been	O
reported	O
.	O

The	O
adenovirus	B-Gene
early	I-Gene
region	I-Gene
3	I-Gene
(	I-Gene
ES	I-Gene
)	I-Gene
gene	I-Gene
products	I-Gene
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B-Gene
I	I-Gene
MHC	I-Gene
antigens	I-Gene
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	O
factors	O
were	O
involved	O
in	O
E3	B-Gene
regulation	O
in	O
lymphocytes	O
as	O
compared	O
with	O
HeLa	O
cells	O
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-Gene
promoter	I-Gene
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

These	O
studies	O
detected	O
two	O
novel	O
domains	O
referred	O
to	O
as	O
L1	O
and	O
L2	O
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
.	O

Transfections	O
of	O
E3	B-Gene
constructs	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	O
NF-kappa	B-Gene
B	I-Gene
motif	O
(	O
L2	O
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	O
cells	O
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	O
cells	O
.	O

In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	O
NF-kappa	B-Gene
B	I-Gene
motif	O
(	O
L1	O
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	O
cells	O
and	O
lymphoid	O
cells	O
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	O
cells	O
when	O
coupled	O
to	O
the	O
L2	O
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	O
and	O
L2	O
domains	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	B-Gene
promoter	I-Gene
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	B-Gene
gene	I-Gene
expression	O
by	O
a	O
novel	O
B-cell-specific	O
enhancer	O
element	O
.	O

A	O
new	O
B-cell-specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'of	O
E4	O
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	B-Gene
immunoglobulin	I-Gene
heavy-chain	I-Gene
gene	I-Gene
enhancer	I-Gene
.	O

Tandem	O
copies	O
of	O
this	O
67-bp	O
MnlI-AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
driven	O
by	O
the	O
conalbumin	B-Gene
promoter	I-Gene
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
or	O
HeLa	O
cells	O
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	O
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	O
cells	O
,	O
T	O
cells	O
,	O
or	O
HeLa	O
cells	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	O
motif	O
detected	O
a	O
B-cell-specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	O
motif	O
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	O
in	O
Jurkat	O
or	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
a	O
mutant	O
E6	O
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	B-Gene
Ig	I-Gene
heavy-chain	I-Gene
enhancer	I-Gene
,	O
in	O
which	O
the	O
octamer	O
motif	O
acts	O
as	O
a	O
B-cell-specific	O
enhancer	O
element	O
,	O
the	O
human	O
enhancer	O
contains	O
an	O
octamerlike	O
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer	B-Gene
-binding	I-Gene
proteins	I-Gene
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own	O
.	O

Interestingly	O
,	O
the	O
MnlI-AluI	O
fragment	O
could	O
suppress	O
the	O
basal-level	O
activity	O
of	O
the	O
conalbumin	B-Gene
promoter	I-Gene
in	O
both	O
Jurkat	O
and	O
HeLa	O
cells	O
.	O

Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI-AluI	O
fragment	O
in	O
HeLa	O
cells	O
but	O
not	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	O
and	O
negative	O
factors	O
.	O

[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney	O
-tonifying	O
and	O
qi	O
-invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
]	O

The	O
plasma	O
cortisol	B-Chemical
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GCR	B-Gene
)	O
in	O
the	O
peripheral	O
lymphocytes	O
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O

In	O
animal	O
experiment	O
,	O
GCR	B-Gene
of	O
spleen	O
lymphocytic	O
cell	O
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O

The	O
results	O
showed	O
that	O
GCR	B-Gene
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	B-Chemical
level	O
did	O
n't	O
change	O
with	O
aging	O
.	O

So	O
we	O
think	O
that	O
GCR	B-Gene
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	B-Chemical
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O

After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney	O
-tonifying	O
and	O
Qi	O
-invigorating	O
,	O
the	O
GCR	B-Gene
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O

An	O
in	O
vitro	O
globin	B-Gene
gene	I-Gene
switching	O
model	O
based	O
on	O
differentiated	O
embryonic	O
stem	O
cells	O
.	O

We	O
used	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
to	O
study	O
globin	B-Gene
gene	I-Gene
expression	O
and	O
switching	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ES	O
-derived	O
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	B-Gene
embryonic	I-Gene
globin	I-Gene
genes	I-Gene
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal	O
/	O
adult	O
genes	O
.	O

In	O
addition	O
,	O
the	O
erythroid-specific	B-Gene
transcription	I-Gene
factor	I-Gene
NF-E1	I-Gene
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B-Gene
in	O
embryoid	O
bodies	O
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O

When	O
the	O
human	O
epsilon-	B-Partial_Gene
or	O
beta-globin	B-Gene
genes	I-Gene
driven	O
by	O
the	O
dominant	O
control	O
region	O
(	O
DCR	O
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	B-Gene
epsilon-globin	I-Gene
gene	I-Gene
,	O
in	O
contrast	O
to	O
the	O
beta-globin	B-Gene
gene	I-Gene
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	O
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	O
gene	O
.	O

We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon-globin	B-Gene
gene	I-Gene
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	B-Gene
beta-globin	I-Gene
locus	I-Gene
.	O

Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	B-Disease
cancers	I-Disease
:	O
a	O
role	O
for	O
hematopoietic	B-Gene
growth	I-Gene
factor	I-Gene
release	O
by	O
tumor	B-Disease
cells	O
?	O

One	O
hundred	O
six	O
primary	O
breast	B-Disease
cancer	I-Disease
samples	O
were	O
analysed	O
for	O
c-erbB2	B-Gene
,	O
int-2	B-Gene
,	O
and	O
c-myc	B-Gene
gene	I-Gene
amplification	O
.	O

Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O

Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and	O
/	O
or	O
slot	O
blot	O
techniques	O
.	O

Amplified	O
c-erbB2	B-Gene
gene	I-Gene
sequences	O
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O

Int-2	B-Gene
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c-myc	B-Gene
was	O
amplified	O
in	O
10.3	O
%	O
.	O

In	O
a	O
non-parametric	O
test	O
(	O
Kruskal-Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c-erbB2	B-Gene
amplification	O
and	O
absence	O
of	O
estrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	B-Gene
receptor	I-Gene
(	O
PR	B-Gene
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O

No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	B-Disease
,	O
or	O
associated	O
carcinoma	B-Disease
in	O
situ	O
.	O

There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c-erbB2	B-Gene
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O

A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	O
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	B-Disease
(	O
P	O
=	O
.05	O
)	O
.	O

This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O

We	O
propose	O
that	O
malignant	O
cell	O
cytokine	O
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O

The	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
independent	O
cis	O
-acting	O
sequences	O
in	O
HIV-1	O
LTR	O
responsive	O
to	O
T-cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	O
LTR	O
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	B-Gene
or	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
.	O

The	O
rate	O
of	O
LTR	O
-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	B-Chemical
ester	I-Chemical
or	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
if	O
either	O
the	O
NFAT-1	B-Gene
or	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
binding	O
sites	O
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O

The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
and	O
NFAT-1	B-Gene
deletion	O
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	B-Gene
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	O
cells	O
.	O

Neither	O
deletion	O
of	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
nor	O
deletion	O
of	O
NFAT-1	B-Gene
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	B-Chemical
ester	I-Chemical
.	O

Specific	O
depletion	O
of	O
the	O
B-cell	O
population	O
induced	O
by	O
aberrant	O
expression	O
of	O
human	B-Gene
interferon	I-Gene
regulatory	I-Gene
factor	I-Gene
1	I-Gene
gene	I-Gene
in	O
transgenic	O
mice	O
.	O

Interferons	B-Gene
(	O
IFNs	B-Gene
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	O
proteins	O
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	B-Gene
inhibit	O
growth	O
of	O
various	O
normal	O
and	O
transformed	O
cell	O
types	O
.	O

Previously	O
,	O
a	O
nuclear	O
factor	O
,	O
IRF-1	B-Gene
(	O
interferon	B-Gene
regulatory	I-Gene
factor	I-Gene
1	I-Gene
)	O
,	O
which	O
binds	O
to	O
type	B-Gene
I	I-Gene
IFN	I-Gene
and	O
some	O
IFN-inducible	B-Gene
gene	O
promoters	O
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	B-Gene
gene	I-Gene
is	O
both	O
virus	O
and	O
IFN	B-Gene
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	B-Gene
gene	I-Gene
is	O
functioning	O
in	O
IFN	B-Gene
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	B-Gene
IRF-1	I-Gene
gene	I-Gene
linked	O
to	O
the	O
human	B-Gene
immunoglobulin	I-Gene
heavy-chain	I-Gene
enhancer	I-Gene
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	O
lymphocytes	O
(	O
B	O
cells	O
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	O
marrow	O
cells	O
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	O
population	O
.	O

In	O
fact	O
,	O
transgenic	O
bone	O
marrow	O
cells	O
cocultured	O
with	O
a	O
bone	O
marrow	O
-derived	O
stromal	O
cell	O
line	O
revealed	O
an	O
altered	O
B-cell	O
maturation	O
pattern	O
.	O

Identification	O
and	O
cloning	O
of	O
TCF-1	B-Gene
,	O
a	O
T	O
lymphocyte-specific	O
transcription	O
factor	O
containing	O
a	O
sequence-specific	O
HMG	B-Gene
box	O
.	O

CD3	B-Gene
-epsilon	I-Gene
expression	O
is	O
controlled	O
by	O
a	O
downstream	O
T	O
lymphocyte-specific	O
enhancer	O
element	O
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
,	O
TCF-1	B-Gene
,	O
binding	O
to	O
this	O
element	O
.	O

The	O
multimerized	O
recognition	O
motif	O
of	O
TCF-1	B-Gene
constituted	O
a	O
T	O
cell-specific	O
enhancer	O
.	O

Subsequent	O
cloning	O
of	O
TCF-1	B-Gene
identified	O
three	O
splice	O
alternatives	O
.	O

TCF-1	B-Gene
contained	O
a	O
single	O
DNA	O
-binding	O
HMG	B-Gene
box	O
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	O
mammalian	B-Gene
sex	I-Gene
-determining	I-Gene
gene	I-Gene
SRY	I-Gene
and	O
in	O
the	O
Schizosaccharomyces	B-Gene
pombe	I-Gene
Mc	I-Gene
mating	I-Gene
type	I-Gene
gene	I-Gene
.	O

TCF-1	B-Gene
mRNA	I-Gene
was	O
expressed	O
uniquely	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
cotransfection	O
into	O
non-T	O
cells	O
,	O
TCF-1	B-Gene
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O

These	O
results	O
identify	O
TCF-1	B-Gene
as	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
,	O
which	O
might	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

Nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
activates	O
proenkephalin	B-Gene
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-Gene
mRNA	I-Gene
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	B-Gene
promoter	I-Gene
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
nuclear	I-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-kappa	I-Gene
B	I-Gene
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF-kappa	B-Gene
B	I-Gene
-like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-Gene
promoter	I-Gene
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	B-Gene
)	O
of	O
the	O
DNA	O
-binding	O
subunit	O
of	O
NF-kappa	B-Gene
B	I-Gene
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	B-Gene
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	B-Gene
plus	O
two	O
p50s	B-Gene
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T-cell-specific	O
activation	O
of	O
the	O
proenkephalin	B-Gene
promoter	I-Gene
is	O
mediated	O
by	O
NF-kappa	B-Gene
B	I-Gene
.	O

However	O
,	O
as	O
NF-kappa	B-Gene
B	I-Gene
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell-specific	O
factor	O
which	O
synergizes	O
with	O
NF-kappa	B-Gene
B	I-Gene
should	O
be	O
considered	O
.	O

Functional	O
analysis	O
of	O
cis	O
-linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	B-Gene
DRA	I-Gene
promoter	I-Gene
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	O
proteins	O
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
(	I-Gene
MHC	I-Gene
)	I-Gene
class	I-Gene
II	I-Gene
promoters	I-Gene
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA-DR	B-Gene
alpha	I-Gene
(	I-Gene
DRA	I-Gene
)	I-Gene
promoter	I-Gene
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	O
octamer	O
''motif	O
of	O
immunoglobulin	B-Gene
variable	I-Gene
region	I-Gene
promoters	I-Gene
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O

This	O
``	O
octamer	O
``	O
in	O
the	O
context	O
of	O
DRA	B-Gene
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	O
(	O
OTF-1	B-Gene
)	O
and	O
lymphoid-specific	O
(	O
OTF-2	B-Gene
)	O
``	O
octamer	O
''binding	O
proteins	O
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
``	O
octamer	O
''complex	O
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis	O
-acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B-Gene
promoter	I-Gene
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	O
II	O
-negative	O
HeLa	O
cells	O
.	O

5	O
'deletion	O
constructs	O
which	O
lacked	O
the	O
Y	O
box	O
,	O
but	O
retained	O
the	O
``	O
octamer	O
''motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	O
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	B-Gene
promoter	I-Gene
,	O
the	O
DRA	B-Gene
``	O
octamer	O
''does	O
not	O
utilize	O
OTF-2	B-Gene
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	B-Gene
promoters	I-Gene
in	O
B	O
cells	O
.	O

Expression	O
of	O
c-jun	B-Gene
,	O
jun	B-Gene
B	I-Gene
and	O
jun	B-Gene
D	I-Gene
proto-oncogenes	I-Gene
in	O
human	O
peripheral-blood	O
granulocytes	O
.	O

We	O
have	O
found	O
that	O
purified	O
human	O
peripheral-blood	O
granulocytes	O
express	O
constitutively	O
significant	O
levels	O
of	O
proto-oncogenes	B-Gene
c-jun	I-Gene
,	O
jun	B-Gene
B	I-Gene
and	O
jun	B-Gene
D	I-Gene
mRNA	I-Gene
.	O

Upon	O
functional	O
activation	O
of	O
granulocytes	O
by	O
4	B-Chemical
beta-phorbol	I-Chemical
12-myristate	I-Chemical
13-acetate	I-Chemical
(	O
PMA	B-Chemical
)	O
,	O
the	O
levels	O
of	O
c-jun	B-Gene
,	O
jun	B-Gene
B	I-Gene
and	O
jun	B-Gene
D	I-Gene
transcripts	I-Gene
were	O
increased	O
.	O

The	O
three	O
jun	B-Gene
genes	I-Gene
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	B-Chemical
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

These	O
results	O
suggest	O
that	O
expression	O
of	O
c-jun	B-Gene
,	O
jun	B-Gene
B	I-Gene
and	O
jun	B-Gene
D	I-Gene
genes	I-Gene
might	O
be	O
involved	O
in	O
terminal	O
granulocyte	O
differentiation	O
or	O
in	O
regulating	O
granulocyte	O
functionality	O
.	O

Oestrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
analysis	O
in	O
B-cell	B-Disease
chronic	I-Disease
lymphocytic	I-Disease
leukemia	I-Disease
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O

Oestrogen	B-Gene
receptors	I-Gene
(	O
ER	B-Gene
)	O
are	O
present	O
in	O
neoplastic	O
lymphoid	O
cells	O
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation	O
.	O

Tamoxifen	B-Chemical
,	O
an	O
oestrogen	B-Chemical
antagonist	O
,	O
has	O
been	O
given	O
in	O
some	O
patients	O
with	O
CLL	B-Disease
and	O
Hodgkin	B-Disease
's	I-Disease
disease	I-Disease
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases	O
.	O

Until	O
now	O
,	O
ER	B-Gene
status	O
has	O
been	O
assessed	O
using	O
a	O
steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems	O
.	O

Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	B-Gene
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	B-Disease
carcinomas	I-Disease
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O

We	O
studied	O
49	O
cases	O
of	O
B-cell	B-Disease
chronic	I-Disease
lymphocytic	I-Disease
leukemia	I-Disease
(	O
CLL	B-Disease
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O

In	O
30	O
of	O
these	O
cases	O
ER	B-Gene
enzyme	O
immunoassay	O
(	O
ER	B-Gene
-EIA	O
)	O
was	O
also	O
performed	O
.	O

Cultured	O
MCF-7	O
cells	O
,	O
derived	O
from	O
a	O
pleural	B-Disease
effusion	I-Disease
of	O
a	O
breast	B-Disease
cancer	I-Disease
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	B-Gene
were	O
used	O
as	O
a	O
positive	O
control	O
(	O
40-48	O
%	O
ER	B-Gene
positive	O
cells	O
by	O
immunocytochemistry	O
;	O
200	O
fmol	O
/	O
mg	O
protein	O
by	O
EIA	O
)	O
.	O

All	O
of	O
the	O
CLL	B-Disease
cases	O
except	O
two	O
(	O
96	O
%	O
)	O
were	O
negative	O
for	O
ER	B-Gene
(	O
less	O
than	O
1	O
%	O
staining	O
;	O
less	O
than	O
4	O
fmol	O
/	O
mg	O
protein	O
)	O
.	O

The	O
two	O
positive	O
cases	O
expressed	O
granular	B-Gene
ER	I-Gene
staining	O
over	O
the	O
nucleus	O
(	O
9.2	O
and	O
12.1	O
%	O
positive	O
cells	O
)	O
and	O
were	O
positive	O
by	O
EIA	O
and	O
SBA	O
.	O

It	O
is	O
concluded	O
that	O
(	O
i	O
)	O
patients	O
with	O
CLL	B-Disease
rarely	O
express	O
ER	B-Gene
and	O
(	O
ii	O
)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	B-Gene
.	O

It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O
was	O
diagnosed	O
as	O
CLL	B-Disease
with	O
Richter	O
's	O
transformation	O
confirming	O
earlier	O
findings	O
.	O

Thyroid	B-Gene
hormone	I-Gene
receptors	I-Gene
form	O
distinct	O
nuclear	O
protein	O
-dependent	O
and	O
independent	O
complexes	O
with	O
a	O
thyroid	B-Chemical
hormone	I-Chemical
response	O
element	O
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	O
proteins	O
and	O
recombinant	B-Gene
thyroid	I-Gene
hormone	I-Gene
receptors	I-Gene
(	O
TRs	B-Gene
)	O
to	O
the	O
palindromic	O
thyroid	B-Chemical
hormone	I-Chemical
responsive	O
element	O
AGGTCATGACCT	O
(	O
TREp	O
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Four	O
specific	O
protein-DNA	O
complexes	O
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3	O
-responsive	O
pituitary	O
(	O
GH3	O
)	O
cells	O
with	O
a	O
TREp	O
-containing	O
DNA	O
fragment	O
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	O
binding	O
of	O
reticulocyte	O
lysate	O
-synthesized	O
TRs	B-Gene
.	O

TR	B-Gene
alpha	I-Gene
1	I-Gene
and	O
TR	B-Gene
beta	I-Gene
2	I-Gene
each	O
formed	O
a	O
single	O
major	O
TR	B-Gene
:	O
TREp	O
complex	O
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-Gene
beta	I-Gene
1	I-Gene
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	O
as	O
an	O
oligomer	O
.	O

Interestingly	O
,	O
coincubation	O
of	O
35S-TR	B-Gene
alpha	I-Gene
1	I-Gene
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	O
resulted	O
in	O
not	O
only	O
the	O
35S-TR	B-Gene
:	O
TREp	O
complex	O
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S-TR	B-Gene
alpha	I-Gene
1	I-Gene
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	B-Gene
with	O
NE	O
from	O
COS-7	O
cells	O
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	B-Gene
TRs	I-Gene
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	O
shifted	O
complex	O
.	O

A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	B-Gene
:	O
TRE	O
complex	O
was	O
also	O
present	O
in	O
NE	O
from	O
T3	O
-unresponsive	O
JEG-3	O
cells	O
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	B-Gene
bound	O
to	O
TREp	O
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

Truncation	O
of	O
TR	B-Gene
alpha	I-Gene
1	I-Gene
at	O
amino	O
acid	O
210	O
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl-terminus	B-Chemical
of	O
the	O
TRs	B-Gene
is	O
essential	O
for	O
interaction	O
with	O
nuclear	O
proteins	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
induces	O
phospholipid	B-Chemical
turnover	O
,	O
calcium	B-Chemical
flux	O
,	O
arachidonic	B-Chemical
acid	I-Chemical
liberation	O
,	O
eicosanoid	B-Chemical
generation	O
,	O
and	O
oncogene	O
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
have	O
centered	O
mainly	O
around	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
platelets	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
on	O
B	O
lymphocytes	O
.	O

Employing	O
the	O
EBV	O
-transformed	O
human	O
B	O
cell	O
line	O
SKW6.4	O
,	O
we	O
demonstrate	O
that	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
significantly	O
alters	O
membrane	O
phospholipid	B-Chemical
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	B-Chemical
,	O
phosphatidylinositol	B-Chemical
,	O
and	O
phosphatidic	B-Chemical
acid	I-Chemical
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	B-Chemical
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-9	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso-platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	B-Chemical
.	O

We	O
also	O
show	O
that	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	B-Chemical
levels	O
,	O
whereas	O
lyso-	B-Chemical
platelet	I-Chemical
-activating	I-Chemical
factor	I-Chemical
was	O
again	O
ineffective	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
binding	O
to	O
B	O
cells	O
by	O
measuring	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
induced	O
arachidonic	B-Chemical
acid	I-Chemical
release	O
and	O
5-hydroxyeicosatetraenoic	B-Chemical
acid	I-Chemical
production	O
.	O

Moreover	O
,	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-Gene
proto-oncogenes	I-Gene
c-fos	I-Gene
and	O
c-jun	B-Gene
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	B-Chemical
acid	I-Chemical
as	O
a	O
regulator	O
of	O
arachidonic	B-Chemical
acid	I-Chemical
liberation	O
demonstrating	O
that	O
endogenous	B-Gene
5-lipoxygenase	I-Gene
activity	O
modulates	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
induced	O
arachidonic	B-Chemical
acid	I-Chemical
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B-Gene
A2	I-Gene
.	O

In	O
summary	O
,	O
platelet	B-Chemical
-activating	I-Chemical
factor	I-Chemical
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	O
B	O
cell	O
line	O
.	O

[	O
Glucocorticoid	B-Gene
receptors	I-Gene
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
bronchial	B-Disease
asthma	I-Disease
]	O

Quantitation	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GCR	B-Gene
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	B-Chemical
(	O
GCS	B-Chemical
)	O
were	O
made	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
bronchial	B-Disease
asthma	I-Disease
(	O
BA	B-Disease
)	O
patients	O
in	O
consideration	O
of	O
GCR	B-Gene
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	B-Chemical
.	O

It	O
is	O
stated	O
that	O
GCR	B-Gene
of	O
healthy	O
controls	O
and	O
GCS	B-Chemical
-untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol	B-Chemical
-dependent	O
BA	B-Disease
patients	O
on	O
hormone	O
therapy	O
.	O

Following	O
discontinuation	O
of	O
glucocorticoid	B-Chemical
drugs	O
GCR	B-Gene
count	O
in	O
cortisol	B-Chemical
-dependent	O
BA	B-Disease
tends	O
to	O
rise	O
.	O

Endogenous	O
cortisol	B-Chemical
has	O
no	O
effect	O
on	O
GCR	B-Gene
level	O
estimated	O
by	O
3H-triamcinolone	B-Chemical
acetonide	I-Chemical
.	O

A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF-kappa	B-Gene
B	I-Gene
element	I-Gene
.	O

Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	O
LTR	O
.	O

Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF-kappa	B-Gene
B	I-Gene
motif	O
.	O

These	O
changes	O
in	O
the	O
enhancer	O
element	O
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O

Subcloning	O
of	O
the	O
variant	O
NF-kappa	B-Gene
B	I-Gene
segments	O
into	O
LTR-driven	O
CAT	O
expression	O
vectors	O
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative	O
/	O
cytopathic	O
capacity	O
.	O

1	B-Gene
,	I-Gene
25-Dihydroxyvitamin	I-Gene
D3	I-Gene
receptor	I-Gene
RNA	I-Gene
:	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

1	B-Chemical
,	I-Chemical
25-Dihydroxyvitamin	I-Chemical
D3	I-Chemical
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	O
leukemic	O
cells	O
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
.	O

Little	O
is	O
known	O
of	O
expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
in	O
hematopoietic	O
cells	O
.	O

We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
in	O
various	O
proliferating	O
and	O
nonproliferating	O
hematopoietic	O
cells	O
.	O

Constitutive	O
expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	O
cells	O
,	O
including	O
macrophages	O
and	O
activated	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	O
(	O
myeloblasts	O
)	O
,	O
HL-60	O
(	O
promyelocytes	O
)	O
,	O
ML-3	O
(	O
myelomonoblasts	O
)	O
,	O
U937	O
,	O
THP-1	O
(	O
monoblasts	O
)	O
,	O
K562	O
(	O
erythroblasts	O
)	O
,	O
and	O
S-LB1	O
(	O
HTLV-1	O
-transfected	O
T	O
lymphocytes	O
)	O
.	O

Receptor	O
transcripts	O
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
.	O

Most	O
B	O
lymphocyte	O
lines	O
expressed	O
negligible	O
levels	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid	O
/	O
myeloid	O
somatic	O
hybrid	O
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
in	O
B	O
lymphocytes	O
may	O
be	O
a	O
dominant	O
characteristic	O
.	O

HL-60	O
cells	O
were	O
cultured	O
with	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
and	O
its	O
RNA	O
were	O
examined	O
.	O

Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	O
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O

Levels	O
of	O
occupied	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
protein	I-Gene
increased	O
in	O
these	O
HL-60	O
cells	O
;	O
but	O
the	O
total	O
number	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Steady-state	O
levels	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
were	O
not	O
affected	O
by	O
terminal	O
differentiation	O
of	O
HL-60	O
toward	O
either	O
granulocytes	O
or	O
macrophages	O
.	O

Nondividing	O
macrophages	O
from	O
normal	O
individuals	O
also	O
expressed	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
.	O

In	O
contrast	O
,	O
nondividing	O
peripheral	O
blood	O
lymphocytes	O
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
increased	O
markedly	O
.	O

Half-life	O
(	O
t1	O
/	O
2	O
)	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
in	O
T	O
lymphocytes	O
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	B-Chemical
D	I-Chemical
.	O

Consistent	O
with	O
this	O
short	O
t1	O
/	O
2	O
,	O
accumulation	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
RNA	I-Gene
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O

Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
in	O
myeloid	O
cells	O
and	O
proliferating	O
T	O
lymphocytes	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
on	O
mononuclear	O
leukocytes	O
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
.	O

In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
in	O
AD	B-Disease
,	O
GR	B-Gene
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	O
leukocytes	O
of	O
12	O
AD	B-Disease
patients	O
and	O
12	O
healthy	O
controls	O
.	O

GR	B-Gene
binding	O
characteristics	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features	O
.	O

These	O
data	O
suggest	O
that	O
the	O
abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	B-Disease
are	O
not	O
related	O
to	O
a	O
GR	B-Gene
deficiency	O
.	O

Kappa	B-Gene
B	I-Gene
binding	I-Gene
proteins	I-Gene
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	B-Gene
autocrine	O
human	O
T	O
cell	O
line	O
.	O

The	O
IL-2	B-Gene
and	O
the	O
IL-2-R	B-Gene
alpha	I-Gene
genes	I-Gene
are	O
both	O
expressed	O
transiently	O
in	O
normal	O
T	O
lymphocytes	O
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O

In	O
contrast	O
,	O
the	O
human	O
T	O
cell	O
line	O
,	O
IARC	O
301	O
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	B-Gene
cell	I-Gene
growth	I-Gene
factor	I-Gene
and	O
high	O
affinity	O
IL-2R	B-Gene
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusual	O
persistent	O
expression	O
of	O
the	O
IL-2	B-Gene
and	O
IL-2-R	B-Gene
alpha	I-Gene
genes	I-Gene
in	O
these	O
IARC	O
301	O
T	O
cells	O
,	O
we	O
have	O
analyzed	O
the	O
interactions	O
of	O
constitutively	O
expressed	O
nuclear	O
proteins	O
with	O
the	O
5	O
'flanking	O
regions	O
of	O
the	O
IL-2	B-Gene
and	O
IL-2-R	B-Gene
alpha	I-Gene
genes	I-Gene
using	O
both	O
DNase	B-Gene
I	I-Gene
footprinting	O
and	O
gel	O
retardation	O
techniques	O
.	O

We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(	O
-276	O
to	O
-250	O
for	O
IL-2-R	B-Gene
alpha	I-Gene
and	O
-203	O
to	O
-183	O
for	O
IL-2	B-Gene
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	O
B	O
enhancer	O
element	O
,	O
is	O
specifically	O
protected	O
by	O
nuclear	O
proteins	O
from	O
IARC	O
301	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	B-Gene
and	O
IL-2-R	B-Gene
alpha	I-Gene
promoters	I-Gene
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	O
301	O
cells	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	O
B	O
enhancer	O
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	O
.	O

Two	O
proteins	O
binding	O
the	O
kappa	O
B	O
sequence	O
,	O
NF-kappa	B-Gene
B	I-Gene
and	O
KBF1	B-Gene
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	O
301	O
nuclei	O
and	O
induced	O
by	O
PMA	B-Chemical
and	O
PHA	B-Gene
in	O
Jurkat	O
.	O

They	O
bind	O
to	O
the	O
kappa	O
B	O
motifs	O
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	O
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	B-Gene
Thy-1	I-Gene
gene	I-Gene
promoter	I-Gene
.	O

The	O
Thy-1	B-Gene
gene	I-Gene
promoter	I-Gene
resembles	O
a	O
``	O
housekeeping	O
''promoter	O
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	O
island	O
,	O
lacks	O
a	O
canonical	O
TATA	O
box	O
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	O
termini	O
of	O
the	O
mRNA	O
.	O

Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	O
does	O
not	O
confer	O
any	O
tissue	O
specificity	O
and	O
is	O
active	O
only	O
in	O
a	O
position	O
-dependent	O
manner	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	O
Thy-1	B-Gene
promoter	I-Gene
and	O
show	O
that	O
the	O
dominant	O
promoter	O
elements	O
consist	O
of	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	B-Gene
factor	I-Gene
Sp1	I-Gene
,	O
an	O
inverted	O
CCAAT	O
box	O
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
.	O

DNase	B-Gene
I	I-Gene
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	O
factors	O
to	O
these	O
elements	O
,	O
including	O
Sp1	B-Gene
and	O
CP1	B-Gene
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	O
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B-Gene
factors	I-Gene
Sp1	I-Gene
and	O
CP1	B-Gene
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	O
sequences	O
.	O

Estrogen	B-Gene
receptor	I-Gene
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early-stage	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O

Confirmation	O
of	O
a	O
model	O
.	O

Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	B-Disease
cancer	I-Disease
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
status	O
of	O
the	O
tumor	B-Disease
and	O
by	O
social	O
factors	O
,	O
namely	O
,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O

As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow-up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O

It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow-up	O
was	O
tumor	B-Disease
ER	B-Gene
concentration	O
,	O
with	O
higher	O
NK	O
activity	O
associated	O
with	O
ER	B-Gene
-status	O
.	O

In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	B-Disease
cancer	I-Disease
control	O
,	O
and	O
since	O
ER	B-Gene
-tumors	B-Disease
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	B-Disease
are	O
resistant	O
to	O
control	O
by	O
NK	O
cells	O
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	O
cells	O
to	O
the	O
tumor	B-Disease
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	B-Disease
prevent	O
local	O
tumor	B-Disease
control	O
at	O
the	O
site	O
of	O
action	O
.	O

The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O

This	O
finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	B-Disease
cancer	I-Disease
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O

Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B	O
-related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	B-Gene
T-cell	I-Gene
leukemia	I-Gene
virus	I-Gene
type	I-Gene
I	I-Gene
tax	I-Gene
gene	I-Gene
.	O

The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF-kappa	B-Gene
B	I-Gene
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	O
B	O
-related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-Gene
2	I-Gene
receptor	I-Gene
alpha-chain	I-Gene
gene	I-Gene
and	O
the	O
beta-interferon	B-Gene
gene	I-Gene
.	O

However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	O
lymphocytes	O
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B	O
-related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	O
plasma	O
cells	O
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell	O
-derived	O
NF-kappa	B-Gene
B	I-Gene
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	B-Gene
2	I-Gene
receptor	I-Gene
or	O
T-cell	B-Gene
receptor	I-Gene
genes	I-Gene
in	O
S194	O
cells	O
.	O

However	O
,	O
in	O
either	O
EL-4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower-affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B-Gene
gene	I-Gene
product	I-Gene
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
,	O
showing	O
that	O
NF-kappa	B-Gene
B	I-Gene
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B-cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Isolation	O
of	O
a	O
rel	B-Gene
-related	O
human	O
cDNA	O
that	O
potentially	O
encodes	O
the	O
65-kD	O
subunit	O
of	O
NF-kappa	B-Gene
B	I-Gene
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O

A	O
DNA	O
probe	O
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto-oncogene	B-Gene
c-rel	I-Gene
,	O
the	O
Drosophila	O
morphogen	O
dorsal	O
,	O
and	O
the	O
p50	B-Gene
DNA	I-Gene
binding	O
subunit	O
of	O
NF-kappa	B-Gene
B	I-Gene
was	O
generated	O
from	O
Jurkat	O
T	O
cell	O
complementary	O
DNA	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel	B-Gene
-related	O
complementary	O
DNA	O
that	O
hybridized	O
to	O
a	O
2.6-kilobase	O
messenger	O
RNA	O
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	O
DNA	O
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	O
kilodaltons	O
(	O
kD	O
)	O
.	O

The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O

This	O
protein-DNA	O
complex	O
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	O
human	B-Gene
p65	I-Gene
NF-kappa	I-Gene
B	I-Gene
subunit	I-Gene
and	O
binding	O
was	O
inhibited	O
by	O
I	B-Gene
kappa	I-Gene
B-alpha	I-Gene
and	O
-beta	B-Partial_Gene
proteins	I-Partial_Gene
.	O

In	O
addition	O
,	O
the	O
65-kD	O
protein	O
associated	O
with	O
the	O
p50	B-Gene
subunit	I-Gene
of	O
NF-kappa	B-Gene
B	I-Gene
and	O
the	O
kappa	O
B	O
probe	O
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	B-Gene
B-DNA	I-Gene
complex	I-Gene
.	O

Therefore	O
the	O
rel	B-Gene
-related	O
65-kD	O
protein	O
may	O
represent	O
the	O
p65	B-Gene
subunit	I-Gene
of	O
the	O
active	O
NF-kappa	B-Gene
B	I-Gene
transcription	I-Gene
factor	I-Gene
complex	I-Gene
.	O

Lymphocyte	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
number	O
in	O
posttraumatic	B-Disease
stress	I-Disease
disorder	I-Disease
.	O

OBJECTIVE	O
:	O
The	O
authors	O
'objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	B-Gene
receptor	I-Gene
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	B-Disease
stress	I-Disease
disorder	I-Disease
(	O
PTSD	B-Disease
)	O
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	O
cytosolic	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
and	O
plasma	O
cortisol	B-Chemical
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	B-Disease
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning-to-afternoon	O
decline	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	B-Chemical
levels	O
.	O

The	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	B-Disease
than	O
in	O
the	O
normal	O
subjects	O
.	O

No	O
group	O
differences	O
in	O
cortisol	B-Chemical
levels	O
were	O
observed	O
,	O
nor	O
were	O
glucocorticoid	B-Gene
receptor	I-Gene
number	O
and	O
cortisol	B-Chemical
levels	O
correlated	O
.	O

The	O
number	O
of	O
morning	O
glucocorticoid	B-Gene
receptors	I-Gene
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	B-Disease
and	O
anxiety	B-Disease
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	B-Disease
.	O

The	O
finding	O
that	O
patients	O
with	O
PTSD	B-Disease
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	B-Chemical
excretion	O
in	O
subjects	O
with	O
PTSD	B-Disease
.	O

Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
.	O

The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	B-Disease
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O

Sex	O
and	O
age	O
distribution	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
human	O
subjects	O
.	O

Specific	O
receptors	O
for	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
Dihydroxyvitamin	I-Chemical
D3	I-Chemical
have	O
been	O
described	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O

Twenty	O
two	O
healthy	O
men	O
aged	O
21-66	O
yr	O
(	O
mean	O
+	O
/	O
-	O
SD	O
41.0	O
+	O
/	O
-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O
yr	O
(	O
38.9	O
+	O
/	O
-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+	O
/	O
-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+	O
/	O
-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+	O
/	O
-	O
0.92	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
vs	O
4.43	O
+	O
/	O
-	O
1.38	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O

No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O
women	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	O
receptors	O
for	O
1.25	B-Chemical
Dihydroxyvitamin	I-Chemical
D3	I-Chemical
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O

Transcriptional	O
down-regulation	O
of	O
c-myc	B-Gene
expression	O
by	O
protein	O
synthesis	O
-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	O
T	B-Disease
lymphoblastic	I-Disease
tumor	I-Disease
cell	O
line	O
.	O

We	O
show	O
that	O
in	O
the	O
human	O
T	B-Disease
lymphoblastic	I-Disease
tumor	I-Disease
cell	O
line	O
Molt4	O
c-myc	B-Gene
mRNA	I-Gene
and	O
protein	O
expression	O
is	O
down	O
-regulated	O
after	O
exposure	O
to	O
dimethyl	B-Chemical
sulfoxide	I-Chemical
,	O
to	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
,	O
or	O
to	O
the	O
calcium	B-Chemical
ionophore	O
A23187	B-Chemical
,	O
which	O
raises	O
the	O
intracellular	O
calcium	B-Chemical
concentration	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	B-Gene
transcription	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	B-Chemical
sulfoxide	I-Chemical
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	B-Chemical
,	O
the	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	B-Chemical
.	O

The	O
calcium	B-Chemical
ionophore	O
-induced	O
c-myc	B-Gene
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c-myc	B-Gene
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium	B-Chemical
-dependent	O
induced	O
gene	O
product	O
.	O

Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	O
and	O
their	O
activation	O
by	O
T-cell	O
activators	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	O
elements	O
in	O
their	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	O
elements	O
in	O
the	O
HIV-2	O
LTR	O
.	O

The	O
HIV-2	O
LTR	O
was	O
found	O
to	O
contain	O
two	O
enhancers	O
.	O

One	O
of	O
these	O
enhancers	O
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	O
enhancer	O
.	O

This	O
enhancer	O
in	O
HIV-1	O
is	O
the	O
T-cell	O
activation	O
response	O
element	O
;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	O
enhancer	O
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	O
activators	O
.	O

The	O
second	O
enhancer	O
interacts	O
with	O
two	O
nuclear	O
binding	O
proteins	O
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B-Gene
Tax	I-Gene
protein	I-Gene
.	O

Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B-Gene
protein	I-Gene
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
.	O

Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
in	O
the	O
nucleus	O
of	O
Namalwa	O
B	O
lymphoid	O
cells	O
,	O
which	O
constitutively	O
express	O
Tax	B-Gene
.	O

In	O
contrast	O
,	O
NF-kappa	B-Gene
B	I-Gene
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long-term	O
expression	O
of	O
Tax	B-Gene
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	O
to	O
activate	O
NF-kappa	B-Gene
B	I-Gene
was	O
also	O
blocked	O
in	O
Jurkat	O
cells	O
constitutively	O
expressing	O
Tax	B-Gene
.	O

However	O
,	O
the	O
activation	O
of	O
other	O
mitogen-inducible	O
transcription	O
factors	O
,	O
such	O
as	O
Fos	B-Gene
and	O
Jun	B-Gene
,	O
was	O
unaffected	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	B-Gene
expression	O
can	O
be	O
quite	O
different	O
.	O

Consequently	O
,	O
one	O
function	O
of	O
Tax	B-Gene
in	O
cells	O
infected	O
with	O
HTLV-I	O
might	O
involve	O
cell-type-specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

A	O
thymus-specific	O
member	O
of	O
the	O
HMG	B-Gene
protein	I-Gene
family	I-Gene
regulates	O
the	O
human	B-Gene
T	I-Gene
cell	I-Gene
receptor	I-Gene
C	I-Gene
alpha	I-Gene
enhancer	I-Gene
.	O

The	O
human	B-Gene
T	I-Gene
cell-specific	I-Gene
transcription	I-Gene
factor	I-Gene
TCF-1	I-Gene
alpha	I-Gene
plays	O
a	O
key	O
role	O
in	O
the	O
tissue-specific	O
activation	O
of	O
the	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
(	I-Gene
TCR	I-Gene
)	I-Gene
C	I-Gene
alpha	I-Gene
enhancer	I-Gene
and	O
binds	O
to	O
pyrimidine-rich	B-Chemical
elements	O
(	O
5'-PyCTTTG-3')	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	O
cell-specific	O
control	O
regions	O
.	O

Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	O
affinity	O
-purified	O
protein	O
,	O
we	O
have	O
now	O
isolated	O
cDNA	O
clones	O
encoding	O
TCF-1	B-Gene
alpha	I-Gene
.	O

The	O
TCF-1	B-Gene
alpha	I-Gene
cDNA	I-Gene
contains	O
a	O
single	O
68-amino-acid	O
domain	O
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	B-Gene
group	I-Gene
(	O
HMG	B-Gene
)	O
and	O
nonhistone	O
chromosomal	O
proteins	O
.	O

Expression	O
of	O
full-length	O
and	O
mutant	O
cDNA	O
clones	O
in	O
bacteria	O
reveal	O
that	O
the	O
single	O
HMG	B-Gene
motif	O
,	O
which	O
is	O
predicted	O
to	O
contain	O
two	O
extended	O
alpha-helical	O
segments	O
,	O
is	O
sufficient	O
to	O
direct	O
the	O
sequence-specific	O
binding	O
of	O
TCF-1	B-Gene
alpha	I-Gene
to	O
DNA	O
.	O

Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	B-Gene
alpha	I-Gene
mRNA	I-Gene
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	O
or	O
T	O
cell	O
lines	O
.	O

The	O
immature	O
CEM	O
T	O
cell	O
line	O
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	B-Gene
alpha	I-Gene
mRNA	I-Gene
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	B-Chemical
esters	I-Chemical
.	O

Interestingly	O
,	O
the	O
cloned	O
TCF-1	B-Gene
alpha	I-Gene
protein	I-Gene
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
human	B-Gene
TCR	I-Gene
alpha	I-Gene
enhancer	I-Gene
in	O
nonlymphoid	O
cell	O
lines	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
endogenous	O
protein	O
in	O
T	O
cell	O
lines	O
is	O
strongly	O
dependent	O
on	O
an	O
additional	O
T	O
cell-specific	O
protein	O
that	O
interacts	O
with	O
the	O
core	O
enhancer	O
.	O

TCF-1	B-Gene
alpha	I-Gene
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA	O
-binding	O
regulatory	O
proteins	O
that	O
share	O
the	O
HMG	B-Gene
motif	O
in	O
that	O
it	O
is	O
a	O
highly	O
tissue-specific	O
RNA	O
polymerase	O
II	O
transcription	O
factor	O
.	O

Immune	O
response	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
to	O
HBx-antigen	B-Gene
of	O
hepatitis	B-Disease
B	I-Disease
virus	O
.	O

The	O
hepatitis	B-Disease
B	I-Disease
virus	O
genome	O
encodes	O
a	O
transcriptional	O
transactivator	O
protein	O
designated	O
HBxAg	B-Gene
.	O

We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	O
T-lymphocytes	O
.	O

Using	O
recombinant	B-Gene
HBxAg	I-Gene
protein	I-Gene
,	O
we	O
found	O
HBxAg	B-Gene
-specific	O
stimulation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
patients	O
with	O
acute	B-Disease
hepatitis	I-Disease
B	I-Disease
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	O
in	O
healthy	O
individuals	O
.	O

With	O
HBxAg	B-Gene
-specific	O
synthetic	O
polypeptides	O
,	O
several	O
T-cell	O
epitopes	O
were	O
identified	O
.	O

Most	O
were	O
located	O
in	O
the	O
carboxyterminal	O
half	O
of	O
the	O
HBxAg	B-Gene
protein	I-Gene
.	O

Five	O
T-cell	O
clones	O
specific	O
for	O
a	O
T-cell	O
epitope	O
located	O
at	O
the	O
carboxyterminal	O
region	O
of	O
HBxAg	B-Gene
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2	B-Gene
/	I-Gene
CD4	I-Gene
-positive	O
,	O
CD8	B-Gene
-negative	O
subtype	O
.	O

These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	B-Gene
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

Circadian	O
rhythm	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
was	O
studied	O
in	O
the	O
rat	O
liver	O
and	O
human	O
peripheral	O
leukocytes	O
.	O

For	O
rats	O
exposed	O
to	O
a	O
natural	O
environmental	O
photic	O
cycle	O
or	O
a	O
12L	O
:	O
12D	O
artificial	O
light	O
regime	O
,	O
peak	O
values	O
of	O
hepatic	B-Gene
GR	I-Gene
were	O
detected	O
between	O
23	O
:	O
00	O
and	O
02	O
:	O
00	O
h	O
.	O

Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	B-Gene
GR	I-Gene
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18	O
:	O
30	O
and	O
06	O
:	O
30	O
h	O
)	O
.	O

In	O
human	O
leukocytes	O
,	O
the	O
peak	O
value	O
of	O
GR	B-Gene
was	O
found	O
to	O
parallel	O
that	O
of	O
plasma	O
cortisol	B-Chemical
with	O
high	O
and	O
low	O
values	O
detected	O
at	O
04	O
:	O
00-08	O
:	O
00	O
h	O
and	O
23	O
:	O
00-24	O
:	O
00	O
h	O
,	O
respectively	O
.	O

In	O
patients	O
suffering	O
from	O
Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	B-Chemical
either	O
disappeared	O
or	O
was	O
inverted	O
while	O
that	O
of	O
GR	B-Gene
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O

For	O
apoplexic	O
patients	O
with	O
lesions	O
localized	O
to	O
the	O
base	O
of	O
the	O
brain	O
as	O
indicated	O
by	O
computerized	O
tomography	O
,	O
the	O
diurnal	O
variation	O
of	O
GR	B-Gene
was	O
abolished	O
.	O

Conversely	O
,	O
diurnal	O
rhythmicity	O
persisted	O
in	O
apoplexy	O
patients	O
whose	O
lesions	O
were	O
in	O
the	O
cerebral	O
cortex	O
.	O

Thus	O
,	O
we	O
postulated	O
that	O
the	O
circadian	O
modification	O
of	O
GR	B-Gene
was	O
independent	O
of	O
the	O
diurnal	O
fluctuations	O
in	O
plasma	O
cortisol	B-Chemical
level	O
or	O
the	O
circadian	O
variations	O
in	O
environmental	O
lighting	O
and	O
that	O
the	O
rhythmicity	O
might	O
be	O
regulated	O
by	O
the	O
'circadian	O
pacemaker	O
'located	O
in	O
the	O
human	O
basal	O
brain	O
.	O

These	O
diurnal	O
variations	O
in	O
GR	B-Gene
might	O
serve	O
to	O
coordinate	O
the	O
reactivity	O
of	O
the	O
target	O
cells	O
to	O
cortisol	B-Chemical
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR	B-Gene
-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	O
leukocytes	O
by	O
cortisol	B-Chemical
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	B-Gene
.	O

Multiple	O
Oct2	B-Gene
isoforms	I-Gene
are	O
generated	O
by	O
alternative	O
splicing	O
.	O

The	O
interaction	O
of	O
the	O
Oct2	B-Gene
transcription	I-Gene
factor	I-Gene
with	O
the	O
cognate	O
octamer	O
motif	O
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	B-Gene
genes	I-Gene
.	O

Ectopic	O
expression	O
of	O
cloned	O
Oct2	B-Gene
cDNA	I-Gene
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non-lymphoid	O
cells	O
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	O
cDNAs	O
encoding	O
mouse	B-Gene
Oct2	I-Gene
from	O
a	O
mature	O
B-cell	O
line	O
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	O
factor	O
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

All	O
the	O
isoforms	O
retain	O
the	O
previously	O
characterized	O
POU-domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	O
motif	O
.	O

Different	O
amounts	O
of	O
the	O
various	O
isoforms	O
are	O
present	O
within	O
the	O
same	O
B-cell	O
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B-cell	O
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	O
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	O
are	O
able	O
to	O
activate	O
an	O
octamer	O
containing	O
promoter	O
element	O
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	O
encodes	O
the	O
previously	O
described	O
lymphoid-specific	B-Gene
Oct2B	I-Gene
protein	I-Gene
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	O
motif	O
in	O
the	O
context	O
of	O
the	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
(	I-Gene
IgH	I-Gene
)	I-Gene
enhancer	I-Gene
.	O

Murine	O
and	O
human	B-Gene
T-lymphocyte	I-Gene
GATA-3	I-Gene
factors	I-Gene
mediate	O
transcription	O
through	O
a	O
cis-regulatory	O
element	O
within	O
the	O
human	B-Gene
T-cell	I-Gene
receptor	I-Gene
delta	I-Gene
gene	I-Gene
enhancer	I-Gene
.	O

A	O
family	O
of	O
transcriptional	O
activators	O
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	O
activators	O
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	O
zinc	B-Chemical
finger	O
DNA	O
-binding	O
domain	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	B-Gene
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	O
cell	O
lineage	O
.	O

Analysis	O
of	O
human	O
and	O
murine	B-Gene
GATA-3	I-Gene
factors	I-Gene
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	O
and	O
human	O
factors	O
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T-cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue-specific	O
GATA	O
-binding	O
site	O
identified	O
within	O
the	O
human	B-Gene
T-cell	I-Gene
receptor	I-Gene
delta	I-Gene
gene	I-Gene
enhancer	I-Gene
.	O

We	O
infer	O
that	O
the	O
murine	O
and	O
human	B-Gene
GATA-3	I-Gene
proteins	I-Gene
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T-cell-specific	O
transcriptional	O
regulation	O
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-Gene
B	I-Gene
by	O
the	O
HIV-1	B-Gene
protease	I-Gene
during	O
acute	O
infection	O
.	O

Transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
genome	O
is	O
regulated	O
in	O
part	O
by	O
cellular	O
factors	O
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	O
infected	O
T	O
cells	O
.	O

T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	B-Gene
NF-kappa	I-Gene
B	I-Gene
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA	O
-binding	O
subunits	O
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	O
subunits	O
.	O

It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	O
B	O
cells	O
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	O
cytoplasmic	O
complex	O
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	O
cells	O
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF-kappa	B-Gene
B	I-Gene
.	O

The	O
cloning	O
of	O
the	O
complementary	O
DNA	O
for	O
the	O
50K	O
subunit	O
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	O
105K	O
precursor	O
(	O
p105	B-Gene
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

The	O
expression	O
of	O
active	O
NF-kappa	B-Gene
B	I-Gene
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B-Gene
.	O

Because	O
HIV-1	O
requires	O
active	O
NF-kappa	B-Gene
B	I-Gene
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	O
105K	O
precursor	O
.	O

We	O
show	O
here	O
that	O
the	O
HIV-1	B-Gene
protease	I-Gene
can	O
process	O
p105	B-Gene
and	O
increases	O
levels	O
of	O
active	O
nuclear	B-Gene
NF-kappa	I-Gene
B	I-Gene
complex	I-Gene
.	O

A	O
novel	O
T-cell	O
trans-activator	O
that	O
recognizes	O
a	O
phorbol	B-Chemical
ester-inducible	I-Chemical
element	O
of	O
the	O
interleukin-2	B-Gene
promoter	I-Gene
.	O

The	O
interleukin	B-Gene
2	I-Gene
(	I-Gene
IL-2	I-Gene
)	I-Gene
gene	I-Gene
promoter	I-Gene
is	O
recognized	O
by	O
several	O
cell-type-specific	O
and	O
ubiquitous	O
transcriptional	O
regulators	O
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	B-Gene
production	O
and	O
T-cell	O
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	O
T-cell-specific	B-Gene
transcriptional	I-Gene
activator	I-Gene
TCF-1	I-Gene
(	O
for	O
T-Cell	B-Gene
Factor-1	I-Gene
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	O
response	O
element	O
(	O
TCE	O
)	O
located	O
within	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

Although	O
the	O
TCE	O
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	B-Gene
is	O
distinct	O
from	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
.	O

However	O
,	O
like	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
,	O
TCF-1	B-Gene
activity	O
is	O
induced	O
by	O
phorbol	B-Chemical
esters	I-Chemical
and	O
other	O
T-cell	O
activators	O
.	O

Vitamin	B-Gene
D	I-Gene
receptor	I-Gene
expression	O
in	O
human	O
lymphocytes	O
.	O

Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O

The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	O
protein	O
for	O
1	B-Chemical
alpha	I-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
in	O
normal	O
human	O
lymphocytes	O
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
were	O
examined	O
.	O

Lymphocytes	O
activated	O
with	O
the	O
OKT3	B-Chemical
antibody	O
to	O
the	O
T-cell	B-Gene
antigen	I-Gene
receptor	I-Gene
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	O
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	B-Gene
(	O
PHA	B-Gene
)	O
.	O

However	O
,	O
combination	O
of	O
OKT3	B-Chemical
and	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA	B-Gene
-activated	O
cells	O
.	O

The	O
receptor	O
from	O
OKT3	B-Chemical
and	O
OKT3	B-Chemical
+	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
-activated	O
lymphocytes	O
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA	B-Gene
-activated	O
lymphocytes	O
.	O

In	O
lymphocytes	O
activated	O
either	O
by	O
PHA	B-Gene
or	O
OKT3	B-Chemical
(	O
but	O
not	O
in	O
resting	O
cells	O
)	O
,	O
a	O
50-kDa	O
species	O
cross	O
-reacting	O
with	O
a	O
monoclonal	O
antibody	O
against	O
the	O
intestinal	B-Gene
vitamin	I-Gene
D	I-Gene
receptor	I-Gene
was	O
detected	O
.	O

Finally	O
,	O
RNA	O
from	O
activated	O
lymphocytes	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	O
base	O
pair	O
long	O
region	O
encoding	O
the	O
DNA	O
-binding	O
domain	O
of	O
the	O
human	O
intestinal	O
receptor	O
.	O

The	O
amplified	O
product	O
showed	O
an	O
identical	O
nucleotide	O
sequence	O
to	O
the	O
DNA	O
-binding	O
domain	O
of	O
the	O
human	O
intestinal	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1	B-Gene
,	I-Gene
25-	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
in	O
lymphocytes	O
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	O
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
.	O

[	O
Estrogen	B-Gene
receptor	I-Gene
content	O
of	O
peripheral	O
blood	O
lymphocytes	O
in	O
patients	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
]	O

ER	B-Gene
content	O
in	O
lymphocytes	O
of	O
peripheral	O
blood	O
from	O
27	O
SLE	B-Disease
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran	O
-coated	O
charcoal	O
assay	O
.	O

ER	B-Gene
content	O
in	O
lymphocytes	O
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol	O
/	O
mg	O
of	O
lymphocyte	B-Gene
cytosolic	I-Gene
protein	I-Gene
and	O
fmol	O
/	O
micrograms	O
of	O
lymphocyte	O
DNA	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B-Gene
content	O
of	O
lymphocytes	O
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	B-Disease
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	B-Gene
content	O
in	O
lymphocytes	O
,	O
expressed	O
by	O
fmol	O
/	O
mg	O
of	O
cytosolic	O
protein	O
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	B-Disease
(	O
0.9356	O
+	O
/	O
-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	B-Disease
(	O
0.2979	O
+	O
/	O
-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+	O
/	O
-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
normal	O
upper	O
limit	O
of	O
ER	B-Gene
content	O
in	O
lymphocytes	O
,	O
expressed	O
by	O
fmol	O
/	O
micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O

The	O
elevated	O
rate	O
of	O
ER	B-Gene
content	O
in	O
lymphocytes	O
in	O
14	O
active	O
SLE	B-Disease
(	O
92.9	O
%	O
)	O
was	O
also	O
higher	O
than	O
that	O
in	O
quieiescent	O
patients	O
(	O
23.1	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
10	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	B-Gene
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	O
antibody	O
and	O
hypocomplementemia	O
.	O

Cloning	O
of	O
murine	B-Gene
TCF-1	I-Gene
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3-epsilon	B-Gene
and	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
alpha	I-Gene
enhancers	I-Gene
.	O

CD3	B-Gene
-epsilon	I-Gene
gene	I-Gene
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	O
transcription	O
factor	O
,	O
TCF-1	B-Gene
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte-specific	O
enhancer	O
of	O
CD3-epsilon	B-Gene
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	B-Gene
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O

TCF-1	B-Gene
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so	O
-called	O
high	B-Gene
mobility	I-Gene
group	I-Gene
1	I-Gene
(	O
HMG	B-Gene
)	O
box	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	B-Gene
TCF-1	I-Gene
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B-Gene
TCF-1	I-Gene
.	O

Murine	O
and	O
human	B-Gene
TCF-1	I-Gene
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	O
murine	O
and	O
human	B-Gene
TCF-1	I-Gene
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	B-Gene
enhancer	I-Gene
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF-1	B-Gene
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	B-Gene
containing	O
the	O
HMG	B-Gene
box	O
was	O
sufficient	O
for	O
sequence-specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	B-Gene
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF-1	B-Gene
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell-specific	O
element	O
in	O
the	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
alpha	I-Gene
(	I-Gene
TCR-alpha	I-Gene
)	I-Gene
enhancer	I-Gene
.	O

The	O
T	O
lineage-specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR-alpha	B-Gene
and	O
CD3-epsilon	B-Gene
enhancers	I-Gene
imply	O
an	O
important	O
role	O
for	O
TCF-1	B-Gene
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF-kappa	B-Gene
B	I-Gene
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF-kappa	B-Gene
B	I-Gene
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
HIV	O
enhancer	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	O
proteins	O
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	O
could	O
be	O
sustained	O
nuclear	B-Gene
NF-kappa	I-Gene
B	I-Gene
expression	O
.	O

However	O
,	O
the	O
U937	O
monocytic	O
cell	O
line	O
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	B-Gene
NF-kappa	I-Gene
B	I-Gene
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	O
factor	O
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	B-Gene
B	I-Gene
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	B-Gene
necrosis	I-Gene
factor	I-Gene
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	O
.	O

Role	O
for	O
the	O
Epstein-Barr	B-Gene
virus	I-Gene
nuclear	I-Gene
antigen	I-Gene
2	I-Gene
in	O
viral	O
promoter	O
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O

During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	O
B	O
lymphocytes	O
,	O
six	O
viral	O
nuclear	O
antigen	O
(	O
EBNAs	B-Gene
)	O
are	O
expressed	O
from	O
long	O
primary	O
transcripts	O
by	O
means	O
of	O
alternative	O
splicing	O
and	O
alternative	O
polyadenylylation	O
sites	O
.	O

These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O

Wp	O
is	O
exclusively	O
utilized	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
primary	O
B	O
lymphocytes	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
usage	O
.	O

These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B-Gene
2	I-Gene
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	O
usage	O
in	O
primary	O
B	O
lymphocytes	O
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	O
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	O
to	O
-245	O
base	O
pairs	O
upstream	O
of	O
Cp	O
is	O
essential	O
for	O
Cp	O
activity	O
in	O
B	O
lymphocytes	O
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	O
and	O
downstream	O
sequences	O
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	B-Gene
2	I-Gene
-dependent	O
enhancer	O
;	O
and	O
(	O
iv	O
)	O
DNase	B-Gene
I	I-Gene
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	O
and	O
T	O
lymphocytes	O
revealed	O
a	O
B-cell-specific	O
footprint	O
in	O
the	O
region	O
of	O
the	O
EBNA	B-Gene
2	I-Gene
-dependent	O
enhancer	O
.	O

These	O
results	O
support	O
a	O
model	O
for	O
viral	O
promoter	O
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	B-Gene
2	I-Gene
,	O
followed	O
by	O
activation	O
of	O
Cp	O
through	O
the	O
EBNA	B-Gene
2	I-Gene
-dependent	O
enhancer	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
characteristics	O
in	O
monocytes	O
of	O
patients	O
with	O
corticosteroid	B-Chemical
-resistant	O
bronchial	B-Disease
asthma	I-Disease
.	O

The	O
mechanism	O
of	O
corticosteroid	B-Chemical
resistance	O
in	O
bronchial	B-Disease
asthma	I-Disease
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	B-Chemical
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
corticosteroid	B-Chemical
-sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid	B-Chemical
-resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	B-Chemical
B4	I-Chemical
(	O
LTB4	B-Chemical
)	O
generation	O
by	O
human	O
neutrophils	O
(	O
PMN	O
)	O
stimulated	O
by	O
calcium	B-Chemical
ionophore	O
.	O

In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	B-Chemical
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	O
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O

The	O
concentration	O
of	O
corticosteroid	B-Chemical
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	B-Chemical
,	O
methylprednisolone	B-Chemical
,	O
and	O
dexamethasone	B-Chemical
,	O
respectively	O
,	O
in	O
monocytes	O
from	O
CS	O
individuals	O
.	O

There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	B-Chemical
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O

The	O
dexamethasone	B-Chemical
Kd	O
was	O
2.45	O
+	O
/	O
-	O
0.58	O
nM	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CS	O
group	O
and	O
1.6	O
+	O
/	O
-	O
0.35	O
nM	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
of	O
patients	O
(	O
p	O
=	O
0.14	O
)	O
.	O

The	O
Ro	O
in	O
the	O
CS	O
group	O
was	O
3	O
,	O
605	O
+	O
/	O
-	O
984	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
and	O
4	O
,	O
757	O
+	O
/	O
-	O
692	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
(	O
p	O
=	O
0.23	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
corticosteroid	B-Chemical
resistance	O
in	O
bronchial	B-Disease
asthma	I-Disease
can	O
not	O
be	O
explained	O
by	O
abnormalities	O
in	O
corticosteroid	B-Gene
receptor	I-Gene
characteristics	O
.	O

Tissue-specific	O
expression	O
of	O
the	O
platelet	B-Gene
GPIIb	I-Gene
gene	I-Gene
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	O
progenitor	O
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	O
lineage	O
.	O

Recent	O
development	O
of	O
primary	O
cultures	O
of	O
human	O
megakaryocytes	O
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	B-Gene
IIb	I-Gene
(	I-Gene
GPIIb	I-Gene
)	I-Gene
gene	I-Gene
;	O
GPIIb	B-Gene
,	O
the	O
alpha	O
subunit	O
of	O
the	O
platelet	B-Gene
cytoadhesin	I-Gene
GPIIb-IIIa	I-Gene
,	O
is	O
produced	O
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B-Gene
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

For	O
these	O
reasons	O
,	O
the	O
5'-flanking	O
region	O
of	O
the	O
GPIIb	B-Gene
gene	I-Gene
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA	O
-binding	O
nuclear	O
factors	O
.	O

A	O
fragment	O
extending	O
from	O
-643	O
to	O
+33	O
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	O
gene	O
in	O
transfection	O
experiments	O
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	O
I	O
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

One	O
region	O
,	O
centered	O
at	O
-54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	B-Gene
factor	I-Gene
E1	I-Gene
-binding	O
site	O
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-233	O
contains	O
a	O
CCAAT	O
motif	O
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-345	O
and	O
-540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	O
cells	O
and	O
nonrelated	O
cells	O
as	O
well	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-460	O
and	O
-510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	O
cells	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	O
activity	O
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte-specific	O
nuclear	O
proteins	O
acting	O
as	O
positive	O
transcription	O
factors	O
.	O

Demonstration	O
of	O
estrogen	B-Chemical
and	O
progesterone	B-Gene
receptors	I-Gene
as	O
well	O
as	O
Ki-67	B-Gene
and	O
p-145	O
antigens	O
in	O
single	O
tumor	B-Disease
cells	O
from	O
blood	O
and	O
pleural	B-Disease
effusions	I-Disease
using	O
a	O
slide	O
assay	O
.	O

We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	O
localized	O
in	O
the	O
nucleus	O
from	O
isolated	O
white	O
blood	O
cells	O
as	O
well	O
as	O
from	O
single	O
tumor	B-Disease
cells	O
derived	O
from	O
malignant	O
effusions	O
.	O

With	O
the	O
antibodies	B-Gene
Ki-67	I-Gene
and	O
anti-p-145	O
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	B-Disease
lymphomas	I-Disease
.	O

An	O
almost	O
identical	O
reaction	O
was	O
obtained	O
when	O
tumor	B-Disease
cells	O
from	O
malignant	O
effusions	O
were	O
tested	O
.	O

Cells	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
leukemic	O
spread	O
of	O
lymphomas	B-Disease
of	O
low	O
malignancy	O
yielded	O
a	O
weak	O
staining	O
comparable	O
to	O
that	O
of	O
normal	O
mesothelial	O
cells	O
from	O
non-tumorous	O
cavity	O
fluids	O
.	O

The	O
detection	O
of	O
estrogen	B-Chemical
and	O
progesterone	B-Gene
receptors	I-Gene
(	O
ER	B-Gene
and	O
PR	B-Gene
)	O
localized	O
in	O
the	O
cell	O
nucleus	O
can	O
be	O
achieved	O
by	O
the	O
same	O
assay	O
.	O

The	O
reaction	O
is	O
enhanced	O
by	O
incubation	O
of	O
the	O
tumor	B-Disease
cells	O
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
prior	O
to	O
fixation	O
.	O

Pleural	B-Disease
effusions	I-Disease
from	O
20	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
were	O
tested	O
.	O

ER	B-Gene
was	O
positive	O
in	O
13	O
and	O
PR	B-Gene
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O

In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	B-Gene
and	O
PR	B-Gene
antibody	I-Gene
.	O

The	O
hormone	O
receptors	O
of	O
the	O
primary	O
tumor	B-Disease
were	O
known	O
in	O
15	O
(	O
ER	B-Gene
)	O
and	O
14	O
(	O
PR	B-Gene
)	O
patients	O
,	O
respectively	O
.	O

In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	B-Disease
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	B-Disease
cells	O
from	O
the	O
pleural	B-Disease
effusions	I-Disease
.	O

These	O
results	O
indicate	O
that	O
the	O
demonstration	O
of	O
hormone	O
receptor	O
proteins	O
in	O
cells	O
from	O
malignant	O
effusions	O
is	O
possible	O
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	B-Disease
.	O

Differentiation	O
-associated	O
expression	O
of	O
the	O
Epstein-Barr	B-Gene
virus	I-Gene
BZLF1	I-Gene
transactivator	I-Gene
protein	I-Gene
in	O
oral	B-Disease
hairy	I-Disease
leukoplakia	I-Disease
.	O

The	O
BZLF1	B-Gene
protein	I-Gene
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate-early	O
protein	O
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV	O
-infected	O
B	O
cells	O
.	O

We	O
have	O
generated	O
a	O
monoclonal	O
antibody	O
,	O
BZ1	O
,	O
to	O
BZLF1	B-Gene
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	O
,	O
dimeric	O
form	O
and	O
the	O
inactive	O
,	O
monomeric	O
form	O
of	O
the	O
protein	O
.	O

Biopsies	O
of	O
oral	B-Disease
hairy	I-Disease
leukoplakia	I-Disease
,	O
an	O
AIDS	B-Disease
-associated	O
lesion	O
characterized	O
by	O
high-level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	O
monoclonal	O
antibody	O
.	O

A	O
differentiation	O
-associated	O
pattern	O
of	O
BZLF1	B-Gene
expression	O
was	O
observed	O
,	O
BZ1	O
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
BZLF1	B-Gene
promoter	I-Gene
may	O
be	O
regulated	O
by	O
the	O
degree	O
of	O
squamous	O
differentiation	O
.	O

A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	O
DNA	O
and	O
viral	O
capsid	O
antigen	O
staining	O
with	O
BZ1	O
reactivity	O
suggested	O
that	O
BZLF1	B-Gene
expression	O
precedes	O
rampant	O
virus	O
replication	O
.	O

The	O
inability	O
to	O
detect	O
EBV	O
in	O
the	O
lower	O
epithelial	O
layers	O
of	O
oral	B-Disease
hairy	I-Disease
leukoplakia	I-Disease
raises	O
questions	O
concerning	O
the	O
nature	O
of	O
EBV	O
latency	O
and	O
persistence	O
in	O
stratified	O
squamous	O
epithelium	O
.	O

Transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	O
human	O
T	O
lymphocytes	O
and	O
identification	O
of	O
transactivating	O
HHV-6	O
(	O
GS	O
)	O
gene	O
fragments	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV	O
-infected	O
human	O
T	O
cells	O
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	O
promoter	O
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	O
human	O
T	O
lymphocytes	O
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O

Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	O
promoter	O
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	O
in	O
both	O
stimulated	O
and	O
resting	O
T	O
cells	O
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	O
promoter	O
activity	O
only	O
in	O
stimulated	O
T	O
cells	O
.	O

Three	O
DNA	O
clones	O
containing	O
HHV-6	O
(	O
GS	O
)	O
genomic	O
fragments	O
transactivated	O
the	O
HIV	O
promoter	O
in	O
cotransfected	O
T	O
cells	O
.	O

A	O
21.4-kb	O
DNA	O
clone	O
,	O
pZVB70	O
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	O
fragments	O
,	O
pZVB10	O
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	O
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	O
,	O
activated	O
the	O
HIV	O
promoter	O
construct	O
containing	O
a	O
mutation	O
in	O
the	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
site	O
.	O

However	O
,	O
this	O
mutated	B-Gene
NF	I-Gene
kappa	I-Gene
B	I-Gene
promoter	I-Gene
was	O
not	O
transactivated	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	O
or	O
pZVB10	O
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
sites	O
of	O
the	O
HIV	O
promoter	O
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O

By	O
increasing	O
HIV	O
promoter	O
activity	O
in	O
primary	O
T	O
lymphocytes	O
,	O
HHV-6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	O
human	O
T	O
cells	O
.	O

The	O
rhombotin	B-Gene
family	I-Gene
of	O
cysteine-rich	B-Chemical
LIM-domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	O
translocations	O
to	O
human	O
chromosomes	O
11p15	O
and	O
11p13	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	B-Disease
leukemia	I-Disease
involving	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
11	O
at	O
band	O
11p15	O
disrupts	O
the	O
rhombotin	B-Gene
gene	I-Gene
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine-rich	B-Chemical
regions	O
called	O
LIM	O
domains	O
,	O
which	O
show	O
homology	O
to	O
zinc	B-Gene
-binding	I-Gene
proteins	I-Gene
and	O
to	O
iron-sulfur	B-Chemical
centers	O
of	O
ferredoxins	B-Gene
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B-Gene
gene	I-Gene
have	O
now	O
been	O
isolated	O
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom-2	B-Gene
,	O
is	O
located	O
on	O
human	O
chromosome	O
11	O
at	O
band	O
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T-cell	B-Disease
leukemia-specific	I-Disease
translocations	O
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	O
are	O
upstream	O
of	O
the	O
Rhom-2	B-Gene
gene	I-Gene
.	O

Human	O
and	O
mouse	B-Gene
Rhom-2	I-Gene
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B-Gene
,	O
encode	O
two	O
tandem	O
cysteine-rich	B-Chemical
LIM	O
domains	O
.	O

Rhom-2	B-Gene
mRNA	I-Gene
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene	O
,	O
designated	O
Rhom-3	B-Gene
,	O
is	O
not	O
on	O
chromosome	O
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	O
domain	O
of	O
rhombotin	B-Gene
.	O

Since	O
the	O
Rhom-2	B-Gene
gene	I-Gene
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T-cell	O
tumors	B-Disease
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	B-Gene
gene	I-Gene
was	O
further	O
examined	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B-Gene
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

Therefore	O
,	O
chromosome	O
bands	O
11p15	O
(	O
rhombotin	B-Gene
)	O
and	O
11p13	O
(	O
Rhom-2	B-Gene
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	B-Disease
leukemia	I-Disease
,	O
with	O
the	O
11p15	O
target	O
more	O
rarely	O
involved	O
.	O

The	O
results	O
define	O
the	O
rhombotin	B-Gene
gene	I-Gene
family	I-Gene
as	O
a	O
class	O
of	O
T-cell	O
oncogenes	O
with	O
duplicated	O
cysteine-rich	B-Chemical
LIM	O
domains	O
.	O

The	O
human	O
myelomonocytic	O
cell	O
line	O
U-937	O
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid	B-Chemical
-induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide	B-Chemical
-stimulated	O
interleukin-1	B-Gene
beta	I-Gene
messenger	I-Gene
RNA	I-Gene
levels	O
by	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
.	O

The	O
active	O
metabolite	O
of	O
vitamin	B-Chemical
D	I-Chemical
,	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte	O
/	O
macrophage	O
function	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
model	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	O
cell	O
lines	O
(	O
U-937	O
,	O
THP-1	O
,	O
and	O
HL-60	O
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1	B-Gene
,	I-Gene
25-	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin-1	B-Gene
beta	I-Gene
(	I-Gene
IL-1	I-Gene
beta	I-Gene
)	I-Gene
mRNA	I-Gene
and	O
IL-1	B-Gene
beta	I-Gene
protein	I-Gene
in	O
response	O
to	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

All	O
three	O
cell	O
lines	O
expressed	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
and	O
had	O
increased	O
levels	O
of	O
IL-1	B-Gene
beta	I-Gene
mRNA	I-Gene
in	O
response	O
to	O
LPS	B-Chemical
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	B-Gene
beta	I-Gene
mRNA	I-Gene
levels	O
only	O
in	O
U-937	O
and	O
HL-60	O
cells	O
.	O

From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U-937	O
was	O
chosen	O
over	O
HL-60	O
and	O
THP-1	O
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O

In	O
U-937	O
cells	O
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12-24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	B-Gene
beta	I-Gene
mRNA	I-Gene
appearance	O
in	O
response	O
to	O
LPS	B-Chemical
.	O

However	O
,	O
exposure	O
of	O
U-937	O
cells	O
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	B-Gene
beta	I-Gene
mRNA	I-Gene
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	B-Chemical
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	O
cells	O
not	O
preincubated	O
with	O
the	O
hormone.2	O
+	O
o	O

Cortivazol	B-Chemical
mediated	O
induction	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
messenger	I-Gene
ribonucleic	I-Gene
acid	I-Gene
in	O
wild-type	O
and	O
dexamethasone	B-Chemical
-resistant	O
human	O
leukemic	O
(	O
CEM	O
)	O
cells	O
.	O

Cortivazol	B-Chemical
is	O
a	O
phenylpyrazolo	B-Chemical
glucocorticoid	I-Chemical
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild-type	O
and	O
highly	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
-resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	B-Chemical
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild-type	O
CEM	O
cells	O
but	O
not	O
in	O
a	O
dex	B-Chemical
-resistant	O
,	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
-defective	O
clone	O
ICR-27	O
TK-3	O
,	O
dex	B-Chemical
induces	O
GR	B-Gene
mRNA	I-Gene
.	O

To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	B-Chemical
acts	O
in	O
dex	B-Chemical
-resistant	O
cells	O
by	O
making	O
use	O
of	O
the	O
residual	O
GR	B-Gene
found	O
there	O
,	O
wild-type	O
and	O
dex	B-Chemical
-resistant	O
clones	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	B-Chemical
and	O
induction	O
of	O
GR	B-Gene
mRNA	I-Gene
was	O
studied	O
.	O

Cortivazol	B-Chemical
significantly	O
induced	O
GR	B-Gene
mRNA	I-Gene
in	O
the	O
normal	O
CEM-C7	O
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex	B-Chemical
-resistant	O
clones	O
,	O
although	O
the	O
dex	B-Chemical
-resistant	O
clones	O
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	B-Chemical
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	B-Gene
mRNA	I-Gene
induction	O
.	O

Increased	O
levels	O
of	O
GR	B-Gene
mRNA	I-Gene
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	B-Gene
mRNA	I-Gene
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex	B-Chemical
-resistant	O
cells	O
was	O
found	O
.	O

Positive	O
induction	O
of	O
GR	B-Gene
mRNA	I-Gene
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	O
and	O
dex	B-Chemical
-resistant	O
CEM	O
cells	O
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex	B-Chemical
-resistant	O
cells	O
is	O
defective	O
in	O
that	O
dex	B-Chemical
-resistant	O
clones	O
needed	O
significantly	O
more	O
cortivazol	B-Chemical
than	O
the	O
normal	O
cells	O
for	O
lysis	O
of	O
the	O
cells	O
.	O

A	O
case	O
of	O
hypersensitivity	B-Disease
to	O
thyroid	B-Chemical
hormones	I-Chemical
with	O
normally	O
functioning	O
thyroid	O
gland	O
and	O
increased	O
nuclear	B-Gene
triiodothyronine	I-Gene
receptors	I-Gene
.	O

A	O
52-year-old	O
male	O
presented	O
himself	O
with	O
tachycardia	B-Disease
crises	O
which	O
appeared	O
first	O
during	O
childhood	O
,	O
increased	O
in	O
frequency	O
without	O
goiter	O
or	O
exophthalmos	O
.	O

Cardiac	O
and	O
adrenergic	O
diseases	O
were	O
excluded	O
.	O

The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	B-Chemical
,	O
free	O
T4	B-Chemical
and	O
T3	B-Chemical
,	O
TBG	B-Gene
,	O
radioiodine	O
uptake	O
,	O
TSH	B-Gene
and	O
T3	B-Chemical
suppressibility	O
;	O
however	O
the	O
TSH	B-Gene
response	O
to	O
TRH	B-Gene
was	O
decreased	O
.	O

The	O
lymphocyte	B-Gene
nuclear	I-Gene
T3	I-Gene
receptor	I-Gene
was	O
found	O
with	O
an	O
affinity	O
close	O
to	O
that	O
of	O
normal	O
volunteers	O
(	O
Ka	O
:	O
1.42	O
x	O
10	O
(	O
10	O
)	O
M-1	O
vs	O
1.95	O
+	O
/	O
-	O
0.35	O
x	O
10	O
(	O
10	O
)	O
M-1	O
)	O
and	O
a	O
binding	O
capacity	O
markedly	O
increased	O
(	O
9.9	O
vs	O
3.7	O
+	O
/	O
-	O
0.4	O
fmol	O
T3	B-Chemical
/	O
100	O
micrograms	O
DNA	O
)	O
.	O

Pindolol	B-Chemical
was	O
inefficient	O
on	O
the	O
dysrhythmia	B-Disease
which	O
disappeared	O
with	O
carbimazole	B-Chemical
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug	O
.	O

Under	O
carbimazole	B-Chemical
,	O
the	O
plasma	O
T4	B-Chemical
markedly	O
decreased	O
(	O
27.7	O
+	O
/	O
-	O
3.6	O
nmol	O
/	O
l	O
)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	B-Disease
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	B-Disease
of	O
the	O
heart	O
to	O
thyroid	B-Chemical
hormones	I-Chemical
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-Gene
nuclear	I-Gene
receptor	I-Gene
sites	O
in	O
lymphocytes	O
.	O

Expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
on	O
alveolar	O
lymphocytes	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	B-Disease
diseases	I-Disease
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O

In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
on	O
peripheral	O
blood	O
T-lymphocytes	O
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	B-Disease
diseases	I-Disease
(	O
tuberculosis	B-Disease
and	O
sarcoidosis	B-Disease
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O

Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	B-Disease
or	O
with	O
sarcoidosis	B-Disease
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor	O
-positive	O
lymphocytes	O
:	O
sarcoidosis	B-Disease
,	O
20	O
+	O
/	O
-	O
12	O
%	O
;	O
tuberculosis	B-Disease
,	O
31	O
+	O
/	O
-	O
17	O
%	O
)	O
.	O

In	O
contrast	O
,	O
blood	O
lymphocytes	O
from	O
patients	O
with	O
granulomatous	B-Disease
diseases	I-Disease
did	O
not	O
express	O
detectable	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
.	O

The	O
percentage	O
of	O
lavage	O
T-lymphocytes	O
expressing	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	B-Disease
presenting	O
with	O
isolated	O
hilar	O
adenopathy	B-Disease
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and	O
/	O
or	O
cavities	O
.	O

1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptors	I-Gene
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8+	B-Gene
T-lymphocytes	O
than	O
on	O
CD4+	B-Gene
T-lymphocytes	O
in	O
sarcoidosis	B-Disease
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4+	B-Gene
than	O
of	O
CD8+	B-Gene
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	B-Disease
were	O
receptor	O
-positive	O
.	O

These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T-lymphocytes	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
granulomatous	O
reactions	O
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	O
populations	O
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	O
molecule	O
is	O
likely	O
different	O
in	O
sarcoidosis	B-Disease
and	O
tuberculosis	B-Disease
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel	B-Gene
/	I-Gene
NF-kappa	I-Gene
B	I-Gene
family	I-Gene
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	B-Gene
factor	I-Gene
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	B-Gene
MHC	I-Gene
class	I-Gene
I	I-Gene
gene	I-Gene
H-2Kb	I-Gene
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-Gene
DNA	I-Gene
binding	O
subunit	O
of	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1	B-Gene
/	I-Gene
p50	I-Gene
factor	I-Gene
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-Gene
and	O
v-rel	B-Gene
(	I-Gene
proto	I-Gene
)	I-Gene
oncogenes	I-Gene
.	O

The	O
dimerization	O
domain	O
of	O
KBF1	B-Gene
/	I-Gene
p50	I-Gene
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1	B-Gene
/	I-Gene
p50	I-Gene
(	O
delta	O
SP	O
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild-type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1	B-Gene
/	I-Gene
p50	I-Gene
,	O
c-	B-Partial_Gene
and	O
v-rel	B-Gene
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF-kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	B-Chemical
ester	I-Chemical
(	O
PMA	B-Chemical
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-transfected	O
into	O
CD4+	B-Gene
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	B-Gene
or	O
IL1	B-Gene
-induced	O
activity	O
of	O
the	O
MHC	B-Gene
class	I-Gene
I	I-Gene
H-2Kb	I-Gene
promoter	I-Gene
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	B-Gene
/	I-Gene
NF-kappa	I-Gene
B	I-Gene
family	I-Gene
.	O

Human	B-Gene
erythroid	I-Gene
5-aminolevulinate	I-Gene
synthase	I-Gene
:	O
promoter	O
analysis	O
and	O
identification	O
of	O
an	O
iron	B-Chemical
-responsive	O
element	O
in	O
the	O
mRNA	O
.	O

5-Aminolevulinate	B-Gene
synthase	I-Gene
(	O
ALAS	B-Gene
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	B-Chemical
biosynthetic	O
pathway	O
.	O

cDNA	O
clones	O
for	O
the	O
human	B-Gene
erythroid	I-Gene
ALAS	I-Gene
isozyme	I-Gene
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O

It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	B-Gene
ALAS	I-Gene
precursor	I-Gene
protein	I-Gene
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	B-Gene
housekeeping	I-Gene
ALAS	I-Gene
precursor	I-Gene
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O

The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B-Gene
ALAS	I-Gene
isozymes	I-Gene
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O

The	O
two	O
isozymes	O
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	O
signal	O
sequences	O
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	O
two-thirds	O
of	O
their	O
proteins	O
.	O

An	O
analysis	O
of	O
the	O
immediate	O
promoter	O
of	O
the	O
human	B-Gene
erythroid	I-Gene
ALAS	I-Gene
gene	I-Gene
revealed	O
several	O
putative	O
erythroid-specific	O
cis	O
-acting	O
elements	O
including	O
both	O
a	O
GATA-1	B-Gene
and	O
an	O
NF-E2	B-Gene
binding	O
site	O
.	O

An	O
iron	B-Chemical
-responsive	O
element	O
(	O
IRE	O
)	O
motif	O
has	O
been	O
identified	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	B-Gene
erythroid	I-Gene
ALAS	I-Gene
mRNA	I-Gene
,	O
but	O
is	O
not	O
present	O
in	O
the	O
housekeeping	B-Gene
ALAS	I-Gene
mRNA	I-Gene
.	O

Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	O
motif	O
formed	O
a	O
protein	O
-	O
RNA	O
complex	O
with	O
cytosolic	O
extracts	O
from	O
human	O
K562	O
cells	O
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	O
transcripts	O
from	O
ferritin	B-Gene
or	O
transferrin	B-Gene
receptor	I-Gene
mRNAs	I-Gene
.	O

A	O
transcript	O
of	O
the	O
ALAS	B-Gene
IRE	I-Gene
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	O
,	O
did	O
not	O
readily	O
form	O
this	O
protein	O
-	O
RNA	O
complex	O
.	O

These	O
results	O
suggest	O
that	O
the	O
IRE	O
motif	O
in	O
the	O
ALAS	B-Gene
mRNA	I-Gene
is	O
functional	O
and	O
imply	O
that	O
translation	O
of	O
the	O
mRNA	O
is	O
controlled	O
by	O
cellular	O
iron	B-Chemical
availability	O
during	O
erythropoiesis	O
.	O

Human	B-Gene
tumor	I-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
gene	I-Gene
regulation	O
in	O
phorbol	B-Chemical
ester	I-Chemical
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O

The	O
minimal	O
region	O
of	O
the	O
human	B-Gene
tumor	I-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	I-Gene
TNF-alpha	I-Gene
)	I-Gene
gene	I-Gene
promoter	I-Gene
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	B-Chemical
esters	I-Chemical
(	O
PMA	B-Chemical
)	O
in	O
human	O
T	O
and	O
B	O
lymphocyte	O
cell	O
lines	O
has	O
been	O
localized	O
between	O
-52	O
and	O
+89	O
nucleotides	O
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
's	O
transcriptional	O
start	O
site	O
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	B-Chemical
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	B-Chemical
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	B-Gene
promoter	I-Gene
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	B-Gene
mRNA	I-Gene
induction	O
by	O
PMA	B-Chemical
does	O
not	O
correlate	O
with	O
NF-kappa	B-Gene
B	I-Gene
binding	O
activities	O
displayed	O
by	O
different	O
T	O
and	O
B	O
cell	O
lines	O
.	O

Moreover	O
,	O
kappa	O
1-kappa	O
3	O
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF-alpha	B-Gene
promoter	I-Gene
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	O
by	O
PMA	B-Chemical
.	O

Therefore	O
,	O
TNF-alpha	B-Gene
mRNA	I-Gene
induction	O
by	O
PMA	B-Chemical
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	B-Chemical
,	O
is	O
not	O
primarily	O
mediated	O
by	O
NF-kappa	B-Gene
B	I-Gene
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	O
factors	O
.	O

Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1-kappa	O
3	O
can	O
confer	O
PMA	B-Chemical
inducibility	O
on	O
a	O
heterologous	O
promoter	O
in	O
a	O
B	O
(	O
Raji	O
)	O
,	O
but	O
not	O
a	O
T	O
(	O
HUT78	O
)	O
cell	O
line	O
.	O

However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	B-Gene
TNF-alpha	I-Gene
promoter	I-Gene
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	B-Chemical
inducible	O
function	O
of	O
these	O
NF-kappa	B-Gene
B	I-Gene
binding	O
sites	O
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T-cell-specific	O
membrane	O
proteins	O
allows	O
the	O
identification	O
of	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
these	O
T-cell	O
genes	O
.	O

Such	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T-cell	O
phenotype	O
by	O
functioning	O
as	O
'master	O
regulators	O
of	O
T-cell	O
differentiation'	O
.	O

Regulation	O
of	O
jun	B-Gene
and	O
fos	B-Gene
gene	I-Gene
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
.	O

The	O
macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
M-CSF	B-Gene
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	B-Gene
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-Gene
and	O
fos	B-Gene
early	I-Gene
response	I-Gene
genes	I-Gene
.	O

Low	O
levels	O
of	O
c-jun	B-Gene
transcripts	I-Gene
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	B-Gene
recombinant	I-Gene
M-CSF	I-Gene
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c-jun	B-Gene
mRNA	I-Gene
levels	O
.	O

Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	B-Gene
regulates	O
c-jun	B-Gene
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	B-Gene
transcripts	I-Gene
.	O

M-CSF	B-Gene
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun-B	B-Gene
gene	I-Gene
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c-jun	B-Gene
.	O

We	O
further	O
demonstrate	O
that	O
M-CSF	B-Gene
increases	O
c-fos	B-Gene
mRNA	I-Gene
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c-fos	B-Gene
gene	I-Gene
was	O
followed	O
by	O
that	O
for	O
the	O
fos-B	B-Gene
gene	I-Gene
.	O

Moreover	O
,	O
M-CSF	B-Gene
-induced	O
expression	O
of	O
the	O
fos	B-Gene
-related	O
gene	O
,	O
fra-1	B-Gene
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	B-Gene
and	O
fos-B	B-Gene
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M-CSF	B-Gene
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun	B-Gene
/	I-Gene
fos	I-Gene
family	I-Gene
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

Cloning	O
of	O
a	O
human	B-Gene
homeobox	I-Gene
gene	I-Gene
that	O
resembles	O
a	O
diverged	O
Drosophila	B-Gene
homeobox	I-Gene
gene	I-Gene
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	O
.	O

A	O
new	O
homeobox	B-Gene
gene	I-Gene
,	O
HB24	B-Gene
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O

Northern	O
blot	O
analysis	O
of	O
polyadenylated	O
RNA	O
purified	O
from	O
activated	O
human	O
B	O
cells	O
revealed	O
a	O
single	O
mRNA	O
transcript	O
of	O
approximately	O
2.3	O
kb	O
.	O

Two	O
cDNA	O
clones	O
were	O
sequenced	O
and	O
provided	O
2	O
,	O
250	O
nucleotides	O
(	O
nt	O
)	O
of	O
DNA	O
sequence	O
information	O
.	O

There	O
is	O
a	O
single	O
methionine	B-Chemical
codon	O
-initiated	O
open	O
reading	O
frame	O
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	O
and	O
a	O
CAX	O
repeat	O
,	O
and	O
the	O
open	O
reading	O
frame	O
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O

When	O
the	O
homeodomain	O
from	O
HB24	B-Gene
was	O
compared	O
to	O
known	O
mammalian	O
and	O
Drosophila	O
homeodomains	O
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved	O
,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	O
homeodomain	O
,	O
H2.0	B-Gene
,	O
it	O
was	O
found	O
to	O
be	O
80	O
%	O
identical	O
.	O

The	O
HB24	B-Gene
mRNA	I-Gene
was	O
absent	O
or	O
present	O
at	O
low	O
levels	O
in	O
normal	O
B	O
and	O
T	O
lymphocytes	O
;	O
however	O
,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	B-Gene
mRNA	I-Gene
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	B-Chemical
.	O

Characterization	O
of	O
HB24	B-Gene
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O

HB24	B-Gene
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	O
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O

Severe	O
5-fluorouracil	B-Chemical
toxicity	O
secondary	O
to	O
dihydropyrimidine	B-Gene
dehydrogenase	I-Gene
deficiency	O
.	O

A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O

This	O
study	O
describes	O
the	O
inheritance	O
of	O
a	O
defect	O
in	O
pyrimidine	B-Chemical
catabolism	O
and	O
its	O
association	O
with	O
drug	O
-induced	O
toxicity	O
in	O
a	O
patient	O
receiving	O
5-fluorouracil	B-Chemical
(	O
FUra	B-Chemical
)	O
as	O
adjuvant	O
chemotherapy	O
for	O
breast	B-Disease
carcinoma	I-Disease
.	O

The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O

The	O
activity	O
of	O
dihydropyrimidine	B-Gene
dehydrogenase	I-Gene
(	O
DPD	B-Gene
)	O
,	O
the	O
initial	O
enzyme	O
of	O
pyrimidine	B-Chemical
(	O
and	O
FUra	B-Chemical
)	O
catabolism	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	B-Chemical
as	O
the	O
substrate	O
.	O

The	O
proband	O
had	O
no	O
detectable	O
DPD	B-Gene
activity	O
.	O

When	O
enzyme	O
levels	O
in	O
the	O
proband	O
and	O
relatives	O
were	O
compared	O
with	O
that	O
in	O
controls	O
,	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
was	O
demonstrated	O
.	O

This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	B-Chemical
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	B-Chemical
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O

Monitoring	O
DPD	B-Gene
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	B-Chemical
chemotherapy	O
.	O

Characterization	O
of	O
an	O
immediate-early	O
gene	O
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	B-Gene
kappa	I-Gene
B	I-Gene
-like	O
activity	O
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	O
representing	O
mRNAs	O
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	O
monocytes	O
.	O

One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD-3	B-Gene
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	O
tandem	O
repeats	O
of	O
the	O
cdc10	B-Gene
/	I-Gene
ankyrin	I-Gene
motif	O
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	B-Gene
repeat	O
region	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-Gene
B	I-Gene
/	I-Gene
KBF1	I-Gene
p50	I-Gene
.	O

The	O
C-terminus	O
has	O
a	O
putative	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
phosphorylation	O
site	O
.	O

In	O
vitro	O
translated	O
MAD-3	B-Gene
protein	I-Gene
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA	O
-binding	O
activity	O
of	O
the	O
p50	B-Gene
/	I-Gene
p65	I-Gene
NF-kappa	I-Gene
B	I-Gene
complex	I-Gene
but	O
not	O
that	O
of	O
the	O
p50	B-Gene
/	I-Gene
p50	I-Gene
KBF1	I-Gene
factor	I-Gene
or	O
of	O
other	O
DNA	O
-binding	O
proteins	O
.	O

The	O
MAD-3	B-Gene
cDNA	I-Gene
encodes	O
an	O
I	B-Gene
kappa	I-Gene
B	I-Gene
-like	I-Gene
protein	I-Gene
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF-kappa	B-Gene
B	I-Gene
,	O
including	O
adhesion	O
-dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O

Reactive	O
oxygen	B-Chemical
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	B-Gene
B	I-Gene
transcription	I-Gene
factor	I-Gene
and	O
HIV-1	O
.	O

Hydrogen	B-Chemical
peroxide	I-Chemical
and	O
oxygen	B-Chemical
radicals	I-Chemical
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF-kappa	B-Gene
B	I-Gene
transcription	I-Gene
factor	I-Gene
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	O
cytoplasmic	O
form	O
.	O

N-acetyl-L-cysteine	B-Chemical
(	O
NAC	B-Chemical
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	B-Chemical
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
by	O
H2O2	O
.	O

NAC	B-Chemical
and	O
other	O
thiol	B-Chemical
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF-kappa	B-Gene
B	I-Gene
by	O
cycloheximide	B-Chemical
,	O
double	O
-stranded	O
RNA	O
,	O
calcium	B-Chemical
ionophore	O
,	O
TNF-alpha	B-Gene
,	O
active	O
phorbol	B-Chemical
ester	I-Chemical
,	O
interleukin-1	B-Gene
,	O
lipopolysaccharide	B-Chemical
and	O
lectin	B-Gene
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF-kappa	B-Gene
B	I-Gene
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	O
subunit	O
I	B-Gene
kappa	I-Gene
B	I-Gene
from	O
NF-kappa	B-Gene
B	I-Gene
.	O

HTLV-1	B-Gene
Tax	I-Gene
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	B-Disease
T-cell	I-Disease
leukemia	I-Disease
(	O
ATL	B-Disease
)	O
.	O

We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B-Gene
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP-1	B-Gene
proteins	I-Gene
,	O
c-Fos	B-Gene
,	O
Fra-1	B-Gene
,	O
c-Jun	B-Gene
,	O
JunB	B-Gene
,	O
and	O
JunD	B-Gene
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c-fos	B-Gene
gene	I-Gene
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	O
transcription	O
factor	O
,	O
Tax1	B-Gene
.	O

By	O
using	O
the	O
human	O
T-cell	O
line	O
(	O
JPX-9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B-Gene
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra-1	B-Gene
,	O
c-Jun	B-Gene
,	O
and	O
JunD	B-Gene
was	O
also	O
transactivated	O
by	O
Tax1	B-Gene
.	O

Moreover	O
,	O
Tax1	B-Gene
activated	O
expression	O
of	O
two	O
other	O
transcription	O
factors	O
having	O
zinc	B-Chemical
finger	O
motifs	O
,	O
Egr-1	B-Gene
and	O
Egr-2	B-Gene
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	B-Gene
transcription	O
factors	O
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B-Gene
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
calcitriol	B-Chemical
)	O
determination	O
in	O
lymphocytes	O
of	O
children	O
with	O
rickets	B-Disease
and	O
rickets	B-Disease
-like	I-Disease
diseases	I-Disease
]	O

The	O
authors	O
provide	O
the	O
results	O
of	O
studying	O
1	B-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
calcitriol	B-Chemical
)	O
in	O
lymphocytes	O
of	O
children	O
with	O
rickets	B-Disease
and	O
rickets	B-Disease
-like	I-Disease
diseases	I-Disease
.	O

It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	B-Chemical
D	I-Chemical
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view	O
.	O

Contribution	O
of	O
NF-kappa	B-Gene
B	I-Gene
and	O
Sp1	B-Gene
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	O
types	O
.	O

Starting	O
with	O
a	O
replication	O
-incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF-kappa	B-Gene
B	I-Gene
and	O
Sp1	B-Gene
binding	O
sites	O
present	O
in	O
the	O
native	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	B-Gene
B	I-Gene
and	O
Sp1	B-Gene
elements	I-Gene
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection-cocultivation	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T-cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF-kappa	B-Gene
B	I-Gene
elements	I-Gene
(	O
and	O
no	O
Sp1	B-Gene
binding	O
sites	O
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	O
greater	O
than	O
H9	O
greater	O
than	O
CEM	O
greater	O
than	O
Jurkat	O
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O

These	O
results	O
suggest	O
that	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
LTR	O
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	O
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	O
factors	O
present	O
.	O

Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	O
by	O
1	B-Chemical
,	I-Chemical
25-dihydroxycholecalciferol	I-Chemical
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

We	O
demonstrate	O
that	O
1	B-Chemical
,	I-Chemical
25-dihydroxycholecalciferol	I-Chemical
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte-	O
and	O
lymphocyte-tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10	O
,	O
000-fold	O
in	O
monocyte	O
cell	O
lines	O
,	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
unfractionated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O

Precursors	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
intracellular	I-Gene
receptor	I-Gene
,	O
suggesting	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O

These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF-kappa	B-Gene
B	I-Gene
activity	O
by	O
cysteine	B-Chemical
and	O
cysteine	B-Chemical
derivatives	O
.	O

HIV-1	O
proviral	O
DNA	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
transcription	B-Gene
factor	I-Gene
NF-kappa	I-Gene
B	I-Gene
.	O

HIV-1	O
-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	O
TNF	B-Gene
alpha	I-Gene
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	B-Chemical
levels	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	B-Chemical
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF-kappa	B-Gene
B	I-Gene
expression	O
.	O

The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	B-Chemical
or	O
N-acetylcysteine	B-Chemical
(	O
NAC	B-Chemical
)	O
raise	O
the	O
intracellular	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
level	O
and	O
inhibit	O
HIV-1	O
replication	O
in	O
persistently	O
infected	O
Molt-4	O
and	O
U937	O
cells	O
.	O

However	O
,	O
inhibition	O
of	O
HIV-1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	B-Chemical
levels	O
.	O

Cysteine	B-Chemical
and	O
NAC	B-Chemical
also	O
inhibit	O
NF-kappa	B-Gene
B	I-Gene
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	O
acetyl-transferase	O
(	O
CAT	O
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	B-Gene
B	I-Gene
binding	O
sites	O
in	O
uninfected	O
cells	O
.	O

This	O
suggests	O
that	O
the	O
cysteine	B-Chemical
deficiency	O
in	O
HIV-1	O
-infected	O
individuals	O
may	O
cause	O
an	O
over-expression	O
of	O
NF-kappa	B-Gene
B	I-Gene
-dependent	I-Gene
genes	I-Gene
and	O
enhance	O
HIV-1	O
replication	O
.	O

NAC	B-Chemical
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1	O
-infected	O
individuals	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
in	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O

Glucocorticosteroids	B-Chemical
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B-Gene
receptors	I-Gene
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	B-Chemical
action	O
.	O

We	O
studied	O
glucocorticosteroid	B-Gene
receptor	I-Gene
density	O
and	O
affinity	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
the	O
glucocorticosteroid	B-Chemical
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	B-Disease
who	O
had	O
taken	O
no	O
glucocorticosteroid	B-Chemical
for	O
the	O
previous	O
6	O
months	O
and	O
in	O
32	O
healthy	O
controls	O
.	O

Patients	O
'disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	B-Disease
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O

Glucocorticosteroid	B-Gene
receptors	I-Gene
on	O
leukocytes	O
of	O
patients	O
with	O
SLE	B-Disease
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
+	O
/	O
-	O
306	O
vs	O
3369	O
+	O
/	O
-	O
196	O
,	O
p	O
less	O
than	O
0.005	O
)	O
.	O

The	O
binding	O
affinity	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O

There	O
was	O
no	O
correlation	O
between	O
glucocorticosteroid	B-Gene
receptor	I-Gene
number	O
and	O
SLE	B-Disease
disease	O
activity	O
.	O

[	O
Changes	O
in	O
leucocytic	B-Gene
estrogen	I-Gene
receptor	I-Gene
levels	O
in	O
patients	O
with	O
gynecomastia	B-Disease
]	O

The	O
number	O
of	O
estrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
13	O
men	O
with	O
gynecomastia	B-Disease
were	O
measured	O
by	O
radioligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex-and	O
age	O
-matched	O
healthy	O
subjects	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-Gene
in	O
leucocytes	O
was	O
significantly	O
increased	O
in	O
gynecomastia	B-Disease
(	O
Rs	O
of	O
leucocytes	O
were	O
1054	O
+	O
/	O
-	O
254	O
sites	O
/	O
cell	O
)	O
.	O

It	O
suggested	O
that	O
increase	O
of	O
ER	B-Gene
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	B-Disease
.	O

[	O
Changes	O
in	O
levels	O
of	O
leucocytic	B-Gene
estrogen	I-Gene
receptor	I-Gene
in	O
patients	O
with	O
menopausal	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
and	O
its	O
significance	O
]	O

The	O
number	O
of	O
estrogen	B-Gene
receptors	I-Gene
(	O
ER	B-Gene
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
12	O
women	O
with	O
menopausal	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
menopausal	O
women	O
without	O
diabetes	B-Disease
and	O
12	O
normal	O
women	O
of	O
childbearing	O
age	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-Gene
in	O
the	O
patients	O
was	O
significantly	O
decreased	O
.	O

Our	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-Gene
level	O
in	O
leukocytes	O
may	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
in	O
menopausal	O
period	O
.	O

Lymphocyte	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
binding	O
during	O
depression	B-Disease
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	B-Disease
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	O
difference	O
in	O
glucocorticoid	B-Gene
receptor	I-Gene
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

Afternoon	O
ACTH	B-Gene
and	O
cortisol	B-Chemical
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	B-Gene
receptor	I-Gene
binding	O
and	O
antidepressant	O
medication	O
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand	O
-induced	O
plasticity	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B-Gene
receptor	I-Gene
numbers	O
during	O
depression	B-Disease
.	O

Nuclear	O
association	O
of	O
a	O
T-cell	O
transcription	O
factor	O
blocked	O
by	O
FK-506	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
[	O
see	O
comments	O
]	O

Cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
inhibit	O
T-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

In	O
T	O
lymphocytes	O
these	O
drugs	O
disrupt	O
an	O
unknown	O
step	O
in	O
the	O
transmission	O
of	O
signals	O
from	O
the	O
T-cell	B-Gene
antigen	I-Gene
receptor	I-Gene
to	O
cytokine	O
genes	O
that	O
coordinate	O
the	O
immune	O
response	O
.	O

The	O
putative	O
intracellular	O
receptors	O
for	O
FK506	B-Chemical
and	O
cyclosporin	B-Chemical
are	O
cis-trans	B-Gene
prolyl	I-Gene
isomerases	I-Gene
.	O

Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	O
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	B-Gene
isomerase	I-Gene
inhibitors	O
and	O
analysis	O
of	O
cyclosporin	B-Chemical
-resistant	O
mutants	O
in	O
yeast	O
suggest	O
that	O
the	O
effects	O
of	O
the	O
drug	O
result	O
from	O
the	O
formation	O
of	O
an	O
inhibitory	O
complex	O
between	O
the	O
drug	O
and	O
isomerase	O
,	O
and	O
not	O
from	O
inhibition	O
of	O
isomerase	O
activity	O
.	O

A	O
transcription	O
factor	O
,	O
NF-AT	B-Gene
,	O
which	O
is	O
essential	O
for	O
early	O
T-cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	O
cells	O
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	O
factors	O
such	O
as	O
AP-1	B-Gene
and	O
NF-kappa	B-Gene
B	I-Gene
.	O

Here	O
we	O
demonstrate	O
that	O
NF-AT	B-Gene
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	O
receptor	O
induces	O
a	O
pre	O
-existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF-AT	B-Gene
.	O

FK506	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
block	O
translocation	O
of	O
the	O
cytoplasmic	O
component	O
without	O
affecting	O
synthesis	O
of	O
the	O
nuclear	O
subunit	O
.	O

Regulation	O
of	O
M-CSF	B-Gene
expression	O
by	O
M-CSF	B-Gene
:	O
role	O
of	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
and	O
transcription	B-Gene
factor	I-Gene
NF	I-Gene
kappa	I-Gene
B	I-Gene
.	O

Macrophage-colony	B-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
M-CSF	B-Gene
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	B-Gene
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high-affinity	O
cell	O
surface	O
receptors	O
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c-fms	B-Gene
protooncogene	I-Gene
.	O

The	O
detection	O
of	O
both	O
M-CSF	B-Gene
and	O
c-fms	B-Gene
expression	O
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	O
that	O
M-CSF	B-Gene
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M-CSF	B-Gene
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M-CSF	B-Gene
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M-CSF	B-Gene
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M-CSF	B-Gene
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M-CSF	B-Gene
.	O

We	O
show	O
that	O
M-CSF	B-Gene
activates	O
and	O
translocates	O
PKC	B-Gene
.	O

Inhibition	O
of	O
PKC	B-Gene
by	O
the	O
isoquinoline	B-Chemical
derivative	O
H7	O
abolishes	O
induction	O
of	O
M-CSF	B-Gene
by	O
M-CSF	B-Gene
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	B-Gene
was	O
pertussis-toxin	B-Gene
-sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
protein	I-Gene
in	O
nuclear	O
extracts	O
of	O
M-CSF	B-Gene
-induced	O
blood	O
monocytes	O
but	O
not	O
in	O
monocytes	O
exposed	O
to	O
medium	O
treatment	O
only	O
.	O

The	O
results	O
suggest	O
that	O
M-CSF	B-Gene
induction	O
of	O
M-CSF	B-Gene
involves	O
G	B-Gene
proteins	I-Gene
,	O
PKC	B-Gene
and	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
.	O

NF-kappa	B-Gene
B	I-Gene
activation	O
by	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	B-Gene
kinase	I-Gene
A	I-Gene
,	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
,	O
and	O
Ca	O
(	O
2+	O
)	O
-regulated	O
kinases	O
.	O

NF-kappa	B-Gene
B	I-Gene
is	O
a	O
DNA	O
-binding	O
regulatory	O
factor	O
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O

In	O
T	O
cells	O
,	O
NF-kappa	B-Gene
B	I-Gene
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	B-Chemical
esters	I-Chemical
and	O
the	O
cytokine	B-Gene
tumor	I-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	O
TNF	B-Gene
alpha	I-Gene
)	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF-kappa	B-Gene
B	I-Gene
activation	O
by	O
TNF	B-Gene
alpha	I-Gene
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
and	O
its	O
subclone	O
JCT6	O
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	B-Gene
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	B-Chemical
ester	I-Chemical
and	O
TNF	B-Gene
alpha	I-Gene
were	O
able	O
to	O
activate	O
NF-kappa	B-Gene
B	I-Gene
.	O

Phorbol	B-Chemical
activation	O
was	O
positively	O
modulated	O
by	O
Ca2+	O
influx	O
while	O
TNF	B-Gene
alpha	I-Gene
activation	O
was	O
not	O
.	O

Furthermore	O
,	O
while	O
PMA	B-Chemical
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B-Gene
inhibitor	O
staurosporin	B-Chemical
,	O
the	O
TNF	B-Gene
alpha	I-Gene
effect	O
was	O
unchanged	O
.	O

TNF	B-Gene
alpha	I-Gene
did	O
not	O
activate	O
cAMP	B-Chemical
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	B-Chemical
activators	O
.	O

Moreover	O
,	O
cAMP	B-Chemical
activators	O
did	O
not	O
activate	O
NF-kappa	B-Gene
B	I-Gene
in	O
Jurkat	O
cells	O
.	O

Thus	O
,	O
TNF	B-Gene
alpha	I-Gene
-induced	O
NF-kappa	B-Gene
B	I-Gene
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal	O
-mediating	O
kinases	O
such	O
as	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
,	O
protein	B-Gene
kinase	I-Gene
A	I-Gene
,	O
or	O
Ca	O
(	O
2+	O
)	O
-regulated	O
kinases	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	B-Gene
B	I-Gene
activation	O
by	O
both	O
TNF	B-Gene
alpha	I-Gene
and	O
PKC	B-Gene
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	B-Gene
B	I-Gene
/	I-Gene
I	I-Gene
kappa	I-Gene
B	I-Gene
dissociation	O
without	O
affecting	O
the	O
NF-kappa	B-Gene
B	I-Gene
translocation	O
step	O
.	O

NF-kappa	B-Gene
B	I-Gene
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	B-Gene
protein	I-Gene
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	B-Gene
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	B-Gene
B	I-Gene
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF-kappa	B-Gene
B	I-Gene
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-Gene
expression	O
vector	O
.	O

Tax	B-Gene
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF-kappa	B-Gene
B	I-Gene
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross	O
-linking	O
using	O
a	O
palindromic	O
NF-kappa	B-Gene
B	I-Gene
probe	O
homologous	O
to	O
the	O
interferon	B-Gene
beta	I-Gene
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	B-Chemical
esters	I-Chemical
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	B-Gene
expressing	O
cells	O
the	O
85-kDa	O
protein	O
and	O
a	O
92-kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	B-Gene
protein	I-Gene
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	B-Gene
NF-kappa	I-Gene
B	I-Gene
-dependent	O
granulocyte-macrophage	B-Gene
colony	I-Gene
stimulating	I-Gene
factor	I-Gene
gene	I-Gene
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	B-Gene
B	I-Gene
-regulated	O
promoters	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	B-Chemical
treatment	O
.	O

Tax	B-Gene
expression	O
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF-kappa	B-Gene
B	I-Gene
DNA	I-Gene
binding	I-Gene
proteins	I-Gene
and	O
thus	O
change	O
the	O
expression	O
of	O
NF-kappa	B-Gene
B	I-Gene
-regulated	O
promoters	O
.	O

Regulation	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
human	O
mononuclear	O
cells	O
:	O
effects	O
of	O
glucocorticoid	B-Chemical
treatment	O
,	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
and	O
ketoconazole	B-Chemical
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
(	O
GcR	B-Gene
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	O
mononulear	O
leukocytes	O
(	O
hMNL	O
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	B-Chemical
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
patients	O
with	O
or	O
without	O
ketoconazole	B-Chemical
therapy	O
.	O

Prolonged	O
corticosteroid	B-Chemical
treatment	O
resulted	O
in	O
down-regulation	O
of	O
GcR	B-Gene
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	B-Gene
in	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
was	O
normal	O
.	O

In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	B-Chemical
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down-regulatory	O
effect	O
.	O

Furthermore	O
,	O
GcR	B-Gene
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	B-Chemical
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	B-Chemical
and	O
urinary	O
free	O
cortisol	B-Chemical
.	O

We	O
also	O
observed	O
that	O
ketoconazole	B-Chemical
was	O
a	O
weak	O
competitor	O
of	O
GcR	B-Gene
in	O
intact	O
cells	O
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O

The	O
results	O
suggested	O
that	O
GcR	B-Gene
in	O
hMNL	O
are	O
down	O
-regulated	O
by	O
synthetic	O
steroids	B-Chemical
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down-regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
.	O

Finally	O
,	O
we	O
did	O
not	O
observed	O
either	O
up-regulation	O
or	O
antagonism	O
of	O
GcR	B-Gene
by	O
ketoconazole	B-Chemical
treatment	O
,	O
at	O
the	O
time	O
that	O
cortisol	B-Chemical
levels	O
of	O
patients	O
with	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
were	O
reduced	O
.	O

This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	B-Chemical
in	O
Cushing	B-Disease
's	I-Disease
disease	I-Disease
are	O
due	O
to	O
adrenal	O
cortisol	B-Chemical
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	B-Gene
of	O
target	O
cells	O
,	O
and	O
that	O
the	O
process	O
of	O
GcR	B-Gene
regulation	O
in	O
hMNL	O
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
in	O
lymphocytes	O
in	O
anorexia	B-Disease
nervosa	I-Disease
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down-regulation	O
of	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
during	O
hypercortisolaemia	B-Disease
in	O
anorexia	B-Disease
nervosa	I-Disease
.	O

DESIGN	O
:	O
Urine	O
and	O
plasma	O
samples	O
were	O
obtained	O
for	O
cortisol	B-Chemical
determination	O
and	O
blood	O
lymphocytes	O
were	O
isolated	O
for	O
receptor	O
binding	O
studies	O
.	O

PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
+	O
/	O
-	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
+	O
/	O
-	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O

Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-Gene
receptors	I-Gene
were	O
measured	O
with	O
dexamethasone	B-Chemical
as	O
ligand	O
on	O
lymphocytes	O
.	O

RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	B-Chemical
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	B-Chemical
;	O
the	O
number	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	B-Chemical
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
+	O
/	O
-	O
1750	O
vs	O
7347	O
+	O
/	O
-	O
1285	O
sites	O
/	O
cell	O
;	O
Kd	O
:	O
7.7	O
+	O
/	O
-	O
2.4	O
vs	O
7.4	O
+	O
/	O
-	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O

After	O
weight	O
gain	O
(	O
14	O
+	O
/	O
-	O
2	O
to	O
16	O
+	O
/	O
-	O
2	O
kg	O
/	O
m2	O
)	O
,	O
receptor	O
numbers	O
were	O
8421	O
+	O
/	O
-	O
2126	O
(	O
pre	O
)	O
and	O
9011	O
+	O
/	O
-	O
500	O
(	O
post	O
)	O
sites	O
/	O
cell	O
,	O
which	O
are	O
not	O
significantly	O
different	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
;	O
the	O
Kd	O
was	O
unchanged	O
(	O
9.3	O
+	O
/	O
-	O
2.6	O
vs	O
9.2	O
+	O
/	O
-	O
2.4	O
nM	O
)	O
.	O

CONCLUSIONS	O
Hypercortisolaemia	B-Disease
does	O
not	O
down-regulate	O
the	O
lymphocyte	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
in	O
anorexia	B-Disease
nervosa	I-Disease
and	O
a	O
post-receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	B-Chemical
hormones	I-Chemical
in	O
undernutrition	B-Disease
.	O

Tumor	B-Gene
necrosis	I-Gene
factor-alpha	I-Gene
mRNA	I-Gene
accumulation	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	O
sequence	O
motifs	O
and	O
mRNA	O
stabilization	O
.	O

The	O
cytokine	B-Gene
TNF	I-Gene
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	B-Disease
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B-Gene
in	O
human	O
myelomonocytic	O
cell	O
lines	O
after	O
PMA	B-Chemical
stimulation	O
.	O

The	O
cell	O
lines	O
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	B-Gene
mRNA	I-Gene
expression	O
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	B-Chemical
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-Gene
mRNA	I-Gene
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	O
cell	O
lines	O
studied	O
.	O

This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	B-Gene
TNF	I-Gene
gene	I-Gene
,	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
is	O
detected	O
within	O
the	O
TNF	B-Gene
promoter	I-Gene
between	O
-200	O
to	O
-100	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O

Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	B-Disease
cell	O
lines	O
,	O
the	O
DNase	O
I	O
site	O
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	O
not	O
changed	O
after	O
PMA	B-Chemical
induction	O
.	O

The	O
PMA	B-Chemical
induction	O
of	O
c-fos	B-Gene
mRNA	I-Gene
correlated	O
well	O
with	O
TNF	B-Gene
gene	I-Gene
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	B-Gene
complex	I-Gene
(	O
junB	B-Gene
and	O
junD	B-Gene
)	O
were	O
also	O
induced	O
by	O
PMA	B-Chemical
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML-1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	B-Gene
,	O
AP-2	B-Gene
,	O
and	O
NF	B-Gene
kappa	I-Gene
B	I-Gene
sequence	O
located	O
within	O
the	O
TNF	B-Gene
promoter	I-Gene
.	O

PMA	B-Chemical
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	O
binding	O
complexes	O
relative	O
to	O
the	O
resting	O
cells	O
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	O
and	O
murine	B-Gene
TNF	I-Gene
genes	I-Gene
are	O
discussed	O
.	O

The	O
effect	O
of	O
toremifene	B-Chemical
therapy	O
on	O
serum	B-Gene
immunoglobulin	I-Gene
levels	O
in	O
breast	B-Disease
cancer	I-Disease
.	O

Estrogens	B-Chemical
and	O
anti-estrogens	B-Chemical
enhance	O
the	O
number	O
of	O
immunoglobulin	B-Gene
(	O
Ig	B-Gene
)	O
-secreting	O
cells	O
in	O
pokeweed	B-Chemical
mitogen	I-Chemical
(	O
PWM	B-Chemical
)	O
-stimulated	O
lymphocyte	O
cultures	O
.	O

Lymphocytes	O
from	O
patients	O
who	O
have	O
received	O
anti-estrogen	B-Chemical
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig	B-Gene
-secreting	O
cells	O
after	O
PWM	B-Chemical
stimulation	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
anti-estrogen	B-Chemical
(	O
toremifene	B-Chemical
)	O
therapy	O
on	O
serum	B-Gene
immunoglobulin	I-Gene
(	O
IgA	B-Gene
,	O
IgM	B-Gene
,	O
IgG	B-Gene
)	O
levels	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
was	O
investigated	O
.	O

Serum	B-Gene
Ig	I-Gene
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	B-Gene
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O

This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	O
.	O

HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB	B-Gene
-related	I-Gene
factors	I-Gene
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	O
,	O
B2	O
and	O
B3	O
)	O
with	O
affinity	O
for	O
the	O
KB-enhancer	O
target	O
sequence	O
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1	O
-infected	O
monocytes	O
and	O
macrophages	O
.	O

The	O
B2	O
factor	O
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	O
cells	O
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	O
monocytes	O
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1	O
-infected	O
macrophages	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	O
factor	O
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	O
and	O
macrophages	O
as	O
a	O
DNA	O
-binding	O
protein	O
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	B-Gene
)	O
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1	O
-infected	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Induction	O
of	O
NF-kappa	B-Gene
B	I-Gene
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV-gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte-macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	O
cell	O
lines	O
induced	O
by	O
phorbol	B-Chemical
esters	I-Chemical
or	O
tumour	B-Gene
necrosis	I-Gene
factor	I-Gene
alpha	I-Gene
(	O
TNF	B-Gene
alpha	I-Gene
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NF-kappa	B-Gene
B	I-Gene
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF-kappa	B-Gene
B	I-Gene
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	B-Gene
B	I-Gene
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	B-Chemical
ester	I-Chemical
or	O
TNF	B-Gene
alpha	I-Gene
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	O
cell	O
lines	O
by	O
phorbol	B-Chemical
esters	I-Chemical
or	O
TNF	B-Gene
alpha	I-Gene
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	B-Disease
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	O
.	O

A	O
nuclear	B-Gene
factor	I-Gene
NF-GM2	I-Gene
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM-CSF	B-Gene
gene	I-Gene
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T-cell	O
activation	O
:	O
purification	O
from	O
human	O
T-cell	B-Disease
leukemia	I-Disease
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF-kappa	B-Gene
B	I-Gene
.	O

Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	B-Gene
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	B-Chemical
acetate	I-Chemical
(	O
PMA	B-Chemical
)	O
and	O
calcium	B-Chemical
ionophore	O
(	O
A23187	B-Chemical
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	O
,	O
including	O
granulocyte-macrophage	B-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
(	O
GM-CSF	B-Gene
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	B-Gene
GM-CSF	I-Gene
promoter	I-Gene
at	O
positions	O
between	O
-95	O
and	O
-73	O
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA	B-Chemical
/	O
A23187	B-Chemical
.	O

This	O
region	O
contains	O
two	O
DNA	O
-binding	O
motifs	O
,	O
GM2	O
and	O
GC-box	O
.	O

The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	O
factor	B-Gene
NF-GM2	I-Gene
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	O
factors	O
A1	O
,	O
A2	O
,	O
and	O
B	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM-CSF	B-Gene
gene	I-Gene
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	O
factor	B-Gene
NF-GM2	I-Gene
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA	O
-binding	O
activity	O
.	O

The	O
purified	B-Gene
NF-GM2	I-Gene
consists	O
of	O
50	O
(	O
p50	B-Gene
)	O
and	O
65	O
kDa	O
(	O
p65	B-Gene
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM-CSF	B-Gene
and	O
immunoglobulin	B-Gene
kappa	I-Gene
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O

Electrophoretically	O
purified	B-Gene
p50	I-Gene
alone	O
can	O
form	O
a	O
protein-DNA	O
complex	O
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	B-Gene
associates	O
preferentially	O
with	O
p65	B-Gene
to	O
form	O
the	O
NF-GM2	B-Gene
complex	I-Gene
.	O

In	O
addition	O
,	O
p65	B-Gene
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein-DNA	O
complex	O
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF-GM2	B-Gene
complex	I-Gene
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	B-Gene
(	O
identical	O
to	O
50	B-Gene
kDa	I-Gene
NF-kappa	I-Gene
B	I-Gene
protein	I-Gene
)	O
reacted	O
with	O
the	O
p50	B-Gene
of	O
NF-GM2	B-Gene
,	O
indicating	O
that	O
the	O
NF-GM2	B-Gene
polypeptide	O
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	O
kDa	O
subunit	O
of	O
NF-kappa	B-Gene
B	I-Gene
.	O

The	O
purified	B-Gene
NF-GM2	I-Gene
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
it	O
failed	O
to	O
stimulate	O
transcription	O
from	O
the	O
GM-CSF	B-Gene
promoter	I-Gene
harboring	O
the	O
GM2	O
sequence	O
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM-CSF	B-Gene
gene	I-Gene
through	O
the	O
GM2	O
/	O
GC-box	O
sequence	O
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	O
B	O
enhancer	O
alone	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
in	O
normal	O
leukocytes	O
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	B-Chemical
concentrations	O
.	O

We	O
measured	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GR	B-Gene
)	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	O
age	O
-related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B-Gene
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B-Gene
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	B-Gene
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	B-Gene
.	O

Eight	O
patients	O
with	O
dermatomyositis	B-Disease
/	O
polymyositis	B-Disease
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B-Gene
in	O
MNL	O
could	O
be	O
down	O
-regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

The	O
number	O
of	O
GR	B-Gene
in	O
MNL	O
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	B-Gene
in	O
MNL	O
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	B-Chemical
.	O

To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O
in	O
T-cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins	O
.	O

Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O

Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O

The	O
reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
(	O
MHC	B-Gene
)	O
haplotypes	O
can	O
mount	O
T-cell	O
responses	O
against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T-cell	B-Gene
receptors	I-Gene
are	O
designed	O
to	O
recognize	O
18-20	O
residue-long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha-helices	O
of	O
class	B-Gene
I	I-Gene
or	O
class	B-Gene
II	I-Gene
MHC	I-Gene
molecules	O
.	O

At	O
this	O
range	O
of	O
peptide	O
lengths	O
,	O
most	O
would	O
appear	O
as	O
self	O
,	O
while	O
nonselfness	O
of	O
the	O
remainders	O
are	O
destined	O
to	O
be	O
quite	O
ambiguous	O
,	O
hence	O
creating	O
responders	O
and	O
nonresponders	O
.	O

Anti-CD2	B-Gene
receptor	I-Gene
antibodies	I-Gene
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	B-Gene
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV	O
-infected	O
PBMC	O
with	O
anti-CD2	B-Gene
mAb	I-Gene
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti-CD2	B-Gene
antibodies	I-Gene
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti-CD2	B-Gene
antibodies	I-Gene
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	O
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat-CAT	O
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF-kappa	B-Gene
B	I-Gene
enhancer	I-Gene
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-Gene
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	B-Gene
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

Nuclear	O
transcription	O
factors	O
that	O
bind	O
to	O
elements	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

Induction	O
requirements	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
in	O
the	O
stimulated	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	B-Gene
B	I-Gene
,	O
AP-1	B-Gene
,	O
AP-3	B-Gene
,	O
OCT-1	B-Gene
,	O
and	O
NF-AT	B-Gene
.	O

The	O
latter	O
``	O
nuclear	B-Gene
factor	I-Gene
for	I-Gene
activated	I-Gene
T	I-Gene
cells	I-Gene
``	O
likely	O
contributes	O
to	O
the	O
tissue	O
specificity	O
of	O
IL-2	B-Gene
gene	I-Gene
expression	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	O
factors	O
in	O
primary	O
T	O
cells	O
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O

All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	O
cells	O
upon	O
activation	O
with	O
mitogens	O
but	O
not	O
with	O
exogenous	B-Gene
IL-2	I-Gene
growth	I-Gene
factor	I-Gene
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Only	O
the	O
activities	O
for	O
NF-AT	B-Gene
and	O
AP-1	B-Gene
sites	O
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	B-Chemical
plus	O
either	O
lectin	B-Gene
or	O
antibody	O
to	O
the	O
CD3	B-Gene
or	O
CD28	B-Gene
surface	O
molecules	O
.	O

Other	O
factors	O
are	O
induced	O
by	O
lectin	B-Gene
,	O
antibody	O
,	O
and	O
/	O
or	O
PMA	B-Chemical
alone	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF-AT	B-Gene
and	O
AP-1	B-Gene
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	B-Chemical
.	O

Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF-AT	B-Gene
and	O
AP-1	B-Gene
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	B-Gene
gene	I-Gene
expression	O
.	O

An	O
erythroid	O
specific	O
enhancer	O
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell-type	O
specific	O
transcription	B-Gene
factor	I-Gene
GATA-1	I-Gene
.	O

The	O
transcription	B-Gene
factor	I-Gene
GATA-1	I-Gene
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	O
cells	O
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	B-Gene
GATA-1	I-Gene
genes	I-Gene
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B-Gene
or	O
to	O
the	O
SV40	B-Gene
promoter	I-Gene
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	O
GATA-1	B-Gene
binding	O
site	O
.	O

Demonstration	O
of	O
a	O
1	B-Gene
,	I-Gene
25-dihydroxyvitamin	I-Gene
D3	I-Gene
-responsive	I-Gene
protein	I-Gene
in	O
human	O
lymphocytes	O
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
.	O

Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	O
antibody	O
recognizing	O
a	O
17-amino	O
acid	O
epitope	O
of	O
the	O
1	B-Gene
,	I-Gene
25-dihydroxyvitamin	I-Gene
D3	I-Gene
[	I-Gene
1	I-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
]	I-Gene
receptor	I-Gene
,	O
we	O
have	O
detected	O
two	O
crossreacting	O
proteins	O
in	O
activated	O
normal	O
human	O
lymphocytes	O
.	O

The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	O
kDa	O
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
and	O
,	O
similar	O
to	O
the	O
classical	O
1	B-Gene
,	I-Gene
25	I-Gene
(	I-Gene
OH	I-Gene
)	I-Gene
2D3	I-Gene
receptor	I-Gene
,	O
was	O
upregulated	O
in	O
a	O
dose	O
-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	O
to	O
be	O
specific	O
for	O
activated	O
lymphocytes	O
since	O
it	O
was	O
not	O
detected	O
in	O
several	O
other	O
human	O
cells	O
including	O
monocytes	O
.	O

More	O
strikingly	O
,	O
the	O
80-kDa	O
protein	O
was	O
downregulated	O
in	O
a	O
dose	O
-dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
;	O
this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	B-Chemical
D3	I-Chemical
.	O

However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
,	O
also	O
inhibited	O
the	O
80-kDa	O
protein	O
.	O

T-helper-cell	O
determinants	O
in	O
protein	O
antigens	O
are	O
preferentially	O
located	O
in	O
cysteine-rich	B-Chemical
antigen	O
segments	O
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B-Gene
B	I-Gene
,	O
L	B-Partial_Gene
,	O
and	O
D	B-Partial_Gene
.	O

We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T-helper-cell	O
epitopes	O
in	O
protein	O
antigen	O
(	O
Ag	O
)	O
by	O
analysing	O
the	O
Ag	O
amino	O
acid	O
sequence	O
.	O

The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	O
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	B-Gene
B	I-Gene
,	O
L	B-Partial_Gene
,	O
and	O
D	B-Partial_Gene
.	O

These	O
are	O
prominent	O
enzymes	O
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	O
protein	O
Ag	O
enter	O
APC	O
,	O
and	O
resistant	O
segments	O
in	O
Ag	O
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	O
determinants	O
than	O
susceptible	O
segments	O
.	O

From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	O
,	O
it	O
is	O
clear	O
that	O
a	O
cysteine	B-Chemical
is	O
not	O
accepted	O
in	O
any	O
of	O
the	O
S2	O
,	O
S1	O
,	O
S1',	O
and	O
S2	O
'subsites	O
of	O
cathepsin	B-Gene
B	I-Gene
and	O
L	B-Partial_Gene
,	O
and	O
not	O
in	O
the	O
S1	O
and	O
S1	O
'subsites	O
of	O
cathepsin	B-Gene
D	I-Gene
.	O

Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine	B-Chemical
-containing	O
T-cell	O
determinants	O
in	O
a	O
number	O
of	O
protein	O
Ag	O
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	B-Chemical
,	O
glycine	B-Chemical
,	O
lysine	B-Chemical
,	O
leucine	B-Chemical
,	O
serine	B-Chemical
,	O
threonine	B-Chemical
,	O
and	O
valine	B-Chemical
.	O

By	O
searching	O
protein	O
Ag	O
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	B-Chemical
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	O
determinants	O
in	O
the	O
Ag	O
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O

Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	O
for	O
potential	O
amphipatic	O
alpha-helical	O
protein	O
segments	O
.	O

Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	O
determinants	O
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O

A	O
human	O
putative	O
lymphocyte	O
G0	O
/	O
G1	O
switch	O
gene	O
containing	O
a	O
CpG-rich	O
island	O
encodes	O
a	O
small	O
basic	O
protein	O
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	O
actively	O
involved	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
(	O
G0S	O
genes	O
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin	B-Gene
-induced	O
switch	O
of	O
lymphocytes	O
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	B-Gene
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	O
genes	O
,	O
for	O
which	O
cDNAs	O
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	B-Gene
mRNA	I-Gene
increases	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B-Gene
or	O
cycloheximide	B-Chemical
to	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
nearly	O
full-length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	O
reading	O
frame	O
in	O
the	O
second	O
exon	O
.	O

The	O
derived	O
103-amino-acid	O
basic	O
protein	O
has	O
two	O
potential	O
alpha-helical	O
domains	O
separated	O
by	O
a	O
hydrophobic	O
region	O
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
and	O
casein	B-Gene
kinase	I-Gene
II	I-Gene
.	O

The	O
gene	O
contains	O
a	O
CpG-rich	O
island	O
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O

An	O
upstream	O
segment	O
contains	O
tandem	O
dinucleotide	O
repeats	O
(	O
CT	O
)	O
19	O
/	O
(	O
CA	O
)	O
16	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	O
box	O
,	O
but	O
potential	O
sites	O
for	O
CCAAT-box	O
binding	O
factors	O
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	O
repeat	O
element	O
.	O

Potential	O
sites	O
for	O
transcription	B-Gene
factors	I-Gene
AP1	I-Gene
,	O
AP2	B-Gene
,	O
and	O
AP3	B-Gene
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV-I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans-activator	O
of	O
HTLV-I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T-cell	B-Disease
leukemia	I-Disease
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
using	O
the	O
human	O
T-cell	O
lines	O
Jurkat	O
and	O
MOLT	O
4	O
,	O
which	O
are	O
negative	O
for	O
HTLV-I	O
,	O
and	O
MT-2	O
and	O
TL-Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV-I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV-I	O
enhancer	O
.	O

One	O
is	O
the	O
21-base-pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans-activation	O
by	O
the	O
HTLV-I	B-Gene
trans-activator	I-Gene
p40tax	I-Gene
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic-AMP	B-Gene
responsive	I-Gene
element	I-Gene
binding	I-Gene
factor	I-Gene
(	I-Gene
CREB	I-Gene
)	I-Gene
-like	I-Gene
factor	I-Gene
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	O
elements	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	O
elements	O
is	O
involved	O
in	O
trans-activation	O
by	O
p40tax	B-Gene
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF-kappa	B-Gene
B	I-Gene
-like	I-Gene
nuclear	I-Gene
factor	I-Gene
or	O
factors	O
.	O

Formation	O
of	O
the	O
protein-DNA	O
complex	O
with	O
the	O
C26	O
subfragment	O
was	O
positively	O
affected	O
by	O
p40tax	B-Gene
.	O

The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	B-Gene
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	B-Gene
.	O

However	O
,	O
the	O
C26	O
element	O
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	B-Gene
,	O
unlike	O
other	O
NF-kappa	B-Gene
B	I-Gene
-binding	O
elements	O
.	O

In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13-acetate	B-Chemical
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV-I	O
enhancer	O
contains	O
multiple	O
functional	O
elements	O
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	B-Gene
and	O
NF-kappa	B-Gene
B	I-Gene
-like	I-Gene
factors	I-Gene
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	O
enhancer	O
in	O
response	O
to	O
p40tax	B-Gene
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA	B-Gene
-dependent	O
activation	O
of	O
the	O
HTLV-I	O
enhancer	O
may	O
be	O
mediated	O
through	O
the	O
C26	O
element	O
.	O

v-erbA	B-Gene
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	B-Gene
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	B-Gene
target	I-Gene
gene	I-Gene
CAII	I-Gene
.	O

The	O
v-erbA	B-Gene
oncoprotein	I-Gene
represents	O
a	O
retrovirus	O
-transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	B-Gene
hormone	I-Gene
(	I-Gene
T3	I-Gene
/	I-Gene
T4	I-Gene
)	I-Gene
receptor	I-Gene
c-erbA	I-Gene
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus	O
-induced	O
erythroleukemia	B-Disease
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte-specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v-erbA	B-Gene
and	O
c-erbA	B-Gene
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte-specific	B-Gene
carbonic	I-Gene
anhydrase	I-Gene
II	I-Gene
(	O
CAII	B-Gene
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	B-Gene
.	O

This	O
erbA	B-Gene
-binding	O
site	O
confers	O
thyroid	B-Chemical
hormone	I-Chemical
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down-regulation	O
of	O
CAII	B-Gene
transcription	O
by	O
the	O
v-erbA	B-Gene
oncoprotein	I-Gene
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v-erbA	B-Gene
oncoprotein	I-Gene
and	O
the	O
c-erbA	B-Gene
/	I-Gene
T3	I-Gene
receptor	I-Gene
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c-erbA	B-Gene
activity	O
is	O
dominant	O
over	O
v-erbA	B-Gene
.	O

T3	B-Chemical
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA	B-Gene
-mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	B-Chemical
activated	O
CAII	B-Gene
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3	B-Chemical
-responsive	O
reporter	O
gene	O
containing	O
the	O
CAII-specific	B-Gene
erbA	B-Gene
-binding	O
site	O
.	O

The	O
c-erbA	B-Gene
-dependent	O
activation	O
of	O
this	O
CAII	B-Gene
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v-erbA	B-Gene
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v-erbA	B-Gene
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O

Inhibition	O
of	O
phorbol	B-Chemical
ester	I-Chemical
-induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	B-Chemical
is	O
associated	O
with	O
down-regulation	O
of	O
c-fos	B-Gene
and	O
c-jun	B-Gene
(	O
AP-1	B-Gene
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	B-Disease
leukemia	I-Disease
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	B-Chemical
(	O
TPA	B-Chemical
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-Gene
and	O
c-fos	B-Gene
early	I-Gene
response	I-Gene
genes	I-Gene
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	B-Chemical
dexamethasone	B-Chemical
inhibits	O
TPA	B-Chemical
-induced	O
increases	O
in	O
c-jun	B-Gene
and	O
c-fos	B-Gene
mRNA	I-Gene
levels	O
in	O
U-937	O
leukemia	B-Disease
cells	O
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	O
of	O
TPA	B-Chemical
-induced	O
increases	O
in	O
lamin	B-Gene
A	I-Gene
,	O
lamin	B-Gene
C	I-Gene
,	O
and	O
vimentin	B-Gene
transcripts	O
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA	B-Chemical
-induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	B-Gene
and	O
c-fos	B-Gene
genes	I-Gene
in	O
myeloid	B-Disease
leukemia	I-Disease
cells	O
are	O
regulated	O
by	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
.	O

The	O
finding	O
that	O
dexamethasone	B-Chemical
has	O
no	O
effect	O
on	O
TPA	B-Chemical
-induced	O
activation	O
of	O
PKC	B-Gene
suggests	O
that	O
this	O
glucocorticoid	B-Chemical
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	O
.	O

Nuclear	O
run-on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c-jun	B-Gene
and	O
c-fos	B-Gene
expression	O
by	O
TPA	B-Chemical
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA	B-Chemical
-induced	O
expression	O
of	O
c-jun	B-Gene
and	O
c-fos	B-Gene
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA	B-Chemical
-induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	B-Chemical
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	B-Chemical
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	B-Gene
promoter	I-Gene
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Increases	O
in	O
CAT	O
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA	B-Chemical
-treated	O
U-937	O
cells	O
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	O
that	O
contains	O
the	O
AP-1	B-Gene
binding	O
site	O
.	O

This	O
induction	O
of	O
CAT	O
activity	O
was	O
sensitive	O
to	O
dexamethasone	B-Chemical
.	O

These	O
findings	O
suggest	O
that	O
dexamethasone	B-Chemical
down-regulates	O
TPA	B-Chemical
-induced	O
transcription	O
of	O
the	O
c-jun	B-Gene
gene	I-Gene
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	B-Gene
site	O
.	O

Charybdotoxin	B-Gene
-sensitive	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	O
or	O
B	O
cell	O
activation	O
and	O
proliferation	O
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	O
binding	O
.	O

Human	O
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	B-Chemical
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O

We	O
have	O
used	O
charybdotoxin	B-Gene
,	O
a	O
known	O
inhibitor	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
K+	O
channels	O
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	B-Gene
inhibits	O
the	O
ligand	O
-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	O
and	O
T	O
cells	O
in	O
a	O
dose	O
-dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2+	O
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	O
(	O
2+	O
)	O
-activated	O
K+	O
channel	O
is	O
not	O
associated	O
with	O
changes	O
in	O
cell-cycle	O
gene	O
activation	O
,	O
IL-2	B-Gene
production	O
,	O
IL-2R	B-Gene
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand	O
-dependent	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-activated	O
K+	O
channels	O
are	O
not	O
involved	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
.	O

We	O
have	O
used	O
a	O
DNA	O
-binding	O
/	O
immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
(	O
hGR	B-Gene
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

In	O
vitro	O
translated	O
hGR	B-Gene
was	O
indistinguishable	O
from	O
native	O
hGR	B-Gene
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	B-Chemical
dodecyl	I-Chemical
sulfate-polyacrylamide	B-Chemical
gels	O
,	O
sedimentation	O
on	O
sucrose	B-Chemical
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	O
antibodies	O
generated	O
against	O
hGR	B-Gene
.	O

In	O
addition	O
,	O
cell-free	O
synthesized	O
hGR	B-Gene
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	B-Chemical
response	O
element	O
(	O
GRE	O
)	O
-containing	O
DNA	O
fragments	O
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

In	O
vitro	O
translated	O
hGR	B-Gene
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	B-Chemical
.	O

Treatment	O
with	O
dexamethasone	B-Chemical
or	O
the	O
antiglucocorticoid	O
RU486	B-Chemical
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA	O
-binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3-fold	O
over	O
that	O
of	O
heat	O
-activated	O
unliganded	O
receptors	O
.	O

Agonist	O
(	O
dexamethasone	B-Chemical
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	B-Chemical
)	O
.	O

DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
GR	B-Gene
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	B-Chemical
molybdate	I-Chemical
to	O
the	O
receptor	O
preparations	O
before	O
steroid	B-Chemical
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA-	O
receptor	O
complex	O
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell-free	O
synthesized	O
hGR	B-Gene
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	O
DNAs	O
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	O
found	O
in	O
the	O
mouse	O
mammary	B-Disease
tumor	I-Disease
virus-long	O
terminal	O
repeat	O
.	O

Oligonucleotides	O
containing	O
the	O
consensus	O
GRE	O
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	O
sequences	O
from	O
glucocorticoid-repressible	B-Chemical
genes	O
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	O
mammary	B-Disease
tumor	I-Disease
virus-long	O
terminal	O
repeat	O
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Together	O
these	O
studies	O
indicate	O
that	O
hGR	B-Gene
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE	O
-specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	B-Gene
receptor	I-Gene
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	O
cells	O
and	O
tissues	O
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	B-Chemical
and	O
RU486	B-Chemical
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	B-Chemical
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell	O
-restricted	O
activity	O
of	O
a	O
kB	B-Gene
-like	I-Gene
proto-enhancer	I-Gene
element	I-Gene
from	O
the	O
interleukin	B-Gene
2	I-Gene
promoter	I-Gene
.	O

The	O
inducible	O
,	O
T	O
cell-specific	O
enhancers	O
of	O
murine	O
and	O
human	B-Gene
Interleukin	I-Gene
2	I-Gene
(	I-Gene
Il-2	I-Gene
)	I-Gene
genes	I-Gene
contain	O
the	O
kB	O
-like	O
sequence	O
GGGATTTCACC	O
as	O
an	O
essential	O
cis	O
-acting	O
enhancer	O
motif	O
.	O

When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so	O
-called	O
TCEd	O
(	O
distal	O
T	O
cell	O
element	O
)	O
acts	O
as	O
an	O
inducible	O
proto-enhancer	O
element	O
in	O
E14	O
T	B-Disease
lymphoma	I-Disease
cells	O
,	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

In	O
extracts	O
of	O
induced	O
,	O
Il-2	B-Gene
secreting	O
El4	O
cells	O
three	O
individual	O
protein	O
factors	O
bind	O
to	O
TCEd	O
DNA	O
.	O

The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF-1	B-Gene
(	O
T	B-Gene
cell	I-Gene
factor	I-Gene
1	I-Gene
)	O
,	O
is	O
correlated	O
with	O
the	O
proto-enhancer	O
activity	O
of	O
TCEd	O
.	O

TCF-1	B-Gene
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	O
kD	O
polypeptide	O
of	O
NF-kB	B-Gene
.	O

Purified	B-Gene
NF-kB	I-Gene
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	O
,	O
but	O
TCF-1	B-Gene
binds	O
stronger	O
than	O
NF-kB	B-Gene
to	O
TCEd	O
DNA	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	O
to	O
a	O
'perfect	O
'NF-kB	B-Gene
binding	O
site	O
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	B-Gene
to	O
TCEd	O
DNA	O
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'converted	O
'TCEd	O
motifs	O
in	O
HeLa	O
cells	O
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	O
motif	O
abolishes	O
its	O
T	O
cell	O
-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	O
cells	O
and	O
HeLa	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
lymphocyte-specific	O
factors	O
binding	O
to	O
the	O
TCEd	O
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific-transcription	O
of	O
the	O
Il-2	B-Gene
gene	I-Gene
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	O
plus	O
50-kDa	B-Gene
NF-kappa	I-Gene
B	I-Gene
dimer	O
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

In	O
THP-1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA-protein	O
binding	O
complex	O
formation	O
with	O
the	O
HIV-1	B-Gene
promoter-enhancer	I-Gene
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O

This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF-kappa	B-Gene
B	I-Gene
region	O
of	O
the	O
HIV-1	O
enhancer	O
;	O
the	O
65-kDa	O
plus	O
50-kDa	B-Gene
NF-kappa	I-Gene
B	I-Gene
heterodimer	O
was	O
preferentially	O
lost	O
.	O

Adding	O
purified	B-Gene
NF-kappa	I-Gene
B	I-Gene
protein	I-Gene
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	B-Chemical
deoxycholate	I-Chemical
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF-kappa	B-Gene
B	I-Gene
activity	O
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	B-Chemical
increased	O
viral	O
production	O
and	O
NF-kappa	B-Gene
B	I-Gene
activity	O
.	O

Antiserum	O
specific	O
for	O
NF-kappa	B-Gene
B	I-Gene
binding	I-Gene
proteins	I-Gene
,	O
but	O
not	O
c-rel-specific	B-Gene
antiserum	I-Gene
,	O
disrupted	O
heterodimer	O
complex	O
formation	O
.	O

Thus	O
,	O
both	O
NF-kappa	B-Gene
B	I-Gene
-binding	I-Gene
complexes	I-Gene
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65-kDa	O
plus	O
50-kDa	O
heterodimer	O
to	O
the	O
HIV-1	O
enhancer	O
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV-1	O
gene	O
expression	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor	O
/	O
activator	O
,	O
NF-E1	B-Gene
(	O
YY-1	B-Gene
,	O
delta	B-Gene
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	B-Gene
kappa	I-Gene
3	I-Gene
'enhancer	I-Gene
and	O
the	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
mu	I-Gene
E1	I-Gene
site	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	B-Gene
kappa	I-Gene
3	I-Gene
'enhancer	I-Gene
(	O
kappa	B-Gene
E3')	I-Gene
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	O
and	O
negative	O
-acting	O
elements	O
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	B-Gene
E3	I-Gene
'enhancer	I-Gene
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	O
negative	O
-acting	O
elements	O
.	O

The	O
negative	O
-acting	O
sequences	O
repress	O
enhancer	O
activity	O
in	O
a	O
position-	O
and	O
orientation	O
-independent	O
manner	O
at	O
the	O
pre-B-cell	O
stage	O
.	O

We	O
have	O
isolated	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
zinc	B-Chemical
finger	O
protein	O
(	O
NF-E1	B-Gene
)	O
that	O
binds	O
to	O
the	O
negative	O
-acting	O
segment	O
of	O
the	O
kappa	B-Gene
E3	I-Gene
'enhancer	I-Gene
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	B-Gene
heavy-chain	I-Gene
enhancer	I-Gene
mu	I-Gene
E1	I-Gene
site	O
.	O

NF-E1	B-Gene
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	B-Gene
protein	I-Gene
,	O
which	O
binds	O
to	O
the	O
adeno	O
-associated	O
virus	O
P5	O
promoter	O
.	O

NF-E1	B-Gene
is	O
also	O
the	O
human	O
homologue	O
of	O
the	O
mouse	B-Gene
delta	I-Gene
protein	I-Gene
,	O
which	O
binds	O
to	O
ribosomal	O
protein	O
gene	O
promoters	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	O
activators	O
as	O
well	O
as	O
transcriptional	O
repressors	O
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	O
indicate	O
that	O
it	O
can	O
repress	O
basal	O
promoter	O
activity	O
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor	O
-induced	O
genes	O
with	O
almost	O
identical	O
zinc	B-Chemical
-finger	O
domains	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS	B-Gene
-like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	O
zinc	B-Chemical
-finger	O
sequences	O
of	O
the	O
type	O
Cys2-Xaa12-His2	B-Chemical
.	O

This	O
zinc	B-Chemical
-finger	O
region	O
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	B-Gene
factors	I-Gene
pAT	I-Gene
225	I-Gene
/	I-Gene
EGR1	I-Gene
and	O
pAT	B-Gene
591	I-Gene
/	I-Gene
EGR2	I-Gene
.	O

Except	O
for	O
the	O
conserved	O
zinc	B-Chemical
-finger	O
domains	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	O
133	O
gene	O
encodes	O
a	O
transcription	O
factor	O
with	O
a	O
specific	O
biological	O
function	O
.	O

Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc	B-Chemical
-finger	O
-encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	B-Gene
225	I-Gene
/	I-Gene
EGR1	I-Gene
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	B-Gene
591	I-Gene
/	I-Gene
EGR2	I-Gene
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O

cAMP	B-Chemical
-dependent	I-Chemical
regulation	O
of	O
proenkephalin	B-Gene
by	O
JunD	B-Gene
and	O
JunB	B-Gene
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	B-Gene
proteins	I-Gene
.	O

We	O
demonstrate	O
that	O
JunD	B-Gene
,	O
a	O
component	O
of	O
the	O
AP-1	B-Gene
transcription	I-Gene
factor	I-Gene
complex	I-Gene
,	O
activates	O
transcription	O
of	O
the	O
human	B-Gene
proenkephalin	I-Gene
gene	I-Gene
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP	B-Gene
-dependent	I-Gene
protein	I-Gene
kinase	I-Gene
,	O
protein	B-Gene
kinase	I-Gene
A	I-Gene
.	O

Activation	O
of	O
proenkephalin	B-Gene
transcription	O
by	O
JunD	B-Gene
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	B-Chemical
,	O
phorbol	B-Chemical
ester-	I-Chemical
,	O
and	O
Ca	O
(	O
2+	O
)	O
-inducible	O
enhancer	O
,	O
and	O
JunD	B-Gene
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O

Another	O
component	O
of	O
the	O
AP-1	B-Gene
transcription	I-Gene
complex	I-Gene
,	O
JunB	B-Gene
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-Gene
.	O

As	O
a	O
homodimer	O
JunB	B-Gene
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	B-Gene
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	B-Gene
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	B-Chemical
and	O
phorbol	B-Chemical
ester	I-Chemical
response	O
elements	O
in	O
a	O
protein	B-Gene
kinase	I-Gene
A	I-Gene
-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1	B-Gene
-related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP	B-Chemical
-dependent	I-Chemical
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-Gene
and	O
other	O
AP-1	B-Gene
-related	O
proteins	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	B-Chemical
-dependent	I-Chemical
intracellular	O
signaling	O
pathways	O
.	O

Glucocorticoid	B-Chemical
resistance	O
in	O
chronic	B-Disease
asthma	I-Disease
.	O

Glucocorticoid	B-Chemical
pharmacokinetics	O
,	O
glucocorticoid	B-Gene
receptor	I-Gene
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	O
blood	O
T	O
cell	O
proliferation	O
by	O
glucocorticoids	B-Chemical
in	O
vitro	O
.	O

A	O
total	O
of	O
37	O
chronic	O
,	O
severe	O
,	O
nonsmoking	O
asthmatic	O
patients	O
with	O
documented	O
reversible	O
airways	B-Disease
obstruction	I-Disease
were	O
classified	O
as	O
glucocorticoid	B-Chemical
-sensitive	O
or	O
-resistant	O
on	O
the	O
basis	O
of	O
changes	O
in	O
FEV1	O
,	O
FVC	O
,	O
and	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
after	O
oral	O
prednisolone	B-Chemical
.	O

The	O
resistant	O
patients	O
showed	O
no	O
significant	O
improvements	O
in	O
airflow	O
limitation	O
.	O

Phytohemagglutinin	B-Gene
(	O
PHA	B-Gene
)	O
-induced	O
proliferation	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
from	O
the	O
sensitive	O
but	O
not	O
the	O
resistant	O
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	B-Chemical
(	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O

When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	O
cells	O
to	O
dexamethasone	B-Chemical
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	B-Chemical
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

No	O
differences	O
were	O
observed	O
between	O
six	O
of	O
the	O
sensitive	O
and	O
resistant	O
patients	O
in	O
the	O
clearance	O
of	O
plasma	O
prednisolone	B-Chemical
derived	O
from	O
orally	O
administered	O
prednisone	B-Chemical
.	O

Peripheral	B-Gene
blood	I-Gene
mononuclear	I-Gene
cell	I-Gene
glucocorticoid	I-Gene
receptors	I-Gene
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O

The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	O
could	O
not	O
account	O
for	O
the	O
observed	O
difference	O
in	O
the	O
susceptibility	O
of	O
these	O
cells	O
to	O
functional	O
inhibition	O
by	O
dexamethasone	B-Chemical
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	B-Chemical
resistance	O
in	O
chronic	B-Disease
asthma	I-Disease
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	B-Chemical
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	O
lymphocytes	O
to	O
glucocorticoids	B-Chemical
.	O

This	O
lack	O
of	O
sensitivity	O
is	O
unexplained	O
but	O
is	O
not	O
attributable	O
to	O
abnormalities	O
of	O
cellular	B-Gene
glucocorticoid	I-Gene
receptors	I-Gene
.	O

Regulation	O
of	O
interleukin-1	B-Gene
beta	I-Gene
production	O
by	O
glucocorticoids	B-Chemical
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	B-Chemical
are	O
known	O
to	O
downregulate	O
interleukin-1	B-Gene
beta	I-Gene
production	O
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	B-Gene
beta	I-Gene
mRNA	I-Gene
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	B-Chemical
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	B-Chemical
or	O
phorbol	B-Chemical
myristate	I-Chemical
,	O
it	O
was	O
found	O
that	O
dexamethasone	B-Chemical
inhibited	O
the	O
lipopolysaccharide	B-Chemical
-induced	O
interleukin-1	B-Gene
beta	I-Gene
protein	I-Gene
production	O
,	O
but	O
the	O
phorbol	B-Chemical
myristate	I-Chemical
-induced	O
production	O
was	O
increased	O
3-10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	B-Chemical
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	B-Gene
beta	I-Gene
mRNA	I-Gene
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA	B-Chemical
-induced	O
mRNA	O
)	O
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	B-Chemical
myristate	I-Chemical
-induced	O
signal	O
(	O
prolonged	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	B-Chemical
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	B-Chemical
.	O

Identification	O
of	O
transcriptional	O
suppressor	O
proteins	O
that	O
bind	O
to	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus	O
-infected	O
human	O
T	O
cell	O
line	O
.	O

One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	O
dyad	O
symmetrical	O
sequence	O
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	O
region	O
of	O
the	O
human	B-Gene
retinoblastoma	I-Gene
gene	I-Gene
.	O

Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus	O
-uninfected	O
human	O
T	O
cell	O
lines	O
and	O
HeLa	O
cells	O
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	O
AP-1	B-Gene
recognition	O
sequence	O
predicted	O
for	O
the	O
HIV-1	O
NRE	O
.	O

However	O
,	O
this	O
factor	O
did	O
not	O
bind	O
to	O
a	O
typical	O
AP-1	B-Gene
site	O
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	O
site	O
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	O
promoter	O
reduced	O
the	O
promoter	O
activity	O
to	O
one	O
-tenth	O
or	O
one-third	O
,	O
respectively	O
.	O

Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
transcription	O
.	O

Constitutive	O
activation	O
of	O
NF-kB	B-Gene
in	O
human	O
thymocytes	O
.	O

NF-kB	B-Gene
is	O
a	O
eukaryotic	O
transcription	O
regulatory	O
factor	O
.	O

In	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
,	O
NF-kB	B-Gene
is	O
bound	O
to	O
a	O
cytoplasmic	O
proteic	O
inhibitor	O
,	O
the	O
IkB	B-Gene
.	O

Treatment	O
of	O
T	O
cells	O
with	O
mitogens	O
(	O
phorbol	B-Chemical
esters	I-Chemical
)	O
or	O
cytokines	O
(	O
TNF	B-Gene
alpha	I-Gene
)	O
induces	O
NF-kB	B-Gene
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF-kB	B-Gene
dependent	O
T	O
cell	O
genes	O
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	B-Gene
in	O
human	O
T	O
cell	O
thymic	O
progenitors	O
.	O

We	O
report	O
differences	O
in	O
(	O
Ca2+	O
)	O
i	O
requirement	O
for	O
NF-kB	B-Gene
activation	O
in	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	O
have	O
a	O
constitutively	O
active	O
form	O
of	O
NF-kB	B-Gene
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O

Elevated	O
glucocorticoid	B-Gene
receptor	I-Gene
concentrations	O
before	O
and	O
after	O
glucocorticoid	B-Chemical
therapy	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	B-Disease
dermatitis	I-Disease
.	O

The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	B-Chemical
binding	O
sites	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	B-Disease
dermatitis	I-Disease
(	O
AD	B-Disease
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	B-Chemical
treatment	O
.	O

Patients	O
with	O
AD	B-Disease
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
GR	B-Gene
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	B-Gene
affinity	O
did	O
not	O
differ	O
.	O

Methylprednisolone	B-Chemical
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-Gene
sites	O
per	O
cell	O
in	O
the	O
steroid	B-Chemical
-treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O

The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	B-Chemical
treatment	O
in	O
either	O
group	O
.	O

In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	B-Chemical
in	O
AD	B-Disease
and	O
findings	O
of	O
abnormal	O
cAMP	B-Chemical
and	O
cAMP-phosphodiesterase	B-Gene
activity	O
,	O
the	O
elevated	O
GR	B-Gene
concentrations	O
in	O
AD	B-Disease
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	B-Gene
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	B-Chemical
or	O
to	O
altered	O
cAMP	B-Chemical
-induced	O
GR	B-Gene
expression	O
.	O

The	O
role	O
of	O
jun	B-Gene
and	O
fos	B-Gene
gene	I-Gene
family	I-Gene
members	O
in	O
12-O-tetradecanoylphorbol-13-acetate	B-Chemical
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U-937	O
and	O
HL-60	O
by	O
12-O-tetradecanoylphorbol-13-acetate	B-Chemical
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	B-Gene
and	O
fos	B-Gene
gene	I-Gene
family	I-Gene
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O-tetradecanoylphorbol-13-acetate	B-Chemical
induced	O
differentiation	O
,	O
with	O
c-jun	B-Gene
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP-1	B-Gene
complexes	I-Gene
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	B-Gene
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	B-Gene
AP-1	I-Gene
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	B-Chemical
soluble	O
phorbol	B-Chemical
esters	I-Chemical
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	B-Gene
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c-jun	B-Gene
expression	O
,	O
the	O
generation	O
of	O
AP-1	B-Gene
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O

TCF-1	B-Gene
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
of	O
the	O
HMG	B-Gene
box	I-Gene
family	I-Gene
,	O
interacts	O
with	O
sequence	O
motifs	O
in	O
the	O
TCR	B-Gene
beta	I-Gene
and	O
TCR	B-Gene
delta	I-Gene
enhancers	I-Gene
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	B-Gene
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	O
motif	O
in	O
the	O
TCR	B-Gene
alpha	I-Gene
enhancer	I-Gene
.	O

TCF-1	B-Gene
belongs	O
to	O
the	O
family	O
of	O
transcription	O
-regulating	O
proteins	O
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG-box	B-Gene
.	O

Here	O
,	O
we	O
show	O
by	O
gel	O
retardation	O
analysis	O
that	O
TCF-1	B-Gene
specifically	O
recognizes	O
the	O
T	O
beta	O
5	O
element	O
of	O
the	O
TCR	B-Gene
beta	I-Gene
enhancer	I-Gene
and	O
the	O
T	O
delta	O
7	O
element	O
of	O
the	O
TCR	B-Gene
delta	I-Gene
enhancer	I-Gene
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	O
recognized	O
by	O
TCF-1	B-Gene
defines	O
a	O
consensus	O
motif	O
A	O
/	O
T	O
A	O
/	O
T	O
C	O
A	O
A	O
/	O
G	O
A	O
G	O
.	O

These	O
observations	O
imply	O
that	O
TCF-1	B-Gene
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	O
cell-specific	O
genes	O
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

The	O
cellular	B-Gene
oncogene	I-Gene
c-myb	I-Gene
can	O
interact	O
synergistically	O
with	O
the	O
Epstein-Barr	B-Gene
virus	I-Gene
BZLF1	I-Gene
transactivator	I-Gene
in	O
lymphoid	O
cells	O
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	O
encoded	O
transcription	O
factor	O
,	O
Z	B-Gene
(	O
BZLF1	B-Gene
)	O
.	O

We	O
have	O
shown	O
that	O
the	O
Z	B-Gene
gene	I-Gene
product	I-Gene
,	O
which	O
binds	O
to	O
AP-1	B-Gene
sites	O
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	B-Gene
,	O
can	O
efficiently	O
activate	O
the	O
EBV	O
early	O
promoter	O
,	O
BMRF1	B-Gene
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	O
cells	O
)	O
but	O
not	O
others	O
(	O
i.e.	O
,	O
Jurkat	O
cells	O
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	B-Gene
proto-oncogene	I-Gene
product	I-Gene
,	O
which	O
is	O
itself	O
a	O
DNA	B-Gene
-binding	I-Gene
protein	I-Gene
and	O
transcriptional	O
transactivator	O
,	O
can	O
interact	O
synergistically	O
with	O
Z	B-Gene
in	O
activating	O
the	O
BMRF1	B-Gene
promoter	I-Gene
in	O
Jurkat	O
cells	O
(	O
a	O
T-cell	O
line	O
)	O
or	O
Raji	O
cells	O
(	O
an	O
EBV	O
-positive	O
B-cell	O
)	O
,	O
whereas	O
the	O
c-myb	B-Gene
gene	I-Gene
product	I-Gene
by	O
itself	O
has	O
little	O
effect	O
.	O

The	O
simian	O
virus	O
40	O
early	O
promoter	O
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z	B-Gene
/	I-Gene
c-myb	I-Gene
combination	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-Gene
promoter	I-Gene
by	O
the	O
Z	B-Gene
/	I-Gene
c-myb	I-Gene
combination	O
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-Gene
protein	I-Gene
but	O
not	O
the	O
c-myb	B-Gene
protein	I-Gene
.	O

A	O
30-bp	O
sequence	O
in	O
the	O
BMRF1	B-Gene
promoter	I-Gene
which	O
contains	O
a	O
Z	B-Gene
binding	O
site	O
(	O
a	O
consensus	O
AP-1	B-Gene
site	O
)	O
is	O
sufficient	O
to	O
transfer	O
high-level	O
lymphoid-specific	O
responsiveness	O
to	O
the	O
Z	B-Gene
/	I-Gene
c-myb	I-Gene
combination	O
to	O
a	O
heterologous	O
promoter	O
.	O

That	O
the	O
c-myb	B-Gene
oncogene	I-Gene
product	I-Gene
can	O
interact	O
synergistically	O
with	O
an	O
EBV	O
-encoded	O
member	O
of	O
the	O
leucine	B-Chemical
zipper	O
protein	O
family	O
suggests	O
c-myb	B-Gene
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	O
encoded	O
transcription	O
factors	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	B-Gene
nuclear	I-Gene
factor-1	I-Gene
alpha	I-Gene
(	O
HNF-1	B-Gene
alpha	I-Gene
)	O
is	O
a	O
homeodomain	O
-containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	B-Gene
cofactor	I-Gene
of	I-Gene
HNF-1	I-Gene
alpha	I-Gene
(	O
DCoH	B-Gene
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	B-Gene
alpha	I-Gene
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH-HNF-1	B-Gene
alpha	I-Gene
complex	I-Gene
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF-1	B-Gene
alpha	I-Gene
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF-1	B-Gene
alpha	I-Gene
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	B-Gene
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	B-Gene
DNA	I-Gene
binding	O
domain	O
.	O

These	O
results	O
indicate	O
that	O
DCoH	B-Gene
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

High	O
affinity	O
aldosterone	B-Chemical
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	O
leukocytes	O
:	O
is	O
there	O
a	O
membrane	O
receptor	O
for	O
mineralocorticoids	B-Chemical
?	O

In	O
vitro	O
effects	O
of	O
aldosterone	B-Chemical
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	B-Chemical
,	O
potassium	B-Chemical
and	O
calcium	B-Chemical
,	O
cell	O
volume	O
and	O
the	O
sodium-proton-antiport	B-Chemical
have	O
been	O
described	O
in	O
intact	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O

In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-labeled	O
aldosterone	B-Chemical
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	O
was	O
studied	O
.	O

High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O

Aldosterone	B-Chemical
displaced	O
the	O
tracer	O
at	O
a	O
similar	O
Kd	O
.	O

Both	O
canrenone	B-Chemical
and	O
cortisol	B-Chemical
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O

The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	B-Chemical
,	O
but	O
not	O
for	O
cortisol	B-Chemical
.	O

These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium-proton-antiport	B-Chemical
in	O
HML	O
and	O
thus	O
very	O
likely	O
represent	O
membrane	O
receptors	O
for	O
aldosterone	B-Chemical
.	O

Transcription	O
factor	O
requirements	O
for	O
U2	B-Gene
snRNA	I-Gene
-encoding	O
gene	O
activation	O
in	O
B	O
lymphoid	O
cells	O
.	O

Transcription	O
of	O
a	O
human	B-Gene
U2	I-Gene
small	I-Gene
nuclear	I-Gene
RNA	I-Gene
(	O
snRNA	O
)	O
-encoding	O
gene	O
in	O
HeLa	O
cells	O
requires	O
a	O
distal	O
enhancer	O
element	O
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	O
motif	O
(	O
Oct	O
)	O
and	O
three	O
Sp	B-Gene
1	I-Gene
-binding	O
sites	O
.	O

To	O
study	O
the	O
transcription	O
factor	O
requirement	O
in	O
B-cells	O
,	O
different	O
U2	B-Gene
enhancer	I-Gene
constructions	O
were	O
transfected	O
into	O
the	O
lymphoid	O
cell	O
line	O
,	O
BJA-B	O
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	B-Gene
snRNA	I-Gene
transcription	O
in	O
B-cells	O
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	O
and	O
at	O
least	O
one	O
Sp	B-Gene
1	I-Gene
-binding	O
site	O
.	O

Deletion	O
of	O
all	O
the	O
Sp	B-Gene
1	I-Gene
-binding	O
sites	O
from	O
the	O
enhancer	O
reduces	O
transcription	O
by	O
80-90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA-B	O
cells	O
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer	O
-binding	O
site	O
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O

Enhancers	O
containing	O
a	O
single	O
Oct	O
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	B-Gene
snRNA	I-Gene
transcription	O
in	O
both	O
HeLa	O
cells	O
,	O
in	O
which	O
only	O
OTF-1	B-Gene
is	O
expressed	O
,	O
and	O
in	O
BJA-B	O
cells	O
in	O
which	O
OTF-2	B-Gene
is	O
the	O
predominantly	O
expressed	O
octamer	B-Gene
-binding	I-Gene
factor	I-Gene
.	O

The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	O
factor	O
,	O
OTF-1	B-Gene
,	O
and	O
the	O
B-cell-specific	O
transcription	O
factor	O
,	O
OTF-2	B-Gene
,	O
can	O
activate	O
U2	B-Gene
snRNA	I-Gene
transcription	O
.	O

The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	O
and	O
the	O
adjacent	O
Sp	B-Gene
1	I-Gene
-binding	O
site	O
in	O
BJA-B	O
cells	O
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	O
cells	O
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	B-Gene
expresses	O
wild-type	O
levels	O
of	O
U2	B-Gene
snRNA	I-Gene
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer	O
-binding	O
site	O
is	O
combined	O
with	O
a	O
Sp	B-Gene
1	I-Gene
-binding	O
site	O
.	O

Cortisol	B-Chemical
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	B-Chemical
receptor	O
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

The	O
first	O
male	O
patient	O
presented	O
with	O
mild	B-Disease
hypertension	I-Disease
.	O

Hydrochlorothiazide	B-Chemical
therapy	O
resulted	O
in	O
life	O
-threatening	O
hypokalemia	B-Disease
.	O

The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	B-Disease
without	O
hypokalemia	B-Disease
.	O

All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20-30	O
yr	O
with	O
acne	B-Disease
,	O
hirsutism	B-Disease
,	O
and	O
irregular	O
menstruations	O
.	O

Low	O
dose	O
dexamethasone	B-Chemical
therapy	O
(	O
1-1.5	O
mg	O
/	O
day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O

All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	B-Chemical
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O

The	O
diurnal	O
rhythm	O
of	O
ACTH	B-Gene
and	O
cortisol	B-Chemical
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O

There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	B-Gene
,	O
cortisol	B-Chemical
,	O
and	O
GH	B-Gene
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin	B-Gene
-induced	O
hypoglycemia	B-Disease
,	O
while	O
cortisol	B-Chemical
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O

Circulating	O
adrenal	O
androgen	B-Chemical
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O

Glucocorticoid	B-Gene
receptors	I-Gene
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O

A	O
lowered	O
affinity	O
to	O
dexamethasone	B-Chemical
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O

In	O
the	O
second	O
male	O
patient	O
,	O
no	O
abnormalities	O
were	O
found	O
.	O

As	O
a	O
bioassay	O
for	O
glucocorticoid	B-Chemical
action	O
we	O
also	O
measured	O
dexamethasone	B-Chemical
suppressibility	O
of	O
mitogen	O
-stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	B-Chemical
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	B-Chemical
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	B-Chemical
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O

Partial	O
cortisol	B-Chemical
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O

Therapy	O
with	O
dexamethasone	B-Chemical
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	B-Disease
and	O
hirsutism	B-Disease
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	B-Chemical
was	O
effectively	O
controlled	O
.	O

Kappa	O
B-specific	O
DNA	O
binding	O
proteins	O
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Kappa	O
B	O
(	O
kappa	O
B	O
)	O
enhancer	O
binding	O
proteins	O
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	O
T	O
cells	O
produce	O
two	O
distinct	O
nucleoprotein	O
complexes	O
when	O
incubated	O
with	O
the	O
kappa	O
B	O
element	O
from	O
the	O
interleukin-2	B-Gene
receptor-alpha	I-Gene
(	I-Gene
IL-2R	I-Gene
alpha	I-Gene
)	I-Gene
gene	I-Gene
.	O

These	O
two	O
DNA-protein	O
complexes	O
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	B-Gene
,	O
p55	B-Gene
,	O
p75	B-Gene
,	O
p85	B-Gene
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v-rel	B-Gene
oncogene	I-Gene
product	I-Gene
.	O

Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	B-Chemical
ester	I-Chemical
activation	O
of	O
T	O
cells	O
(	O
p55	B-Gene
/	I-Gene
p75	I-Gene
early	O
and	O
p50	B-Gene
/	I-Gene
p85	I-Gene
late	O
)	O
.	O

DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	O
complex	O
contains	O
both	O
p50	B-Gene
and	O
p55	B-Gene
while	O
the	O
more	O
slowly	O
migrating	O
B1	O
complex	O
is	O
composed	O
of	O
p50	B-Gene
,	O
p55	B-Gene
,	O
p75	B-Gene
,	O
and	O
p85	B-Gene
.	O

Site	O
-directed	O
mutagenesis	O
of	O
the	O
wild-type	B-Gene
IL-2R	I-Gene
alpha	I-Gene
kappa	O
B	O
enhancer	O
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	B-Gene
and	O
p55	B-Gene
(	O
B2	O
complex	O
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	O
'triplet	O
of	O
deoxyguanosine	B-Chemical
residues	I-Chemical
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	O
complex	O
,	O
reflecting	O
the	O
binding	O
of	O
p75	B-Gene
and	O
p85	B-Gene
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'sequences	O
of	O
this	O
enhancer	O
element	O
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel	B-Gene
-related	O
factors	O
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	B-Chemical
and	O
arginine	B-Chemical
residues	I-Chemical
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	O
B	O
element	O
.	O

Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	B-Chemical
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N-ethylmaleimide	B-Chemical
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B-Gene
oxidase	I-Gene
selectively	O
inhibits	O
p75	B-Gene
and	O
p85	B-Gene
binding	O
while	O
not	O
blocking	O
p50	B-Gene
and	O
p55	B-Gene
interactions	O
.	O

These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	B-Chemical
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel	B-Gene
-related	O
transcription	O
factors	O
.	O

A	O
novel	O
mitogen-inducible	O
gene	O
product	O
related	O
to	O
p50	B-Gene
/	I-Gene
p105-NF-kappa	I-Gene
B	I-Gene
participates	O
in	O
transactivation	O
through	O
a	O
kappa	O
B	O
site	O
.	O

A	O
Rel	B-Gene
-related	O
,	O
mitogen-inducible	O
,	O
kappa	O
B	O
-binding	O
protein	O
has	O
been	O
cloned	O
as	O
an	O
immediate-early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97-kDa	O
protein	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF-kappa	B-Gene
B	I-Gene
.	O

Like	O
the	O
105-kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino-terminal	O
Rel	B-Gene
-related	O
domain	O
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy-terminal	B-Chemical
domain	O
containing	O
six	O
full	O
cell	O
cycle	O
or	O
ankyrin	B-Gene
repeats	O
.	O

In	O
vitro	O
-translated	O
proteins	O
,	O
truncated	O
downstream	O
of	O
the	O
Rel	B-Gene
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	O
B	O
sites	O
.	O

We	O
refer	O
to	O
the	O
kappa	O
B	O
-binding	O
,	O
truncated	O
protein	O
as	O
p50B	B-Gene
by	O
analogy	O
with	O
p50-NF-kappa	B-Gene
B	I-Gene
and	O
to	O
the	O
full-length	O
protein	O
as	O
p97	B-Gene
.	O

p50B	B-Gene
is	O
able	O
to	O
form	O
heteromeric	O
kappa	O
B	O
-binding	O
complexes	O
with	O
RelB	B-Gene
,	O
as	O
well	O
as	O
with	O
p65	B-Gene
and	O
p50	B-Gene
,	O
the	O
two	O
subunits	O
of	O
NF-kappa	B-Gene
B	I-Gene
.	O

Transient-transfection	O
experiments	O
in	O
embryonal	B-Disease
carcinoma	I-Disease
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	B-Gene
and	O
RelB	B-Gene
or	O
p65	B-Gene
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	O
B	O
site	O
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	B-Gene
B	I-Gene
-like	O
transcription	O
factors	O
.	O

[	O
Changes	O
in	O
leucocytic	B-Gene
estrogen	I-Gene
receptor	I-Gene
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	B-Chemical
dihuang	I-Chemical
pills	I-Chemical
]	O

The	O
numbers	O
of	O
estrogen	B-Gene
receptor	I-Gene
(	O
ER	B-Gene
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
normal	O
child	O
-bearing-age	O
women	O
.	O

It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	B-Gene
ER	I-Gene
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child	O
-bearing-age	O
women	O
.	O

The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	B-Chemical
Dihuang	I-Chemical
Pills	I-Chemical
(	O
LDP	B-Chemical
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O

The	O
numbers	O
of	O
leucocytic	B-Gene
ER	I-Gene
were	O
significantly	O
increased	O
after	O
treatment	O
.	O

The	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-Gene
levels	O
in	O
cell	O
may	O
involve	O
in	O
the	O
pathogenesis	O
of	O
climacteric	O
syndrome	O
.	O

LDP	B-Chemical
not	O
only	O
increases	O
plasma	O
estradiol	B-Chemical
levels	O
,	O
but	O
also	O
increases	O
the	O
leucocytic	B-Gene
ER	I-Gene
levels	O
.	O

This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O

A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	B-Gene
receptor	I-Gene
gene	I-Gene
in	O
families	O
with	O
X	B-Disease
-linked	I-Disease
spinal	I-Disease
and	I-Disease
bulbar	I-Disease
muscular	I-Disease
atrophy	I-Disease
.	O

X	B-Disease
-linked	I-Disease
spinal	I-Disease
and	I-Disease
bulbar	I-Disease
muscular	I-Disease
atrophy	I-Disease
(	O
SBMA	B-Disease
)	O
,	O
an	O
adult-onset	O
form	O
of	O
motor	B-Disease
neuron	I-Disease
disease	I-Disease
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	B-Gene
receptor	I-Gene
gene	I-Gene
.	O

We	O
report	O
here	O
a	O
simple	O
and	O
rapid	O
strategy	O
to	O
detect	O
the	O
precise	O
number	O
of	O
the	O
CAGs	O
.	O

After	O
the	O
DNA	O
fragment	O
containing	O
the	O
CAG	O
repeats	O
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O
the	O
extension	O
of	O
the	O
end	O
-labelled	O
reverse	O
primer	O
adjacent	O
to	O
3	O
'end	O
of	O
CAG	O
repeats	O
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	O
repeats	O
with	O
the	O
incorporation	O
of	O
dideoxy	B-Chemical
ATP	I-Chemical
in	O
the	O
reaction	O
mixture	O
.	O

The	O
resultant	O
primer	O
products	O
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O

This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	O
repeats	O
in	O
SBMA	B-Disease
but	O
also	O
other	O
polymorphic	O
dinucleotide	O
and	O
trinucleotide	O
repeats	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin-2	B-Gene
receptor	I-Gene
alpha	I-Gene
chain	I-Gene
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	B-Gene
B	I-Gene
.	O

The	O
two	O
nuclear	O
proteins	O
NF-kappa	B-Gene
B	I-Gene
(	O
consisting	O
of	O
subunits	O
p50	B-Gene
an	O
dp65	B-Gene
)	O
and	O
the	O
DNA	O
-binding	O
subunit	O
of	O
NF-kappa	B-Gene
B	I-Gene
(	O
p50	B-Gene
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B-Gene
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	O
T-cell	O
line	O
IARC	O
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301.5	O
and	O
a	O
murine	O
myeloma	B-Disease
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	B-Gene
and	O
NF-kappa	B-Gene
B	I-Gene
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B-Gene
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B-Gene
(	I-Gene
IL-2	I-Gene
)	I-Gene
receptor	I-Gene
alpha	I-Gene
chain	I-Gene
(	O
IL-2R	B-Gene
alpha	I-Gene
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	B-Gene
NF-kappa	I-Gene
B	I-Gene
.	O

These	O
findings	O
show	O
that	O
nuclear	B-Gene
NF-kappa	I-Gene
B	I-Gene
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	B-Gene
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	B-Gene
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	B-Gene
B	I-Gene
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B-Gene
and	O
IL-2	B-Gene
alpha	I-Gene
genes	I-Gene
during	O
the	O
immune	O
response	O
.	O

Influence	O
of	O
estradiol	B-Chemical
and	O
tamoxifen	B-Chemical
on	O
susceptibility	O
of	O
human	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
to	O
lysis	O
by	O
lymphokine	O
-activated	O
killer	O
cells	O
.	O

The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	B-Disease
cancer	I-Disease
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O

Estrogen	B-Gene
receptor	I-Gene
positive	O
(	O
ER+	B-Gene
:	O
MCF-7	O
)	O
and	O
negative	O
(	O
ER-	B-Gene
:	O
MDA-MB-231	O
)	O
human	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	B-Chemical
(	O
TAM	B-Chemical
)	O
and	O
estradiol	B-Chemical
(	O
E2	B-Chemical
)	O
on	O
modulation	O
of	O
breast	B-Disease
cancer	I-Disease
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine	O
-activated	O
killer	O
(	O
LAK	O
)	O
cells	O
.	O

E2	B-Chemical
-stimulated	O
ER+	B-Gene
cells	O
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	O
cells	O
than	O
corresponding	O
TAM	B-Chemical
-treated	O
or	O
control	O
cells	O
,	O
while	O
treatment	O
of	O
ER-	B-Gene
cells	O
with	O
either	O
E2	B-Chemical
or	O
TAM	B-Chemical
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune	O
-mediated	O
lysis	O
.	O

All	O
ER+	B-Gene
and	O
ER-	B-Gene
cells	O
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	B-Chemical
to	O
lysis	O
by	O
LAK	O
cells	O
.	O

In	O
addition	O
,	O
an	O
adenocarcinoma	B-Disease
reactive	O
human-mouse	O
chimeric	O
monoclonal	O
antibody	O
(	O
ING-1	B-Gene
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell	O
-mediated	O
lysis	O
of	O
control	O
,	O
E2	B-Chemical
-treated	O
,	O
and	O
TAM	B-Chemical
-treated	O
ER+	B-Gene
and	O
ER-	B-Gene
cells	O
.	O

These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	B-Chemical
,	O
interleukin-2	B-Gene
(	O
IL-2	B-Gene
)	O
,	O
and	O
breast	B-Disease
cancer	I-Disease
reactive	O
antibody	O
-dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	B-Disease
cancer	I-Disease
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
and	O
inhibition	O
of	O
3-O-methyl-D-glucose	B-Chemical
uptake	O
by	O
glucocorticoids	B-Chemical
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

We	O
have	O
measured	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
concentration	O
in	O
mononuclear	O
and	O
polymorphonuclear	O
leukocytes	O
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	B-Chemical
on	O
3-O-methyl-D-glucose	B-Chemical
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	O
leukocytes	O
.	O

The	O
glucocorticoid	B-Gene
receptor	I-Gene
levels	O
in	O
mononuclear	O
leukocytes	O
correlated	O
with	O
those	O
in	O
polymorphonuclear	O
leukocytes	O
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
levels	O
and	O
glucocorticoid	B-Chemical
-mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O-methyl-D-glucose	B-Chemical
in	O
mononuclear	O
leukocytes	O
.	O

When	O
mononuclear	O
leukocytes	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo-cAMP	B-Chemical
,	O
cellular	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	B-Chemical
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O-methyl-D-glucose	B-Chemical
.	O

We	O
conclude	O
that	O
the	O
cellular	B-Gene
glucocorticoid	I-Gene
receptor	I-Gene
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	B-Chemical
in	O
mononuclear	O
leukocytes	O
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
.	O

Stimulation	O
of	O
interferon	B-Gene
beta	I-Gene
gene	I-Gene
transcription	O
in	O
vitro	O
by	O
purified	B-Gene
NF-kappa	I-Gene
B	I-Gene
and	O
a	O
novel	O
TH	B-Gene
protein	I-Gene
.	O

The	O
human	B-Gene
interferon	I-Gene
beta	I-Gene
(	I-Gene
IFN-beta	I-Gene
)	I-Gene
regulatory	I-Gene
element	I-Gene
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	O
for	O
transcription	O
factors	O
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	O
.	O

To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	B-Gene
induction	O
,	O
positive	O
regulatory	O
domain	O
(	O
PRD	O
)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	B-Chemical
ester	I-Chemical
induced	O
Jurkat	O
T-cells	O
and	O
from	O
IFN	B-Gene
primed	O
,	O
cycloheximide	B-Chemical
/	O
polyinosinic-polycytidylic	B-Chemical
acid	I-Chemical
treated	O
HeLa	O
S3	O
cells	O
.	O

From	O
HeLa	O
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(	O
kD	O
)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	O
,	O
four	O
proteins	O
--	O
a	O
major	O
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	O
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43-47	O
kD	O
--	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	O
DNA	O
binding	O
protein	O
was	O
purified	O
from	O
HeLa	O
cells	O
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1	B-Gene
/	I-Gene
ISGF2	I-Gene
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	B-Gene
beta	I-Gene
promoter	I-Gene
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O

A	O
2-4-fold	O
increase	O
in	O
IFN-beta	B-Gene
promoter	I-Gene
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	O
and	O
tetrahexamer	O
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN-beta	B-Gene
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN-beta	B-Gene
transcription	O
.	O

Structure	O
function	O
analysis	O
of	O
vitamin	B-Chemical
D	I-Chemical
analogs	O
with	O
C	O
-ring	O
modifications	O
.	O

Analogs	O
of	O
1	B-Chemical
alpha	I-Chemical
,	I-Chemical
25-dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O

Their	O
affinity	O
for	O
the	O
vitamin	B-Gene
D	I-Gene
-binding	I-Gene
protein	I-Gene
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O

The	O
biological	O
activity	O
of	O
11	B-Chemical
alpha-methyl-1	I-Chemical
alpha	I-Chemical
,	I-Chemical
25-	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D3	I-Chemical
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	O
cell	O
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	B-Chemical
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O

The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	O
promyeloid	O
leukemia	B-Disease
cells	O
(	O
HL-60	O
)	O
agreed	O
well	O
with	O
their	O
bone	O
-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O

Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B-Gene
D	I-Gene
-binding	I-Gene
protein	I-Gene
.	O

The	O
effects	O
of	O
many	O
C-11	O
-substituted	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	O
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	B-Chemical
metabolism	O
.	O

Transcriptional	O
regulation	O
during	O
T-cell	O
development	O
:	O
the	O
alpha	B-Gene
TCR	I-Gene
gene	I-Gene
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	O
T-cell-specific	O
gene	O
,	O
alpha	B-Gene
TCR	I-Gene
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T-cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T-cell	O
activation	O
,	O
are	O
described	O
.	O

Cortisol	B-Chemical
resistance	O
in	O
acquired	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
(	O
AIDS	B-Disease
)	O
who	O
developed	O
hypercortisolism	B-Disease
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	B-Disease
.	O

All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	B-Disease
,	O
hyponatremia	B-Disease
,	O
and	O
intense	O
mucocutaneous	O
melanosis	B-Disease
)	O
.	O

An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	B-Chemical
was	O
suspected	O
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-Gene
receptor	I-Gene
characteristics	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	B-Chemical
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	B-Chemical
on	O
[	O
3H	O
]	O
thymidine	B-Chemical
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
activation	O
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
density	O
was	O
increased	O
in	O
AIDS	B-Disease
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+	O
/	O
-	O
9.4	O
fmol	O
/	O
million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	B-Disease
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+	O
/	O
-	O
2.6	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age	O
-matched	O
controls	O
(	O
3.15	O
+	O
/	O
-	O
2.3	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
affinity	O
of	O
glucocorticoid	B-Gene
receptors	I-Gene
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+	O
/	O
-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+	O
/	O
-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+	O
/	O
-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

[	O
3H	O
]	O
Thymidine	B-Chemical
incorporation	O
was	O
decreased	O
dose	O
-dependently	O
by	O
dexamethasone	B-Chemical
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
abnormality	O
.	O

In	O
conclusion	O
,	O
AIDS	B-Disease
patients	O
with	O
hypercortisolism	B-Disease
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	B-Chemical
are	O
characterized	O
by	O
abnormal	O
glucocorticoid	B-Gene
receptors	I-Gene
on	O
lymphocytes	O
.	O

Resistance	O
to	O
glucocorticoids	B-Chemical
implies	O
a	O
complex	O
change	O
in	O
immune-endocrine	O
function	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
course	O
of	O
immunodeficiency	B-Disease
syndrome	I-Disease
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	B-Gene
B	I-Gene
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	B-Gene
B	I-Gene
DNA	I-Gene
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB-985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-Gene
on	O
the	O
cell	O
surface	O
,	O
PLB-985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

PLB-IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c-fms	B-Gene
proto-oncogene	I-Gene
.	O

NF-kappa	B-Gene
B	I-Gene
binding	O
activity	O
was	O
inducible	O
by	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
and	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
in	O
PLB-985	O
.	O

However	O
,	O
in	O
PLB-IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF-kappa	B-Gene
B	I-Gene
complex	I-Gene
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF-kappa	B-Gene
B	I-Gene
site	O
from	O
the	O
interferon	B-Gene
beta	I-Gene
(	I-Gene
IFN-beta	I-Gene
)	I-Gene
promoter	I-Gene
.	O

Mutations	O
affecting	O
the	O
5	O
'guanine	B-Chemical
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF-kappa	B-Gene
B	I-Gene
-related	O
proteins	O
.	O

Inducibility	O
of	O
endogenous	B-Gene
IFN-beta	I-Gene
and	O
IFN-alpha	B-Gene
RNA	I-Gene
was	O
also	O
increased	O
in	O
PLB-IIIB	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF-kappa	B-Gene
B	I-Gene
DNA	I-Gene
binding	I-Gene
proteins	I-Gene
may	O
contribute	O
to	O
differential	O
NF-kappa	B-Gene
B	I-Gene
-mediated	O
gene	O
expression	O
.	O

The	O
AP-1	B-Gene
site	O
at	O
-150	O
bp	O
,	O
but	O
not	O
the	O
NF-kappa	B-Gene
B	I-Gene
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
in	O
the	O
interleukin	B-Gene
2	I-Gene
promoter	I-Gene
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation	O
-related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	B-Gene
in	O
induction	O
of	O
the	O
interleukin	B-Gene
2	I-Gene
(	I-Gene
IL-2	I-Gene
)	I-Gene
gene	I-Gene
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	B-Gene
cell	I-Gene
receptor	I-Gene
/	I-Gene
CD3	I-Gene
complex	I-Gene
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar-5	O
with	O
phorbol	B-Chemical
esters	I-Chemical
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	B-Gene
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	B-Gene
mRNA	I-Gene
and	O
protein	O
.	O

Here	O
we	O
show	O
that	O
phorbol	B-Chemical
ester	I-Chemical
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-Gene
acetyltransferase	I-Gene
activity	O
in	O
Ar-5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	B-Gene
promoter	I-Gene
linked	O
to	O
this	O
reporter	O
gene	O
.	O

The	O
IL-2	B-Gene
promoter	I-Gene
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT-1	B-Gene
,	O
Oct	B-Gene
,	O
NF-kappa	B-Gene
B	I-Gene
,	O
and	O
AP-1	B-Gene
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	B-Gene
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	B-Gene
and	O
Oct	B-Gene
sites	O
is	O
not	O
sensitive	O
to	O
phorbol	B-Chemical
ester	I-Chemical
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	B-Gene
B	I-Gene
site	O
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	B-Gene
site	O
located	O
at	O
-150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	B-Gene
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c-fos	B-Gene
and	O
c-jun	B-Gene
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	B-Gene
promoter	I-Gene
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-Gene
site	O
at	O
-150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B-Gene
responsiveness	O
in	O
the	O
IL-2	B-Gene
promoter	I-Gene
.	O

Interleukin	B-Gene
6	I-Gene
-induced	O
differentiation	O
of	O
a	O
human	O
B	O
cell	O
line	O
into	O
IgM	B-Gene
-secreting	O
plasma	O
cells	O
is	O
mediated	O
by	O
c-fos	B-Gene
.	O

The	O
role	O
of	O
the	O
protooncogene	B-Gene
c-fos	I-Gene
in	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
6	I-Gene
-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	B-Gene
6	I-Gene
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c-fos	B-Gene
sense	I-Gene
mRNA	I-Gene
expression	O
.	O

The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c-fos	B-Gene
significantly	O
inhibited	O
IL	B-Gene
6	I-Gene
-induced	O
IgM	B-Gene
production	O
by	O
SKW	O
6.4	O
cells	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
c-fos	B-Gene
is	O
involved	O
in	O
IL	B-Gene
6	I-Gene
-induced	O
differentiation	O
of	O
SKW	O
6.4	O
cells	O
into	O
IgM	B-Gene
-secreting	O
cells	O
.	O

Binding	O
of	O
erythroid	O
and	O
non-erythroid	O
nuclear	O
proteins	O
to	O
the	O
silencer	O
of	O
the	O
human	B-Gene
epsilon-globin	I-Gene
-encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin	B-Gene
-encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-392	O
to	O
-177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	B-Gene
epsilon-globin	I-Gene
-encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc.Natl.Acad.Sci.USA	O
86	O
(	O
1989	O
)	O
5306-5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	B-Disease
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis	O
-cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	O
to	O
-251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	O
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon-globin	B-Gene
-encoding	O
gene	O
in	O
erythroid	O
and	O
non-erythroid	O
cells	O
are	O
discussed	O
.	O

Gangliosides	B-Chemical
suppress	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
production	O
in	O
human	O
monocytes	O
.	O

Both	O
normal	O
and	O
malignant	O
cells	O
contain	O
gangliosides	B-Chemical
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	O
influence	O
cells	O
of	O
the	O
immune	O
system	O
.	O

We	O
have	O
studied	O
the	O
impact	O
of	O
gangliosides	B-Chemical
on	O
the	O
expression	O
of	O
TNF	B-Gene
in	O
blood	O
monocytes	O
and	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
.	O

Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	B-Chemical
(	O
100	O
micrograms	O
/	O
ml	O
)	O
suppressed	O
LPS	B-Chemical
-stimulated	O
TNF	B-Gene
production	O
5-fold	O
in	O
PBMC	O
and	O
10-fold	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum-free	O
conditions	O
.	O

Looking	O
at	O
highly	O
purified	O
gangliosides	B-Chemical
,	O
GD3	B-Chemical
,	O
GD1a	B-Chemical
,	O
GM3	B-Chemical
,	O
GM2	B-Chemical
,	O
and	O
GM1	B-Chemical
were	O
all	O
effective	O
in	O
reducing	O
TNF	B-Gene
production	O
in	O
PBMC	O
,	O
and	O
in	O
Mono	O
Mac	O
6	O
by	O
factor	O
10	O
to	O
50	O
.	O

The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	O
the	O
sugar	O
moiety	O
or	O
the	O
lipid	B-Chemical
moiety	O
.	O

Gangliosides	B-Chemical
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	B-Gene
transcripts	I-Gene
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
was	O
blocked	O
.	O

Furthermore	O
,	O
in	O
time	O
kinetics	O
,	O
gangliosides	B-Chemical
were	O
effective	O
for	O
up	O
to	O
30	O
min	O
after	O
addition	O
of	O
LPS	B-Chemical
,	O
but	O
not	O
thereafter	O
.	O

However	O
,	O
the	O
expression	O
of	O
the	O
CD14	B-Gene
Ag	I-Gene
,	O
a	O
receptor	O
molecule	O
for	O
LPS-LPS	B-Gene
binding	I-Gene
protein	I-Gene
complexes	I-Gene
,	O
was	O
unaffected	O
by	O
gangliosides	B-Chemical
.	O

Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	B-Chemical
activating	I-Chemical
factor	I-Chemical
as	O
a	O
stimulus	O
,	O
gangliosides	B-Chemical
were	O
able	O
to	O
suppress	O
TNF	B-Gene
production	O
in	O
Mono	O
Mac	O
6	O
cells	O
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O

On	O
the	O
other	O
hand	O
,	O
phorbol	B-Chemical
ester	I-Chemical
-induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	B-Chemical
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	B-Gene
gene	I-Gene
expression	O
in	O
monocytes	O
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	B-Chemical
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O

T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	B-Gene
cytokine	I-Gene
IL-4	I-Gene
.	O

IL-4	B-Gene
secreted	O
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	O
cytokine	O
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O

We	O
investigated	O
the	O
upstream	O
regulatory	O
elements	O
of	O
the	O
human	B-Gene
IL-4	I-Gene
promoter	I-Gene
.	O

A	O
novel	O
T	O
cell-specific	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
composed	O
of	O
two	O
protein	O
-binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'flanking	O
region	O
of	O
the	O
IL-4	B-Gene
gene	I-Gene
:	O
-311CTCCCTTCT-303	O
(	O
NRE-I	O
)	O
and	O
-288CTTTTTGCTT-TGC-300	O
(	O
NRE-II	O
)	O
.	O

A	O
T	B-Gene
cell-specific	I-Gene
protein	I-Gene
Neg-1	I-Gene
and	O
a	O
ubiquitous	O
protein	B-Gene
Neg-2	I-Gene
binding	O
to	O
NRE-I	O
and	O
NRE-II	O
,	O
respectively	O
,	O
were	O
identified	O
.	O

Furthermore	O
,	O
a	O
positive	O
regulatory	O
element	O
was	O
found	O
45	O
bp	O
downstream	O
of	O
the	O
NRE	O
.	O

The	O
enhancer	O
activity	O
of	O
the	O
PRE	O
was	O
completely	O
suppressed	O
when	O
the	O
NRE	O
was	O
present	O
.	O

These	O
data	O
suggest	O
that	O
IL-4	B-Gene
promoter	I-Gene
activity	O
is	O
normally	O
down	O
-regulated	O
by	O
an	O
NRE	O
via	O
repression	O
of	O
the	O
enhancer	O
positive	O
regulatory	O
element	O
.	O

These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL-4	B-Gene
expression	O
in	O
T	O
cells	O
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	B-Gene
on	O
glucocorticoid	B-Gene
receptor	I-Gene
in	O
human	O
peripheral	O
leukocytes	O
]	O

The	O
regulatory	O
effect	O
of	O
insulin	B-Gene
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
of	O
human	O
leukocytes	O
was	O
assessed	O
by	O
the	O
unoccupied	O
receptor	O
sites	O
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	B-Chemical
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	B-Gene
added	O
to	O
the	O
medium	O
.	O

After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	B-Chemical
was	O
decreased	O
by	O
23.3	O
+	O
/	O
-	O
10.0	O
,	O
32.2	O
+	O
/	O
-	O
13.2	O
and	O
54.3	O
+	O
/	O
-	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	B-Gene
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU	O
/	O
L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU	O
/	O
L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2	O
,	O
000	O
mU	O
/	O
L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	B-Gene
in	O
the	O
incubation	O
medium	O
.	O

After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
+	O
/	O
-	O
19.0	O
,	O
56.1	O
+	O
/	O
-	O
20.7	O
and	O
80.2	O
+	O
/	O
-	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O

Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	B-Gene
on	O
the	O
GR	B-Gene
binding	O
power	O
is	O
both	O
dose-	O
and	O
time	O
-dependent	O
,	O
which	O
strongly	O
suggests	O
that	O
GR	B-Gene
is	O
tonically	O
controlled	O
by	O
insulin	B-Gene
concentration	O
change	O
under	O
physiological	O
conditions	O
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation-inducer	B-Gene
molecule	I-Gene
/	I-Gene
CD69	I-Gene
enhances	O
the	O
activity	O
of	O
transcription	B-Gene
factor	I-Gene
AP-1	I-Gene
.	O

The	O
induction	O
of	O
the	O
AP-1	B-Gene
transcription	I-Gene
factor	I-Gene
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	B-Gene
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
stimulated	O
through	O
the	O
activation	B-Gene
inducer	I-Gene
molecule	I-Gene
(	I-Gene
AIM	I-Gene
)	I-Gene
/	I-Gene
CD69	I-Gene
activation	O
pathway	O
.	O

Phorbol	B-Chemical
esters	I-Chemical
are	O
required	O
to	O
induce	O
AIM	B-Gene
/	I-Gene
CD69	I-Gene
cell-surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	O
cells	O
in	O
conjunction	O
with	O
anti-AIM	B-Gene
mAb	I-Gene
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti-AIM	B-Gene
mAb	I-Gene
to	O
PMA	B-Chemical
-treated	O
T	O
lymphocytes	O
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	B-Gene
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	B-Chemical
ester	I-Chemical
response	O
element	O
.	O

In	O
contrast	O
,	O
anti-AIM	B-Gene
mAb	I-Gene
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
binding	O
activity	O
of	O
NF-kappa	B-Gene
B	I-Gene
,	O
a	O
transcription	O
factor	O
whose	O
activity	O
is	O
also	O
regulated	O
by	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
.	O

The	O
increase	O
in	O
AP-1	B-Gene
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	B-Gene
but	O
not	O
that	O
of	O
c-jun	B-Gene
.	O

Blockade	O
of	O
the	O
DNA	O
-binding	O
complexes	O
with	O
an	O
anti-Fos	B-Gene
mAb	I-Gene
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	B-Gene
in	O
the	O
AP-1	B-Gene
complexes	I-Gene
induced	O
by	O
anti-AIM	B-Gene
mAb	I-Gene
.	O

Most	O
of	O
the	O
AP-1	B-Gene
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti-AIM	B-Gene
mAb	I-Gene
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	B-Chemical
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1	B-Gene
-binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	B-Gene
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP-1	B-Gene
.	O

Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O

cis	O
-acting	O
sequences	O
required	O
for	O
inducible	O
interleukin-2	B-Gene
enhancer	I-Gene
function	O
bind	O
a	O
novel	O
Ets	B-Gene
-related	O
protein	O
,	O
Elf-1	B-Gene
.	O

The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	O
binding	O
sequence	O
for	O
the	O
Ets	B-Gene
family	I-Gene
of	O
transcription	O
factors	O
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	B-Gene
binding	O
sites	O
in	O
the	O
promoters	O
and	O
enhancers	O
of	O
many	O
inducible	O
T-cell	O
genes	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	B-Gene
binding	O
sites	O
,	O
EBS1	O
and	O
EBS2	O
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	O
and	O
murine	B-Gene
interleukin-2	I-Gene
enhancers	I-Gene
.	O

Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	O
I	O
footprints	O
,	O
NFAT-1	B-Gene
and	O
NFIL-2B	B-Gene
,	O
respectively	O
.	O

Electrophoretic	O
mobility	O
shift	O
and	O
methylation	O
interference	O
analyses	O
demonstrated	O
that	O
EBS1	O
and	O
EBS2	O
are	O
essential	O
for	O
the	O
formation	O
of	O
the	O
NFAT-1	B-Gene
and	O
NFIL-2B	B-Gene
nuclear	I-Gene
protein	I-Gene
complexes	I-Gene
.	O

Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	B-Gene
enhancer	I-Gene
function	O
requires	O
the	O
presence	O
of	O
either	O
EBS1	O
or	O
EBS2	O
.	O

Two	O
well	O
-characterized	O
Ets	B-Gene
family	I-Gene
members	O
,	O
Ets-1	B-Gene
and	O
Ets-2	B-Gene
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O

Surprisingly	O
,	O
however	O
,	O
neither	O
of	O
these	O
proteins	O
bound	O
in	O
vitro	O
to	O
EBS1	O
or	O
EBS2	O
.	O

We	O
therefore	O
screened	O
a	O
T-cell	O
cDNA	O
library	O
under	O
low	O
-stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	O
binding	O
domain	O
of	O
Ets-1	B-Gene
and	O
isolated	O
a	O
novel	O
Ets	B-Gene
family	I-Gene
member	O
,	O
Elf-1	B-Gene
.	O

Elf-1	B-Gene
contains	O
a	O
DNA	O
binding	O
domain	O
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	B-Gene
,	O
the	O
ecdysone-inducible	B-Chemical
Drosophila	O
transcription	O
factor	O
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	B-Gene
,	O
for	O
E74	B-Gene
-like	I-Gene
factor	I-Gene
1	I-Gene
)	O
.	O

Elf-1	B-Gene
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
also	O
bound	O
to	O
the	O
purine-rich	B-Chemical
CD3R	B-Gene
element	I-Gene
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
long	O
terminal	O
repeat	O
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T-cell	B-Gene
receptor	I-Gene
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	O
Ets	B-Gene
family	I-Gene
members	O
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	B-Chemical
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B-Gene
receptors	I-Gene
.	O

Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	B-Gene
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well	O
-documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	B-Chemical
may	O
inhibit	O
concanavalin	B-Gene
A	I-Gene
(	O
Con	B-Gene
A	I-Gene
)	O
-	O
and	O
phytohemagglutinin	B-Gene
(	O
PHA	B-Gene
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-Chemical
mitogen	I-Chemical
(	O
PWM	B-Chemical
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	B-Chemical
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	B-Gene
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B-Gene
receptor	I-Gene
function	O
,	O
dose-response	O
curves	O
were	O
obtained	O
for	O
Con	B-Gene
A	I-Gene
-and	O
PHA	B-Gene
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	O
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	B-Chemical
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	B-Chemical
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	B-Chemical
(	O
MET	B-Chemical
)	O
and	O
subsequent	O
glucocorticoid	B-Chemical
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	O
-induced	O
B-cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	B-Chemical
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	B-Chemical
treatment	O
when	O
compared	O
with	O
the	O
DEX	B-Chemical
plus	O
MET	B-Chemical
pretreated	O
condition	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	B-Chemical
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B-Gene
receptor	I-Gene
function	O
.	O

The	O
decrease	O
in	O
PWM	O
-generated	O
B-cell	O
proliferation	O
following	O
cortisol	B-Chemical
depletion	O
by	O
MET	B-Chemical
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid	B-Chemical
-mediated	O
induction	O
of	O
interleukin-1	B-Gene
receptor	I-Gene
synthesis	O
.	O

Mineralocorticoids	B-Chemical
and	O
mineralocorticoid	B-Gene
receptors	I-Gene
in	O
mononuclear	O
leukocytes	O
in	O
patients	O
with	O
pregnancy	B-Disease
-induced	I-Disease
hypertension	I-Disease
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	B-Chemical
in	O
the	O
pathophysiology	O
of	O
pregnancy	B-Disease
-induced	I-Disease
hypertension	I-Disease
(	O
PIH	B-Disease
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	B-Chemical
and	O
18-hydroxycorticosterone	B-Chemical
levels	O
in	O
25	O
women	O
with	O
PIH	B-Disease
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-Gene
receptor	I-Gene
(	O
MR	B-Gene
)	O
status	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O

MR	B-Gene
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	B-Disease
group	O
(	O
148	O
+	O
/	O
-	O
9	O
binding	O
sites	O
/	O
cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
+	O
/	O
-	O
17	O
binding	O
sites	O
/	O
cell	O
;	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

Plasma	O
aldosterone	B-Chemical
in	O
women	O
with	O
PIH	B-Disease
was	O
281	O
+	O
/	O
-	O
61	O
pmol	O
/	O
L	O
;	O
in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
+	O
/	O
-	O
172	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Plasma	O
18-hydroxycorticosterone	B-Chemical
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	B-Disease
,	O
1071	O
+	O
/	O
-	O
149	O
pmol	O
/	O
L	O
;	O
controls	O
,	O
1907	O
+	O
/	O
-	O
318	O
pmol	O
/	O
L	O
)	O
.	O

These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	B-Disease
.	O

These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	B-Chemical
in	O
PIH	B-Disease
;	O
a	O
hitherto	O
unknown	O
mineralocorticoid	B-Chemical
may	O
,	O
thus	O
,	O
be	O
responsible	O
for	O
the	O
hypertension	B-Disease
and	O
altered	O
MR	B-Gene
status	O
.	O

Mineralocorticoid	B-Chemical
effector	O
mechanism	O
in	O
preeclampsia	B-Disease
.	O

Mineralocorticoid	B-Chemical
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	B-Disease
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	B-Chemical
,	O
levels	O
of	O
mineralocorticoid	B-Gene
receptor	I-Gene
(	O
MR	B-Gene
)	O
in	O
mononuclear	O
leucocytes	O
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	B-Gene
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O

Mean	O
values	O
for	O
plasma	O
aldosterone	B-Chemical
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	B-Gene
(	O
preeclampsia	B-Disease
,	O
81	O
+	O
/	O
-	O
44	O
receptors	O
/	O
cell	O
;	O
controls	O
,	O
306	O
+	O
/	O
-	O
168	O
)	O
and	O
SPD	B-Gene
(	O
preeclampsia	B-Disease
,	O
65	O
+	O
/	O
-	O
7	O
mV	O
;	O
controls	O
,	O
12	O
+	O
/	O
-	O
5	O
mV	O
)	O
.	O

In	O
six	O
cases	O
we	O
determined	O
MR	B-Gene
,	O
plasma	O
aldosterone	B-Chemical
,	O
and	O
SPD	B-Gene
in	O
patients	O
with	O
preeclampsia	B-Disease
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O

MR	B-Gene
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+	O
/	O
-	O
27	O
receptors	O
/	O
cell	O
)	O
,	O
and	O
SPD	B-Gene
increased	O
(	O
64	O
+	O
/	O
-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B-Gene
,	O
242	O
+	O
/	O
-	O
79	O
;	O
SPD	B-Gene
,	O
14.0	O
+	O
/	O
-	O
4	O
mV	O
)	O
.	O

Aldosterone	B-Chemical
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
abnormalities	O
in	O
mineralocorticoid	B-Chemical
effector	O
mechanisms	O
in	O
the	O
etiology	O
of	O
preeclampsia	B-Disease
and	O
could	O
be	O
an	O
useful	O
marker	O
for	O
diagnosis	O
.	O

A	O
lymphoid	O
cell-specific	O
nuclear	O
factor	O
containing	O
c-Rel	B-Gene
-like	I-Gene
proteins	I-Gene
preferentially	O
interacts	O
with	O
interleukin-6	B-Gene
kappa	I-Gene
B	I-Gene
-related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O

The	O
proto-oncoprotein	B-Gene
c-Rel	I-Gene
is	O
a	O
member	O
of	O
the	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
transcription	I-Gene
factor	I-Gene
family	I-Gene
,	O
which	O
includes	O
the	O
p50	B-Gene
and	O
p65	B-Gene
subunits	I-Gene
of	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
.	O

We	O
show	O
here	O
that	O
c-Rel	B-Gene
binds	O
to	O
kappa	O
B	O
sites	O
as	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
p50	B-Gene
.	O

These	O
homodimers	O
and	O
heterodimers	O
show	O
distinct	O
DNA	O
-binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	O
B	O
motifs	O
.	O

In	O
particular	O
,	O
the	O
c-Rel	B-Gene
homodimer	O
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	B-Gene
(	O
IL-6	B-Gene
)	O
and	O
beta	B-Gene
interferon	I-Gene
kappa	I-Gene
B	I-Gene
sites	O
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	B-Gene
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	O
cell-specific	O
nuclear	O
factor	O
in	O
vivo	O
that	O
contains	O
c-Rel	B-Gene
but	O
not	O
p50	B-Gene
epitopes	O
;	O
this	O
factor	O
,	O
termed	O
IL-6	B-Gene
kappa	I-Gene
B	I-Gene
binding	I-Gene
factor	I-Gene
II	I-Gene
,	O
appears	O
to	O
contain	O
the	O
c-Rel	B-Gene
homodimer	O
and	O
preferentially	O
recognizes	O
several	O
IL-6	B-Gene
kappa	I-Gene
B	I-Gene
-related	O
kappa	O
B	O
motifs	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	B-Gene
kappa	I-Gene
B	I-Gene
motif	O
functions	O
as	O
a	O
potent	O
IL-1	B-Gene
/	I-Gene
tumor	I-Gene
necrosis	I-Gene
factor	I-Gene
-responsive	I-Gene
element	I-Gene
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T-cell	O
line	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL-6	B-Gene
kappa	I-Gene
B	I-Gene
binding	I-Gene
factor	I-Gene
II	I-Gene
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	B-Gene
kappa	I-Gene
B	I-Gene
-related	O
kappa	O
B	O
motifs	O
in	O
lymphoid	O
cells	O
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	B-Chemical
hormone	I-Chemical
and	O
retinoic	B-Gene
acid	I-Gene
receptors	I-Gene
:	O
a	O
possible	O
target	O
for	O
v-erbA	B-Gene
oncogene	I-Gene
action	O
.	O

The	O
v-erbA	B-Gene
oncogene	I-Gene
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	B-Gene
hormone	I-Gene
receptor	I-Gene
alpha	I-Gene
(	O
c-erbA	B-Gene
/	I-Gene
TR-alpha	I-Gene
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	O
genes	O
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto-oncogene	B-Gene
c-erbA	I-Gene
in	O
erythropoiesis	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	B-Gene
thyroid	I-Gene
hormone	I-Gene
receptor	I-Gene
alpha	I-Gene
(	O
c-erbA	B-Gene
/	I-Gene
TR-alpha	I-Gene
)	O
and	O
the	O
closely	O
related	O
retinoic	B-Gene
acid	I-Gene
receptor	I-Gene
alpha	I-Gene
(	O
RAR-alpha	B-Gene
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O

Retinoic	B-Chemical
acid	I-Chemical
(	O
RA	B-Chemical
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	O
erythroid	O
progenitors	O
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	B-Gene
kinase	I-Gene
oncogene	I-Gene
.	O

When	O
added	O
pulsewise	O
to	O
immature	O
cells	O
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	O
cells	O
underwent	O
premature	O
cell	O
death	O
.	O

Thyroid	B-Chemical
hormone	I-Chemical
(	O
T3	B-Chemical
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Interestingly	O
,	O
T3	B-Chemical
strongly	O
enhanced	O
the	O
action	O
of	O
RA	B-Chemical
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O

Expression	O
of	O
the	O
human	B-Gene
RAR-alpha	I-Gene
in	O
receptor	O
-negative	O
erythroblasts	O
conferred	O
RA	B-Chemical
-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	O
cells	O
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	B-Gene
is	O
essential	O
for	O
the	O
RA	B-Chemical
effect	O
.	O

Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	B-Gene
c-erbA	I-Gene
/	I-Gene
TR-alpha	I-Gene
in	O
erythroblasts	O
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	B-Chemical
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O

Leukotriene	B-Chemical
B4	I-Chemical
stimulates	O
c-fos	B-Gene
and	O
c-jun	B-Gene
gene	I-Gene
transcription	O
and	O
AP-1	B-Gene
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	B-Chemical
B4	I-Chemical
(	O
LTB4	B-Chemical
)	O
,	O
a	O
potent	O
lipid	B-Chemical
proinflammatory	O
mediator	O
,	O
on	O
the	O
expression	O
of	O
the	O
proto-oncogenes	B-Gene
c-jun	I-Gene
and	O
c-fos	B-Gene
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	O
factors	O
binding	O
specifically	O
to	O
the	O
AP-1	B-Gene
element	I-Gene
after	O
LTB4	B-Chemical
stimulation	O
.	O

LTB4	B-Chemical
increased	O
the	O
expression	O
of	O
the	O
c-fos	B-Gene
gene	I-Gene
in	O
a	O
time-	O
and	O
concentration	O
-dependent	O
manner	O
.	O

The	O
c-jun	B-Gene
mRNA	I-Gene
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral-blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	B-Chemical
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c-fos	B-Gene
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c-fos	B-Gene
mRNA	I-Gene
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c-jun	B-Gene
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	O
of	O
the	O
c-fos	B-Gene
and	O
c-jun	B-Gene
mRNA	I-Gene
was	O
not	O
affected	O
by	O
LTB4	B-Chemical
,	O
as	O
assessed	O
after	O
actinomycin	B-Chemical
D	I-Chemical
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	B-Chemical
increased	O
the	O
transcription	O
of	O
the	O
c-fos	B-Gene
gene	I-Gene
7-fold	O
and	O
the	O
c-jun	B-Gene
gene	I-Gene
1.4-fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	O
factors	O
binding	O
to	O
the	O
AP-1	B-Gene
element	I-Gene
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	B-Chemical
induced	O
greater	O
AP-1	B-Gene
-binding	O
activity	O
of	O
nuclear	O
proteins	O
.	O

These	O
results	O
indicate	O
that	O
LTB4	B-Chemical
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	O
by	O
modulating	O
the	O
yield	O
and	O
/	O
or	O
the	O
function	O
of	O
transcription	O
factors	O
such	O
as	O
AP-1	B-Gene
-binding	O
proto-oncogene	O
products	O
.	O

An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	B-Gene
interleukin	I-Gene
4	I-Gene
gene	I-Gene
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	B-Gene
interleukin	I-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
4	I-Gene
gene	I-Gene
in	O
Jurkat	O
cells	O
.	O

The	O
human	B-Gene
IL-4	I-Gene
gene	I-Gene
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O

A	O
cis	O
-acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'upstream	O
region	O
;	O
no	O
additional	O
DNA	O
segments	O
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	B-Gene
IL-4	I-Gene
gene	I-Gene
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte	B-Gene
/	I-Gene
macrophage	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
basic	I-Gene
promoter	I-Gene
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	B-Gene
granulocyte	I-Gene
/	I-Gene
macrophage	I-Gene
colony	I-Gene
-stimulating	I-Gene
factor	I-Gene
gene	I-Gene
and	O
various	O
lengths	O
of	O
the	O
5	O
'upstream	O
sequence	O
of	O
the	O
IL-4	B-Gene
gene	I-Gene
.	O

The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-79	O
and	O
-69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	B-Gene
IL-4	I-Gene
gene	I-Gene
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base-substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	O
protein	O
(	O
s	O
)	O
that	O
recognize	O
the	O
P	O
sequence	O
of	O
the	O
IL-4	B-Gene
gene	I-Gene
were	O
identified	O
by	O
DNA-mobility-shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	O
(	O
P	O
)	O
(	O
a	O
DNA	O
binding	O
protein	O
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	O
(	O
P	O
)	O
interaction	O
is	O
sequence-specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	B-Gene
expression	O
in	O
vivo	O
.	O

The	O
P	O
sequence	O
does	O
not	O
share	O
homology	O
with	O
the	O
5	O
'upstream	O
sequence	O
of	O
the	O
IL-2	B-Gene
gene	I-Gene
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	B-Gene
gene	I-Gene
share	O
high	O
homology	O
with	O
the	O
IL-2	B-Gene
gene	I-Gene
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	O
recognize	O
IL-2	B-Gene
and	O
IL-4	B-Gene
genes	I-Gene
.	O

Glucocorticoid	B-Gene
receptor	I-Gene
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
:	O
lack	O
of	O
evidence	O
of	O
receptor	O
binding	O
defect	O
.	O

1	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
apparent	O
glucocorticoid	B-Chemical
resistance	O
in	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
,	O
circadian	O
variation	O
in	O
cortisol	B-Chemical
concentration	O
,	O
dexamethasone	B-Chemical
suppression	O
and	O
glucocorticoid	B-Gene
receptor	I-Gene
binding	O
in	O
mononuclear	O
leukocytes	O
,	O
polymorphonuclear	O
leukocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
were	O
measured	O
in	O
rigidly	O
defined	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
patients	O
and	O
non	O
-depressed	O
psychiatric	O
controls	O
.	O

2	O
.	O

Mononuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	B-Chemical
correlated	O
significantly	O
with	O
polymorphonuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	B-Chemical
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
and	O
control	O
subjects	O
.	O

3	O
.	O

Initial	O
and	O
post-dexamethasone	B-Chemical
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	B-Chemical
was	O
not	O
different	O
between	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
and	O
non	O
-depressed	O
control	O
subjects	O
.	O

4	O
.	O

The	O
phenomenon	O
of	O
glucocorticoid	B-Chemical
resistance	O
in	O
major	B-Disease
depressive	I-Disease
disorder	I-Disease
remains	O
unexplained	O
.	O

[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B-Gene
receptors	I-Gene
in	O
patients	O
with	O
the	O
nephrotic	B-Disease
syndrome	I-Disease
]	O

As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	B-Disease
were	O
examined	O
.	O

Four	O
variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O
variants	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
were	O
distinguished	O
:	O
1	O
)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	B-Disease
,	O
2	O
)	O
biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	B-Disease
,	O
3	O
)	O
low	O
content	O
of	O
T3	B-Chemical
,	O
4	O
)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O

It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B-Gene
receptors	I-Gene
,	O
thyroid	B-Chemical
hormones	I-Chemical
that	O
the	O
low	O
level	O
of	O
steroid	B-Gene
receptors	I-Gene
,	O
thyroid	B-Chemical
hormones	I-Chemical
(	O
T3	B-Chemical
and	O
T4	B-Chemical
)	O
and	O
cortisol	B-Chemical
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	B-Disease
dysplasia	I-Disease
.	O

It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	B-Disease
(	O
glomerulonephritis	B-Disease
and	O
nephrotic	B-Disease
syndrome	I-Disease
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	B-Chemical
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B-Gene
D	I-Gene
receptor	I-Gene
in	O
human	O
HL60	O
leukemia	B-Disease
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
--	O
coincident	O
rise	O
of	O
DNA	O
-relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	O
affinity	O
receptors	O
(	O
VDR	B-Gene
)	O
for	O
1	B-Chemical
,	I-Chemical
25-dihydroxycholecalciferol	I-Chemical
(	O
calcitriol	B-Chemical
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	B-Disease
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

HL60	O
cells	O
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	O
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	B-Chemical
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol	B-Chemical
/	O
VDR	B-Gene
was	O
examined	O
after	O
exposure	O
of	O
whole	O
cells	O
to	O
10	O
(	O
-9	O
)	O
M	O
/	O
l	O
calcitriol	B-Chemical
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol	B-Chemical
/	O
VDR	B-Gene
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites	O
/	O
nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	O
cells	O
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites	O
/	O
nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	O
.	O

Pulse	O
exposure	O
of	O
HL60	O
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	B-Chemical
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	O
radiolabeled	O
VDR	B-Gene
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B-Gene
by	O
24	O
h	O
.	O

Radiolabeled	O
VDR	B-Gene
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse	O
/	O
chase	O
-experiments	O
)	O
.	O

No	O
difference	O
of	O
VDR	B-Gene
retention	O
in	O
pulse	O
and	O
pulse	O
/	O
chase	O
-experiments	O
was	O
seen	O
in	O
PBL	O
,	O
where	O
VDR	B-Gene
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	B-Chemical
.	O

Radiolabeled	O
hormone	O
/	O
receptor	O
complexes	O
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O

The	O
activity	O
of	O
DNA	O
relaxing	O
enzymes	O
(	O
e.g	O
.	O
topoisomerases	B-Gene
I	I-Gene
and	O
II	B-Partial_Gene
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation-assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	B-Chemical
(	O
final	O
ethanol	B-Chemical
concentration	O
0.0001	O
%	O
v	O
/	O
v	O
)	O
in	O
HL60	O
and	O
PBL	O
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	O
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	O
.	O

No	O
effect	O
was	O
seen	O
in	O
ethanol	B-Chemical
treated	O
controls	O
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	B-Chemical
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	O
proteins	O
after	O
hormone	O
binding	O
.	O

Translocated	O
hormone	O
/	O
receptor	O
complexes	O
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	B-Gene
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B-Gene
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA	O
-unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

